PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DIETZEN, DJ; HASTINGS, WR; LUBLIN, DM				DIETZEN, DJ; HASTINGS, WR; LUBLIN, DM			CAVEOLIN IS PALMITOYLATED ON MULTIPLE CYSTEINE RESIDUES - PALMITOYLATION IS NOT NECESSARY FOR LOCALIZATION OF CAVEOLIN TO CAVEOLAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ROUS-SARCOMA VIRUS; DECAY-ACCELERATING FACTOR; TRANS-GOLGI-NETWORK; ANCHORED PROTEINS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; ALPHA-SUBUNITS; COMPONENT; RECEPTOR	Caveolae are subdomains of the plasma membrane which concentrate cholesterol, glycosphingolipids, and glycosylphosphatidylinositol-linked proteins. It has recently been demonstrated that specific members of the Src family of protein tyrosine kinases require palmitoylation of NH2-terminal cysteine residues to localize in caveolae. Here we report that caveolin, an integral membrane protein which forms part of the coat of caveolae, also incorporates palmitate through linkage to cysteine residues. Caveolin contains only three cysteine residues which are all located on the COOH-terminal side of the hydrophobic transmembrane region. Immunofluorescent staining of cells transfected with caveolin indicated that, like the NH2 terminus, this COOH-terminal region is located on the cytoplasmic side of the plasma membrane. Studies of cysteine substitution mutants showed that all three cysteines are capable of incorporating palmitate and that the juxtamembrane Cys(133) residue is the predominant site of palmitoylation. Simultaneous mutation of all three cysteine residues in caveolin resulted in the loss of ability to incorporate palmitate; however, this did not affect localization of the protein. Thus, palmitoylation of cysteine residues in nonmembrane spanning Src family protein tyrosine kinases has different consequences than in the transmembrane protein caveolin.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV LAB MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM041297, R01GM041297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07038] Funding Source: Medline; NIGMS NIH HHS [GM 41297] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CINEK T, 1992, J IMMUNOL, V149, P2262; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PALADE GE, 1953, J APPL PHYS, V24, P1424; PALADE GE, 1958, ANAT REC, V130, P467; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SEYA T, 1987, J IMMUNOL, V139, P1260; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	41	282	287	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6838	6842		10.1074/jbc.270.12.6838	http://dx.doi.org/10.1074/jbc.270.12.6838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896831	hybrid			2022-12-27	WOS:A1995QQ85500062
J	ZHANG, J; ZHANG, J; BENOVIC, JL; SUGAI, M; WETZKER, R; GOUT, I; RITTENHOUSE, SE				ZHANG, J; ZHANG, J; BENOVIC, JL; SUGAI, M; WETZKER, R; GOUT, I; RITTENHOUSE, SE			SEQUESTRATION OF A G-PROTEIN BETA-GAMMA SUBUNIT OR ADP-RIBOSYLATION OF RHO CAN INHIBIT THROMBIN-INDUCED ACTIVATION OF PLATELET PHOSPHOINOSITIDE 3-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; GTP-BINDING PROTEIN; ADENYLATE-CYCLASE; PURIFICATION	Stimulation of platelets by thrombin leads to an increased association of activated phosphoinositide 3-kinase (PI 3-K) with a membrane cytoskeletal fraction (CSK). Activation of PI 3-K is dependent upon GTP-binding protein(s), since PI 3-K in permeabilized platelets is stimulated by GTP gamma S (guanosine 5'-3-O-(thio)triphosphate), and stimulation of platelet cytosolic PI 3-K by GTP gamma S requires a functional small G protein, Rho. Recent reports indicate that cytosolic PI 3-Ks can also be activated by the beta gamma subunits of heterotrimeric G-proteins (G beta gamma). We now report that the activated PI 3-K that is associated with CSK can be inhibited by a recombinant protein containing the G beta gamma-binding pleckstrin homology domain of beta-adrenergic receptor kinase 1 (beta ARK-PH). Inhibition is blocked by G beta gamma. PI 3-K in nonactivated platelet CSK is activated by GTP gamma S but unaffected by beta ARK-PH or G beta gamma, Western blots indicate that activated platelet CSK contains a novel 110-kDa PI 3-K(gamma) that has been shown to be stimulated by G beta gamma and to lack binding sites for the 85-kDa subunit of conventional PI 3-K. PI 3-K in immunoprecipitates obtained via p85 subunit-directed antibodies can be activated by GTP gamma S but not by G beta gamma. PI 3-K that is stimulatable by G beta gamma remains soluble, as does PI 3-K(gamma), and is unaffected by Rho, In contrast, ADP-ribosylation of Rho present in p85 immunoprecipitates is inhibitory, Further, activation of PI 3-K in permeabilized platelets exposed to thrombin or GTP gamma S is inhibited by beta ARK-PH and/or Rho-specific ADP-ribosylating enzymes. We conclude that Rho and G beta gamma each, respectively, contributes to the activation of different PI 3-Ks (p85-containing heterodimer and PI3-K (gamma)) in thrombin-stimulated platelets.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, CARDEZA FDN HEMATOL RES, PHILADELPHIA, PA 19107 USA; HIROSHIMA UNIV, SCH DENT, DEPT MICROBIOL, MINAMI KU, HIROSHIMA 734, JAPAN; UNIV JENA, MAX PLANCK RES GRP GROWTH FACTROR SIGNAL TRANSDUC, D-07747 JENA, GERMANY; UCL, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Jefferson University; Jefferson University; Hiroshima University; Friedrich Schiller University of Jena; Max Planck Society; Ludwig Institute for Cancer Research; University of London; University College London			Wetzker, Reinhard/AAD-8713-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38622] Funding Source: Medline; CGH CDC HHS [GH 44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CGH CDC HHS		AKTORIES K, 1984, EUR J BIOCHEM, V145, P333, DOI 10.1111/j.1432-1033.1984.tb08558.x; BANGA HS, 1988, BIOCHEM J, V252, P297, DOI 10.1042/bj2520297; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HUANG R, 1991, J BIOL CHEM, V266, P1652; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; MORII N, 1992, J BIOL CHEM, V267, P20921; OKADA T, 1994, J BIOL CHEM, V269, P3563; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; RITTENHOUSE SE, 1995, IN PRESS METHODS E B; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	23	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6589	6594		10.1074/jbc.270.12.6589	http://dx.doi.org/10.1074/jbc.270.12.6589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896797	hybrid			2022-12-27	WOS:A1995QQ85500027
J	ZHANG, SY; JAGENDORF, AT				ZHANG, SY; JAGENDORF, AT			SOME UNIQUE CHARACTERISTICS OF THYLAKOID UNISITE ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST COUPLING FACTOR; HEART MITOCHONDRIAL ATPASE; ESCHERICHIA-COLI F1-ATPASE; BINDING CHANGE MECHANISM; CATALYTIC SITE; FACTOR-I; F1 ATPASE; MG-2+-ATPASE ACTIVITY; ANION ACTIVATION; H+-ATPASE	Under unisite conditions (ratio of ATP to chloroplast coupling factor (CF0CF1), approximately 1:2.8), spinach thylakoid ATPase depends on prior reductive activation of CF1, just as multisite ATPase does, and is sensitive to removal of CF1, by EDTA, Faster rates in room light than in semidarkness and up to 80% inhibition by uncouplers only in room light indicate a strong effect of protonmotive force, which can be provided by room light. In addition, unisite ATPase is inhibited by azide as long as some ADP is bound to the CF1. Several differences were found between unisite and multisite ATPase, 1) The unisite activities of both membrane-bound and free enzyme were stimulated up to 3-fold by 4 mM free MgCl2 (a strong inhibitor of multisite ATPase). 2) Thylakoid unisite ATPase was inhibited by sulfite (50% inhibition at 5 mM), a powerful activator of multisite ATPase. This inhibition is attributed to a nonspecific ionic strength effect. 3) Unisite ATPase was inhibited by trypsin treatment, which increases multisite ATPase severalfold. 4) The pH profile of thylakoid unisite ATPase is somewhat different from that of mul tisite. 5) Alkylation of Cys-89 of the gamma subunit by N-ethylmaleimide did not affect the unisite activity, but inhibited multisite activity more than 90%.	CORNELL UNIV,PLANT BIOL SECT,ITHACA,NY 14853	Cornell University								ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ANDRALOJC PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P55, DOI 10.1016/0005-2728(90)90006-P; COHEN WS, 1989, PLANT PHYSIOL, V91, P1107, DOI 10.1104/pp.91.3.1107; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1020, P187, DOI 10.1016/0005-2728(90)90050-E; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; HARRIS DA, 1985, BIOCHEMISTRY-US, V24, P3876, DOI 10.1021/bi00336a010; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; HOCHMAN Y, 1976, FEBS LETT, V61, P255, DOI 10.1016/0014-5793(76)81051-4; IZAWA S, 1966, PLANT PHYSIOL, V41, P544, DOI 10.1104/pp.41.3.544; IZAWA S, 1966, PLANT PHYSIOL, V41, P533, DOI 10.1104/pp.41.3.533; JAGENDORF AT, 1982, METHODS CHLOROPLAST, P881; KASHO VN, 1984, J BIOENERG BIOMEMBR, V16, P407, DOI 10.1007/BF00743235; KHYM JX, 1975, CLIN CHEM, V21, P1245; KRAMER DM, 1990, PHOTOSYNTH RES, V26, P213, DOI 10.1007/BF00033134; LABAHN A, 1993, BIOCHIM BIOPHYS ACTA, V1141, P288, DOI 10.1016/0005-2728(93)90055-K; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P67, DOI 10.1016/S0005-2728(89)80404-9; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P78, DOI 10.1016/S0005-2728(89)80405-0; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; MILGROM YM, 1987, FEBS LETT, V222, P32, DOI 10.1016/0014-5793(87)80186-2; MINKOV IB, 1989, BIOCHIM BIOPHYS ACTA, V973, P7, DOI 10.1016/S0005-2728(89)80394-9; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1982, J BIOL CHEM, V257, P5910; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; NALIN CM, 1983, J BIOL CHEM, V258, P3376; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1984, H PLUS ATPASE ATP SY, P195; POSORSKE L, 1976, ARCH BIOCHEM BIOPHYS, V177, P276, DOI 10.1016/0003-9861(76)90437-9; QUICK WP, 1986, BIOCHIM BIOPHYS ACTA, V851, P166, DOI 10.1016/0005-2728(86)90122-2; ROVERI OA, 1985, FEBS LETT, V192, P123, DOI 10.1016/0014-5793(85)80056-9; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; VAMBUSTA.VK, 1965, J BIOL CHEM, V240, P2660; WEI JM, 1988, BIOCHIM BIOPHYS ACTA, V934, P72, DOI 10.1016/0005-2728(88)90121-1; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; ZHANG SY, 1993, PLANT PHYSIOL, V101, P127, DOI 10.1104/pp.101.1.127	44	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6607	6614		10.1074/jbc.270.12.6607	http://dx.doi.org/10.1074/jbc.270.12.6607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896800	hybrid			2022-12-27	WOS:A1995QQ85500030
J	BALL, K; PREISS, J				BALL, K; PREISS, J			ALLOSTERIC SITES OF THE LARGE SUBUNIT OF THE SPINACH LEAF ADPGLUCOSE PYROPHOSPHORYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; CDNA CLONES; STARCH; EXPRESSION; ENDOSPERM; PROTEINS; CLONING; SUCROSE; WHEAT; MAIZE	Pyridoxal-P, an analog of 3-phosphoglycerate, activates spinach leaf ADPglucose pyrophosphorylase. Reductive phosphopyridoxylation of the enzyme yields enzyme less dependent on the presence of activator for activity. Labeled pyridoxal-P is incorporated into both the 51- and 54-kDa subunits of the enzyme. The sequence of the single tryptic labeled peptide of the small subunit has been reported (Morell, M., Bloom, M., and Preiss, J. (1988) J. Biol. Chem. 263, 633-637). Three distinct labeled peptides are isolated from the tryptic digest of the large subunit. 3-Phosphoglycerate inhibits incorporation of pyridoxal-P by 80% into all three large subunit tryptic peptides, whereas inorganic phosphate, the allosteric inhibitor, inhibits incorporation into only one of those peptides. Comparison of the sequences of the labeled tryptic peptides with those of large and small subunits of the enzyme from other species indicate their positions in the primary structure of the spinach enzyme large subunit. The conservation in the amino acid sequences surrounding the lysyl residue in the small subunit and of the lysyl residue in the large subunit in higher plant and in cyanobacterial ADPglucose pyrophosphorylases, which are protected from phosphopyridoxylation by both allosteric effecters, suggests that these lysyl residues are involved in activator binding.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University								AHRENS H, 1969, ANAL BIOCHEM, V30, P413, DOI 10.1016/0003-2697(69)90135-3; AINSWORTH C, 1993, PLANT MOL BIOL, V23, P23, DOI 10.1007/BF00021416; ANDERSON JM, 1989, J BIOL CHEM, V264, P12238; BAE JM, 1990, MAYDICA, V35, P317; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BHAVE MR, 1990, PLANT CELL, V2, P581, DOI 10.1105/tpc.2.6.581; CHARNG YY, 1992, PLANT MOL BIOL, V20, P37, DOI 10.1007/BF00029147; CHARNG YY, 1994, IN PRESS J BIOL CHEM; DUJARDIN P, 1991, PLANT MOL BIOL, V16, P349, DOI 10.1007/BF00020568; FORREY AW, 1971, BIOCHIMIE, V53, P269, DOI 10.1016/S0300-9084(71)80093-7; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; IGLESIAS AA, 1993, J BIOL CHEM, V268, P1081; KAKEFUDA G, 1992, PLANT PHYSIOL, V99, P359, DOI 10.1104/pp.99.1.359; KLECZKOWSKI LA, 1993, PLANT PHYSIOL, V101, P179, DOI 10.1104/pp.101.1.179; KLECZKOWSKI LA, 1993, J BIOL CHEM, V268, P6228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORELL M, 1988, J BIOL CHEM, V263, P633; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; NEUHAUS HE, 1990, PLANTA, V182, P445, DOI [10.1007/BF02411398, 10.1007/BF00197565]; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; OKITA TW, 1992, PLANT PHYSIOL, V100, P560, DOI 10.1104/pp.100.2.560; OLIVE MR, 1989, PLANT MOL BIOL, V12, P525, DOI 10.1007/BF00036967; Preiss J, 1987, Basic Life Sci, V41, P133; PREISS J, 1990, PLANT PHYSIOL, V92, P881, DOI 10.1104/pp.92.4.881; PREISS J, 1989, BIOCATALYSIS AGR BIO, P84; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; SANWAL GG, 1968, PLANT PHYSIOL, V43, P417, DOI 10.1104/pp.43.3.417; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; STOCK A, 1966, BIOCHEM Z, V344, P353; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; VILLAND P, 1992, PLANT PHYSIOL, V100, P1617, DOI 10.1104/pp.100.3.1617	34	49	52	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24706	24711						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929144				2022-12-27	WOS:A1994PQ49000031
J	BAUKAL, AJ; HUNYADY, L; CATT, KJ; BALLA, T				BAUKAL, AJ; HUNYADY, L; CATT, KJ; BALLA, T			EVIDENCE FOR PARTICIPATION OF CALCINEURIN IN POTENTIATION OF AGONIST-STIMULATED CYCLIC-AMP FORMATION BY THE CALCIUM-MOBILIZING HORMONE, ANGIOTENSIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENAL GLOMERULOSA CELLS; PROTEIN-KINASE-C; PHORBOL ESTER TREATMENT; ADENYLATE-CYCLASE; SIGNALING PATHWAYS; EXPRESSION; RECEPTOR; CLONING; GS; METABOLISM	Angiotensin II (AII) receptors are known to interact with two distinct guanine nucleotide binding proteins, G(q/11) and G(i), in rat adrenal glomerulosa cells to activate phospholipase C and to inhibit adenylate cyclase, respectively. However, in cultured bovine glomerulosa cells AII potentiates rather than inhibits the stimulatory effect of adrenocorticotropin (ACTH) on cAMP levels. This effect of AII was partially mimicked by phorbol 12-myristate 13-acetate (PMA) and was partially inhibited by staurosporine or depletion of protein kinase C but was unaffected by pertussis toxin treatment. No potentiation was detectable in disrupted cells or in membrane preparations. In intact glomerulosa cells, treatment with cyclosporin A or FK506 completely inhibited AII- or PMA-induced potentiation of cAMP production without affecting the response to ACTH. In COS-7 cells transfected with the rat AT(1) receptor, AII caused 2-3-fold enhancement of the ACTH-induced cAMP response, an effect that was partially reproduced by PMA. These potentiating actions of AII and PMA were prevented by preincubation with cyclosporin A or FK506, and the latter effect was abolished by rapamycin. These results implicate the Ca2+- and calmodulin-dependent protein phosphatase, calcineurin, in AII-induced enhancement of adenylate cyclase activity in both adrenal glomerulosa and transfected COS-7 cells. The finding that AII enhances ACTH stimulated production of cAMP by a second messenger-mediated mechanism that involves the participation of calcineurin reveals an additional mode of cross-talk between pathways activated by Ca2+-mobilizing and cAMP-generating receptors.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Balla, Tamas/0000-0002-9077-3335				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; BALLA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P398, DOI 10.1016/0003-9861(89)90043-X; BAUKAL AJ, 1990, MOL ENDOCRINOL, V4, P1712, DOI 10.1210/mend-4-11-1712; BEGEOT M, 1988, EUR J BIOCHEM, V174, P317, DOI 10.1111/j.1432-1033.1988.tb14100.x; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BRAMI B, 1987, MOL CELL ENDOCRINOL, V50, P131, DOI 10.1016/0303-7207(87)90085-2; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CLARK AJL, 1992, MOL ENDOCRINOL, V6, P1889, DOI 10.1210/me.6.11.1889; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; GUILLEMETTE G, 1987, BIOCHEM BIOPH RES CO, V142, P15, DOI 10.1016/0006-291X(87)90445-1; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KAWABE J, 1994, J BIOL CHEM, V269, P16554; LONDOS C, 1975, J BIOL CHEM, V250, P3459; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MORIMOTO BH, 1994, J BIOL CHEM, V269, P4065; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; RAINEY WE, 1991, MOL CELL ENDOCRINOL, V81, P33, DOI 10.1016/0303-7207(91)90202-4; SALA GB, 1979, J BIOL CHEM, V254, P3861; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; WARHURST G, 1994, CELL CALCIUM, V15, P162, DOI 10.1016/0143-4160(94)90055-8; WEBER A, 1993, BIOCHEM BIOPH RES CO, V197, P172, DOI 10.1006/bbrc.1993.2456; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	28	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24546	24549						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929124				2022-12-27	WOS:A1994PQ49000008
J	CULVER, GM; CONSAUL, SA; TYCOWSKI, KT; FILIPOWICZ, W; PHIZICKY, EM				CULVER, GM; CONSAUL, SA; TYCOWSKI, KT; FILIPOWICZ, W; PHIZICKY, EM			TRANSFER-RNA SPLICING IN YEAST AND WHEAT-GERM - A CYCLIC PHOSPHODIESTERASE IMPLICATED IN THE METABOLISM OF ADP-RIBOSE 1'',2''-CYCLIC PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA LIGASE; HELA-CELL EXTRACT; 3',5'-PHOSPHODIESTER LINKAGE; INTERVENING SEQUENCES; XENOPUS-LAEVIS; ENDONUCLEASE; MECHANISM; PURIFICATION; PRECURSORS; SUBSTRATE	Adenosine diphosphate (ADP)-ribose 1'',2'' cyclic phosphate (Appr>p) is produced as a result of transfer RNA (tRNA) splicing in the yeast Saccharomyces cerevisiae and probably in other eukaryotes. Endonucleolytic cleavage and ligation result in a mature length tRNA with a 2'-phosphate at the splice junction. This 2'-phosphate is transferred to NAD to produce Appr>p. Metabolism of Appr>p requires hydrolysis of the 1'',2''-cyclic phosphate linkage. We show here that yeast has a unique cyclic phosphodiesterase that can hydrolyze Appr>p, ribose 1,2-cyclic phosphate, and ribose 1,3-cyclic phosphate to the crresponding ribose 1-phosphate derivatives. The cyclic phosphodiesterase is highly specific for Appr>p; there is 20-fold less activity on ribose 1,3-cyclic phosphate and no detectable activity on nucleoside 2',3'-cyclic phosphates. A similar cyclic phosphodiesterase is present in wheat germ. The wheat perm cyclic phosphodiesterase activity co-chromatographs with a 2',3'-cyclic nucleotide 3'-phosphodiesterase that was previously identified and purified. The purified wheat germ enzyme has a distinct preference for Appr>p and ribose cyclic phosphate compared to guanosine 2',3'-cyclic phosphate and shares other biochemical characteristics with the yeast enzyme.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	University of Rochester; Friedrich Miescher Institute for Biomedical Research					NIDCR NIH HHS [NIDR DE07202] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; DRUMMOND GI, 1962, J BIOL CHEM, V237, P3535; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; FURNEAUX H, 1983, P NATL ACAD SCI-BIOL, V80, P3933, DOI 10.1073/pnas.80.13.3933; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HELFMAN DM, 1982, J BIOL CHEM, V257, P1044; KALCKAR HM, 1947, J BIOL CHEM, V167, P477; KNAPP G, 1979, CELL, V18, P37, DOI 10.1016/0092-8674(79)90351-9; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MIRO A, 1989, FEBS LETT, V244, P123, DOI 10.1016/0014-5793(89)81176-7; NEU HC, 1964, J BIOL CHEM, V239, P2927; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; OHTSU E, 1971, METHODS ENZYMOL B, V18, P127; OLAFSON RW, 1969, CAN J BIOCHEM CELL B, V47, P961, DOI 10.1139/o69-151; OTSUKA A, 1981, MOL CELL BIOL, V1, P269, DOI 10.1128/MCB.1.3.269; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1986, J BIOL CHEM, V261, P1119; RUSHIZKY GW, 1963, J BIOL CHEM, V238, P371; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; STANGE N, 1988, EMBO J, V7, P3823, DOI 10.1002/j.1460-2075.1988.tb03267.x; STANGE N, 1992, EUR J BIOCHEM, V210, P193, DOI 10.1111/j.1432-1033.1992.tb17408.x; TYC K, 1983, EMBO J, V2, P605, DOI 10.1002/j.1460-2075.1983.tb01470.x; TYC K, 1987, J BIOL CHEM, V262, P12994; UCHIDA T, 1967, BIOCHEM TOKYO, V261, P44; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZILLMANN M, 1992, J BIOL CHEM, V267, P10289	46	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24928	24934						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929175				2022-12-27	WOS:A1994PQ49000062
J	HUNYADY, L; BAUKAL, AJ; BALLA, T; CATT, KJ				HUNYADY, L; BAUKAL, AJ; BALLA, T; CATT, KJ			INDEPENDENCE OF TYPE-I ANGIOTENSIN-II RECEPTOR ENDOCYTOSIS FROM G-PROTEIN COUPLING AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ADRENAL GLOMERULOSA CELLS; SMOOTH-MUSCLE CELLS; MEDIATED ENDOCYTOSIS; POTENTIAL MECHANISM; CARBOXYL-TERMINUS; INTERNALIZATION; SEQUESTRATION; MUTAGENESIS; GENERATION	The relationship between angiotensin II-induced activation of G proteins and receptor internalization was analyzed by transiently expressing mutant and wild type cDNAs for the rat AT(1a) receptor in COS-7 cells. Pertussis toxin-sensitive G proteins did not appear to play a role in endocytosis since the receptor showed normal internalization kinetics in pertussis toxin-treated cells. Three deletion mutants of the third cytoplasmic loop revealed that the N-terminal part of this region is important for both receptor endocytosis and intracellular signaling. Three point mutations of Asp(74), which has been implicated in signal transduction by the AT(1a) receptor, caused impaired G protein coupling and inositol phosphate responses. However, each of these mutants (D74N, D74H, and D74Y) showed markedly different internalization kinetics. The D74Y mutant showed the greatest impairment of internalization but retained the highest degree of inositol phosphate stimulation. In contrast, the D74N mutant, which showed the most impaired G protein coupling and inositol phosphate responses, had similar internalization kinetics to the wild type receptor. The combined mutant receptor containing the D74N substitution and deletion of residues 221-226 from the third cytoplasmic loop showed no G protein coupling or inositol phosphate response but was internalized about 60% as rapidly as the wild type receptor. These data demonstrate that endocytosis of the AT(1) receptor is independent of agonist-activated signal transduction and indicate that receptor internalization and activation of phospholipase C have different structural requirements.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Balla, Tamas/0000-0002-9077-3335				ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; BALLA T, 1991, J BIOL CHEM, V266, P24719; BECK KA, 1991, J BIOL CHEM, V266, P4442; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BIANCHI C, 1986, ENDOCRINOLOGY, V118, P2605, DOI 10.1210/endo-118-6-2605; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CARPENTIER JL, 1992, PROG HISTOCHEM CYTOC, V26, P77, DOI 10.1016/S0079-6336(11)80081-1; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CATT KJ, 1991, J BIOENERG BIOMEMBR, V23, P7; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CROZAT A, 1986, ENDOCRINOLOGY, V118, P2312, DOI 10.1210/endo-118-6-2312; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; HAUSDORFF WP, 1992, ASIA PAC J PHARMACOL, V7, P149; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JARD S, 1981, J BIOL CHEM, V256, P2603; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHULTZ G, 1993, ARZNEIMITTEL-FORSCH, V43-1, P229; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YAMASAKI H, 1993, MOL ENDOCRINOL, V7, P681, DOI 10.1210/me.7.5.681; YU SS, 1993, J BIOL CHEM, V268, P337; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	35	130	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24798	24804						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929158				2022-12-27	WOS:A1994PQ49000045
J	RANJAN, M; WONG, JM; SHI, YB				RANJAN, M; WONG, JM; SHI, YB			TRANSCRIPTIONAL REPRESSION OF XENOPUS TR-BETA GENE IS MEDIATED BY A THYROID-HORMONE RESPONSE ELEMENT LOCATED NEAR THE START SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC-ACID RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; X-RECEPTOR; AMPHIBIAN METAMORPHOSIS; PREINITIATION COMPLEX; GENOMIC STRUCTURE; ONCOGENE PRODUCT; MESSENGER-RNA; EXPRESSION; PROTEIN	We report here the detailed analysis of the promoter of a thyroid hormone receptor (TR) gene that is regulated by the hormone itself. The receptor gene, TR beta A, is one of the two TR beta genes in Xenopus laevis. It has two transcription start sites. The mRNAs derived from one of them are up-regulated by thyroid hormone, whereas those derived from the other are independent of the hormone. We have characterized the hormone inducible promoter using a transient transfection assay in a Xenopus tissue culture cell line (A6). Deletion and mutational analysis identifies the first amphibian thyroid hormone response element (TRE). This TRE consists of near perfect direct repeats of AGGTCA with a 4-base pair spacing similar to mammalian TREs. The TRE forms specific complexes with extracts of A6 cells that have similar sequence specificities as those found for the complexes between mammalian TRs and TREs. However, unlike TREs found in other thyroid hormone-inducible promoters, this TRE is located at the putative transcription start site and mediates transcriptional repression by unliganded TRs. The addition of thyroid hormone at physiological concentrations overcomes the repression and induces further transcriptional activation at higher concentrations. These results suggest a potential mechanism for the regulation of amphibian metamorphosis, a process that is entirely controlled by thyroid hormone.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Wong, Jiemin/0000-0002-5311-842X; Shi, Yun-Bo/0000-0002-6330-0639				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Gilbert L, 1981, METAMORPHOSIS PROBLE; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUCKABY CS, 1987, P NATL ACAD SCI USA, V84, P8380, DOI 10.1073/pnas.84.23.8380; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; JELTSCH JM, 1990, J BIOL CHEM, V265, P3967; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHNEIDER MJ, 1991, MOL ENDOCRINOL, V5, P201, DOI 10.1210/mend-5-2-201; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHI YB, 1992, J BIOL CHEM, V267, P733; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; TATA JR, 1991, DEV BIOL, V146, P72, DOI 10.1016/0012-1606(91)90447-B; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG Z, 1993, J BIOL CHEM, V268, P16270; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU YC, 1991, CELL, V67, P1251; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	56	161	162	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24699	24705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929143				2022-12-27	WOS:A1994PQ49000030
J	BEGUIN, P; BEGGAH, AT; CHIBALIN, AV; BURGENERKAIRUZ, P; JAISSER, F; MATHEWS, PM; ROSSIER, BC; COTECCHIA, S; GEERING, K				BEGUIN, P; BEGGAH, AT; CHIBALIN, AV; BURGENERKAIRUZ, P; JAISSER, F; MATHEWS, PM; ROSSIER, BC; COTECCHIA, S; GEERING, K			PHOSPHORYLATION OF THE NA,K-ATPASE ALPHA-SUBUNIT BY PROTEIN KINASE-A AND KINASE-C IN-VITRO AND IN INTACT-CELLS - IDENTIFICATION OF A NOVEL MOTIF FOR PKC-MEDIATED PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; (NA+ + K+)-ATPASE; XENOPUS OOCYTES; INTRACELLULAR-TRANSPORT; FUNCTIONAL EXPRESSION; PRIMARY SEQUENCE; DISTAL NEPHRON; NA/K-ATPASE; NA+,K+-ATPASE; KIDNEY	Na,K-ATPase is a potential target for regulatory phosphorylation by protein kinase A and C (PKA and PKC). To identify the phosphorylation sites, we have mutated the alpha(1)-subunit of Bufo marinus in a highly conservative PKA and in 20 different PKC consensus sequences. The mutants were expressed in Xenopus oocytes and their phosphorylation capacity tested in homogenates upon stimulation of PKA or PKC. While serine 943 (Ser-943) was identified as a unique target site for PKA, none of the PKC consensus serine or threonine residues are implicated in PKC phosphorylation. Controlled trypsinolysis of phosphorylated alpha-subunits of various purified enzyme preparations and of alpha/beta complexes from oocyte homogenates revealed that PKC phosphorylation was exclusively associated with the N terminus. A fusion protein containing the first 32 amino acids of the Bufo alpha-subunit was phosphorylated in vitro and serine and threonine residues (Thr-15 and Ser-16) in this region were identified by site-directed mutagenesis as the PKC phosphorylation sites. Finally, the Bufo alpha-subunit was phosphorylated by protein kinases in transfected COS-7 cells. In intact cells, PKA stimulation induced phospho rylation exclusively on Ser-943 and PKC stimulation mainly on Thr-15 and Ser-16, which are contained in a novel PKC phosphorylation motif.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND; RUSSIAN CARDIOL RES CTR, INST EXPTL CARDIOL, MOSCOW 121552, RUSSIA	University of Lausanne; National Medical Research Center of Cardiology			Jaisser, Frederic/P-4287-2017	Jaisser, Frederic/0000-0001-9051-1901; Chibalin, Alexander/0000-0002-6339-6271				BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; CHIBALIN AV, 1991, BIOL MEMBRANY, V8, P1140; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; FISONE G, 1994, J BIOL CHEM, V269, P9368; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FRYCKSTEDT J, 1992, ACTA PHYSIOL SCAND, V144, P185, DOI 10.1111/j.1748-1716.1992.tb09284.x; FUKUDA Y, 1991, PEDIATR RES, V30, P131, DOI 10.1203/00006450-199108000-00001; GEERING K, 1979, BIOCHIM BIOPHYS ACTA, V566, P157, DOI 10.1016/0005-2744(79)90258-4; GEERING K, 1982, J BIOL CHEM, V257, P338; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GEERING K, 1985, J BIOL CHEM, V260, P5154; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; HOOTMAN SR, 1987, AM J PHYSIOL, V252, pG499, DOI 10.1152/ajpgi.1987.252.4.G499; HORISBERGER JD, 1994, NAKATPASE STRUCTURE; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LATTIMER SA, 1989, AM J PHYSIOL, V256, pE264, DOI 10.1152/ajpendo.1989.256.2.E264; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; MORITA K, 1991, NEUROCHEM INT, V19, P81, DOI 10.1016/0197-0186(91)90122-T; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1993, AM J PHYSIOL, V265, pF399, DOI 10.1152/ajprenal.1993.265.3.F399; SILVA P, 1983, J MEMBRANE BIOL, V75, P105, DOI 10.1007/BF01995630; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEMOTO F, 1992, PFLUG ARCH EUR J PHY, V421, P302, DOI 10.1007/BF00374216; TUNG P, 1990, J BIOL CHEM, V265, P3936; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; ZAMOFING D, 1987, BIOCHIM BIOPHYS ACTA, V904, P381, DOI 10.1016/0005-2736(87)90388-9	45	171	172	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24437	24445						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929106				2022-12-27	WOS:A1994PQ34600091
J	KARLSSON, A; JOHANSSON, M; ERIKSSON, S				KARLSSON, A; JOHANSSON, M; ERIKSSON, S			CLONING AND EXPRESSION OF MOUSE DEOXYCYTIDINE KINASE - PURE RECOMBINANT MOUSE AND HUMAN ENZYMES SHOW DIFFERENCES IN SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKEMIA-CELLS; NUCLEOSIDE ANALOGS; MOLECULAR-CLONING; METABOLISM; CDNA; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; 2',3'-DIDEOXYCYTIDINE; PHOSPHORYLATION; PURINE; GENE	A cDNA encoding mouse deoxycytidine kinase (dCK) (EC 2.7.1.74) was cloned from a mouse T-cell lambda ZAP cDNA library. An insert of 2.8 kilobases (kb) contained the entire coding sequence of 780 base pairs. The protein coding sequence was 88% homologous at the nucleotide level with human dCK cDNA (Chottiner, E. G., Shewach, D. S., Datta, N. S., Ashcraft, E., Gribbin, D., Ginsburg, D., Fox, I. H., and Mitchell, B. S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1531-1535). At the amino acid level the homology was greater with only 16 of the 260 amino acids being different. Northern blot analyses revealed a size of 3.4 kb for mouse dCK mRNA as compared with 2.8 kb for human dCK. Part of the 3'-untranslated region was conserved between human and mouse dCK cDNA in contrast to the remainder of the 3'-sequence which was unrelated and about 500 nucleotides longer in mouse dCK cDNA. Mouse dCK cDNA showed cross-hybridization with several bands in EcoRI-digested genomic DNA from seven different mammalian species and chicken but not with yeast DNA. Both mouse and human dCK were cloned into the T5 promotor pQE30 vector system, expressed in Escherichia coli and purified to homogeneity. The kinetic constants for dCyd phosphorylation were similar for the human and mouse enzymes and also similar to what previously has been observed for dCK purified from human tissues. Mouse dCK was less efficient with regard to dAdo, dGuo, and ddCyd phosphorylation as compared with human dCK when using ATP as phosphate donor in a phosphoryl transfer assay.			KARLSSON, A (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN.		Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; CARSON DA, 1980, J IMMUNOL, V124, P8; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; HABTEYESUS A, 1991, BIOCHEM PHARMACOL, V42, P1829, DOI 10.1016/0006-2952(91)90522-7; HENGSTSCHLAGER M, 1993, FEBS LETT, V321, P237, DOI 10.1016/0014-5793(93)80116-C; Ives D H, 1978, Methods Enzymol, V51, P337; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KIERDASZUK B, 1990, BIOCHEMISTRY-US, V29, P4109, DOI 10.1021/bi00469a013; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; MITCHELL BS, 1993, ADV ENZYME REGUL, V33, P61; PLUNKETT W, 1991, PHARMACOL THERAPEUT, V49, P239, DOI 10.1016/0163-7258(91)90057-S; SARUP JC, 1987, BIOCHEMISTRY-US, V26, P590, DOI 10.1021/bi00376a034; SHEWACH DS, 1992, MOL PHARMACOL, V42, P518; SONG JJ, 1993, P NATL ACAD SCI USA, V90, P431, DOI 10.1073/pnas.90.2.431; ULLMAN B, 1988, J BIOL CHEM, V263, P12391; WHITE JC, 1987, CANCER RES, V47, P1820; WHITE JC, 1991, CANCER RES, V51, P2559	20	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24374	24378						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929097				2022-12-27	WOS:A1994PQ34600081
J	LEPLEY, RA; FITZPATRICK, FA				LEPLEY, RA; FITZPATRICK, FA			5-LIPOXYGENASE CONTAINS A FUNCTIONAL SRC HOMOLOGY-3 BINDING MOTIF THAT INTERACTS WITH THE SRC HOMOLOGY-3 DOMAIN OF GRB2 AND CYTOSKELETAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE BIOSYNTHESIS INHIBITOR; RECEPTOR TYROSINE KINASES; SH3 DOMAINS; ACTIVE 5-LIPOXYGENASE; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; TRANSLOCATION; LEUKOCYTES; CELLS; ACTIVATION	A short, proline-rich region spanning residues 566-577 in human 5-lipoxygenase is a binding site for the Src homology 3 (SH3) domain of growth factor receptor-bound protein 2 (Grb2), an ''adaptor'' protein for tyrosine kinase-mediated cell signaling. Purified 5-lipoxygenase bound to glutathione S-transferase fusion products of Grb2 and a truncated version of Grb2 containing its SH3 domain. A peptide corresponding to the proline-rich, SH3-binding motif inhibited formation of the 5-lipoxygenase.Grb2 complex in vitro. The peptide also inhibited the redistribution of 5-lipoxygenase from the cytosol to the membrane in intact or permeabilized neutrophils activated by calcium ionophore A23187. 5-Lipoxygenase did not bind to the SH3 domains of other signaling proteins, such as GTPase-activating protein and phosphilipase C gamma however, it bound to certain cytoskeletal proteins including alpha-actinin and actin. 5-Lipoxygenase contains a consensus guanine nucleotide-binding site at residues 296-299, and guanine nucleotides inhibit 5-lipoxygenase activity in vitro. Our results suggest that 5-lipoxygenase may have a previously unrecognized role in tyrosine kinase signaling, distinct from its catalysis of lipid mediator formation. Our results also clarify the molecular basis for compartmentalization and translocation of 5-lipoxygenase in myeloid cells, implying that it binds to proteins other than its activating protein.			LEPLEY, RA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BELL RL, 1992, INT J IMMUNOPHARMACO, V14, P505, DOI 10.1016/0192-0561(92)90182-K; BROCK TG, 1994, 9TH INT C PROST REL, P19; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARLESON S, 1992, MOL PHARMACOL, V41, P873; COFFEY M, 1992, J BIOL CHEM, V267, P570; DENIS D, 1991, J BIOL CHEM, V266, P5072; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEBART MC, 1994, J BIOL CHEM, V269, P4279; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OCHI K, 1983, J BIOL CHEM, V258, P5754; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEPPELENBOSCH MP, 1993, CELL, V74, P566; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SIERKE SL, 1993, BIOCHEMISTRY-US, V32, P10102, DOI 10.1021/bi00089a028; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WISEMAN JS, 1989, BIOCHEMISTRY-US, V28, P2106, DOI 10.1021/bi00431a021; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	38	108	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24163	24168						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929073				2022-12-27	WOS:A1994PQ34600051
J	YAMASHIRO, DJ; ADACHI, M; KONITZER, P; SURREY, S; ADACHI, K				YAMASHIRO, DJ; ADACHI, M; KONITZER, P; SURREY, S; ADACHI, K			POLYMERIZATION AND INSTABILITY OF A RECOMBINANT HEMOGLOBIN CONTAINING VALINE BETA-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; HB-S; SOLUBILITY; STABILITY; HYDROPHOBICITY; YEAST; KINETICS; GELATION; DISEASE	A recombinant hemoglobin containing Val(beta 7) (Hb beta E7V) was engineered and expressed in yeast to evaluate amino acid specificity of the Glu(beta 6) --> Val mutation (Hb beta E6V) in promoting polymer formation of deoxyhemoglobin. The purified CO Hb beta E7V migrated as a single band on electrophoresis with a slightly decreased positive charge compared with CO Hb S. The oxygen affinity of Hb beta E7V was slightly higher than Hb S, while the absorption spectrum of the mutant was similar to Hb S. Critical concentrations for polymerization in 1.8 M phosphate of the deoxy forms of Hb beta E7V and Hb A were 15- and 25-fold, respectively, higher than Hb S. Oversaturated deoxy Hb beta E7V polymerized without a delay time prior to polymerization like deoxy Hb beta E6F and Hb beta E6W. These results demonstrate that Val(beta 6) in Hb S is critical for rapid polymerization of deoxyhemoglobin. The oxy form of Hb beta E7V was approximately 2-3-fold more unstable to heat and mechanical agitation than oxy Hb S, suggesting that instability and polymerization of hemoglobin are distinct properties,	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DIV HEMATOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Childrens Hospital of Philadelphia			Adachi, Megumi/M-7746-2017	Adachi, Megumi/0000-0003-3404-6640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632, R01HL032908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32908, P60 HL-38632] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, HEMOGLOBIN, V17, P329, DOI 10.3109/03630269308997486; ADACHI K, 1984, BIOCHIM BIOPHYS ACTA, V790, P132, DOI 10.1016/0167-4838(84)90216-4; ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1979, J BIOL CHEM, V254, P2273; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1987, J BIOL CHEM, V262, P12920; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; Antonini E., 1971, FRONT BIOL, V21, P19; ASAKURA T, 1974, P NATL ACAD SCI USA, V71, P1594, DOI 10.1073/pnas.71.5.1594; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BLACKWELL RQ, 1970, BIOCHIM BIOPHYS ACTA, V214, P396; BUNN HF, 1966, HEMOGLOBIN MOL GENET; CUO D, 1986, J CHROMATOGR, V359, P499; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; HEBBEL RP, 1991, BLOOD, V77, P214; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RHODA MD, 1986, HEMOGLOBIN, V10, P21, DOI 10.3109/03630268609072468; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; ROTH EF, 1977, J LAB CLIN MED, V90, P837; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57	26	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23996	23999						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929049				2022-12-27	WOS:A1994PQ34600025
J	KUZNETSOV, G; CHEN, LB; NIGAM, SK				KUZNETSOV, G; CHEN, LB; NIGAM, SK			SEVERAL ENDOPLASMIC-RETICULUM STRESS PROTEINS, INCLUDING ERP72, INTERACT WITH THYROGLOBULIN DURING ITS MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE ISOMERASE; BINDING-PROTEINS; CELLS; RAT; BIP; CALCIUM; AGGREGATION; EXPRESSION; GLUCOSE; OCCURS	We have previously demonstrated that several endoplasmic reticulum (ER) proteins, including BiP, ERp72, grp94, and protein disulfide isomerase, bind to a denatured thyroglobulin (Tg) affinity column and can be specifically eluted by ATP (Nigam, S. K., Goldberg, A. L., Ho, S., Rohde, M. F., Bush, K. T., and Sherman, M. Y. (1994) J. Biol. Chem. 269, 1744-1749). Using chemical cross linking, we now demonstrate that BiP, ERp72, and grp94 associate with Tg in two types of cultured thyroid cells, FRTL-5 and PCCl3. Whereas BiP could be coimmunoprecipitated with anti-Tg antibodies in the absence of crosslinking, only trace amounts of ERp72 and grp94 were coimmunoprecipitated. Likewise, in both cell types, anti BiP antibodies were able to coimmunoprecipitate Tg in the absence of cross-linking, though ERp72 and grp94 were only minimally present. Coprecipitation of BiP and Tg was abolished when ATP and Mg2+ were added to cell lysates. In contrast, after cross-linking, there was a large increase in the amount of ERp72 and grp94 that coimmunoprecipitated with anti-Tg antibodies, although there was only a slight increase in BiP. Similarly, in cross-linked lysates, grp94 and ERp72 were also coimmunoprecipitated with anti-BiP antibodies. An apparently novel 200-kDa protein was also consistently immunoprecipitated by anti-BiP antibodies in both cell types. In addition, anti-ERp72 antibodies coimmunoprecipitated Tg, BiP, and grp94 only after cross-linking. Analysis of uncross-linked and cross-linked samples by sucrose density gradient centrifugation confirmed that Tg, BiP, grp94, and ERp72 are present together in high molecular weight complexes only after treatment of cells with cross linking reagent. These results suggest that ERp72, as well as BiP and grp94, function as molecular chaperones in the maturation of Tg, potentially as part of a macromolecular complex.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute					NIGMS NIH HHS [GM38318-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038318] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROLLMAN EF, 1993, J BIOL CHEM, V268, P3604; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; KIM PS, 1993, J BIOL CHEM, V268, P4873; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MELNICK J, 1992, J BIOL CHEM, V267, P21303; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; URADE R, 1993, J BIOL CHEM, V268, P22004; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; WAGAR G, 1974, ACTA ENDOCRINOL-COP, V77, P64, DOI 10.1530/acta.0.0770064	28	95	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22990	22995						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916014				2022-12-27	WOS:A1994PQ16400016
J	CALDENHOVEN, E; COFFER, P; YUAN, JP; VANDESTOLPE, A; HORN, F; KRUIJER, W; VANDERSAAG, PT				CALDENHOVEN, E; COFFER, P; YUAN, JP; VANDESTOLPE, A; HORN, F; KRUIJER, W; VANDERSAAG, PT			STIMULATION OF THE HUMAN INTERCELLULAR-ADHESION MOLECULE-1 PROMOTER BY INTERLEUKIN-6 AND INTERFERON-GAMMA INVOLVES BINDING OF DISTINCT FACTORS TO A PALINDROMIC RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-2-MACROGLOBULIN GENE; SIGNAL-TRANSDUCTION PATHWAY; LEUKEMIA INHIBITORY FACTOR; HUMAN ENDOTHELIAL-CELLS; REGULATORY FACTOR-I; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATOR; NUCLEAR FACTOR; IFN-GAMMA; MYELOID DIFFERENTIATION	Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein that promotes adhesion in immunological and inflammatory reactions. ICAM-1 is expressed on cells of many lineages and is induced by interleukin-6 (IL-6) and interferon-gamma (IFN-gamma). Functional analysis of ICAM-1 promoter-luciferase constructs in HepG2 cells enabled us to identify a region between -110 and -37 mediating IL-6 and IFN-gamma responsiveness and containing a palindromic IL-6/IFN-gamma response element (pIRE). Site-directed mutagenesis of key nucleotides in the ICAM-1 pIRE abolished the effect of both IL-6 and IFN-gamma stimulation, while this pIRE element was sufficient to confer IL-6 and IFN-gamma responsiveness to a heterologous promoter. We further show by gel retardation analysis that distinct nuclear factors induced by both IL-6 or IFN-gamma specifically bind to this pIRE. Furthermore, treatment with IL-6 results in the formation of multiple complexes while IFN-gamma induces a single binding complex, both in HepG2 and monocytic U937 cells. Differentiation of U937 cells by exposure to 12-O-tetradecanoyl phorbol-13-acetate abolishes response to IL-6 but not IFN-gamma. Supershift data utilizing the ICAM-1 pIRE revealed that IFN-gamma and IL-6 both induce a factor antigenically related to IFN-gamma activation factor. me further provide data suggesting that IL-6 additionally activates an ICAM-1 pIRE binding factor related to the previously described acute-phase response factor in disparate cell types. We therefore conclude that the activation of these related nuclear factors by IL-6 and IFN-gamma is important in the regulation of ICAM-1 gene expression.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; INST BIOCHEM,D-52057 AACHEN,GERMANY; UNIV UTRECHT HOSP,DEPT PULM DIS,UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center			Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009					ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ADAMS DO, 1989, IMMUNOL TODAY, V10, P33, DOI 10.1016/0167-5699(89)90298-3; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AMALDI I, 1989, J IMMUNOL, V142, P999; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRECHNER T, 1991, MOL BIOL MED, V8, P267; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; Demaeyer E., 1988, INTERFERONS OTHER RE; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUITS AJ, 1992, J LEUKOCYTE BIOL, V51, P237, DOI 10.1002/jlb.51.3.237; DUSTIN ML, 1986, J IMMUNOL, V137, P245; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; KRESS C, 1990, DEVELOPMENT, V109, P775; KVALE D, 1993, J HEPATOL, V17, P347, DOI 10.1016/S0168-8278(05)80216-8; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MOST J, 1992, J IMMUNOL, V148, P1635; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MYERS CL, 1992, AM J PHYSIOL, V263, pC767, DOI 10.1152/ajpcell.1992.263.4.C767; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	70	121	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					21146	21154						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7914891				2022-12-27	WOS:A1994PC40300052
J	BIBI, E; BEJA, O				BIBI, E; BEJA, O			MEMBRANE TOPOLOGY OF MULTIDRUG-RESISTANCE PROTEIN EXPRESSED IN ESCHERICHIA-COLI - N-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; ALKALINE-PHOSPHATASE; GENE FUSIONS; BACTERIAL TRANSPORT; STRUCTURAL MODEL; EXPORT SIGNALS; MOUSE MDR1; SEQUENCE; CDNA; ORIENTATION	Expression of eukaryotic polytopic membrane proteins in Escherichia coli could provide an invaluable system for structure-function studies. Recently, the functional expression of a mouse multidrug resistance protein (Mdr1) in E. coli was described (Bibi, E., Gros, P., and Kaback, H. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9209-9213). In the present study, the phoA gene fusion approach has been utilized to determine the membrane topology of the N-terminal domain of Mdr. The results support the idea that the N-terminal half of Mdr contains six transmembrane helices (TMs). However, our observations suggest that the previously proposed TM4 (amino acid residues Thr(214)-Ala(232)) is located at the periplasmic face of the membrane. Alternatively, we propose that another stretch of amino acid residues (Leu(243) (out) to Ile(260) (in)) traverses the membrane. This assignment is indicated also by the following observations: 1) deletion of a segment containing the originally predicted TM4 (Delta T214-K241) does not reverse the orientation of the Mdr-alkaline phosphatase hybrid that is located in the following cytoplasmic loop; 2) a ''sandwich'' chimera, in which alkaline phosphatase is inserted in-frame between amino acid residues Leu(226) and Ser(227), exhibits high alkaline phosphatase activity. The existence of an externally exposed hydrophobic domain in Mdr may have special structural and functional implications, and these may also be relevant to other members of the ABC superfamily.			BIBI, E (corresponding author), WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL.			Bibi, Eitan/0000-0003-3700-2707				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHURR E, 1989, CANCER RES, V49, P2729; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YUN CH, 1991, J BIOL CHEM, V266, P10967; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	36	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19910	19915						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914193				2022-12-27	WOS:A1994PA12600040
J	FISHER, MT				FISHER, MT			THE EFFECT OF GROES ON THE GROEL-DEPENDENT ASSEMBLY OF DODECAMERIC GLUTAMINE-SYNTHETASE IN THE PRESENCE OF ATP AND ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; TIME-RESOLVED FLUORESCENCE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; PROTEIN; STATE; INTERMEDIATE; COMPLEXES; PLANT; MODEL	The yields of active dodecameric glutamine synthetase (GS) are significantly increased when in vitro folding is initiated in the presence of the Escherichia coli groE chaperonins and ATP (37 degrees C). To observe the effects of chaperonins and ATP on GS assembly, the GS assembly intermediates were separated by nondenaturing gel electrophoresis, visualized by Western analysis, and studied as a function of time. The form of GS that was initially released from groEL is monomeric, After the monomers formed dimers, active GS oligomers were assembled by the association of assembly competent dimers with higher order even-numbered oligomers until the dodecamer was formed, When ATP was added to the groEL GS complex (no groES), a groEL GS complex remained visible for up to 30 min after the renaturation was initiated. This slow disappearance of the groEL.GS complex is consistent with observed lags in both the GS activity regain profile and the assembly-dependent increase in GS tryptophan fluorescence. When groES was present, the addition of ATP resulted in the disappearance of observable complex at early sample times (<2 min). Concomitantly, the rates of the regain of GS activity and the GS-dependent increase in tryptophan fluorescence intensity showed substantial accelerations. These results indicate that groES facilitates GS assembly from groEL by inducing the rapid release of GS from groEL, which in turn increases the concentration of assembly competent GS monomers. In addition, groES can initiate renaturation of GS from the groEL.GS arrested complex in the presence of ADP. When chaperonin-dependent GS renaturation was initiated with ATP or ADP (greater than or equal to 2 mM), the rates were identical. Since ATP hydrolysis is not absolutely required, the combined binding energies of groES and ATP (or ADP) appear to be sufficient to weaken the binding affinity of groEL for GS subunits and facilitate the release and refolding of assembly competent GS monomers from groEL.			FISHER, MT (corresponding author), UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66160 USA.				NCRR NIH HHS [S07RR05373] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005373] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; ATKINS WM, 1991, BIOCHEMISTRY-US, V30, P3406, DOI 10.1021/bi00228a008; ATKINS WM, 1992, PROTEIN SCI, V1, P342; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARRILLO N, 1992, J BIOL CHEM, V267, P15537; DEMCHENKO AP, 1986, ULTRAVIOLET SPECTROS, P122; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1993, J BIOL CHEM, V268, P13777; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FONG GH, 1992, BIOCHEMISTRY-US, V31, P5661, DOI 10.1021/bi00139a033; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HASCHEMEYER RH, 1982, J BIOL CHEM, V257, P7252; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOHMAN RJ, 1978, BIOCHEM BIOPH RES CO, V82, P865, DOI 10.1016/0006-291X(78)90863-X; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hurn B A, 1980, Methods Enzymol, V70, P104; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; KUBO T, 1993, J BIOL CHEM, V268, P19346; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P23; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MATTINGLY JR, 1993, PROT SCI S1, V2, P139; MAURIZI MR, 1982, J BIOL CHEM, V257, P7246; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; RAGONE R, 1984, BIOCHEMISTRY-US, V26, P2130; ROY H, 1992, PROTEIN SCI, V1, P925, DOI 10.1002/pro.5560010711; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SATHER S, 1991, COLD SPRING HARB SYM, V19, P84; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; Shapiro B., 1970, METHOD ENZYMOL, V17A, P910, DOI 10.1016/0076-6879(71)17305-3; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; TIMMONS RB, 1974, BIOCHEMISTRY-US, V13, P4479, DOI 10.1021/bi00719a002; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	56	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13629	13636						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909810				2022-12-27	WOS:A1994NK18400083
J	MELLOR, H; FLOWERS, KM; KIMBALL, SR; JEFFERSON, LS				MELLOR, H; FLOWERS, KM; KIMBALL, SR; JEFFERSON, LS			CLONING AND CHARACTERIZATION OF CDNA-ENCODING RAT HEMIN-SENSITIVE INITIATION FACTOR-2-ALPHA (EIF-2-ALPHA) KINASE - EVIDENCE FOR MULTITISSUE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GCN2 PROTEIN-KINASE; MOLECULAR-CLONING; P68 KINASE; FACTOR-II; INTERFERON; DOMAINS; RETICULOCYTES; ANTIBODIES; MECHANISM; HOMOLOGY	Reticulocytes contain an eukaryotic initiation factor-2 alpha (eIF-2 alpha) kinase that is negatively regulated by hemin. This protein kinase, which has been termed heme-regulated inhibitor and heme-controlled repressor (HCR), has a strong inhibitory effect on the initiation of protein synthesis and plays:an important role in translational control in these cells. Previous evidence has suggested that HCR may be an erythroid-specific enzyme. As reported herein, we have cloned and characterized the cDNA encoding an eIF-2 alpha kinase from rat brain. The predicted amino acid sequence of the kinase from rat brain shows 82% homology to rabbit reticulocyte HCR with the greatest variation concentrated in a central region of approximately 135 amino acids located between protein kinase subdomains IV and VI. We have expressed the rat brain cDNA in Escherichia coli and have demonstrated that the recombinant enzyme is a hemin-sensitive eIF-2 alpha kinase. We have also shown that mRNA recognized by the rat brain cDNA is expressed in a wide range of non-erythroid rat tissues at a lower but significant level compared with reticulocytes. These findings raise the possibility of additional, uncharacterized roles for HCR in non erythroid cells.	PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Mellor, Harry/0000-0003-3894-0623	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658, R01DK013499, T32DK007684, R37DK013499] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15658, DK13499, DK07684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CLEMENS MJ, 1974, P NATL ACAD SCI USA, V71, P2946, DOI 10.1073/pnas.71.8.2946; DUNCANR, 1984, J BIOL CHEM, V259, P11882; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSHEY JWB, 1993, CELL BIOL BIOTECHNOL, P93; ICELY PL, 1991, J BIOL CHEM, V266, P16073; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MELLOR H, 1993, EUR J BIOCHEM, V211, P529, DOI 10.1111/j.1432-1033.1993.tb17579.x; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PORZIG H, 1991, J CELL PHYSIOL, V147, P439, DOI 10.1002/jcp.1041470309; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; SATOH H, 1987, BIOCHEM BIOPH RES CO, V146, P618, DOI 10.1016/0006-291X(87)90573-0; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579	24	61	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10201	10204						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908290				2022-12-27	WOS:A1994NF01700005
J	KOLLMAR, R; SUKOW, KA; SPONAGLE, SK; FARNHAM, PJ				KOLLMAR, R; SUKOW, KA; SPONAGLE, SK; FARNHAM, PJ			START SITE SELECTION AT THE TATA-LESS CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING) ASPARTATE CARBAMOYLTRANSFERASE DIHYDROOROTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PROXIMAL PROMOTER; SP1 ACTIVATION; CAD GENE; SEQUENCES; IDENTIFICATION; ORGANIZATION; INITIATION; COMPLEXES	Transcription of the carbamoyl-phosphate synthase (glutamine-hydrolyzing)/aspartate carbamoyltransferase/dihydroorotase (CAD) gene from the Syrian hamster, Mesocricetus auratus, starts at a single major site. We characterized the cis-acting elements that position RNA polymerase II at the correct start site in the CAD promoter. Sequence alignment showed that the CAD promoter lacks a TATA box, but contains a consensus initiator. Mutational analysis of the CAD promoter demonstrated that the sequences between -81 and +26 were sufficient for accurate and efficient transcription in vitro and in vivo; binding sites for the transcription factor Spl around -70 and -49 were necessary for transcriptional activity. The binding site at -49 directed initiation about 50 base pairs downstream. A ubiquitous activator protein, Honk, bound to the CAD promoter between -30 and -12, but did not participate in start site selection. The sequences around +1, which contain the consensus initiator, contributed to promoter activity; however, the presence of a consensus initiator in this region was neither necessary nor sufficient for transcription. We concluded from these results that the Spl binding site at -49 substituted for the missing TATA box and played a major role in start site selection at the CAD promoter.	UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,PROGRAM CELL & MOLEC BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P30CA007175, P01CA023076] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA23076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIN K, 1991, J BIOL CHEM, V266, P3791; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; FARNHAM PJ, 1990, CELL GROWTH DIFFER, V1, P179; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; FREUND JN, 1986, J MOL BIOL, V189, P25, DOI 10.1016/0022-2836(86)90378-5; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GILMAN M, 1987, CURRENT PROTOCOLS MO; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; KOLLMAR R, 1992, J BIOL CHEM, V267, P385; KOLLMAR RJE, 1993, THESIS U WISCONSIN M; LEE KAW, 1992, J CELL SCI, V103, P9; LESCURE A, 1992, NUCLEIC ACIDS RES, V20, P1573, DOI 10.1093/nar/20.7.1573; MARK WH, 1981, THESIS U WISCONSIN M; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIELAND S, 1990, NUCLEIC ACIDS RES, V18, P5113, DOI 10.1093/nar/18.17.5113	27	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2252	2257						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7905000				2022-12-27	WOS:A1994MR98800104
J	KORNBERG, TB				KORNBERG, TB			UNDERSTANDING THE HOMEODOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-BINDING SPECIFICITY; SINGLE AMINO-ACID; HOMEO DOMAIN; TRANSACTIVATOR VP16; RECOGNITION HELIX; CRYSTAL-STRUCTURE; I-POU; DROSOPHILA; PROTEIN; COMPLEX				KORNBERG, TB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143, USA.							AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; CASANOVA J, 1988, EMBO J, V7, P1097, DOI 10.1002/j.1460-2075.1988.tb02918.x; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRISTIE TM, 1990, GENE DEV, V4, P383; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; ROWE A, 1988, EMBO J, V7, P1107, DOI 10.1002/j.1460-2075.1988.tb02919.x; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZENG WL, 1993, DEVELOPMENT, V118, P339	40	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26813	26816						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903298				2022-12-27	WOS:A1993MM26200001
J	MONFARDINI, C; KIEBEREMMONS, T; VONFELDT, JM; OMALLEY, B; ROSENBAUM, H; GODILLOT, AP; KAUSHANSKY, K; BROWN, CB; VOET, D; MCCALLUS, DE; WEINER, DB; WILLIAMS, WV				MONFARDINI, C; KIEBEREMMONS, T; VONFELDT, JM; OMALLEY, B; ROSENBAUM, H; GODILLOT, AP; KAUSHANSKY, K; BROWN, CB; VOET, D; MCCALLUS, DE; WEINER, DB; WILLIAMS, WV			RECOMBINANT ANTIBODIES IN BIOACTIVE PEPTIDE DESIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-SURFACE RECEPTOR; GM-CSF RECEPTOR; MONOCLONAL-ANTIBODIES; COMBINATORIAL LIBRARY; AFFINITY BINDING; GRANULOCYTE; IDENTIFICATION; REGIONS	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is important in many immune and inflammatory processes. GM-CSF binds to specific cellular receptors which belong to a recently described supergene family, These receptors are potential targets for pharmacologic design, and such design depends on a molecular understanding of ligand-receptor interactions, One approach to dissecting out critical intermolecular interactions is to develop analogs of specific interaction sites of potential importance, Monoclonal antibodies have been employed for these purposes in prior studies, Here we present application of recombinant antibody technology to the development of analogs of a site on GM-CSF bound by a neutralizing anti-GM-CSF monoclonal antibody, Polyclonal antisera with high titer neutralizing activity against human GM-CSF were developed in BALB/c mice, purified immunoglobulins were prepared and used to immunize syngeneic mice, Anti-anti-GM-CSF was developed which demonstrated biological antagonist activity against GM-CSF-dependent cellular proliferation, RNA was extracted from spleen cells of mice with biologically active anti-anti-GM-CSF, cDNA synthesized, and polymerase chain reaction performed with primers specific for murine kappa light chain V regions, Polymerase chain reaction products were cloned into the pDAB(L) vector and an expression library developed, This was screened with anti GM-CSF neutralizing mAb 126.213, and several binding clones isolated, One clone (23.2) which inhibited 126.213 binding to GM CSF was sequenced revealing a murine kappa light chain of subgroup III, Comparison of the 23.2 sequence with the human GM-CSF sequence revealed only weak sequence similarity of specific complementarity determining regions (CDRs) with human GM-CSF, Structural analysis revealed potential mimicry of specific amino acids in the CDR I, CDR II and FR3 regions of 23.2 with residues on the B and C helices of GM-CSF. A synthetic peptide analog of the CDR I was bound by 126.213, specifically antagonized GM-CSF binding to cells and blocked GM-CSF bioactivity, These studies indicate the feasibility of using recombinant antibody libraries as sources of interaction site analogs.	UNIV PENN,SCH MED,INST BIOTECHNOL & ADV MOLEC MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; UNIV WASHINGTON,DIV HEMATOL,SEATTLE,WA 98195; UNIV CALGARY,HLTH SCI CTR,CALGARY,AB T2N 4N1,CANADA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Washington; University of Washington Seattle; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	MONFARDINI, C (corresponding author), UNIV PENN,SCH MED,DEPT MED,DIV RHEUMATOL,PHILADELPHIA,PA 19104, USA.		Weiner, David B/H-8579-2014		NCI NIH HHS [R01 CA 31615] Funding Source: Medline; NIGMS NIH HHS [GM-46400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046400] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; Ausubel FM, 1988, MOL REPROD DEV; BALAJI VN, 1992, BIOL ACTIVE PEPTIDES, V1, P35; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P10164, DOI 10.1073/pnas.89.21.10164; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOROFSKY MA, 1992, IMMUNOL RES, V11, P154, DOI 10.1007/BF02918620; BROWN CB, 1990, J IMMUNOL, V144, P2184; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CARDWELL MC, 1988, J CELL BIOL, V107, P1551, DOI 10.1083/jcb.107.4.1551; CHIBA S, 1990, LEUKEMIA, V4, P29; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOUGH NM, 1987, EUR J BIOCHEM, V169, P353, DOI 10.1111/j.1432-1033.1987.tb13619.x; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GREENFIELD RS, 1993, J IMMUNOL, V150, P5241; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kabat EA, 1991, SEQUENCES PROTEINS I; KANAKURA Y, 1991, BLOOD, V77, P1033; KARP SL, 1983, J IMMUNOL, V150, P867; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KIEBEREMMONS T, 1994, LUPUS, V3, P379, DOI 10.1177/096120339400300504; KIEBEREMMONS T, 1992, BIOL ACTIVE PEPTIDES, V1, P3; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; LOHMAN KL, 1993, MOL IMMUNOL, V30, P1295, DOI 10.1016/0161-5890(93)90046-E; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MCCALLUS DE, 1992, VIRAL IMMUNOL, V5, P163, DOI 10.1089/vim.1992.5.163; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; Nice E, 1990, GROWTH FACTORS, V3, P159, DOI 10.3109/08977199009108278; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; PARK LS, 1986, J BIOL CHEM, V261, P4177; PRIDE MW, 1992, P NATL ACAD SCI USA, V89, P1190; ROMANO C, 1989, J NEUROCHEM, V53, P362, DOI 10.1111/j.1471-4159.1989.tb07343.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SEELIG G, 1990, J CELL BIOCHEM, V14, P246; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; TAUB R, 1989, J BIOL CHEM, V264, P259; TAUB R, 1992, J BIOL CHEM, V267, P5977; UGEN KE, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P215; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; VONFELDT JM, 1992, BIOL ACTIVE PEPTIDES, V1, P55; WANG H, 1932, BIOTECHNIQUES, V13, P527; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WEIGERT M, 1978, NATURE, V276, P785, DOI 10.1038/276785a0; WEINER D, 1989, NATURE, V389, P230; WEINER DB, 1989, ONCOGENE, V4, P1175; WILLIAMS WV, 1988, P NATL ACAD SCI USA, V85, P6488, DOI 10.1073/pnas.85.17.6488; WILLIAMS WV, 1991, J BIOL CHEM, V266, P9241; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1994, ARTHRITIS RHEUM, V37, P1468, DOI 10.1002/art.1780371010; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; WILLIAMS WV, 1993, TRANSGENE, V1, P113; YOKOTA T, 1993, LEUKEMIA, V7, pS102	65	19	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6628	6638		10.1074/jbc.270.12.6628	http://dx.doi.org/10.1074/jbc.270.12.6628			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896802	hybrid			2022-12-27	WOS:A1995QQ85500033
J	ALAM, J				ALAM, J			MULTIPLE ELEMENTS WITHIN THE 5' DISTAL ENHANCER OF THE MOUSE HEME OXYGENASE-1 GENE MEDIATE INDUCTION BY HEAVY-METALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOMA-CELLS; TRANSCRIPTION FACTOR; BINDING-PROTEIN; C/EBP FAMILY; CHLORAMPHENICOL ACETYLTRANSFERASE; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; JUN GENE; C-JUN; EXPRESSION	A 268-base pair 5' distal fragment, SX2, which mediates basal level and inducer dependent activation of the mouse heme oxygenase-1 gene, contains two activator protein-1 (AP-1) binding sites (Alam, J., and Zhining, D. (1992) J. Biol. Chem. 267, 21894-21900). Mutation of both AP-1 binding elements diminishes (by 50-70%), but does not abolish, the enhancer activity of SX2 in transient expression assays, suggesting that other sequences contribute to enhancer function. Directly upstream of the AP-1 binding sites are two copies of a sequence motif, TGAGGAAAT, which resemble elements found in cellular and viral genes that are known to interact with the CCAAT/enhancer binding protein (C/EBP) family of transcription factors. These SX2 sequences bind specifically to liver enriched, heat-stable nuclear proteins and confer C/EBP alpha-dependent transactivation of the heterologous chloramphenicol acetyltransferase (CAT) gene. Site-directed mutagenesis of these 9-base pair elements abolishes protein binding and transactivation, establishing these sequences as functional C/EBP binding sites. Stably transfected SX2/CAT fusion genes are induced between 37- and 44-fold in mouse hepatoma, Hepa, cells and between 52- and 111-fold in mouse fibroblast L929 cells in response to CdCl2 treatment. Subfragments of SX2 lacking the AP-1 binding elements do not mediate cadmium dependent activation of the CAT gene, whereas subfragments containing the AP-1 binding elements, but lacking the C/EBP binding sites, exhibit only partial transcriptional activity. Site-directed mutagenesis of one or more of the C/EBP and AP-1 binding sites indicates that each of these elements is required for optimal activity of the SX2 enhancer fragment. The AP-1 binding elements, however, appear to be more important for induction as constructs containing multiple copies of either of the AP-1 binding elements, but not the C/EBP binding sequences, are readily activated by CdCl2. Treatment of Hepa cells with cadmium or heme does not alter the nuclear concentration of AP-1 or C/EBP binding activity.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70121 USA	Louisiana State University System	ALAM, J (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN, DEPT MOLEC GENET, 1516 JEFFERSON HIGHWAY, NEW ORLEANS, LA 70121 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43135] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 1991, BIOTECHNIQUES, V10, P422; APPLEGATE LA, 1991, CANCER RES, V51, P974; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DAILEY HA, 1987, ANN NY ACAD SCI, V514, P81, DOI 10.1111/j.1749-6632.1987.tb48763.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LAVROVSKY Y, 1993, BIOCHEM BIOPH RES CO, V196, P336, DOI 10.1006/bbrc.1993.2253; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Maines M.D., 1992, HEME OXYGENASE CLIN; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; MAINES MD, 1976, BIOCHEM J, V154, P125, DOI 10.1042/bj1540125; MITANI K, 1990, BIOCHEM BIOPH RES CO, V166, P1429, DOI 10.1016/0006-291X(90)91026-O; MITANI K, 1993, BIOCHEM J, V290, P819, DOI 10.1042/bj2900819; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NATSUKA S, 1992, BLOOD, V79, P460; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; PEI J, 1990, J BIOL CHEM, V265, P14061; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918	51	115	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25049	25056						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929191				2022-12-27	WOS:A1994PQ49000079
J	OU, WJ; KUMAMOTO, T; MIHARA, K; KITADA, S; NIIDOME, T; ITO, A; OMURA, T				OU, WJ; KUMAMOTO, T; MIHARA, K; KITADA, S; NIIDOME, T; ITO, A; OMURA, T			STRUCTURAL REQUIREMENT FOR RECOGNITION OF THE PRECURSOR PROTEINS BY THE MITOCHONDRIAL PROCESSING PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-ORNITHINE TRANSCARBAMYLASE; ADRENAL-CORTEX MITOCHONDRIA; RAT-LIVER; CYTOCHROME-P-450(SCC) PRECURSOR; PROTEOLYTIC CLEAVAGE; PARTIAL-PURIFICATION; EXTENSION PEPTIDES; YEAST MITOCHONDRIA; ENZYME PRECURSORS; LEADER PEPTIDE	We examined the structural characteristics of the extension peptides responsible for the recognition by the mitochondrial processing peptidase by using pre-adrenodoxin, which has a long extension peptide of 58 amino acid residues, as the substrate. The deletion of various parts of the extension peptide of pre-adrenodoxin indicated that more than 40 amino acid residues and the presence of basic amino acid residues in the distal portion (20-40 amino acid residues upstream of the cleavage site) were necessary for the recognition of the precursor by the peptidase. The processing of pre-adrenodoxin was strongly inhibited by the synthetic peptide corresponding to the middle portion of the extension peptide, whereas the peptide corresponding to the amino-terminal portion exhibited weak inhibition of the processing. The replacement of arginine residues in the middle portion of the extension peptide with neutral amino acids resulted in a great decrease in the processing. We conclude that basic amino acids at a position distal to the cleavage site are necessary for the recognition of the precursor proteins by the processing peptidase and that basic amino acids required for the mitochondrial targeting and those for the recognition by the peptidase are separately located in the extension peptide of pre adrenodoxin.	KYUSHU UNIV,FAC SCI,DEPT CHEM,FUKUOKA 812,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University			Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708				AOYAGI H, 1987, J BIOCHEM-TOKYO, V102, P813, DOI 10.1093/oxfordjournals.jbchem.a122120; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; FURUYA S, 1987, J BIOCHEM, V102, P821, DOI 10.1093/oxfordjournals.jbchem.a122121; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HURT EC, 1987, J BIOL CHEM, V262, P1420; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; ITO A, 1985, J BIOCHEM-TOKYO, V98, P1571, DOI 10.1093/oxfordjournals.jbchem.a135426; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1992, EMBO J, V11, P1803; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KRAUS JP, 1988, P NATL ACAD SCI USA, V85, P8905, DOI 10.1073/pnas.85.23.8905; KUMAMOTO T, 1989, J BIOCHEM-TOKYO, V105, P72, DOI 10.1093/oxfordjournals.jbchem.a122622; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCADA PC, 1982, J BIOL CHEM, V257, P3177; MIURA S, 1982, EUR J BIOCHEM, V122, P641; NEUPERT W, 1981, TRENDS BIOCHEM SCI, V6, P1, DOI 10.1016/0968-0004(81)90002-5; OGISHIMA T, 1985, J BIOCHEM, V98, P781, DOI 10.1093/oxfordjournals.jbchem.a135335; OU W, 1986, J BIOCHEM-TOKYO, V100, P1287, DOI 10.1093/oxfordjournals.jbchem.a121835; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5335; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	42	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24673	24678						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929139				2022-12-27	WOS:A1994PQ49000026
J	BOCHKAREVA, ES; GIRSHOVICH, AS				BOCHKAREVA, ES; GIRSHOVICH, AS			ATP INDUCES NONIDENTITY OF 2 RINGS IN CHAPERONIN GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; HYDROLYSIS; COOPERATIVITY; PURIFICATION; MUTATION	For its function, the Escherichia coli chaperonin GroEL requires the presence of ATP and co-chaperonin GroES. We have observed that ADP displays a two-step inhibition of GroEL-dependent ATP hydrolysis, wherein one-half of the GroEL ATPase sites is strongly inhibited by ADP while the other half is affected very mildly. It is suggested that interaction with ATP induces structural and functional differences between two initially identical rings in GroEL (inter-ring negative cooperativity) and that the subsequent binding of GroES occurs to the ring that is occupied first by ATP in a positively cooperative manner.	WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BANEYX F, 1992, J BIOL CHEM, V267, P11637; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P44; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIRSHOVICH AS, 1981, J MOL BIOL, V151, P229, DOI 10.1016/0022-2836(81)90513-1; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEVITZKI A, 1969, FED EUR BIOCHEM SOC, V19, P263; LONG CW, 1970, J BIOL CHEM, V245, P80; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	27	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23869	23871						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929031				2022-12-27	WOS:A1994PQ34600005
J	HOFMANN, F; ANAGLI, J; CARAFOLI, E; VORHERR, T				HOFMANN, F; ANAGLI, J; CARAFOLI, E; VORHERR, T			PHOSPHORYLATION OF THE CALMODULIN-BINDING DOMAIN OF THE PLASMA-MEMBRANE CA2+ PUMP BY PROTEIN-KINASE-C REDUCES ITS INTERACTION WITH CALMODULIN AND WITH ITS PUMP RECEPTOR-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; CA-2+-PUMPING ATPASE; MUSCLE-CELLS; PHOSPHOLAMBAN; IDENTIFICATION; SARCOLEMMA; ACTIVATION; SUBSTRATE	Two versions of the calmodulin binding domain of the plasma membrane Ca(2+)ATPase, a 24-amino acid peptide, C24W (Q-I-L-W-F-R-G-L-N-R-I-Q-T-Q-I-R-V-V-N-A-F-R-S-S-NH2), and the corresponding phosphothreonine containing peptide, C24W-P (Q-I-L-W-F-R-G-L-N-R-I-Q-T(phospho)-Q-I-R-V-V-N-A-F-R-S-S-NH2), were synthesized. They were used to investigate the effect of threonine phosphorylation by protein kinase C on the binding of calmodulin by the calmodulin binding domain and on the inhibitory role of the domain on the activity of the Ca2+ pump. The phosphopeptide C24W-P was obtained after global phosphorylation of the free Thr side chain on the protected resin bound peptide. The phosphorylated calmodulin binding domain failed to bind calmodulin; this was shown by gel shift experiments, by fluorescence energy transfer studies and by competition experiments against calmodulin stimulation of the pump. The inhibition of the Ca2+ pump activity by the calmodulin binding domain in the absence of calmodulin was also affected by the phosphorylation of the threonine; the inhibition of the fully active calpain-truncated pump by the phosphothreonine containing peptide was lower than that by the unphosphorylated synthetic domain.	ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND; HOFFMANN LA ROCHE AG,CH-4002 BASEL,SWITZERLAND	ETH Zurich; Roche Holding			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARONI P, 1981, J BIOL CHEM, V256, P9371; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; CHIESI M, 1991, BIOCHEMISTRY-US, V30, P7978, DOI 10.1021/bi00246a015; DIXON DA, 1989, J BIOL CHEM, V264, P13612; ERIKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HOUSE C, 1987, J BIOL CHEM, V262, P772; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KUO TH, 1991, J BIOL CHEM, V266, P2520; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; MOVSESIAN MA, 1984, J BIOL CHEM, V259, P8029; NEYES L, 1985, J BIOL CHEM, V260, P10283; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1991, ARCH BIOCHEM BIOPHYS, V289, P103, DOI 10.1016/0003-9861(91)90448-R	35	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24298	24303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929086				2022-12-27	WOS:A1994PQ34600069
J	WILSON, MT; ANTONINI, G; MALATESTA, F; SARTI, P; BRUNORI, M				WILSON, MT; ANTONINI, G; MALATESTA, F; SARTI, P; BRUNORI, M			PROBING THE OXYGEN-BINDING SITE OF CYTOCHROME-C-OXIDASE BY CYANIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGULAR VALUE DECOMPOSITION; ELECTRON-TRANSFER; PROTON TRANSLOCATION; REDUCTION; COPPER; ACTIVATION; ENZYME; FORM; PH	Cyanide binding to cytochrome c oxidase has been investigated by sequential mixing and rapid scan stopped flow spectroscopy. Double mixing experiments confirm earlier reports that cyanide binds rapidly to partially reduced enzyme species formed in turnover. The absorbance/time/wavelength matrices, captured during the onset of cyanide inhibition of cytochrome c oxidase by rapid scan stopped flow, were analyzed by singular value decomposition and the spectral contributions of the chromophores separated. Examination of the time courses and amplitudes of the spectral signals provide evidence that entry of a single (1-1.3) electron into the enzyme is sufficient to trigger rapid cyanide binding. This electron resides predominantly on the cytochrome a/Cu-A, pair in the inhibited enzyme. In addition, although cytochrome a(3) remains oxidized, it does not appear to be the site for the initial inhibitory binding of cyanide. Our data suggest that CU(B)2+ is the initial binding site.	UNIV ROMA LA SAPIENZA, DEPT BIOCHEM SCI, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR MOLEC BIOL, I-00185 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT BIOCHEM SCI, ROME, ITALY; UNIV ROMA TOR VERGATA, CNR, CTR MOLEC BIOL, ROME, ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata	WILSON, MT (corresponding author), UNIV ESSEX, DEPT CHEM & BIOL CHEM, WIVENHOE PK, COLCHESTER CO4 3SQ, ESSEX, ENGLAND.		Malatesta, Francesco/AAT-4757-2020; Sarti, Paolo/D-2946-2009	Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827; Antonini, Giovanni/0000-0002-2115-8961				ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; ANTONINI E, 1971, EUR J BIOCHEM, V23, P396, DOI 10.1111/j.1432-1033.1971.tb01633.x; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAKER GM, 1987, J BIOL CHEM, V262, P595; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BERKA V, 1993, FEBS LETT, V315, P237, DOI 10.1016/0014-5793(93)81171-U; BRUNORI M, 1979, J BIOL CHEM, V254, P769; BRZEZINSKI P, 1987, BIOCHIM BIOPHYS ACTA, V894, P29, DOI 10.1016/0005-2728(87)90209-X; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JENSEN P, 1984, BIOCHEM J, V224, P829, DOI 10.1042/bj2240829; JONES MG, 1984, BIOCHEM J, V220, P57, DOI 10.1042/bj2200057; LINDSAY JG, 1975, ARCH BIOCHEM BIOPHYS, V169, P492, DOI 10.1016/0003-9861(75)90192-7; MALATESTA F, 1990, P NATL ACAD SCI USA, V74, P2222; MITCHELL P, 1988, ANN NY ACAD SCI, V550, P185, DOI 10.1111/j.1749-6632.1988.tb35335.x; MITCHELL R, 1992, BIOCHIM BIOPHYS ACTA, V1100, P40, DOI 10.1016/0005-2728(92)90124-K; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; ROUSSEAU DL, 1993, J BIOENERG BIOMEMBR, V25, P165, DOI 10.1007/BF00762858; SCHOLES CP, 1986, FEBS LETT, V198, P125, DOI 10.1016/0014-5793(86)81197-8; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P164, DOI 10.1021/bi00052a022; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; WILSON MT, 1975, BIOCHEM J, V147, P145, DOI 10.1042/bj1470145; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; WRIGGLESWORTH JM, 1988, BIOCHIM BIOPHYS ACTA, V936, P452, DOI 10.1016/0005-2728(88)90023-0; YONETANI T, 1960, J BIOL CHEM, V235, P845; YOSHIKAWA S, 1990, J BIOL CHEM, V265, P7945	29	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24114	24119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929065				2022-12-27	WOS:A1994PQ34600043
J	GROSS, M; OLIN, A; HESSEFORT, S; BENDER, S				GROSS, M; OLIN, A; HESSEFORT, S; BENDER, S			CONTROL OF PROTEIN-SYNTHESIS BY HEMIN - PURIFICATION OF A RABBIT RETICULOCYTE HSP-70 AND CHARACTERIZATION OF ITS REGULATION OF THE ACTIVATION OF THE HEMIN-CONTROLLED EIF-2(ALPHA) KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED TRANSLATIONAL REPRESSOR; DOUBLE-STRANDED-RNA; HEAT-SHOCK PROTEINS; GLOBIN-SYNTHESIS; EIF-2-ALPHA KINASE; INITIATION-COMPLEXES; HEMOGLOBIN SYNTHESIS; 67-KDA POLYPEPTIDE; SUPERNATANT FACTOR; CHAIN INITIATION	We have purified a soluble rabbit reticulocyte protein, previously termed the supernatant factor, that reverses the inhibition of protein synthesis in hemin-deficient lysate by promoting the inactivation of the hemin-controlled eIF-2 alpha kinase (HCR) mediating the effect of hemin deficiency. We have identified the supernatant factor as a member of the heat shock protein 70 family, denoted hsp 70(R), based upon its size (72 kDa), specific: reaction to a monoclonal antibody against eukaryotic hsp 70, strong binding affinity for ATP, and endogenous ATPase activity. me have investigated the role of hsp 70(R) and hemin in the regulation of the activation of HCR from its latent precursor (ProHCR) and the translational control of protein synthesis in rabbit reticulocyte lysate. We find that autophosphorylation of ProHCR is reduced by about 75% by adding saturating hsp 70(R) and almost completely reduced by adding either saturating hemin or limiting hemin plus Limiting hsp 70(R). In contrast, autophosphorylation of HCR, which is similar in magnitude to that of ProHCR, is unaffected by adding either saturating hsp 70(R), saturating hemin, or limiting amounts of both. The activation of HCR (measured by inhibition of protein synthesis) hom isolated ProHCR is completely prevented by hsp 70(R) in the presence, but not absence, of dithiothreitol. This suppression appears to be due to the association of hsp 70(R) with ProHCR, since hsp 70(R) action is prevented by ATP/mg(2+) and because activation of HCR from less purified ProHCR, that has associated hsp 70(R), is suppressed by dithiothreitol alone. This association is confirmed by sucrose gradient centrifugation, which shows co-sedimentation of some hsp 70(R) with ProHCR following preincubation together that is prevented by ATP/ Mg2+ and does not occur after conversion of ProHCR to HCR. Limiting hsp 70(R) reduces the concentration of hemin required to prevent activation of HCR from isolated ProHCR from 0.75 to 0.15 mu M and the optimal hemin concentration needed to maintain protein synthesis in reticulocyte lysate from 25 to 10 mu M. Limiting hsp 70(R) also allows the delayed addition of hemin to suppress activation of HCR hom ProHCR and to reverse inhibition of protein synthesis in hemin deficient lysate. The association of hsp 70(R) with ProHCR also underlies the observation that much more protein is synthesized in reticulocyte lysate in the absence of hemin at 25 degrees C than at temperatures of 30 degrees C or greater. These observed effects may be specific to hsp 70(R), since they are not observed with rabbit reticulocyte eIF-2 or eIF-2B, and since the comparable hsp 70 from bovine brain is incapable of maintaining or restoring protein synthesis in hemin-deficient lysate.			GROSS, M (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON SD, 1972, J MOL BIOL, V63, P247, DOI 10.1016/0022-2836(72)90373-7; ADAMSON SD, 1969, J MOL BIOL, V42, P247, DOI 10.1016/0022-2836(69)90041-2; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CLEMENS MJ, 1974, P NATL ACAD SCI USA, V71, P2946, DOI 10.1073/pnas.71.8.2946; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GRAYZEL AI, 1966, P NATL ACAD SCI USA, V55, P650, DOI 10.1073/pnas.55.3.650; GROSS M, 1972, BIOCHIM BIOPHYS ACTA, V287, P340, DOI 10.1016/0005-2787(72)90383-8; GROSS M, 1987, J BIOL CHEM, V262, P6899; GROSS M, 1991, BIOCHEM BIOPH RES CO, V181, P1500, DOI 10.1016/0006-291X(91)92109-W; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1972, P NATL ACAD SCI USA, V69, P1565, DOI 10.1073/pnas.69.6.1565; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1980, J BIOL CHEM, V255, P6270; GROSS M, 1973, BIOCHIM BIOPHYS ACTA, V299, P472, DOI 10.1016/0005-2787(73)90272-4; GROSS M, 1974, BIOCHIM BIOPHYS ACTA, V366, P319, DOI 10.1016/0005-2787(74)90292-5; GROSS M, 1974, BIOCHIM BIOPHYS ACTA, V340, P484, DOI 10.1016/0005-2787(74)90069-0; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; GROSS M, 1979, J BIOL CHEM, V254, P2370; GROSS M, 1981, BIOCHIM BIOPHYS ACTA, V654, P219, DOI 10.1016/0005-2787(81)90175-1; GROSS M, 1976, BIOCHIM BIOPHYS ACTA, V447, P445, DOI 10.1016/0005-2787(76)90082-4; GROSS M, 1977, BIOCHEM BIOPH RES CO, V74, P559, DOI 10.1016/0006-291X(77)90340-0; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; HUNTER AR, 1975, EUR J BIOCHEM, V58, P421, DOI 10.1111/j.1432-1033.1975.tb02389.x; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; KRAMER G, 1976, P NATL ACAD SCI USA, V73, P3078, DOI 10.1073/pnas.73.9.3078; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LEGON S, 1973, NATURE-NEW BIOL, V241, P150, DOI 10.1038/newbio241150a0; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LEVIN DH, 1976, P NATL ACAD SCI USA, V73, P3112, DOI 10.1073/pnas.73.9.3112; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MAXWELL CR, 1971, J MOL BIOL, V58, P317, DOI 10.1016/0022-2836(71)90249-X; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PETRYSHYN R, 1982, P NATL ACAD SCI-BIOL, V79, P6512, DOI 10.1073/pnas.79.21.6512; PETRYSHYN R, 1979, P NATL ACAD SCI USA, V76, P1575, DOI 10.1073/pnas.76.4.1575; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; RAY MK, 1993, BIOCHEMISTRY-US, V32, P5151, DOI 10.1021/bi00070a026; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; SCHMID SL, 1985, J BIOL CHEM, V260, P57; VELAZQUEZ JM, 1983, J CELL BIOL, V96, P286, DOI 10.1083/jcb.96.1.286; WAXMAN HS, 1965, BIOCHEM BIOPH RES CO, V19, P538, DOI 10.1016/0006-291X(65)90159-2; WAXMAN HS, 1966, BIOCHIM BIOPHYS ACTA, V129, P369, DOI 10.1016/0005-2787(66)90379-0; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WU CH, 1988, PLANT PHYSIOL, V88, P731, DOI 10.1104/pp.88.3.731; YANG JM, 1992, J BIOL CHEM, V267, P20519	51	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22738	22748						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915718				2022-12-27	WOS:A1994PQ16300045
J	MURTHY, SNP; WILSON, J; ZHANG, Y; LORAND, L				MURTHY, SNP; WILSON, J; ZHANG, Y; LORAND, L			RESIDUE GLN-30 OF HUMAN ERYTHROCYTE ANION TRANSPORTER IS A PRIME SITE FOR REACTION WITH INTRINSIC TRANSGLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; ANKYRIN-BINDING SITE; INTERCALATED CELLS; MEMBRANE-PROTEINS; COLLECTING DUCT; ENZYMATIC BASIS; BAND-3 PROTEIN; CDNA SEQUENCE; HUMAN-KIDNEY; EXCHANGER	Elevating the intracellular concentration of Ca2+ ions in human erythrocytes leads to the formation of membrane-associated polymers, composed of skeletal and cytoplasmic proteins. The anion transporter band 3 serves as a membrane anchor for this N-epsilon-(gamma-glutamyl)lysine cross-linked polymer. The reaction is catalyzed by an intrinsic transglutaminase, and it can be observed in broken cells merely by the addition of Ca2+. Certain primary amines, such as dansylcadaverine, inhibit the process by virtue of competition against the epsilon-lysyl or donor functionalities of the protein substrates. Dansylcadaverine itself becomes incorporated into the enzyme-specific gamma-glutaminyl or acceptor residues, blocking these from participating in the formation of protein-to-protein cross-links. This labeling procedure, coupled with an anti-dansyl antibody affinity procedure to isolate dansyl-labeled compounds, was employed to identify Gln-30 as the preferred transglutaminase-reactive acceptor site in the band 3 protein.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC & CELL BIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611	Northwestern University; Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045168] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45168] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJERRUM OJ, 1981, J SUPRAMOL STR CELL, V16, P289, DOI 10.1002/jsscb.1981.380160309; BJERRUMOJ, 1974, BIOCHIM BIOPHYS ACTA, V342, P69; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DRENCKHAHN D, 1987, EUR J CELL BIOL, V45, P107; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; HAZENMARTIN DJ, 1986, J HISTOCHEM CYTOCHEM, V34, P823, DOI 10.1177/34.6.3517151; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KAUL R K, 1983, Journal of Biological Chemistry, V258, P7981; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P6882, DOI 10.1073/pnas.80.22.6882; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LORAND L, 1986, BIOCHEM BIOPH RES CO, V134, P685, DOI 10.1016/S0006-291X(86)80474-0; LORAND L, 1979, SEMIN HEMATOL, V16, P65; LORAND L, 1978, J SUPRAMOL STR CELL, V9, P427, DOI 10.1002/jss.400090313; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; MARCHESI V. T., 1968, SCIENCE, V159, P203, DOI 10.1126/science.159.3811.203; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; MURTHY SNP, 1984, H-S Z PHYSIOL CHEM, V365, P9, DOI 10.1515/bchm2.1984.365.1.9; MURTHY SNP, 1988, FASEB J, V2, pA1300; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SMITH BD, 1981, J MEMBRANE BIOL, V61, P75, DOI 10.1007/BF02007633; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WALDER JA, 1984, J BIOL CHEM, V259, P238; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	37	29	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22907	22911						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915720				2022-12-27	WOS:A1994PQ16300068
J	JOYCEBRADY, M; TAKAHASHI, Y; OAKES, SM; RISHI, AK; LEVINE, RA; KINLOUGH, CL; HUGHEY, RP				JOYCEBRADY, M; TAKAHASHI, Y; OAKES, SM; RISHI, AK; LEVINE, RA; KINLOUGH, CL; HUGHEY, RP			SYNTHESIS AND RELEASE OF AMPHIPATHIC GAMMA-GLUTAMYL-TRANSFERASE BY THE PULMONARY ALVEOLAR TYPE-2 CELL - ITS REDISTRIBUTION THROUGHOUT THE GAS-EXCHANGE PORTION OF THE LUNG INDICATES A NEW ROLE FOR SURFACTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE COPY GENE; RAT-KIDNEY; GLUTATHIONE METABOLISM; NUCLEOTIDE-SEQUENCE; MEMBRANE-PROTEINS; MOLECULAR-CLONING; TRANSPEPTIDASE; IDENTIFICATION; EXPRESSION; SECRETION	gamma-Glutamyl transferase (gamma-GT) catalyzes a transpeptidation reaction which is involved in the metabolism of glutathione. Glutathione is abundant within the epithelial lining fluid of the lung. However, little is known about gamma-GT expression in the epithelial cells of the lung alveolus. Herein we show that the pulmonary alveolar epithelial type 2 cell expresses the gene for gamma-GT We were unable to detect expression in the pulmonary alveolar epithelial type 1 cell or in the pulmonary alveolar macrophage. gamma-GT expression in the pulmonary alveolar epithelial type 2 cell is via mRNA III, a transcript that was initially cloned from the liver. This cell synthesizes gamma-GT protein and releases enzyme activity into a surfactant-associated pool within the lung alveolus. The specific activity of this surfactant-associated enzyme is almost 10-fold higher than that of whole lung. This activity results from amphipathic gamma-GT since it partitions with lung surfactant phospholipid and with the detergent phase of Triton X-114. Activity can be dissociated from each by papain proteolysis. These results demonstrate that gamma-GT is expressed in the differentiated pulmonary alveolar epithelial type 2 cell and that amphipathic gamma-GT protein is released by this cell along with lung surfactant. These results suggest that surfactant may serve an expanded role in lung cell biology as the vehicle for the redistribution of amphipathic signal anchored proteins throughout the gas exchange surface of the lung.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	JOYCEBRADY, M (corresponding author), BOSTON UNIV,CTR PULM,SCH MED,K603,80 E CONCORD ST,BOSTON,MA 02118, USA.			Joyce-Brady, Martin/0000-0002-1898-6002	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049, R01HL043395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026012] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL47049, R01 HL43395] Funding Source: Medline; NIDDK NIH HHS [R01 DK26012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATTISTINI B, 1990, LIFE SCI, V47, P2435, DOI 10.1016/0024-3205(90)90488-D; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRODY JS, 1986, LAB INVEST, V59, P522; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CASTLE JD, 1985, J MEMBRANE BIOL, V87, P13; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; COLOMA J, 1986, NUCLEIC ACIDS RES, V14, P1393, DOI 10.1093/nar/14.3.1393; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; CRYSTAL RG, 1991, LUNG SCI F, P247; CURTHOYS NP, 1979, ENZYME, V24, P383, DOI 10.1159/000458694; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; DINSDALE D, 1992, HISTOCHEM J, V24, P144, DOI 10.1007/BF01047464; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; EDWARDS AM, 1985, CARCINOGENESIS, V6, P733, DOI 10.1093/carcin/6.5.733; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P203, DOI 10.3109/09687687809063848; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORKERT PG, 1989, HISTOCHEM J, V21, P634, DOI 10.1007/BF01002482; FORMAN HJ, 1990, AM J PHYSIOL, V259, pL102, DOI 10.1152/ajplung.1990.259.2.L102; FUNKHOUSER JD, 1991, AM J PHYSIOL, V260, pL381, DOI 10.1152/ajplung.1991.260.6.L381; GLENNER GG, 1962, J HISTOCHEM CYTOCHEM, V10, P481, DOI 10.1177/10.4.481; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; HABIB GM, 1992, MOL CARCINOGEN, V5, P75; HENDRICH S, 1987, CANCER METAST REV, V6, P155, DOI 10.1007/BF00052847; HIRATA E, 1984, J BIOCHEM-TOKYO, V96, P289, DOI 10.1093/oxfordjournals.jbchem.a134837; HOOFTMAN RN, 1988, J APPL TOXICOL, V8, P59, DOI 10.1002/jat.2550080110; HUGHEY RP, 1976, J BIOL CHEM, V251, P7863; HUGHEY RP, 1986, BIOCHIM BIOPHYS ACTA, V874, P150, DOI 10.1016/0167-4838(86)90112-3; INGBAR D H, 1989, American Review of Respiratory Disease, V139, pA256; JONES DT, 1987, J BIOL CHEM, V262, P14241; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; JOYCEBRADY MF, 1990, DEV BIOL, V137, P331, DOI 10.1016/0012-1606(90)90258-K; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; KURAUCHI O, 1991, BIOCHEMISTRY-US, V30, P1618, DOI 10.1021/bi00220a025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LEVINE RA, 1990, CELL REGUL, V1, P215, DOI 10.1091/mbc.1.2.215; MARSHALL BC, 1988, BIOCHIM BIOPHYS ACTA, V966, P403, DOI 10.1016/0304-4165(88)90091-8; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P5296, DOI 10.1073/pnas.86.14.5296; MATSUDA Y, 1983, ADV ENZYME REGUL, V21, P103, DOI 10.1016/0065-2571(83)90010-9; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; NIELSON DW, 1981, P NATL ACAD SCI-BIOL, V78, P7119, DOI 10.1073/pnas.78.11.7119; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; RAJAGOPALAN S, 1990, J BIOL CHEM, V265, P11721; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SERABJITSINGH CJ, 1988, MOL PHARMACOL, V33, P279; SMITH GD, 1979, ANAL BIOCHEM, V100, P136, DOI 10.1016/0003-2697(79)90122-2; TATE SS, 1987, J BIOL CHEM, V262, P11403; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TATE SS, 1985, METHOD ENZYMOL, V113, P400; TSUJI A, 1980, CLIN CHIM ACTA, V104, P361; TSUJI A, 1980, BIOMED RES-TOKYO, V1, P410, DOI 10.2220/biomedres.1.410; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; VINA J, 1991, GLUTATHIONE METABOLI, P79; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WILLIAMS MC, 1981, J HISTOCHEM CYTOCHEM, V29, P291, DOI 10.1177/29.2.7019304; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426; YAMAMOTO K, 1988, CARCINOGENESIS, V9, P399, DOI 10.1093/carcin/9.3.399; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098	66	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14219	14226						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910609				2022-12-27	WOS:A1994NL60600075
J	VENIER, P; MAGGS, AC; CARLIER, MF; PANTALONI, D				VENIER, P; MAGGS, AC; CARLIER, MF; PANTALONI, D			ANALYSIS OF MICROTUBULE RIGIDITY USING HYDRODYNAMIC FLOW AND THERMAL FLUCTUATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; SURFACE LATTICE; TUBULIN; MICROSCOPY; POLYMERIZATION; RESOLUTION; HYDROLYSIS; PHOSPHATE; ANALOGS	We report the use of two independent new methods to measure the flexural rigidity of microtubules. Microtubules were grown off axonemal pieces adhering to a glass coverslip. In the first method, a hydrodynamic flow was applied to microtubules and the flexural rigidity was derived from the analysis of the bending shape of the microtubules at equilibrium in the flow. In the second method, the flexural rigidity was derived from the thermal fluctuations of the free end of axoneme-bound microtubules. With both methods, the flexural rigidity of standard GDP microtubules was estimated to be 0.85 +/- 0.2 x 10(-23) newtons x m(2) which corresponded to a persistence length of 2 +/- 0.2 mm. Binding of ligands known to affect the biochemical properties of microtubules affected their rigidity. The structural analogs of inorganic phosphate A1F(4)(-) and [BeF3-, H2O], which bind to the site of the gamma-phosphate of GTP on GDP microtubule and reconstitute the GDP-P-i microtubule intermediate state of GTP hydrolysis, cause an similar to 3-fold increase in microtubule flexural rigidity and persistence length. Taxol and taxotere, antitumoral microtubule stabilizing drugs, in contrast cause a decrease in flexural rigidity and appear to affect the three-dimensional superstructure of microtubules, which can no longer be considered as semi-flexible rods. The relationship between the mechanical properties of microtubules and their biological function is discussed.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEOR GRP, F-75231 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	VENIER, P (corresponding author), CNRS, ENZYMOL LAB, F-91198 GIF SUR YVETTE, FRANCE.							AMOS LA, 1974, J CELL SCI, V14, P523; AMOS LA, 1991, J CELL SCI, P95; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BISSERY MC, 1991, CANCER RES, V51, P4845; CARLIER MF, 1989, INT REV CYTOL, V115, P139; CARLIER MF, 1987, P NATL ACAD SCI USA, V84, P5257, DOI 10.1073/pnas.84.15.5257; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P1783, DOI 10.1021/bi00430a054; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; CROSS AR, 1991, CELL MOTIL CYTOSKEL, V20, P272, DOI 10.1002/cm.970200403; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DOI M, 1989, THEORY POLYM DYNAMIC, P318; DYE RB, 1993, J BIOL CHEM, V268, P6847; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; INOUE S, 1986, VIDEO MICROSCOPY, P118; Landau LD., 1986, THEORY ELASTICITY, V3; MAGGS AC, 1990, EUROPHYS LETT, V12, P19, DOI 10.1209/0295-5075/12/1/004; MARKO JF, 1994, MACROMOLECULES, V27, P981, DOI 10.1021/ma00082a015; MIZUSHIMASUGANO J, 1983, BIOCHIM BIOPHYS ACTA, V755, P257, DOI 10.1016/0304-4165(83)90212-X; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHREVEL J, 1975, J CELL BIOL, V66, P492, DOI 10.1083/jcb.66.3.492; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	29	216	219	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13353	13360						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909808				2022-12-27	WOS:A1994NK18400047
J	WADA, I; OU, WJ; LIU, MC; SCHEELE, G				WADA, I; OU, WJ; LIU, MC; SCHEELE, G			CHAPERONE FUNCTION OF CALNEXIN FOR THE FOLDING INTERMEDIATE OF GP80, THE MAJOR SECRETORY PROTEIN IN MDCK CELLS - REGULATION BY REDOX STATE AND ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; POLYACRYLAMIDE-GEL ELECTROPHORESIS; ENDOPLASMIC-RETICULUM MEMBRANE; MOLECULAR CHAPERONE; DISULFIDE BONDS; BIP; SUBUNITS; GLYCOPROTEIN; GLUTATHIONE; RECEPTOR	The endoplasmic reticulum (ER) not only links the translational machinery to the endomembrane system in eukaryotic cells but also provides a protective environment for the folding of exoplasmic proteins translocated across the ER membrane. Here we describe that the lumenal surface of the ER membranes transiently tethers the folding intermediate of secretory proteins via a 90-kDa ER membrane protein, calnexin. We demonstrate that p70, the precursor to gp80, the major secretory protein in Madin-Darby canine kidney (MDCK) cells, was bound transiently to calnexin in the immediate post synthetic period (0-10 min) and showed a t(1/2) for dissociation from calnexin of 2.5 min. The bound p70 was found to be incompletely folded as assessed by susceptibility to proteinase K digestion. Perturbation of the redox state by 5 mM dithiothreitol or 1 mM diamide markedly inhibited the dissociation of p70 from calnexin (t(1/2) > 30 min). Cellular depletion of ATP led to premature dissociation of p70 from calnexin and the formation of p70 aggregates that did not bind calnexin. These findings demonstrate that nascent unfolded p70 is tethered to calnexin during normal protein maturation, including the formation and editing of disulfide bonds and that ATP is required for the productive interaction of gp80 and calnexin.	BETH ISRAEL HOSP, DIV GASTROENTEROL, CHARLES A DANA RES INST, CELL & MOLEC BIOL LAB, BOSTON, MA 02155 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02155 USA; MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL H3A 2B2, PQ, CANADA; UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; McGill University; University of Oklahoma System; University of Oklahoma - Norman				Wada, Ikuo/0000-0001-5668-6994				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CALA SE, 1993, J BIOL CHEM, V268, P2969; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEVIRGILIO C, 1993, YEAST, V9, P185, DOI 10.1002/yea.320090209; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HORWICH AL, 1990, TRENDS BIOTECHNOL, V8, P126, DOI 10.1016/0167-7799(90)90153-O; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LIU JW, 1991, BIOCHEM INT, V25, P109; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MERILE JP, 1983, CELL, V34, P747; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE G, 1981, ANAL BIOCHEM, V112, P304, DOI 10.1016/0003-2697(81)90298-0; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; SELA M, 1957, SCIENCE, V125, P691, DOI 10.1126/science.125.3250.691; SILVA AD, 1993, J CELL BIOL, V260, P647; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; WADA I, 1991, J BIOL CHEM, V266, P19599	45	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7464	7472						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907329				2022-12-27	WOS:A1994NA03200069
J	MENDOZA, JA; DEMELER, B; HOROWITZ, PM				MENDOZA, JA; DEMELER, B; HOROWITZ, PM			ALTERATION OF THE QUATERNARY STRUCTURE OF CPN60 MODULATES CHAPERONIN-ASSISTED FOLDING - IMPLICATIONS FOR THE MECHANISM OF CHAPERONIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; MITOCHONDRIAL RHODANESE; ESCHERICHIA-COLI; PROTEIN; GROEL; PURIFICATION; PATHWAY; ATP	Chaperonin-mediated, in vitro folding of rhodanese by the intact protein cpn60 has previously been shown to require cpn10 and ATP hydrolysis (Martin, J., Langer, T., Boteva, R., Schramel, A, Horwich, A. L., and Hartl, F.-U. (1991) Nature 352, 36-42; Mendoza, J. A., Rogers, E., Lorimer, G. H., and Horowitz, P. M. (1991) J. Biol. Chem. 266, 13044-13049). The present work demonstrates that the rhodanese-cpn60 complex can be dissociated by urea to allow folding to proceed, thus removing the obligatory requirement for cpn10 and ATP. Analytical ultracentrifugation and circular dichroism show that tetradecameric cpn60 can be disassembled into monomers that retain substantial secondary structure. Unfolded rhodanese induces the reassembly of tetradecameric cpn60 from monomers, and binding of rhodanese stabilizes cpn60 quaternary structure. Intermediate cpn60 species, possibly heptamers, are detected at intermediate urea concentrations after addition of unfolded rhodanese. The use of urea has demonstrated a functionally related loosening of subunit interactions in cpn60 that is not detectable under usual solution conditions. Our data suggest a highly dynamic role for the quaternary structure of cpn60 in chaperonin-mediated protein folding.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78240	University of Texas System; University of Texas Health San Antonio				Demeler, Borries/0000-0002-2414-9518	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JARABAK R, 1993, J BIOCHEM TOXICOL, V8, P41, DOI 10.1002/jbt.2570080107; LANDRY SJ, 1994, IN PRESS NATURE; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1986, J BIOL CHEM, V261, P5615; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665; VITANEN PV, 1992, J BIOL CHEM, V267, P695; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	32	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2447	2451						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905478				2022-12-27	WOS:A1994MV43200019
J	ALTUVIA, S; STEIN, WD; GOLDENBERG, S; KANE, SE; PASTAN, I; GOTTESMAN, MM				ALTUVIA, S; STEIN, WD; GOLDENBERG, S; KANE, SE; PASTAN, I; GOTTESMAN, MM			TARGETED DISRUPTION OF THE MOUSE MDR1B GENE REVEALS THAT STEROID-HORMONES ENHANCE MDR GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; DEPENDENT PROTEIN-KINASE; P-GLYCOPROTEIN; SECRETORY EPITHELIUM; TISSUES; UTERUS; MUTATIONS; FAMILY; CELLS	To evaluate the role of P-glycoprotein in steroid secretion in adrenal cells, we have used gene targeting to introduce a null mutation into one allele of the mdr1b gene in mouse Y1 adrenal cells. Characterization of both the wild-type and the mutant cell lines revealed the following. 1) The expression of mdr1b is enhanced by steroid hormones, in a feedback regulatory mechanism. Inhibition of steroid biosynthesis by 2-aminoglutethimide blocks the adrenocorticotropin (ACTH)-induced increase in mdr1b mRNA levels. 2) ACTH-stimulated steroid secretion is markedly decreased in the mutant cell line. This decreased steroid secretion in the mutant cells occurs despite an increase in the levels of mdr1b mRNA and P-glycoprotein. Kinetic analyses of vinblastine and daunomycin accumulation in both the wild-type and the mutant cell lines during ACTH-stimulated steroidogenesis show that in the mutant cells both drugs accumulated to higher levels than in Y1 cells, suggesting that the remaining mdr1b allele in the mutant cells is relatively inactive as an exporter of steroids, or that the targeted disruption of the mdr1b allele is associated with other changes in the mutant cells which block ACTH-stimulated steroid secretion.	NCI,CELL BIOL LAB,9000 ROCKVILLE PIKE,37-4E16,BETHESDA,MD 20892; CITY HOPE NATL MED CTR,DEPT CELLULAR & MOLEC BIOL,DUARTE,CA 91010; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892; HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hebrew University of Jerusalem			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUHAN SS, 1992, GENE, V120, P281, DOI 10.1016/0378-1119(92)90106-Y; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; COHEN D, 1991, J BIOL CHEM, V266, P2239; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; KOREN R, 1979, EUR J BIOCHEM, V95, P333, DOI 10.1111/j.1432-1033.1979.tb12970.x; Kowal J, 1970, Recent Prog Horm Res, V26, P623; KOWAL J, 1968, ARCH BIOCHEM BIOPHYS, V128, P406, DOI 10.1016/0003-9861(68)90047-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PIEKARZ RL, 1993, J BIOL CHEM, V268, P7613; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1992, J BIOL CHEM, V267, P2428; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; WOLF CR, 1992, INT J CANCER, V52, P3141; YANG CPH, 1989, J BIOL CHEM, V264, P782	28	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27127	27132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903303				2022-12-27	WOS:A1993MM26200044
J	CARR, SF; PAPP, E; WU, JC; NATSUMEDA, Y				CARR, SF; PAPP, E; WU, JC; NATSUMEDA, Y			CHARACTERIZATION OF HUMAN TYPE-I AND TYPE-II IMP DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; MYCOPHENOLIC-ACID; ESCHERICHIA-COLI; GENE-EXPRESSION; HEPATOMA 3924A; CELL LINES; INHIBITION; PURIFICATION; TIAZOFURIN	Human IMP dehydrogenase, a target for anticancer and immunosuppressive chemotherapy, exists as two isoforms, types I and II. Nonfusion sequences of each isoform were overexpressed in an IMP dehydrogenase-deficient strain of Escherichia coli and purified to homogeneity. Both recombinant isoforms were tetramers, which was in agreement with the subunit structure of the native mammalian enzyme. The results of initial velocity and product inhibition studies were consistent with an Ordered Bi Bi kinetic mechanism for both isoforms. Substrate affinities were similar for types I and II with K(m) values of 18 and 9.3 muM, respectively, for IMP, and 46 and 32 muM, respectively, for NAD. k(cat) values were 1.5 and 1.3 s-1 at 37-degrees-C for types I and II, respectively. Xanthosine 5'-monophosphate and NADH inhibited the two isoforms with identical inhibition patterns and inhibition constants. Mycophenolic acid, however, inhibited the type II enzyme with a 4.8-fold lower K(i) than the type I. Selective inhibitors of the inducible type II isoform may mitigate toxicity caused by inhibition of the constitutively expressed type I isoform.	SCHERING PLOUGH KK, 2-3-7 HIRANOMACHI, CHUO KU, OSAKA 541, JAPAN; SYNTEX DISCOVERY RES, INST BIOCHEM & CELL BIOL, PALO ALTO, CA 94303 USA	Merck & Company; Schering Plough Corporation; Syntex Corporation					NATIONAL CANCER INSTITUTE [R55CA060344] Funding Source: NIH RePORTER; NCI NIH HHS [1R55 CA60344-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANDERSON JH, 1967, FED PROC, V26, P730; BROX LW, 1968, BIOCHEMISTRY-US, V7, P2589, DOI 10.1021/bi00847a021; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; DEIERHOI MH, 1993, TRANSPLANT P, V25, P693; EPINETTE WW, 1987, J AM ACAD DERMATOL, V17, P962, DOI 10.1016/S0190-9622(87)70285-0; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; Gosio B., 1896, RIV DIGIENE SANITA P, V7, P825; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HODGES SD, 1989, J BIOL CHEM, V264, P18137; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUPE DJ, 1986, J BIOL CHEM, V261, P8363; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; KHARBANDA SM, 1990, BLOOD, V75, P583; KONNO Y, 1991, J BIOL CHEM, V266, P506; LIU MS, 1984, J BIOL CHEM, V259, P5078; METZ SA, 1992, J BIOL CHEM, V267, P12517; MORRIS RE, 1990, TRANSPLANT P, V22, P1659; MORRIS RE, 1991, TRANSPLANT P, V23, P19; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; PLATZ KP, 1991, TRANSPLANTATION, V51, P27, DOI 10.1097/00007890-199101000-00003; Sambrook J, 1989, MOL CLONING LABORATO; Segel I.H., 1975, ENZYME KINETICS; SIDI Y, 1988, BRIT J CANCER, V58, P61, DOI 10.1038/bjc.1988.162; SOLLINGER HW, 1993, TRANSPL P, V25, P698; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; TRICOT GJ, 1989, CANCER RES, V49, P3696; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057	39	342	361	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27286	27290						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903306				2022-12-27	WOS:A1993MM26200065
J	AROCA, P; URABE, K; KOBAYASHI, T; TSUKAMOTO, K; HEARING, VJ				AROCA, P; URABE, K; KOBAYASHI, T; TSUKAMOTO, K; HEARING, VJ			MELANIN BIOSYNTHESIS PATTERNS FOLLOWING HORMONAL-STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN MELANOCYTES; HAIR FOLLICULAR MELANOCYTES; TYROSINASE MESSAGE LEVEL; MAMMALIAN TYROSINASE; DOPACHROME OXIDOREDUCTASE; CONTROL POINT; METAL-IONS; CELL-LINE; MELANOGENESIS; MOUSE	The effect of melanocyte-stimulating hormone (MSH) on the differentiation of mammalian melanocytes has been widely studied since the early 1950s. There have been many reports about the stimulatory effect of MSH on melanin production and specifically on the activity of tyrosinase, the critical enzyme in the melanogenic pathway. However, few and variable results have been obtained concerning the effect of this hormone on the regulation of DOPAchrome tautomerase (TRP2), another melanogenic enzyme which functions later in the melanogenic pathway, or on other melanogenic activities, such as TRP1. In this study, we show that the MSH-induced stimulation of tyrosinase is accompanied by no significant change in the synthesis or catalytic activities of other melanogenic enzymes such as TRP1 or TRP2. This in turn elicits a dramatic increase in melanin production accompanied by a significant decrease in the incorporation of carboxylated precursors into that melanin biopolymer, although the biological implication of that is still unclear.	NCI, CELL BIOL LAB, BLDG 37, RM 1B22, BETHESDA, MD 20892 USA; YAMANASHI MED UNIV, DEPT DERMATOL, YAMANASHI 40938, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Yamanashi				Kobayashi, Takeshi/0000-0002-4372-5285; Aroca, Pilar/0000-0002-7557-6931				ABDELMALEK ZA, 1987, CANCER RES, V47, P3141; ABDELMALEK ZA, 1988, J CELL PHYSIOL, V136, P273, DOI 10.1002/jcp.1041360209; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BARBER JI, 1985, J HERED, V76, P59, DOI 10.1093/oxfordjournals.jhered.a110019; BARBER JI, 1984, J INVEST DERMATOL, V83, P145, DOI 10.1111/1523-1747.ep12263381; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; BURCHILL SA, 1986, J ENDOCRINOL, V111, P225, DOI 10.1677/joe.0.1110225; CHAKRABORTY AK, 1991, J CELL PHYSIOL, V147, P1, DOI 10.1002/jcp.1041470102; CHAKRABORTY AK, 1992, PIGM CELL RES, V5, P84; DEXTER TJ, 1987, EXP CELL RES, V168, P255, DOI 10.1016/0014-4827(87)90433-2; ELLER M, 1990, J INVEST DERMATOL, V94, P521; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1981, BIOCHEM BIOPH RES CO, V100, P823, DOI 10.1016/S0006-291X(81)80248-3; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FULLER BB, 1987, J BIOL CHEM, V262, P4024; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HOSOI J, 1985, CANCER RES, V45, P1474; IMOKAWA G, 1982, CANCER RES, V42, P1994; IMOKAWA G, 1986, J INVEST DERMATOL, V87, P319, DOI 10.1111/1523-1747.ep12524388; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KAMEYAMA K, 1993, J INVEST DERMATOL, V100, P126, DOI 10.1111/1523-1747.ep12462778; KAMEYAMA K, 1989, DIFFERENTIATION, V42, P28, DOI 10.1111/j.1432-0436.1989.tb00604.x; KAMEYAMA K, 1989, J CLIN INVEST, V83, P213, DOI 10.1172/JCI113861; KAMEYAMA K, 1988, J CELL PHYSIOL, V137, P35, DOI 10.1002/jcp.1041370105; KORNER A, 1977, NATURE, V267, P444, DOI 10.1038/267444a0; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LERNER AB, 1950, PHYSIOL REV, V30, P91, DOI 10.1152/physrev.1950.30.1.91; MALEK ZAA, 1986, J NATL CANCER I, V76, P857; MARTINEZLIARTE JH, 1992, J INVEST DERMATOL, V99, P435, DOI 10.1111/1523-1747.ep12616139; MIRANDA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P159, DOI 10.1016/0304-4165(85)90017-0; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; ORLOW SJ, 1992, PIGM CELL RES, V5, P113, DOI 10.1111/j.1600-0749.1992.tb00007.x; ORLOW SJ, 1990, J CELL PHYSIOL, V142, P129, DOI 10.1002/jcp.1041420116; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PAVLOVITCH JH, 1982, MOL CELL ENDOCRINOL, V25, P295, DOI 10.1016/0303-7207(82)90085-5; PAWELEK J, 1980, NATURE, V286, P617, DOI 10.1038/286617a0; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PAWELEK JM, 1991, PIGM CELL RES, V4, P53, DOI 10.1111/j.1600-0749.1991.tb00315.x; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; PAWELEK JM, 1992, PIGM CELL RES, V5, P91; PRESTON SF, 1987, P NATL ACAD SCI USA, V84, P5247, DOI 10.1073/pnas.84.15.5247; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1989, J IMMUNOL, V142, P1943; TOMITA Y, 1988, J INVEST DERMATOL, V90, P882, DOI 10.1111/1523-1747.ep12462151; TOMITA Y, 1986, TOHOKU J EXP MED, V149, P451, DOI 10.1620/tjem.149.451; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; TSUKAMOTO K, 1992, BIOCHEM J, V286, P491, DOI 10.1042/bj2860491; URABE K, 1993, PIGM CELL RES, V6, P186, DOI 10.1111/j.1600-0749.1993.tb00601.x; VALVERDE P, 1992, FEBS LETT, V304, P114, DOI 10.1016/0014-5793(92)80600-L; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; WONG G, 1973, NATURE-NEW BIOL, V241, P213, DOI 10.1038/newbio241213a0; [No title captured]	67	94	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25650	25655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902353				2022-12-27	WOS:A1993MK10000055
J	SASAKI, K; WATANABE, E; KAWASHIMA, K; SEKINE, S; DOHI, T; OSHIMA, M; HANAI, N; NISHI, T; HASEGAWA, M				SASAKI, K; WATANABE, E; KAWASHIMA, K; SEKINE, S; DOHI, T; OSHIMA, M; HANAI, N; NISHI, T; HASEGAWA, M			EXPRESSION CLONING OF A NOVEL GAL-BETA(1-3/1-4)G1CNAC ALPHA-2,3-SIALYLTRANSFERASE USING LECTIN RESISTANCE SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR VIRUS; MONOCLONAL-ANTIBODIES; CARBOHYDRATE LIGAND; MAMMALIAN-CELLS; SUGAR CHAINS; ANTIGEN; LEWIS; CDNA; ADHESION; GENE	This report describes the isolation of a cDNA encoding a novel human Galbeta(1-3/1-4)GlcNAc alpha2,3-sialyltransferase involved in the biosynthesis of the sialyl Lewis x determinant (NeuAcalpha2-3Galbeta1-4(Fucalpha1-3)GlcNAc). A cDNA library of the human melanoma cell line WM266-4 was constructed in an Epstein-Barr virus-based cloning vector. Selection of the B-cell line Namalwa expressing transfected cDNAs in the presence of the cytotoxic lectin Ricinus communis agglutinin 120 gave a cDNA encoding a protein with type II transmembrane topology, as found for mammalian glycosyltransferases. The use of this lectin, which is specific to galactose residues (especially the Galbeta1-4GlcNAc structure), originates from our prediction that the modification of the Galbeta1-4GlcNAc structure (a backbone of the sialyl Lewis x structure) by glycosyltransferases may increase the levels of resistance to this lectin. Comparison of this cDNA sequence with those of three other cloned sialyltransferases revealed two conserved regions shared by all four enzymes. Expression of the COOH-terminal catalytic domain of this protein showed alpha2,3-sialyltransferase activity with substrate specificity different from that of CMP-N-acetylneuraminate: N-acetyllactosaminide alpha-2,3-sialyltransferase (Gal-beta1-3(4)GlcNAc alpha2,3-sialyltransferase, EC 2.4.99.6). Furthermore, expression of this cDNA in Namalwa cells increased the level of sialyl Lewis x antigens. The cloning approach based on lectin resistance may be useful for the isolation of cDNAs encoding other mammalian glycosyltransferases.	NATL MED CTR,CLIN RES INST,DIV CLIN BIOCHEM,TOKYO 162,JAPAN		SASAKI, K (corresponding author), KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN.							BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HANAI N, 1990, ANTICANCER RES, V10, P1579; HOSOI S, 1991, CYTOTECHNOLOGY, V5, pS17, DOI 10.1007/BF00573878; ISHIMOTO A, 1985, VIROLOGY, V141, P30, DOI 10.1016/0042-6822(85)90180-1; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUGA T, 1990, BIOTECHNOL LETT, V12, P87, DOI 10.1007/BF01022421; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MATSUSHITA Y, 1991, EXP CELL RES, V196, P20, DOI 10.1016/0014-4827(91)90451-Y; MIYAJI H, 1990, CYTOTECHNOLOGY, V3, P133, DOI 10.1007/BF00143675; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SADLER JE, 1984, BIOL CARBOHYDRATES, V2, P87; SAITO A, 1989, PROTEIN ENG, V2, P481, DOI 10.1093/protein/2.6.481; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Sato S, 1983, J TISSUE CULT METHOD, V8, P167; SHITARA K, 1987, CANCER RES, V47, P1267; STANLEY P, 1987, TRENDS GENET, V3, P77, DOI 10.1016/0168-9525(87)90180-6; VANDENEIJNDEN DH, 1981, J BIOL CHEM, V256, P3159; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	36	178	189	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22782	22787						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901202				2022-12-27	WOS:A1993MD34800087
J	KILBOURNE, EJ; WIDOM, R; HARNISH, DC; MALIK, S; KARATHANASIS, SK				KILBOURNE, EJ; WIDOM, R; HARNISH, DC; MALIK, S; KARATHANASIS, SK			INVOLVEMENT OF EARLY GROWTH-RESPONSE FACTOR EGR-1 IN APOLIPOPROTEIN AI GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE; RETINOIC ACID; RECEPTOR SUPERFAMILY; CONTROL EXPRESSION; CELL-GROWTH; 3T3 CELLS; C-FOS; BINDING; DNA; RAT	Liver-specific expression of the apolipoprotein AI (apoAI) gene is mediated by transcription factors bound to three sites (A, B, and C) in the apoAI enhancer. Sites A and C bind various members of the nuclear receptor superfamily, including the orphan nuclear receptor apolipoprotein regulatory protein-1 (ARP-1); site B binds the liver enriched factor hepatic nuclear factor-3. The immediate early growth response factor (Egr-1), which is transiently expressed in various pathophysiologic states of the liver, activates the apoAI enhancer and overcomes ARP-1-mediated repression of the enhancer in hepatoblastoma HepG2 cells. Deletion mapping analysis revealed two Egr-1 binding sites, E1 and E2, flanking site A. Egr-1 bound efficiently to both E1 and E2. Sp1 in HepG2 nuclear extracts bound to E2 but not E1. In HepG2 cells, E1 functioned as an Egr-1 response element, whereas E2 had high basal activity and was not further induced by Egr-1. Mutations that prevent Egr-1 binding to the apoAI enhancer abolished its responsiveness to Egr-1, while they had only minor effects on its constitutive activity. These mutations also diminished the ability of Egr-1 to overcome ARP-1-mediated repression. Elimination of transcription factor binding to sites A, B, or C reduced enhancer activity without affecting Egr-1 dependent activation. We argue that Egr-1 is recruited to the apoAI enhancer complex under unusual circumstances, such as those prevailing during liver regeneration, to maintain apoAI transcription levels by overriding prior transcriptional controls.	AMER CYANAMID CO, LEDERLE LABS, DEPT CARDIOVASC MOLEC BIOL, PEARL RIVER, NY 10965 USA; CHILDRENS HOSP, DEPT CARDIOL, MOLEC & CELLULAR CARDIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School								ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; APOSTOLOPOULOS JJ, 1988, BIOCHEM BIOPH RES CO, V154, P997, DOI 10.1016/0006-291X(88)90238-0; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; GE RW, 1994, J BIOL CHEM, V269, P13185; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HARNISH DC, 1994, J BIOL CHEM, V269, P28220; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MERRYMAN PF, 1993, ARTHRITIS RHEUM, V36, P1414, DOI 10.1002/art.1780361014; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIRKOVITCH J, 1991, GENE DEV, V1, P256; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PANDURO A, 1990, BIOCHEMISTRY-US, V29, P8430, DOI 10.1021/bi00488a033; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TAM SP, 1986, P NATL ACAD SCI USA, V83, P3111, DOI 10.1073/pnas.83.10.3111; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIPODI M, 1991, EMBO J, V10, P3177, DOI 10.1002/j.1460-2075.1991.tb04879.x; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	54	51	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					7004	7010		10.1074/jbc.270.12.7004	http://dx.doi.org/10.1074/jbc.270.12.7004			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896852	hybrid			2022-12-27	WOS:A1995QQ85500083
J	DRAGO, GA; COLYER, J				DRAGO, GA; COLYER, J			DISCRIMINATION BETWEEN 2 SITES OF PHOSPHORYLATION ON ADJACENT AMINO-ACIDS BY PHOSPHORYLATION SITE-SPECIFIC ANTIBODIES TO PHOSPHOLAMBAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INTRACELLULAR CALCIUM; VENTRICULAR MYOCYTES; MONOCLONAL-ANTIBODY; MYOCARDIUM; SEQUENCE; BOVINE; DEPHOSPHORYLATION; CHROMATOGRAPHY; PURIFICATION	A pair of polyclonal antibodies have been produced in rabbits which recognize the two phosphorylated forms of the cardiac muscle protein, phospholamban. The two sites of phosphorylation of this protein are situated on neighboring residues and yet one antibody, PS-16, recognizes the Ser(16) phosphoprotein, while the other, PT-17, recognizes the Thr(17) phosphoprotein. Neither antibody recognizes phospholamban phosphorylated at ''the other site,'' nor do they recognize free phosphoamino acids or dephosphorylated protein. This represents the most demanding test of the technique of phosphorylation site-specific antibody production to date, which these antibodies have satisfied without ambiguity. These antibodies remain specific for phospholamban in the company of other muscle phosphoproteins and will be invaluable in determining the role of each phosphorylation site in the biology of the heart. They also demonstrate the absolute specificity of phosphorylation site-specific antibodies and augur well for the use of this approach in the study of other phosphoproteins.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds								BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BOYETT MR, 1988, J PHYSIOL-LONDON, V407, P77, DOI 10.1113/jphysiol.1988.sp017404; BRIAND JP, 1985, J IMMUNOL METHODS, V78, P59, DOI 10.1016/0022-1759(85)90329-1; CHIU RC, 1990, TRANSFORMED MUSCLE C; COLYER J, 1991, J BIOL CHEM, V266, P17486; Corbin J D, 1974, Methods Enzymol, V38, P287; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; GASSER J, 1988, EUR J BIOCHEM, V176, P535, DOI 10.1111/j.1432-1033.1988.tb14311.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; Hudson L, 1989, PRACTICAL IMMUNOLOGY, P348; HUGGINS JP, 1989, BIOCHEM J, V260, P829, DOI 10.1042/bj2600829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CF, 1990, BIOCHEMISTRY-US, V29, P4535, DOI 10.1021/bi00471a005; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; POULTER L, 1993, J BIOL CHEM, V268, P9636; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	28	94	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25073	25077						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929194				2022-12-27	WOS:A1994PQ49000083
J	DUCHE, D; BATY, D; CHARTIER, M; LETELLIER, L				DUCHE, D; BATY, D; CHARTIER, M; LETELLIER, L			UNFOLDING OF COLICIN-A DURING ITS TRANSLOCATION THROUGH THE ESCHERICHIA-COLI ENVELOPE AS DEMONSTRATED BY DISULFIDE BOND ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEIN; FORMATION INVIVO; UPTAKE SYSTEMS; TOLR PROTEINS; MEMBRANE; IMPORT; EXPORT; ENTRY	Three double cysteine mutants, each possessing a disulfide bond in its pore forming domain, were used to study the translocation of colicin A through the Escherichia coli envelope. These mutated colicins were able to exert their in vivo channel activity only after their disulfide bonds had been reduced by dithiothreitol. In solution, the reduction of the disulfide bonds by dithiothreitol was a slow process whose kinetics depended on the position of the sidulfide bond (t(1/2) varying between 35 and 100 s), This t(1/2) was strongly decreased (t(1/2) = 8-9 s) upon predenaturation of the mutated colicins with urea. The t(1/2) values of reduction of the mutants bound to E. coli-sensitive cells were similar to those of predenatured colicins. This suggested that the interaction of the oxidized double cysteine mutants with the E. coli envelope triggered their unfolding. The disulfide bonds did not prevent but delayed the translocation of the colicins. The amplitude of the delay and the time at which it occurred during translocation depended on the position of the disulfide bond. We could discriminate between the delays accumulated during binding to the receptor and those during the translocation via OmpF and the Tol proteins.	UNIV PARIS 11,BIOMEMBRANES LAB,CNRS,URA 1116,F-91405 ORSAY,FRANCE; CNRS,CTR BIOCHIM & BIOL MOLEC,INGN & DYNAM SYST MEMBRANAIRES LAB,F-13402 MARSEILLE 20,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)				Duche, Denis/0000-0002-4208-6661; Baty, Daniel/0000-0001-8443-4444				BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BATY D, 1988, MOL MICROBIOL, V2, P806; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1989, J GEN MICROBIOL, V135, P3413; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; DUCHE D, 1994, J BIOL CHEM, V269, P6332; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; JASCUR T, 1992, J BIOL CHEM, V267, P13636; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; MAHER PA, 1986, P NATL ACAD SCI USA, V83, P9001, DOI 10.1073/pnas.83.23.9001; MULLER G, 1988, EMBO J, V7, P639, DOI 10.1002/j.1460-2075.1988.tb02858.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; TANI K, 1990, J BIOL CHEM, V265, P17341; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	27	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24820	24825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929161				2022-12-27	WOS:A1994PQ49000048
J	HASAN, S; KODA, T; KAKINUMA, M				HASAN, S; KODA, T; KAKINUMA, M			AN UPSTREAM NF-Y-BINDING SITE IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION FROM THE HST PROMOTER IN F9 EMBRYONAL CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-FGF PROTOONCOGENE; TRANSFORMING GENE; STOMACH CANCERS; STEM-CELLS; CLASS-II; EXPRESSION; PROTEINS; DIFFERENTIATION; GROWTH; FAMILY	Expression of hst (k-FGF, FGF-4), a member of the fibroblast growth factor gene family, is restricted to early stages of developing embryos and to embryonal carcinoma cells. In F9, which is a prototype of embryonal carcinoma cells expressing hst, the expression of hst gene is positively regulated by a downstream octamer motif that functions as an enhancer. We have investigated, by chloramphenicol acetyltransferase (CAT) reporter fusion gene analysis in F9, the cis-acting regulatory element within the hst promoter region that interacts with this enhancer. Electrophoretic mobility shift assay and methylation interference analysis showed that the hst promoter contains, in a segment termed Y, the sequence 5'-CTGATTGGCA-3', which closely resembles the consensus binding motif for the CCAAT-binding factor NF-Y. Deletions or mutations in this element substantially reduced expression of hst-CAT constructs. The nuclear factor binding to the Y segment of the hst promoter was indistinguishable from NF-Y, as inferred from interactions with specific anti-NF-Y monoclonal and polyclonal antibodies. We conclude that the expression of the hst gene in F9 is positively regulated by the coordinated interaction between an NF-Y-binding site and an octamer motif.	HOKKAIDO UNIV, INST IMMUNOL SCI, BACTERIAL INFECT SECT, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, GRAD SCH ENVIRONM SCI, ENVIRONM MED SECT, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Hokkaido University			Koda, Toshiaki/F-5268-2011	Koda, Toshiaki/0000-0003-1421-6964				BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COONEY AJ, 1993, TRANSCRIPTION FACTOR, P49; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HOWE CC, 1981, DEV BIOL, V84, P239, DOI 10.1016/0012-1606(81)90390-0; KODA T, 1987, JPN J CANCER RES, V78, P325; KODA T, 1994, FEBS LETT, V342, P71, DOI 10.1016/0014-5793(94)80587-3; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LI XY, 1992, J BIOL CHEM, V267, P8984; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARICS I, 1989, ONCOGENE, V4, P335; Maxam A M, 1980, Methods Enzymol, V65, P499; NISWANDER L, 1992, DEVELOPMENT, V114, P755; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SASAKI A, 1991, JPN J CANCER RES, V82, P1191, DOI 10.1111/j.1349-7006.1991.tb01778.x; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOORLEMMER J, 1991, MECH DEVELOP, V36, P75, DOI 10.1016/0925-4773(91)90074-G; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VELCICH A, 1989, ONCOGENE RES, V5, P31; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X	35	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25042	25048						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929190				2022-12-27	WOS:A1994PQ49000078
J	VIVEKANANDA, J; LIN, A; COALSON, JJ; KING, RJ				VIVEKANANDA, J; LIN, A; COALSON, JJ; KING, RJ			ACUTE INFLAMMATORY INJURY IN THE LUNG PRECIPITATED BY OXIDANT STRESS INDUCES FIBROBLASTS TO SYNTHESIZE AND RELEASE TRANSFORMING GROWTH-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-ALPHA; HUMAN KERATINOCYTES; MESSENGER-RNA; INDUCTION; MACROPHAGES; RECEPTORS; PROTEINS	Although transforming growth factor-alpha (TGF-alpha) is widely distributed in transformed cells and in some normal cells and much is known about its structure and metabolism, there is little information about its physio logical actions. TGF a is not thought to be synthesized by nontransformed fibroblasts, but it is thought to be a mitogen for these and epithelial cells (Derynck, R. (1986) J. Cell. Biochem. 32, 293-304). We report here that fibroblasts obtained from hamsters with oxidant-induced lung injury release TGF-alpha at levels comparable with those reported for transformed cells. In conditioned media, one isoform of 18 kDa was recognized by a monoclonal antibody to mature TGF-alpha; five isoforms ranging from 18 to 42 kDa were recognized in cell lysates. Conditioned media from these fibroblasts stimulated tyrosine phosphorylation of the epidermal growth factor (EGF)/TGF-alpha receptor, competed with radioactive EGF for binding sites on A431 cells, and were mitogenic for mesenchymal and epithelial cells. This mitogenic activity could be almost completely blocked by anti-TGF-alpha. Conditioned media from normal lung fibroblasts exhib ited none of these activities. Using normal lung fibroblasts, we found that TGF-alpha synthesis could be induced in vitro with 25 nmol/ml EGF, suggesting that the induction in vivo may have been due, in part, to a stimulation by EGF (or TGF-alpha) released by other cell types such as alveolar macrophages recruited to the injury site. TGF-alpha is, in general, a mitogen for epithelial cells (Derynck, 1986); more specific to acute injury in the lung, it may affect the proliferation (Ryan, R. M., Mineo-Kuhn, M. M., Kromer, C. M., and Finkelstein, J. N. (1994) Am. J. Physiol. 266, L17-L23) and metabolic activities (Whitsett, J. A., Weaver, T. E., Lieberman, M. A., Clark, J. G., and Daugherty, C. (1987) J. Biol. Chem. 262, 7908-7913) of alveolar epithelial type II cells. This is, we believe, the first report of a fibroblast-derived TGF-alpha induced with oxidant injury If this response was ubiquitously manifested in other tissues, then fibroblast derived TGF-alpha might be an important determinant of the epithelial and mesenchymal hyperplasia commonly observed in tissue repair.	UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043704] Funding Source: NIH RePORTER; NHLBI NIH HHS [NHLBI HL 43704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1990, AM J PATHOL, V137, P385; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1986, J CELL BIOCHEM, V32, P293, DOI 10.1002/jcb.240320406; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; JONES MB, 1987, AM REV RESPIR DIS, V135, P997; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MINOO P, 1992, AM J PHYSIOL, V263, pL291, DOI 10.1152/ajplung.1992.263.2.L291; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RYAN RM, 1994, AM J PHYSIOL, V266, pL17, DOI 10.1152/ajplung.1994.266.1.L17; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552; WHITSETT JA, 1987, J BIOL CHEM, V262, P7908; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; 1972, DHEW NIH73432 PUBL, P167	24	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25057	25061						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929192				2022-12-27	WOS:A1994PQ49000080
J	ZHANG, L; SACHS, CW; FINE, RL; CASEY, PJ				ZHANG, L; SACHS, CW; FINE, RL; CASEY, PJ			INTERACTION OF PRENYLCYSTEINE METHYL-ESTERS WITH THE MULTIDRUG-RESISTANCE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSECT CELLS; EXPRESSION; IDENTIFICATION; QUANTITATION; GLYCOPROTEIN; BINDING	The multidrug resistance transporter is an integral membrane protein, termed P-glycoprotein, which can function as an ATP dependent drug efflux pump to reduce intracellular drug accumulation in treated cells. The physiologic function of this protein in normal cells, however, is not completely understood. We report here that prenylcysteine methyl esters, which represent the C-terminal structures of prenylated proteins, both stimulate the transporter's intrinsic ATPase activity and compete for drug binding. The structural elements of prenylcysteine methyl esters involved in their interaction with P-glycoprotein include the isoprenoid moiety, the carboxyl methyl group, and the free amino group. These findings indicate that these molecules are potential physiologic ligands of the transporter. Furthermore, as the structures of the active prenylcysteines are distinct from the known substrates of P-glycoprotein, this information may facilitate design of novel inhibitors of the transporter.	DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,VET ADM MED CTR,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Casey, Patrick/0000-0002-7366-9309				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BODANSKY M, 1984, PRACTICE PEPTIDE SYN, P16; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MJ, 1991, J AM CHEM SOC, V113, P2176; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Michaelis S, 1993, Semin Cell Biol, V4, P17, DOI 10.1006/scel.1993.1003; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; WANG WWH, 1993, P NATL ACAD SCI USA, V90, P868	25	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15973	15976						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7911465				2022-12-27	WOS:A1994NQ72900005
J	KIM, TD; BURSTYN, JN				KIM, TD; BURSTYN, JN			IDENTIFICATION AND PARTIAL-PURIFICATION OF AN ENDOGENOUS INHIBITOR OF SOLUBLE GUANYLYL CYCLASE FROM BOVINE LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; CYCLIC-GMP; RELAXING FACTOR; PROTOPORPHYRIN-IX; HEME-DEFICIENT; NITROSYL-HEME; ACTIVATION; ENZYME	An endogenous inhibitor of soluble guanylyl cyclase from bovine lung has been partially purified by use of anion exchange, hydrophobic interaction, and gel filtration chromatography. This inhibitor is a protein with a molecular weight of about 149,000 which was estimated from its elution behavior, versus that of a series of standards, on a Sephacryl S-300-HR column. Its activity was measured by comparison of the level of cGMP production from soluble guanylyl cyclase in the presence and absence of the inhibitor protein. Soluble guanylyl cyclase is inhibited by this protein when either Mg2+ or Mn2+ is used as a cofactor. The insensitivity of its inhibitory activity to both isobutylmethylxanthine and the presence of cGMP demonstrates that this new protein is not a phosphodiesterase. This new protein inhibits both activated and unactivated soluble guanylyl cyclase. Because the inhibition was found to be noncompetitive with respect to the substrate, GTP, it appears that this inhibitor may be an allosteric regulator of soluble guanylyl cyclase.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Burstyn, Judith/0000-0003-3245-5563				Bliss CI, 1935, ANN APPL BIOL, V22, P134, DOI 10.1111/j.1744-7348.1935.tb07713.x; BRANDWEIN HJ, 1981, J BIOL CHEM, V256, P2958; BUSYGINA OG, 1991, BIOCHEMISTRY-US, V55, P1354; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; FARRUKH IS, 1992, AM REV RESPIR DIS, V145, P1389, DOI 10.1164/ajrccm/145.6.1389; FELBEL J, 1988, J BIOL CHEM, V263, P16764; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GARBERS DL, 1991, PHARMACOL THERAPEUT, V50, P337, DOI 10.1016/0163-7258(91)90049-R; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, BIOCHIM BIOPHYS ACTA, V982, P160; KAVIPURAPU PR, 1982, EXP EYE RES, V34, P181, DOI 10.1016/0014-4835(82)90052-5; LAVAN BE, 1989, BIOCHEM PHARMACOL, V38, P4123, DOI 10.1016/0006-2952(89)90694-1; MARLETTA M A, 1990, Biofactors, V2, P219; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; RAIFER J, 1992, NEW ENGL J MED, V326, P90; SARCEVIC B, 1989, J BIOL CHEM, V264, P20648; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; TAKAI Y, 1981, BIOCHEM BIOPH RES CO, V101, P61, DOI 10.1016/S0006-291X(81)80010-1; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819	36	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15540	15545						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7910826				2022-12-27	WOS:A1994NP51300025
J	SU, MJ; BIKLE, DD; MANCIANTI, ML; PILLAI, S				SU, MJ; BIKLE, DD; MANCIANTI, ML; PILLAI, S			1,25-DIHYDROXYVITAMIN D-3 POTENTIATES THE KERATINOCYTE RESPONSE TO CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EPIDERMAL-CELLS; CULTURED HUMAN KERATINOCYTES; MESSENGER-RNA STABILITY; HL-60 LEUKEMIA-CELLS; TERMINAL DIFFERENTIATION; EXTRACELLULAR CALCIUM; RETINOIC ACID; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; GROWTH; GENE	Extracellular calcium (Ca-0) stimulates the differentiation of keratinocytes; 1,25 dihydroxyvitamin D-3 (1,25(OH)(2)D-3) does likewise. Since 1,25(OH)(2)D-3 regulates calcium flux in other cells, we hypothesized that 1,25(OH)(2)D-3 acted through and promoted the effects of calcium on keratinocyte differentiation. To test this hypothesis, we evaluated the effects of calcium and 1,25(OH)(2)D-3 alone and in combination on the mRNA and protein levels of involucrin and transglutaminase in neonatal human keratinocytes. Ca-0 alone increased these mRNA levels in a dose-dependent fashion (0.03 to 1.2 mM) over a 24-h period. This increase in mRNA levels was associated with a stimulation by calcium of involucrin and transglutaminase gene transcription. However, by 72 h, the mRNA levels of involucrin and transglutaminase decreased. At 0.03 mM Ca-0, 1,25(OH)(2)D-3 showed a dose-dependent stimulation of involucrin and transglutaminase mRNA for up to 48 h and potentiated the initial (4-h) stimulation by Ca-0 of involucrin and transglutaminase mRNA As for calcium alone, this increase in mRNA was associated with an increase in transcription of the involucrin and transglutaminase genes. However, by 24 h of exposure to both calcium and 1,25(OH)(2)D-3, a dose-dependent fall in mRNA levels was seen. The mRNA levels of involucrin and transglutaminase were stable for 24 h when neonatal human keratinocytes were grown in serum-free keratinocyte growth medium containing 0.03 or 1.2 mM Ca-0 alone. However, the mRNAs of both genes underwent rapid degradation when neonatal human keratinocytes were treated with 1,25(OH)(2)D-3, especially in high Ca-0. 1,25(OH)(2)D-3 and Ca-0 increased the protein levels of involucrin and transglutaminase activity in a synergistic fashion throughout the 48-h time course. These data support the hypothesis that 1,25(OH)(2)D-3 promotes calcium-induced differentiation at the level of both gene expression and mRNA stability.	UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94121; VET ADM MED CTR,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SU, MJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038386, P01AR039448] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 39448, AR 38386] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; BIKLE DD, 1991, J INVEST DERMATOL, V97, P435, DOI 10.1111/1523-1747.ep12481267; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BIKLE DD, 1986, J CLIN INVEST, V78, P557, DOI 10.1172/JCI112609; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KWAN SW, 1972, P NATL ACAD SCI USA, V69, P3247, DOI 10.1073/pnas.69.11.3247; MAJESKA RJ, 1982, J BIOL CHEM, V257, P3362; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCLANE JA, 1990, IN VITRO CELL DEV B, V26, P379; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURAO S, 1983, CANCER RES, V43, P4989; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; PILLAI S, 1988, Skin Pharmacology, V1, P149; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; PILLAI S, 1991, J CELL PHYSIOL, V146, P94, DOI 10.1002/jcp.1041460113; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; PRESTON GM, 1990, MOL CELL BIOL, V10, P442, DOI 10.1128/MCB.10.2.442; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SCHMIDT R, 1985, FEBS LETT, V186, P201, DOI 10.1016/0014-5793(85)80708-0; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; TANG W, 1987, J CELL PHYSIOL, V132, P131, DOI 10.1002/jcp.1041320118; VANDENPLAS ML, 1990, BIOCHEM J, V267, P349, DOI 10.1042/bj2670349; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; YUSPA SH, 1982, J BIOL CHEM, V257, P9906; YUSPA SH, 1988, J CELL BIOL, V109, P1217; YUSPA SH, 1985, METHODS SKIN RES, P213; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517	40	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14723	14729						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7910167				2022-12-27	WOS:A1994NM06500066
J	RAO, PV; HORWITZ, J; ZIGLER, JS				RAO, PV; HORWITZ, J; ZIGLER, JS			CHAPERONE-LIKE ACTIVITY OF ALPHA-CRYSTALLIN - THE EFFECT OF NADPH ON ITS INTERACTION WITH ZETA-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GUINEA-PIG LENS; B-CRYSTALLIN; ESCHERICHIA-COLI; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; EYE LENS; GROEL; EXPRESSION; TISSUES	alpha-Crystallin, a major structural protein of the ocular lens of vertebrates, has been characterized recently as a molecular chaperone (Horwitz, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10449-10453 and Jakob, U., Gaestel, M., Engel, K., and Buchner, J. (1993) J. Biol. Chem. 268, 1517-1520). While alpha-crystallins prevent the aggregation of various proteins denatured by heat or chaotropic agents, neither the mode of interaction between target proteins and alpha-crystallin nor the specific conformational requirements, if any, of the target protein are known. Here, we demonstrate that the ability of alpha-crystallin to prevent thermally induced aggregation of xi-crystallin/NADPH:quinone oxidoreductase, an abundant crystallin of guinea pigs and camelids, is strongly dependent on the presence of the obligate cofactor (NADPH) of the target enzyme. xi-crystallin in the absence of NADPH is readily aggregated at 41 degrees C, and alpha-crystallin added at a 1:1 (w/w) ratio offers very little protection. In contrast, in the presence of NADPH xi-crystallin remains stable to 45 degrees C and with the addition of alpha-crystallin (1:1 (w/w)) is protected from aggregation even at 55 degrees C. Cibacron blue 3GA a nonmetabolized pyridine nucleotide analog, which has very high binding affinity to xi-crystallin had similar effects. NADH and NAD(+), which are not bound by xi-crystallin, had no such effect. Complex formation between alpha-crystallin and non-native xi-crystallin was demonstrated in the presence of either cibacron blue 3GA or NADPB Circular dichroism spectroscopy of xi-crystallin in the presence and absence of NADPH or cibacron blue indicated that nucleotide binding was accompanied by a change in the protein's aromatic amino acid environment but that the secondary structure was unaffected. The data suggest that subtle change in the conformation of denaturing proteins can markedly affect the ability of alpha-crystallin to protect them from aggregation.	NEI,MECHANISMS OCULAR DIS LAB,BETHESDA,MD 20892; UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90024	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NEI NIH HHS [EY03897] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003897, R37EY003897] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bloemendal H., 1981, MOL CELLULAR BIOL EY; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DEJONG WW, 1986, J CELL BIOL, V102, P104, DOI 10.1083/jcb.102.1.104; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; EDWARDS RA, 1977, BIOCHEM BIOPH RES CO, V79, P470, DOI 10.1016/0006-291X(77)90181-4; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUANG QL, 1987, CURR EYE RES, V6, P725, DOI 10.3109/02713688709034836; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; PARK K, 1993, PROTEIN SCI, V2, P325; RAO PV, 1992, J BIOL CHEM, V267, P96; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RIZZO V, 1987, PYRIDINE NUCLEOTID A, P129; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; TAGUCHI H, 1993, J BIOL CHEM, V268, P5371; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	66	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13266	13272						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909806				2022-12-27	WOS:A1994NK18400035
J	LEMAS, MV; HAMRICK, M; TAKEYASU, K; FAMBROUGH, DM				LEMAS, MV; HAMRICK, M; TAKEYASU, K; FAMBROUGH, DM			26 AMINO-ACIDS OF AN EXTRACELLULAR DOMAIN OF THE NA,K-ATPASE ALPHA-SUBUNIT ARE SUFFICIENT FOR ASSEMBLY WITH THE NA,K-ATPASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; NA+-K+-ATPASE; INTRACELLULAR-TRANSPORT; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; COMPLEMENTARY-DNA; XENOPUS OOCYTES; SODIUM-PUMP; EXPRESSION; NA+,K+-ATPASE	Chimeric cDNAs encoding a sarcoplasmic/endoplasmic reticulum Ca-ATPase (SERCA1) and regions of the Na,K-ATPase alpha-subunit were constructed to seek the minimal region of the alpha-subunit sufficient for assembly with the Na,K-ATPase beta-subunit. cDNAs encoding a chimera and the chicken beta-subunit were coexpressed in mammalian cells and assembly was assayed by immune precipitation of the chimeric subunit with a monoclonal antibody to the chicken beta-subunit. A chimera containing 26 amino acyl residues of the Na,K-ATPase alpha 1-subunit (NDVEDSYGQQWTFEQRKIVEFTCHTA) (Asn(894) to Ala(919)) that replaced the corresponding avian SERCA1 Ca-ATPase amino acyl residues (Thr(871) to Thr(898)) was able to assemble with the chicken beta-subunit. This alpha-subunit region is predicted to be extracellular, located between membrane-spanning domains 7 and 8 (H7-H8). Chimeras that assembled with full-length beta-subunit also assembled with a beta-subunit chimera that retained only the ectodomain of the chicken beta 1-subunit. These results suggest that the Na,K ATPase alpha-subunit has the same topology in the membrane as the sarcoplasmic reticulum Ca-ATPase, probably with 10 membrane-spanning domains, and that the aminoacyl residues between membrane domains H7 and H8 are involved in assembly with the beta-subunit in the extracellular/lumenal space.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA	Johns Hopkins University; Ohio State University					NHLBI NIH HHS [HL-27867] Funding Source: Medline; NIGMS NIH HHS [GM-44373] Funding Source: Medline; NINDS NIH HHS [NS-23241] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044373, R21GM044373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FAMBROUGH DM, 1988, TRENDS NEUROSCI, V11, P325, DOI 10.1016/0166-2236(88)90096-3; FLACHMANN R, 1992, J BIOL CHEM, V267, P10576; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH DL, 1993, J BIOL CHEM, V268, P22469; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; TAKEYASU K, 1990, AM J PHYSIOL, V259, pC619, DOI 10.1152/ajpcell.1990.259.4.C619; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	33	103	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8255	8259						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907590				2022-12-27	WOS:A1994NB40900065
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			FUNCTIONAL CONSEQUENCES OF GLYCINE MUTATIONS IN THE PREDICTED CYTOPLASMIC LOOPS OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANT CELLS; CYSTIC-FIBROSIS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; SARCOPLASMIC-RETICULUM; MOLECULAR-BASIS; BINDING-SITE; TUMOR-CELLS; PROTEINS; GENE	Site-directed mutagenesis was used to investigate whether glycine residues in the predicted cytoplasmic loops play essential roles in the structure and function of human P-glycoprotein. Mutant cDNAs in which codons for each of the 20 glycine residues were changed to valine, were expressed in mouse NIH 3T3 cells and analyzed with respect to their ability to confer resistance to various drugs. Mutation of Gly-251, -268, -269, or -781 yielded mutant proteins which were unable to confer drug resistance in transfected cells. Each of these mutant P-glycoproteins had an apparent mass of 150 kDa, compared with 170 kDa for wild-type P-glycoprotein and the apparent mass was altered by endoglycosidase H digestion. These observations suggest that these mutant proteins were improperly processed so that they were located in the endoplasmic reticulum and were not targeted correctly to the plasma membrane. The in vivo processing of mutants Gly-269 to Val and Gly-781 to Val was temperature sensitive. When cells expressing these mutants were grown at a lower temperature (26 degrees C), the mature 170 kDa form of P-glycoprotein was the major product. Substitution of glycine with alanine at positions 251, 268, 269, or 781 yielded mutants with structural and functional characteristics similar to wild-type enzyme. Mutation of Gly-141, 187, 288, 812, or 830 to Val, altered the drug resistance profile conferred by P-glycoproteins expressed in transfected cells. All five mutations increased relative resistance to colchicine or adriamycin, without altering relative resistance to vinblastine. These results demonstrate that glycines located in the cytoplasmic loops play important roles in structure and function of P-glycoprotein.	UNIV TORONTO,DEPT MED,MED RES COUNCIL,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,MED RES COUNCIL,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALLEY MC, 1988, CANCER RES, V48, P589; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P553; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURUNKA PF, 1989, FASEB J, V3, P2583; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; PASTAN I, 1993, ANNU REV BIOCHEM, V62, P385; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7606; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	42	120	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7243	7248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907326				2022-12-27	WOS:A1994NA03200034
J	MOHAMED, AH; HUANG, WY; HUANG, WZ; VENKATACHALAM, KV; WAKIL, SJ				MOHAMED, AH; HUANG, WY; HUANG, WZ; VENKATACHALAM, KV; WAKIL, SJ			ISOLATION AND CHARACTERIZATION OF A NOVEL ACETYL-COA CARBOXYLASE KINASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COENZYME-A CARBOXYLASE; FATTY-ACID SYNTHESIS; PHOSPHORYLATION SITES; PURIFICATION; POLYMERIZATION; PEPTIDE	Acetyl-CoA carboxylase is regulated allosterically by citrate and covalently by a phosphorylation/ dephosphorylation mechanism. We have isolated and purified from rat livers a novel kinase that phosphorylates and inactivates the carboxylase, This kinase is: bound to the carboxylase and can be eluted in salt-rich solution, The native kinase exists as high molecular weight aggregates of a subunit that has a molecular weight of 40,000. The phosphorylation sites of the carboxylase were determined after tryptic and cyanogen bromide digestions of P-32-labeled carboxylase and separation of the peptides by various chromatographic pro cedures. Amino acid analyses of the phosphopeptides showed that the Ser(77) and Ser(1200) residues were the sites of phosphorylation. Treating the phosphorylated carboxylase with the Mn2+-dependent acetyl-CoA carboxylase phosphatase 2 removed the phosphate and reactivated the carboxylase. These results suggest that both this kinase and the acetyl-CoA carboxylase phosphatase 2 act at the same site(s) in the acetyl-CoA carboxylase molecule. Citrate dramatically inhibits the kinase-mediated phosphorylation of the carboxylase, suggesting that the allosteric modification and activation by citrate render the phosphorylation sites inaccessible to the kinase and therefore maintain high carboxylase activity. This observation indicates that there is a close interplay between the citrate effect on and phosphorylation of the carboxylase in regulating its activity.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine				Venkatachalam, K.V./0000-0001-6692-9099	NIGMS NIH HHS [GM-19091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATY NB, 1983, J BIOL CHEM, V258, P3043; BEATY NB, 1983, J BIOL CHEM, V258, P3051; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1986, BIOCHEM SOC T, V14, P1076, DOI 10.1042/bst0141076; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; GROSS E, 1962, J BIOL CHEM, V237, P1856; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1986, USERS MANUAL APPLIED; JAMIL H, 1987, J BIOL CHEM, V262, P638; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENT B, 1982, J BIOL CHEM, V257, P1897; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MEREDITH MJ, 1978, J BIOL CHEM, V253, P3381; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG YH, 1986, J BIOL CHEM, V261, P6909	29	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6859	6865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907095				2022-12-27	WOS:A1994MZ50300093
J	MURLEY, LL; MEJIA, NR; MACKENZIE, RE				MURLEY, LL; MEJIA, NR; MACKENZIE, RE			THE NUCLEOTIDE-SEQUENCE OF PORCINE FORMIMINOTRANSFERASE CYCLODEAMINASE - EXPRESSION AND PURIFICATION FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; PROTEINS; QUANTITIES; BINDING; LIVER; SITE	We have isolated and characterized cDNA clones encoding the porcine liver octameric enzyme, 5-formiminotetrahydrofolate:L-glutamate N-formiminotransferase (EC 2.1.2.5)-formiminotetrahydrofolate cyclodeaminase (EC 4.3.1.4). The cDNA encodes a novel amino acid sequence of 541 residues which contains exact matches to two sequences derived by automated sequence analysis of CNBr cleavage fragments isolated from the porcine enzyme. The recombinant enzyme has been expressed as a soluble protein in Escherichia coli at levels 4-fold higher than those observed in liver, and is bifunctional, displaying both transferase and deaminase activities. With a calculated subunit molecular mass of 58,926 Da, it is similar in size to the enzyme isolated from porcine liver. Purification of the enzyme from E. coli involves chromatography on a novel polyglutamate column which might interact with the folylpolyglutamate binding site of the protein. The purified recombinant enzyme has a transferase specific activity of 39-41 units/mg/min.	MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEAUDET R, 1976, BIOCHIM BIOPHYS ACTA, V453, P151, DOI 10.1016/0005-2795(76)90259-2; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK RJ, 1991, J BIOL CHEM, V266, P4965; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINDLAY WA, 1989, BIOCHIM BIOPHYS ACTA, V999, P52, DOI 10.1016/0167-4838(89)90029-0; FINDLAY WA, 1987, BIOCHEMISTRY-US, V26, P1948, DOI 10.1021/bi00381a024; FINDLAY WA, 1988, BIOCHEMISTRY-US, V27, P3404, DOI 10.1021/bi00409a042; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAFFE JJ, 1980, J PARASITOL, V66, P428, DOI 10.2307/3280743; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKenzie R E, 1980, Methods Enzymol, V66, P626; MACKENZIE RE, 1980, J BIOL CHEM, V255, P9474; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NOUR JM, 1992, J BIOL CHEM, V267, P16292; OLINS PO, 1989, J BIOL CHEM, V264, P16973; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RABINOWITZ JC, 1956, J AM CHEM SOC, V78, P5702, DOI 10.1021/ja01602a073; RANKIN CA, 1993, PROTEIN SCI, V2, P197; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANE B, 1984, FOLATES PTERINS, V1, P433; TABOR H, 1959, J BIOL CHEM, V234, P1830; TABOR H, 1956, J AM CHEM SOC, V78, P5705, DOI 10.1021/ja01602a075; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	33	22	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22820	22824						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901203				2022-12-27	WOS:A1993MD34800093
J	GUO, DQ; JIA, Q; SONG, HY; WARREN, RS; DONNER, DB				GUO, DQ; JIA, Q; SONG, HY; WARREN, RS; DONNER, DB			VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR PROMOTES TYROSINE PHOSPHORYLATION OF MEDIATORS OF SIGNAL-TRANSDUCTION THAT CONTAIN SH2 DOMAINS - ASSOCIATION WITH ENDOTHELIAL-CELL PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; DEVELOPMENTAL EXPRESSION; MOLECULAR-CLONING; PROTEIN; ANGIOGENESIS; RECEPTOR; KINASE; MITOGEN; BINDING; PDGF	Vascular endothelial cell growth factor (VEGF), an endothelial cell-specific mitogen that plays an important role in angiogenesis, promotes the tyrosine phosphorylation of at least 11 proteins in bovine aortic endothelial cells (BAEC). Proteins immunoprecipitated fr om lysates of control- and VEGF stimulated BAEC with antisera to phospholipase C-gamma (PLC-gamma) were fractionated by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P. Evaluation of the Western blots with antisera to phosphotyrosine demonstrated that PLC-gamma and two proteins (100 and 85 kDa) that associate with PLC-gamma were phosphorylated in response to VEGF. By using antisera specific to other mediators of signal transduction that contain SH2 domains for immunoprecipitation, it was demonstrated that VEGF promotes phosphorylation of phosphatidylinositol 3-kinase, Ras GTPase activating protein (GAP), and the oncogenic adaptor protein NcK. Proteins of M(r) consistent with the VEGF receptors Flt-1 and Flk-1/KDR were also tyrosine phosphorylated in stimulated cells, Tyrosine-phosphorylated Nck, PLC-gamma, and two GAP-associated proteins, p190 and p62, were in GAP immunoprecipitates of VEGF-stimulated BAEC, and tyrosine-phosphorylated NcK was in phosphatidylinositol 3-kinase immunoprecipitates, These observations suggest that VEGF promotes formation of multimeric aggregates of VEGF receptors with proteins that contain SH2 domains and activate various signaling pathways. VEGF-promoted proliferation of endothelial cells and tyrosine phosphorylation of SH2 domain containing signaling molecules were inhibited by the tyrosine kinase inhibitor genistein.	INDIANA UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of California System; University of California San Francisco								BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; MATHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1988, ONCOGENE, V3, P491; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHWEIKI D, 1993, J CLIN INVEST, V91, P2235; SENGER DR, 1986, CANCER RES, V46, P5629; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	40	393	401	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6729	6733		10.1074/jbc.270.12.6729	http://dx.doi.org/10.1074/jbc.270.12.6729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896817	hybrid			2022-12-27	WOS:A1995QQ85500048
J	MATHIEU, M; KIEFER, P; MASON, I; DICKSON, C				MATHIEU, M; KIEFER, P; MASON, I; DICKSON, C			FIBROBLAST GROWTH-FACTOR (FGF)-3 FROM XENOPUS-LAEVIS (XFGF3) BINDS WITH HIGH-AFFINITY TO FGF RECEPTOR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE INT-2; LIGAND-BINDING; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; FACTOR FAMILY; DEVELOPMENTAL EXPRESSION; MOUSE EMBRYO; CDNA CLONING; INNER-EAR; GENE	We demonstrate that purified fibroblast growth factor (FGF) 3 from Xenopus laevis (XFGF3) activates the mitogen-activated protein kinase pathway and induces DNA synthesis in quiescent cells. To characterize the high affinity cell surface receptors that mediate these responses, the ligand binding domains of different FGF receptors (FGFR) were expressed on COS-1 cells, and their affinity for XFGF3 was determined. Unlabeled XFGF3 efficiently competed with I-125-FGF1 for binding to the IIIb and IIIc isoforms of FGFR2, giving 50% displacement (ID50) at 0.3-0.8 nM. Higher XFGF3 concentrations were needed to displace I-125-FGF1 from FGFR3 and FGFR1 (ID50 similar to 4 and 21 nM, respectively), indicating that XFGF3 has a lower affinity for these receptors. No association of XFGF3 with FGFR4 was found using this assay. FGFR2 isoforms isolated from both mouse and Xenopus showed similar high affinity binding of XFGF3 as determined by direct binding assays (K-d values in the range of 0.2-0.6 nM). These results indicate that the binding specificity of XFGF3 is different from that of other FGFs, and identifies FGFR2 as its high affinity receptor.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND	Cancer Research UK			Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELL KR, 1992, J BIOL CHEM, V267, P21225; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; EMORI Y, 1992, FEBS LETT, V314, P176, DOI 10.1016/0014-5793(92)80968-M; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; GIMOND S, 1993, J BIOL CHEM, V268, P23906; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GRAVES L, 1964, P NATL ACAD SCI USA, V91, P1662; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1990, DEV BIOL, V138, P453; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN M, 1991, METHOD ENZYMOL C, V198, P158; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SATO M, 1991, ONCOGENE, V6, P1279; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; SHI DL, 1992, DEVELOPMENT, V116, P261; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; STARK KL, 1991, DEVELOPMENT, V113, P641; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TANNAHILL D, 1992, DEVELOPMENT, V115, P695; UEKI K, 1994, J BIOL CHEM, V269, P15756; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	74	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6779	6787		10.1074/jbc.270.12.6779	http://dx.doi.org/10.1074/jbc.270.12.6779			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896824	hybrid			2022-12-27	WOS:A1995QQ85500055
J	BRENNAN, TV; ANDERSON, JW; JIA, ZC; WAYGOOD, EB; CLARKE, S				BRENNAN, TV; ANDERSON, JW; JIA, ZC; WAYGOOD, EB; CLARKE, S			REPAIR OF SPONTANEOUSLY DEAMIDATED HPR PHOSPHOCARRIER PROTEIN CATALYZED BY THE L-ISOASPARTATE-(D-ASPARTATE) O-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-CONTAINING PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; L-ISOASPARTYL RESIDUES; D-ASPARTYL RESIDUES; CARBOXYL METHYLTRANSFERASE; ASPARAGINYL RESIDUES; SPONTANEOUS DEGRADATION; SUCCINIMIDE FORMATION; ESCHERICHIA-COLI; PEPTIDE DEGRADATION	The non-enzymatic deamidation at residues Asn-la and Asn-38 of Escherichia coli phosphocarrier protein, HPr, and the repair of the resulting L-isoaspartyl (or beta-aspartyl) derivatives, HPr-1 and HPr-2, by recombinant human S-adenosylmethionine-dependent L-isoaspartate-(D-aspartate) O-methyltransferase (EC 2.1.1.77) were investigated. HPr is a component of the bacterial phosphoenolpyruvate:sugar phosphotransferase system that is involved in the concomitant translocation and phosphorylation of many hexose sugars. The major products of the deamidation reaction, L-isoaspartyl (or P-aspartyl) residues at positions 12 and 38, were found to be substrates for the L-isoaspartate-(D-aspartate) O-methyltransferase, an enzyme active on a wide variety of peptides and proteins containing these abnormal residues. This enzyme has been shown to catalyze the first step in a process that can convert L-isoaspartyl residues in peptides to normal L-aspartyl residues. The affinity of a recombinant human methyltransferase for HPr-1, a form deamidated at Asn-38, was relatively poor (K-m = 3.6 mM), while a greater affinity was found for HPr-2, a form deamidated at both Asn-12 and Asn-38 (K-m = 197 mu M). When HPr-2 was incubated with S-adenosylmethionine and the methyltransferase, the bulk of the L-isoaspartyl residues at position 12 was converted to L-aspartyl residues, The major by-product was the D-isoaspartyl form. The conversion of L-isoaspartyl residues at position 38 to L-aspartyl residues was less complete, reflecting the lower affinity of the methyltransferase for this site. The phosphohydrolysis activity of the repaired form was found to be midway between the form containing only L-aspartyl residues at positions 12 and 38 and the deamidated HPr-2 form.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SK,CANADA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Saskatchewan					NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANDERSON JW, 1993, BIOCHEMISTRY-US, V32, P5913, DOI 10.1021/bi00073a025; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAPASSO S, 1993, J CHEM SOC PERK T 2, P679, DOI 10.1039/p29930000679; CHAZIN WJ, 1989, BIOCHEMISTRY-US, V28, P8646, DOI 10.1021/bi00447a055; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; CLARKE S, 1992, STABILITY PROTEIN PH, P1; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENT.C, 1990, BIOCHEMISTRY-US, V29, P9586; JIA ZC, 1993, J BIOL CHEM, V268, P22490; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI C, 1992, J BACTERIOL, V174, P355, DOI 10.1128/jb.174.2.355-361.1992; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P364, DOI 10.1016/0167-7799(92)90269-2; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MACLAREN DC, 1992, BIOCHEM BIOPH RES CO, V185, P277, DOI 10.1016/S0006-291X(05)80987-8; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; MURRAY ED, 1984, J BIOL CHEM, V259, P722; MURRAY ED, 1986, J BIOL CHEM, V261, P306; OTA IM, 1989, J BIOL CHEM, V264, P54; OTA IM, 1989, BIOCHEMISTRY-US, V28, P4020, DOI 10.1021/bi00435a058; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; PATEL K, 1990, PHARMACEUT RES, V7, P787, DOI 10.1023/A:1015999012852; PATEL K, 1990, PHARMACEUT RES, V7, P703, DOI 10.1023/A:1015807303766; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SHARMA S, 1993, J BIOL CHEM, V268, P17695; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; YAMADA H, 1985, BIOCHEMISTRY-US, V24, P7953, DOI 10.1021/bi00348a017	43	119	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24586	24595						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929130				2022-12-27	WOS:A1994PQ49000015
J	MARTIN, GEM; SEAMON, KB; BROWN, FM; SHANAHAN, MF; ROBERTS, PE; HENDERSON, PJF				MARTIN, GEM; SEAMON, KB; BROWN, FM; SHANAHAN, MF; ROBERTS, PE; HENDERSON, PJF			FORSKOLIN SPECIFICALLY INHIBITS THE BACTERIAL GALACTOSE H+ TRANSPORT PROTEIN, GALP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE TRANSPORTER; ESCHERICHIA-COLI; SUGAR-TRANSPORT; CYTOCHALASIN-B; SALMONELLA-TYPHIMURIUM; PHOTOAFFINITY LABEL; HUMAN-ERYTHROCYTES; ARABINOSE; GENE; MEMBRANE	Forskolin is a potent inhibitor of mammalian passive glucose transporters. Here we show that forskolin is a remarkably specific inhibitor of energized D-galactose transport by the GalP sugar-H+ symport protein of Escherichia coli. Surprisingly, it does not inhibit transport of L-arabinose or D-xylose by the related E. coli AraE and XylE transporters, even though the amino acid sequences of their proteins are 30-64% identical to GalP and to the mammalian GLUT family. However, unlike GLUT1, photoactivation of the [H-3]forskolin-GalP complex fails to incorporate radioactivity covalently into the protein, in contrast to the effective incorporation of radioactivity from [H-3]cytochalasin B into both proteins, However, 3-[I-125]iodo-4-azidophenethylamido-7-O- succinyldesacetylforskolin ([I-125]APS-forskolin), which labels GLUT1, is a potent labeling reagent for GalP and, to a lesser extent, for AraE. The appropriate sugar substrates of each transporter protect it against the [I-125]APS-forskolin. Equilibrium binding studies using membranes from an E. coli strain that overexpresses GalP reveal a single set of high affinity binding sites for [H-3]forskolin with a K-d of 1.3-1.4 mu M, probably forming a 1:1 complex, compared with a value of 7.5 mu M for GLUT1. Sugar substrates of GalP and cytochalasin B displace forskolin from the protein. The nonhomologous sugar-H+ symporters for L-rhamnose (RhaT), L-fucose (FucP) and lactose (LacY) in E. coli are insensitive to forskolin. Forskolin and [I-125]APS-forskolin, therefore, constitute novel probes for exploring the structure-activity relationship of the bacterial GalP protein. GalP will provide an excellent model for the human glucose transporters and for elucidating the molecular basis of subtle differences in substrate and inhibitor recognition by individual members of this widespread family of transport proteins.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; US FDA, DIV BIOCHEM & BIOPHYS, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA; UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1EW, ENGLAND; SO ILLINOIS UNIV, SCH MED, DEPT PHYSIOL, CARBONDALE, IL 62901 USA	University of Leeds; US Food & Drug Administration (FDA); University of Cambridge; Southern Illinois University System; Southern Illinois University			Henderson, Peter JF/Q-1907-2018	Henderson, Peter/0000-0002-9187-0938	NIDDK NIH HHS [DK 36855] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036855] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1975, J BIOL CHEM, V250, P6032; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BLOCH R, 1973, BIOCHEMISTRY-US, V12, P4799, DOI 10.1021/bi00747a036; CAIRNS MT, 1991, J BIOL CHEM, V266, P8176; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CHARALAMBOUS BM, 1989, BIOCHEM SOC T, V17, P441; Cleland W W, 1979, Methods Enzymol, V63, P103; DARUWALLA KR, 1981, BIOCHEM J, V200, P611, DOI 10.1042/bj2000611; DAVIS EO, 1984, J BIOL CHEM, V259, P1520; DENT HC, 1993, THESIS U CAMBRIDGE; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; FUTAI M, 1978, BACTERIAL TRANSPORT, P7; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HENDERSON PJF, 1992, INT REV CYTOL, V137A, P149; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; HENDERSON PJF, 1977, BIOCHEM J, V168, P15, DOI 10.1042/bj1680015; HORNE P, 1983, BIOCHEM J, V210, P699, DOI 10.1042/bj2100699; JOOST HG, 1988, MOL PHARMACOL, V33, P449; JUNG CY, 1977, J BIOL CHEM, V252, P5456; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KRUPKA RM, 1971, BIOCHEMISTRY-US, V10, P1143, DOI 10.1021/bi00783a007; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEIVE L, 1965, BIOCHEM BIOPH RES CO, V21, P290, DOI 10.1016/0006-291X(65)90191-9; MACPHERSON AJS, 1983, J BIOL CHEM, V258, P4390; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MCKEOWN BJ, 1992, THESIS U CAMBRIDGE; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; MUIRY JAR, 1993, BIOCHEM J, V290, P833, DOI 10.1042/bj2900833; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PETRO KR, 1988, THESIS U CAMBRIDGE; ROBBINS AR, 1975, J BACTERIOL, V123, P69, DOI 10.1128/JB.123.1.69-74.1975; ROBBINS AR, 1975, P NATL ACAD SCI USA, V72, P423, DOI 10.1073/pnas.72.2.423; ROBERTS PE, 1992, THESIS U CAMBRIDGE; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SERGEANT S, 1985, J BIOL CHEM, V260, P4677; SHANAHAN MF, 1987, J BIOL CHEM, V262, P5978; TATE CG, 1993, J BIOL CHEM, V268, P26850; TATE CG, 1992, J BIOL CHEM, V267, P6923; WADZINSKI BE, 1988, BIOCHEM J, V255, P983, DOI 10.1042/bj2550983; WADZINSKI BE, 1987, J BIOL CHEM, V262, P17683; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WALMSLEY AR, 1993, EUR J BIOCHEM, V215, P43, DOI 10.1111/j.1432-1033.1993.tb18005.x; WALMSLEY AR, 1994, EUR J BIOCHEM, V221, P513, DOI 10.1111/j.1432-1033.1994.tb18763.x; WALMSLEY AR, 1994, J BIOL CHEM, V269, P17009; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; WITHOLT B, 1978, BIOCHIM BIOPHYS ACTA, V508, P296, DOI 10.1016/0005-2736(78)90332-2	49	21	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24870	24877						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929167				2022-12-27	WOS:A1994PQ49000054
J	OHASHI, M; HUTTNER, WB				OHASHI, M; HUTTNER, WB			AN ELEVATION OF CYTOSOLIC PROTEIN-PHOSPHORYLATION MODULATES TRIMERIC G-PROTEIN REGULATION OF SECRETORY VESICLE FORMATION FROM THE TRANS-GOLGI NETWORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; HETEROTRIMERIC G-PROTEIN; ADP-RIBOSYLATION FACTOR; POLYMERIC IMMUNOGLOBULIN RECEPTOR; KINASE-C PHOSPHORYLATION; BREFELDIN-A; GUANINE-NUCLEOTIDE; POTENT INHIBITOR; EGF RECEPTOR; ENDOPLASMIC-RETICULUM	The role of protein phosphorylation in the formation of secretory vesicles from the trans Golgi network (TGN) and in the regulation of this process by TGN-associated trimeric G-proteins was investigated, using a previously established and a novel cell-free system derived from the neuroendocrine cell line PC12. In the absence of exogenous activators of trimeric G-proteins, okadaic acid, an inhibitor of protein serine/threonine phosphatase types 1, 2A, and PPX, had no significant effect on secretory vesicle formation as reconstituted in a postnuclear supernatant. However, okadaic acid antagonized the inhibition of secretory vesicle formation which occurred upon activation of trimeric G-proteins by either aluminum fluoride or guanosine 5'-3-O-(thio)-triphosphate (GTP gamma S). Microcystin LR, a protein phosphatase inhibitor structurally distinct from okadaic acid, also antagonized the trimeric G-protein-mediated inhibition of secretory vesicle formation but, in contrast to okadaic acid, alone was sufficient to stimulate this process. The antagonistic effect of the phosphatase inhibitors was abolished by a broad spectrum protein kinase inhibitor, staurosporine, which alone, however, did not affect vesicle formation. The effect of okadaic acid was promoted by activators of protein kinase C (phorbol myristate acetate) and protein kinase A (cyclic AMP). To investigate the subcellular localization of the phosphoprotein that is involved in the antagonistic effect of protein phosphatase inhibitors, a novel cell-free system was established which reconstitutes the formation of secretory vesicles from TGN membranes supplemented with cytosol. Using this cell-free system, the relevant phosphoprotein was found to reside in the cytosol. In conclusion, our results suggest that serine/threonine protein phosphorylation is not required for secretory vesicle formation from the TGN but modulates, via a cytosolic phosphoprotein, the regulation of this process by TGN-associated trimeric G-proteins.	UNIV HEIDELBERG, INST NEUROBIOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg			Huttner, Wieland B./P-4080-2018					ANTONNY B, 1992, J BIOL CHEM, V267, P6710; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRIFFITHS G, 1990, J CELL SCI, V96, P691; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LUCOCQ J, 1991, J CELL SCI, V100, P753; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; OHASHI M, 1991, EXP CELL RES, V197, P168, DOI 10.1016/0014-4827(91)90419-U; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROSA P, 1992, EUR J CELL BIOL, V59, P265; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STUART RA, 1993, J BIOL CHEM, V268, P4050; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TBOZE SA, 1992, METHOD ENZYMOL, V219, P81; TBOZE SA, 1990, CELL, V60, P837; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331	73	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24897	24905						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929171				2022-12-27	WOS:A1994PQ49000058
J	TAWFIC, S; AHMED, K				TAWFIC, S; AHMED, K			GROWTH STIMULUS-MEDIATED DIFFERENTIAL TRANSLOCATION OF CASEIN KINASE-2 TO THE NUCLEAR MATRIX - EVIDENCE BASED ON ANDROGEN ACTION IN THE PROSTATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; DNA TOPOISOMERASE-II; C-MYC PROTEIN; POLYCLONAL ANTIBODIES; CELLULAR-REGULATION; PHOSPHORYLATION; BINDING; ENZYME; IDENTIFICATION; TRANSCRIPTION	Recently, we documented that a significant amount of nuclear casein kinase 2 (CK2) (a ubiquitous multipotential messenger-independent serine/threonine protein kinase) is associated with the nuclear matrix (NM), where it may be involved in the phosphorylation of several intrinsic proteins (Tawfic, S., and Ahmed, K. (1994) J. Biol. Chem. 269, 7489-7493). Both CK2 and NM have been implicated in cell growth and proliferation. To examine whether CK2 in the NM was regulated in relation to a growth stimulus, we employed androgen action in the prostate as a model of growth control. In rats, androgen deprivation leads to a differential loss of CK2 activity and protein from the NM fraction in the prostate. At 24 h after androgen deprivation, the NM-associated CK2 activity as well as immunoreactive protein decline by about 80%. By comparison, total nuclear CK2 activity decreased by only 37%. Androgen administration to the castrated rats evokes a rapid differential increase in CK2 activity in the NM, so that within 1 h following the androgenic stimulus, the CK2 activity increases by 110% in the NM fraction versus 45% in the total nuclei. We propose that the stimulus-mediated differential translocation of CK2 to NM may play a role in the transduction of growth signal.	DEPT VET AFFAIRS MED CTR, CELLULAR & MOLEC BIOCHEM RES LAB 151, MINNEAPOLIS, MN 55417 USA; DEPT VET AFFAIRS MED CTR, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [U01CA015062, R37CA015062, R01CA015062] Funding Source: NIH RePORTER; NCI NIH HHS [CA-15062] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; AHMED K, 1993, CELL MOL BIOL RES, V39, P451; AHMED K, 1987, BIOCHEM ACTION HORM, V14, P237; AHMED K, 1993, P NATL ACAD SCI USA, V90, P4426, DOI 10.1073/pnas.90.10.4426; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; AHMED K, 1971, MOL PHARMACOL, V7, P323; AHMED K, 1992, RECENT ADV CELLULAR, V4, P7; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AURICCHIO F, 1981, BIOCHEM J, V194, P569, DOI 10.1042/bj1940569; BARRACK ER, 1980, J BIOL CHEM, V255, P7265; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHAN PK, 1986, J BIOL CHEM, V261, P1868; Coffey D.S., 1988, P1081; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DUMBAR TS, 1989, THESIS U MISSISSIPPI; ENGLISH HF, 1989, PROSTATE, V15, P233, DOI 10.1002/pros.2990150304; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GETZENBERG RH, 1990, MOL ENDOCRINOL, V4, P1336, DOI 10.1210/mend-4-9-1336; GETZENBERG RH, 1991, J CELL BIOCHEM, V47, P289, DOI 10.1002/jcb.240470402; GETZENBERG RH, 1990, ENDOCR REV, V11, P399, DOI 10.1210/edrv-11-3-399; GOLSTEYN EJ, 1989, PROSTATE, V14, P91, DOI 10.1002/pros.2990140203; GOUELI SA, 1990, BIOCHEM INT, V21, P685; GOUELI SA, 1984, ARCH BIOCHEM BIOPHYS, V234, P646, DOI 10.1016/0003-9861(84)90315-1; GOUELI SA, 1980, EUR J BIOCHEM, V113, P45; GOUELI SA, 1991, MOL CELL BIOCHEM, V101, P145; GOUELI SA, 1984, BIOCHEM BIOPH RES CO, V123, P778, DOI 10.1016/0006-291X(84)90297-3; HOTZ MA, 1992, EXP CELL RES, V201, P184, DOI 10.1016/0014-4827(92)90362-C; HOUSLEY PR, 1982, J BIOL CHEM, V257, P8615; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; LIAO S, 1966, P NATL ACAD SCI USA, V55, P1593, DOI 10.1073/pnas.55.6.1593; LIAO S, 1989, J STEROID BIOCHEM, V34, P41, DOI 10.1016/0022-4731(89)90064-2; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MAINWARING WIP, 1983, J STEROID BIOCHEM, V19, P101, DOI 10.1016/S0022-4731(83)80012-0; MCCABE MJ, 1993, BIOCHEM BIOPH RES CO, V194, P944, DOI 10.1006/bbrc.1993.1912; MEEK DW, 1992, BIOCHEM J, V287, P1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOUDGIL VK, 1990, BIOCHIM BIOPHYS ACTA, V1055, P243, DOI 10.1016/0167-4889(90)90040-K; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NICKERSON JA, 1990, EUKARYOTIC NUCLEUS M, V2, P763; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; SAMUELS DS, 1992, J BIOL CHEM, V267, P11156; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TAWF, 1994, J BIOL CHEM, V269, P7489; TAWFIC S, 1993, CELL MOL BIOL RES, V39, P43; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WAITZ W, 1991, ONCOGENE, V6, P29; WILLIAMSASHMAN HG, 1979, ENDOCRINOLOGY, V3, P1527; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	71	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24615	24620						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929133				2022-12-27	WOS:A1994PQ49000019
J	GETHER, U; NILSSON, L; LOWE, JA; SCHWARTZ, TW				GETHER, U; NILSSON, L; LOWE, JA; SCHWARTZ, TW			SPECIFIC RESIDUES AT THE TOP OF TRANSMEMBRANE SEGMENT-V AND SEGMENT-VI OF THE NEUROKININ-1 RECEPTOR INVOLVED IN BINDING OF THE NONPEPTIDE ANTAGONIST CP-96,345	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P NK1 RECEPTOR; SUBSTANCE-P; EXPRESSION; EPITOPES	Previously we have found that binding of the nonpeptide substance P antagonists, CP 96,345, to the neurokinin-1 (NK-1) receptor was critically dependent on two short segments adjacent to the top of transmembrane segments (TM) V and VI, called segments A (residues 183-195) and D (residues 271-276), respectively. In the present study we have systematically performed substitutions of nonconserved residues within these two segments with residues from the homologous NK-3 and/or NK-2 receptor. In segment A, deletion of residues Glu(193) and Lys(194), which are not present in the NK-3 receptor, or substituting them with leucines as in the NK-2 receptor, decreased the affinity of CP 96,345 10- and 22-fold, respectively. Surprisingly, switching the position of Glu(193) and Lys(194) did not affect the affinity of CP 96,345, suggesting that, rather than interacting directly with CP 96,345, an interaction of these residues with one another is important for CP 96,345 binding. In segment D substitution of Tyr(272) with threonine as in the NK-2 receptor and with alanine as in the NK-3 receptor decreased the affinity of CP 96,345 7- and 24-fold, respectively. Mutation of the preceding Pro(271) to, glycine alone did not affect CP 96,345 binding, but, combined with the mutation of Tyr(272) to threonine, the affinity decreased 28-fold. A series of CP 96,345 analogues with modifications of the major chemical moieties exhibited equally reduced affinity as that of CP 96,345 for the Tyr(272)- and Lys(193)-Glu(194)- substituted constructs, except CP 95,555, which lacks one of the phenyl rings in the benzhydryl group and which was almost unaffected by these mutations, In conclusion, our data indicate a direct interaction between CP 96,345 and Tyr(272), which are located at the top of TM VI likely in close spatial proximity to the previously identified interaction point, His(197), at the top of the adjacent TM V. Furthermore, the data demonstrated a critical involvement in CP 96,345 binding of Lys(193) and Glu(194) located one alpha-helical turn above His(197).	UNIV COPENHAGEN,RIGSHOSP 6321,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK; PFIZER INC,DIV CENT RES,DEPT EXPLORATORY MED CHEM,GROTON,CT 06340	Rigshospitalet; University of Copenhagen; Pfizer				Schwartz, Thue W./0000-0002-0261-6904; Gether, Ulrik/0000-0002-0020-3807; nilsson, lars/0000-0002-8362-1042				BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; Freidinger R M, 1993, Prog Drug Res, V40, P33; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; GETHER U, 1994, MOL PHARMACOL, V45, P500; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; LOWE JA, 1993, BIOORG MED CHEM LETT, V3, P921, DOI 10.1016/S0960-894X(00)80693-9; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; TOTA MR, 1990, J BIOL CHEM, V265, P16891; WATLING KJ, 1992, TRENDS PHARMACOL SCI, V13, P266, DOI 10.1016/0165-6147(92)90082-H; WATLING KJ, 1993, TRENDS PHARMACOL SCI, V14, P14; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	26	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23959	23964						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929043				2022-12-27	WOS:A1994PQ34600019
J	MAO, XD; SHUMAN, S				MAO, XD; SHUMAN, S			INTRINSIC RNA (GUANINE-7) METHYLTRANSFERASE ACTIVITY OF THE VACCINIA VIRUS CAPPING ENZYME D1 SUBUNIT IS STIMULATED BY THE D12 SUBUNIT - IDENTIFICATION OF AMINO-ACID-RESIDUES IN THE D1 PROTEIN REQUIRED FOR SUBUNIT ASSOCIATION AND METHYL-GROUP TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; SCANNING MUTAGENESIS; DNA; SEQUENCE; GUANYLYLTRANSFERASE; CATALYSIS; DOMAINS	Vaccinia virus mRNA capping enzyme, a heterodimer of virus-encoded D1 and D12 subunits, catalyzes three steps in the synthesis of the m(7)GpppN cap. By expressing portions of the subunits in bacteria, singly and together, we have localized the RNA (guanine-7) methyltransferase domain to a 305-amino acid carboxyl-terminal segment of the D1 polypeptide (residues 540-844) complexed with the D12 protein. We find that the purified carboxyl D1 protein has a weak intrinsic methyltransferase activity, indicating that the catalytic center resides within this subunit. The basal level of activity can be stimulated 100-fold by addition of purified D12 protein, which is itself catalytically inert. The carboxyl region of D1 forms a heterodimer with the D12 subunit in vivo and in vitro. Analysis of alanine substitution mutants of the D1 protein identifies amino acid residues important for subunit interaction. Our results suggest that subunit heterodimerization is necessary, but not sufficient, for full methyltransferase activity. A mutation of vicinal positions His-682-Tyr-683 that specifically affects catalytic activity but not subunit interaction implicates these residues as constituents of the active site.			MAO, XD (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT WF, 1991, J BIOL CHEM, V266, P5191; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; PENA L, 1993, VIROLOGY, V193, P319, DOI 10.1006/viro.1993.1128; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; UPTON C, 1991, VIROLOGY, V183, P773, DOI 10.1016/0042-6822(91)91009-6; VENKATESAN S, 1980, J BIOL CHEM, V255, P903	25	77	90	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24472	24479						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929111				2022-12-27	WOS:A1994PQ34600096
J	SPUHLER, P; ANANTHARAMAIAH, GM; SEGREST, JP; SEELIG, J				SPUHLER, P; ANANTHARAMAIAH, GM; SEGREST, JP; SEELIG, J			BINDING OF APOLIPOPROTEIN-A-I MODEL PEPTIDES TO LIPID BILAYERS - MEASUREMENT OF BINDING ISOTHERMS AND PEPTIDE-LIPID HEADGROUP INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CYCLIC SOMATOSTATIN ANALOG; PHOSPHOLIPID HEAD GROUPS; AMPHIPATHIC HELIX; PHOSPHATIDYLCHOLINE BILAYERS; ELECTRIC CHARGE; CALCIUM-BINDING; MEMBRANES; DEUTERIUM; HYDROPHOBICITY	Amphiphatic cu-helices are the lipid-binding motif in many apolipoproteins. Two model peptides, namely Asp-Trp-Leu-Lys-Ala-Phe-Tyr-Asp-Lys-Val-Ala-Glu-Lys-Leu-Lys-Glu-Ala-Phe (18A) and Lys-Trp-Leu-Asp-Ala-Phe-Tyr-Lys-Asp-Val -Ala-Lys-Glu-Leu-Glu-Lys-Ala-Phe (18R), have been synthesized previously to mimic the structural and functional properties of apolipoprotein A-1. Here a quantitative thermodynamic analysis of the binding process of 18A and 18R to neutral and negatively charged lipid membranes is provided. Peptide 18A has a higher lipid affinity than 18R, and both peptides bind better to mixed 1-palmitoyl-2-oleoyl-3-sn-glycero phosphocholine/1-palmitoyl-2-oleoyl-3-sn-glycero-phosphoglycerol (POPC/POPG) bilayers than to pure POPC bilayers. At lipid-to-peptide ratios >100, the binding of 18A and 18R to phospholipid bilayers can be described by an apparent surface partition equilibrium with binding constants in the range of 40-900 M(-1). At high peptide concentrations, the membrane affinity of 18A and 18R increases dramatically NMR studies provide evidence that peptide-peptide interactions make additional contributions to the binding energy. A cooperative binding model is developed to describe the binding process over the whole concentration range. The cooperativity parameter a is identical for 18A and 18R yielding a peptide-peptide interaction energy of about -2.4 kcal/mol. The free energy of membrane insertion is about -6.5 kcal/mol for 18A and -5.5 kcal/mol for 18R. The binding reaction is driven by the hydrophobic surface energy which is partially balanced by the loss in translational and rotational degrees of freedom. A molecular analysis of the free energy of binding predicts a 40-60% insertion of the peptides into the hydrophobic membrane environment. Deuterium and phosphorus solid state NMR were used to monitor the influence of 18A and 18R on the long range and short range order of the phospholipids. The sprectra are characteristic of fluid-like lipid bilayers and provide no evidence for the formation of discoidal particles. However, both peptides change the conformation of the phosphocholine dipoles, moving the N+ end of the latter toward the water phase. The rotation of the P---N+ dipoles is due to the interaction of the phospholipids with the positive charges on 18A and 18R, with 18A being more effective than 18R. For 18R the NMR data predict a pK shift and a partial charge neutralization of the carboxylate groups located at the edge of the polar/nonpolar interface.	UNIV BASEL,BIOCTR,DEPT BIOPHYS,CH-4056 BASEL,SWITZERLAND; UNIV ALABAMA,MED CTR,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,ARTERIOSCLEROSIS RES UNIT,BIRMINGHAM,AL 35294	University of Basel; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTENBACH C, 1984, BIOCHEMISTRY-US, V23, P3913, DOI 10.1021/bi00312a019; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P109; BAUERLE HD, 1991, BIOCHEMISTRY-US, V30, P7203, DOI 10.1021/bi00243a023; BAUERLE HD, 1991, THESIS U BASEL; BECHINGER B, 1991, BIOCHEMISTRY-US, V30, P3923, DOI 10.1021/bi00230a017; BESCHIASCHVILI G, 1992, BIOCHEMISTRY-US, V31, P10044, DOI 10.1021/bi00156a026; BESCHIASCHVILI G, 1991, BIOCHIM BIOPHYS ACTA, V1061, P78, DOI 10.1016/0005-2736(91)90270-I; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P10995, DOI 10.1021/bi00501a018; BOULANGER Y, 1981, BIOCHEMISTRY-US, V20, P6824, DOI 10.1021/bi00527a013; CANTOR CR, 1980, BIOPHYSICAL CHEM, V1, P283; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; EPAND RM, 1987, J BIOL CHEM, V262, P9389; EPAND RM, 1989, J BIOL CHEM, V264, P4628; FERNANDEZ MS, 1977, J PHYS CHEM-US, V81, P1755, DOI 10.1021/j100533a009; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HABIGER RGK, 1992, BIOCHIM BIOPHYS ACTA, V1103, P69, DOI 10.1016/0005-2736(92)90058-T; JAHNIG F, 1983, P NATL ACAD SCI-BIOL, V80, P3691, DOI 10.1073/pnas.80.12.3691; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; KUCHINKA E, 1989, BIOCHEMISTRY-US, V28, P4216, DOI 10.1021/bi00436a014; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P6292, DOI 10.1021/bi00393a050; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P1231, DOI 10.1021/bi00379a005; MACDONALD PM, 1988, BIOCHEMISTRY-US, V27, P6769, DOI 10.1021/bi00418a019; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROBINSON BH, 1975, CHEM BIOL APPLICATIO, P481; ROUX M, 1989, BIOCHEMISTRY-US, V28, P2313, DOI 10.1021/bi00431a050; SCHERER PG, 1989, BIOCHEMISTRY-US, V28, P7720, DOI 10.1021/bi00445a030; SEELIG A, 1988, BIOCHIM BIOPHYS ACTA, V939, P267, DOI 10.1016/0005-2736(88)90070-3; SEELIG J, 1993, BIOCHEMISTRY-US, V32, P9714, DOI 10.1021/bi00088a025; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1991, MOL CONFORMATION BIO, P597; TAMM LK, 1983, BIOCHEMISTRY-US, V22, P1474, DOI 10.1021/bi00275a023; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; YEAGLE PL, 1993, BIOCHEMISTRY-US, V32, P12197, DOI 10.1021/bi00096a032	38	49	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23904	23910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929037				2022-12-27	WOS:A1994PQ34600012
J	YUKIHIRO, S; POSNER, GH; GUGGINO, SE				YUKIHIRO, S; POSNER, GH; GUGGINO, SE			VITAMIN-D-3 ANALOGS STIMULATE CALCIUM CURRENTS IN RAT OSTEOSARCOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; OSTEO-SARCOMA; CHANNEL; OSTEOBLASTS; TRANSCALTACHIA; METABOLITES; CALCITRIOL; D3	1 alpha,25-Dihydroxyvitamin D-3 (1,25-D-3) rapidly (within seconds) shifts the threshold for activation of inward calcium currents to more negative and physiological potentials. To determine whether the opening of calcium channels in bone cells is mediated by the cytosolic 1,25-dihydroxyvitamin D-3 receptor (VDR), several natural metabolites 1,25-D-3, 25-hydroxyvitamin D-3, and 24R,25-dihydroxyvitamin D-3 and synthetic analogs 25-hydroxy-16,23E-diene D-3 (HO), 25-hydroxy-23-yne D-3 (Y), and 1 alpha,25-dihydroxy-16-ene-23-yne-26,27-F6 D-3 (EO) were tested on dihydropyridine-sensitive inward barium currents. In order to probe the structural specificity at the 1 position of the steroid for stimulation of barium currents, we used several synthetic 1-(1'-hydroxyethyl) (NP, ON, NN, OP) and 1-(2'-hydroxyethyl)-25-hydroxyvitamin D-3 analogs (14w-1 alpha and 14w-1 beta). Using the perforated patch-clamp technique, we found that the naturally occurring vitamin D-3 analogs gave nearly the same rank order potency for stimulation of barium currents as their affinity for VDR with 1,25-D-3 being the most potent analog. Using the synthetic analogs which have minimal affinity for VDR, we found that the compounds without 1-OH group but with additional double bonds in positions 16 and 23 or with a triple bond in position 23 retained high affinity for calcium channel activation. Furthermore, 1-hydroxyethyl-25-hydroxyvitamin D-3 R isomers at the 1' position had greater affinity than the S isomers at this position, and a beta oriented 2'-hydroxyethyl group gave the homolog greater affinity than did the alpha-oriented 2'-hydroxyethyl group. The fact that these synthetic analogs cause rapid effects on calcium channels and show pharmacological specificity different from the binding to the cytosolic vitamin D-3 receptor suggests that calcium influx is mediated by a distinct signal transduction pathway. The high and physiological affinity of 1,25-D-3 (50 pM) suggests that it is a biological regulator of calcium channels.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH ARTS & SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43423] Funding Source: Medline; NIGMS NIH HHS [GM-30052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIKLE DD, 1978, J BIOL CHEM, V253, P8382; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHESNOYMARCHAIS D, 1988, J PHYSIOL-LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043; DUNCAN RL, 1992, FEBS LETT, V307, P219, DOI 10.1016/0014-5793(92)80771-8; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FERRARA J, 1994, J BIOL CHEM, V269, P2971; GUGGINO SE, 1989, P NATL ACAD SCI USA, V86, P2957, DOI 10.1073/pnas.86.8.2957; HENRY PD, 1980, AM J CARDIOL, V46, P1047, DOI 10.1016/0002-9149(80)90366-5; KIM YS, 1994, 9TH WORKSH VIT D ORL; KRAFTE DS, 1988, J GEN PHYSIOL, V91, P641, DOI 10.1085/jgp.91.5.641; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; POSNER GH, 1993, BIOORG MED CHEM LETT, V3, P1829, DOI 10.1016/S0960-894X(00)80114-6; POSNER GH, 1993, J ORG CHEM, V58, P7209, DOI 10.1021/jo00077a052; PROCSAL DA, 1975, J BIOL CHEM, V250, P8382; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; SCHAUF CL, 1975, J PHYSIOL-LONDON, V248, P613, DOI 10.1113/jphysiol.1975.sp010991; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; ZHOU LX, 1992, J BONE MINER RES, V7, P457	23	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23889	23893						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929036				2022-12-27	WOS:A1994PQ34600010
J	BAUBICHONCORTAY, H; BAGGETTO, LG; DAYAN, G; DIPIETRO, A				BAUBICHONCORTAY, H; BAGGETTO, LG; DAYAN, G; DIPIETRO, A			OVEREXPRESSION AND PURIFICATION OF THE CARBOXYL-TERMINAL NUCLEOTIDE-BINDING DOMAIN FROM MOUSE P-GLYCOPROTEIN - STRATEGIC LOCATION OF A TRYPTOPHAN RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTATHIONE-S-TRANSFERASE; CONFER MULTIDRUG RESISTANCE; ATP-DEPENDENT TRANSPORT; CYSTIC-FIBROSIS; ESCHERICHIA-COLI; ADENYLATE KINASE; CATALYTIC SITE; SCHIZOSACCHAROMYCES-POMBE; ADENOSINE-TRIPHOSPHATASE	The cDNA encoding the C-terminal nucleotide binding domain (NBD2) from mouse P-glycoprotein involved in multidrug resistance was obtained from adrenal cell mRNA and amplified by reverse transcriptase polymerase chain reaction. NBD2 was highly overexpressed in Escherichia coli in fusion with glutathione S-transferase and could be purified after efficient thrombin cleavage. Both fused and purified NBD2 bound TNP (2',3'-O-(2,4,6-trinitrophenyl))-derivatives of nucleotides with high affinity. TNP-ATP or TNP-ADP binding at micromolar concentrations produced a characteristic blueshifted enhancement of extrinsic fluorescence and was specifically prevented or chased by ATP or ADP at millimolar concentrations. A similar affinity binding was monitored by quenching of intrinsic fluorescence. The spectrum of fusion protein, containing 5 tryptophan residues, was maximally quenched at 328 nm upon interaction with TNP-nucleotides. TNP-GTP exhibited a lower affinity than TNP-ATP but produced a higher maximal quenching (44% instead of 28%). The intrinsic fluorescence of purified NBD2, containing a single tryptophan residue, exhibited a narrow spectrum with a maximum at 328 nm characteristic of a hydrophobic tryptophan environment. A high quenching was observed upon nucleotide interaction with similar affinity The results put forward a functional role for the tryptophan-containing sequence of P-glycoprotein NBD2 that was not detected up to now.	UNIV LYON 1, INST BIOL & CHIM PROT,BIOCHIM STRUCT & FONCT LAB, CNRS,UPR 412, F-69367 LYON 07, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1				, Loris G/0000-0002-2412-8661				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1994, J BIOL CHEM, V269, P2206; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIEDERICHS K, 1991, J MOL BIOL, V217, P541, DOI 10.1016/0022-2836(91)90756-V; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DIVITA G, 1992, BIOCHEMISTRY-US, V31, P5791, DOI 10.1021/bi00140a015; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P14; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FALSON P, 1993, BIOCHEMISTRY-US, V32, P10387, DOI 10.1021/bi00090a014; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUILLOT D, 1993, J BIOL CHEM, V268, P20911; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HIRATSUKA T, 1985, J BIOL CHEM, V260, P4784; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HOYER PB, 1986, ARCH BIOCHEM BIOPHYS, V245, P369, DOI 10.1016/0003-9861(86)90228-6; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JAULT JM, 1993, J BIOL CHEM, V268, P20762; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KO YH, 1993, J BIOL CHEM, V268, P24330; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P3; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; LOO TW, 1994, J BIOL CHEM, V269, P7750; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MORBACH S, 1993, J BIOL CHEM, V268, P18617; OKAJIMA T, 1993, FEBS LETT, V334, P86, DOI 10.1016/0014-5793(93)81687-U; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; UEDA K, 1992, J BIOL CHEM, V267, P24248; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; YAN HG, 1990, BIOCHEMISTRY-US, V29, P10956, DOI 10.1021/bi00501a013; YANG CPH, 1989, J BIOL CHEM, V264, P782	70	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					22983	22989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916013				2022-12-27	WOS:A1994PQ16400015
J	PARKINSON, SJ; CARRITHERS, SL; WALDMAN, SA				PARKINSON, SJ; CARRITHERS, SL; WALDMAN, SA			OPPOSING ADENINE NUCLEOTIDE-DEPENDENT PATHWAYS REGULATE GUANYLYL CYCLASE-C IN RAT INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ENTEROTOXIN; NATRIURETIC-PEPTIDE RECEPTOR; ESCHERICHIA-COLI; CELL-LINE; ACTIVATION; TOXIN; ATP; BINDING; EXPRESSION; MEMBRANES	Opposing adenine nucleotide-dependent pathways regulating guanylyl cyclase C (GC-C) in rat intestinal membranes have been identified and characterized. ATP analogues substituted in the 2-position were potent inhibitors of basal and Escherichia coli heat-stable enterotoxin (ST)-stimulated GC-C, independent of the metal cation cofactor present. Inhibition of GC-C was associated with large changes in V-max but only small changes in the S-0.5, suggesting a noncompetitive mechanism. Also, inhibition of GC-C was associated with a concentration-dependent shift from positive to negative cooperativity when manganese served as the cation cofactor. These data support the existence of a noncompetitive allo steric regulatory mechanism mediating adenine nucleotide-dependent inhibition of GC-C. Adenine nucleotides not substituted in the 2-position potentiated the activation of GC-C by ST in intestinal membranes. The potentiating and inhibitory pathways regulating GC-C enzyme activity were separate and distinct. A specific inhibitor (2-chloroadenosine 5'-triphosphate (2C1ATP)), was without effect on the potency of a selective activator (adenosine 5'-O-thiomonophosphate (AMPS)) of GC-C. Similarly AMPS was without effect on the potency of 2C1ATP to inhibit GC-C. These data suggest that adenine nucleotide-dependent activation and inhibition are mediated by independent sites which may modulate the second messenger response of GC-C to ST.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,DIV CLIN PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University	PARKINSON, SJ (corresponding author), THOMAS JEFFERSON UNIV,DEPT MED,PHILADELPHIA,PA 19107, USA.			Waldman, Scott/0000-0001-6619-175X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK043805] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 R55 DK43805] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYER JL, 1989, J BIOL CHEM, V264, P884; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER RM, 1970, J BIOL CHEM, V245, P6274; CARR S, 1989, INT J BIOCHEM, V21, P1211, DOI 10.1016/0020-711X(89)90005-0; CHANG CH, 1990, EUR J PHARM-MOLEC PH, V189, P293, DOI 10.1016/0922-4106(90)90122-E; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COHEN MB, 1993, J CELL PHYSIOL, V156, P138, DOI 10.1002/jcp.1041560119; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; GARBERS DL, 1974, BIOCHEMISTRY-US, V13, P4166, DOI 10.1021/bi00717a015; GARBERS DL, 1992, CELL, V71, P1; GAZZANO H, 1991, BIOCHIM BIOPHYS ACTA, V1077, P99, DOI 10.1016/0167-4838(91)90531-4; GAZZANO H, 1991, INFECT IMMUN, V59, P1552, DOI 10.1128/IAI.59.4.1552-1557.1991; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; GUERRANT RL, 1980, J INFECT DIS, V142, P220, DOI 10.1093/infdis/142.2.220; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HUGUES M, 1991, BIOCHEMISTRY-US, V30, P10738, DOI 10.1021/bi00108a019; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; IVENS K, 1990, INFECT IMMUN, V58, P1817, DOI 10.1128/IAI.58.6.1817-1820.1990; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LI ZP, 1993, AM J PHYSIOL, V265, pG394, DOI 10.1152/ajpgi.1993.265.2.G394; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MARALA RB, 1991, FEBS LETT, V281, P73, DOI 10.1016/0014-5793(91)80361-6; OKAJIMA F, 1990, J BIOL CHEM, V265, P21741; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P19598; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; VISWESWARIAH SS, 1994, EUR J BIOCHEM, V219, P727, DOI 10.1111/j.1432-1033.1994.tb18551.x; WALDMAN SA, 1984, J INFECT DIS, V149, P83, DOI 10.1093/infdis/149.1.83	40	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22683	22690						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915717				2022-12-27	WOS:A1994PQ16300037
J	SOMMERLADE, HJ; SELMER, T; INGENDOH, A; GIESELMANN, V; VONFIGURA, K; NEIFER, K; SCHMIDT, B				SOMMERLADE, HJ; SELMER, T; INGENDOH, A; GIESELMANN, V; VONFIGURA, K; NEIFER, K; SCHMIDT, B			GLYCOSYLATION AND PHOSPHORYLATION OF ARYLSULFATASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LYSOSOMAL-ENZYME; LINKED OLIGOSACCHARIDES; PROTEIN; FIBROBLASTS; EXPRESSION; RECEPTOR; SIGNAL	The glycosylation and phosphorylation of the lysosomal enzyme arylsulfatase A was analyzed by a combination of metabolic labeling, tryptic fragmentation, mass spectrometry, and radiosequencing. The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides. Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350). Both are phosphorylated with comparable efficiency. An earlier study had shown that a mutant arylsulfatase A containing only the second N-glycosylation site at Asn-184 folds correctly and is phosphorylated (Gieselmann, V., Schmidt, B., and von Figura, K. (1992) J. Biol. Chem. 267, 13262-13266). The lack of phosphorylation at Asn-184 in wild type arylsulfatase A therefore indicates that in vivo the presence of oligosaccharides can interfere with phosphorylation of other sites or that phosphorylation occurs in an ordered manner whereby phosphorylation of one site can affect the phosphorylation of another site.	UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOLEK ZELLBIOL,BIOCHEM ABT 2,D-37073 GOTTINGEN,GERMANY; UNIV MUNSTER,INST MED PHYS & BIOPHYS,D-48149 MUNSTER,GERMANY	University of Gottingen; University of Munster								BACH G, 1983, BIOCHEM BIOPH RES CO, V112, P198, DOI 10.1016/0006-291X(83)91816-8; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; FLUHARTY AL, 1983, BIOCHEM BIOPH RES CO, V112, P191, DOI 10.1016/0006-291X(83)91815-6; GIESELMANN V, 1989, P NATL ACAD SCI USA, V86, P9436, DOI 10.1073/pnas.86.23.9436; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; HERMANS MMP, 1993, BIOCHEM J, V289, P681, DOI 10.1042/bj2890681; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; INGENDOH A, 1994, INT J MASS SPECTROM, V131, P345, DOI 10.1016/0168-1176(93)03873-K; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MORREAU H, 1992, J BIOL CHEM, V267, P17949; RODRIGUEZ H, 1981, ANAL BIOCHEM, V140, P538; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; SOMMERLADE HJ, 1994, BIOCHEM J, V297, P123, DOI 10.1042/bj2970123; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; STEIN C, 1989, J BIOL CHEM, V264, P1252; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1982, H-S Z PHYSIOL CHEM, V363, P425, DOI 10.1515/bchm2.1982.363.1.425; WAHEED A, 1983, AM J HUM GENET, V35, P228; WEITZ G, 1992, J BIOL CHEM, V267, P10039	25	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 19	1994	269	33					20977	20981						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PC403	7914890				2022-12-27	WOS:A1994PC40300027
J	FRIMPONG, K; RODWELL, VW				FRIMPONG, K; RODWELL, VW			CATALYSIS BY SYRIAN-HAMSTER 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE - PROPOSED ROLES OF HISTIDINE-865, GLUTAMATE-558, AND ASPARTATE-766	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; IDENTIFICATION	We employed the overexpressed catalytic domains of wild-type Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase, EC 1.1.1.34) and of mutant enzymes E558Q, H865Q, and D766N to investigate the roles of Glu558, His865, and Asp766 in catalysis. Five reactions were studied: reductive deacylation of HMG-CoA or of mevaldyl-CoA to mevalonate, reduction of mevaldehyde to mevalonate, oxidation of mevaldyl-CoA to HMG-CoA, and oxidative acylation of mevaldehyde to HMG-CoA. While only the wild-type enzyme catalyzed all five reactions, mutant enzymes E558Q and H865Q catalyzed other reactions at significant rates. Mutant enzyme D766N, although apparently structurally similar to the wild-type enzyme, was inactive for all five reactions. While an ineffective catalyst for the overall reaction, mutant enzyme H865Q catalyzed the reduction of mevaldehyde to mevalonate at about the wild-type rate. Coenzyme A, which stimulated mevaldehyde reduction by the wild-type enzyme, inhibited mutant enzyme H865Q, apparently due to an impaired ability to protonate the coenzyme A thioanion, CoAS-. Based on these data, we infer that Glu556, His865 and Asp766 function in catalysis at the indicated stage of the overall reaction, [GRAPHICS] and we propose a revised mechanism for catalysis by mammalian HMG-CoA reductases.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISCHOFF KM, 1992, BIOCHEM MED METAB B, V48, P149, DOI 10.1016/0885-4505(92)90060-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CORKEY BE, 1981, ANAL BIOCHEM, V118, P30, DOI 10.1016/0003-2697(81)90152-4; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CUI JS, 1993, J BIOL CHEM, V268, P5040; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; DARNAY BG, 1992, J BIOL CHEM, V267, P15064; ENDO A, 1992, J LIPID RES, V33, P1569; FRIMPONG K, 1993, PROTEIN EXPRES PURIF, V4, P337, DOI 10.1006/prep.1993.1044; FRIMPONG K, 1993, J BIOL CHEM, V269, P1217; JAENICKE L, 1959, ENZYMES, V3, P3; LIENHARD GE, 1966, J AM CHEM SOC, V88, P3982, DOI 10.1021/ja00969a017; QURESHI N, 1976, BIOCHEMISTRY-US, V15, P4191, DOI 10.1021/bi00664a010; RETEY J, 1970, EUR J BIOCHEM, V15, P72, DOI 10.1111/j.1432-1033.1970.tb00977.x; SHERBAN DG, 1985, J BIOL CHEM, V260, P2579; Tipton K F, 1979, Methods Enzymol, V63, P183; VELOSO D, 1981, BIOCHEMISTRY-US, V20, P887, DOI 10.1021/bi00507a036; WANG YL, 1990, J BIOL CHEM, V265, P21634	20	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11478	11483						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7908908				2022-12-27	WOS:A1994NF96600074
J	GUTHEIL, JC; HART, SR; BELANI, CP; MELERA, PW; HUSSAIN, A				GUTHEIL, JC; HART, SR; BELANI, CP; MELERA, PW; HUSSAIN, A			ALTERATIONS IN CA2+ TRANSPORT ATPASE AND P-GLYCOPROTEIN EXPRESSION CAN MEDIATE RESISTANCE TO THAPSIGARGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; MULTIDRUG-RESISTANCE; CELLULAR RESISTANCE; ENDOTHELIAL-CELLS; CROSS-RESISTANCE; DRUG-RESISTANCE; ACTINOMYCIN-D; IN-VITRO; GROWTH; BRAIN	Resistance to the intracellular Ca2+ pump inhibitor thapsigargin (TG) is associated with overexpression of both Ca2+ transport ATPase and the multidrug resistance (mdr) transporter P-glycoprotein (pgp). This is supported by increased resistance to TG following transfection of a functional pgp1 cDNA, and reversal of TG resistance with known inhibitors of pgp function. However, pgp is unlikely to represent the only mechanism of resistance to TG. Cell lines selected for high levels of resistance to TG (250-fold) show only a 3.7-fold increase in pgp expression and a 2-fold increase in cross-resistance to other drugs of the mdr class. Overexpression of endogenous Ca2+ transport ATPase may represent a second mechanism of resistance to TG. Increased Ca2+ ATPase expression (3-fold) is seen in cells made resistant to TG, and TG resistance increases with the transfection of a specific Ca2+ ATPase cDNA into DC-3F cells. If these transfectants are then made resistant to TG, both the endogenous Ca2+ ATPase and the exogenously transfected Ca2+ ATPase become overexpressed. These studies suggest that while TG may be a substrate for pgp, acquired resistance to TG can involve alterations in both pgp and Ca(2+)ATPase expression. Additional, as yet unidentified, mechanisms of resistance may be involved in resistance to TG.	UNIV MARYLAND,CTR CANC,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MED,DIV MED ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,GRAD PROGRAM MOLEC & CELL BIOL,BALTIMORE,MD 21201; VET ADM MED CTR,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Belani, Chandra/0000-0001-5049-5329				BATES SE, 1991, J CLIN ENDOCR METAB, V73, P18, DOI 10.1210/jcem-73-1-18; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BIEDLER JL, 1975, J NATL CANCER I, V55, P671, DOI 10.1093/jnci/55.3.671; BIEDLER JL, 1970, CANCER RES, V30, P1174; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; DEVINE SE, 1994, J BIOL CHEM, V269, P6133; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GESSNER T, 1990, CANCER RES, V50, P3921; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GOLDIE JH, 1984, CANCER RES, V44, P3643; GOSLAND M P, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P426; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GREENWOOD J, 1992, J NEUROIMMUNOL, V39, P123, DOI 10.1016/0165-5728(92)90181-J; GROS P, 1992, BIOCHEMISTRY-US, V31, P1992, DOI 10.1021/bi00122a014; HOLLAND JF, 1993, CANCER MED, P618; HUSSAIN A, 1992, ARCH BIOCHEM BIOPHYS, V296, P539, DOI 10.1016/0003-9861(92)90608-Y; HWANG JL, 1987, J CELL PHYSIOL, V133, P127, DOI 10.1002/jcp.1041330116; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU DHM, 1991, CANCER RES, V51, P5181; LEWIS AD, 1988, P NATL ACAD SCI USA, V85, P8511, DOI 10.1073/pnas.85.22.8511; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OZOLS RF, 1989, DRUG RESISTANCE CANC, P27; PETERSON RH, 1974, J CELL BIOL, V63, P773, DOI 10.1083/jcb.63.3.773; RIEHM H, 1971, CANCER RES, V31, P409; Scanlon K J, 1989, Cancer Commun, V1, P269; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUJI A, 1992, LIFE SCI, V51, P1427, DOI 10.1016/0024-3205(92)90537-Y; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54	35	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7976	7981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907587				2022-12-27	WOS:A1994NB40900025
J	DEVINE, SE; MELERA, PW				DEVINE, SE; MELERA, PW			DIVERSITY OF MULTIDRUG-RESISTANCE IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; MDR GENE FAMILY; P-GLYCOPROTEIN GENES; HIGH-LEVEL; CELLULAR RESISTANCE; CROSS-RESISTANCE; DRUG-RESISTANCE; FULL-LENGTH; IN-VITRO; 5 GENES	Mammalian cells displaying the multidrug resistance (mdr) phenotype are refractory to the toxic effects of a group of unrelated natural product drugs, many of which are used for cancer chemotherapy. The pattern of cross-resistance can be extremely variable among independently selected cell lines, even though such cells are often exposed to only a single drug. The overexpression of P-glycoprotein (pgp), a 150-180-kDa drug efflux pump, has been shown to confer mdr to otherwise drug-sensitive cells; however, the variable nature of cross-resistance indicates that normal pgps alone are unlikely to account for all of the observed cross-resistance phenotypes. In this report, we examined possible factors contributing to cross-resistance diversity in mammalian cells. We show that drug-resistant Chinese hamster lung cells selected during relatively short periods of drug exposure in vitro (less than 6-8 weeks) routinely overexpressed endogenous pgps and predominantly showed a cross-resistance pattern that was similar to that conferred by the introduction and overexpression of the hamster wild-type pgp1 cDNA alone. Longer drug exposure periods at higher drug concentrations, however, led to the selection of cell lines with altered cross-resistance properties. Like the short term clones, these cell lines all overexpressed endogenous pgp. In one case, the altered phenotype was shown to be caused by the acquisition of point mutations within codons 338 and 339 of the pgp1 gene, leading to two adjacent amino acid substitutions within the encoded pgp. Although the basis for the remaining altered phenotypes remains unknown, these results indicate that additional genetic alterations beyond those responsible for the initial acquisition of mdr emerge in the face of increased selective pressure, thus further modifying or complementing the cross-resistance phenotype initially conferred by wildtype pgp.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,MOLEC & CELL BIOL GRAD PROGRAM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NATIONAL CANCER INSTITUTE [R01CA044678] Funding Source: NIH RePORTER; NCI NIH HHS [CA44678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; BASS F, 1990, CANCER RES, V50, P5392; BECK WT, 1991, MOL CELLULAR BIOL MU, P3; BIEDLER JL, 1970, CANCER RES, V30, P1174; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CROOP JM, 1987, CANCER RES, V47, P5982; DEBRUIJN MHL, 1986, MOL CELL BIOL, V6, P4717, DOI 10.1128/MCB.6.12.4717; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVINE SE, 1991, J BIOL CHEM, V266, P4545; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; ENDICOTT JA, 1987, MOL CELL BIOL, V7, P4075, DOI 10.1128/MCB.7.11.4075; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS, P129; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HOWELL N, 1984, CANCER RES, V44, P4023; HSU SIH, 1989, J BIOL CHEM, V264, P12053; HUSSAIN A, 1992, GENE, V112, P179, DOI 10.1016/0378-1119(92)90374-X; KARTNER N, 1989, SCI AM, V260, P44, DOI 10.1038/scientificamerican0389-44; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; MEYERS MB, 1985, J CELL BIOL, V100, P588, DOI 10.1083/jcb.100.2.588; Mickley L., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P233; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; PETERSON RHF, 1983, CANCER RES, V43, P222; RIEHM H, 1971, CANCER RES, V31, P409; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0; ROY SN, 1985, CANCER RES, V45, P3856; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGIMOTO Y, 1991, MOL CELLULAR BIOL MU, P57; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671	46	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6133	6139						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907088				2022-12-27	WOS:A1994MY84000098
J	ZIEMIENOWICZ, A; SKOWYRA, D; ZEILSTRARYALLS, J; FAYET, O; GEORGOPOULOS, C; ZYLICZ, M				ZIEMIENOWICZ, A; SKOWYRA, D; ZEILSTRARYALLS, J; FAYET, O; GEORGOPOULOS, C; ZYLICZ, M			BOTH THE ESCHERICHIA-COLI CHAPERONE SYSTEMS, GROEL GROES AND DNAK DNAJ GRPE, CAN REACTIVATE HEAT-TREATED RNA-POLYMERASE - DIFFERENT MECHANISMS FOR THE SAME ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS; MOLECULAR CHAPERONE; REPLICATION PROTEIN; ATP HYDROLYSIS; GENE-PRODUCTS; PURIFICATION; RECONSTITUTION; TEMPERATURES; HSP60	In this work we show that the GroEL (Hsp60 equivalent) chaperone protein can protect purified Escherichia coli RNA polymerase (RNAP) holoenzyme from heat inactivation better than the DnaK (Hsp70 equivalent) chaperone can. In this protection reaction, the GroES protein is not essential, but its presence reduces the amount of GroEL required. GroEL and GroES can also reactivate heat-inactivated RNAP in the presence of ATP. The mutant GroEL673 protein, with or without GroES, is incapable of reactivating heat-inactivated RNAP. GroEL673 can only protect RNAP, and this protecting ability is not stimulated by GroES. The mechanism by which the DnaJ and GrpE heat shock proteins contribute to DnaK's ability to reactivate heat-inactivated RNAP GroEL673 has also been investigated. We found that the DnaJ protein substantially reduces the levels of DnaK protein needed in this reactivation assay. However, the observed lag in reactivation is diminished only in the additional presence of the GrpE protein. Hence, DnaJ and GrpE are involved in both steps of this reactivation reaction (recognition of substrate and release of chaperone from the substrate-chaperone complex) while, in the case of the GroEL-dependent reaction, GroES is involved only during the release of chaperone from the substrate-chaperone complex.	UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,KLADKI 24,PL-80822 GDANSK,POLAND; UNIV UTAH,MED CTR,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; CNRS,CTR RECH BIOCHIM & GENET CELLULAIRES,F-31062 TOULOUSE,FRANCE; UNIV GENEVA,MED CTR,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Fahrenheit Universities; University of Gdansk; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); University of Geneva					NIGMS NIH HHS [GM23917] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023917, R01GM023917] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG D, 1991, J BIOL CHEM, V266, P24233; BANECKI B, 1992, J BIOL CHEM, V267, P25051; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Gross C. A., 1990, STRESS PROTEINS BIOL, P166; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WADA M, 1984, J BACTERIOL, V157, P694, DOI 10.1128/JB.157.2.694-696.1984; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	39	121	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25425	25431						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902351				2022-12-27	WOS:A1993MK10000025
J	SASAKI, Y; HAKAMADA, K; SUAMA, Y; NAGANO, Y; FURUSAWA, I; MATSUNO, R				SASAKI, Y; HAKAMADA, K; SUAMA, Y; NAGANO, Y; FURUSAWA, I; MATSUNO, R			CHLOROPLAST-ENCODED PROTEIN AS A SUBUNIT OF ACETYL-COA CARBOXYLASE IN PEA PLANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ZINC FINGER PROTEIN; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GENE ORGANIZATION; GENOME; PURIFICATION; RECOMBINATION; POLYPEPTIDE; EXPRESSION	The gene product of an open reading frame of the chloroplast genome, accD, that has sequence similarity with a subunit of acetyl-CoA carboxylase from Escherichia coli was detected immunochemically in pea chloroplasts. The apparent molecular mass of the accD protein was 87 kDa on SDS-polyacrylamide gel electrophoresis. The protein was acidic and had less mobility than the calculated value, 67,116. Acetyl-CoA carboxylase activity solubilized from pea chloroplasts was inhibited by antibodies against recombinant accD protein. The antibodies precipitated a polypeptide of 35 kDa containing biotin and a polypeptide of 91 kDa together with the 87-kDa-accD protein. The accD protein formed a complex with the molecular mass of about 700 kDa, probably with the 35- and 91-kDa proteins. These results indicate that the chloroplast-encoded polypeptide, accD protein, is a component of a functional acetyl-CoA carboxylase in chloroplasts and this enzyme is a multi-subunit complex, like that from E. coli. The synthesis of accD protein was not induced by light.	KYOTO UNIV,FAC AGR,PLANT PATHOL LAB,KYOTO 606,JAPAN	Kyoto University	SASAKI, Y (corresponding author), KYOTO UNIV,FAC AGR,DEPT FOOD SCI & TECHNOL,KYOTO 606,JAPAN.			Nagano, Yukio/0000-0001-5030-676X				EGINBUHLER B, 1983, EUR J BIOCHEM, V133, P335, DOI 10.1111/j.1432-1033.1983.tb07467.x; EGLI MA, 1993, PLANT PHYSIOL, V101, P499, DOI 10.1104/pp.101.2.499; HARLOW E, 1988, ANTIBODIES LABORATOR, P488; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; KANNANGA.CG, 1972, ARCH BIOCHEM BIOPHYS, V152, P83, DOI 10.1016/0003-9861(72)90196-8; KASTEN B, 1992, CURR GENET, V22, P327, DOI 10.1007/BF00317930; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SJ, 1992, J BIOL CHEM, V267, P16841; LI SJ, 1992, PLANT MOL BIOL, V20, P759, DOI 10.1007/BF00027147; LIVNE A, 1990, PLANT CELL PHYSIOL, V31, P851; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGANO Y, 1991, MOL GEN GENET, V228, P62, DOI 10.1007/BF00282448; NAGANO Y, 1991, CURR GENET, V20, P431, DOI 10.1007/BF00317074; NAKAMURA Y, 1979, PLANT SCI LETT, V14, P291, DOI 10.1016/S0304-4211(79)90173-1; NIELSEN NC, 1981, METHOD ENZYMOL, V71, P44; NIKOLAU BJ, 1981, ARCH BIOCHEM BIOPHYS, V211, P605, DOI 10.1016/0003-9861(81)90495-1; NIKOLAU BJ, 1984, ARCH BIOCHEM BIOPHYS, V228, P86, DOI 10.1016/0003-9861(84)90049-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGIHARA Y, 1988, P NATL ACAD SCI USA, V85, P8573, DOI 10.1073/pnas.85.22.8573; OGURA Y, 1991, AGR BIOL CHEM TOKYO, V55, P2259, DOI 10.1080/00021369.1991.10870948; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OROZCO EM, 1986, METHOD ENZYMOL, V118, P232; PALMER JD, 1981, GENE, V15, P21, DOI 10.1016/0378-1119(81)90100-1; ROSCOE TJ, 1982, METHODS CHLOROPLAST, P1015; SASAKI Y, 1989, NUCLEIC ACIDS RES, V17, P6217, DOI 10.1093/nar/17.15.6217; SASAKI Y, 1985, EUR J BIOCHEM, V152, P179, DOI 10.1111/j.1432-1033.1985.tb09179.x; SASAKI Y, 1993, FEBS LETT, V316, P93, DOI 10.1016/0014-5793(93)81743-J; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SLABAS AR, 1985, PLANT SCI, V39, P177, DOI 10.1016/0168-9452(85)90171-2; SMITH AG, 1991, CURR GENET, V19, P403, DOI 10.1007/BF00309603; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; YOSHINAGA K, 1992, PLANT MOL BIOL, V18, P79, DOI 10.1007/BF00018458	38	115	129	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25118	25123						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901221				2022-12-27	WOS:A1993MG67300086
J	CATASUS, L; VENDRELL, J; AVILES, FX; CARREIRA, S; PUIGSERVER, A; BILLETER, M				CATASUS, L; VENDRELL, J; AVILES, FX; CARREIRA, S; PUIGSERVER, A; BILLETER, M			THE SEQUENCE AND CONFORMATION OF HUMAN PANCREATIC PROCARBOXYPEPTIDASE A2 - CDNA CLONING, SEQUENCE-ANALYSIS, AND 3-DIMENSIONAL MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE GENE FAMILY; RAT CARBOXYPEPTIDASE; PROTEIN; IDENTIFICATION	A full-length cDNA clone coding for human pancreatic preprocarboxypeptidase A2 has been isolated from a lambda gt11 human pancreatic library, Expression clones were identified by specific interaction with antisera raised against the native protein. The open reading frame of the polynucleotide sequence is 1254 base pairs in length and encodes a protein of 417 amino acids, This cDNA includes a short leader signal peptide of 16 amino acids and a 94-amino acid-long activation segment, The amino acid sequence shows 89% identity to that of rat procarboxypeptidase A2, the only A2 form sequenced so far, and 64% identity to that of human procarboxypeptidase A1. The newly determined sequence was modeled to the three-dimensional crystal structures of both bovine carboxypeptidase A and porcine procarboxypeptidase A1 by a novel distance geometry approach, Biases in the modeling were avoided by relying exclusively on automatic procedures and by using random structures as starting points, Information taken from the known homologous structures refers only to the backbone since no explicit data describing the conformation of side chains were transferred, Ten structures of human carboxypeptidase A2 were determined on the basis of each of the two known crystal structures, The root-mean-square distance for the backbone atoms between the 10 structures and their mean for 237 selected residues is 0.7 Angstrom when starting from the bovine protein and 0.8 Angstrom for 251 selected residues when starting from the porcine protein. The 94 residue-long activation segment was also determined in the modeling based on the porcine zymogen; its structure is well defined but not its orientation with respect to the enzyme moiety. The model obtained for human procarboxypeptidase A2 is discussed with respect to the specificity and activation of the enzyme.	UNIV AUTONOMA BARCELONA, DEPT BIOQUIM & BIOL MOLEC, UNITAT CIENCIAS, E-08193 BARCELONA, SPAIN; UNIV AIX MARSEILLE 3, FAC SCI ST JEROME,BIOCHIM & BIOL NUTR LAB,CNRS, URA 1820, F-13397 MARSEILLE 20, FRANCE; ETH HONGGERBERG, INST MOLEK BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Autonomous University of Barcelona; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Swiss Federal Institutes of Technology Domain; ETH Zurich			Avilés, Francesc Xavier/A-2664-2015; Carreira, Suzanne/C-8445-2012; Billeter, Martin/A-8293-2010; Catasus, Lluis/K-4620-2013; Vendrell, Josep/A-6731-2010; Aviles, Francesc Xavier/F-3482-2019; Catasus, Luis/G-6811-2011	Avilés, Francesc Xavier/0000-0002-1399-6789; Catasus, Lluis/0000-0001-6075-6238; Vendrell, Josep/0000-0002-9378-4742; Aviles, Francesc Xavier/0000-0002-1399-6789; Carreira, Suzanne/0000-0002-5077-5379				AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; BENSON JA, 1987, BIOTECHNIQUES, V2, P126; CATASUS L, 1992, BIOCHEM J, V287, P299, DOI 10.1042/bj2870299; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; COLL M, 1991, EMBO J, V10, P1; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GUASCH A, 1992, J MOL BIOL, V224, P149; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HOBOHM U, 1992, PROTEIN SCI, V1, P409; KOBAYASHI R, 1978, J BIOL CHEM, V253, P5526; LEHUEROU I, 1991, BIOCHEM BIOPH RES CO, V175, P110, DOI 10.1016/S0006-291X(05)81207-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; OPPEZZO O, 1994, EUR J BIOCHEM, V222, P55, DOI 10.1111/j.1432-1033.1994.tb18841.x; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VENDRELL J, 1986, BIOCHEM BIOPH RES CO, V141, P517, DOI 10.1016/S0006-291X(86)80203-0; YAMAMOTO KK, 1992, J BIOL CHEM, V267, P2575; ZHANG FM, 1991, J BIOL CHEM, V266, P24606	24	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6651	6657		10.1074/jbc.270.12.6651	http://dx.doi.org/10.1074/jbc.270.12.6651			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896805	hybrid			2022-12-27	WOS:A1995QQ85500036
J	MA, GT; HONG, YS; IVES, DH				MA, GT; HONG, YS; IVES, DH			CLONING AND EXPRESSION OF THE HETERODIMERIC DEOXYGUANOSINE KINASE DEOXYADENOSINE KINASE OF LACTOBACILLUS-ACIDOPHILUS R-26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DEOXYCYTIDINE KINASE; NUCLEOSIDE-BINDING-SITE; ADENYLATE KINASE; DEOXYTHYMIDINE KINASE; GENERAL PROPERTIES; BACILLUS-SUBTILIS; DNA; PURIFICATION; MECHANISM; TRANSCRIPTION	Two uniquely paired deoxynucleoside kinases, deoxycytidine kinase/deoxyadenosine kinase (dCK/dAK) and deoxyguanosine kinase/deoxyadenosine kinase (dGK/dAK) are required, together with thymidine kinase (TK), for deoxynucleotide synthesis in Lactobacillus acidophilus R-26. Using polymerase chain reaction-generated probes based on N-terminal amino acid sequences, me have cloned tandem genes for 25- and 26-kDa polypeptides, whose derived amino acid sequences and size correspond to wild-type Lactobacillus enzyme subunits. Expression in Escherichia coli uses a single endogenous promoter and yields active dGK/dAK (similar to 3% of extracted protein) closely resembling wild-type dGK/dAK in specificity, kinetics, heterotropic activation, and end product inhibition. Alignment of cloned genes reveals 65% identity in their DNA sequences and 61% identity in derived amino acid sequences. Comparison with herpes-viral TKs reveals three conserved regions: glycine- and arginine-rich ATP-binding motifs and a D/E-R-S/H motif at the putative TK deoxynucleoside site. Greater homology, however, is seen upon multiple alignment of dGK with mammalian deoxycytidine kinases, yielding the consensus sequence -D/E-R-S-I/V-Y-x-D-, dGK also shares a sequence (-Y-D-P-T-I/L-E-D-S/Y-Y-) required for GTP hydrolysis by p21(ras).	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NATIONAL CANCER INSTITUTE [R01CA047828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049635] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47828] Funding Source: Medline; NIGMS NIH HHS [GM49635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1994, J MOL BIOL, V215, P403; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAKRAVARTY R, 1984, BIOCHEMISTRY-US, V23, P6235, DOI 10.1021/bi00320a053; CHENG YC, 1974, BIOCHEMISTRY-US, V13, P1179, DOI 10.1021/bi00703a019; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; DATTA NS, 1989, BIOCHEMISTRY-US, V28, P114, DOI 10.1021/bi00427a017; Deibel M R Jr, 1978, Methods Enzymol, V51, P346, DOI 10.1016/S0076-6879(78)51046-X; DEIBEL MR, 1977, J BIOL CHEM, V252, P8240; DEIBEL MR, 1977, J BIOL CHEM, V252, P8235; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DUBE DK, 1991, BIOCHEMISTRY-US, V30, P11760, DOI 10.1021/bi00115a004; DURHAM JP, 1970, J BIOL CHEM, V245, P2276; DURHAM JP, 1971, BIOCHIM BIOPHYS ACTA, V228, P9, DOI 10.1016/0005-2787(71)90542-9; FIRSHEIN W, 1970, BIOCHIM BIOPHYS ACTA, V204, P60, DOI 10.1016/0005-2787(70)90490-9; GENTRY GA, 1992, PHARMACOL THERAPEUT, V54, P319, DOI 10.1016/0163-7258(92)90006-L; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HOFFJORGENSEN E, 1952, BIOCHEM J, V50, P400, DOI 10.1042/bj0500400; HONG YS, 1995, J BIOL CHEM, V270, P6602, DOI 10.1074/jbc.270.12.6595; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; IKEDA S, 1988, BIOCHEMISTRY-US, V27, P8648, DOI 10.1021/bi00423a021; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P13373, DOI 10.1021/bi00249a025; JOVIN TM, 1973, BIOCHEMISTRY-US, V12, P891; KARLSSON A, 1994, J BIOL CHEM, V269, P24374; KIM MY, 1989, BIOCHEMISTRY-US, V28, P9043, DOI 10.1021/bi00449a012; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MCELWAIN MC, 1988, INT J SYST BACTERIOL, V38, P417, DOI 10.1099/00207713-38-4-417; MIHOVILOVIC M, 1989, BIOTECHNIQUES, V7, P14; MOLLGAARD H, 1980, J BIOL CHEM, V255, P8216; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; OKAZAKI R, 1964, J BIOL CHEM, V239, P275; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POUWELS PH, 1994, NUCLEIC ACIDS RES, V22, P929, DOI 10.1093/nar/22.6.929; RIMA BK, 1977, J BACTERIOL, V129, P574, DOI 10.1128/JB.129.2.574-579.1977; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; WACHSMAN JT, 1973, APPL MICROBIOL, V25, P506, DOI 10.1128/AEM.25.3.506-508.1973; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007; [No title captured]	43	16	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6595	6601		10.1074/jbc.270.12.6595	http://dx.doi.org/10.1074/jbc.270.12.6595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896798	hybrid			2022-12-27	WOS:A1995QQ85500028
J	SAMSON, SLA; GEDAMU, L				SAMSON, SLA; GEDAMU, L			METAL-RESPONSIVE ELEMENTS OF THE RAINBOW-TROUT METALLOTHIONEIN-B GENE-FUNCTION FOR BASAL AND METAL-INDUCED ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; NUCLEAR FACTOR; I PROMOTER; DEPENDENT BINDING; MAMMALIAN-CELLS; MESSENGER-RNA; IIA GENE; TRANSCRIPTION; ACTIVATION; INDUCTION	In this study, the contributions of the two metal-responsive elements (MREs) of the rainbow trout (Salmo gairdnerii) metallothionein (tMT)-B gene promoter (-137 to +5) were analyzed. The effect of MRE mutations on the basal and zinc-induced activities of tMT-B promoter-reporter gene fusions were determined by transfection of a rainbow trout hepatoma (RTH-149) cell line. Together, MREa and MREb cooperate to elicit a significant response to zinc but exhibit differential basal and metal-induced activity. The MREa sequence (-62 to -51) is important for basal promoter activity and can function independently, whereas the more distal MREb (-89 to -100) mainly contributes to metal induction through cooperative interactions with MREa. The degree of basal character of the MREs is partially determined by nucleotide differences at the flexible position N of the MRE consensus TGC(G/A)CNC. In mouse L and HepG2 cells, MREa activity is conserved, but the contributions of the MREb region differ, including reduced cooperativity with MREa. There are also differences in the apparent molecular masses of the rainbow trout and mammalian nuclear factors that bind to the tMT-B promoter and MREa sequence.	UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA	University of Calgary								ANDERSEN RD, 1990, NUCLEIC ACIDS RES, V18, P6049, DOI 10.1093/nar/18.20.6049; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; Ausubel FM, 1988, MOL REPROD DEV; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; CZUPRYN M, 1992, P NATL ACAD SCI USA, V89, P10395, DOI 10.1073/pnas.89.21.10395; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOSTER R, 1991, J BIOL CHEM, V266, P9866; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRYER JL, 1980, ANN NY ACAD SCI, V126, P566; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1989, CELL, V47, P767; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; IMBERT J, 1990, ADV INORG BIOCHEM, V8, P140; IMBERT J, 1989, MOL CELL BIOL, V9, P5313; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1985, MOL CELL BIOL, V5, P2866, DOI 10.1128/MCB.5.10.2866; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; KNOWLES BB, 1984, ADV HEPATITIS RES; KOIZUMI S, 1992, J BIOL CHEM, V267, P18659; KOIZUMI S, 1992, EUR J BIOCHEM, V210, P555, DOI 10.1111/j.1432-1033.1992.tb17454.x; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; Maniatis T., 1982, MOL CLONING; MEULLER PR, 1988, GENE DEV, V2, P412; OLSSON PE, 1990, BIOCHIM BIOPHYS ACTA, V1049, P78, DOI 10.1016/0167-4781(90)90086-H; PRICEHAUGHEY J, 1987, BIOCHIM BIOPHYS ACTA, V908, P158, DOI 10.1016/0167-4781(87)90055-8; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; SADHU C, 1988, J BIOL CHEM, V263, P2679; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1990, NUCLEIC ACIDS RES, V19, P4683; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; ZAFARULLAH M, 1988, MOL CELL BIOL, V8, P4469, DOI 10.1128/MCB.8.10.4469; ZAFARULLAH M, 1989, GENE, V83, P85, DOI 10.1016/0378-1119(89)90406-X; [No title captured]	42	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6864	6871		10.1074/jbc.270.12.6864	http://dx.doi.org/10.1074/jbc.270.12.6864			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896834	hybrid			2022-12-27	WOS:A1995QQ85500065
J	ABUGO, OO; RIFKIND, JM				ABUGO, OO; RIFKIND, JM			OXIDATION OF HEMOGLOBIN AND THE ENHANCEMENT PRODUCED BY NITROBLUE TETRAZOLIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL HISTIDINE; NUCLEOPHILIC DISPLACEMENT; COLORIMETRIC ASSAY; AUTOXIDATION; SUPEROXIDE; MECHANISM; OXYHEMOGLOBIN; OXYMYOGLOBIN; MYOGLOBIN; AUTOOXIDATION	The autoxidation of hemoglobin as a function of oxygen pressure and the effect of added nitroblue tetrazolium have been studied. It has been shown that the enhanced autoxidation at intermediate oxygen pressures can only be partially explained by the outer-sphere reaction of oxygen with deoxygenated chains. An additional enhancement associated with the properties of partially oxygenated hemoglobins has been attributed to the mobility on the distal side of the heme which facilitates the nucleophilic displacement of bound oxygen by the distal histidine. Nitroblue tetrazolium, in addition to reacting with the superoxide formed during autoxidation, is shown to oxidize directly both deoxygenated and oxygenated hemoglobin in two steps, proceeding through the one electron reduced intermediate, a tetrazolinyl radical. Even though the oxygenated chains are oxidized by nitroblue tetrazolium, much less overall reduction of nitroblue tetrazolium is observed at high oxygen pressures. This phenomenon is attributed to the reoxidation by oxygen of both the tetrazolinyl radical and the formazan. The reaction with nitroblue tetrazolium is also found to con tribute to enhanced oxidation at intermediate oxygen pressures. This behavior is explained by the two-electron reaction with nitroblue tetrazolium and the oxygen dependence of the various processes involved in the reaction of nitroblue tetrazolium.	NIA, GERONTOL RES CTR, CELLULAR & MOLEC BIOL LAB, MOLEC DYNAM SECT, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								Altman F P, 1976, Prog Histochem Cytochem, V9, P1; ANTONINI E, 1965, BIOCHEMISTRY-US, V4, P545, DOI 10.1021/bi00879a026; Auclair C., 1985, CRC HDB METHODS OXYG, P123, DOI DOI 10.1201/9781351072922; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BIELSKI BHJ, 1980, J PHYS CHEM-US, V84, P830, DOI 10.1021/j100445a006; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; Brooks J, 1935, PROC R SOC SER B-BIO, V118, P560, DOI 10.1098/rspb.1935.0072; DICKERSON LD, 1993, J AM CHEM SOC, V115, P3623, DOI 10.1021/ja00062a028; FARBER E, 1956, J HISTOCHEM CYTOCHEM, V4, P254, DOI 10.1177/4.3.254; GEORGE P, 1952, BIOCHEM J, V51, P418, DOI 10.1042/bj0510418; Hanahan D J, 1974, Methods Enzymol, V31, P168; IMAI K, 1982, ALLOSTERIC EFFECTS H, P145; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LEVY A, 1990, BIOCHEMISTRY-US, V29, P9311, DOI 10.1021/bi00492a002; LEVY A, 1992, BIOPHYS J, V61, P750, DOI 10.1016/S0006-3495(92)81879-9; LEVY A, 1985, BIOCHEMISTRY-US, V24, P6050, DOI 10.1021/bi00343a005; LEVY A, 1988, OXY RADICALS MOL BIO, P11; LEVY A, 1991, J INORG BIOCHEM, V43, P327, DOI DOI 10.1016/0162-0134(91)84314-Y; MANSOURI A, 1973, BIOCHEMISTRY-US, V12, P4946, DOI 10.1021/bi00748a020; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NACHLAS MM, 1957, J HISTOCHEM CYTOCHEM, V5, P420, DOI 10.1177/5.4.420; PENNELL RB, 1964, RED BLOOD CELL COMPR, P37; RIFKIND JM, 1991, FREE RADICAL RES COM, V12-3, P645; RIFKIND JM, 1976, BIOCHEMISTRY-US, V15, P5337, DOI 10.1021/bi00669a021; RIFKIND JM, 1974, BIOCHEMISTRY-US, V13, P2475, DOI 10.1021/bi00709a003; RIFKIND JM, 1993, 6TH INT C BIOIN CHEM, P344; RIFKIND JM, 1992, SURVIVING HYPOXIA ME, P509; RIFKIND JM, 1994, IN PRESS OXYGEN TRAN; RIFKIND JM, 1989, OXYGEN RADICALS BIOL, P157; ROOK GAW, 1985, J IMMUNOL METHODS, V82, P161, DOI 10.1016/0022-1759(85)90235-2; SATOH Y, 1981, J BIOL CHEM, V256, P272; SEIDLER E, 1991, PROG HISTOCHEM CYTOC, V24, P1; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SUTTON HC, 1976, BIOCHEM J, V155, P503, DOI 10.1042/bj1550503; THAYER WS, 1990, ARCH BIOCHEM BIOPHYS, V276, P139, DOI 10.1016/0003-9861(90)90020-Y; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; WALLACE WJ, 1975, BIOCHEM BIOPH RES CO, V62, P561, DOI 10.1016/0006-291X(75)90435-0; WALLACE WJ, 1974, BIOCHEM BIOPH RES CO, V57, P1104, DOI 10.1016/0006-291X(74)90810-9; WEVER R, 1973, BIOCHIM BIOPHYS ACTA, V302, P475, DOI 10.1016/0005-2744(73)90180-0; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; WINTERBOURN CC, 1985, CRC HDB METHODS OXYG, P277; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018; ZHANG L, 1990, 34TH ANN BIOPH SOC M, P2399	47	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24845	24853						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929164				2022-12-27	WOS:A1994PQ49000051
J	WLAD, H; MACCARANA, M; ERIKSSON, I; KJELLEN, L; LINDAHL, U				WLAD, H; MACCARANA, M; ERIKSSON, I; KJELLEN, L; LINDAHL, U			BIOSYNTHESIS OF HEPARIN - DIFFERENT MOLECULAR-FORMS OF O-SULFOTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							D-GLUCOSAMINYLTRANSFERASE REACTIONS; FIBROBLAST GROWTH-FACTOR; POLYMER-MODIFICATION; SULFATE; PURIFICATION; BINDING; DEPOLYMERIZATION; IDENTIFICATION; ANTITHROMBIN; SEQUENCE	O-Sulfotransferases involved in heparin biosynthesis were purified greater than or equal to 10,000-fold from detergent extracts of mouse mastocytoma tissue by sequential chromatographies on DEAE-Sephacel, heparin-agarose, blue Sepharose, and 3',5'-ADP-Sepharose. The resultant preparation catalyzed the transfer of S-35 from 3'-phosphoadenosyl-5'-phospho-[S-35]sulfate into N,O-desulfated, re;hr-sulfated heparin. Anion-exchange high performance liquid chromatography of disaccharides obtained by deaminative cleavage of the S-35-labeled polysaccharide product revealed O-S-35-sulfation at C-2 of L-iduronic acid and at C-6 of D-glucosamine units. SDS-polyacrylamide gel electrophoresis of semipurified enzyme followed by extraction of gel segments and renaturation of proteins consistently showed two distinct fractions of O-sulfotransferase activity, corresponding to proteins of similar to 20 and similar to 60 kDa. The similar to 60-kDa enzyme(s) catalyzed both the 2-O- and 6-O-sulfotransferase reactions, whereas the similar to 20-kDa fraction promoted iduronosyl 2-O-sulfation only. These results are discussed in relation to previous findings, indicating that some of the enzymes involved in heparin biosynthesis catalyze more than one reaction.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; BIOMED CTR,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University			Kjellen, Lena/F-1362-2011; maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921				BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; LEVY L, 1962, P SOC EXP BIOL MED, V190, P901; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U., 1989, HEPARIN, P159; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; ROBBINS PW, 1962, METHOD ENZYMOL, V5, P964, DOI 10.1016/S0076-6879(62)05343-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	24	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24538	24541						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929122				2022-12-27	WOS:A1994PQ49000006
J	DALY, SE; LANE, LK; BLOSTEIN, R				DALY, SE; LANE, LK; BLOSTEIN, R			FUNCTIONAL CONSEQUENCES OF AMINO-TERMINAL DIVERSITY OF THE CATALYTIC SUBUNIT OF THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE; ALPHA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; SODIUM; POTASSIUM; K+; ACTIVATION; EXPRESSION; TRANSPORT; VESICLES	One region of marked sequence diversity among the highly homologous a isoforms of the Na,K-ATPase is the lysine rich NH2 terminus. Expression of a mutant cDNA encoding an alpha 1 protein, minus the 32 NH2-terminal residues, results in a modified enzyme (alpha 1M32), which be haves similarly to alpha 1 in overall Na/K exchange activity (V-max) and apparent affinities for intracellular Na+ and extracellular K+. However, with membranes isolated from HeLa cells expressing the rat alpha 1M32 mutant, as well as membranes from cells expressing the rat alpha 1 and the ouabain-resistant mutated forms of rat alpha 2 (alpha 2*) and alpha 3 (alpha 3*) developed by Jewell and Lingrel (Jewell, E. A., and Lingrel, J. B (1991) J. Biol. Chem. 266, 16925-16930), distinct Na,K-ATPase kinetics are observed. Thus, at 1 mu M ATP, the effects of K+ on the Na-ATPase activity of alpha 2* and (alpha 1M32 are similar; both are activated, whereas alpha 1 and (alpha 3 are inhibited by the addition of K+ at low (0.1 mM) concentration. These effects are attributed to different rates of a step involved in K+ deocclusion (E(2)(K) <----> E(1)K <---->, E(1) + K+) and are consistent with our earlier evidence (Wierzbicki, W., and Blostein, R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 70-74) for a role of the NH2 terminus in the K+ deocclusion pathway of the Na,K-ATPase reaction. These differences are not directly related to differences in apparent affinities for ATP, since alpha 3* has alpha 1-like high affinity K+ inhibition but resembles (alpha 2* and (alpha 1M32 with respect to a lower K'(ATP).Na-ATPase activities of alpha 2*, alpha 3*, and alpha 1M32, but not alpha 1, are activated by Li+ but not Rb+, consistent with a relatively faster rate of Li+ deoclusion (Post, R. L., Hegyvary, C., and Kume, S. (1972) J. Biol. Chem. 247, 6530-6540), as well as higher affinity of alpha 3 for extracellular K+(Li+) activation of dephosphorylation (E(2)P + K+ <----> E(2)(K) + P-i). Inhibition of Na ATPase by higher concentrations (greater than or equal to mM) of K+ is observed with all isoforms and is attributed to K+ acting at inhibitory cytoplasmic sites. Taken together, these results suggest that the weakening of intramolecular associations between the lysine-rich NH2 terminus and other parts of the protein, either by removal of the terminus as in alpha 1M32 or by alteration in secondary structure as expected of the Gly-14-Gly-16 triplet in rat (alpha 2*, alters the rate of the K+ deocclusion pathway of the Na,K-ATPase reaction mechanism.	MCGILL UNIV, DEPT MED, MONTREAL H3G 1A4, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA	McGill University; University of Cincinnati								BEAUGE L, 1978, BIOCHIM BIOPHYS ACTA, V527, P472, DOI 10.1016/0005-2744(78)90361-3; BEAUGE LA, 1976, BIOCHIM BIOPHYS ACTA, V433, P547, DOI 10.1016/0005-2736(76)90280-7; BLOSTEIN R, 1977, J BIOL CHEM, V252, P3035; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BLOSTEIN R, 1979, NA K ATPASE STRUCTUR, P233; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1067, P227, DOI 10.1016/0005-2736(91)90048-D; DUNHAM PB, 1977, P NATL ACAD SCI USA, V74, P3099, DOI 10.1073/pnas.74.7.3099; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HORISBERGER JD, 1993, 7 INT C SOD PUMP, V374, P593; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; JORGENSEN PL, 1988, NA PLUS K PLUS PUM A, P85; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1993, J BIOL CHEM, V268, P17930; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; POST RL, 1972, J BIOL CHEM, V247, P6530; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; VASILETS LA, 1993, EUR BIOPHYS J BIOPHY, V21, P433, DOI 10.1007/BF00185871; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	27	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23944	23948						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929042				2022-12-27	WOS:A1994PQ34600017
J	KIM, JI; TAKAHASHI, M; OGURA, A; KOHNO, T; KUDO, Y; SATO, K				KIM, JI; TAKAHASHI, M; OGURA, A; KOHNO, T; KUDO, Y; SATO, K			HYDROXYL GROUP OF TYR(13) IS ESSENTIAL FOR THE ACTIVITY OF OMEGA-CONOTOXIN GVIA, A PEPTIDE TOXIN FOR N-TYPE CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE SODIUM-CHANNELS; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL EXPRESSION; GEOGRAPHUTOXIN-II; CA2+ CHANNELS; SAXITOXIN; BLOCKER; TETRODOTOXIN; SITE; INHIBITOR	A series of analogs of omega-conotoxin GVIA, a peptide neurotoxin having 27 amino acid residues with three disulfide bridges, were synthesized by replacing each amino acid residue except for Cys and Hyp with Ala. CD spectra were virtually identical between native and all of the analogs, indicating the overall conformations were not changed by the substitutions. The inhibitory effects of these analogs on I-125-omega-conotoxin GVIA binding to chick brain synaptic plasma membranes showed that replacement of Tyr(13) with Ala drastically lowered the affinity of the toxin to the N-type Ca2+ channel. Substitution of Tyr(13) with Phe also showed reduction of the affinity, indicating that the hydroxyl group of Tyr(13) is critical for binding. Since Lys(2) is also important for binding (Sato, K. Park, N.-G., Kohno, T. Maeda, T., Kim, J.-I., Kato, R., and Takahashi, M. (1993) Biochem. Biophys. Res. Commun. 194, 1292-1296), we propose a two-point binding model in which Tyr(13) and Lys(2) interact with specific amino acid residues of the Ca2+ channel through hydrogen bonding and ionic interaction, respectively.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN					Kudo, Yoshihisa/0000-0002-5978-8264				CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KAO CY, 1982, J PHYSIOL-LONDON, V323, P619, DOI 10.1113/jphysiol.1982.sp014095; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KURODA Y, 1992, NEUROSCI LETT, V135, P255, DOI 10.1016/0304-3940(92)90449-H; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; OGURA A, 1990, NEUROSCI RES, V9, P103, DOI 10.1016/0168-0102(90)90026-B; OGURA A, 1987, NEUROSCI LETT, V78, P69, DOI 10.1016/0304-3940(87)90563-5; OHIZUMI Y, 1986, J BIOL CHEM, V261, P6149; OHIZUMI Y, 1986, J PHARMACOL EXP THER, V239, P243; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; SATO K, 1991, J BIOL CHEM, V266, P16989; SATO K, 1993, BIOCHEM BIOPH RES CO, V194, P12932; SEVILLA P, 1993, BIOCHEM BIOPH RES CO, V192, P1238, DOI 10.1006/bbrc.1993.1549; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; YOOL AJ, 1991, NATUR, V349, P702	28	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23876	23878						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929033				2022-12-27	WOS:A1994PQ34600007
J	MA, H; YANG, HQ; TAKANO, E; HATANAKA, M; MAKI, M				MA, H; YANG, HQ; TAKANO, E; HATANAKA, M; MAKI, M			AMINO-TERMINAL CONSERVED REGION IN PROTEINASE-INHIBITOR DOMAIN OF CALPASTATIN POTENTIATES ITS CALPAIN INHIBITORY ACTIVITY BY INTERACTING WITH CALMODULIN-LIKE DOMAIN OF THE PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; ACTIVATED NEUTRAL PROTEASE; 4 REPEATING DOMAINS; ENDOGENOUS INHIBITOR; ESCHERICHIA-COLI; PIG CALPASTATIN; PEPTIDE COMPLEX; THIOL PROTEASE; BINDING; RECOGNITION	Calpastatin is a widely distributed endogenous inhibitor protein specifically acting on calpain (Ca2+-dependent proteinase) and is known to interact with the calmodulin-like domain (CaMLD) of the proteinase in a Ca2+-dependent fashion. The calpastatin molecule consists of four inhibitory domains (domains 1-4) with mutually homologous sequences in three regions designated as A, B, and C. Acidic amphiphilic alpha-helical motifs are found in both regions A and C. We investigated the correlation between the calpain inhibition potency and the ability of calpastatin to bind to recombinant CaMLD of the mu-calpain large subunit using various mutant proteins of pig calastatin domain 1 expressed in Escherichia coli. Substitution of conserved Leu-161 with Pro in region A caused a reduction in activity of both calpain inhibition and CaMLD binding. Additional substitution of Leu-236 with Pro in region C further decreased the calpain inhibitory activity and caused a loss of CaMLD binding ability. The effects of mutation in region C alone on the above activities were smaller than those in region A. Although a mutant of deletion in the entire region B had no calpain inhibitory activity, it retained the CaMLD binding ability. On the other hand, although a region B oligopeptide had a moderate inhibitory activity, it had no CaMLD binding ability. These results suggest that region A has a role in potentiating the inhibitory activity of calpastatin by interacting with CaMLD of calpain to form a tighter complex where region B exerts the inhibitory function,	KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University			Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				COTTIN P, 1981, FEBS LETT, V136, P221, DOI 10.1016/0014-5793(81)80622-9; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1988, J BIOL CHEM, V263, P2364; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ISHIMA R, 1991, FEBS LETT, V294, P64, DOI 10.1016/0014-5793(91)81344-8; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAWASAKI H, 1993, ARCH BIOCHEM BIOPHYS, V305, P467, DOI 10.1006/abbi.1993.1448; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WJ, 1992, J BIOL CHEM, V267, P8437; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P10254; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MELLGREN RL, 1990, INTRACELLULAR CALCIU, P1; MURAKAMI T, 1981, J BIOCHEM-TOKYO, V90, P1809, DOI 10.1093/oxfordjournals.jbchem.a133659; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PARR T, 1992, EUR J BIOCHEM, V208, P333, DOI 10.1111/j.1432-1033.1992.tb17191.x; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SHIGETA K, 1984, BIOCHEM INT, V9, P327; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; UEMORI T, 1990, BIOCHEM BIOPH RES CO, V166, P1485, DOI 10.1016/0006-291X(90)91035-Q; YANG HQ, 1994, J BIOL CHEM, V269, P18977	31	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24430	24436						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929105				2022-12-27	WOS:A1994PQ34600090
J	ZENG, XR; HAO, HL; JIANG, YQ; LEE, MYWT				ZENG, XR; HAO, HL; JIANG, YQ; LEE, MYWT			REGULATION OF HUMAN DNA-POLYMERASE-DELTA DURING THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; REPLICATION FACTOR; CATALYTIC SUBUNIT; THYMIDINE KINASE; SIMIAN VIRUS-40; EXCISION REPAIR; S-PHASE; ALPHA	The expression of polymerase delta (pol delta) during the cell cycle was studied in Molt 4 cells separated by counterflow centrifugal elutriation. Northern blotting showed that pol delta mRNA levels increased by 3-fold at the G(1)/S border. Levels of pol delta protein determined by Western blotting also peaked at the G(1)/S border with qualitatively similar changes as the mRNA levels, Thus, pol delta gene expression appears to be regulated during the cell cycle at the transcriptional level. The mRNA half-life for pol delta was determined to be about 8 h and the protein half-life about 10 h. Parallel examination of the expression of proliferating cell nuclear antigen showed that the mRNA levels also increased about 2-fold at the G(1)/S border, while the protein levels of proliferating cell nuclear antigen increased steadily through the whole cell cycle period, and remained high at G(2)/M. Analysis of pol or expression showed qualitatively similar behavior as pol delta, but the magnitude of the changes were higher. Pulse labeling of cells metabolically arrested in G(1), S, or G(2)/M with P-32(i) showed that pol delta is a phosphoprotein and that it is most actively phosphorylated during the S phase.	UNIV MIAMI, SCH MED, DEPT MED R57, MIAMI, FL 33101 USA	University of Miami					NIAID NIH HHS [AI 29158] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; BASNAKIAN A, 1989, NUCLEIC ACIDS RES, V17, P4757, DOI 10.1093/nar/17.12.4757; BROTT DA, 1993, J CELL BIOCHEM, V52, P362, DOI 10.1002/jcb.240520312; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HAO HL, 1992, CHROMOSOMA, V102, pS121, DOI 10.1007/BF02451795; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; KONIECKI J, 1991, CANCER RES, V51, P1465; KRISHAN A, 1981, CANCER RES, V41, P2745; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MARRACCINO RL, 1987, BIOCHEMISTRY-US, V26, P7864, DOI 10.1021/bi00398a049; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; YANG CL, 1991, BIOCHEMISTRY-US, V30, P7534, DOI 10.1021/bi00244a024; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG SJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P24, DOI 10.1016/0003-9861(87)90004-X	48	55	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24027	24033						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929054				2022-12-27	WOS:A1994PQ34600030
J	PUIG, A; LYLES, MM; NOIVA, R; GILBERT, HF				PUIG, A; LYLES, MM; NOIVA, R; GILBERT, HF			THE ROLE OF THE THIOL/DISULFIDE CENTERS AND PEPTIDE BINDING-SITE IN THE CHAPERONE AND ANTI-CHAPERONE ACTIVITIES OF PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; AGGREGATION; CATALYSIS; LYSOZYME; RESIDENT; SEQUENCE; LUMEN; BONDS	The complexity of protein folding is often aggravated by the low solubility of the denatured state. The inefficiency of the oxidative refolding of reduced, denatured lysozyme results from a kinetic partitioning of the unfolded protein between pathways leading to aggregation and pathways leading to the native structure. Protein disulfide isomerase (PDI), a resident foldase of the endoplasmic reticulum, catalyzes the in vitro oxidative refolding of reduced, disulfide containing proteins, including denatured lysozyme. Depending on the concentrations of foldase and denatured substrate and the order in which they are added to initiate folding, PDI can exhibit either a chaperone activity or an anti-chaperone activity (Puig, A., and Gilbert, H. F. (1994) J. Biol. Chem 269, 7764-7771). PDI's chaperone activity leads to quantitative recovery of native lysozyme. Its anti-chaperone activity diverts substrate away from productive folding and facilitates disulfide cross-linking of lysozyme into large, inactive aggregates that specifically incorporate PDI. A mutant PDI (NmCm-PDI), in which both the N- and C-terminal active site cysteines have been changed to serines, loses all chaperone activity and behaves as an anti chaperone at all substrate and PDI concentrations tested. The dithiol/disulfide sites of PDI are essential for the chaperone activity observed at high PDI concentrations, but they are not required for the anti-chaperone activity found at low PDI concentrations. Inactivation of PDI's peptide/protein binding site by a specific photoaffinity label (Noiva, R., Freedman, R. B., and Lennarz, W. J. (1993) J. Biol. Chem. 268, 19210-19217) inhibits the disulfide isomerase and chaperone activity, but the protein still retains its anti-chaperone activity. In a glutathione redox buffer, lysozyme PDI aggregates are disulfide crosslinked; however, disulfide cross-linking is not required for aggregate formation or for the incorporation of PDI into the aggregates. Although both the peptide binding site and the catalytic active sites of PDI are required for chaperone and disulfide isomerase activity, neither of these sites are involved in PDI's anti-chaperone activity. PDI's anti-chaperone activity could serve as a quality control device by providing an efficient mechanism to retain misfolded proteins in the endoplasmic reticulum (Marquardt, T., and Helenius, A. (1992) J. Cell. Biol. 117, 505-513).	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,VERMILLION,SD 57069	Baylor College of Medicine; University of South Dakota					NIGMS NIH HHS [GM40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LU X, 1992, BIOCHEMISTRY-US, V3, P4205; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PUIG A, 1994, J BIOL CHEM, V269, P7764; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; VUORI K, 1992, J BIOL CHEM, V267, P7211; WETLAUFER DB, 1974, LYSOZYME, P269; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	28	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19128	19135						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913469				2022-12-27	WOS:A1994NX32700065
J	TAE, HJ; LUO, XC; KIM, KH				TAE, HJ; LUO, XC; KIM, KH			ROLES OF CCAAT/ENHANCER-BINDING PROTEIN AND ITS BINDING-SITE ON REPRESSION AND DEREPRESSION OF ACETYL-COA CARBOXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; TUMOR-NECROSIS-FACTOR; HANDED Z-DNA; MESSENGER-RNA; 5' END; 3T3-L1 PREADIPOCYTES; FATTY-ACIDS; EXPRESSION; DIFFERENTIATION; CELLS	The gene for acetyl-CoA carboxylase, the rate-limiting enzyme in the biosynthesis of long-chain fatty acids, contains two distinct promoter regions, denoted PI and PII, which control the generation of different forms of mRNA. Multiple forms of acetyl-CoA carboxylase (ACC) mRNA with 5'-end heterogeneity are generated as a result of differential splicing of two primary transcripts formed under the control of these two promoters. PI is responsible for the generation of class I mRNAs of ACC, which are induced in a tissue-specific manner under lipogenic conditions. PII generates class II mRNAs of ACC, which are expressed constitutively. Possible mechanisms for the regulation of PI under normal physiological conditions and agents that activate the promoter have been investigated. PI contains a TATA and a CCAAT box. In addition to these sequences, this promoter contains a 28-CA repeat sequence 220 bases upstream from the transcription initiation site; the presence of this sequence leads to about 70% repression of the basal promoter activity. Repression by the 28-CA repeat sequence requires the GCAAT sequence in the CCAAT box. The negative effect of the 28-CA repeat sequence is relieved by a CCAAT/enhancer-binding protein (C/EBP), which binds to the GCAAT sequence. Insertion of the 28-CA repeat sequence into the thymidine kinase promoter results in repression that can also be relieved by the C/EBP gene product. However, the same sequence exerts no effect on ACC promoter II, which has no CCAAT box. During the differentiation of 30A5 preadipocytes into adipocytes, the expression of class I ACC mRNA and C/EBP mRNA is coordinately increased. Therefore, the presence of the CA repeat in the promoter may be responsible for the inactivity of PI, and C/EBP may be one of the factors that is responsible for the activation of PI under lipogenic conditions. Interaction of the CA repeat and the CCAAT box in the repression and derepression of the ACC gene provides a novel function for the CCAAT box and C/EBP in gene regulation.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAI DH, 1986, J BIOL CHEM, V261, P2395; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1985, J MOL BIOL, V183, P251, DOI 10.1016/0022-2836(85)90218-9; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LOPEZCASILLAS F, 1991, EUR J BIOCHEM, V201, P119, DOI 10.1111/j.1432-1033.1991.tb16264.x; LOPEZCASILLAS F, 1989, GENE, V83, P311, DOI 10.1016/0378-1119(89)90117-0; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO X, 1990, THESIS PURDUE U; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NORDHEIM A, 1982, P NATL ACAD SCI-BIOL, V79, P7729, DOI 10.1073/pnas.79.24.7729; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; Numa S, 1974, Curr Top Cell Regul, V8, P197; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PAPE ME, 1989, THESIS PURDUE U; PARK K, 1993, J BIOL CHEM, V268, P17811; PARK KR, 1991, J BIOL CHEM, V266, P12249; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIH C, 1990, J VIROL, V64, P1517; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; TAVININI MA, 1994, J BIOL CHEM, V259, P11798; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135	51	85	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10475	10484						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908293				2022-12-27	WOS:A1994NF01700045
J	BARRY, SC; BAGLEY, CJ; PHILLIPS, J; DOTTORE, M; CAMBARERI, B; MORETTI, P; DANDREA, R; GOODALL, GJ; SHANNON, MF; VADAS, MA; LOPEZ, AF				BARRY, SC; BAGLEY, CJ; PHILLIPS, J; DOTTORE, M; CAMBARERI, B; MORETTI, P; DANDREA, R; GOODALL, GJ; SHANNON, MF; VADAS, MA; LOPEZ, AF			2 CONTIGUOUS RESIDUES IN HUMAN INTERLEUKIN-3, ASP(21) AND GLU(22), SELECTIVELY INTERACT WITH THE ALPHA-CHAIN AND BETA-CHAIN OF ITS RECEPTOR AND PARTICIPATE IN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECOMBINANT HUMAN INTERLEUKIN-3; HUMAN GROWTH-HORMONE; GM-CSF; BIOLOGICAL-ACTIVITY; BINDING CHARACTERISTICS; EXTRACELLULAR DOMAIN; AFFINITY BINDING; HUMAN-MONOCYTES; CELL-LINE	We have previously reported that the predicted first helix of human interleukin (IL)-3 contains a hydrophilic region encompassing residues Asp(21), Glu(22), and Thr(25) that is crucial for biological activity and IL-3 receptor binding. Using single amino acid substitution mutagenesis, we have now determined that Asp(21) and Glu(22), but not Thr(25), were crucial for full IL-3 activity. Mutant D21R was 30-fold less potent than wild type IL-3 in the stimulation of biological activity. It also exhibited a similar reduction in its ability to bind to the cloned high affinity IL-3 receptor complex (alpha- and beta-chains) or to the receptor alpha-chain alone, indicating that residue 21 is involved in contacts with the alpha-chain. Mutant E22R was approximately 20,000-fold less potent than wild type IL-3 in the stimulation of biological activity and in binding to the IL-3 receptor high affinity complex. However, the binding of E22R to the IL-3 receptor alpha-chain alone was similar to that of wild type IL-3, suggesting that this mutant was defective in interactions with the receptor beta-chain. These results show that two contiguous residues in the N-terminal region of IL-3 mediate binding to the two different chains of the IL-3 receptor and emphasize the functional significance of the conserved Glu in the first helix of the IL-3, granulocyte-macrophage colony-stimulating factor, and IL-5 cytokine subfamily.	INST MED & VET SCI,HANSON CTR CANC RES,DIV HUMAN IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA	Institute Medical & Veterinary Science Australia			Vadas, Mathew/R-1378-2019; Lopez, Angel F/E-2260-2011	Goodall, Gregory/0000-0003-1294-0692; Barry, Simon/0000-0002-0597-7609; Lopez, Angel F/0000-0001-7430-0135	NCI NIH HHS [CA 45822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLAYBERGER C, 1992, J EXP MED, V175, P371, DOI 10.1084/jem.175.2.371; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; Elliott MJ, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008868; ELLIOTT MJ, 1990, J IMMUNOL, V145, P167; ELLIOTT MJ, 1989, BLOOD, V74, P2349; Garnier J., 1989, PREDICTION PROTEIN S, P417; GESNER TG, 1988, J CELL PHYSIOL, V136, P493, DOI 10.1002/jcp.1041360314; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KAUSHANSKY K, 1992, J CLIN INVEST, V90, P1879, DOI 10.1172/JCI116065; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1992, BLOOD, V80, P84; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KORPELAINEN EI, 1993, P NATL ACAD SCI USA, V90, P11137, DOI 10.1073/pnas.90.23.11137; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; KREMER E, 1993, BLOOD, V82, P22, DOI 10.1182/blood.V82.1.22.bloodjournal82122; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J BIOL CHEM, V266, P10624; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1988, BLOOD, V72, P1797; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; MCPHEARSON G, 1982, J PHARMACOL METHOD, V14, P213; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; PHILLIPS JA, 1989, GENE, V84, P501, DOI 10.1016/0378-1119(89)90527-1; RAPOPORT AP, 1993, J CELL BIOCHEM, V17, P81; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1992, J BIOL CHEM, V267, P2546; TAMURA S, 1990, BLOOD, V76, P501; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T	39	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8488	8492						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907592				2022-12-27	WOS:A1994NB40900098
J	VENTURA, C; GUARNIERI, C; VAONA, I; CAMPANA, G; PINTUS, G; SPAMPINATO, S				VENTURA, C; GUARNIERI, C; VAONA, I; CAMPANA, G; PINTUS, G; SPAMPINATO, S			DYNORPHIN GENE-EXPRESSION AND RELEASE IN THE MYOCARDIAL-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; CHROMAFFIN CELLS; SPINAL-CORD; DEPOLARIZATION; CHANNELS; RABBIT; ALPHA; HEART; BRAIN; CA2+	The expression of the prodynorphin gene was investigated in adult cultured rat ventricular cardiac myocytes by using a sensitive solution hybridization RNase protection assay for the quantitative analysis of prodynorphin mRNA. Myocyte culture in high KCL resulted, after 4 h, in a marked increase in cellular prodynorphin mRNA, while a KCl treatment for 6, 12, or 24 h progressively down-regulated the levels of prodynorphin mRNA below the control value. Immunoreactive dynorphin B, a biologically active end product of the precursor, was found to be present in the culture medium in significantly higher amounts than in the cardiac myocytes. The levels of this biologically active K opioid receptor agonist significantly increased after 4 h of KCl treatment and were markedly reduced following a 24-h exposure of the cardiac myocytes to KCl. These KCl-induced effects were all abolished by cell incubation in the presence of the calcium channel blocker verapamil. In single cardiac myocytes, acute stimulation of K opioid receptors with dynorphin B or with the selective agonist U-50,488H increased the level of cytosolic calcium. This effect was abolished by the specific K opioid receptor antagonist (Mr-1452) and was not affected by the removal of calcium from the bathing medium. These results suggest that an opioid gene may influence the myocardial function in an autocrine or paracrine fashion.	UNIV BOLOGNA, DEPT BIOCHEM, I-40126 BOLOGNA, ITALY; UNIV BOLOGNA, DEPT PHARMACOL, I-40126 BOLOGNA, ITALY	University of Bologna; University of Bologna	VENTURA, C (corresponding author), UNIV SASSARI, INST BIOL CHEM A BONSIGNORE, VIALE SAN PIETRO 43-B, I-07100 SASSARI, ITALY.		Campana, Gabriele/A-8285-2010; Pintus, Gianfranco/C-2975-2009	Campana, Gabriele/0000-0001-8978-0530; Pintus, Gianfranco/0000-0002-3031-7733; Spampinato, Santi/0000-0001-5656-564X				BLUM M, 1989, METHOD ENZYMOL, V168, P618; CANOSSA M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P247, DOI 10.1016/0167-4781(93)90210-5; CAPOGROSSI MC, 1986, J GEN PHYSIOL, V88, P589, DOI 10.1085/jgp.88.5.589; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONE RI, 1983, J NEUROSCI, V3, P2146; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; FOSTER KA, 1990, AM J PHYSIOL, V259, pH432, DOI 10.1152/ajpheart.1990.259.2.H432; GAUTRET B, 1985, EUR J PHARMACOL, V111, P263, DOI 10.1016/0014-2999(85)90766-6; GOLDSTEIN A, 1983, PEPTIDES ANAL SYNTHE, V7, P95; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; HUGHES J, 1981, TRENDS PHARMACOL SCI, V2, P21, DOI 10.1016/0165-6147(81)90249-2; JAMIESON JD, 1964, J CELL BIOL, V23, P151, DOI 10.1083/jcb.23.1.151; KLEY N, 1987, J BIOL CHEM, V262, P4083; KLEY N, 1988, EMBO J, V5, P970; KRAUSE JE, 1989, METHOD ENZYMOL, V168, P634; LAHTI RA, 1982, LIFE SCI, V31, P2257, DOI 10.1016/0024-3205(82)90132-1; LANG RE, 1983, LIFE SCI, V32, P399, DOI 10.1016/0024-3205(83)90086-3; LUETJE CW, 1988, J NEUROCHEM, V50, P1775, DOI 10.1111/j.1471-4159.1988.tb02478.x; PANERAI AE, 1984, BRAIN RES, V304, P153, DOI 10.1016/0006-8993(84)90872-2; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; PRUSS RM, 1988, J BIOL CHEM, V263, P13173; SPAMPINATO S, 1992, BRAIN RES, V580, P225, DOI 10.1016/0006-8993(92)90948-9; SPAMPINATO S, 1991, LIFE SCI, V48, P551, DOI 10.1016/0024-3205(91)90470-V; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; WONGDUSTING HK, 1985, EUR J PHARMACOL, V111, P65, DOI 10.1016/0014-2999(85)90114-1; XIE GX, 1987, J NEUROSCI, V7, P2049	32	57	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5384	5386						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906274				2022-12-27	WOS:A1994MX57100102
J	GONZALEZGRONOW, M; GAWDI, G; PIZZO, SV				GONZALEZGRONOW, M; GAWDI, G; PIZZO, SV			CHARACTERIZATION OF THE PLASMINOGEN RECEPTORS OF NORMAL AND RHEUMATOID-ARTHRITIS HUMAN SYNOVIAL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; MEMBRANE GLYCOPROTEIN-IIB; HUMAN-ENDOTHELIAL CELLS; AFFINITY CHROMATOGRAPHY; PLATELET-AGGREGATION; POLYACRYLAMIDE GELS; MONOCLONAL-ANTIBODY; HEYMANN NEPHRITIS; HUMAN-PLASMA; PROTEIN	Plasminogen (Pg) activation on the surface of rheumatoid arthritis (RA) synovial fibroblasts by the urinary-type Pg activator induced a significant increase in cytosolic free Ca2+ concentration. This response was not observed in normal synovial fibroblasts, suggesting different Pg binding and activation mechanisms in these cell types. Pg receptors from both cell types were isolated by affinity chromatography using Pg covalently bound to Sepharose 4B. RA synovial fibroblasts express a Pg receptor complex composed of a glycoprotein IIb/ IIIa-related protein in association with a 130-kDa protein that is antigenically related to the alpha 2-macroglobulin receptor-associated protein and dipeptidyl peptidase IV. This receptor complex appears to bind to both Pg and fibronectin. The Pg ''receptor'' in normal synovial fibroblasts is composed of a 97-kDa protein also antigenically related to the alpha 2-macroglobulin receptor-associated protein. Both cell types express the urinary-type Pg activator receptor on their surfaces. Our results suggest that RA synovial fibroblasts express novel proteins involved in Pg binding, activation, and signal transduction, which are absent in normal synovial fibroblasts.			GONZALEZGRONOW, M (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710, USA.				NHLBI NIH HHS [HL-43339, HL-31932] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031932, R01HL043339] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN B, 1988, BLOOD, V72, P1530; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CASTOR CW, 1971, J LAB CLIN MED, V77, P65; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHUCHOLOWSKI N, 1992, FIBRINOLYSIS, V6, P95; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; GANZ PR, 1991, BIOCHEM CELL BIOL, V69, P442, DOI 10.1139/o91-067; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; GONZALEZGRONOW M, 1993, J BIOL CHEM, V268, P20791; GRABER N, 1990, J IMMUNOL, V145, P819; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUCCIONE MA, 1985, THROMB HAEMOSTASIS, V53, P8; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; Harlow E, 1988, ANTIBODIES LABORATOR, P359; IBRAHIM GK, 1993, J UROLOGY, V149, P170, DOI 10.1016/S0022-5347(17)36032-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFYATIS R, 1989, J CLIN INVEST, V83, P1267, DOI 10.1172/JCI114011; LO SK, 1989, J CLIN INVEST, V84, P793, DOI 10.1172/JCI114238; MAKKER SP, 1984, LAB INVEST, V50, P287; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCGREGOR BC, 1989, AM J CLIN PATHOL, V92, P495, DOI 10.1093/ajcp/92.4.495; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PENNY WF, 1992, BLOOD, V79, P91; PHILLIPS DR, 1988, BLOOD, V71, P831; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; RUAN CG, 1987, BLOOD, V69, P570; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHAFER AI, 1986, J CLIN INVEST, V78, P73, DOI 10.1172/JCI112576; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TANAKA T, 1992, J IMMUNOL, V149, P481; THIAGARAJAN P, 1985, J CLIN INVEST, V75, P896, DOI 10.1172/JCI111789; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRANQUI L, 1979, BIOL CELLULAIRE, V34, P39; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WALBORG EF, 1985, EXP CELL RES, V158, P509, DOI 10.1016/0014-4827(85)90474-4; WILDER RL, 1991, J CELL BIOCHEM, V45, P162, DOI 10.1002/jcb.240450207; WINTERS KJ, 1990, BLOOD, V76, P1546; YOCUM DE, 1988, AM J PATHOL, V132, P32; ZIFF M, 1989, RHEUMATOL INT, V9, P97	50	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4360	4366						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905877				2022-12-27	WOS:A1994MW98900073
J	ANTOINE, R; TALLETT, A; VANHEYNINGEN, S; LOCHT, C				ANTOINE, R; TALLETT, A; VANHEYNINGEN, S; LOCHT, C			EVIDENCE FOR A CATALYTIC ROLE OF GLUTAMIC ACID-129 IN THE NAD-GLYCOHYDROLASE ACTIVITY OF THE PERTUSSIS TOXIN-S1 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA EXOTOXIN; ISLET-ACTIVATING PROTEIN; ADP-RIBOSYLTRANSFERASE ACTIVITY; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; S-1 SUBUNIT; BORDETELLA-PERTUSSIS; ENZYMATIC-ACTIVITIES; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE	The Sl subunit of pertussis toxin is an ADP-ribosyltransferase capable of transferring the ADP-ribose moiety of NAD+ to nucleotide-binding signal-transducing proteins of the G(i)/G(o) family. In the absence of G proteins, the enzyme also catalyzes the hydrolysis of NAD+. Glu-129 was previously shown to be critical for both enzymatic activities. In this study, site-directed mutagenesis was used to make the conservative substitution of aspartate for Glu-129. The recombinant wild type and mutant proteins were purified to near homogeneity and used for enzymatic analyses. Kinetic experiments showed that the k(cat) of the mutant protein was about 200 times less than that of the wild type enzyme, whereas the K(m) for NAD+ of the two proteins were very similar, suggesting that Glu-129 is a catalytic residue for the NAD-glycohydrolase reaction of S1. This hypothesis was confirmed by a less than 2-fold change in K(d) as measured by fluorescence quenching studies, indicating that the binding of NAD+ is not affected in the mutant protein in any important way. In another experiment, the replacement of Glu-129 by cysteine resulted in a disulfide bridge between Cys-129 and Cys-41 in rS1d-E129C, suggesting that the folding of the polypeptide chain is such that the catalytic Glu-129 residue is close to the amino-terminal NAD-binding site of S1. These findings imply that Glu-129 plays a key role in catalysis of the NAD-glycohydrolase reaction, possibly by electrostatically stabilizing a cationic transition state intermediate, or by serving as a general base to deprotonate the ADP-ribosyl acceptor substrates.	INST PASTEUR, CJF9109,INSERM,MICROBIOL GENET & MOLEC, 1 RUE PROF CALMETTE, F-59019 LILLE, FRANCE; UNIV EDINBURGH, DEPT BIOCHEM, EDINBURGH EH8 9XD, SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Edinburgh			Locht, Camille/L-3516-2018; Antoine, Rudy/CAH-6653-2022; Antoine, Rudy/L-1630-2018	Antoine, Rudy/0000-0002-7369-0626; Antoine, Rudy/0000-0002-7369-0626				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANTOINE R, 1990, INFECT IMMUN, V58, P1518, DOI 10.1128/IAI.58.6.1518-1526.1990; BARBIERI JT, 1988, INFECT IMMUN, V56, P1934, DOI 10.1128/IAI.56.8.1934-1941.1988; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1988, BIO-TECHNOL, V6, P699, DOI 10.1038/nbt0688-699; BURNETTE WN, 1988, SCIENCE, V242, P72, DOI 10.1126/science.2459776; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CIEPLAK W, 1990, BIOCHEM J, V268, P547, DOI 10.1042/bj2680547; COCKLE SA, 1989, FEBS LETT, V249, P329, DOI 10.1016/0014-5793(89)80652-0; CORTINA G, 1989, J BIOL CHEM, V264, P17322; CORTINA G, 1991, J BIOL CHEM, V266, P23810; DOUGLAS CM, 1990, BIOCHEMISTRY-US, V29, P5043, DOI 10.1021/bi00473a007; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Fishman P.H., 1990, ADP RIBOSYLATING TOX, P127; Francotte M., 1989, VACCINES 89, P243; HONORE B, 1989, BIOCHEM J, V258, P199, DOI 10.1042/bj2580199; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KASLOW HR, 1989, J BIOL CHEM, V264, P6386; KATADA T, 1982, J BIOL CHEM, V257, P7210; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBBAN MD, 1991, BIOCHIM BIOPHYS ACTA, V1078, P155, DOI 10.1016/0167-4838(91)99004-C; LOBET Y, 1993, J EXP MED, V177, P79, DOI 10.1084/jem.177.1.79; LOCHT C, 1990, VACCINES 90, P435; LOCHT C, 1989, P NATL ACAD SCI USA, V86, P3075, DOI 10.1073/pnas.86.9.3075; LOCHT C, 1990, J BIOL CHEM, V265, P4552; LOCHT C, 1986, NUCLEIC ACIDS RES, V14, P3251, DOI 10.1093/nar/14.8.3251; LOCHT C, 1987, INFECT IMMUN, V55, P2546, DOI 10.1128/IAI.55.11.2546-2553.1987; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; LOCHT C, 1990, Zentralblatt fuer Bakteriologie Supplement, V19, P89; LOOSMORE SM, 1990, INFECT IMMUN, V58, P3653, DOI 10.1128/IAI.58.11.3653-3662.1990; LUKAC M, 1988, J BIOL CHEM, V263, P6146; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; PIZZA M, 1988, P NATL ACAD SCI USA, V85, P7521, DOI 10.1073/pnas.85.20.7521; Sambrook J, 1989, MOL CLONING LABORATO; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAMURA M, 1983, J BIOL CHEM, V258, P6756; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; VANHEYNINGEN S, 1992, POST TRANSLATIONAL M, P153; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	54	30	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24149	24155						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901213				2022-12-27	WOS:A1993MF29400066
J	JESSBERGER, R; RIWAR, B; ROLINK, A; RODEWALD, HR				JESSBERGER, R; RIWAR, B; ROLINK, A; RODEWALD, HR			STIMULATION OF DEFECTIVE-DNA TRANSFER ACTIVITY IN RECOMBINATION DEFICIENT SCID CELL-EXTRACTS BY A 72-KDA PROTEIN FROM WILD-TYPE THYMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; LYMPHOID V(D)J RECOMBINATION; MOUSE L-CELLS; GENE REARRANGEMENT; MOLECULAR-CLONING; ANTIGEN RECEPTOR; SIGNAL SEQUENCE; CODING SEGMENTS; KINASE; MECHANISM	The SCID (Severe Combined Immune Deficiency) mutation causes two DNA recombination deficiencies: an aberrant joining of V(D)J immunoglobulin gene elements and a failure to perform efficient repair of DNA double-strand breaks. A recently established cell-free assay for DNA transfer (DTA) was applied to study nuclear extracts from normal and SCID-derived cells. The recombination deficiency was reflected in the cell-free system: SCID lymphocyte and fibroblast extracts showed reduced levels of DTA activity on a variety of DNA substrates. Analysis of nuclear extracts prepared from wild-type thymocytes and B cells representing different stages in lymphocyte ontogeny revealed the highest activities at the most immature stages. With progression of development, DTA activity decreased. Corresponding to their early developmental arrest, V(D)J rearrangement-incompetent RAG-2(-/-) lymphocyte extracts show high DTA activity. In contrast, extracts from SCID early lymphocytes express very low DNA transfer activity. Induction of V(D)J rearrangement in vivo in a normal preB cell line lead to a co-induction of the cell-free recombination activity. This indicates a development stage specificity of cell-free DNA recombination, which temporally parallels V(D)J recombination. A protein could be purified to near-homogeneity from wild-type thymocytes which stimulates the recombination activity specifically in SCID thymocyte and proB cell extracts. This protein, SRSP (SCID Recombination Stimulatory Protein), migrates as a single band of approximately 72 kDa in SDS-polyacrylamide gel electrophoresis.			JESSBERGER, R (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							AGUILERA RJ, 1987, CELL, V51, P909, DOI 10.1016/0092-8674(87)90578-2; ANDREWS R, 1993, BIOCHEM BIOPH RES CO, V193, P139, DOI 10.1006/bbrc.1993.1601; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500, DOI 10.1016/0968-0004(94)90138-4; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; JESSBERGER R, 1994, IMMUNOLOGIST, V2, P201; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LI M, 1989, GENE DEV, V3, P1801, DOI 10.1101/gad.3.11.1801; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LIN FLM, 1990, MOL CELL BIOL, V10, P113, DOI 10.1128/MCB.10.1.113; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROLINK A, 1993, CURR OPIN IMMUNOL, V5, P207, DOI 10.1016/0952-7915(93)90006-E; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STAUNTON JE, 1994, MOL CELL BIOL, V14, P3876, DOI 10.1128/MCB.14.6.3876; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Taccioli G E, 1992, Curr Top Microbiol Immunol, V182, P107; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Warburg O., 1942, BIOCHEM Z, V310, P384; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WU JM, 1993, BIOCHEM BIOPH RES CO, V193, P13, DOI 10.1006/bbrc.1993.1583; WU LC, 1993, NUCLEIC ACIDS RES, V21, P5067, DOI 10.1093/nar/21.22.5067	62	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6788	6797		10.1074/jbc.270.12.6788	http://dx.doi.org/10.1074/jbc.270.12.6788			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896825	hybrid			2022-12-27	WOS:A1995QQ85500056
J	DEWEERS, M; BROUNS, GS; HINSHELWOOD, S; KINNON, C; SCHUURMAN, RKB; HENDRIKS, RW; BORST, J				DEWEERS, M; BROUNS, GS; HINSHELWOOD, S; KINNON, C; SCHUURMAN, RKB; HENDRIKS, RW; BORST, J			B-CELL ANTIGEN RECEPTOR STIMULATION ACTIVATES THE HUMAN BRUTONS TYROSINE KINASE, WHICH IS DEFICIENT IN X-LINKED AGAMMAGLOBULINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LYMPHOCYTES-B; AGAMMAGLOBULINEMIA; PROTEIN; GENE; PHOSPHORYLATION; EXPRESSION; MOUSE	X-linked agammaglobulinemia (XLA) is an inherited human immunodeficiency disease, characterized by an arrest in B-cell development, which results in a dramatic decrease in immunoglobulin production. The gene product defective in XLA has been identified as a cytoplasmic protein tyrosine kinase, named Bruton's tyrosine kinase (Btk). The dramatic XLA phenotype indicates a critical role for Btk in the regulation of B-cell development. However, neither external stimuli leading to Btk activation nor any of its in vivo substrates have thus far been identified, and the mechanism of disease induction remains unexplained, We report here that stimulation of the B-cell antigen receptor (membrane immunoglobulin) on mature B-cells induces tyrosine phosphorylation of Btk in vivo, accompanied by an increase in its kinase activity in vitro. These results place Btk in the B-cell receptor signal transduction pathway, which is known to be essential in driving B-cell differentiation.	UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1006 CX AMSTERDAM,NETHERLANDS; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Netherlands Cancer Institute; University of London; University College London; Erasmus University Rotterdam			Kinnon, Christine/A-1585-2010	Borst, Jannie/0000-0002-8043-5009				BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; BRUTON OC, 1952, PEDIATRICS, V9, P722; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPANA D, 1990, J IMMUNOL, V145, P1675; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1985, J IMMUNOL, V134, P3070; DESIDERIO S, 1993, NATURE, V361, P201; DEWEERS M, 1994, HUM MOL GENET, V3, P161, DOI 10.1093/hmg/3.1.161; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KATZ FE, 1994, LEUKEMIA, V8, P574; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; PEARL ER, 1978, J IMMUNOL, V120, P1169; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SMIT L, 1994, J BIOL CHEM, V269, P20209; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; SMITH CIE, 1994, J IMMUNOL, V152, P567; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TIMMERS E, 1991, CLIN IMMUNOL IMMUNOP, V61, pS83, DOI 10.1016/S0090-1229(05)80042-X; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0	33	162	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23857	23860						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929028				2022-12-27	WOS:A1994PQ34600002
J	CAPLOW, M; SHANKS, J; RUHLEN, R				CAPLOW, M; SHANKS, J; RUHLEN, R			HOW TAXOL MODULATES MICROTUBULE DISASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								Measurement of the affinity of microtubules for the anti-cancer drug taxol is problematic, because microtubules are not stable at the very low concentrations required to detect taxol dissociation. We have circumvented this problem by using the GTP analogue GMPCPP (guanylyl alpha,beta-methylenediphosphonate), which renders microtubules sufficiently stable to allow binding studies with nonsaturating concentrations of taxol. A K-d value equal to about 10 nM was estimated from the effect of taxol concentration on the dilution-induced disassembly rate and on the binding of [H-3]taxol. With GTP-microtubules the K-d value for taxol binding by tubulin-GDP subunits in the core of the microtubule appears to be comparable with that of GMPCPP-microtubules. However, the stabilizing effect of the drug bound to tubulin subunits that arrive at ends of disassembling microtubules is attenuated by a two-step reaction sequence in which taxol dissociates (k = 30 s(-1)), followed by rapid (k = 1000 s(-1)) loss of the taxol-free tubulin subunit. This sequential reaction can be disrupted by high (micromolar) concentrations of taxol, which react rapidly with tubulin subunits at the ends of microtubules (k = 2 x 10(9) M(-1) s(-1)). The inhibitory effect of taxol on microtubule disassembly at concentrations a thousand-fold greater than the K-d value suggests the desirability of using high taxol concentrations in chemotherapy with this compound.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM46773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Butler J A, 1940, J Gen Physiol, V24, P189, DOI 10.1085/jgp.24.2.189; CAPLOW M, 1982, EUR J BIOCHEM, V127, P319, DOI 10.1111/j.1432-1033.1982.tb06873.x; CAPLOW M, 1989, BIOCHEMISTRY-US, V28, P8136, DOI 10.1021/bi00446a026; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0	7	60	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23399	23402						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916343				2022-12-27	WOS:A1994PQ34500005
J	ROSPERT, S; MULLER, S; SCHATZ, G; GLICK, BS				ROSPERT, S; MULLER, S; SCHATZ, G; GLICK, BS			FUSION PROTEINS CONTAINING THE CYTOCHROME B(2) PRESEQUENCE ARE SORTED TO THE MITOCHONDRIAL INTERMEMBRANE SPACE INDEPENDENTLY OF HSP60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED YEAST MITOCHONDRIA; HEAT-SHOCK PROTEIN-70; PRECURSOR PROTEIN; OUTER-MEMBRANE; NUCLEOSIDE TRIPHOSPHATES; INNER MEMBRANE; IMPORT; MATRIX; TRANSLOCATION; BINDING	hsp60 is a chaperonin located in the mitochondrial matrix. It has been suggested that hsp60 participates in two processes: protein folding in the matrix, and the sorting of imported proteins to the intermembrane space. We analyzed hsp60 function by allowing isolated mitochondria to import two model precursor proteins and then measuring the binding of these proteins to the chaperonin. Of the methods that we tested for monitoring the association of imported proteins with hsp60, only co-immunoprecipitation with specific anti-hsp60 antibodies proved to be reliable. A chimeric matrix-targeted precursor, consisting of a mitochondrial presequence fused to a chloroplast-encoded protein, bound stably to hsp60 after import. In contrast, there was no detectable binding to hsp60 with a fusion protein that was targeted to the intermembrane space by the bipartite cytochrome b(2) presequence. Analysis of a translocation intermediate demonstrated that the cytochrome b(2) presequence arrests import through the inner membrane, with the result that the attached passenger protein is never exposed to hsp60.	UNIV BASEL, BIOCTR, CH-4056 BASEL, SWITZERLAND	University of Basel				Rospert, Sabine/0000-0002-3089-9614; Muller, Sabina/0000-0002-4580-2758	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 R01 GM37803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; CHAPMAN SK, 1991, ADV INORG CHEM, V36, P257, DOI 10.1016/S0898-8838(08)60041-0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DAUM G, 1982, J BIOL CHEM, V257, P3075; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ENDO T, 1989, J BIOL CHEM, V264, P2951; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GUIARD B, 1976, BIOCHIMIE, V58, P305, DOI 10.1016/S0300-9084(76)80437-3; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORWICH AL, 1993, MOL CHAPERONES, P55; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1986, J BIOL CHEM, V261, P1440; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; Lorimer G. H., 1993, P41; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1993, STRUCTURE, V1, P161, DOI 10.1016/0969-2126(93)90017-B; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PRASAD TK, 1990, MOL CELL BIOL, V10, P3979, DOI 10.1128/MCB.10.8.3979; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x	47	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17279	17288						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7911803				2022-12-27	WOS:A1994NT84600047
J	VAANDRAGER, AB; VANDERWIEL, E; HOM, ML; LUTHJENS, LH; DEJONGE, HR				VAANDRAGER, AB; VANDERWIEL, E; HOM, ML; LUTHJENS, LH; DEJONGE, HR			HEAT-STABLE ENTEROTOXIN RECEPTOR GUANYLYL CYCLASE-C IS AN OLIGOMER CONSISTING OF FUNCTIONALLY DISTINCT SUBUNITS, WHICH ARE NONCOVALENTLY LINKED IN THE INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; ESCHERICHIA-COLI; RADIATION-INACTIVATION; ELECTROLYTE TRANSPORT; DIARRHEAL DISEASE; CELL-LINE; EXPRESSION; IDENTIFICATION; ACTIVATION; MODULATION	Guanylyl cyclase (GC) C is a heat-stable enterotoxin (STa) receptor with a monomeric M(r) of approximately 140,000. We calculated from its hydrodynamic parameters that an active GC-C complex has a M(r) of 393,000, suggesting that GC-C is a trimer under native conditions. Both trimeric and dimeric GC-C complexes were detected by I-125-STa binding and SDS-polyacrylamide gel electrophoresis under non-reducing conditions. The GC activity and STa binding from intestinal brush border membranes comigrated in gel filtration and velocity sedimentation with recombinant GC-C. However, I-125-STa cross-linking demonstrated that STa receptors with molecular masses of 52 and 74 kDa are non-covalently attached to GC in the intestine. Radiation inactivation revealed different functional sizes for basal GC activity, STa-stimulated GC activity, and STa binding (59, 210-240, and 32-52 kDa, respectively). At low radiation doses, basal GC activity was stimulated, suggesting that GC-C is inhibited by a relatively large, probably internal structure. These results suggest that STa may activate GC-C by promoting monomer-monomer interaction (internal ''dimerization'') within a homotrimeric GC-C complex, and that GC-C is proteolytically modified in the brush border membrane but retains its function.	DELFT UNIV TECHNOL,INTERFAC REACTOR INST,DEPT RADIAT CHEM,2629 JB DELFT,NETHERLANDS	Delft University of Technology	VAANDRAGER, AB (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,DEPT BIOCHEM,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.			Vaandrager, Arie/0000-0001-9394-9239				BRAUN HJ, 1984, BIOCHIM BIOPHYS ACTA, V774, P81, DOI 10.1016/0005-2736(84)90277-3; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; COHEN MB, 1993, J CELL PHYSIOL, V156, P138, DOI 10.1002/jcp.1041560119; CRANE MR, 1992, MOL PHARMACOL, V41, P1073; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1990, TXB SECRETORY DIARRH, P190; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HARMON JT, 1980, J BIOL CHEM, V255, P3412; HIRAYAMA T, 1992, INFECT IMMUN, V60, P4213, DOI 10.1128/IAI.60.10.4213-4220.1992; ISHIDO M, 1989, J BIOL CHEM, V264, P641; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; KUNO T, 1986, J BIOL CHEM, V261, P1470; LEE JS, 1993, J BIOL CHEM, V268, P4092; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; MCINTYRE JO, 1985, ANAL BIOCHEM, V147, P468, DOI 10.1016/0003-2697(85)90300-8; MCKERNAN RM, 1990, BIOCHEM J, V269, P623, DOI 10.1042/bj2690623; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; THORPE DS, 1991, BIOCHEM BIOPH RES CO, V180, P538, DOI 10.1016/S0006-291X(05)81098-8; TREMBLAY J, 1991, J BIOL CHEM, V266, P8171; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P19598; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; VANHOEK AN, 1992, BIOCHEM BIOPH RES CO, V184, P331; VANNDRAGER AB, 1994, ADV PHARMACOL, V26, P253; WILSON SP, 1988, SEC MESS PHOSPHOPROT, V12, P1; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	37	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16409	16415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7911466				2022-12-27	WOS:A1994NQ72900069
J	SCHREIER, H; MORAN, P; CARAS, IW				SCHREIER, H; MORAN, P; CARAS, IW			TARGETING OF LIPOSOMES TO CELLS EXPRESSING CD4 USING GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED GP120 - INFLUENCE OF LIPOSOME COMPOSITION ON INTRACELLULAR TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DECAY-ACCELERATING FACTOR; MEMBRANE ANCHOR; COMPLEMENT ACTIVATION; T4 MOLECULE; ATTACHMENT; VESICLES; PROTEINS; BINDING; INVITRO	To test the concept that glycosylphosphatidylinositol (GPI)-anchored proteins might be useful as targeting molecules for liposomes, we engineered a GPI-anchored form of gp120 from human immunodeficiency virus type 1 (termed gp120DAF) using the GPI signal of decay-accelerating factor (DAF). We show that (i) purified gp120DAF spontaneously inserts into liposome membranes via the GPI anchor; (ii) liposomes bearing gp120DAF bind specifically to cells expressing CD4, the cellular receptor for gp120; and (iii) the receptor-bound liposomes are internalized and recycle in Chinese ham ster ovary cells. To test whether the lipid composition of the liposome affects any of these processes, we compared small unilamellar liposomes containing only phosphatidylcholine and cholesterol in a 7:1 molar ratio with artificial viral envelopes that mimic the lipid com position of human immunodeficiency virus type 1. We show that when tagged with gp120DAF, both liposome preparations bind specifically to cells expressing CD4, and both are endocytosed. However, artificial viral en velope liposomes are transported to late endosomes or lysosomes in the cell interior, whereas phosphatidylcholine:cholesterol liposomes are confined to a population of vesicles that remain close to the plasma membrane. Since the binding and internalization of both liposome preparations are mediated by the same receptor, we conclude that the lipid composition of the liposome pro foundry influences the subsequent intracellular trafficking of the liposome-receptor complex.	GENENTECH INC,DEPT NEUROBIOL,S SAN FRANCISCO,CA 94080; VANDERBILT UNIV,SCH MED,CTR LUNG RES,NASHVILLE,TN 37232	Roche Holding; Genentech; Vanderbilt University				Caras, Ingrid/0000-0002-8902-808X				ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900; BERMAN PW, 1989, J VIROL, V63, P3489, DOI 10.1128/JVI.63.8.3489-3498.1989; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANDER R, 1992, LIFE SCI, V50, P481, DOI 10.1016/0024-3205(92)90387-5; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; HELENIUS A, 1982, CIBA F SYMP, V92, P59; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; MARSH M, 1984, BIOCHEM J, V218, P1; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1992, J IMMUNOL, V149, P1736; RALSTON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P133, DOI 10.1016/0005-2736(81)90019-5; RUBAS W, 1990, J MICROENCAPSUL, V7, P385, DOI 10.3109/02652049009021848; SATO T, 1992, PROG LIPID RES, V31, P345, DOI 10.1016/0163-7827(92)90001-Y; SCHREIER H, 1992, INT J PHARMACEUT, V87, P183, DOI 10.1016/0378-5173(92)90242-T; SCHWENDENER RA, 1990, BIOCHIM BIOPHYS ACTA, V1026, P69, DOI 10.1016/0005-2736(90)90334-K; SECHOY O, 1989, EXP CELL RES, V185, P122, DOI 10.1016/0014-4827(89)90042-6; STECENKO AA, 1992, PHARM PHARM LETT, V1, P127; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WEISSING V, 1993, LIPOSOME TECHNOLOGY, V3, P231; WEISSMANN G, 1975, P NATL ACAD SCI USA, V72, P88, DOI 10.1073/pnas.72.1.88; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WRIGHT S, 1989, Advanced Drug Delivery Reviews, V3, P343, DOI 10.1016/0169-409X(89)90027-6	33	29	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9090	9098						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7907597				2022-12-27	WOS:A1994NB41100072
J	KREIENKAMP, HJ; SINE, SM; MAEDA, RK; TAYLOR, P				KREIENKAMP, HJ; SINE, SM; MAEDA, RK; TAYLOR, P			GLYCOSYLATION SITES SELECTIVELY INTERFERE WITH ALPHA-TOXIN BINDING TO THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CHOLINERGIC RECEPTOR; SUBUNIT; SNAKE; LOPHOTOXIN; MOUSE; CELLS; GAMMA	Sequence analysis reveals unique features in the alpha-subunit of nicotinic acetylcholine receptors from the alpha-toxin-resistant cobra and mongoose. Included are N-linked glycosylation signals just amino-terminal to the Tyr(190), Cys(192)-Cys(193) region of the Ligand binding domain, substitution of Trp(187) and Phe(189) by non-aromatic residues and alteration of the proline sequence Pro(194)-X-X-Pro(197). Glycosylation signals were inserted into the toxin sensitive mouse alpha-subunit by the mutations F189N and W187N/F189T. The F189N alpha-subunit, when trans-fected with beta, gamma and delta, showed a 140-fold loss of alpha-bungarotoxin affinity, whereas the W187N/F189T double mutation exhibited a divergence in alpha-toxin affinities at the two sites, one class showing a 600-fold and the other showing an 11-fold reduction. The W187N mutant and the double mutant F189N/S191A lacking the requisite glycosylation signals exhibited little alteration in affinity, as did the P194L and P197H mutations. The glycosylation sites had little or no influence on binding of toxins of intermediate (alpha-conotoxin, 1500 Da) or small mass (lophotoxin, 500 Da) and of the agonist, carbamylcholine. The two sites for the binding of alpha-conotoxin M1 have widely divergent dissociation constants of 2.1 and 14,800 nM. Expression of alpha/gamma- and alpha/delta-subunit pairs indicated that the high and low affinity sites are formed by the alpha/delta and alpha/delta contacts, respectively.	MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,RECEPTOR BIOL LAB,ROCHESTER,MN 55905	Mayo Clinic	KREIENKAMP, HJ (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.			Kreienkamp, Hans-Jurgen/0000-0002-8871-9970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24437] Funding Source: Medline; NINDS NIH HHS [NS 31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ABRAMSON SN, 1988, J BIOL CHEM, V263, P18568; BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BURDEN SJ, 1975, P NATL ACAD SCI USA, V72, P3245, DOI 10.1073/pnas.72.8.3245; CHATURVEDI V, 1992, BIOCHEMISTRY-US, V31, P1370, DOI 10.1021/bi00120a012; CHATURVEDI V, 1993, BIOCHEMISTRY-US, V32, P9579; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; GREEN WN, 1993, CELL, V74, P51; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; KREIENKAMP HJ, 1992, BIOCHEMISTRY-US, V31, P8239, DOI 10.1021/bi00150a017; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE BS, 1991, J BIOL CHEM, V266, P11448; MYERS RA, 1991, BIOCHEMISTRY-US, V30, P9370, DOI 10.1021/bi00102a034; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9520; OHANA B, 1991, BIOCHEM BIOPH RES CO, V179, P648, DOI 10.1016/0006-291X(91)91421-8; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1980, J BIOL CHEM, V255, P144; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1	25	103	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8108	8114						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907588				2022-12-27	WOS:A1994NB40900044
J	OHNISHI, H; MATSUMOTO, H; SAKAI, H; OHTA, T				OHNISHI, H; MATSUMOTO, H; SAKAI, H; OHTA, T			FUNCTIONAL ROLES OF TRP(337) AND GLU(632) IN CLOSTRIDIUM GLUCOAMYLASE, AS DETERMINED BY CHEMICAL MODIFICATION, MUTAGENESIS, AND THE STOPPED-FLOW METHOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIGER; TRYPTOPHANYL RESIDUES; MOLECULAR-CLONING; AWAMORI; BINDING; GLUCONOLACTONE; GENE; MALTOSE; ENZYME	Chemical modification of glucoamylase (EC 3.2.1.3) from Clostridium sp. G0005 (CGA) with N-bromosuccinimide (NBS) was carried out in the presence or absence of an inhibitor, acarbose. CGA lost its catalytic activity through NBS oxidation in the absence of acarbose. The absorbance change at 280 nm suggested that acarbose protects about 2 Trp residues from NBS oxidation. We performed peptide mapping analysis to identify the protected Trp residues, and Trp321, Trp337, Trp433, and Trp569 were identified as candidates to be protected by acarbose. These 4 Trp residues were replaced by site-directed mutagenesis with Phe. The Trp337 --> Phe mutant showed very weak catalytic activity, so Trp337 is proposed as an important residue for the catalytic activity. Further, we constructed a Glu632 --> Gln mutant. Glu632 is the putative catalytic base. The presteady-state kinetics of the Trp337 --> Phe and Glu632 --> Gln mutants and the wild-type CGA were investigated using maltotriose as a substrate. The reaction of wild-type CGA can be explained as one involving three intermediates. On the other hand, the two mutants' reactions are explained by a two-step mechanism lacking the third intermediate. Trp337 and Glu632 appear to be crucial for the formation of the third intermediate in the wild-type reaction, which precedes the transition state.	UNIV TOKYO,DEPT AGR CHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ALESHIN A, 1992, J BIOL CHEM, V267, P19291; BOEL E, 1984, EMBO J, V3, P1097, DOI 10.1002/j.1460-2075.1984.tb01935.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P559, DOI 10.1007/BF02908684; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P111, DOI 10.1007/BF02913970; FAGERSTROM R, 1991, J GEN MICROBIOL, V137, P1001, DOI 10.1099/00221287-137-4-1001; HAKANSSON K, 1989, CARLSBERG RES COMMUN, V54, P145, DOI 10.1007/BF02907184; HARRIS EMS, 1993, BIOCHEMISTRY-US, V32, P1618, DOI 10.1021/bi00057a028; HIROMI K, 1982, BIOCHEMISTRY-US, V21, P102, DOI 10.1021/bi00530a018; HYUN HH, 1985, APPL ENVIRON MICROB, V49, P1168, DOI 10.1128/AEM.49.5.1168-1173.1985; ITO T, 1987, J BACTERIOL, V169, P4171; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NUNBERG JH, 1984, MOL CELL BIOL, V4, P2306, DOI 10.1128/MCB.4.11.2306; OHNISHI H, 1992, EUR J BIOCHEM, V207, P413, DOI 10.1111/j.1432-1033.1992.tb17064.x; OHNISHI M, 1983, BIOCHIM BIOPHYS ACTA, V744, P64, DOI 10.1016/0167-4838(83)90341-2; OHNISHI M, 1978, CARBOHYD RES, V61, P335, DOI 10.1016/S0008-6215(00)84493-6; OHNISHI M, 1976, J BIOCHEM-TOKYO, V79, P11, DOI 10.1093/oxfordjournals.jbchem.a131037; OLSEN K, 1992, EUR J BIOCHEM, V209, P777, DOI 10.1111/j.1432-1033.1992.tb17348.x; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SIERKS MR, 1993, BIOCHEMISTRY-US, V32, P1113, DOI 10.1021/bi00055a017; SIERKS MR, 1989, PROTEIN ENG, V2, P621, DOI 10.1093/protein/2.8.621; Spande T.F., 1967, DETERMINATION TRYPTO, P498; SPECKA U, 1991, APPL ENVIRON MICROB, V57, P2317, DOI 10.1128/AEM.57.8.2317-2323.1991; SVENSSON B, 1986, CARLSBERG RES COMMUN, V51, P61, DOI 10.1007/BF02907996; SVENSSON B, 1990, EUR J BIOCHEM, V118, P29; TANAKA A, 1982, J BIOCHEM-TOKYO, V91, P1; TANAKA A, 1982, BIOCHEMISTRY-US, V21, P107, DOI 10.1021/bi00530a019; TANAKA Y, 1986, AGR BIOL CHEM TOKYO, V50, P965, DOI 10.1080/00021369.1986.10867492; YAMASHITA I, 1985, J BACTERIOL, V161, P567, DOI 10.1128/JB.161.2.567-573.1985	29	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3503	3510						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906268				2022-12-27	WOS:A1994MV63100058
J	GARCIA, KC; DESAUVAGE, FJ; STRUBLE, M; HENZEL, W; REILLY, D; GOEDDEL, DV				GARCIA, KC; DESAUVAGE, FJ; STRUBLE, M; HENZEL, W; REILLY, D; GOEDDEL, DV			PROCESSING AND CHARACTERIZATION OF HUMAN PROGUANYLIN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ENTEROTOXIN; INTESTINAL GUANYLATE-CYCLASE; ENDOGENOUS ACTIVATOR; HUMAN RECEPTOR; CYCLIC-GMP; PRECURSOR	Guanylin is a 15-amino acid peptide hormone that was originally isolated from the jejunum of the rat small intestine and shown to be an endogenous activator of the intestinal heat-stable enterotoxin receptor-guanylyl cyclase. Guanylin is synthesized as a 115-amino acid prohormone, proguanylin, which is processed at a site yet to be determined, into a C-terminal bioactive fragment(s). In order to examine the processing of proguanylin in vitro, we have generated large quantities of the properly folded prohormone by constructing an expression vector that directs its secretion into the periplasmic space of Escherichia coli. The bacterially expressed human proguanylin was then processed to smaller C-terminal fragments by protease digestion. Digestion with trypsin or lysine-C generated C-terminal peptides of different length, which have been purified and characterized. Guanylin-22 and guanylin-32 have binding affinities and biological activities similar to guanylin-15, while guanylin-63 and the entire proguanylin have only minimal bioactivity. Circular dichroism spectroscopy reveals that proguanylin is a stably folded protein containing mostly beta-sheet and beta-turn structure.	GENENTECH INC, DEPT MOLEC BIOL, 460 POINT SAN BRUNO BLVD, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT BIOORGAN CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT PROC DEV, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584; Henzel, William/0000-0003-2940-3797				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHAN SK, 1981, J BIOL CHEM, V256, P7744; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DESAUVAGE FJ, 1992, J BIOL CHEM, V267, P6479; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; SAXENA VP, 1971, P NATL ACAD SCI USA, V68, P969, DOI 10.1073/pnas.68.5.969; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; STADER JA, 1990, METHOD ENZYMOL, V185, P166; WIEGAND RC, 1992, BIOCHEM BIOPH RES CO, V185, P812, DOI 10.1016/0006-291X(92)91699-Q; YOSHIMURA S, 1985, FEBS LETT, V181, P138, DOI 10.1016/0014-5793(85)81129-7	16	25	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22397	22401						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901199				2022-12-27	WOS:A1993MD34800034
J	CRAWFORD, MJ; SHERMAN, DR; GOLDBERG, DE				CRAWFORD, MJ; SHERMAN, DR; GOLDBERG, DE			REGULATION OF SACCHAROMYCES-CEREVISIAE FLAVOHEMOGLOBIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING FLAVOHEMOPROTEIN; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; BACTERIAL HEMOGLOBIN; NUCLEOTIDE-SEQUENCE; YEAST HEMOGLOBIN; STATIONARY-PHASE; LACZ FUSIONS; CLONED GENES; VITREOSCILLA	The Saccharomyces cerevisiae hemoglobin is a flavoprotein of unknown function. It shares extensive sequence homology with the globin of Candida as well as those of several bacterial species. We have studied its gene regulation in order to better understand its purpose in the cell. Transcriptional analyses indicate that, in sharp contrast to the bacterial globins of Vitreoscilla and Alcaligenes eutrophus, the S. cerevisiae globin message is induced during logarithmic growth and under oxygen-replete conditions. Transcription of the S. cerevisiae hemoglobin gene is positively regulated by the transcription factors heme-activated protein (HAP) 1 and HAP2/3/4, which respond to intracellular heme levels. Anaerobically, there is a low level, HAP-independent induction of hemoglobin mRNA. Unlike other systems influenced by the HAP2/3/4 transcription factor complex, no activation of hemoglobin expression by growth in non-fermentable carbon sources is observed. Flavohemoglobin gene disruption does not alter cell viability or growth in a variety of oxygen conditions and carbon sources. Physical and genetic mapping of the S. cerevisiae flavohemoglobin gene places it on chromosome seven near the formyltetrahydrofolate synthase (ADE3) locus. These data indicate that, despite the high degree of homology, the S. cerevisiae globin may have a function distinct from those proposed for bacterial globins.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309; BOERMAN SJ, 1982, J GEN APPL MICROBIOL, V28, P35, DOI 10.2323/jgam.28.35; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COSTANZO MC, 1989, GENETICS, V122, P297; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CRAMM R, 1994, J BIOL CHEM, V269, P7349; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DIKSHIT KL, 1990, NUCLEIC ACIDS RES, V18, P4149, DOI 10.1093/nar/18.14.4149; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GALIAZZO F, 1993, FEBS LETT, V315, P197, DOI 10.1016/0014-5793(93)81162-S; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GILLESGONZALES MA, 1991, NATURE, V360, P170; GOLDRING ES, 1970, J MOL BIOL, V52, P323, DOI 10.1016/0022-2836(70)90033-1; GONZALESPREVATT V, 1980, J BIOL CHEM, V255, P1478; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1988, ANTIBODIES LAB MANUA, pCH12; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; JOSHI M, 1994, BIOCHEM BIOPH RES CO, V202, P535, DOI 10.1006/bbrc.1994.1961; KHOSLA C, 1989, J BACTERIOL, V171, P5995, DOI 10.1128/jb.171.11.5995-6004.1989; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; Konat Gregory W., 1994, P37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT JR, 1994, P NATL ACAD SCI USA, V91, P7345, DOI 10.1073/pnas.91.15.7345; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; MATOON JR, 1979, BIOL CLIN ASPECTS OX, P421; METHA KD, 1990, J BIOL CHEM, V265, P8802; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; ORII Y, 1986, J BIOL CHEM, V261, P3544; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; PILLAR TM, 1991, CURR GENET, V20, P185, DOI 10.1007/BF00326230; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; RIGGS AF, 1991, AM ZOOL, V31, P535; RILES L, 1993, GENETICS, V134, P81; Sambrook J, 1989, MOL CLONING LABORATO; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Sherman F., 1983, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WEIHS V, 1989, ARCH MICROBIOL, V151, P546, DOI 10.1007/BF00454873; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WINKLER H, 1988, EMBO J, V7, P1799, DOI 10.1002/j.1460-2075.1988.tb03011.x; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	55	43	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6991	6996		10.1074/jbc.270.12.6991	http://dx.doi.org/10.1074/jbc.270.12.6991			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896850	hybrid			2022-12-27	WOS:A1995QQ85500081
J	PULIDO, R; KRUEGER, NX; SERRAPAGES, C; SAITO, H; STREULI, M				PULIDO, R; KRUEGER, NX; SERRAPAGES, C; SAITO, H; STREULI, M			MOLECULAR CHARACTERIZATION OF THE HUMAN TRANSMEMBRANE PROTEIN-TYROSINE-PHOSPHATASE-DELTA - EVIDENCE FOR TISSUE-SPECIFIC EXPRESSION OF ALTERNATIVE HUMAN TRANSMEMBRANE PROTEIN-TYROSINE-PHOSPHATASE-DELTA ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; CELL-ADHESION MOLECULES; IMMUNOGLOBULIN SUPERFAMILY; NERVOUS-SYSTEM; EXTRACELLULAR REGION; SURFACE RECOGNITION; POINT MUTATION; CLEAVAGE SITE; VASE EXON; NG-CAM	Protein-tyrosine phosphatases (PTPases) play an essential role in the regulation of cell activation, proliferation, and differentiation. A major subfamily of these enzymes is the transmembrane-type PTPases that contain extracellular regions comprised of Ig-like and fibronectin type III (FN-III)-like domains, Characterization of the human transmembrane PTPase delta (HPTP delta) revealed the existence of multiple HPTP delta isoforms that vary in their extracellular regions. The full-length HPTP delta isoform has an extracellular region containing three Ig-like and eight FN-III-like domains connected via a transmembrane peptide to an intracellular region with two PTPase domains, whereas another isoform lacks four of the eight FN-III like domains. Furthermore, other HPTP delta isoforms exist that lack 9 amino acids within the second Ig-like domain and 4 amino acids at the junction of the second and third Ig-like domains or 9 amino acids within the fifth FN-III-like domain, Reverse transcription polymerase chain reaction analysis demonstrated that HPTP delta isoforms lacking these short peptides are expressed in kidney, whereas isoforms containing these peptides are expressed in the brain, Analysis of HPTP delta biosynthesis demonstrated that HPTP delta is expressed as a complex of two noncovalently associated subunits derived from a proprotein and that the HPTP delta ectodomain is shed from the cell surface. Mutational analysis of the HPTP delta proprotein cleavage site revealed the existence of two or three functional and overlapping furin-like endoprotease cleavage sites.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PULIDO, R (corresponding author), CHILDRENS HOSP, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA.		Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689; Pulido, Rafael/0000-0001-9100-248X	NCI NIH HHS [CA55547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055547] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; DAUM G, 1994, J BIOL CHEM, V269, P10524; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KAYYEM JF, 1992, J CELL BIOL, V118, P1259, DOI 10.1083/jcb.118.5.1259; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OGRADY P, 1994, J BIOL CHEM, V269, P25193; PAN MG, 1993, J BIOL CHEM, V268, P19284; PULIDO R, 1994, J EXP MED, V179, P1035, DOI 10.1084/jem.179.3.1035; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; YAN H, 1993, J BIOL CHEM, V268, P24880; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	54	68	70	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6722	6728		10.1074/jbc.270.12.6722	http://dx.doi.org/10.1074/jbc.270.12.6722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896816	hybrid			2022-12-27	WOS:A1995QQ85500047
J	SLATER, SJ; KELLY, MB; TADDEO, FJ; LARKIN, JD; YEAGER, MD; MCLANE, JA; HO, C; STUBBS, CD				SLATER, SJ; KELLY, MB; TADDEO, FJ; LARKIN, JD; YEAGER, MD; MCLANE, JA; HO, C; STUBBS, CD			DIRECT ACTIVATION OF PROTEIN-KINASE-C BY 1-ALPHA,25-DIHYDROXYVITAMIN D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DIFFERENTIATION; CYTOSOLIC CALCIUM; GENE-EXPRESSION; PHORBOL ESTERS; CELLS; 1,25-DIHYDROXYVITAMIN-D3; DIACYLGLYCEROL; INVOLVEMENT; MEMBRANES; RECEPTOR	The key metabolite of vitamin D-3, 1 alpha,25-dihydroxyvitamin D-3 (1,25-D-3), induces rapid cellular responses that constitute a so-called ''non-genomic'' response. This effect is distinguished from its ''classic'' genomic role in calcium homeostasis involving the nuclear 1,25-D-3 receptor. Evidence is presented that protein kinase C (PKC) is directly activated by 1,25-D, at physiological concentrations (EC(50) = 16 +/- 1 nM). The effect was demonstrable with single PKC-alpha, -gamma, and -epsilon isoform preparations, assayed in a system containing only purified enzyme, substrate, co-factors, and lipid vesicles, from which it is inferred that a direct interaction with the enzyme is involved. The finding that calcium-dependent isoform PKC-epsilon was also activated by 1,25-D-3 shows that the calcium binding C2 domain is not required. The level of 1,25-D-3-induced activation, paired with either diacylglycerol or 4 beta-12-O-tetradecanoylphorbol-13-acetate, was greater than that achievable by any individual activator alone, each at a saturating concentration, a result that implies two distinct activator sites on the PKC molecule. Phosphatidylethanolamine present in the lipid vesicles potentiated 4 beta-12-O-tetradecanoyl-phorbol-13-acetate- and diacylglycerol-induced PKC activities, whereas 1,25-D-3-induced activity decreased, consistent with 1,25 D-3-activated PKC possessing a distinct conformation. The results suggest that PKC is a ''membrane-bound receptor'' for 1,25-D-3 and that it could be important in the control of non-genomic cellular responses to the hormone.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; HOFFMANN LA ROCHE INC, NUTLEY, NJ 07110 USA	Jefferson University; Roche Holding				Larkin, Jonathan/0000-0002-1202-9287	NIAAA NIH HHS [AA08022, AA07215, AA07186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA008022, R01AA008022, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BELL R, 1992, ADV EXP MED BIOL, V318, P275; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOLAND RL, 1991, BIOCHEM BIOPH RES CO, V180, P833, DOI 10.1016/S0006-291X(05)81140-4; BONI LT, 1985, J BIOL CHEM, V260, P819; BOSCA L, 1993, BIOCHEM J, V290, P827, DOI 10.1042/bj2900827; BOURDEAU A, 1990, ENDOCRINOLOGY, V127, P2738, DOI 10.1210/endo-127-6-2738; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; BURGOSTRINIDAD M, 1990, ANAL BIOCHEM, V190, P102, DOI 10.1016/0003-2697(90)90141-U; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DEBOLAND AR, 1990, ENDOCRINOLOGY, V127, P39, DOI 10.1210/endo-127-1-39; DEBOLAND AR, 1994, J BIOL CHEM, V269, P8675; DELUCA HF, 1990, KIDNEY INT, V38, pS2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUI SW, 1989, P NATL ACAD SCI USA, V86, P5825, DOI 10.1073/pnas.86.15.5825; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KHARE S, 1993, ENDOCRINOLOGY, V133, P2213, DOI 10.1210/en.133.5.2213; KIRK GL, 1984, BIOCHEMISTRY-US, V23, P1093, DOI 10.1021/bi00301a009; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; Kitano T, 1986, Methods Enzymol, V124, P349; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; NELSESTUEN GL, 1993, J BIOENERG BIOMEMBR, V3, P277; NEMERE I, 1993, RECEPTOR, V3, P277; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; SIMBOLICAMPBELL M, 1992, CELL SIGNAL, V4, P99, DOI 10.1016/0898-6568(92)90011-V; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SNOEK GT, 1988, BIOCHEM J, V255, P629; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WENDER PA, 1988, P NATL ACAD SCI USA, V85, P7197, DOI 10.1073/pnas.85.19.7197; WOLF M, 1985, J BIOL CHEM, V260, P5718	61	117	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6639	6643		10.1074/jbc.270.12.6639	http://dx.doi.org/10.1074/jbc.270.12.6639			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896803	hybrid			2022-12-27	WOS:A1995QQ85500034
J	TAYLOR, ICA; ROY, S; YASWEN, P; STAMPFER, MR; VARMUS, HE				TAYLOR, ICA; ROY, S; YASWEN, P; STAMPFER, MR; VARMUS, HE			MOUSE MAMMARY-TUMORS EXPRESS ELEVATED LEVELS OF RNA-ENCODING THE MURINE HOMOLOG OF SKY, A PUTATIVE RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; PP60C-SRC PROTEIN-KINASE; EPITHELIAL-CELL LINE; SIGNAL TRANSDUCTION; TRANSGENIC MICE; GROWTH-FACTOR; GENE; ONCOGENE; TRANSFORMATION; VIRUS	To gain insight into the signal transduction pathways utilized by the Wnt-1-responsive mammary epithelial cell line C57MG, we screened for non-src family member tyrosine kinases expressed in these cells using a polymerase chain reaction-based technique. We identified five cDNA clones encoding receptor tyrosine kinases for which the ligand is known (fibroblast growth factor receptor, platelet-derived growth factor receptor, epithelial growth factor receptor, insulin receptor, and insulin-like growth factor receptor), two putative receptor tyrosine kinases for which the ligand remains to be identified (the products of ryk and the mouse klg homolog), and a novel tyrosine kinase. We cloned cDNAs encoding both the murine and human homologs of this kinase, the sequences of which were subsequently published under the names sky (Ohashi, K., Mizuno, K., Kuma, K., Miyata, T., and Nakamura, T. (1994) Oncogene 9, 699-705) and rse (Mark, M. R., Scadden, D. T., Wang, Z., Gu, Q., Goddard, A., and Godowski, P. J. (1994) J. Biol. Chem. 269, 10720-10728). Mouse sky RNA levels are abundant in mammary tumors derived from transgenic mice that express wnt-1, fgf-3, or both oncogenes in their mammary glands. However, little or no expression of sky is detected in mammary glands from virgin animals or in preneoplastic mammary glands from wnt-1 transgenic mice. Moreover, we find that the human homolog of sky is expressed at elevated levels when normal human mammary epithelial cells are rendered tumorigenic by the introduction of two viral oncogenes. Transient transfection of the human SKY cDNA into the quail fibrosarcoma cell line QT6 reveals that SKY is an active tyrosine kinase that augments the level of cellular phosphotyrosine. Introduction of murine Sky into RatB1a fibroblasts by retrovirus-mediated gene transfer results in morphological transformation, growth in soft agar, and the formation of tumors in nude mice. These data raise the possibility that the Sky tyrosine kinase is involved in the development and/or progression of mammary tumors.	NCI,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA024844, R55CA054247, R01CA054247, R37CA024844, R35CA039832] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24844, CA-39832, CA-54247] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES AC, 1994, ONCOGENE, V9, P1461; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK R, 1988, CANCER RES, V48, P4689; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENNIPMAN A, 1989, CANCER RES, V49, P516; HIRSCH R, 1988, VIROLOGY, V167, P136, DOI 10.1016/0042-6822(88)90062-1; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; JACOBS C, 1983, CANCER RES, V43, P1696; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419; MARK MR, 1994, J BIOL CHEM, V269, P10720; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P118; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8	37	48	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6872	6880		10.1074/jbc.270.12.6872	http://dx.doi.org/10.1074/jbc.270.12.6872			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896835	hybrid			2022-12-27	WOS:A1995QQ85500066
J	HAUSKEN, ZE; COGHLAN, VM; HASTINGS, CAS; REIMANN, EM; SCOTT, JD				HAUSKEN, ZE; COGHLAN, VM; HASTINGS, CAS; REIMANN, EM; SCOTT, JD			TYPE-II REGULATORY SUBUNIT (RII) OF THE CAMP-DEPENDENT PROTEIN-KINASE INTERACTION WITH A-KINASE ANCHOR PROTEINS REQUIRES ISOLEUCINE-3 AND ISOLEUCINE-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; HIGH-AFFINITY BINDING; AMINO-ACID-SEQUENCE; BOVINE BRAIN; CLONING; DOMAIN; BETA; IDENTIFICATION; LOCALIZATION; EXPRESSION	Compartmentalization of the type II cAMP-dependent protein kinase is maintained by association of the regulatory subunit (RII) with A-Kinase Anchor Proteins (AKAPs). In previous studies (Scott, J. D., Stofko, R.E., McDonald, J. R., Comer, J. D., Vitalis, E. A., and Mangili J. (1990) J. Biol. Chem. 265, 21561-21566) we have shown that dimerization of RII alpha was required for interaction with the cytoskeletal component microtubule-associated protein 2. In this report we show that the localization and dimerization domains of RII alpha are contained within the first thirty residues of each RII protomer, RII des-5 (an amino terminal deletion mutant lacking residues 1-5) was unable to bind AKAPs but retained the ability to dimerize. RII alpha I3,I5A (a mutant where isoleucines 3 and 5 were replaced with alanine) was unable to bind a variety of AKAPs. Mutation of both isoleucines decreased AKAP binding without affecting dimerization, cAMP binding, or the overall secondary structure of the protein. Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold. Therefore, we propose that two isoleucine side chains on each RII protomer are principle sites of contact with the conserved amphipathic helix binding domain on AKAPs.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; MED COLL OHIO,TOLEDO,OH 43699	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044238] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44238] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEEBE SJ, 1986, ENZYMES, V17, P43; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BREGMAN DB, 1991, J BIOL CHEM, V266, P7202; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR DW, 1993, J BIOL CHEM, V268, P20729; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; FIRST EA, 1984, J BIOL CHEM, V259, P4011; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; REIMANN EM, 1986, BIOCHEMISTRY-US, V25, P119, DOI 10.1021/bi00349a018; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SCOTT JD, 1994, MOL ENDOCRINOL, V13, P5; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	40	101	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24245	24251						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929081				2022-12-27	WOS:A1994PQ34600062
J	MACINTYRE, S; SAMOLS, D; DAILEY, P				MACINTYRE, S; SAMOLS, D; DAILEY, P			2 CARBOXYLESTERASES BIND C-REACTIVE PROTEIN WITHIN THE ENDOPLASMIC-RETICULUM AND REGULATE ITS SECRETION DURING THE ACUTE-PHASE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCURONIDASE; MOLECULAR-CLONING; RAT-LIVER; TRANSMEMBRANE PROTEINS; NUCLEOTIDE-SEQUENCE; HEPATOMA-CELLS; KDEL RECEPTOR; ESTERASE; EGASYN; RETENTION	We have previously reported that C-reactive protein (CRP) is normally synthesized by rabbit hepatocytes at relatively low rates and is retained in the endoplasmic reticulum (ER), apparently by specific interaction with a 60-kDa lumenal ER protein. During the acute phase response to tissue injury, a marked increase in CRP synthesis is associated with a decrease in the CRP binding capacity of the 60-kDa protein, with accompanying rapid secretion of CRP. In the present studies, we purified two 60-kDa ER lumenal glycoproteins (referred to as gp60a and gp60b) capable of binding CRP. gp60b, though present at only 5% the level of gp60a, was found to account for 80% of the total CRP binding capacity. Amino-terminal amino acid sequence analysis and biochemical characterization identified gp60a and gp60b as two microsomal carboxylesterases previously reported by others to contain COOH-terminal ER retention signals (HIEL and HTEL). The CRP binding activities of gp60a and gp60b were found to be independent of their esterase activities. In animals undergoing the acute phase response, the levels of gp60a and gp60b were diminished by about 50%, but the CRP binding capacities were reduced by 4-6-fold for gp60a and 25-30-fold for gp60b. These findings indicate that CRP is normally retained within the ER via interaction with gp60a and gp60b, while during the acute phase response a decrease in the CRP binding affinity of these proteins, particularly gp60b, results in efficient secretion of CRP.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44109 USA	Case Western Reserve University	MACINTYRE, S (corresponding author), CASE WESTERN RESERVE UNIV, METROHLTH MED CTR, DEPT MED, 2500 METROHLTH DR, CLEVELAND, OH 44109 USA.				NIAMS NIH HHS [AR34313] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034313, R23AR034313] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRES DA, 1990, J BIOL CHEM, V265, P5952; CANONICO PG, 1977, AM J CLIN NUTR, V30, P1359, DOI 10.1093/ajcn/30.8.1359; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLD AM, 1964, BIOCHEMISTRY-US, V3, P783, DOI 10.1021/bi00894a009; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; HU SI, 1986, BIOCHEMISTRY-US, V25, P7834, DOI 10.1021/bi00372a008; HU SI, 1988, J BIOL CHEM, V263, P1500; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORZA G, 1988, J BIOL CHEM, V263, P3486; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; KUSHNER I, 1961, J EXP MED, V114, P961, DOI 10.1084/jem.114.6.961; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LEDFORD BE, 1983, J BIOL CHEM, V258, P3304; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LI H, 1990, J BIOL CHEM, V265, P14732; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACINTYRE SS, 1988, METHOD ENZYMOL, V163, P383; MACINTYRE SS, 1992, J CELL BIOL, V118, P253, DOI 10.1083/jcb.118.2.253; MACINTYRE SS, 1985, J BIOL CHEM, V260, P4169; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MEDDA S, 1985, J BIOL CHEM, V260, P5802; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OVNIC M, 1991, GENOMICS, V9, P344, DOI 10.1016/0888-7543(91)90263-E; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SCHEELE G, 1985, J BIOL CHEM, V260, P926; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHIBATA F, 1993, GENOMICS, V17, P76, DOI 10.1006/geno.1993.1285; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YEO KT, 1985, J BIOL CHEM, V260, P7896; ZHEN LD, 1993, ARCH BIOCHEM BIOPHYS, V304, P402, DOI 10.1006/abbi.1993.1368	52	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24496	24503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929114				2022-12-27	WOS:A1994PQ34600099
J	MCCORMICK, SPA; LINTON, MF; HOBBS, HH; TAYLOR, S; CURTISS, LK; YOUNG, SG				MCCORMICK, SPA; LINTON, MF; HOBBS, HH; TAYLOR, S; CURTISS, LK; YOUNG, SG			EXPRESSION OF HUMAN APOLIPOPROTEIN B90 IN TRANSGENIC MICE - DEMONSTRATION THAT APOLIPOPROTEIN B90 LACES THE STRUCTURAL REQUIREMENTS TO FORM LIPOPROTEIN(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FAMILIAL HYPOBETALIPOPROTEINEMIA; MYOCARDIAL-INFARCTION; HEART-DISEASE; B GENE; BINDING; PLASMA; ANTIBODIES; CYSTEINE; RISK	Lipoprotein(a) (Lp(a)) is a lipoprotein formed by the disulfide linkage of apolipoprotein(a) (apo(a)) to the apoB100 of a low density lipoprotein particle. Earlier site-directed mutagenesis studies of apo(a) demonstrated that apo(a) cysteine 4057 is required for the disulfide linkage; however, the cysteine residue within apoB100 that is involved in the disulfide bond has not been identified. We previously demonstrated that the apoB100 produced by human apoB transgenic mice binds to apo(a) and forms Lp(a) (Linton, M. F., Farese, R. V., Jr., Chiesa, G., Grass, D. S., Chin, P., Hammer, R. E., Hobbs, H. H., and Young, S. G. (1993) J. Clin. Invest. 92, 3029-3037). To further explore the structural features of human apoB that are required for the formation of Lp(a), we used a transposon-interrupted human apoB gene clone to develop transgenic mice that express high levels of a truncated form of human apoB, apoB90, which contains the amino-terminal 4084 amino acids of apoB. In vitro incubation of apo(a) with the plasma of human apoB90 transgenic mice did not yield Lp(a), as judged by Western blots of SDS-polyacrylamide gels or by a monoclonal antibody-based radioimmunoassay. In contrast, incubation of apo(a) with the plasma of a mouse that expressed an equivalent amount of the full-length apoB100 did yield Lp(a). In addition to these in vitro incubation studies, no Lp(a) could be detected in the plasma of a ''double transgenic'' mouse expressing both human apoB90 and apo(a). These data indicate that the carboxyl-terminal 10% of apoB100 contains amino acid sequences that are essential for the formation of Lp(a).	UNIV CALIF SAN FRANCISCO, DEPT MED, GLADSTONE INST CARDIOVASC DIS, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, INST CARDIOVASC RES, SAN FRANCISCO, CA 94141 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT VASC BIOL IMM17, LA JOLLA, CA 92037 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute				Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL41633, HL-02925] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, K08HL002925] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLEMAN RD, 1990, BIOCHIM BIOPHYS ACTA, V1037, P129, DOI 10.1016/0167-4838(90)90111-R; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; GUEVARA J, 1993, CIRCULATION, V88, P271; GUREWICH V, 1994, JAMA-J AM MED ASSOC, V271, P1025, DOI 10.1001/jama.271.13.1025; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOGAN B, 1986, MANIPULATING MOUSE E; HORIE Y, 1992, J BIOL CHEM, V267, P1962; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KRUL ES, 1988, J LIPID RES, V29, P937; LAWN RM, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0692-54; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1993, J LIPID RES, V34, P521; LINTON MF, 1992, P NATL ACAD SCI USA, V89, P11431, DOI 10.1073/pnas.89.23.11431; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; PEASE RJ, 1990, J BIOL CHEM, V265, P553; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; STERNBERG N, 1994, MAMM GENOME, V5, P397, DOI 10.1007/BF00356999; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WELTY FK, 1991, J CLIN INVEST, V87, P1748, DOI 10.1172/JCI115193; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; YOUNG SG, 1994, HUM MOL GENET, V3, P741; YOUNG SG, 1988, SCIENCE, V241, P591, DOI 10.1126/science.3399894; YOUNG SG, 1986, J BIOL CHEM, V261, P2995	44	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24284	24289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929084				2022-12-27	WOS:A1994PQ34600067
J	MULLER, EGD				MULLER, EGD			DEOXYRIBONUCLEOTIDES ARE MAINTAINED AT NORMAL LEVELS IN A YEAST THIOREDOXIN MUTANT DEFECTIVE IN DNA-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN RIBONUCLEOTIDE REDUCTASE; CELL-CYCLE REGULATION; AMINO-ACID SEQUENCE; RABBIT BONE-MARROW; SACCHAROMYCES-CEREVISIAE; ORNITHINE DECARBOXYLASE; ESCHERICHIA-COLI; BINDING ACTIVITY; GENE; EXPRESSION	Deletion of both thioredoxin genes TRX1 and TRX2 of Saccharomyces cerevisiae reduces the rate of DNA replication. This observation, originally determined by flow cytometry, was confirmed by radiochemical labeling of synchronized cultures. Since thioredoxin is a hydrogen donor to ribonucleotide reductase, a priori the inhibition of DNA synthesis was predicted to be caused by a reduction in the deoxyribonucleotide pools. However, the levels of TTP, dCTP, dATP, and dGTP were either unchanged or slightly greater in the thioredoxin mutant (3.2, 0.91, 1.4, and 1.21 pmol/10(6) cells, respectively) versus the wild-type culture (2.5, 0.91, 1.0, and 0.68 pmol/10(6) cells, respectively). An impact on ribonucleotide reduction was seen by an increased accumulation of RNR1 and RNR2 transcripts in the thioredoxin mutant (4.3-and 6.8-fold, respectively). Increased RNR expression did not reflect a general response of the DNA replication machinery. POL1 (DNA polymerase I) and CDC8 (thymidylate kinase) transcription were unaltered, while histone H2B transcripts actually decreased by half. Two alternative models incorporating these results are discussed. One suggests that thioredoxin reduces a multiprotein complex channeling nucleotides to the replication apparatus. The second proposes that thioredoxin regulates the tempo of DNA replication directly by activating a component of the replication machinery.			MULLER, EGD (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.			Muller, Eric/0000-0002-3915-4520	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG A, 1989, J BIOL CHEM, V264, P12249; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; ECKSTEIN H, 1974, Z NATURFORSCH C, VC 29, P272; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; FLAMIGNI F, 1989, BIOCHEM J, V259, P111, DOI 10.1042/bj2590111; FONZI WA, 1987, J BIOL CHEM, V262, P10127; FONZI WA, 1989, J BIOL CHEM, V264, P18110; GAN ZR, 1992, BIOCHEM BIOPH RES CO, V187, P949, DOI 10.1016/0006-291X(92)91289-3; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARVEY G, 1988, J CELL PHYSIOL, V134, P25, DOI 10.1002/jcp.1041340104; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOPPER S, 1983, J BIOL CHEM, V258, P3453; HOPPER S, 1989, J BIOL CHEM, V264, P20438; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; LAMMERS M, 1984, EUR J BIOCHEM, V140, P281, DOI 10.1111/j.1432-1033.1984.tb08099.x; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MATHEWS CK, 1986, EXP CELL RES, V162, P285, DOI 10.1016/0014-4827(86)90335-6; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCFARLAN SC, 1989, EUR J BIOCHEM, V179, P389, DOI 10.1111/j.1432-1033.1989.tb14565.x; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MULLER EGD, 1989, J BIOL CHEM, V264, P4008; MULLER EGD, 1992, YEAST, V8, P117, DOI 10.1002/yea.320080206; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; OREDSSON SM, 1990, EUR J BIOCHEM, V190, P483, DOI 10.1111/j.1432-1033.1990.tb15599.x; PAYNE SM, 1982, ANAL BIOCHEM, V123, P151, DOI 10.1016/0003-2697(82)90636-4; POGOLOTTI AL, 1982, ANAL BIOCHEM, V126, P335, DOI 10.1016/0003-2697(82)90524-3; POON PP, 1994, J BIOL CHEM, V269, P8341; Reddy G P, 1993, Crit Rev Eukaryot Gene Expr, V3, P255; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SALZ HK, 1994, GENETICS, V136, P1075; Sambrook J, 1989, MOL CLONING LABORATO; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; Sherman F., 1986, METHODS YEAST GENETI; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SIKORSKA M, 1990, BIOCHEM CELL BIOL, V68, P880, DOI 10.1139/o90-130; SRIVASTAVA VK, 1988, MUTAT RES, V200, P45, DOI 10.1016/0027-5107(88)90070-X; TAGAYA Y, 1990, MOL IMMUNOL, V27, P1279; TANAKA K, 1984, ANAL BIOCHEM, V139, P35, DOI 10.1016/0003-2697(84)90386-5; TONISSEN K, 1993, J BIOL CHEM, V268, P22485; WAGA S, 1994, J BIOL CHEM, V269, P10923; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WAWRA E, 1988, J BIOL CHEM, V263, P9908; WETTERAUER B, 1992, J BIOL CHEM, V267, P9895; WIEGAND M, 1989, J STEROID BIOCHEM, V32, P53, DOI 10.1016/0022-4731(89)90013-7; WU Y, 1994, J CELL BIOCHEM, V54, P32, DOI 10.1002/jcb.240540105; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAGLE K, 1990, MOL CELL BIOL, V10, P5553, DOI 10.1128/MCB.10.10.5553; ZHOU Z, 1992, GENETICS, V131, P851; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	68	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24466	24471						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929110				2022-12-27	WOS:A1994PQ34600095
J	WANG, TW; LUO, Y; SMALL, GM				WANG, TW; LUO, Y; SMALL, GM			THE POX1 GENE ENCODING PEROXISOMAL ACYL-COA OXIDASE IN SACCHAROMYCES-CEREVISIAE IS UNDER THE CONTROL OF MULTIPLE REGULATORY ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PROLIFERATION; TRANSCRIPTION; BINDING; PROTEIN; EXPRESSION; GAL4; SITE; ADR1	Transcription of POX1, the gene encoding peroxisomal acyl-CoA oxidase in the yeast Saccharomyces cerevisiae, is controlled by the carbon source given for cell growth. The gene is repressed in glucose, derepressed in glycerol, and induced in oleate. This regulation is controlled by cis-acting elements in the 5' region of the gene, which bind regulatory proteins. By deletion analysis and DNA band shift assays, we have characterized three such elements in the POX1 upstream sequence, two upstream repression sequences and an upstream activating sequence. Each was able to regulate the transcription of a heterologous gene construct iso-l-cyto chrome-c (CYC1)lacZ.	CUNY MT SINAI SCH MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KOVARI L, 1990, MOL CELL BIOL, V10, P5087, DOI 10.1128/MCB.10.10.5087; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Sambrook J, 1989, MOL CLONING LABORATO; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANG TW, 1992, NUCLEIC ACIDS RES, V20, P3495, DOI 10.1093/nar/20.13.3495; YOO HS, 1989, MOL CELL BIOL, V9, P3231, DOI 10.1128/MCB.9.8.3231	24	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24480	24485						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929112				2022-12-27	WOS:A1994PQ34600097
J	XU, HX; SHIELDS, D				XU, HX; SHIELDS, D			PROSOMATOSTATIN PROCESSING IN PERMEABILIZED CELLS - ENDOPROTEOLYTIC CLEAVAGE IS MEDIATED BY A VACUOLAR ATPASE THAT GENERATES AN ACIDIC PH IN THE TRANS-GOLGI NETWORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED XENOPUS OOCYTES; PROHORMONE CONVERTASES PC1; SITE-DIRECTED MUTAGENESIS; ISLET SECRETORY GRANULES; HAMSTER OVARY CELLS; PROPROTEIN CONVERTASE; SUBTILISIN FAMILY; VESICLE MEMBRANE; H+-ATPASE; PROINSULIN	To investigate the relationship between prohormone processing and sorting of mature polypeptides into nascent secretory vesicles, we recently developed a permeabilized cell system that supports both these reactions (Xu, H., and Shields, D. (1993) J. Cell Biol. 122, 1169-1184). Rat anterior pituitary GH(3) cells expressing high levels of prosomatostatin (proSRIF) were incubated at 20 degrees C; this temperature prevented exit from the trans-Golgi network and inhibited proSRIF processing. Following the 20 degrees C block, the cells mere mechanically permeabilized and incubated at 37 degrees C, and proSRIF processing was determined. Cleavage of proSRIF to the mature hormone required ATP hydrolysis and was inhibited by chloroquine, a weak base, or carbonyl cyanide m-chlorophenylhydrazone, a protonophore. This suggested that a proton gradient and/or an acidic pH facilitated by a vacuolar H+-ATPase was required for prohormone processing. We have now utilized the permeabilized cell system in conjunction with the antibiotic bafilomycin A(1), a specific inhibitor of vacuolar H+-ATPases, to elucidate the role of acidic pH in prohormone processing. Here we report that (i) proSRIF processing was inhibited in vivo and in vitro by low concentrations of bafilomycin A(1), confirming the involvement of a vacuolar type ATPase in prohormone processing; (ii) the ATP requirement for processing could be circumvented in vitro by incubating permeabilized cells at acidic pH in the presence of protonophores, indicating that an acidic pH rather than a H+ gradient is necessary for processing; and (iii) a pH of between 6 and 6.2 in the trans-Golgi network was optimal for proSRIF cleavage. We also demonstrate that prohormone convertase 2 exhibited temperature-dependent activity in which proSRIF processing was inhibited at 20 degrees C in vitro. This result explains our previous observation that prohormone processing is inhibited when intact cells are incubated at 20 degrees C.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOLEC BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Xu, Huaxi/AAV-7177-2021		NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK21860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021860, R01DK021860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; FLETCHER DJ, 1981, J CELL BIOL, V90, P312, DOI 10.1083/jcb.90.2.312; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HAASS C, 1993, J BIOL CHEM, V268, P3021; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KIELIAN M, 1994, IN PRESS ADV VIRUS R; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MAINS RE, 1988, J BIOL CHEM, V263, P7887; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PARISH DC, 1986, J BIOL CHEM, V261, P4392; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TORII S, 1993, FEBS LETT, V316, P12, DOI 10.1016/0014-5793(93)81726-G; UMATA T, 1990, J BIOL CHEM, V265, P21940; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; XU H, 1994, IN PRESS BIOCHIMIE P; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YI Z, 1993, J BIOL CHEM, V268, P5615; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590; ZHOU A, 1993, J BIOL CHEM, V268, P1763	62	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22875	22881						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915719				2022-12-27	WOS:A1994PQ16300063
J	ZENG, XR; JIANG, YQ; ZHANG, SJ; HAO, HL; LEE, MYWT				ZENG, XR; JIANG, YQ; ZHANG, SJ; HAO, HL; LEE, MYWT			DNA-POLYMERASE-DELTA IS INVOLVED IN THE CELLULAR-RESPONSE TO UV DAMAGE IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BUTYLPHENYL-DEOXYGUANOSINE TRIPHOSPHATE; PERMEABLE HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; NUCLEAR ANTIGEN; EXCISION REPAIR; REPLICATION; PROTEIN; ALPHA; BETA; INHIBITION	We have used antibodies specific for either polymerase delta (pol delta) or its accessory protein, proliferating cell nuclear antigen (PCNA), to demonstrate that they can markedly inhibit the capacity of HeLa nuclear extracts to effect repair of UV-damaged plasmid DNA. This pro vides the first unambiguous evidence for the involvement of pol delta in DNA repair synthesis. The mRNA levels of both pol delta and PCNA were significantly stimulated subsequent to UV irradiation of cultured cells, providing the first evidence that the cellular response to UV damage may involve regulation of pol delta and PCNA at the gene level. Thus, DNA polymerase delta and its accessory proteins, in addition to their function in replicative DNA synthesis, also function in DNA repair synthesis.	UNIV MIAMI,SCH MED,DEPT MED R57,MIAMI,FL 33101	University of Miami					NIAID NIH HHS [AI 29158] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DRESLER SL, 1988, BIOCHEM PHARMACOL, V37, P1033, DOI 10.1016/0006-2952(88)90506-0; DRESLER SL, 1988, BIOCHEMISTRY-US, V27, P7247, DOI 10.1021/bi00419a011; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HAO HL, 1992, CHROMOSOMA, V102, pS121, DOI 10.1007/BF02451795; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KEENEY S, 1990, MUTAT RES, V236, P239, DOI 10.1016/0921-8777(90)90008-S; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; LEE MYWT, 1989, ARCH BIOCHEM BIOPHYS, V272, P1, DOI 10.1016/0003-9861(89)90187-2; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1987, BIOCHEMISTRY-US, V26, P1076, DOI 10.1021/bi00378a014; LEE MYWT, 1985, NUCLEIC ACIDS RES, V13, P8623, DOI 10.1093/nar/13.23.8623; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U; NAZIMIEC M, 1992, J BIOL CHEM, V267, P24716; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OHNISHI T, 1990, NUCLEIC ACIDS RES, V18, P5673, DOI 10.1093/nar/18.19.5673; POPANDA O, 1992, BIOCHIM BIOPHYS ACTA, V1129, P155, DOI 10.1016/0167-4781(92)90480-N; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TYRRELL RM, 1987, CANCER RES, V47, P3725; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; YANG CL, 1991, BIOCHEMISTRY-US, V30, P7534, DOI 10.1021/bi00244a024	41	105	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13748	13751						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910606				2022-12-27	WOS:A1994NL60600007
J	WANG, KY; SPECTOR, A				WANG, KY; SPECTOR, A			THE CHAPERONE ACTIVITY OF BOVINE ALPHA-CRYSTALLIN - INTERACTION WITH OTHER LENS CRYSTALLINS IN NATIVE AND DENATURED STATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CRYSTALLIN; A-CRYSTALLIN; HEAT-SHOCK; QUATERNARY STRUCTURE; CATARACT FORMATION; PROTEIN; TISSUES; GENE; PHOSPHORYLATION; DIFFERENTIATION	It has previously been reported that alpha crystallin (alpha) a major lens protein composed of alpha(A) and alpha(B) subunits, can act as a chaperone interacting with other proteins to prevent heat-induced insolubilization. It is now shown that with gamma (gamma), beta(L) (beta(L)), and beta(H) (beta(H)), other major crystallin groups, this interaction occurs exclusively with soluble denatured protein. Based on studies primarily conducted with the gamma and the beta(L) crystallins, there is at least one binding site per alpha monomer (alpha(m)). This conclusion is derived from the following evidence. The binding of soluble denatured protein to alpha increases in a linear stoichiometric manner until a 1:1 ratio of alpha(m) to gamma or to the presumed (beta(L))(m) is achieved. This is based upon determination of the apparent molecular weight of the a denatured protein aggregate with a calibrated TSK-G4000 SW column and on the determination of the relative masses from the areas of the aggregate peak and those of the reactants. SDS-polyacrylamide gel electrophoresis confirms that the aggregates contain the presumed components following reaction with either gamma, beta(L), or beta(H). Studies in which gamma or beta(L) crystallins have been independently heat denatured indicate that species representing 50% of the gamma population and 30% of beta(L) population have not heat denatured under the conditions employed. When the abundance of the denatured soluble protein exceeds that of the alpha subunits present in the macromolecular complex, further interaction occurs leading to a loss of solubility of the complex. A small increase in the size of the complex remaining in solution is also observed. The results contribute to understanding earlier observations that soluble native low molecular weight alpha species cannot be found in the inner regions of old human lenses but have shifted to large aggregates containing other crystallin components. The work tentatively suggests that the interaction rates of alpha with denatured soluble crystallins are gamma > beta(L) > beta(H).	COLUMBIA UNIV,COLL PHYS & SURG,DEPT OPHTHALMOL,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10032	Columbia University								AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; AUGUSTEYN RC, 1971, BIOCHEM J, V124, P345, DOI 10.1042/bj1240345; BERBERS GAM, 1984, EUR J BIOCHEM, V139, P467, DOI 10.1111/j.1432-1033.1984.tb08029.x; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAKENHOFF RH, 1990, HUM GENET, V85, P237, DOI 10.1007/BF00193203; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1987, CURR EYE RES, V6, P539, DOI 10.3109/02713688709025211; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; de Jong W W, 1974, Eur J Biochem, V48, P271; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GARNER WH, 1978, P NATL ACAD SCI USA, V75, P3618, DOI 10.1073/pnas.75.8.3618; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAWKINS JW, 1987, HUM GENET, V76, P375, DOI 10.1007/BF00272448; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWITZ J, 1992, CURR EYE RES, V11, P817, DOI 10.3109/02713689209000754; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAENICKE R, 1993, CHEMTRACTS BIOCH MOL, V4, P1; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NGO JT, 1989, GENOMICS, V5, P665, DOI 10.1016/0888-7543(89)90106-7; PERRY RE, 1986, J CHROMATOGR, V351, P103, DOI 10.1016/S0021-9673(01)83476-2; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; ROY D, 1976, P NATL ACAD SCI USA, V73, P3484, DOI 10.1073/pnas.73.10.3484; ROY D, 1976, BIOCHEMISTRY-US, V15, P1180, DOI 10.1021/bi00650a034; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SPECTOR A, 1971, BIOCHEM J, V124, P337, DOI 10.1042/bj1240337; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SPECTOR A, 1976, INVEST OPHTH VISUAL, V15, P288; SPECTOR A, 1968, INVEST OPHTH VISUAL, V7, P179; SPECTOR A, 1967, J BIOL CHEM, V242, P3594; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENHEUVEL R, 1985, J MOL BIOL, V185, P273, DOI 10.1016/0022-2836(85)90403-6; VANKLEEF FS, 1974, EUR J BIOCHEM, V48, P563; VERMORKEN AJM, 1978, J CELL BIOL, V76, P175, DOI 10.1083/jcb.76.1.175; VOORTER CEM, 1992, FEBS LETT, V309, P111, DOI 10.1016/0014-5793(92)81075-W; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WANG K, 1993, INVEST OPHTH VIS SCI, V34, P1340; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090	59	185	187	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13601	13608						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909809				2022-12-27	WOS:A1994NK18400079
J	MATSUOKA, S; YAMAGUCHI, M; MATSUKAGE, A				MATSUOKA, S; YAMAGUCHI, M; MATSUKAGE, A			D-TYPE CYCLIN-BINDING REGIONS OF PROLIFERATING CELL NUCLEAR ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AUXILIARY PROTEIN; EUKARYOTIC DNA-POLYMERASES; ESCHERICHIA-COLI; REPLICATION INVITRO; ACCESSORY PROTEINS; MOLECULAR-CLONING; PCNA; GENE; EXPRESSION; YEAST	Proliferating cell nuclear antigen (PCNA) is an auxiliary protein for DNA polymerase delta and is required for both DNA replication and DNA repair. PCNA forms complexes with D-type cyclins, candidate G1 cyclins in mammalian cells. To better understand the functions of the complexes, we examined interactions between PCNA and D-type cyclins, using in vitro-translated mouse PCNA and mouse cyclin D1 or D3 fused to glutathione S-transferase (GST). Analysis of a set of deletion mutants of PCNA revealed that either the N-terminal (residues 2-64) or the C-terminal (residues 197-228) region is necessary for association with D-type cyclins. The cyclin binding of the chimeric protein of the N-terminal (residues 1-68) or the C-terminal (residues 195-261) region of PCNA and rat DNA polymerase beta which does not bind to the cyclins by itself supports this notion. The purified recombinant mouse PCNA expressed in Escherichia coli bound to the D-type cyclin-GST fusion proteins, thereby suggesting that PCNA binds directly to D-type cyclins, without the requirement of other cellular factors. This is apparently the first report on the structure-function relationship of PCNA which may link DNA replication and DNA repair with cell cycle control.	AICHI CANC CTR, RES INST, CELL BIOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; TOHOKU UNIV, INST CHEM REACT SCI, AOBA KU, SENDAI, MIYAGI 980, JAPAN	Aichi Cancer Center; Tohoku University								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HANNA Z, 1993, ONCOGENE, V8, P1661; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LEIBOVICI M, 1990, DEV BIOL, V141, P183, DOI 10.1016/0012-1606(90)90113-W; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NG L, 1993, J BIOL CHEM, V268, P13571; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKA I, 1991, EUR J BIOCHEM, V195, P571, DOI 10.1111/j.1432-1033.1991.tb15739.x; SUZUKA I, 1989, P NATL ACAD SCI USA, V86, P3189, DOI 10.1073/pnas.86.9.3189; TAN CK, 1986, J BIOL CHEM, V261, P2310; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WASEEM NH, 1990, J CELL SCI, V96, P121; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; [No title captured]	40	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11030	11036						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7908906				2022-12-27	WOS:A1994NF96600013
J	GUY, HI; EVANS, DR				GUY, HI; EVANS, DR			CLONING, EXPRESSION, AND FUNCTIONAL INTERACTIONS OF THE AMIDOTRANSFERASE DOMAIN OF MAMMALIAN CAD CARBAMYL-PHOSPHATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; EHRLICH ASCITES-CARCINOMA; GLUTAMINE BINDING-SITE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; REVERSIBLE DISSOCIATION; SERRATIA-MARCESCENS; CYSTEINE RESIDUE; HAMSTER CELLS	The trpG-type amidotransferases, a homologous but structurally diverse family of molecules, catalyze glutamine hydrolysis to supply ammonia for many biosynthetic reactions. The amidotransferase or glutaminase (GLNase) domain of mammalian carbamyl phosphate synthetase (CPSase), part of a 243-kDa polypeptide that initiates de novo pyrimidine biosynthesis, has been cloned and expressed in Escherichia coli. Complementation studies showed that a functional protein was produced in vivo which could provide ammonia for carbamyl phosphate synthesis by the host CPSase synthetase subunit. The recombinant 38-kDa protein was identified by immunoblotting, but when purified to homogeneity, had marginal glutaminase activity. Titration of the E. coli CPSase synthetase subunit with the mammalian GLNase domain resulted in the formation of a fully active 1:1 stoichiometric stable complex which catalyzed the glutamine-dependent overall reaction. The hybrid, isolated by gel filtration, had kinetic parameters (K-m(GLN) = 102 mu M, K-m(ATP) = 1.8 mM, k(cat) = 5.7 s-(1)) similar to those of the native E. coli CPSase. Thus, the amidotransferase activity of mammalian CPSase is carried by an autonomous domain which folds independently. However, optimal catalytic activity requires association of the glutaminase and synthetase domains. The conservation of this linkage in the mammalian E. coli hybrid suggests that the subunit interfaces must be nearly identical in the eukaryotic and prokaryotic proteins.			GUY, HI (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA.							ANDERSON PM, 1973, BIOCHEM BIOPH RES CO, V55, P246, DOI 10.1016/S0006-291X(73)80086-5; ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; GOTO Y, 1976, J BIOL CHEM, V251, P941; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; Hartman SC, 1973, ENZYMES GLUTAMINE ME, P319; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HOOGENRAAD NJ, 1971, BIOCHEM BIOPH RES CO, V44, P981, DOI 10.1016/0006-291X(71)90808-4; KAWAMURA M, 1978, J BIOL CHEM, V253, P4659; KELLY RE, 1986, THESIS WAYNE STATE U; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; MALLY MI, 1980, J BIOL CHEM, V255, P1372; Maniatis T., 1982, MOL CLONING; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NICHOLS BP, 1980, J MOL BIOL, V142, P503, DOI 10.1016/0022-2836(80)90260-0; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PALUH JL, 1985, J BIOL CHEM, V260, P1889; PAUKERT JL, 1982, ARCH BIOCHEM BIOPHYS, V218, P443, DOI 10.1016/0003-9861(82)90366-6; PERBAL B, 1988, PRACTICAL GUIDE MOL, P305; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SHOAF WT, 1971, BIOCHEM BIOPH RES CO, V45, P796; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; TSO JY, 1980, J BIOL CHEM, V255, P1451; WELLNER VP, 1975, J BIOL CHEM, V250, P3261; WENG M, 1987, J BACTERIOL, V169, P3023, DOI 10.1128/jb.169.7.3023-3028.1987; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	46	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7702	7708						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907330				2022-12-27	WOS:A1994NA03200104
J	PUIG, A; GILBERT, HF				PUIG, A; GILBERT, HF			PROTEIN DISULFIDE-ISOMERASE EXHIBITS CHAPERONE AND ANTI-CHAPERONE ACTIVITY IN THE OXIDATIVE REFOLDING OF LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; AGGREGATION; CATALYSIS; BONDS; REDUCTION; RESIDENT; SEQUENCE; BINDING; LUMEN	Reduced, denatured lysozyme tends to aggregate at neutral pH, and competition between productive folding and aggregation substantially reduces the efficiency of refolding (Goldberg, M. E., Rudolph; R., and Jaenicke, R. (1991) Biochemistry 30, 2790-2797). Protein disulfide isomerase (PDI), a catalyst of oxidative protein folding, has a variety of effects on the yield of native lysozyme during the oxidative refolding of the reduced, denatured protein. Depending on the concentration of lysozyme, the concentration of PDI, and the order in which lysozyme and PDI are added to initiate folding, PDI can produce a substantial increase or a substantial decrease in the recovery of native lysozyme, when compared with the uncatalyzed reaction. In the presence of a glutathione redox buffer, denatured lysozyme (1-10 mu M) partitions almost equally between productive folding leading to native lysozyme (50-63%) and non-productive fates including the formation of disulfide cross-linked aggregates. At the higher lysozyme concentrations examined (5-10 mu M), substoichiometric concentrations of PDI (0.5-1 mu M) exhibit ''anti-chaperone'' activity; PDI actively diverts most of the denatured lysozyme away from productive folding so that only 17 +/- 9% of the lysozyme is recovered as native enzyme, PDI's anti-chaperone activity results in extensive intermolecular disulfide crosslinking of lysozyme into large, inactive aggregates. On the other hand, if PDI is initially present at a large molar excess (5-10-fold) when denatured lysozyme is diluted to initiate folding, PDI demonstrates a chaperone-like activity that prevents aggregate formation and promotes correct folding. When PDI's chaperone activity is dominant, virtually all of the denatured lysozyme is correctly folded. The schizophrenic chaperone/anti-chaperone nature of PDI activity accounts for a number of observations on in vivo protein folding, including the necessity for maintaining a high concentration of PDI in the endoplasmic reticulum and the formation of disulfide cross-linked aggregates in the endoplasmic reticulum during the expression of disulfide containing proteins (deSilva, A., Braakman, I., and Helenius, A. (1993) J. Cell. Biol. 120, 647-655).	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine					NIGMS NIH HHS [GM40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HUTH JR, 1993, J BIOL CHEM, V268; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LODISH HF, 1993, J BIOL CHEM, V268; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PACE M, 1979, INT J PEPT PROT RES, V14, P409; PUIG A, 1992, ASBMB KEYSTONE S MOL, P59; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; VUORI K, 1992, J BIOL CHEM, V267, P7211; WETLAUFER DB, 1974, LYSOZYME, P269; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	34	249	266	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7764	7771						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907332				2022-12-27	WOS:A1994NA03200112
J	HANSEN, JE; GAFNI, A				HANSEN, JE; GAFNI, A			FLUORESCENCE DETECTION OF CONFORMATIONAL-CHANGES IN GROEL INDUCED BY THERMAL SWITCHING AND NUCLEOTIDE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; MOLECULAR CHAPERONE; ATP HYDROLYSIS; PROTEIN; COOPERATIVITY; CARBOXYLASE; PRECURSOR; INVITRO	GroEL assists other proteins to fold in vivo, usually requiring Mg2+ and ATP to function. Electron micrographs reveal that ATP binding induces a conformational change in this protein. Previously we have suggested that a thermally induced conformational change in GroEL results in the switching between enhanced and arrested reactivation of bacterial glucose-6-phosphate dehydrogenase. This thermal switching occurs over a narrow temperature range (25-30 degrees C). Recently it has also been reported that the binding affinity of the P22 tail spike polypeptide to GroEL changes abruptly over this same temperature range. To determine whether these conformational changes occur in GroEL in solution in absence of folding intermediates, the protein was stoichiometrically labelled with AEDANS (N-(acetylaminoacyl)-5-naphthalene-1-sulfonic acid), a fluorescent label whose emission is environment sensitive. By measuring changes in the fluorescence Stokes shift we have detected two thermally induced conformational changes between 25 and 30 degrees C. The first change occurs between 25 and 26 degrees C, resulting in less than a 1-nm shift in the fluorescence. The second conformational change occurs between 27 and 30 degrees C, re suiting in a 3-nm fluorescence shift. The conformational change induced by ATP binding also results in a 3-nm shift in fluorescence. Our data provide a correlation between functional change and structural change in GroEL.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, INST GERONTOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIA NIH HHS [AG09761, T32AG00114] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009761, T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; SAIBIL H, 1993, CURR OPIN STRUC BIOL, V3, P207, DOI 10.1016/S0959-440X(05)80154-X; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1993, ACS SYM SER, V526, P72; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021	24	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6286	6289						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907093				2022-12-27	WOS:A1994MZ50300008
J	CHABRE, O; CONKLIN, BR; BRANDON, S; BOURNE, HR; LIMBIRD, LE				CHABRE, O; CONKLIN, BR; BRANDON, S; BOURNE, HR; LIMBIRD, LE			COUPLING OF THE ALPHA(2A)-ADRENERGIC RECEPTOR TO MULTIPLE G-PROTEINS - A SIMPLE APPROACH FOR ESTIMATING RECEPTOR-G-PROTEIN COUPLING EFFICIENCY IN A TRANSIENT EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC RECEPTORS; CYCLIC-AMP ACCUMULATION; ADENYLATE-CYCLASE; ALPHA-2-ADRENERGIC RECEPTORS; CALCIUM CURRENTS; ALPHA-SUBUNITS; LIGAND-BINDING; ACTIVATION; CELLS	It is now widely appreciated that G-protein-coupled cell-surface receptors can modulate distinct signal transduction pathways via coupling to different GTP-binding proteins. In the present study, we have used a transient co expression approach to study the coupling of a single alpha(2)-adrenergic receptor (alpha(2A)AR) population to three different G protein subtypes (G(i), C-q, and G(s)) acting on two different cellular effecters in HER 293 cells. In all cases, the affinity of the receptor for the alpha(2A)-adrenergic agonist, UK14304, is unchanged (K-D congruent to 670 nM). However there is a dramatic difference in the EC(50) of UK14304 in eliciting inhibition of endogenous adenylyl cyclase via endogenous G(i) (0.09 nM) versus activation of phospholipase C via co-transfected G(q) (50 nm) or stimulation of endogenous adenylyl cyclase via co-transfected G(s) (70 nm) in HEK 293 cells. These findings are consistent with the interpretations that the alpha(2A)AR preferentially interacts with G(i) rather than G(s) or G(q). When the alpha(2A)AR was mutated at Asp(79), a residue highly conserved among G-protein-coupled receptors, the mutant D79N alpha(2A)AR lost the ability to couple to G,and G, and, although it was able to couple to inhibition of cyclase via pertussis toxin-sensitive pathways (Gi), it did so with a lower potency than observed for the wild-type alpha(2A)AR (EC(50) = 7.2 nM). The most straightforward interpretation of these data is that the D79N mutation in the alpha(2A)AR reduces the efficiency of coupling of the alpha(2A)AR to all G-proteins, thus eliminating signal transduction through those path ways less efficiently coupled to the alpha(2A)AR Since the transient expression assays described permit manipulation of the structure of both the receptor or the G-protein, the present strategies could be exploited to delineate the complementary domains specifying the affinity and/or efficacy of receptor coupling to distinct GTP-binding proteins.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37215; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143	Vanderbilt University; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	CHABRE, Olivier/0000-0001-8756-7218; Conklin, Bruce/0000-0003-1463-6061	NCI NIH HHS [CA54427] Funding Source: Medline; NHLBI NIH HHS [K11HL02555] Funding Source: Medline; NIGMS NIH HHS [GM27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ASANO T, 1984, J BIOL CHEM, V259, P9351; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; EASON MG, 1992, J BIOL CHEM, V267, P15795; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NUNNARI JM, 1987, J BIOL CHEM, V262, P12387; SMITH SK, 1981, P NATL ACAD SCI-BIOL, V78, P4026, DOI 10.1073/pnas.78.7.4026; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WANG CD, 1991, MOL PHARMACOL, V40, P168; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	31	144	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5730	5734						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907086				2022-12-27	WOS:A1994MY84000041
J	FRODIN, M; PERALDI, P; VANOBBERGHEN, E				FRODIN, M; PERALDI, P; VANOBBERGHEN, E			CYCLIC-AMP ACTIVATES THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ADENOSINE 3'-5'-CYCLIC MONOPHOSPHATE; MAP KINASE; ADENYLATE-CYCLASE; TYROSINE-HYDROXYLASE; NEURITE OUTGROWTH; PHEOCHROMOCYTOMA CELLS; RECEPTOR ACTIVATION; STIMULATED PROTEIN; PHOSPHORYLATION	Mitogen-activated protein (MAP) kinases are activated in response to a large variety of extracellular signals, including growth factors, hormones, and neurotransmitters, which activate distinct intracellular signaling pathways. Their activation by the cAMP-dependent pathway, however, has not been reported. In rat pheochromocytoma PC12 cells, we demonstrate here a stimulation of the MAP kinase isozyme extracellular signal-regulated kinase 1 (ERK1) following elevation of intracellular cAMP after exposure of the cells to isobutyl-methylxanthine, cholera toxin, forskolin, or cAMP-analogues. cAMP acted synergistically with phorbol ester, an activator of protein kinase C, in the stimulation of ERK1. In accordance with this observation, the peptide neurotransmitter pituitary adenylate cyclase-activating polypeptide 38 (PACAP38), which stimulates cAMP production as well as phosphatidylinositol breakdown in PC12 cells, was an efficient activator of ERK1. In combination with various growth factors, cAMP acted in a more than additive manner on ERK1 activity. Elevation of intracellular cAMP increased in vivo P-32-labeling of ERK1, suggesting that cAMP stimulated ERK1 by activating MAP kinase kinase, an immediate upstream activator of ERK1 in the MAP kinase cascade. Supporting this view, forskolin and a cAMP analogue were found to increase the activity of MAP kinase kinase in PC12 cells, alone as well as in combination with phorbol ester. PACAP38 also stimulated in vivo P-32-labeling of ERK1 and MAP kinase kinase activity. Finally, cAMP or PACAP38 increased by 3-fold nerve growth factor-stimulated neurite formation in PC12 cells, which may be correlated with the potentiating effect of these agents on nerve growth factor-stimulated ERK1 activity.	FAC MED NICE, INSERM, U145, F-06107 NICE 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Peraldi, Pascal/O-4592-2016	Peraldi, Pascal/0000-0003-0205-9252; Frodin, Morten/0000-0003-3691-9820				AHN NG, 1991, J BIOL CHEM, V266, P4220; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BEEBE SJ, 1986, ENZYMES, V17, P43; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYCOCK JW, 1992, J NEUROCHEM, V58, P57, DOI 10.1111/j.1471-4159.1992.tb09276.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; KAUFMAN S, 1985, FOLATE PTERINS, V2; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MONTAGUE W, 1971, BIOCHEM J, V122, P115, DOI 10.1042/bj1220115; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PIPER RC, 1993, J BIOL CHEM, V268, P16557; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Posternak T, 1974, Methods Enzymol, V38, P399; PRASAD KN, 1971, NATURE-NEW BIOL, V233, P141, DOI 10.1038/newbio233141a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RICHTERLANDSBERG C, 1986, J CELL BIOL, V102, P821, DOI 10.1083/jcb.102.3.821; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SALOMON Y, 1991, METHODS ENZYMOL, V22; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; WATANABE T, 1990, BIOCHEM BIOPH RES CO, V173, P252, DOI 10.1016/S0006-291X(05)81049-6; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	67	325	330	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6207	6214						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907091				2022-12-27	WOS:A1994MY84000108
J	TAKEBAYASHI, K; SASAI, Y; SAKAI, Y; WATANABE, T; NAKANISHI, S; KAGEYAMA, R				TAKEBAYASHI, K; SASAI, Y; SAKAI, Y; WATANABE, T; NAKANISHI, S; KAGEYAMA, R			STRUCTURE, CHROMOSOMAL LOCUS, AND PROMOTER ANALYSIS OF THE GENE ENCODING THE MOUSE HELIX-LOOP-HELIX FACTOR HES-1 - NEGATIVE AUTOREGULATION THROUGH THE MULTIPLE N-BOX ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; NERVOUS-SYSTEM; BINDING-SITE; TRANSCRIPTION; PROTEIN; SEGMENTATION; SELECTION; REPRESSOR; ENHANCER; HAIRY	HES-1 is a mammalian helix-loop-helix factor structurally related to the Drosophila hairy and Enhancer of split proteins. It binds more preferentially to the N box (CACNAG) than to the E box (CANNTG) and acts as a negative regulator. In this study, we have isolated and characterized the mouse HES-1 gene. This gene consists of four exons, and the positions of introns are well conserved when compared with those of the Drosophila hairy gene, except for the third intron. Southern blot and interspecies backcross analyses suggest that the mouse HES-1 gene is a single-copy gene and is located around position 26 on chromosome 16. The transcription initiation site, determined by the S1 nuclease and primer extension experiments, is located 31 nucleotides downstream of a TATA box. In the 5'-regulatory region, there are four N box sequences, and the DNase I footprinting and gel mobility shift analyses show that HES-1 binds to these sequences. Transient transfection assays using C3H10T1/2 cells suggest that there are several positive regulatory regions in the HES-1 gene. However, cotransfection of the Hes-1 expression vector leads to similar to-40-fold repression in promoter activity. Furthermore, when the N box sequences are disrupted, this negative regulation is severely impaired. These results raise the possibility that HES-1 gene expression may be negatively autoregulated through the N box sequences.	KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN; AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN	Kyoto University								AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; EPSTEIN R, 1986, IMMUNOGENETICS, V23, P78, DOI 10.1007/BF00377965; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Green MC., 1989, GENETIC VARIANTS STR, P12; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1987, J BIOL CHEM, V262, P2345; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WATANABE T, 1989, BIOCHEM GENET, V27, P689, DOI 10.1007/BF02396061	24	265	267	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5150	5156						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906273				2022-12-27	WOS:A1994MX57100072
J	YUKSEL, KU; SUN, AQ; GRACY, RW; SCHNACKERZ, KD				YUKSEL, KU; SUN, AQ; GRACY, RW; SCHNACKERZ, KD			THE HINGED LID OF YEAST TRIOSE-PHOSPHATE ISOMERASE - DETERMINATION OF THE ENERGY BARRIER BETWEEN THE 2 CONFORMATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE; ACTIVE-SITE; LACTATE-DEHYDROGENASE; MAGNETIC-RESONANCE; SUBSTRATE-ANALOGS; CRYSTAL-STRUCTURE; 2.5-A RESOLUTION; FLEXIBLE LOOP; CATALYSIS; PROTEIN	Covalent modification of GlU(165) in the catalytic center of triose-phosphate isomerase with the substrate analogue 3-chloroacetol phosphate traps the complex in two conformations. The two resulting P-31 NMR resonances at 6.9 and 5.7 ppm appear to reflect conformations in which the hinged lid (residues 167-176) is in the open and closed positions. The conformation represented by the 5.7-ppm resonance is more stable, and unfolding and refolding in guanidine converts all of the molecules to the 5.7-ppm conformation. The complete conformational transition from 6.9 to 5.7 ppm also takes place as a function of time and temperature. Under these conditions the native enzyme retains more than 80% of the catalytic activity, indicating that this conversion is not due to thermal denaturation of the enzyme. Circular dichroic and fluorescence spectroscopy indicate that the 3-chloroacetol phosphate-modified enzyme does not undergo major structural changes. From the temperature dependence of this transition, an energy barrier of 144 kJ/mol (34.4 kcal/mol) was calculated for this conversion.	UNIV N TEXAS, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, MOLEC AGING UNIT, FT WORTH, TX 76107 USA; UNIV WURZBURG, THEODOR BOVERI INST BIOSCI, D-97074 WURZBURG, GERMANY	University of North Texas System; University of North Texas Health Science Center; University of Wurzburg					NATIONAL INSTITUTE ON AGING [R37AG001274, R01AG001274] Funding Source: NIH RePORTER; NIA NIH HHS [AG01274] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS MJ, 1970, NATURE, V227, P1098, DOI 10.1038/2271098a0; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BROWNE CA, 1976, J MOL BIOL, V100, P319, DOI 10.1016/S0022-2836(76)80066-6; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; GERSTEIN M, 1991, J MOL BIOL, V220, P133, DOI 10.1016/0022-2836(91)90387-L; HARTMAN FC, 1971, BIOCHEMISTRY-US, V10, P146, DOI 10.1021/bi00777a021; JONES RB, 1979, BIOCJ J, V178, P623; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NOBLE MEM, 1991, PROTEINS, V10, P50, DOI 10.1002/prot.340100106; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; ROSSMANN MG, 1971, COLD SPRING HARB SYM, V36, P179; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHNACKERZ KD, 1990, BIOCHEM BIOPH RES CO, V173, P736, DOI 10.1016/S0006-291X(05)80097-X; SCHNACKERZ KD, 1991, EUR J BIOCHEM, V199, P231, DOI 10.1111/j.1432-1033.1991.tb16114.x; SUN AQ, 1993, J BIOL CHEM, V268, P26872; SUN AQ, 1992, ARCH BIOCHEM BIOPHYS, V295, P421, DOI 10.1016/0003-9861(92)90536-6; SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X; WIERENGA RK, 1992, FEBS LETT, V307, P34, DOI 10.1016/0014-5793(92)80897-P; WIERENGA RK, 1991, PROTEINS, V10, P33, DOI 10.1002/prot.340100105; WIERENGA RK, 1987, J MOL BIOL, V198, P109, DOI 10.1016/0022-2836(87)90461-X	26	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5005	5008						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906272				2022-12-27	WOS:A1994MX57100049
J	CHELEY, S; PANCHAL, RG; CARR, DW; SCOTT, JD; BAYLEY, H				CHELEY, S; PANCHAL, RG; CARR, DW; SCOTT, JD; BAYLEY, H			TYPE-II REGULATORY SUBUNITS OF CAMP-DEPENDENT PROTEIN-KINASE AND THEIR BINDING-PROTEINS IN THE NERVOUS-SYSTEM OF APLYSIA-CALIFORNICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEURAL SENSORY NEURONS; LONG-TERM SENSITIZATION; BOVINE CARDIAC-MUSCLE; HIGH-AFFINITY BINDING; 2 CATALYTIC SUBUNITS; BEHAVIORAL SENSITIZATION; TRANSMITTER RELEASE; SYNAPTIC FACILITATION; CYCLIC-AMP; MODULATION	Two type II regulatory (R) subunits of cAMP-dependent protein kinase (PKA) of 50 and 47 kDa have been identified in Aplysia neurons by several criteria which include phosphorylation by the catalytic subunit of PKA and nanomolar affinity for a peptide fragment of the human thyroid protein Ht 31, properties that in mammals distinguish type II from type I R subunits. The neuronal type II R subunits are differentially localized within cells. For example, the 50-kDa polypeptide is enriched in taxol-stabilized microtubules. In addition, at least seven high molecular mass neuronal RII-binding proteins ranging in mass from 110 to 420 kDa have been demonstrated by a blot overlay technique, which uses P-32-labeled bovine RIIalpha as a probe. The RII-binding proteins also exhibit discrete patterns of subcellular localization. For example, the 420 kDa species is enriched in taxol-stabilized microtubules and therefore may serve to anchor the 50-kDa RH subunit. The localization of PKA through the association of RII subunits with the binding proteins may anchor the multifunctional kinase close to key substrates and thereby contribute to the spatial organization required to mediate the orderly phosphorylation events that underly neuronal modulation.	WORCESTER FDN EXPTL BIOL INC,222 MAPLE AVE,SHREWSBURY,MA 01545; VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Worcester Foundation for Biomedical Research			Panchal, Rekha/None	Panchal, Rekha/0000-0001-8621-9078; Bayley, Hagan/0000-0003-2499-6116	NIGMS NIH HHS [GM 48231] Funding Source: Medline; NINDS NIH HHS [NS26760] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026760] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBRON RT, 1992, J NEUROSCI, V12, P2813; ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BERGOLD PJ, 1992, NEURON, V8, P387, DOI 10.1016/0896-6273(92)90304-V; BERNIER L, 1982, J NEUROSCI, V2, P1682; BEUSHAUSEN S, 1992, P NATL ACAD SCI USA, V89, P1641, DOI 10.1073/pnas.89.5.1641; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; BUXBAUM JD, 1989, J BIOL CHEM, V264, P9344; CARR DW, 1992, J BIOL CHEM, V267, P13376; CASTELLUCCI VF, 1982, J NEUROSCI, V2, P1673; CASTELLUCCI VF, 1980, P NATL ACAD SCI-BIOL, V77, P7492, DOI 10.1073/pnas.77.12.7492; CHELEY S, 1991, BIOTECHNIQUES, V10, P730; CHELEY S, 1991, BIOCHEMISTRY-US, V30, P10246, DOI 10.1021/bi00106a024; CHELEY S, 1992, J CELL SCI, V102, P739; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; CLARK GA, 1993, IN PRESS P NATL ACAD; CORBIN JD, 1981, J BIOL CHEM, V256, P1671; DALE N, 1988, SCIENCE, V239, P282, DOI 10.1126/science.2892269; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; EPPLER CM, 1986, J CELL BIOL, V102, P320, DOI 10.1083/jcb.102.1.320; GOLDSMITH BA, 1992, P NATL ACAD SCI USA, V89, P11481, DOI 10.1073/pnas.89.23.11481; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; HAWKINS RD, 1989, J NEUROSCI, V9, P4214; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KLEIN M, 1978, P NATL ACAD SCI USA, V75, P3512, DOI 10.1073/pnas.75.7.3512; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LU XY, 1990, J BIOL CHEM, V265, P3293; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; Panchal R. G., 1992, Society for Neuroscience Abstracts, V18, P942; Probst W. C., 1992, Society for Neuroscience Abstracts, V18, P1104; RANGELALDAO R, 1979, J BIOL CHEM, V254, P2499; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SCHWARTZ JH, 1987, ANNU REV NEUROSCI, V10, P459; SCHWARTZ JH, 1987, METHOD ENZYMOL, V139, P227; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207	61	12	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2911	2920						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905481				2022-12-27	WOS:A1994MV43200081
J	CASADO, M; BENDAHAN, A; ZAFRA, F; DANBOLT, NC; ARAGON, C; GIMENEZ, C; KANNER, BI				CASADO, M; BENDAHAN, A; ZAFRA, F; DANBOLT, NC; ARAGON, C; GIMENEZ, C; KANNER, BI			PHOSPHORYLATION AND MODULATION OF BRAIN GLUTAMATE TRANSPORTERS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED GLIAL-CELLS; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; RECONSTITUTED PREPARATIONS; GABA TRANSPORTER; ACID TRANSPORTER; EXPRESSION; SODIUM; CLONING; INHIBITION	High affinity sodium- and potassium-coupled L-glutamate transport into presynaptic nerve terminals and fine glial processes removes the neurotransmitter from the synaptic cleft, thereby terminating glutamergic transmission. This report describes that the purified L-glutamate transporter from pig brain is phosphorylated by protein kinase C, predominantly at serine residues. Upon exposure of C6 cells, a cell line of glial origin, to 12-O-tetradecanoylphorbol-13-acetate, about a 2-fold stimulation of L-glutamate transport is observed within 30 min. Concomitantly, the level of phosphorylation increases with similar kinetics. The phorbol ester also stimulates L-glutamate transport in HeLa cells infected with a recombinant vaccinia virus expressing T7 RNA polymerase and transfected with pT7-GLT-1. The latter is a recently cloned rat brain glutamate transporter of glial origin. Mutation of serine 113 to asparagine does not affect the levels of expressed transport but abolishes its stimulation by the phorbol ester. To our knowledge, this is the first direct demonstration of the regulation of a neurotransmitter transporter by phosphorylation.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT BIOCHEM, POB 1172, IL-91010 JERUSALEM, ISRAEL; UNIV AUTONOMA MADRID, FAC CIENCIAS, CTR BIOL MOLEC, MADRID 34, SPAIN; UNIV OSLO, INST ANAT, OSLO 3, NORWAY	Hebrew University of Jerusalem; Autonomous University of Madrid; University of Oslo			Danbolt, Niels Christian/A-1907-2014; Gimenez, Cecilio/K-8027-2014; Aragon, Carmen/K-9783-2014; Zafra, Francisco/A-6121-2008	Danbolt, Niels Christian/0000-0003-4227-4520; Gimenez, Cecilio/0000-0001-6726-8405; Aragon, Carmen/0000-0001-8287-9386; Zafra, Francisco/0000-0003-3801-3109; Casado, Mariano/0000-0001-8049-8096				BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CHO Y, 1990, J NEUROCHEM, V55, P2091, DOI 10.1111/j.1471-4159.1990.tb05800.x; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUNDERSEN V, 1993, IN PRESS NEUROSCIENC; HARLOW E, 1988, ANTIBODIES, P506; HENN FA, 1974, NATURE, V249, P663, DOI 10.1038/249663a0; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KERKERIAN L, 1987, J NEUROCHEM, V48, P1301, DOI 10.1111/j.1471-4159.1987.tb05661.x; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KUHAR MJ, 1973, LIFE SCI, V13, P1623, DOI 10.1016/0024-3205(73)90110-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIEOULLON A, 1983, NEUROSCI LETT, V43, P191, DOI 10.1016/0304-3940(83)90186-6; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1990, J NEUROSCI, V10, P1319; RHOADS DE, 1983, BIOCHEMISTRY-US, V22, P1965, DOI 10.1021/bi00277a035; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VOLPE JJ, 1975, J NEUROCHEM, V25, P333, DOI 10.1111/j.1471-4159.1975.tb06976.x; ZAFRA F, 1990, BIOCHEM J, V271, P237, DOI 10.1042/bj2710237; [No title captured]	35	271	274	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27313	27317						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903307				2022-12-27	WOS:A1993MM26200069
J	GREEN, SA; COLE, G; JACINTO, M; INNIS, M; LIGGETT, SB				GREEN, SA; COLE, G; JACINTO, M; INNIS, M; LIGGETT, SB			A POLYMORPHISM OF THE HUMAN BETA(2)-ADRENERGIC RECEPTOR WITHIN THE 4TH TRANSMEMBRANE DOMAIN ALTERS LIGAND-BINDING AND FUNCTIONAL-PROPERTIES OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; CYTOPLASMIC DOMAINS; DISTINCT PATHWAYS; GS; DESENSITIZATION; SPECIFICITY; ACTIVATION	We have recently identified several naturally occurring variants of the human beta2-adrenergic receptor (beta2AR). One of these polymorphisms, which is relatively uncommon, is a mutation occurring in the fourth transmembrane spanning domain, with Ile substituted for Thr at amino acid 164 within the proposed ligand binding pocket. This mutation is adjacent to Ser165 which has been predicted to interact with the beta-carbon hydroxyl group of adrenergic ligands. To determine the functional significance of this variant, we constructed by site-directed techniques a mutated beta2AR (Ile164) with this substitution and expressed it in CHW-1102 cells. In the presence of guanine nucleotide, Ile164 displayed a lower binding affinity for epinephrine as compared with the wild-type beta2AR (K(i) = 1450 +/- 79 versus 368 +/- 39 nM; p < 0.001). A similarly decreased affinity was found with the catecholamines isoproterenol and norepinephrine, but not with dobutamine or dopamine which lack hydroxyl groups on their beta-carbons. In addition, antagonists without aromatic ring polar substituents displayed a decreased affinity for the mutated receptor. In agonist competition experiments conducted in the absence of guanine nucleotide, Ile164 failed to exhibit detectable high affinity binding, suggesting an impairment in the formation of the agonist-receptor-Gs complex. Consistent with this finding, functional coupling to Gs as determined in adenylyl cyclase assays was significantly (approximately 50%) depressed with Ile164 under both basal and agonist-stimulated conditions. Beta2AR sequestration, which is also triggered by agonist binding, was also found to be approximately 65% reduced in the Ile164 polymorphism. This study represents the first characterization of a naturally occurring mutation of a human adrenergic receptor. Our findings generally support the hypothesized role of this region of the receptor for ligand binding and receptor activation, as well as for establishing critical interactions for overall receptor conformation.	UNIV CINCINNATI,COLL MED,DEPT MED PULM,231 BETHESDA AVE,ML 0564,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET & PHARMACOL,CINCINNATI,OH 45267; CETUS CHIRON CORP,EMERYVILLE,CA 94608	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL45967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1988, AM J PHYSIOL, V254, pE795, DOI 10.1152/ajpendo.1988.254.6.E795; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIGGETT SB, 1993, CATECHOLAMINES, P279; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PERKINS JP, 1991, MECHANISMS LIGAND IN, P125; REISHAUS E, 1993, AM J RESPIR CELL MOL, V8, P334; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, J BIOL CHEM, V264, P16470; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002	30	380	400	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23116	23121						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901205				2022-12-27	WOS:A1993MF51500027
J	GARDE, J; KINGHORN, JR; TOMSETT, AB				GARDE, J; KINGHORN, JR; TOMSETT, AB			SITE-DIRECTED MUTAGENESIS OF NITRATE REDUCTASE FROM ASPERGILLUS-NIDULANS - IDENTIFICATION OF SOME ESSENTIAL AND SOME NONESSENTIAL AMINO-ACIDS AMONG CONSERVED RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-CYTOCHROME-B5 REDUCTASE; ASSIMILATORY NADH; HEME DOMAIN; NIAD; EXPRESSION; CHLORELLA; CYSTEINE; MUTANTS; CORN; DNA	Nitrate reductase is a multiredox enzyme possessing three functional domains associated with the prosthetic groups FAD, heme iron, and molybdopterin, In Aspergillus nidulans, it is encoded by the niaD gene, A homologous transformation system has been used whereby a major deletion at the niiAniaD locus of the host was repaired by gene replacement, Employing site directed mutagenesis and this transformation system, nine niaD mutants were generated carrying specific amino acid substitutions, Mutants in which alanine replaced cysteine 150, which is thought to bind the molybdenum atom of the molybdenum-pterin, and in which alanine replaced histidine 547, which putatively binds heme iron, had no detectable nitrate reductase (NAR) activity, This clearly establishes an essential catalytic role for these residues, Of the remaining mutants, all altered in the NADPH/FAD domain, two were temperature-sensitive for NAR activity, two had reduced NAR activity levels, and three had normal levels, Since some of these mutants change residues conserved between homologous nitrate reductases from a wide range of species, it is clear that such amino acid identities do not necessarily signify essential roles for the activity of the enzyme, These findings are considered in the light of predicted structural/functional roles for the altered amino acids.	UNIV LIVERPOOL, DEPT GENET & MICROBIOL, DONNAN LABS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND; UNIV ST ANDREWS, DEPT BIOCHEM & MICROBIOL, ST ANDREWS KY16 9AL, FIFE, SCOTLAND	University of Liverpool; University of St Andrews								BAIJAL M, 1987, PHYTOCHEMISTRY, V27, P1969; BARBER MJ, 1990, J BIOL CHEM, V265, P20912; BARBER MJ, 1986, J BIOL CHEM, V261, P4562; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL WH, 1986, PLANT PHYSIOL, V82, P729, DOI 10.1104/pp.82.3.729; CAMPBELL WH, 1986, BIOCH BASIS PLANT BR, V11, P1; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; COOLEY RN, 1985, BIOCHIM BIOPHYS ACTA, V831, P89, DOI 10.1016/0167-4838(85)90153-0; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CRAWFORD NM, 1993, ANNU REV GENET, V27, P115, DOI 10.1146/annurev.ge.27.120193.000555; DUNNCOLEMAN NS, 1977, MOL GEN GENET, V152, P285, DOI 10.1007/BF00693082; DWIVEDI UN, 1994, J BIOL CHEM, V269, P13785; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEMANN A, 1991, MOL GEN GENET, V227, P97, DOI 10.1007/BF00260713; GARRETT RH, 1976, MOL GEN GENET, V149, P179, DOI 10.1007/BF00332887; GARRETT RH, 1969, J BIOL CHEM, V244, P2870; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; HACKETT CS, 1986, J BIOL CHEM, V261, P9854; HAWKER KL, 1992, MOL GEN GENET, V231, P485, DOI 10.1007/BF00292720; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; HYDE GE, 1989, PLANT MOL BIOL, V13, P233, DOI 10.1007/BF00016141; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; KUBO Y, 1988, J BIOL CHEM, V263, P19684; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; MACDONALD DW, 1974, MOL GEN GENET, V128, P187, DOI 10.1007/BF00267108; MATTHEWS FS, 1972, NATURE-NEW BIOL, V233, P15; MEYER C, 1991, J BIOL CHEM, V266, P20561; MINAGAWA N, 1982, J BIOCHEM, V91, P761, DOI 10.1093/oxfordjournals.jbchem.a133763; OKAMOTO PM, 1993, MOL GEN GENET, V240, P221, DOI 10.1007/BF00277060; PATEMAN JA, 1967, BIOCHEM J, V104, P103, DOI 10.1042/bj1040103; ROUZE P, 1992, SOC EXP BIOL SEMIN S, V49, P45, DOI 10.1017/CBO9780511600395.004; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOMONSON LP, 1986, J BIOL CHEM, V261, P1290; SOLOMONSON LP, 1987, J BIOL CHEM, V262, P8934; STRITTMATTER P, 1961, J BIOL CHEM, V236, P2329; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TOMSETT AB, 1979, GENET RES, V34, P19, DOI 10.1017/S001667230001925X; TOMSETT AB, 1989, NITROGEN PHOSPHORUS, P33; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WAHL RC, 1984, ARCH BIOCHEM BIOPHYS, V230, P264, DOI 10.1016/0003-9861(84)90107-3; Wray J.L., 1989, MOL GENETIC ASPECTS	46	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6644	6650		10.1074/jbc.270.12.6644	http://dx.doi.org/10.1074/jbc.270.12.6644			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896804	hybrid			2022-12-27	WOS:A1995QQ85500035
J	GARDELLA, TJ; LUCK, MD; WILSON, AK; KEUTMANN, HT; NUSSBAUM, SR; POTTS, JT; KRONENBERG, HM				GARDELLA, TJ; LUCK, MD; WILSON, AK; KEUTMANN, HT; NUSSBAUM, SR; POTTS, JT; KRONENBERG, HM			PARATHYROID-HORMONE (PTH)-PTH-RELATED PEPTIDE HYBRID PEPTIDES REVEAL FUNCTIONAL INTERACTIONS BETWEEN THE 1-14 AND 15-34 DOMAINS OF THE LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAINS; NMR SOLUTION STRUCTURE; HUMORAL HYPERCALCEMIA; MALIGNANCY; FRAGMENT; PROTEIN; KIDNEY; SPECTROSCOPY; MEMBRANES; SEQUENCES	Parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) bind to a common PTH/ PTHrP receptor. To explore structure-function relations in these ligands, we synthesized and functionally evaluated PTH-PTHrP hybrid peptides in which the homologous 1-14 portions were exchanged. Hybrid-2, PTH(1-14)-PTHrP-(15-34)NH2, bound to LLC-PK1 cells expressing the cloned rat PTH/PTHrP receptor with high affinity (IC50 congruent to 7 nM). In contrast, hybrid-1, PTHrP(1-14)-PTH-(15-34)NH2, bound with much weaker affinity (IC50 congruent to 8,700 nM). Thus, the 1-14 region of PTHrP is incompatible with the 15-34 region of PTH. The carboxyl-terminal incompatibility site was identified as residues 19-21 (Glu-Arg-Val in PTH and Arg-Arg-Arg in PTHrP); extending the amino-terminal PTHrP sequence to residue 21 but not to 18 cured the hybrid's binding defect. The amino-terminal incompatibility site was identified as position 5 (Ile in PTH and His in PTHrP), because Ile(5)-hybrid-1 bound with high affinity (IC50 congruent to 20 nM). The importance of these identified residues in the native ligands was established by evaluating the effects of substitutions at these sites in a series of PTH and PTHrP analog peptides. Overall, the results are consistent with the hypothesis that, in both PTH and PTHrP, the 1-14 and 15-34 domains interact when binding to the receptor and that residues 5, 19, and 21 contribute either directly or indirectly to this interaction.	HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	GARDELLA, TJ (corresponding author), MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114, USA.							ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BARANY G, 1979, PEPTIDES ANAL SYNTHE, P1; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; COHEN FE, 1991, J BIOL CHEM, V266, P1997; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRELINGER AL, 1986, ARCH BIOCHEM BIOPHYS, V244, P641, DOI 10.1016/0003-9861(86)90632-6; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KEMP BE, 1987, SCIENCE, V238, P1558; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; MCFARLANE DR, 1993, BIOCHIM BIOPHYS ACTA, V1162, P187, DOI 10.1016/0167-4838(93)90146-I; MCKEE RL, 1988, ENDOCRINOLOGY, V122, P3008, DOI 10.1210/endo-122-6-3008; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; ORLOFF JJ, 1992, ENDOCRINOLOGY, V131, P1603, DOI 10.1210/en.131.4.1603; POTTS JT, 1971, P NATL ACAD SCI USA, V68, P63, DOI 10.1073/pnas.68.1.63; RAY FR, 1993, EUR J BIOCHEM, V211, P205, DOI 10.1111/j.1432-1033.1993.tb19887.x; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; ROSENBLATT M, 1982, ENDOCRINOLOGY CALCIU, P103; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SMITH LM, 1987, ARCH BIOCHEM BIOPHYS, V253, P81, DOI 10.1016/0003-9861(87)90639-4; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; ZULL JE, 1980, P NATL ACAD SCI-BIOL, V77, P3791, DOI 10.1073/pnas.77.7.3791	29	54	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6584	6588		10.1074/jbc.270.12.6584	http://dx.doi.org/10.1074/jbc.270.12.6584			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896796	hybrid			2022-12-27	WOS:A1995QQ85500026
J	GERENDASY, DD; HERRON, SR; JENNINGS, PA; SUTCLIFFE, JG				GERENDASY, DD; HERRON, SR; JENNINGS, PA; SUTCLIFFE, JG			CALMODULIN STABILIZES AN AMPHIPHILIC ALPHA-HELIX WITHIN RC3/NEUROGRANIN AND GAP-43/NEUROMODULIN ONLY WHEN CA2+ IS ABSENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PERTUSSIS ADENYLATE-CYCLASE; LONG-TERM POTENTIATION; LIGHT CHAIN KINASE; BINDING DOMAIN; B-50 GAP-43; PHOSPHORYLATION SITE; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; GANGLION-CELLS	Two neuronal protein kinase C substrates, RC3/neurogranin and GAP-43/neuromodulin, preferentially bind to calmodulin (CaM) when Ca2+ is absent. We examine RC3 . CaM and GAP-43 . CaM interactions by circular dichroism spectroscopy using purified, recombinant RC3 and GAP-43, sequence variants of RC3 displaying qualitative and quantitative differences in CaM binding affinities, and overlapping peptides that cumulatively span the entire amino acid sequence of RC3. We conclude that CaM stabilizes a basic, amphiphilic cu-helix within RC3 and GAP-43 under physiological salt concentrations only when Ca2+ is absent. This provides structural confirmation for two binding modes and suggests that CaM regulates the biological activities of RC3 and GAP-43 through an allosteric, Ca2+-sensitive mechanism that can be uncoupled by protein kinase C-mediated phosphorylation. More generally, our observations imply an alternative allosteric regulatory role for the Ca2+-free form of CaM.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego					NINDS NIH HHS [NS22111, NS22347] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022347, R01NS022111] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P2; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BENOWITZ LI, 1991, ANN NY ACAD SCI, V627, P58; BLUMENTHAL DK, 1988, MOL ASPECTS CELLULAR, V5, P341; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUELT MK, 1994, J BIOL CHEM, V269, P29367; CARAFOLI E, 1992, ANN NY ACAD SCI, V671, P58, DOI 10.1111/j.1749-6632.1992.tb43784.x; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CHEN SJ, 1993, 23RD P ANN M SOC NEU; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COGGINS PJ, 1989, BIOCHEM SOC T, V17, P785, DOI 10.1042/bst0170785; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN P, 1988, CALMODULIN, V5; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEGRAAN PNE, 1991, PROG BRAIN RES, V89, P187; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; FITZGERALD M, 1991, NEUROSCIENCE, V41, P187, DOI 10.1016/0306-4522(91)90209-7; FORSEN S, 1986, CALCIUM CELL FUNCT, V6, P114; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1995, IN PRESS J MOL NEURO; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1986, BIOCHEM SOC T, V14, P163, DOI 10.1042/bst0140163; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; HENNESSEY JP, 1987, BIOPOLYMERS, V26, P561, DOI 10.1002/bip.360260409; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, CELL CALCIUM, V13, P391, DOI 10.1016/0143-4160(92)90052-T; KINCAID RL, 1986, CALCIUM CELL FUNCTIO, V6, P44; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KRETSINGER RH, 1992, CELL CALCIUM, V13, P363, DOI 10.1016/0143-4160(92)90050-3; LADANT D, 1988, J BIOL CHEM, V263, P2612; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LIN LH, 1992, MOL BRAIN RES, V14, P147, DOI 10.1016/0169-328X(92)90024-6; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MEANS AR, 1987, CELLULAR REGULATORS; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MUNIER H, 1993, J BIOL CHEM, V268, P1695; NEEL VA, 1994, DEVELOPMENT, V120, P2235; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRECHEUR B, 1992, BIOCHEMISTRY-US, V31, P229, DOI 10.1021/bi00116a032; PRECHEUR B, 1991, EUR J BIOCHEM, V196, P67; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SEEHOLZER SH, 1986, P NATL ACAD SCI USA, V83, P3634, DOI 10.1073/pnas.83.11.3634; SHARMA RK, 1986, J BIOL CHEM, V261, P14160; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SOMMERVAILLE T, 1991, NEUROSCIENCE, V45, P213, DOI 10.1016/0306-4522(91)90117-7; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TALLANT EA, 1986, CALCIUM CELL FUNCTIO, V6, P72; TANAKA T, 1980, J BIOL CHEM, V255, P1078; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114; ZWIERS H, 1991, PROG BRAIN RES, V89, P3	89	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6741	6750		10.1074/jbc.270.12.6741	http://dx.doi.org/10.1074/jbc.270.12.6741			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896819	hybrid			2022-12-27	WOS:A1995QQ85500050
J	IMAI, K; YOKOHAMA, Y; NAKANISHI, I; OHUCHI, E; FUJII, Y; NAKAI, N; OKADA, Y				IMAI, K; YOKOHAMA, Y; NAKANISHI, I; OHUCHI, E; FUJII, Y; NAKAI, N; OKADA, Y			MATRIX METALLOPROTEINASE-7 (MATRILYSIN) FROM HUMAN RECTAL-CARCINOMA CELLS - ACTIVATION OF THE PRECURSOR, INTERACTION WITH OTHER MATRIX METALLOPROTEINASES AND ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; MONOCLONAL-ANTIBODIES; ENZYMATIC-PROPERTIES; COLLAGENASE FAMILY; HUMAN-NEUTROPHILS; TERMINAL DOMAIN; IV COLLAGENASE; STROMELYSIN; PURIFICATION; PROCOLLAGENASE	Matrix metalloproteinase 7 (MMP-7) has been purified as an inactive zymogen of M(r), 28,000 (proMMP-7) from the culture medium of CaR-1 human rectal carcinoma cells. The NH2-terminal sequence of proMMP-7 is Lys-Pro-Lys-Pro-Gln-Glu, which is identical to that of matrilysin. The zymogen is activated by 4-aminophenylmercuric acetate (APMA), yielding an intermediate form of M(r) 21,000 and an active species of M(r) 19,000 which shows the new NH2-terminal sequence of Tyr(78)-Ser-Leu-Phe-Pro-Asn-Ser. Although trypsin fully activates the zymogen, the activation rate by plasmin or leukocyte elastase is confined to similar to 50%. ProMMP-7 can be activated by MMP-3 (stromelysin 1) to its full activity in a single-step mechanism and generates the same NH2 terminus obtained by APMA activation, whereas MMP-1 (tissue collagenase), MMP-2 (gelatinase A), and MMP-9 (gelatinase B) do not have such an effect, On the other hand, proMMP-1 is activated by MMP-7 to an activity similar to that obtained by APMA and the activation by MMP-7 is enhanced up to similar to 6.5 fold in the presence of APMA, This enhanced activity is donated by specific cleavage at the Gln(80)-Phe(81) bond of proMMP-1. MMP-7 can also activate proMMP-9 up to similar to 50% of the full activity with a new NH2 terminus of Leu(16)-Arg-Thr-(Asn)-Leu. Incubation of proMMP-2 or proMMP-3 with MMP-7 results in no activation of these proMMPs. MMP-7 degrades type IV collagen, laminin-1, fibronectin, proteoglycan, type I gelatin, and insoluble elastin, These results suggest that in vivo MMP-7 may play a role in degradation of extracellular matrix macromolecules in concert with MMP-1, -3, and -9 under pathological conditions.	KANAZAWA UNIV, CANC RES INST, DEPT MOLEC IMMUNOL & PATHOL, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, SCH MED, DEPT ORTHOPED SURG, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, SCH MED, DEPT PATHOL, KANAZAWA, ISHIKAWA 920, JAPAN; FUJI CHEM IND CO LTD, TAKAOKA, TOYAMA 933, JAPAN; FUKUI MED SCH, DEPT CHEM, FUKUI 91011, JAPAN	Kanazawa University; Kanazawa University; Kanazawa University; University of Fukui			Imai, Kazushi/E-7206-2012; Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755; Fujii, Yutaka/0000-0001-6357-3795				ALLAN JA, 1991, J CELL SCI, V99, P789; BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; DAVIS GE, 1990, CANCER RES, V50, P1113; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FUJIMOTO N, 1993, CLIN CHIM ACTA, V220, P31, DOI 10.1016/0009-8981(93)90004-N; GIRARD MT, 1993, J CELL SCI, V104, P1001; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KNAUPER V, 1993, BIOCHEM J, V295, P581; KODAMA S, 1990, J IMMUNOL METHODS, V127, P103, DOI 10.1016/0022-1759(90)90345-V; MARTI HP, 1992, BIOCHEM J, V285, P899, DOI 10.1042/bj2850899; MARTI HP, 1994, AM J PATHOL, V144, P82; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; MINAMOTO T, 1988, HUM PATHOL, V19, P815, DOI 10.1016/S0046-8177(88)80265-X; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; NAKANO A, 1993, BIOCHEM BIOPH RES CO, V192, P999, DOI 10.1006/bbrc.1993.1515; OBATA K, 1992, CLIN CHIM ACTA, V211, P59, DOI 10.1016/0009-8981(92)90105-Y; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OKADA Y, 1995, IN PRESS LAB INVEST; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Ruoslahti E, 1978, Ann N Y Acad Sci, V312, P178, DOI 10.1111/j.1749-6632.1978.tb16802.x; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SIRES UI, 1993, J BIOL CHEM, V268, P2069; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WINDSOR LJ, 1993, J BIOL CHEM, V268, P17341; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; ZHANG J, 1993, CLIN CHIM ACTA, V219, P1, DOI 10.1016/0009-8981(93)90192-7	57	259	265	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6691	6697		10.1074/jbc.270.12.6691	http://dx.doi.org/10.1074/jbc.270.12.6691			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896811	hybrid			2022-12-27	WOS:A1995QQ85500042
J	JIN, JP				JIN, JP			CLONED RAT CARDIAC TITIN CLASS-I AND CLASS-II MOTIFS - EXPRESSION, PURIFICATION, CHARACTERIZATION, AND INTERACTION WITH F-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEBULIN FRAGMENTS; LIGHT CHAIN KINASE; SKELETAL-MUSCLE; TROPONIN-T; MONOCLONAL-ANTIBODIES; STRIATED-MUSCLE; Z-LINE; MOLECULAR CHARACTERIZATION; IMMUNOELECTRON MICROSCOPY; SARCOMERE MATRIX	Titin (connectin) is a giant protein that forms a single-molecule elastic filament extending from the M-line to the Z-line in the striated muscle sarcomere. The sequence of titin consists mainly of repeats of two types of similar to 100-amino acid motifs (class I and class II that show homology to the fibronectin type III and immunoglobulin-C2 domains, respectively). To investigate the functions of the two classes of titin moths as the basic units of this large sarcomere organizer molecule, titin cDNA segments encoding single class I or class II or linked class I-II motifs were cloned by polymerase chain reaction from a rat cardiac cDNA library into the T7 RNA polymerase-based pAED4 vector to express non-fusion titin fragments in Escherichia coli. High level expression of the three titin fragments was achieved, and effective rapid purification procedures were developed. The purified titin fragments were verified by their amino acid composition, apparent molecular mass, and charge. Antibodies raised against the genetically expressed titin motifs specifically recognized intact rat cardiac and skeletal muscle titins in Western blotting and immunofluorescence microscopy, confirming the authenticity of the cloned fragments. High beta-sheet contents of these titin motifs indicate a folding state very similar to that of intact native titin. Solid-phase protein-binding assays demonstrated that a single class I motif was able to bind both myosin and F-actin. In comparison, a single class II motif had weaker binding to only F-actin but the fragment containing linked class I and class II motifs showed significantly stronger interactions with both myosin and F-actin. The binding of titin motifs to myosin supports the proposed association of A-band titin with the thick filament, and the novel titin-F-actin interaction was confirmed by F actin cosedimentation assays, suggesting that titin may also be involved in the structure and/or function of the thin filament.			JIN, JP (corresponding author), UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.			Jin, JP/0000-0001-9932-1063				Ausubel F.M., 1987, CURRENT PROTOCOL MOL; AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; FRITZ JD, 1993, J MUSCLE RES CELL M, V14, P347, DOI 10.1007/BF00123100; FULTON AB, 1991, BIOESSAYS, V13, P157, DOI 10.1002/bies.950130403; FURST DO, 1989, J CELL SCI, V94, P119; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; GAUTEL M, 1993, NEUROLOGY, V43, P1581, DOI 10.1212/WNL.43.8.1581; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; HILL C, 1986, J CELL BIOL, V102, P1099, DOI 10.1083/jcb.102.3.1099; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOROWITS R, 1992, BIOPHYS J, V61, P392, DOI 10.1016/S0006-3495(92)81845-3; JIN JP, 1994, FEBS LETT, V341, P135, DOI 10.1016/0014-5793(94)80256-4; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1991, J BIOL CHEM, V266, P21215; JIN JP, 1991, FEBS LETT, V281, P93, DOI 10.1016/0014-5793(91)80366-B; JIN JP, 1989, J BIOL CHEM, V264, P14471; JIN JP, 1990, HYBRIDOMA, V9, P597, DOI 10.1089/hyb.1990.9.597; KIMURA S, 1983, BIOMED RES-TOKYO, V4, P607; KIMURA S, 1984, J BIOCHEM, V96, P499, DOI 10.1093/oxfordjournals.jbchem.a134862; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAKI K, 1962, ARCH BIOCHEM BIOPHYS, V98, P323, DOI 10.1016/0003-9861(62)90190-X; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARUYAMA K, 1985, J CELL BIOL, V101, P2167, DOI 10.1083/jcb.101.6.2167; MARUYAMA K, 1993, BIOCHEM BIOPH RES CO, V194, P1288, DOI 10.1006/bbrc.1993.1963; MARUYAMA K, 1986, INT REV CYTOL, V104, P81, DOI 10.1016/S0074-7696(08)61924-5; MULLERSEITZ M, 1993, GENOMICS, V18, P559, DOI 10.1016/S0888-7543(05)80356-8; NAVE R, 1990, J CELL SCI, V95, P535; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PAN KM, 1994, BIOCHEMISTRY-US, V33, P8255, DOI 10.1021/bi00193a012; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PRICE MG, 1993, J BIOL CHEM, V268, P21800; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; SOTERIOU A, 1993, J CELL SCI, V104, P119; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN KO, 1993, J BIOL CHEM, V268, P22900; TRINICK J, 1992, FEBS LETT, V307, P44, DOI 10.1016/0014-5793(92)80899-R; Trinick J, 1991, CURR OPIN CELL BIOL, V3, P112, DOI 10.1016/0955-0674(91)90173-V; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P416, DOI 10.1007/BF00121293; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WANG K, 1991, P NATL ACAD SCI USA, V88, P7101, DOI 10.1073/pnas.88.16.7101; Wang K, 1985, Cell Muscle Motil, V6, P315; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; WANG K, 1986, METHOD ENZYMOL, V85, P264	55	78	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6908	6916						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896840				2022-12-27	WOS:A1995QQ85500071
J	HECK, RW; TANHAUSER, SM; MANDA, R; TU, CK; LAIPIS, PJ; SILVERMAN, DN				HECK, RW; TANHAUSER, SM; MANDA, R; TU, CK; LAIPIS, PJ; SILVERMAN, DN			CATALYTIC PROPERTIES OF MOUSE CARBONIC-ANHYDRASE-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIDE HYDRATION ACTIVITY; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; EXPRESSION; MECHANISM; NUCLEOTIDE; ISOENZYME; CLONING	A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH,terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several aminoterminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a pro tein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of k(cat)/K-m at 3 x 10(7) M(-1) s(-1) and k(cat) at 3 x 10(5) s(-1) with an apparent pK(a), for catalysis of 7.4 determined from k(cat)/K-m. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr(64) --> His showed that the unique kinetic properties of CAV are not due to the presence of tyrosine at position 64.	UNIV FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMORGUERET M, 1990, NUCLEIC ACIDS RES, V18, P1646, DOI 10.1093/nar/18.6.1646; DATTA PK, 1959, ARCH BIOCHEM BIOPHYS, V81, P124, DOI 10.1016/0003-9861(59)90182-1; DODGSON SJ, 1989, AM J PHYSIOL, V257, pE791, DOI 10.1152/ajpendo.1989.257.6.E791; DODGSON SJ, 1991, CARBONIC ANHYDRASES, P297; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; FRASER PJ, 1986, J MOL EVOL, V23, P294, DOI 10.1007/BF02100637; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, BIOCHEMISTRY-US, V28, P4056; HEWETTEMMETT D, 1986, ISOZYME B, V19, P13; JEWELL DA, 1991, BIOCHEMISTRY-US, V30, P1484, DOI 10.1021/bi00220a006; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIANG ZW, 1993, EUR J BIOCHEM, V211, P821, DOI 10.1111/j.1432-1033.1993.tb17614.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MAREN TH, 1967, MOL PHARMACOL, V3, P503; NAGAO Y, 1993, P NATL ACAD SCI USA, V90, P7623, DOI 10.1073/pnas.90.16.7623; OHLIGER DE, 1993, FASEB J, V7, pA676; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; SANYAL G, 1982, MOL PHARMACOL, V22, P211; SEGEL IH, 1975, ENZYME KINETICS, P150; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SIMONSSON I, 1982, EUR J BIOCHEM, V123, P29, DOI 10.1111/j.1432-1033.1982.tb06494.x; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; TWEEDIE S, 1989, BIOCHEM GENET, V27, P17, DOI 10.1007/BF00563015; VENTA PJ, 1985, J BIOL CHEM, V260, P2130	30	54	54	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24742	24746						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929150				2022-12-27	WOS:A1994PQ49000037
J	RAMANATHAN, M; LANTZ, M; MACGREGOR, RD; GAROVOY, MR; HUNT, CA				RAMANATHAN, M; LANTZ, M; MACGREGOR, RD; GAROVOY, MR; HUNT, CA			CHARACTERIZATION OF THE OLIGODEOXYNUCLEOTIDE-MEDIATED INHIBITION OF INTERFERON-GAMMA-INDUCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I AND INTERCELLULAR-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDES; ENHANCED EXPRESSION; CELL-LINES; ANTIGENS; ICAM-1; ACTIVATION; ANTIBODIES; MACROPHAGE; ALLOGRAFT; INDUCTION	The major histocompatibility complex (MHC) Class I and II genes and intercellular adhesion molecule-1 (ICAM-1) are regulated by interferon-gamma in a variety of cell types. We have previously shown that the oligodeoxynucleotide 5'-GGG GTT GGT TGT GTT GGG TGT TGT GT-RNH(2) (oligo I) inhibits the interferon-gamma-mediated enhancement of MHC Class I and ICAM-1 proteins in the K562 cell line. We have now investigated the mechanism of action of oligo I and report that it acts by inhibiting the binding of interferon-gamma to cells. We also show that the dose-response curves, the selectivity profile, and the kinetics of oligo I are consistent with this novel mechanism of action. The dose-response curves for oligo I, obtained using antibodies against the MHC Class I heavy chain, beta(2)-microglobulin, or ICAM-1, are almost superimposable at each observation time. MHC Class I induction by 6400 units/ml interferon-alpha or interferon-beta or ICAM-1 enhancement by 800 units/ml tumor necrosis factor-alpha is not inhibited by oligo I. However, the synergistic induction of MHC Class I by mixtures of tumor necrosis factor-alpha and interferon-gamma is inhibited. Oligo I belongs to a class of active oligodeoxynucleotides that inhibits interferon-gamma-induced MHC Class I and ICAM-1 in K562 cells. The activity and potency is sequence-dependent, but remarkably different sequences can have comparable effects. The activity of oligo I in the HeLa S3 cell line inhibits the interferon-gamma-mediated enhancement of both ICAM-1 and MHC Class II DR and the interferon-gamma-mediated reduction in transferrin receptor expression. Thus, oligo I appears to specifically inhibit interferon-gamma-induced changes in protein expression, which is consistent with oligo I acting at an early step(s) in the induction process. Taken together, our results show that oligo I exerts its effects by inhibiting the association of interferon-gamma with the cell surface, which is a novel mechanism of action for oligodeoxynucleotides.	UNIV CALIF SAN FRANCISCO,UNIV CALIF SAN FRANCISCO UNIV CALIF BERKELEY PROG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARM & PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hunt, C. Anthony/0000-0001-9372-6860				CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; FEDOSEYEVA EV, 1994, TRANSPLANTATION, V52, P606; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KANBE M, 1992, ANTI-CANCER DRUG DES, V7, P341; LICHTENSTEIN A, 1992, CELL IMMUNOL, V141, P219, DOI 10.1016/0008-8749(92)90141-B; LINDAHL P, 1976, P NATL ACAD SCI USA, V73, P1284, DOI 10.1073/pnas.73.4.1284; NORONHA IL, 1992, TRANSPLANTATION, V54, P1017, DOI 10.1097/00007890-199212000-00015; PACE JL, 1983, J IMMUNOL, V130, P2011; RAMANATHAN M, 1994, TRANSPLANTATION, V52, P612; ROSA FM, 1988, J IMMUNOL, V140, P1660; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SIEGRIST CA, 1993, EUR J IMMUNOL, V23, P2903, DOI 10.1002/eji.1830231126; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; WONG GHW, 1983, J IMMUNOL, V131, P788	19	30	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24564	24574						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929128				2022-12-27	WOS:A1994PQ49000012
J	FRONTICELLI, C; PECHIK, I; BRINIGAR, WS; KOWALCZYK, J; GILLILAND, GL				FRONTICELLI, C; PECHIK, I; BRINIGAR, WS; KOWALCZYK, J; GILLILAND, GL			CHLORIDE-ION INDEPENDENCE OF THE BOHR EFFECT IN A MUTANT HUMAN HEMOGLOBIN BETA(V1M+H2DELETED)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; HUMAN DEOXYHEMOGLOBIN; ESCHERICHIA-COLI; BINDING-SITE; RESOLUTION	A mutant human hemoglobin, beta(V1M+H2 Delta), has been constructed. Analysis of the oxygen binding curves obtained at pH 8.3, where the Bohr effect is inoperative, indicates that this mutation results in an additional stabilization of the T-state conformation by 0.9 kcal/mol. The crystal structure of deoxy-beta(V1M+H2 Delta) has been determined to 2.2-Angstrom resolution and compared with the deoxy structure of human hemoglobin at the same resolution. In human hemoglobin, a sulfate anion is anchored to the beta-chains by a complex network of H-bonds and electrostatic interactions with the amino terminus and Lys(beta 82). In the mutant hemoglobin, the shortening of the amino-terminal region of the A helix by 1 residue results in the formation of an intrachain electrostatic interaction between the amino-terminal amino and Asp(beta 79). This eliminates the sulfate binding site, and the sulfate is replaced by two water molecules. At variance with human hemoglobin, the alkaline Bohr effect for beta(V1M+H2 Delta) is not sensitive to the presence of Cl-. This indicates that the sulfate binding site in human hemoglobin also serves as a Cl- binding site, and that the amino terminal Val(beta 1) is essential for oxygen-linked Cl- binding to hemoglobin as well as the Cl--dependent Bohr effect. Analysis of the oxygen binding curves indicates that the oxygen-linked Cl- ions are released upon binding of the first oxygen molecule.	UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; TEMPLE UNIV,DEPT CHEM,PHILADELPHIA,PA 19122; NATL INST STAND & TECHNOL,ROCKVILLE,MD 20850	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institute of Standards & Technology (NIST) - USA	FRONTICELLI, C (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOCHEM,108 N GREENE ST,BALTIMORE,MD 21201, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013164, P01HL048517] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48517, HLBI-13164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adair GS, 1925, J BIOL CHEM, V63, P529; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; BUCCI E, 1988, BIOPHYS CHEM, V32, P187, DOI 10.1016/0301-4622(88)87006-6; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; FRONTICELLI C, 1982, TECHNIQUES PROTEIN C, V3, P399; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P8640, DOI 10.1021/bi00151a034; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; PERUTZ MF, 1980, J MOL BIOL, V136, P183, DOI 10.1016/0022-2836(80)90312-5; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J, 1990, BINDING LINKAGE FUNC	25	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23965	23969						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929044				2022-12-27	WOS:A1994PQ34600020
J	STALLINGSMANN, ML; BURKE, MG; TROUT, WE; ROBERTS, RM				STALLINGSMANN, ML; BURKE, MG; TROUT, WE; ROBERTS, RM			PURIFICATION, CHARACTERIZATION, AND CDNA CLONING OF A KUNITZ-TYPE PROTEINASE-INHIBITOR SECRETED BY THE PORCINE UTERUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PLASMINOGEN-ACTIVATOR PRODUCTION; RETINOL-BINDING PROTEIN; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PIG TROPHOBLAST; MESSENGER-RNA; EXPRESSION; PREGNANCY; IMPLANTATION	The porcine uterus synthesizes a proteinase inhibitor (M(r) 14,000) under the influence of progesterone that is relatively specific for plasmin and trypsin, but that also has weak affinity for chymotrypsin. Several isoforms of this uterine plasmin/trypsin inhibitor were purified by a procedure whose final two steps involved affinity chromatography on immobilized chymotrypsin and cation exchange chromatography. Amino-terminal sequencing showed that at least three of the isoforms were closely related. An oligonucleotide probe based on the protein sequence was used to identify a cDNA that contained an open reading frame coding for a mature protein (M(r) 10,295) of 98 amino acids. The inhibitor had a well defined, but unique, Kunitz domain of 64 residues at its amino terminus that shared 67% sequence identity to bovine pancreatic trypsin inhibitor. Its P-1 residue was arginine rather than lysine. Northern analysis showed the presence of a single mRNA species (700 bases) that in adult female pigs appeared to be confined to the uterus. During pregnancy, UPTI mRNA expression was high until Day 30 and decreased significantly thereafter. By contrast, uteroferrin mRNA reached maximal concentrations in late pregnancy. These data are consistent with an earlier hypothesis that the inhibitor serves to neutralize the activities of one or more serine proteinases generated by the proliferating trophoblast during the formation of the noninvasive placenta of the pig.	UNIV MISSOURI,AMIM SCI RES CTR 158,DEPT ANIM SCI,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia				Stallings-Mann, Melody/0000-0003-3227-6063	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021980] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21980] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APLIN JD, 1991, J CELL SCI, V99, P681; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BAZER FW, 1983, J ANIM SCI, V57, P425; BISCHOF P, 1992, PLACENTA, V13, P17, DOI 10.1016/0143-4004(92)90003-C; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CREIGHTON TE, 1987, COLD SPRING HARB SYM, V52, P511, DOI 10.1101/SQB.1987.052.01.058; DANIEL JC, 1978, METHODS MAMMALIAN RE, P503; DAVIS LG, 1986, BASIC METHODS MOL BI, P75; DROBNICKOSOROK M, 1990, BIOL CHEM H-S, V371, P57, DOI 10.1515/bchm3.1990.371.1.57; FAZLEABAS AT, 1982, J BIOL CHEM, V257, P6886; FAZLEABAS AT, 1983, BIOL REPROD, V29, P225, DOI 10.1095/biolreprod29.1.225; FAZLEABAS AT, 1984, ENDOCRINOLOGY, V116, P240; FRANK M, 1977, PROSTAGLANDINS, V14, P1183, DOI 10.1016/0090-6980(77)90295-7; FRIESS AE, 1980, ANAT EMBRYOL, V158, P179, DOI 10.1007/BF00315905; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; HAFEZ ESE, 1987, REPRODUCTION FARM AN, P229; HARNEY JP, 1994, BIOL REPROD, V50, P1126, DOI 10.1095/biolreprod50.5.1126; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; KINGSTON IB, 1986, BIOCHEM J, V233, P443, DOI 10.1042/bj2330443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MALATHY PV, 1990, MOL ENDOCRINOL, V4, P428, DOI 10.1210/mend-4-3-428; MARTIN O, 1982, AM J OBSTET GYNECOL, V142, P402, DOI 10.1016/S0002-9378(16)32380-8; MATTA MS, 1977, J BIOL CHEM, V252, P8423; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLINS DE, 1980, CELL, V20, P865, DOI 10.1016/0092-8674(80)90333-5; MURRAY FA, 1972, BIOL REPROD, V7, P314, DOI 10.1093/biolreprod/7.3.314; QUEENAN JT, 1987, J BIOL CHEM, V262, P10903; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL CA, 1972, J ANAT, V113, P139; SAMUEL CA, 1971, J REPROD FERTIL, V27, P494; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SIMMEN RCM, 1988, MOL ENDOCRINOL, V2, P253, DOI 10.1210/mend-2-3-253; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TROUT WE, 1992, ENDOCRINOLOGY, V130, P2557, DOI 10.1210/en.130.5.2557; TROUT WE, 1991, MOL ENDOCRINOL, V5, P1533, DOI 10.1210/mend-5-10-1533; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	47	18	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24090	24094						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929061				2022-12-27	WOS:A1994PQ34600039
J	KANDROR, O; BUSCONI, L; SHERMAN, M; GOLDBERG, AL				KANDROR, O; BUSCONI, L; SHERMAN, M; GOLDBERG, AL			RAPID DEGRADATION OF AN ABNORMAL PROTEIN IN ESCHERICHIA-COLI INVOLVES THE CHAPERONES GROEL AND GROES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; HEAT-SHOCK; CLP PROTEASE; GENE-PRODUCT; ACTIVATED ATPASE; HSP70 HOMOLOG; ION GENE; DNAK; PROTEOLYSIS; COMPONENT	In Escherichia coli, the molecular chaperones (DnaK, DnaJ, and GrpE) are essential for the rapid degradation of certain proteins. To see if chaperones are involved more generally in proteolysis, we studied the degradation of a short-lived fusion protein, CRAG, which associates with DnaK and GroEL in vivo. Its rapid degradation requires ATP and ClpP, the proteolytic subunit of protease Ti (Clp). However, this process is not reduced in strains lacking the complementary ATPase subunit, ClpA, or its homologs, ClpB and CLpX. At 37 degrees C, but not at 42 degrees C, protease La also contributes partially to CRAG degradation. Nevertheless, CRAG is not degraded in cell-free extracts or upon incubation with ClpP or protease La. We tested whether the chaperones associated with CRAG might be involved in its degradation. CRAG breakdown was accelerated 2-3 fold in strains with high levels of heat-shock proteins (hsps), i.e. in those that overproduce the hsp transcription factor (sigma(32)) or carry a dnaK deletion. A similar stimulation of proteolysis was observed in cells overproducing GroEL or both GroEL and GroES; in these cells, more CRAG was associated with GroEL than in the wild type. In a temperature-sensitive groEL44 mutant at the nonpermissive temperature, CRAG breakdown was accelerated, and more CRAG was found complexed with GroEL. However, in a temperature-sensitive groES mutant, CRAG was completely stable at the nonpermissive temperature and accumulated bound to GroEL. These findings indicate that the association of CRAG with GroEL is a rate-limiting step in CRAG degradation, which also requires a subsequent action of GroES. We propose that if the hsp60/ hsp10 chaperonins fail to catalyze the proper folding of a protein, they can facilitate its rapid degradation.			KANDROR, O (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.							BANEYX F, 1992, J BIOL CHEM, V267, P11637; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; CRAIG E, 1990, TRENDS BIOCHEM SCI, V16, P135; DAMERAU K, 1993, J BACTERIOL, V175, P53, DOI 10.1128/JB.175.1.53-63.1993; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOFF SA, 1987, J BIOL CHEM, V262, P4508; Goff SA, 1988, UBIQUITIN, P207; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; Hartl F U, 1991, Semin Immunol, V3, P5; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; Miller J.H., 1972, EXPT MOL GENETICS; OLDEN K, 1978, BIOCHIM BIOPHYS ACTA, V542, P385, DOI 10.1016/0304-4165(78)90370-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFANNER N, 1990, ANTON LEEUW INT J G, V58, P191, DOI 10.1007/BF00548932; SHERMAN M, 1991, J BACTERIOL, V173, P4249; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SHERMAN MY, 1992, EMBO J, V11, P71; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES C, 1991, J BACTERIOL, V173, P4259; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; WOO KM, 1989, J BIOL CHEM, V264, P2088; WOO KM, 1992, J BIOL CHEM, V267, P20429	43	118	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23575	23582						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916344				2022-12-27	WOS:A1994PQ34500031
J	DESSAUER, CW; BARTLETT, SG				DESSAUER, CW; BARTLETT, SG			IDENTIFICATION OF A CHAPERONIN BINDING-SITE IN A CHLOROPLAST PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SMALL SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; MOLECULAR CHAPERONE; BETA-LACTAMASE; GROEL PROTEIN; HSP60; GENES; HELIX; PURIFICATION	Although chaperonin-assisted protein folding has been studied in vitro by a number of investigators, the feature(s) of the unfolded polypeptide that are recognized and bound by chaperonins is not known. We have addressed this question using the precursor of the small subunit of ribulose-1,5-bisphosphate carboxylase (pS) as a substrate for GroEL. The protein was expressed in Escherichia coli as a C-terminal fusion to protein A. Protein A-pS and any associated cellular proteins were then purified by affinity chromatography. GroEL could be eluted from the fusion protein by incubation with ATP and either GroES or casein, consistent with results of in vitro folding assays. At least half of the transit sequence of pS is required to maintain this high stoichiometry of chaperonin binding. Using deletion mutagenesis from the C terminus of pS, we defined the smallest truncation of pS, PAxpS90T, that binds GroEL with high avidity (dissociation constant = 53 nM). A series of site-specific mutations targeting the C-terminal 15-20 amino acids of PAxpS90T was constructed and analyzed for the ability to bind GroEL. Our results show that complex formation between GroEL and pS is not dependent upon any single feature such as overall hydrophobicity, a net positive charge, or secondary structure but may be dependent upon a combination of these features.	LOUISIANA STATE UNIV, DEPT BIOCHEM, BATON ROUGE, LA 70803 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Louisiana State University System; Louisiana State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280				BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROGLIE R, 1983, BIO-TECHNOL, V1, P55, DOI 10.1038/nbt0383-55; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; FAWCETT TW, 1990, BIOTECHNIQUES, V9, P46; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOVEZENSKY D, 1991, J BACTERIOL, V173, P6339, DOI 10.1128/jb.173.20.6339-6346.1991; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1989, J BIOL CHEM, V264, P9090; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LIU G, 1988, J BIOL CHEM, V263, P14790; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PINGCHIANG LC, 1990, SCIENCE, V250, P669; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROSENBERG HF, 1993, J BIOL CHEM, V268, P4499; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; STREHLOW KG, 1991, BIOCHEMISTRY-US, V30, P5810, DOI 10.1021/bi00237a026; TANDON S, 1986, J BIOL CHEM, V261, P5615; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	50	23	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19766	19776						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914191				2022-12-27	WOS:A1994PA12600021
J	CZYZYKRZESKA, MF; DOMINSKI, Z; KOLE, R; MILLHORN, DE				CZYZYKRZESKA, MF; DOMINSKI, Z; KOLE, R; MILLHORN, DE			HYPOXIA STIMULATES BINDING OF A CYTOPLASMIC PROTEIN TO A PYRIMIDINE-RICH SEQUENCE IN THE 3'-UNTRANSLATED REGION OF RAT TYROSINE-HYDROXYLASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPYRIMIDINE TRACT; UNTRANSLATED REGION; SPLICE SITES; GENE; IDENTIFICATION; TRANSLATION; STABILITY; ELEMENTS	Reduced oxygen tension (hypoxia) induces a 3-fold increase in stability of mRNA for tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, in the pheochromocytoma (PC12) clonal cell line. To investigate the possibility that RNA-protein interactions are involved in mediating this increase in stability, RNA gel shift assays were performed using different fragments of labeled TH mRNA and the S-100 fraction of PC12 cytoplasmic protein extracts. We identified a sequence within the 3'-untranslated region of TH mRNA that binds cytoplasmic protein. RNase T1 mapping revealed that the protein was bound to a 28 nucleotide long sequence that is located between bases 1551-1579 of TH mRNA. Moreover, protein binding to this fragment was prevented with an antisense oligonucleotide directed against bases 1551-1579 and subsequent RNase H digestion. This fragment of the 3'-untranslated region of TH mRNA is rich in pyrimidine nucleotides, and the binding of cytoplasmic protein to this fragment was reduced by competition with other polypyrimidine sequences including poly(C) but not poly(U) polymers. The binding of the protein to TH mRNA was increased when cytoplasmic proteins were extracted from PC12 cells exposed to hypoxia (5% O2) for 24 h. Electrophoresis of the UV cross-linked RNA-protein complex on SDS-polyacrylamide gel electrophoresis revealed a complex of 74 kDa. The potential role of this protein-TH mRNA interaction in regulation of TH mRNA stability during hypoxia is discussed.	UNIV N CAROLINA,MOLEC & DEV NEUROSCI LAB,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	CZYZYKRZESKA, MF (corresponding author), UNIV N CAROLINA,DEPT PHYSIOL,474 MED RES BLDG,CHAPEL HILL,NC 27599, USA.				NHLBI NIH HHS [HL 33831, HL 51078, HL 34919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051078, R37HL033831, R01HL033831, R01HL034919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAYR SM, 1992, CURRENT PROTOCOLS MO, V2; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; CARTER BZ, 1991, LAB INVEST, V65, P610; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; FEINSILVER SH, 1987, BIOCHIM BIOPHYS ACTA, V928, P56, DOI 10.1016/0167-4889(87)90085-1; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GONZALEZ C, 1979, J NEUROCHEM, V33, P713, DOI 10.1111/j.1471-4159.1979.tb05216.x; GRIMA B, 1985, P NATL ACAD SCI USA, V74, P4835; HANBAUER I, 1977, NEUROPHARMACOLOGY, V16, P277, DOI 10.1016/0028-3908(77)90107-1; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KAUFMAN S, 1966, PHARMACOL REV, V18, P61; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P6910, DOI 10.1021/bi00396a007; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; UNDENFRIEND S, 1966, PHARMACOL REV, V18, P43; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463	30	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9940	9945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7908289				2022-12-27	WOS:A1994NE05300083
J	ADAMS, AD; CHOATE, DM; THOMPSON, MA				ADAMS, AD; CHOATE, DM; THOMPSON, MA			NF1-L IS THE DNA-BINDING COMPONENT OF THE PROTEIN COMPLEX AT THE PERIPHERIN NEGATIVE REGULATORY ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INTERMEDIATE FILAMENT PROTEIN; NEURAL-SPECIFIC GENE; C-FOS; TRANSCRIPTION FACTOR; PC12 CELLS; RETINOBLASTOMA PROTEIN; EXPRESSION; PURIFICATION; PROMOTER	The peripherin gene, which encodes a neuronal-specific intermediate filament protein, is transcriptionally induced with a late time course when nerve growth factor stimulates PC12 cells to differentiate into neurons. We have defined a negative regulatory element (NRE) that has a functional role in repressing peripherin expression in undifferentiated and nonneuronal cells. Nerve growth factor-induced derepression of peripherin gene expression is associated with alterations in proteins binding to a GC-rich DNA sequence in the NRE as detected by the DNA electrophoretic mobility shift assay (EMSA). We have utilized DNA affinity chromatography to purify from rat liver a 33-kDa DNA-binding protein that specifically recognizes the NRE. Microsequencing reveals identity with NF1-L, a member of the CTF/NF-1 transcription factor family. This protein forms a single complex when incubated with the NRE probe using EMSA analysis. The more slowly migrating complexes characteristic of crude undifferentiated PC12 cell extract are reconstituted by mixing the purified protein with the flow-through from the DNA affinity column, thereby demonstrating that protein-protein interactions are involved in complex formation. Supershift experiments incubating anti-CTF-1 antibody with undifferentiated PC12 cell extract prior to EMSA analysis confirm that NF1-L, or a closely related family member, is the DNA-binding protein component of the multiprotein complex at the NRE.	VANDERBILT UNIV, MED CTR N C2210, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NINDS NIH HHS [NS-30943] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030943] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALDWIN AS, 1987, CURRENT PROTOCOLS MO; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRODY BA, 1989, J NEUROSCI, V9, P2391; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHODOSH LA, 1991, CURRENT PROTOCOLS MO; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; LANDIS SC, 1981, TRENDS NEUROSCI, V4, P172, DOI 10.1016/0166-2236(81)90056-4; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MARKOVITZ A, 1972, BIOCHIM BIOPHYS ACTA, V281, P522, DOI 10.1016/0005-2787(72)90153-0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHOONJANS K, 1993, FEBS LETT, V329, P89, DOI 10.1016/0014-5793(93)80200-E; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SPANDAU DF, 1992, J GEN VIROL, V73, P131, DOI 10.1099/0022-1317-73-1-131; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; THOMPSON MA, 1992, MOL CELL BIOL, V12, P2501, DOI 10.1128/MCB.12.6.2501; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	55	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6975	6983		10.1074/jbc.270.12.6975	http://dx.doi.org/10.1074/jbc.270.12.6975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896848	hybrid			2022-12-27	WOS:A1995QQ85500079
J	FUKUDA, K; KATO, S; MORI, K				FUKUDA, K; KATO, S; MORI, K			LOCATION OF REGIONS OF THE OPIOID RECEPTOR INVOLVED IN SELECTIVE AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL CHARACTERIZATION; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; OPIATE RECEPTOR; HIGH-AFFINITY; CDNA CLONING; SUBSTANCE-P; DELTA; ANTAGONIST	To elucidate which portions of the opioid receptor molecules are involved in the ligand selectivity, we have expressed chimeric receptors between the rat delta- and mu-opioid receptors from cDNAs and analyzed their ligand binding properties, We demonstrate that the major binding determinant for the delta-selective enkephalin related peptide, [D-Pen(2),D-Pen(5)]enkephalin, resides within the region comprising the transmembrane segments V-VII and the intervening loop regions, On the other hand, the region spanning from the intracellular loop I to the amino terminal half of the transmembrane segment III is shown to be involved in determining high-affinity binding of the mu-selective enkephalin-related peptides, [D-Ala(2),MePhe(4),Gly-ol(5)]enkephalin and [D-Ala(2), MePhe(4),Met-ol(5)]enkephalin, whereas the major determinant nant for binding of the mu-selective alkaloids, morphine and codeine, is demonstrated to exist in the region spanning the transmembrane segments V-VII, These results indicate that distinct regions of the opioid receptor determine the selectivity for the delta- and the mu-selective enkephalin-related peptides and that the binding determinant for the mu-selective alkaloids is distinct from that for the mu-selective enkephalin-related peptides.			FUKUDA, K (corresponding author), KYOTO UNIV HOSP,DEPT ANESTHESIA,SAKYO KU,54 KAWAHARA CHO,KYOTO 60601,JAPAN.							BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BZDEGA T, 1993, P NATL ACAD SCI USA, V90, P9305, DOI 10.1073/pnas.90.20.9305; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEN Y, 1993, BIOCHEM J, V295, P625, DOI 10.1042/bj2950625; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1993, J BIOL CHEM, V268, P23055; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; MINAMI M, 1993, FEBS LETT, V329, P291, DOI 10.1016/0014-5793(93)80240-U; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NISHI M, 1993, FEBS LETT, V330, P77, DOI 10.1016/0014-5793(93)80923-I; PORTOGHESE PS, 1989, TRENDS PHARMACOL SCI, V10, P230, DOI 10.1016/0165-6147(89)90267-8; ROEMER D, 1977, NATURE, V268, P547, DOI 10.1038/268547a0; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; Schiller P. W., 1984, PEPTIDES ANAL SYNTHE, V6, P219; SIMON EJ, 1986, ANN NY ACAD SCI, V463, P31, DOI 10.1111/j.1749-6632.1986.tb21501.x; SIMONDS WF, 1988, ENDOCR REV, V9, P200, DOI 10.1210/edrv-9-2-200; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; XIE YB, 1990, J BIOL CHEM, V265, P21411; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	31	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6702	6709		10.1074/jbc.270.12.6702	http://dx.doi.org/10.1074/jbc.270.12.6702			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896813	hybrid			2022-12-27	WOS:A1995QQ85500044
J	RAO, US				RAO, US			MUTATION OF GLYCINE-185 TO VALINE ALTERS THE ATPASE FUNCTION OF THE HUMAN P-GLYCOPROTEIN EXPRESSED IN SF9 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MULTIDRUG-RESISTANCE; PHOTOACTIVE ANALOGS; BINDING; GENE; COLCHICINE; AZIDOPINE; PROTEINS; PATTERN	A single amino acid substitution, Gly(185) --> Val, in the human P-glycoprotein (Pgp) was previously shown to cause an altered pattern of drug resistance in cell lines transfected with the MDR1 cDNA carrying this mutation, To further define the function of amino acid 185 in the Pgp, the wild-type and the mutant Val(185) Pgps were expressed in Sf9 insect cells, and their biochemical properties were compared, Verapamil- and colchicine-stimulated ATPase activities were markedly increased with concomitant increase in affinity for these compounds with Gly(185) --> Val substitution in the Pgp, However, the vinblastine-stimulated ATPase activities of the wild type and Val(185) Pgps were nearly identical. Because transport substrate-induced ATP hydrolysis is generally thought to reflect transport function, these data suggest that colchicine and verapamil are transported at an increased rate with Gly(185) --> Val substitution in the Pgp. These results also indicate that amino acid 185 is involved in verapamil and colchicine, but not in vinblastine, binding/transport. Kinetic analyses indi cate that cyclosporin A, an inhibitor of Pgp, binds to the verapamil and vinblastine binding/transport site(s) in the Pgp, Taken together, the results presented herein reveal that the verapamil and vinblastine binding/transport site(s) are in close proximity and that the cyclosporin A binding site spans the common region of these two drug binding/transport site(s) in the Pgp molecule.			RAO, US (corresponding author), UNIV N CAROLINA,DEPT PHARMACOL,CB 7020,BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA058491] Funding Source: NIH RePORTER; NCI NIH HHS [CA58491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOMOLYA L, 1993, J BIOL CHEM, V268, P21498; KAJIJI S, 1994, BIOCHEMISTRY-US, V33, P5041, DOI 10.1021/bi00183a006; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOWRY OH, 1961, J BIOL CHEM, V193, P265; MAHANTY SK, 1994, J BIOL CHEM, V269, P17705; MARTIN DW, 1984, P NATL ACAD SCI-BIOL, V81, P6623, DOI 10.1073/pnas.81.21.6623; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; RAO US, 1994, MOL PHARMACOL, V45, P773; RAO US, 1994, BIOCHEM PHARMACOL, V48, P287, DOI 10.1016/0006-2952(94)90099-X; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4864; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SUMMERS MD, 1988, B TEXAS AGR EXPT STA, V1555	34	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6686	6690						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896810				2022-12-27	WOS:A1995QQ85500041
J	REMPEL, RE; SLEIGHT, SB; MALLER, JL				REMPEL, RE; SLEIGHT, SB; MALLER, JL			MATERNAL XENOPUS CDK2-CYCLIN-E COMPLEXES FUNCTION DURING MEIOTIC AND EARLY EMBRYONIC-CELL CYCLES THAT LACK A G(1) PHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-TYPE CYCLINS; MATURATION-PROMOTING FACTOR; PROTEIN-KINASE COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; S-PHASE; A-TYPE; RETINOBLASTOMA PROTEIN; MAMMALIAN FIBROBLASTS; CDC2-RELATED KINASE	Earlier work demonstrated that cyclins A1, B1, and B2 are not associated with Cdk2 from unfertilized Xenopus eggs. As a potential Cdk2 partner during meiosis, a cyclin E homolog was cloned from a Xenopus oocyte cDNA library and found to be 60% identical at the amino acid level to human cyclin E. Cyclin E1 protein was detected in resting oocytes, and the level increased severalfold in meiosis II, concomitant with the appearance of forms with decreased electrophoretic mobility. During oocyte maturation, the patterns of cyclin E1-associated kinase activity and Cdk2 activity were identical, with activity low until after germinal vesicle breakdown, peaking during meiosis II. Cyclin E1 complexes immunoprecipitated from unfertilized Xenopus eggs contained Cdk2 but not Cdc2. In cycling egg extracts Cdk2-cyclin E1-associated kinase activity oscillated, but the level of cyclin E1 protein and its association with Cdk2 did not vary appreciably; complex activity appeared to be regulated neither by the synthesis and destruction of the cyclin subunit nor by association/disassociation of the two subunits. During the early cleavage divisions in embryos, cyclin E1 and Cdk2 remained associated. The data indicate that the Cdk2-cyclin E complex functions during meiotic and embryonic cell cycles in addition to performing its established role during G(1) in somatic cells.	UNIV COLORADO, SCH MED, HOWARD HUGHES MED INST, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BENBOW RM, 1975, P NATL ACAD SCI USA, V72, P2437, DOI 10.1073/pnas.72.6.2437; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FREDERICK DL, 1994, J EXP ZOOL, V270, P410, DOI 10.1002/jez.1402700411; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GURDON JB, 1967, P NATL ACAD SCI USA, V58, P545, DOI 10.1073/pnas.58.2.545; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Honigberg SM, 1993, CURR OPIN CELL BIOL, V5, P219, DOI 10.1016/0955-0674(93)90106-Z; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEHNER CF, 1991, COLD SH Q B, V56, P465; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILARSKI KL, 1991, COLD SH Q B, V56, P377; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEVINS JR, 1992, SCIENCE, V258, P424; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PHILPOTT A, 1994, MOL CELL BIOL, V14, P5000, DOI 10.1128/MCB.14.7.5000; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SCLAFANI RA, 1988, MOL CELL BIOL, V8, P293, DOI 10.1128/MCB.8.1.293; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	89	136	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6843	6855		10.1074/jbc.270.12.6843	http://dx.doi.org/10.1074/jbc.270.12.6843			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896832				2022-12-27	WOS:A1995QQ85500063
J	ZIMMERMANN, AG; SPYCHALA, J; MITCHELL, BS				ZIMMERMANN, AG; SPYCHALA, J; MITCHELL, BS			CHARACTERIZATION OF THE HUMAN INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE TYPE-II GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; INOSINE 5'-PHOSPHATE DEHYDROGENASE; RNA POLYMERASE-II; IMP DEHYDROGENASE; TRANSCRIPTION FACTOR; LEUKEMIA-CELLS; DEOXYCYTIDINE KINASE; MYCOPHENOLIC-ACID; CHROMOSOMAL LOCALIZATION; DEPENDENT REGULATION	Inosine-5'-monophosphate dehydrogenase (IMPDH) activity and mRNA levels are induced up to 15-fold upon mitogenic or antigenic stimulation of human peripheral blood T lymphocytes. This increase in IMPDH activity is required for cellular proliferation and has been associated with malignant transformation. We have cloned the human IMPDH type II gene and show that it contains 14 exons and is approximately 5.8 kilobases in length. Exons vary in size from 49 to 207 base pairs and introns from 73 to 1065 base pairs. The transcription start site was mapped to a position 50 nucleotides upstream of the translation initiation site. The 5'-flanking region consisting of 463 base pairs upstream of the translation initiation site confers induced transcription and differential regulation upon a chloramphenicol acetyltransferase reporter gene when transfected into Jurkat T cells and human peripheral blood T lymphocytes, respectively. DNase I footprinting analysis using Jurkat T cell nuclear extract identified four protected regions in the promoter which coincide with consensus transcription factor binding sites for the nuclear factors AP2, ATF, CREB, Egr-1, Nm23, and Sp1. These findings suggest that several of these nuclear factors may play a critical role in the regulation of IMPDH type II gene expression during T lymphocyte activation.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA034085, R01CA064192] Funding Source: NIH RePORTER; NCI NIH HHS [CA34085, CA64192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARR SF, 1993, J BIOL CHEM, V268, P27286; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; DAYTON JS, 1994, J IMMUNOL, V152, P984; DAYTON JS, 1992, MOL PHARMACOL, V41, P671; DAYTON JS, 1994, RECENT DEV TRANSPLAN, P129; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GLESNE D, 1993, GENOMICS, V16, P274, DOI 10.1006/geno.1993.1177; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; GU JJ, 1994, GENOMICS, V24, P179, DOI 10.1006/geno.1994.1597; HAGER PW, 1995, IN PRESS BIOCH PHARM; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIGUCHI K, 1990, EXP CELL RES, V187, P47, DOI 10.1016/0014-4827(90)90114-P; KIGUCHI K, 1990, CELL GROWTH DIFFER, V1, P259; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL BS, 1993, ADV ENZYME REGUL, V33, P61; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; NELSON PH, 1990, J MED CHEM, V33, P833, DOI 10.1021/jm00164a057; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OLAH E, 1988, P NATL ACAD SCI USA, V85, P6533, DOI 10.1073/pnas.85.17.6533; PARK JH, 1993, J BIOL CHEM, V268, P6299; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SOKOLOSKI JA, 1986, CANCER RES, V46, P2314; SONG JJ, 1993, P NATL ACAD SCI USA, V90, P431, DOI 10.1073/pnas.90.2.431; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SZEKERES T, 1992, LIFE SCI, V51, P1309, DOI 10.1016/0024-3205(92)90021-G; TRICOT GJ, 1989, CANCER RES, V49, P3696; YOUNG CJ, 1994, RECENT DEV TRANSPLAN, P93	55	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6808	6814		10.1074/jbc.270.12.6808	http://dx.doi.org/10.1074/jbc.270.12.6808			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896827	hybrid, Green Published			2022-12-27	WOS:A1995QQ85500058
J	HADAD, N; ZABLE, AC; ABRAMSON, JJ; SHOSHANBARMATZ, V				HADAD, N; ZABLE, AC; ABRAMSON, JJ; SHOSHANBARMATZ, V			CA2+ BINDING-SITES OF THE RYANODINE RECEPTOR CA2+ RELEASE CHANNEL OF SARCOPLASMIC-RETICULUM - LOW-AFFINITY BINDING SITE(S) AS PROBED BY TERBIUM FLUORESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CA-2+ RELEASE; ADENOSINE-TRIPHOSPHATASE; LANTHANIDE IONS; CALCIUM; PURIFICATION; VESICLES	Fluorescence spectroscopy has been used to study the interaction of Tb3+ (as a Ca2+ analog) with the purified ryanodine receptor (RyR)/Ca2+ release channel of skeletal muscle sarcoplasmic reticulum. Tb3+ replaces Ca2+ in both the high- and the low-affinity sites. Occupation of the low-affinity site (inhibitory), but not of the high-affinity Ca2+ binding site (activating), by Tb3+ results in a strong enhanced green fluorescence (at 543 nm) and in an inhibition of ryanodine binding. The Tb3+ concentrations required for half-maximal enhanced fluorescence and inhibition of ryanodine binding were: 22.5 +/- 2.5 mu M (n = 4) and 22.3 +/- 3.1 mu M (n = 2), respectively. Tb3+ appears to bind to the protein at two or more cooperative sites (n(H) = 2.4) and to dissociate from these sites with three different rate constants (K--1,K-1 = 361 +/- 250 min(-1) (n = 6); K--1,K-2 = 0.45 +/- 0.22 min(-1) (n = 11); K--1,K-3 = 0.011 +/- 0.013 min(-1) (n = 7). The enhancement in Tb3+ fluorescence is very fast (K-1 >> 5 x 10(5) M(-1).min(-1)), and it is quenched by EGTA, La3+, or Ca2+ addition. About 20% of the bound Tb3+ was not displaced by EGTA or Ca2+; suggesting its ''occlusion'' in the RyR. This is also reflected in the partially irreversible inhibition of ryanodine binding by Tb3+. Reconstitution of sarcoplasmic reticulum vesicles into a planar bilayer lipid membrane showed that the Ca2+ release channel was activated by submicromolar and inhibited by micromolar concentrations of Tb3+ and La3+. The Tb3+-activated channel showed an enhancement of the open dwell time of the channel. The results suggest that RyR/Ca2+ release channel undergoes conformational changes due to Tb3+ binding to the low-affinity Ca2+ binding site, and this binding results in the closing of the Ca2+ release channel.	BEN GURION UNIV NEGEV, DEPT LIFE SCI, IL-84105 BEER SHEVA, ISRAEL; PORTLAND STATE UNIV, DEPT PHYS, PORTLAND, OR 97202 USA	Ben Gurion University; Portland State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM044337] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R15GM44337-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAPUS C, 1990, J BIOL CHEM, V265, P3726; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; EPSTEIN M, 1977, BIOCHEMISTRY-US, V16, P2449, DOI 10.1021/bi00630a021; Evans C.H, 2013, BIOCH LANTHANIDES, V8; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FURIE BC, 1976, J BIOL CHEM, V251, P3235; FURIE BC, 1975, J BIOL CHEM, V250, P601; GOMEZ JE, 1974, BIOCHEMISTRY-US, V13, P3745, DOI 10.1021/bi00715a020; HIGHSMITH SR, 1983, J BIOL CHEM, V258, P6858; HUTTON WC, 1977, CHEM PHYS LIPIDS, V19, P255, DOI 10.1016/0009-3084(77)90047-0; INUI M, 1987, J BIOL CHEM, V262, P15637; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P95; KILHOFFER MC, 1980, FEBS LETT, V116, P269, DOI 10.1016/0014-5793(80)80660-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SHOSHANBARMATZ V, 1992, BIOCHEM J, V285, P61, DOI 10.1042/bj2850061; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SOLER F, 1992, INT J BIOCHEM, V24, P903, DOI 10.1016/0020-711X(92)90095-I; SONOLKA GE, 1971, BIOCHEMISTRY-US, V10, P4556; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THOMAS DD, 1981, MOL BIOL, V154, P145; YAMAMOTO N, 1982, J BIOCHEM-TOKYO, V92, P485, DOI 10.1093/oxfordjournals.jbchem.a133956; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24864	24869						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929166				2022-12-27	WOS:A1994PQ49000053
J	SHIMAN, R; GRAY, DW; HILL, MA				SHIMAN, R; GRAY, DW; HILL, MA			REGULATION OF RAT-LIVER PHENYLALANINE-HYDROXYLASE .1. KINETIC-PROPERTIES OF THE ENZYMES IRON AND ENZYME REDUCTION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; MECHANISM; 4-MONOOXYGENASE; ACTIVATION; PHOSPHORYLATION; HYDROPEROXIDES; STATE	Tetrahydropterins react with phenylalanine hydroxylase at a redox site, a regulatory site, and the catalytic site, but neither the properties of nor relationships among these sites are well understood. We have studied the redox site using the fluorescent iron chelators 2,3-dihydroxynaphthalene and bathophenanthroline; these compounds act as site-specific reporter groups for reactions on oxidized and reduced enzyme, respectively. The chelators bind reversibly and specifically to the enzyme's iron with 1:1 stoichiometry, high affinity (K-d values similar to 1 nM), and complete quenching of their own fluorescence. The kinetic behavior of these and other iron chelators indicates that the enzyme's iron is solvent ac cessible and in a hydrophobic pocket of the protein. Both ferrous and ferric chelators inhibit phenylalanine hydroxylase activity. Bathophenanthroline inhibits by binding to Fe2+ on reduced, active enzyme. 2,3-Dihydroxynaphthalene inhibits by binding to Fe3+ on enzyme that is oxidized during catalysis. This oxidation occurs similar to 1/150 enzyme turnovers, and its rate is increased when p-chloro- or p-fluorophenylalanine is used as the reaction substrate. Studies of the reaction of tetrahydrobiopterin (BH4) at the enzyme's redox site showed that BH4 reduces the enzyme more slowly than 6-methyltetrahydropterin under catalytic and non-catalytic conditions. Reduction occurs at a distinct site whose binding determinants and reaction characteristics are different from those of the BH4 regulatory or catalytic sites, and phenylalanine activated enzyme is reduced more rapidly than unactivated enzyme. In reducing phenylalanine activated enzyme, BH4 donates one electron/subunit (1/iron atom); the reduction kinetics suggest a trihydrobiopterin-free radical as a reaction intermediate.			SHIMAN, R (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOCHEM & MOLEC BIOL, HERSHEY, PA 17033 USA.							BAILEY SW, 1978, J BIOL CHEM, V253, P1598; BLOOM LM, 1986, BIOCHEMISTRY-US, V25, P4204, DOI 10.1021/bi00363a006; Cotton F. A., 1988, ADV INORGANIC CHEM; COX DD, 1988, J AM CHEM SOC, V110, P2026, DOI 10.1021/ja00215a002; DEGRAW JI, 1967, J MED CHEM, V10, P64, DOI 10.1021/jm00313a013; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5839, DOI 10.1021/bi00342a022; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; FISHER DB, 1972, J BIOL CHEM, V247, P5161; FUNK MO, 1976, LIPIDS, V11, P113, DOI 10.1007/BF02532660; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; HILL MA, 1988, J BIOL CHEM, V263, P5646; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P562; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; KAUFMAN S, 1961, BIOCHIM BIOPHYS ACTA, V51, P619, DOI 10.1016/0006-3002(61)90632-1; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; MARTINEZ A, 1991, EUR J BIOCHEM, V198, P675, DOI 10.1111/j.1432-1033.1991.tb16066.x; MARTINEZ A, 1990, EUR J BIOCHEM, V193, P211, DOI 10.1111/j.1432-1033.1990.tb19325.x; MILLER MR, 1976, J BIOL CHEM, V251, P3671; MILLER MR, 1975, J BIOL CHEM, V250, P1132; MOAD G, 1979, J AM CHEM SOC, V101, P6068, DOI 10.1021/ja00514a033; PHILLIPS RS, 1984, J BIOL CHEM, V259, P2474; Press W., 1986, NUMERICAL RECIPES; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1994, J BIOL CHEM, V269, P24647; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1971, J BIOL CHEM, V246, P1330; SHIMAN R, 1982, J BIOL CHEM, V257, P839; SHIMAN R, 1985, CHEM BIOCH PTERINS, V2, P179; STORM CB, 1971, J ORG CHEM, V36, P3925; STORM CB, 1968, BIOCHEM BIOPH RES CO, V32, P788, DOI 10.1016/0006-291X(68)90309-4; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; XIA T, 1994, J BIOL CHEM, V269, P24657	37	41	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24637	24646						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929135				2022-12-27	WOS:A1994PQ49000022
J	CHARNG, YY; IGLESIAS, AA; PREISS, J				CHARNG, YY; IGLESIAS, AA; PREISS, J			STRUCTURE-FUNCTION-RELATIONSHIPS OF CYANOBACTERIAL ADP-GLUCOSE PYROPHOSPHORYLASE - SITE-DIRECTED MUTAGENESIS AND CHEMICAL MODIFICATION OF THE ACTIVATOR-BINDING SITES OF ADP-GLUCOSE PYROPHOSPHORYLASE FROM ANABAENA PCC-7120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; BACTERIAL GLYCOGEN; REGULATORY PROPERTIES; NUCLEOTIDE-SEQUENCE; GLGC GENE; MUTANT; BIOSYNTHESIS; EXPRESSION; CLONING; ACID	Chemical modification studies of spinach leaf ADP-glucose pyrophosphorylase with pyridoxal-P have shown that a highly conserved lysyl residue near the C terminus might be involved in the binding of 3-P-glycerate, the allosteric activator. Site directed mutagenesis of the corresponding residue (Lys(419)) of the Anabaena enzyme was performed to determine the role of this conserved residue. Replacing Lys(419) with either arginine, alanine, glutamine, or glutamic acid produced mutant enzymes with apparent affinities for 3-P-glycerate, 25-150-fold lower than that of the wild-type enzyme. The mutant enzymes, however, were still activated to a great extent at higher concentrations of activator suggesting that an additional site or residue was involved in the binding of the activator. These mutations caused lesser or no effect on the kinetic constants for the substrates and inhibitor, P-i, as well as on the catalytic efficiency and thermal stability. The results suggest that both the charge and size of lysine residue 419 are required for the proper binding of 3-P-glycerate. Chemical modification of the Anabaena wild-type enzyme with pyridoxal-P indicated that Lys(419) was the only lysyl residue modified. We further performed the same experiment on the K419R mutant enzyme and found another lysyl residue, Lys(382), was modified. Reductive phosphopyridoxylation of the wild-type and K419R enzymes caused dramatic alteration in allosteric properties. The activator, 3-P-glycerate, and inhibitor, P-i, protected the enzyme from reductive phosphopyridoxylation, The modified enzymes were more active in the absence of 3-P-glycerate and less sensitive to P-i inhibition.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University			Charng, Yee-yung/F-3296-2015	Charng, Yee-yung/0000-0002-9107-3955; Iglesias, Alberto/0000-0001-9729-7338	NIAID NIH HHS [AI 022385] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHRENS H, 1969, ANAL BIOCHEM, V30, P413, DOI 10.1016/0003-2697(69)90135-3; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; CANELLAS PF, 1980, ARCH BIOCHEM BIOPHYS, V199, P259, DOI 10.1016/0003-9861(80)90279-9; CARLSON CA, 1976, J BIOL CHEM, V251, P7886; CHARNG YY, 1992, PLANT MOL BIOL, V20, P37, DOI 10.1007/BF00029147; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; GHOSH P, 1992, ARCH BIOCHEM BIOPHYS, V296, P122, DOI 10.1016/0003-9861(92)90553-9; GOVONS S, 1973, J BIOL CHEM, V248, P1731; IGLESIAS AA, 1993, AN ASOC QUIM ARGENT, V81, P213; IGLESIAS AA, 1991, PLANT PHYSIOL, V97, P1187, DOI 10.1104/pp.97.3.1187; KUMAR A, 1989, J BIOL CHEM, V264, P10464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVI C, 1976, PLANT PHYSIOL, V58, P753, DOI 10.1104/pp.58.6.753; MEYER CR, 1992, J BACTERIOL, V174, P4509, DOI 10.1128/JB.174.13.4509-4512.1992; MORELL M, 1988, J BIOL CHEM, V263, P633; NAKAMURA Y, 1985, PLANT PHYSIOL, V78, P601, DOI 10.1104/pp.78.3.601; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PREISS J, 1966, BIOCHEMISTRY-US, V5, P1833, DOI 10.1021/bi00870a008; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; PREISS J, 1992, PHOTOSYNTH RES, V3, P697; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANWAL GG, 1967, ARCH BIOCHEM BIOPHYS, V119, P454, DOI 10.1016/0003-9861(67)90477-8; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; STEBBINS JW, 1992, BIOCHEMISTRY-US, V31, P2328, DOI 10.1021/bi00123a017; STOCK A, 1966, BIOCHEM Z, V344, P353; [No title captured]	30	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24107	24113						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929064				2022-12-27	WOS:A1994PQ34600042
J	HACKER, KJ; ALBERTS, BM				HACKER, KJ; ALBERTS, BM			THE SLOW DISSOCIATION OF THE T4 DNA-POLYMERASE HOLOENZYME WHEN STALLED BY NUCLEOTIDE OMISSION - AN INDICATION OF A HIGHLY PROCESSIVE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN COMPLEX; PRIMER-TEMPLATE JUNCTION; CELL NUCLEAR ANTIGEN; III HOLOENZYME; ESCHERICHIA-COLI; REPLICATION COMPLEX; ATP HYDROLYSIS; BACTERIOPHAGE-T4 PROTEINS; INVITRO REPLICATION; T4-DNA POLYMERASE	We have developed an experimental assay to monitor the rate of dissociation of the T4 DNA polymerase holoenzyme (polymerase plus gene 44/62 and 45 proteins) once it has been stalled by nucleotide omission. Using this assay, we determined that the dissociation of the DNA polymerase holoenzyme follows a first order decay with a half-life of 2.5 min. The long half-life resembles that expected for the holoenzyme processively synthesizing DNA on the leading strand of the replication fork. The holoenzyme dissociation rate is independent of polymerase accessory protein concentration and of ATP hydrolysis. The dissociation rate is increased if the gene 32 protein is omitted or if the primer-template region is shortened from 46 to 28 base pairs. But the rate of holoenzyme dissociation is most strikingly increased when the circular DNA template is converted to a linear form. By analogy with other well studied systems, these results support a model in which ATP hydrolysis by the 44/62 proteins serves to load a ring-like 45 protein onto the DNA. Once loaded, the 45 protein, possibly along with the 44/62 complex, acts as a sliding clamp that tethers the DNA polymerase to the template.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [T32CA009270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09270] Funding Source: Medline; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BITTNER M, 1979, J BIOL CHEM, V254, P9565; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1988, EUKARYOTIC DNA REPLI, P1; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HACKER KJ, 1994, THESIS U CALIF, V269, P24221; HERPICH B, 1992, HRC-J HIGH RES CHROM, V15, P41; HIBNER U, 1980, NATURE, V285, P300, DOI 10.1038/285300a0; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1909, DNA REPLICATION; LABAER J, 1989, COMMENTS, V15, P19; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MCCARTHY D, 1976, J MOL BIOL, V106, P963, DOI 10.1016/0022-2836(76)90346-6; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; NEWPORT JW, 1980, THESIS U OREGON EUGE; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; RUSH J, 1989, J BIOL CHEM, V264, P10943; Sambrook J, 1989, MOL CLONING LABORATO; SELICK HE, 1987, DNA REPLICATION RECO, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; VENKATESAN M, 1982, J BIOL CHEM, V257, P1243; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	57	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24209	24220						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929077				2022-12-27	WOS:A1994PQ34600058
J	RAJAGOPALAN, LE; MALTER, JS				RAJAGOPALAN, LE; MALTER, JS			MODULATION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR MESSENGER-RNA STABILITY IN-VITRO BY THE ADENOSINE-URIDINE BINDING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; CELL-FREE SYSTEM; 3'-UNTRANSLATED REGION; RICH SEQUENCES; PROTEIN; DEGRADATION; IDENTIFICATION; LYMPHOKINE; INVITRO	In vitro decay of granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA was examined on polysomes prepared from normal human peripheral blood mononuclear cells stimulated with phorbol ester (TPA) and phytohemagglutinin for 14 h. GM-CSF mRNA decayed with a half-life of 90 min while 18 S rRNA was stable. RNA gel mobility assay performed on crude cytosolic lysate (S20) with radiolabeled AUUUA containing RNA identified a 42-kDa RNA-protein complex on SDS-polyacrylamide gel electrophoresis. The binding specificity was identical to that of the previously described adenosine-uridine binding factor (AUBF) (Malter, J. S. (1989) Science 246, 664-666). Further fractionation of the S20 cytosol through a sucrose gradient showed >90% of AUBF activity associated with polysomes and <10% with the S130 fraction. Solution phase RNAs containing AUUUA reiterations specifically competed for polysome-bound AUBF and accelerated the decay of GM-CSF mRNA (t(1/2) = 17 min). We linked biotinylated AUUUA RNA to streptavidin magnetic beads and removed >95% of polysome-associated AUBF. A decay system thus depleted of AUBF activity also showed accelerated decay of GM-CSF mRNA (t(1/2) = 20 min). These data show that AUBF is preferentially located on polysomes and that its removal destabilizes GM-CSF mRNA. Therefore, AUBF likely prevents GM-CSF mRNA decay by binding to the AUUUA instability determinants in the 3'-untranslated region.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53792; UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK45213] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045213] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ALTUS MS, 1991, J BIOL CHEM, V266, P21190; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BICKEL M, 1990, J IMMUNOL, V145, P840; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BICKEL M, 1987, J IMMUNOL, V139, P2984; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HEPLER JE, 1990, ENDOCRINOLOGY, V127, P1550, DOI 10.1210/endo-127-3-1550; IWAI Y, 1991, J BIOL CHEM, V266, P17959; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; ROSS HJ, 1991, BLOOD, V77, P1787; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	32	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23882	23888						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929035				2022-12-27	WOS:A1994PQ34600009
J	BARBIERI, MA; LI, GP; COLOMBO, MI; STAHL, PD				BARBIERI, MA; LI, GP; COLOMBO, MI; STAHL, PD			RAB5, AN EARLY ACTING ENDOSOMAL GTPASE, SUPPORTS IN-VITRO ENDOSOME FUSION WITHOUT GTP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR-MEDIATED ENDOCYTOSIS; CELL-FREE SYSTEM; BINDING-PROTEINS; GOLGI MEMBRANES; VESICLE FUSION; TRANSPORT; PATHWAY; RECONSTITUTION; REQUIRES	Endocytosis is regulated by several GTPases including Rab5 and one or more heterotrimeric G proteins. We show here that RabS, in the GTP gamma S (guanosine 5'-O-(thiotriphosphate))-bound form, fully supports in vitro endosome fusion, indicating that GTP hydrolysis is not required, whereas Rab5:S34N and Rab5:N133I, mutants unable to bind GTP, are potent inhibitors of endosome fusion. Double mutants (Rab5:S34N/Delta C4 and Rab5: N133I/Delta C4) lacking the C-terminal prenylation site were inactive, indicating that prenylation is required. Endosomes became resistant to the inhibitory effects of Rab5:S34N by preincubating the vesicles with cytosol prior to the addition of the inhibitor. The acquisition of resistance to Rab5:S34N was more rapid than to N-ethylmaleimide, indicating that Rab5 mutants are early acting. G(beta gamma) subunits of heterotrimeric G proteins block endosome fusion. However the effect of G(beta gamma) Was abrogated by Rab5.GTP gamma S, indicating that a heterotrimeric G protein may operate upstream of Rab5.	ST LOUIS UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Saint Louis University			Stahl, Philip/D-6315-2012; Li, Guangpu/GRS-5397-2022					BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COLOMBO MI, 1994, MOL MEMBR BIOL, V11, P93, DOI 10.3109/09687689409162226; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LENHARD J, IN PRESS ARCH BIOCH; LENHARD J, 1992, J BIOL CHEM, V267; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; MAYORGA LS, 1989, METHOD CELL BIOL, V31, P179; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x	33	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18720	18722						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913465				2022-12-27	WOS:A1994NX32700005
J	MENDEZ, R; DEHARO, C				MENDEZ, R; DEHARO, C			CASEIN KINASE-II IS IMPLICATED IN THE REGULATION OF HEME-CONTROLLED TRANSLATIONAL INHIBITOR OF RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; INITIATION-FACTOR EIF-2; EIF-2-ALPHA KINASE; ALPHA-SUBUNIT; CALCIUM-IONS; BINDING-SITE; RNA; PHOSPHORYLATION; ACTIVATION; CLONING	The hemin-controlled inhibitor, or HCI, is a cyclic nucleotide-independent protein kinase which specifically phosphorylates the cu subunit of eukaryotic initiation factor 2 (eIF-2) leading to potential Limitations in functional eIF-2 and decreases in protein synthesis initiation. We have recently demonstrated that hemin regulates eIF-2 alpha kinase activity by promoting formation of the inactive heterodimer between HCI and the 90-kDa heat shock protein (hsp90). The formation of the inactive form of HCI by hemin is prevented by treatment with sulfhydryl reagents such as N-ethylmaleimide or when hsp90 is previously phosphorylated (Mendez, R., Moreno, A., and de Haro, C. (1992) J. Biol. Chem. 267, 11500-11501). In this report, using isoelectric focusing and Western blot analyses with antibodies against a synthetic HCI peptide, we have demonstrated that HCT was also phosphorylated when a heme-reversible HCI preparation was preincubated with ATP. Furthermore, our results indicate that casein kinase II (CH II) is the enzyme involved in the regulation of HCI. Thus, the synthetic peptide RRREEETEEE, which is a specific substrate for CK II, acts as a competitive inhibitor of HCI and hsp90 phosphorylation and, at the same time, inhibits the activation of HCI, whereas a synthetic peptide which corresponds to residues 45-59 of the a subunit of eIF-2, including the Ser(51) phosphorylated by HCI, only inhibits competitively the phosphorylation of eIF-2 alpha. In addition, treatments which modify hsp90 disabling the formation of the inactive dimer with HCI make unnecessary the presence of CK II for activation of HCI. The data strongly suggest that hemin promotes formation of an inactive HCI-hsp90 dimer preventing phosphorylation by CK II. Interestingly, the addition of the CK II peptide substrate also prevents the activation of HCI in a heme-deficient reticulocyte lysate. We hypothesize, therefore, that under physiological conditions, CK II activity appears to be necessary for activation of HCI.	UNIV AUTONOMA MADRID,CONSEJO SUPER INVEST CIENT,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)				Mendez, Raul/0000-0002-1952-6905				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; DEHARO C, 1983, P NATL ACAD SCI-BIOL, V80, P6843; DEHERREROS AG, 1985, P NATL ACAD SCI USA, V82, P3119, DOI 10.1073/pnas.82.10.3119; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ERNST H, 1987, J BIOL CHEM, V262, P1206; GAITERO F, 1989, FEBS LETT, V257, P297, DOI 10.1016/0014-5793(89)81556-X; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOSOWER NS, 1972, BIOCHIM BIOPHYS ACTA, V272, P623, DOI 10.1016/0005-2787(72)90518-7; KUDLICKI W, 1985, P NATL ACAD SCI USA, V82, P5332, DOI 10.1073/pnas.82.16.5332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEESMILLER SP, 1989, J BIOL CHEM, V264; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LONDON IM, 1987, ENZYMES, V18, P359; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MATTS RL, 1992, J BIOL CHEM, V267; MENDEZ R, 1992, J BIOL CHEM, V267; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PALOMO C, 1985, ARCH BIOCHEM BIOPHYS, V239, P497, DOI 10.1016/0003-9861(85)90718-0; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PELAEZ F, 1989, FEBS LETT, V250, P523, DOI 10.1016/0014-5793(89)80789-6; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG JM, 1992, J BIOL CHEM, V267, P20519	42	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6170	6176						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907089				2022-12-27	WOS:A1994MY84000103
J	HARADA, R; DUFORT, D; DENISLAROSE, C; NEPVEU, A				HARADA, R; DUFORT, D; DENISLAROSE, C; NEPVEU, A			CONSERVED CUT REPEATS IN THE HUMAN CUT HOMEODOMAIN PROTEIN FUNCTION AS DNA-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL TYPE SPECIFICATION; SENSORY ORGAN IDENTITY; POU-DOMAIN; PAIRED BOX; DROSOPHILA; EXPRESSION; TRANSCRIPTION; MUTATION; LOCUS; GENE	Homeodomain-containing proteins are believed to function as sequence-specific DNA binding proteins, regulating gene expression. Specificity of sequence recognition is conferred by the homeodomain acting either alone or in conjunction with other conserved.DNA binding domains as is the case for Pou domain and Paired domain proteins. The recent isolation of cDNAs encoding mammalian homologues of the Drosophila Cut homeodomain protein has revealed that the 72-amino acid Cut Repeats are conserved in evolution. We have investigated the biochemical activity of human Cut Repeats by expressing fusion proteins containing glutathione S-transferase linked to various combinations of Cut Repeats and Cut homeodomain. We show by gel retardation and DNase footprinting assays that Cut Repeats can function as DNA binding domains, either independently or in cooperation with the homeodomain. The binding affinity (K(D)) to a specific recognition site was estimated to be 8 x 10(-9) m for Cut Repeat 3 and 4 x 10(-10) m for Cut Repeat 1. When both Cut Repeat 3 and the Cut homeodomain were present in the fusion protein, the binding affinity was increased to 4 x 10(-11) m. These results define a novel class of proteins that contain in addition to the homeodomain a second conserved protein domain, the Cut Repeats, that also function as a DNA binding domain.	MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MOLEC ONCOL GRP,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MOLEC ONCOL GRP,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital			/AAB-8315-2020	Dufort, Daniel/0000-0002-6477-596X				ANDRES V, 1992, DEVELOPMENT, V116, P324; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CLEAT PH, 1989, FEBS LETT, V258, P51, DOI 10.1016/0014-5793(89)81613-8; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JACK J, 1991, DEVELOPMENT, V113, P735; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; MCGUINNIS, 1992, CELL, V68, P283; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x	38	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2062	2067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7904999				2022-12-27	WOS:A1994MR98800078
J	BRUSCHI, SA; WEST, KA; CRABB, JW; GUPTA, RS; STEVENS, JL				BRUSCHI, SA; WEST, KA; CRABB, JW; GUPTA, RS; STEVENS, JL			MITOCHONDRIAL HSP60 (P1 PROTEIN) AND A HSP70-LIKE PROTEIN (MORTALIN) ARE MAJOR TARGETS FOR MODIFICATION DURING S-(1,1,2,2-TETRAFLUOROETHYL)-L-CYSTEINE-INDUCED NEPHROTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; GLUTAMINE TRANSAMINASE-K; RAT-KIDNEY; YEAST MITOCHONDRIA; ESCHERICHIA-COLI; ADDUCT FORMATION; CHAPERONIN; TOXICITY; BINDING; HALOTHANE	The potent and site-selective nephrotoxicity of S-(1,1,2,2-tetrafluoroethyl)-L-cysteine (TFEC) in vivo has been associated with difluorothioamidyl-L-lysine formation on critical mitochondrial target proteins. Dose-response studies in the Fischer 344 rat indicate that five proteins with apparent molecular masses of 99, 84, 66, 52, and 48 kDa are predominantly adducted in vivo after nephrotoxic doses of TFEC (>10 mg/kg, intraperitoneally). Microsequence analysis of the major difluorothioamidyl-L-lysine proteins indicated that P66 is identical, over 14 NH2-terminal residues, to mitochondrial P1 protein (HSP60, a chaperonin) and that P84 is identical, over 14 residues, to a recently isolated novel member of the HSP70 family known as mortalin. These studies indicate that mitochondrial heat shock proteins are major targets for modification by reactive metabolites of TFEC. The implications of these data in relation to the nephrotoxicity of cysteine conjugates are discussed.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University					NIDDK NIH HHS [DK38925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANDERSON NL, 1992, FUND APPL TOXICOL, V18, P570, DOI 10.1016/0272-0590(92)90116-Y; BOOGAARD PJ, 1989, BIOCHEM PHARMACOL, V38, P3731, DOI 10.1016/0006-2952(89)90579-0; BUTLER LE, 1992, CHEM RES TOXICOL, V5, P406, DOI 10.1021/tx00027a014; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COOPER AJL, 1985, METHOD ENZYMOL, V113, P344; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; DARNERUD PO, 1988, TOXICOL APPL PHARM, V95, P423, DOI 10.1016/0041-008X(88)90360-2; DAVILA JC, 1992, TOXICOLOGIST, V12, P255; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY RE, 1990, FEBS LETT, V267, P265; GUPTA RS, 1987, EUR J CELL BIOL, V45, P170; HARGUS SJ, 1991, BIOCHEM PHARMACOL, V42, pR17, DOI 10.1016/0006-2952(91)90580-X; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HARRIS JW, 1992, CHEM RES TOXICOL, V5, P34, DOI 10.1021/tx00025a007; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NELSON SD, 1990, ANNU REV PHARMACOL, V30, P169; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PASSARELLA S, 1990, BIOCHIM BIOPHYS ACTA, V1022, P273, DOI 10.1016/0005-2736(90)90274-R; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHERMAN MY, 1992, EMBO J, V11, P71; SINGH B, 1992, DNA CELL BIOL, V11, P489, DOI 10.1089/dna.1992.11.489; SPEICHER DW, 1989, TECHNIQUES PROTEIN C, V1, P24; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STEVENS JL, 1988, J BIOL CHEM, V263, P3395; THOMPSON D, 1992, BIOTECHNIQUES, V12, P656; VENNER TJ, 1990, NUCLEIC ACIDS RES, V18, P5309, DOI 10.1093/nar/18.17.5309; WADA I, 1991, J BIOL CHEM, V266, P19599; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WAKSMAN A, 1977, BIOCHEMISTRY-US, V16, P4703, DOI 10.1021/bi00640a026	40	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23157	23161						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901206				2022-12-27	WOS:A1993MF51500033
J	ALI, H; RICHARDSON, RM; TOMHAVE, ED; DUBOSE, RA; HARIBABU, B; SNYDERMAN, R				ALI, H; RICHARDSON, RM; TOMHAVE, ED; DUBOSE, RA; HARIBABU, B; SNYDERMAN, R			REGULATION OF STABLY TRANSFECTED PLATELET-ACTIVATING-FACTOR RECEPTOR IN RBL-2H3 CELLS - ROLE OF MULTIPLE G-PROTEINS AND RECEPTOR PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; C5A CHEMOATTRACTANT RECEPTORS; GAMMA-SUBUNITS; POLYMORPHONUCLEAR NEUTROPHILS; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; INDUCED DESENSITIZATION; DISTINCT PATHWAYS; ADENYLATE-CYCLASE; PERTUSSIS TOXIN	Platelet activating factor (PAF) interacts with cell surface receptors to mediate inflammatory responses. To determine the mechanisms of PAF receptor regulation, we constructed epitope-tagged human PAF receptor cDNA (ET-PAFR) and generated stable transfectants in a rat basophilic cell line (RBL-2H3 cells). The expressed receptors displayed ligand binding and functional properties similar to the native receptors in neutrophils. PAF-stimulated intracellular Ca2+ mobilization was not inhibited by pertussis toxin (PTx), whereas phosphoinositide hydrolysis and secretion were blocked by similar to 40%. The PTx-resistant secretion mediated by PAF was, however, inhibited by guanosine 5'-O-(2-thiodiphosphate) in permeabilized RBL-2H3 cells, indicating a role for PTx-insensitive G protein. In contrast to the PAF receptor, responses mediated by formylpeptide and C5a chemoattractants were inhibited by PTx. PAF stimulated a dose- and time dependent phosphorylation of its receptor. ET-PAFR was also phosphorylated by phorbol la-myristate 13-acetate (PMA) and dibutyryl cyclic AMP. Staurosporine caused complete inhibition of ET-PAFR phosphorylation by PMA but only partial inhibition by PAF Receptor phosphorylation by PAF and PMA correlated with desensitization as measured by a decrease in both PAF-stimulated GTPase activity in membranes and Ca2+ mobilization in intact cells. Phosphorylation of ET-PAFR by dibutyryl cyclic AMP was not, however, associated with desensitization. These data demonstrate that a single PAF receptor population interacts with multiple G proteins to mediate its biological responses. Moreover, ET-PAFR, unlike the formylpeptide or C5a receptors, is phosphorylated by at least three kinases (most likely protein kinases A and C and a receptor kinase). The functional consequences of cellular activation by various chemoattractants may depend upon the G protein to which their receptor is coupled.	DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA	Duke University	ALI, H (corresponding author), DUKE UNIV, MED CTR, DEPT MED, BOX 3680, DURHAM, NC 27710 USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NCI NIH HHS [CA-29589] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1993, J BIOL CHEM, V268, P24247; ALI H, 1990, J BIOL CHEM, V265, P745; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BATES MD, 1993, J BIOL CHEM, V268, P14757; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOMMA H, 1988, ARCH BIOCHEM BIOPHYS, V262, P32, DOI 10.1016/0003-9861(88)90165-8; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1988, J BIOL CHEM, V263, P3225; HWANG SB, 1991, ANN NY ACAD SCI, V629, P217; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLEIN P, 1987, J BIOL CHEM, V262, P358; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; KROEGEL C, 1989, BIOCHEM BIOPH RES CO, V162, P511, DOI 10.1016/0006-291X(89)92027-5; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAD PM, 1985, BIOCHEM BIOPH RES CO, V129, P632, DOI 10.1016/0006-291X(85)91938-2; MURPHY PM, 1990, J IMMUNOL, V145, P2227; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; NACCACHE PH, 1986, J LEUKOCYTE BIOL, V40, P533, DOI 10.1002/jlb.40.5.533; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; OFLAHERTY JT, 1992, BIOCHEM J, V288, P241, DOI 10.1042/bj2880241; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SHUKLA SD, 1989, MOL PHARMACOL, V35, P409; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; TARDIF M, 1993, J IMMUNOL, V150, P3534; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; UKENA D, 1988, FEBS LETT, V228, P285, DOI 10.1016/0014-5793(88)80017-6; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	46	133	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24557	24563						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929127				2022-12-27	WOS:A1994PQ49000011
J	WOSCHOLSKI, R; DHAND, R; FRY, MJ; WATERFIELD, MD; PARKER, PJ				WOSCHOLSKI, R; DHAND, R; FRY, MJ; WATERFIELD, MD; PARKER, PJ			BIOCHEMICAL-CHARACTERIZATION OF THE FREE CATALYTIC P110-ALPHA AND THE COMPLEXED HETERODIMERIC P110-ALPHA-CENTER-DOT-P85-ALPHA - FORMS OF THE MAMMALIAN PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; SIGNALING COMPLEXES; SH2 DOMAINS; PROTEIN; EXPRESSION; SUBUNIT; CLONING; P85; PHOSPHORYLATION	The regulatory (p85 alpha) and catalytic (p110 alpha) subunits of the mammalian phosphatidylinositol 3-kinase have been expressed in insect cells using the baculovirus system. The free catalytic subunit p110 alpha and the coexpressed heterodimeric complex of p85 alpha and p110 alpha were purified and their enzymological properties compared, While many kinetic parameters were similar, the coexpressed complex was found to have a 20-fold higher K-m for ATP in comparison with the free catalytic subunit p110 alpha using phosphatidylinositol 4,5-bisphosphate as a substrate; no significant difference was detectable when phosphatidylinositol was used. Reconstitution of the p110 alpha.p85 alpha complex in vitro showed that it had the properties of the free p110 alpha and not the p110 alpha.p85 alpha in vivo complex. Therefore, a post-translational modification dependent upon the presence of the regulatory subunit p85 alpha rather than the physical subunit interaction itself is responsible for the observed properties of the lipid kinase activity of the p110 alpha.p85 alpha complex. Phosphatase treatment of the purified lipid kinase complex reduced the high K-m for ATP, suggesting that a phosphorylation of the heterodimeric complex (p85 alpha.p110 alpha) caused this effect. This mode of regulation is discussed in the context of lipid kinase activation in vivo.	IMPERIAL CANC RES FUND, PROT PHOSPHORYLAT LAB, LONDON WC2A 3PX, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; INST CANC RES, HADDOW LABS, SUTTON SM2 5NG, SURREY, ENGLAND; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK; University of London; University College London			Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Fry, Michael/0000-0001-8518-1370				BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KODAKI T, 1994, EUR J BIOCHEM, V219, P775, DOI 10.1111/j.1432-1033.1994.tb18557.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHIBASAKI F, 1993, BIOCHEM J, V289, P227, DOI 10.1042/bj2890227; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25067	25072						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929193				2022-12-27	WOS:A1994PQ49000082
J	COFFIELD, JA; CONSIDINE, RV; JEYAPAUL, J; MAKSYMOWYCH, AB; ZHANG, RD; SIMPSON, LL				COFFIELD, JA; CONSIDINE, RV; JEYAPAUL, J; MAKSYMOWYCH, AB; ZHANG, RD; SIMPSON, LL			THE ROLE OF TRANSGLUTAMINASE IN THE MECHANISM OF ACTION OF TETANUS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; AMINO-ACID-SEQUENCE; NEUROTOXIN TYPE-A; NEUROTRANSMITTER RELEASE; CLOSTRIDIAL NEUROTOXINS; INHIBITS EXOCYTOSIS; ENCODING GENE; LIGHT CHAIN; BOTULINUM; SYNAPTOBREVIN	Tetanus toxin is a zinc-dependent metalloendoprotease that cleaves synaptobrevin, a polypeptide found in the membranes of synaptic vesicles. This action is thought to account for toxin-induced blockade of transmitter release. However, Facchiano and Luini (Facchiano, F., and Luini, A. (1992) J. Biol Chem. 267, 13267-13271) have proposed that tetanus toxin can stimulate transglutaminase, and Facchiano et al. (Facchiano, F., Benfenati, F., Valtorta, F., and Luini, A. (1993) J. Biol Chem. 268, 4588-4591) have further proposed that the stimulated enzyme produces cross-linking of synapsin. These actions might also account for toxin-induced blockade of exocytosis. Therefore, a series of experiments were performed to evaluate the possibility that tetanus toxin exerts its effects via transglutaminase. The results indicated that clostridial neurotoxins were poor substrates for the cross-linking effects of transglutaminase, and transglutaminase was a poor substrate for the proteolytic actions of tetanus toxin. In addition, at concentrations relevant to blockade of exocytosis, clostridial neurotoxins did not act on intact cells to stimulate transglutaminase, nor did they act on the isolated enzyme to stimulate cross-linking of putrescine and dimethylcasein. When used as competitive inhibitors of endogenous transglutaminase substrates, glycine methyl ester and monodansylcadaverine did not block toxin action. Furthermore, concentrations of calcium that were too low to support transglutaminase activity did not prevent toxin action. The data suggest that stimulation of transglutaminase is not the principal mechanism by which tetanus toxin blocks exocytosis in nerve cells.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009472, R01NS022153] Funding Source: NIH RePORTER; NIDDK NIH HHS [1-F32-DK08888-01] Funding Source: Medline; NINDS NIH HHS [NINCDS NS-22153, 1-F32-NS09472-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; BARSIGIAN C, 1988, J BIOL CHEM, V263, P14015; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; BLAUSTEIN MP, 1988, HDB EXPT PHARM, V83, P275; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; FACCHIANO F, 1992, J BIOL CHEM, V267, P13267; FACCHIANO F, 1993, J BIOL CHEM, V268, P4588; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCGEE R, 1978, P NATL ACAD SCI USA, V75, P1314, DOI 10.1073/pnas.75.3.1314; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SENNER A, 1985, ENDOCRINOLOGY, V117, P237; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; WHELAN SM, 1992, EUR J BIOCHEM, V204, P657, DOI 10.1111/j.1432-1033.1992.tb16679.x; WHELAN SM, 1992, APPL ENVIRON MICROB, V58, P2345, DOI 10.1128/AEM.58.8.2345-2354.1992	25	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24454	24458						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929108				2022-12-27	WOS:A1994PQ34600093
J	DING, L; SETO, BL; AHMED, SA; COLEMAN, WG				DING, L; SETO, BL; AHMED, SA; COLEMAN, WG			PURIFICATION AND PROPERTIES OF THE ESCHERICHIA-COLI K-12 NAD-DEPENDENT NUCLEOTIDE DIPHOSPHOSUGAR EPIMERASE, ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE GALACTOSE 4-EPIMERASE; RFAD GENE; BINDING; BIOSYNTHESIS; ENZYME; EXPRESSION; ADENOSINE; MECHANISM; REDUCTION; SUBSTRATE	The Escherichia coli K-12 NAD-dependent nucleotide-diphosphosugar epimerase, ADP-L-glycero-D-mannoheptose 6-epimerase, catalyzes the conversion of ADP-D-glycero-D-mannoheptose to ADP-L-glycero-D-mannoheptose. ADP-L-glycero-D-mannoheptose is a key intermediate of lipopolysaccharide inner core biosynthesis in several genera of Gram-negative bacteria. Sedimentation equilibrium and sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified epimerase revealed that the native enzyme has a molecular mass of 240 kDa and a subunit molecular weight of 37,000 +/- 3,000. Lectin binding studies of the purified epimerase indicated that the protein is glycosylated. There was 1 mol of tightly bound NAD(+) per enzyme subunit. Variable but small fractions of purified preparations of epimerase are highly fluorescent and contain NADH. The native enzyme can be resolved into apoenzyme and NAD(+) by acidic ammonium sulfate precipitation. The catalytic activity can be reconstituted with the addition of NAD(+) to the apoenzyme. Optimum pH range for enzyme activity is broad, between 5.5 and 9.5. It exhibits a temperature optimum at 42 degrees C. The K-m and V-max for the substrate is 0.1 mM and 46 mu mol 30 min(-1) mg(-1), respectively. The native enzyme displays UV and fluorescence spectra that are consistent with the presence of enzyme bound NAD(+). CD spectra of the holoepimerase indicate 11% alpha-helical and 36% beta-sheet structures.	NIDDK, BIOCHEM PHARMACOL LAB, PHARMACOL SECT, BETHESDA, MD 20892 USA; NIDDK, BIOCHEM PHARMACOL LAB, ENZYME STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ATTRI AK, 1983, ANAL BIOCHEM, V133, P142, DOI 10.1016/0003-2697(83)90235-X; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIOTTI MM, 1957, METHOD ENZYMOL, V3, P896; COLEMAN WG, 1992, PSEUDOMONAS : MOLECULAR BIOLOGY AND BIOTECHNOLOGY, P161; COLEMAN WG, 1979, J BACTERIOL, V139, P899, DOI 10.1128/JB.139.3.899-910.1979; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; EIDELS L, 1974, J BIOL CHEM, V249, P5642; FLENTKE GR, 1990, BIOCHEMISTRY-US, V29, P2430, DOI 10.1021/bi00461a029; GINSBURG V, 1962, J BIOL CHEM, V237, P497; GLASER L, 1972, ENZYMES, V6, P355; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GORNALL AG, 1949, J BIOL CHEM, V177, P751; KALCKAR HM, 1970, P NATL ACAD SCI USA, V65, P113; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MAXWELL ES, 1960, J BIOL CHEM, V235, P308; MCPHIE P, 1993, BIOCHEMISTRY-US, V32, P7460, DOI 10.1021/bi00080a017; MINTON AP, 1986, COMPUT APPL BIOSCI, V2, P167; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PORTER DJT, 1992, J BIOL CHEM, V267, P3205; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; SHARON N, 1989, LECTINS; SWANSON BA, 1993, BIOCHEMISTRY-US, V32, P13231, DOI 10.1021/bi00211a035; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEE TG, 1973, J BIOL CHEM, V248, P33; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON DB, 1964, J BIOL CHEM, V239, P2469; WINER AD, 1959, J BIOL CHEM, V234, P1149; WINER AD, 1959, J BIOL CHEM, V234, P1155	32	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24384	24390						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929099				2022-12-27	WOS:A1994PQ34600083
J	IVANOVA, VS; HATCH, CL; BONNER, WM				IVANOVA, VS; HATCH, CL; BONNER, WM			CHARACTERIZATION OF THE HUMAN HISTONE H2A.X GENE - COMPARISON OF ITS PROMOTER WITH OTHER H2A GENE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CELL-CYCLE; DNA-REPLICATION; S-PHASE; EXPRESSION; SEQUENCE; PROTEIN; PHOSPHORYLATION; TRANSCRIPTION; BINDING	The human gene for the replication-unlinked histone protein H2A.X is a naturally occurring chimera that contains a replication-unlinked promoter yet produces a stemloop mRNA characteristic of replication-linked histone genes. Consistent with the latter attribute, the H2A.X gene was found to lack introns. The promoter of the H2A.X gene was localized to a 120-base pair region upstream of the transcription start site, a region which included a TATA and two CCAAT sequence elements. The proximal of the two CCAAT elements was shown to be an important determinant of H2A.X gene promoter activity. In a comparative study with the CCAAT elements from the replication-linked H2A.1a gene and the replication-unlinked H2A.Z gene, the proximal CCAAT element of the H2A.X gene was found to bind nuclear factors also bound by CCAAT elements in the latter but not in the former, The specificity of the replication-unlinked H2A.X and H2A.Z gene promoters for CCAAT-binding transcription factors appeared to also reside in short homologous sequences about 10 base pairs away on either side of the CCAAT sequence.	NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BONNER WM, 1993, MOL CELL BIOL, V13, P984, DOI 10.1128/MCB.13.2.984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLONER PB, 1989, MOL CELL BIOL, V9, P902, DOI 10.1128/MCB.9.3.902; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FELGNER PL, 1989, FOCUS, V11, P21; GREEN GR, 1989, DEV BIOL, V134, P413, DOI 10.1016/0012-1606(89)90113-9; GREEN GR, 1991, EXP CELL RES, V195, P8, DOI 10.1016/0014-4827(91)90493-E; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HATCH CL, 1990, J BIOL CHEM, V265, P15211; HATCH CL, 1988, NUCLEIC ACIDS RES, V16, P1113, DOI 10.1093/nar/16.3.1113; HEINTZ N, 1981, CELL, V24, P661, DOI 10.1016/0092-8674(81)90092-1; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; IVANOVA VS, 1994, IN PRESS HUMAN GENET; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; MANNIRONI C, 1994, DNA CELL BIOL, V13, P161, DOI 10.1089/dna.1994.13.161; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; TRIPPUTI P, 1986, P NATL ACAD SCI USA, V83, P3185, DOI 10.1073/pnas.83.10.3185; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; YOO HW, 1993, GENOMICS, V15, P21, DOI 10.1006/geno.1993.1005; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409; 1991, PROGRAM MANUAL GCG P	34	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24189	24194						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929075				2022-12-27	WOS:A1994PQ34600055
J	TURI, TG; WEBSTER, P; ROSE, JK				TURI, TG; WEBSTER, P; ROSE, JK			BREFELDIN-A SENSITIVITY AND RESISTANCE IN SCHIZOSACCHAROMYCES-POMBE - ISOLATION OF MULTIPLE GENES CONFERRING RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE GENE; PLEIOTROPIC DRUG-RESISTANCE; FISSION YEAST; G-PROTEIN; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDE; GOLGI MEMBRANES; RAT HEPATOCYTES	The fungal metabolite brefeldin A (BFA) causes the inhibition of protein Secretion and the disruption of the structure and function of the Golgi complex in mammalian cells. Here we show that BFA has identical effects in the fission yeast Schizosaccharomyces pombe which normally contains a Golgi complex of stacked cisternae similar to the Golgi complexes in animal cells. After treatment with BFA, secretion was inhibited, Golgi complexes disappeared, and there was an accumulation of endoplasmic reticulum. These results indicate that the effects of BFA in fungi are very similar to those in mammalian cells and provide direct evidence for an effect of BFA on Golgi morphology in fungi. Five spontaneous BFA-resistant mutants were isolated. Genetic analysis showed that the mutations conferring BFA resistance were dominant and in two separate linkage groups. One of the BFA-resistant mutations was found to be allelic: to crm1, a gene affecting chromatin structure. Ah BFA-resistant mutants overexpressed a 20-kDa protein, and the corresponding gene obr1 was isolated and sequenced. However, obr1 overexpression was not sufficient to confer BFA resistance. Plasmids capable of conferring BFA resistance to wild type cells were isolated from libraries constructed from the two BFA-resistant mutants. These plasmids contain six different genes capable of conferring resistance when present in high copy. One of these genes encoded the transcription factor pap1, a homolog of the mammalian AP1 protein. The overexpression of pap1 probably confers BFA resistance indirectly by inducing expression of one or more other proteins. The isolation of several genes conferring BFA resistance suggests several mechanisms are involved.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015502] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA46128-03] Funding Source: Medline; NIGMS NIH HHS [GM15502-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; BRUNING A, 1992, J BIOL CHEM, V267, P7726; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FALCO SC, 1985, GENETICS, V109, P21; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; KNEUSEL RE, 1994, J BIOL CHEM, V269, P3449; KNEUSEL RE, 1990, FEBS LETT, V275, P107, DOI 10.1016/0014-5793(90)81450-3; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPERT G, 1990, GENETICS, V125, P13; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; RANK GH, 1973, MOL GEN GENET, V126, P93, DOI 10.1007/BF00330986; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAUNDERS GW, 1982, CAN J GENET CYTOL, V24, P493, DOI 10.1139/g82-053; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; Sherman F., 1981, METHODS YEAST GENETI; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; ULASZEWSKI S, 1986, CURR GENET, V10, P359, DOI 10.1007/BF00418407; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; WU AL, 1993, J BIOL CHEM, V268, P18850; [No title captured]	50	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24229	24236						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929079				2022-12-27	WOS:A1994PQ34600060
J	YUAN, CJ; HUANG, CYF; GRAVES, DJ				YUAN, CJ; HUANG, CYF; GRAVES, DJ			OXIDATION AND SITE-DIRECTED MUTAGENESIS OF THE SULFHYDRYL-GROUPS OF A TRUNCATED GAMMA-CATALYTIC SUBUNIT OF PHOSPHORYLASE-KINASE - FUNCTIONAL AND STRUCTURAL EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CONSERVED FEATURES; PEPTIDE INHIBITOR; IDENTIFICATION; BINDING; DOMAINS; FAMILY	A truncated form of the gamma subunit of phosphorylase kinase is inactivated by CU2+ with the formation of two intra-molecular disulfide bonds. The formation of a disulfide bond between Cys-36 and Cys-172 (semioxidized form) results in approximately 50% loss of specific activity because the K-m for MgATP is about 10-fold higher. The second disulfide bond is between Cys-184 and Cys-197 and causes further loss of activity. Eight Cys mutants, i.e. C36S, C36A, C42S, C138S, C172S, C184S, C184A, and C197S, were expressed and purified. Kinetic studies suggest that Cys-36 is important for interaction at the nucleotide site because of its hydrophobicity. With Cys-184 mutants, C184S and C184A, tyrosyl phosphorylation of angiotensin II is affected much more than serine kinase activity. The loss of tyrosine kinase activity is related to a lowered activity with Mn2+. With Mn2+, angiotensin II is a competitive inhibitor with respect to seryl kinase activity of C184S. With Mg2+, however, angiotensin II is a noncompetitive inhibitor. We suggest that metal ions influence the conformation of truncated gamma and that the protein substrate binding region containing Cys-184 is important for the dual specificity of this kinase.	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	Iowa State University				Huang, Chi-Ying F/0000-0003-4898-4937	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM009587] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-09587] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRON ESG, 1951, ADV ENZYMOL REL S BI, V11, P201; BARRON ESG, 1947, BIOCHEM J, V41, P62, DOI 10.1042/bj0410062; BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN KFJ, 1982, J BIOL CHEM, V257, P5939; CHAN KFJ, 1984, CALCIUM CELL FUNCTIO, V5, P1; CHANG JY, 1983, BIOCHEM J, V211, P163, DOI 10.1042/bj2110163; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; HALL PK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P325, DOI 10.1016/0167-4838(92)90164-9; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; JAMES P, 1991, J BIOL CHEM, V266, P7087; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEE SM, 1987, J BIOL CHEM, V262, P9448; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LEWIS CT, 1993, J BIOL CHEM, V268, P1628; MALENCIK DA, 1982, CALCIUM CELL FUNCTIO, V3, P161; PAUDEL HK, 1991, J BIOL CHEM, V266, P16524; PICKETTGIES CA, 1986, ENZYMES, V175, P396; SILVA EFD, 1987, FEBS LETT, V220, P36, DOI 10.1016/0014-5793(87)80871-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEHLAN HA, 1993, FASEB J, V7, pA1161; YUAN CJ, 1993, J BIOL CHEM, V268, P17683; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	30	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24367	24373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929096				2022-12-27	WOS:A1994PQ34600080
J	KREYSING, J; POLTEN, A; LUKATELA, G; MATZNER, U; VONFIGURA, K; GIESELMANN, V				KREYSING, J; POLTEN, A; LUKATELA, G; MATZNER, U; VONFIGURA, K; GIESELMANN, V			TRANSLATIONAL CONTROL OF ARYLSULFATASE-A EXPRESSION IN MOUSE TESTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SPERMATOGENIC CELLS; GENE-EXPRESSION; SEQUENCES	Arylsulfatase A is a lysosomal enzyme that is involved in the degradation of sulfated glycolipids. High levels of arylsulfatase A mRNA are found in germ cells of mouse testis. In late pachytene and secondary spermatocytes the level of arylsulfatase A mRNA is increased 20-fold when compared with other tissues. These high levels of arylsulfatase A mRNA are maintained in round spermatids and decrease in late elongating spermatids. The increase of arylsulfatase A mRNA levels is not accompanied by a similar increase in enzyme activity or polypeptides. Subcellular fractionation revealed that the majority of arylsulfatase A mRNA is not associated with polysomes but is found in fractions of lower buoyancy. The failure to become translated is ascribed to the association of arylsulfatase A mRNA with nonpolysomal ribonucleoproteins. This translational repression may be due to proteins that bind to arylsulfatase A mRNA and prevent its translation. Within the 639-nucleotide B'-untranslated region and the 700-nucleotide 3'-untranslated region of the arylsulfatase A mRNA, we identified two regions that specifically bind proteins present in extracts prepared from testicular cells, These RNA binding proteins were absent from extracts prepared from liver or brain.	UNIV GOTTINGEN, D-37073 GOTTINGEN, GERMANY	University of Gottingen								Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FAROOQUI AA, 1979, BIOCHEM J, V181, P331, DOI 10.1042/bj1810331; FLUHARTY AL, 1974, BIOCHEM BIOPH RES CO, V61, P348, DOI 10.1016/0006-291X(74)90573-7; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GRABSKE RJ, 1975, J CELL PHYSIOL, V86, P177, DOI 10.1002/jcp.1040860119; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; KOLODNY EH, 1989, METABOLIC BASIS INHE, V2, P1721; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; KREYSING J, 1990, EUR J BIOCHEM, V191, P627, DOI 10.1111/j.1432-1033.1990.tb19167.x; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATZNER U, 1992, DEVELOPMENT, V114, P965; STEIN C, 1989, J BIOL CHEM, V264, P1252; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; YANG CH, 1974, P SOC EXP BIOL MED, V145, P721; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	24	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23255	23261						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916017				2022-12-27	WOS:A1994PQ16400054
J	WOLBRING, G; HOLLENBERG, MD; SCHNETKAMP, PPM				WOLBRING, G; HOLLENBERG, MD; SCHNETKAMP, PPM			INHIBITION OF GTP-UTILIZING ENZYMES BY TYRPHOSTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE INHIBITORS; EPIDERMAL GROWTH-FACTOR; ROD OUTER SEGMENTS; CELL-PROLIFERATION; PROTEIN-KINASE; GENE-PRODUCT; ACTIVATION; EXPRESSION	Tyrphostins are a group of organic compounds which are widely used as a tool to specifically inhibit protein tyrosine kinases (Yaish, P., Gazit, A, Gilon, C., and Levitzki A. (1988) Science 242, 933-935; Gazit, A., Yaish, P., Gilon, C., and Levitzki A. (1989) J. Med. Chem. 32, 2344-2352; Lyall, R. M., Zilberstein, A., Gazit, A., Gilon, C., Levitzki, A., and Schlessinger J. (1989) J. Biol. Chem. 264, 14503-14509; Osherov, N., Gazit, A., Gilon, C., and Levitzki, A. (1993) J. Biol. Chem. 268, 11134-11142). We report here that members of the tyrphostin family inhibit the GTPase activity of transducin and the enzymatic activities of other GTP-utilizing proteins in retinal rod outer segments, such as guanylyl cyclase or fructose-6-phosphate kinase. In contrast, ATP-utilizing enzymes such as hexokinase or rhodopsin kinase were not effected.	UNIV CALGARY,DEPT MED,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT PHARMACOL & THERAPEUT,CALGARY T2N 4N1,AB,CANADA	University of Calgary; University of Calgary	WOLBRING, G (corresponding author), UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY T2N 4N1,AB,CANADA.		Hollenberg, Morley/AFV-6966-2022	Wolbring, Gregor/0000-0003-1363-0346				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, 1991, J MED CHEM, V34, P1396; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEVITZKI A, 1991, J BIOL CHEM, V266, P2965; LEVITZKI A, 1992, FASEB J, V6, P3276; LYALL RM, 1989, J BIOL CHEM, V264, P14503; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; RENDU F, 1992, BIOCHEM PHARMACOL, V44, P8881; ROIFMAN CM, 1991, J IMMUNOL, V146, P2965; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1979, BIOCHIM BIOPHYS ACTA, V552, P379, DOI 10.1016/0005-2736(79)90182-2; SCHNETKAMP PPM, 1981, BIOCHIM BIOPHYS ACTA, V672, P307, DOI 10.1016/0304-4165(81)90298-1; SECKL M, 1993, J BIOL CHEM, V268, P9548; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	24	40	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22470	22472						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915715				2022-12-27	WOS:A1994PQ16300004
J	HANSSON, E				HANSSON, E			METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION INDUCES ASTROGLIAL SWELLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; AMINO-ACID RECEPTORS; CYCLIC-AMP FORMATION; CULTURED ASTROCYTES; GLIAL-CELLS; CALCIUM CURRENTS; POTASSIUM; CHANNELS; RELEASE; NEURONS	The activation of metabotropic glutamate receptors (mGluRs) by 1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) or ibotenate induced a rapid cell volume increase in primary cultures of type 1 astroglial cells from the cerebral cortex of a newborn rat. These relative volume changes and parallel Ca2+ transients in single cells were examined by microspectrofluorimetry after loading the cells with fura-2/AM and varying the excitation wavelengths between the isosbestic point of the probe and its ion- sensitive wavelength. L(+)-2-Amino-4-phosphonobutyric acid (L-AP4) evoked an astroglial swelling but few or no cytosolic Ca2+ transients. No rapid swelling was observed after stimulation of ionotropic Glu receptors. The Glu-induced volume increase was unaffected by gluconate or amiloride, partially blocked by Glu-carrier blockers, and totally blocked by ketamine. The Glu- or L-AP4-induced volume increases were blocked by BaCl2 or furosemide. Tetraethylammoniumchloride-1-hydrate blocked the Glu- and 1S,3R-ACPD-induced astroglial swelling but the voltage-dependent L-, N-, or T-type Ca2+ channels were not primarily involved in the Glu-, 1S,3R-ACPD-, or L-AP4-induced swelling. mGluRs induce inositol 1,4,5-trisphosphate synthesis, intracellular Ca2+ increase, and the opening of a delayed outward K+ rectifier, and along another route they activate a G(i) protein and open an inward K+ rectifier. One Na+-K+-2Cl(-) cotransporter and a Na+-K+-ATPase is activated and so also is an electrogenic Na+-dependent Glu carrier. Thus, Glu-induced astroglial swelling is not only the result of the above mechanisms, but requires another, until now unidentified mechanism, probably some ketamine-sensitive K+ outflux or Na+ influx.	LINKOPING UNIV,FAC HLTH SCI,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN	Linkoping University	HANSSON, E (corresponding author), GOTHENBURG UNIV,INST NEUROBIOL,MEDICINAREGATAN 5,S-41390 GOTHENBURG,SWEDEN.							BABA A, 1993, NEUROSCI LETT, V149, P182, DOI 10.1016/0304-3940(93)90766-E; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BEVAN S, 1985, PROC R SOC SER B-BIO, V225, P299, DOI 10.1098/rspb.1985.0063; BIRNBAUMER L, 1991, BIOL REPROD, V44, P207, DOI 10.1095/biolreprod44.2.207; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BOSS V, 1992, J NEUROCHEM, V59, P2340; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; Boyle PJ, 1941, J PHYSIOL-LONDON, V100, P1; CHAN PH, 1989, BRAIN RES, V487, P380, DOI 10.1016/0006-8993(89)90845-7; CONN PJ, 1991, DRUG DEVELOP RES, V24, P207, DOI 10.1002/ddr.430240303; DAVIS CW, 1985, FED PROC, V44, P2520; ERECINSKA M, 1989, J NEUROCHEM, V52, P135, DOI 10.1111/j.1471-4159.1989.tb10907.x; ERECINSKA M, 1988, BRIT J PHARMACOL, V94, P871, DOI 10.1111/j.1476-5381.1988.tb11599.x; ERIKSSON PS, 1992, NEUROSCI LETT, V143, P195, DOI 10.1016/0304-3940(92)90264-8; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; GECK P, 1985, ANN NY ACAD SCI, V456, P166, DOI 10.1111/j.1749-6632.1985.tb14862.x; GECK P, 1986, J MEMBRANE BIOL, V91, P97, DOI 10.1007/BF01925787; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSSON E, 1984, BRAIN RES, V300, P9, DOI 10.1016/0006-8993(84)91335-0; HANSSON E, 1994, IN PRESS NEUROSCIENC; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIMELBERG HK, 1990, BRAIN RES, V529, P255, DOI 10.1016/0006-8993(90)90835-Y; KIMELBERG HK, 1988, GLIA, V1, P219, DOI 10.1002/glia.440010307; KOYAMA Y, 1991, NEUROSCI LETT, V122, P210, DOI 10.1016/0304-3940(91)90860-V; KOYAMA Y, 1991, NEUROSCI LETT, V124, P235, DOI 10.1016/0304-3940(91)90102-Y; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MANZONI O, 1992, EUR J PHARM-MOLEC PH, V225, P357, DOI 10.1016/0922-4106(92)90112-9; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MCBEAN GJ, 1985, J NEUROCHEM, V44, P247, DOI 10.1111/j.1471-4159.1985.tb07137.x; MCCARTHY KD, 1988, GLIAL CELL RECEPTORS, P1; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON M, 1993, NEUROSCIENCE, V54, P605, DOI 10.1016/0306-4522(93)90232-5; PEARCE B, 1993, ASTROCYTES PHARM FUN, P47; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; RAFF MC, 1984, TRENDS NEUROSCI, V7, P469; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SCHNEIDER GH, 1992, J PHYSL PHARM, V70, pS334; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP DD, 1992, J NEUROCHEM, V58, P1184, DOI 10.1111/j.1471-4159.1992.tb09381.x; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SURPRENANT A, 1988, PROC R SOC SER B-BIO, V234, P85, DOI 10.1098/rspb.1988.0039; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TAUC M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P278, DOI 10.1016/0167-4889(90)90222-Y; THOMSEN C, 1992, EUR J PHARM-MOLEC PH, V227, P361, DOI 10.1016/0922-4106(92)90018-Q; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; TSE FW, 1992, J NEUROSCI, V12, P1781; WALZ W, 1989, PROG NEUROBIOL, V33, P309, DOI 10.1016/0301-0082(89)90005-1; WILLIAMS JT, 1988, J NEUROSCI, V8, P4299; WINDER DG, 1992, J NEUROCHEM, V59, P375, DOI 10.1111/j.1471-4159.1992.tb08914.x; WONG BS, 1993, LIFE SCI, V53, P359	54	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					21955	21961						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915278				2022-12-27	WOS:A1994PE09800009
J	TAGUCHI, H; MAKINO, Y; YOSHIDA, M				TAGUCHI, H; MAKINO, Y; YOSHIDA, M			MONOMERIC CHAPERONIN-60 AND ITS 50-KDA FRAGMENT POSSESS THE ABILITY TO INTERACT WITH NONNATIVE PROTEINS, TO SUPPRESS AGGREGATION, AND TO PROMOTE PROTEIN-FOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GROE; RHODANESE; PURIFICATION; INVITRO	Chaperonin-60 is usually isolated as a tetradecameric form arranged as two stacked seven-member rings, and this structure has been considered to be required for promoting protein folding. However, monomeric chaperonin-60 (cpn60(m)), isolated from holo-chaperonin of Thermus thermophilus, and its proteolytic 50-kDa fragment, which lacks amino-terminal 78 amino acid residues, can interact with non-native rhodanese and lactate dehydrogenase, suppress formation of aggregates, and promote productive folding under the appropriate conditions. However, different from tetradecameric chaperonin-60, folding promoted by cpn60(m) and the 50-kDa fragment produces lower yields of active enzymes and does not require ATP or chaperonin-10. These effects are not due to transient reassembly of cpn60(m) into a tetradecamer during the reaction, since immobilized cpn60(m), and the 50-kDa fragment, both of which can not reassemble into a tetradecamer, can still promote protein folding. An excess amount of the 50-kDa fragment shows an inhibitory effect on MgATP-triggered holechaperonin-dependent folding, indicating the 50-kDa fragment and holo-chaperonin can interact with the same species of non-native proteins. Thus, cpn60(m), has an intrinsic activity as a molecular chaperone and amino-terminal region of cpn60 is dispensable for this activity.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology			taguchi, hideki/AAM-2663-2021; Taguchi, Hideki/B-6946-2009	taguchi, hideki/0000-0002-6612-9339; Taguchi, Hideki/0000-0002-6612-9339				ALCONADA A, 1993, TRENDS BIOCHEM SCI, V18, P81, DOI 10.1016/0968-0004(93)90158-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; LORIMER GH, 1992, CURR OPIN STRUC BIOL, V2, P26; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YOSHIDA M, 1993, PHILOS T ROY SOC B, V339, P305, DOI 10.1098/rstb.1993.0029; YUTANI K, 1967, J BIOCHEM-TOKYO, V62, P576, DOI 10.1093/oxfordjournals.jbchem.a128707; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	38	47	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8529	8534						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907593				2022-12-27	WOS:A1994NB40900105
J	AOYAGI, N; MATSUOKA, S; FURUNOBU, A; MATSUKAGE, A; SAKAGUCHI, K				AOYAGI, N; MATSUOKA, S; FURUNOBU, A; MATSUKAGE, A; SAKAGUCHI, K			DROSOPHILA DNA-POLYMERASE-DELTA - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; MOLECULAR-CLONING; RIBONUCLEASE-H; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; MELANOGASTER EMBRYOS; REPLICATION INVITRO; AUXILIARY PROTEIN; PRIMASE COMPLEX; SV40 ORIGIN	A DNA polymerase with properties similar to mammalian polymerase delta has been isolated to near homogeneity from early embryos of Drosophila melanogaster. A combination of exclusion chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicates that this enzyme has a total molecular mass of 185 kDa and is composed of 138- and 47-kDa polypeptides. Its isoelectric point is 6.8. This polymerase activity is strongly inhibited by N-ethylmaleimide, aphidicolin, and high KCl concentration but is relatively insensitive to 2',3' dideoxythymidine 5'-triphosphate. There was no reaction in an immunological test using monoclonal antibody against Drosophila DNA polymerase alpha. In a final purification step, this polymerase activity was accompanied by 3' --> 5' exonuclease activity as expected proofreading activity. This polymerase activity is remarkably stimulated by mouse proliferating cell nuclear antigen, which is structurally and immunologically very similar to a Drosophila counterpart. These properties clearly indicate this enzyme belongs to the category of DNA polymerase delta.	SCI UNIV TOKYO,FAC SCI & TECHNOL,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Tokyo University of Science; Aichi Cancer Center								ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BANKS GR, 1979, J BIOL CHEM, V254, P9886; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BIALEK G, 1993, J BIOL CHEM, V268, P6024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; DIFRANCESCO RA, 1985, J BIOL CHEM, V260, P4764; GAUDETTE MF, 1986, P NATL ACAD SCI USA, V83, P5953, DOI 10.1073/pnas.83.16.5953; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HAGEMEIER A, 1989, EUR J BIOCHEM, V185, P621, DOI 10.1111/j.1432-1033.1989.tb15158.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221; KARWAN R, 1983, BIOCHEMISTRY-US, V22, P5500, DOI 10.1021/bi00293a008; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KURODA K, 1990, J BIOCHEM-TOKYO, V108, P926, DOI 10.1093/oxfordjournals.jbchem.a123316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SK, 1993, FEBS LETT, V316, P261, DOI 10.1016/0014-5793(93)81304-I; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LU CD, 1992, BIOCHEMISTRY-US, V31, P12403, DOI 10.1021/bi00164a015; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MICCHELI G, 1982, EXP CELL RES, V137, P127; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NG L, 1990, J BIOL CHEM, V265, P11948; NIRANJANAKUMARI S, 1992, J BIOL CHEM, V263, P17531; PECK VM, 1992, NUCLEIC ACIDS RES, V20, P5779, DOI 10.1093/nar/20.21.5779; SAKAGUCHI K, 1992, MUTAT RES, V274, P11, DOI 10.1016/0921-8777(92)90039-6; SAKAGUCHI K, 1985, J BIOL CHEM, V260, P406; SPRADLING A, 1987, ANNU REV GENET, V21, P373, DOI 10.1146/annurev.ge.21.120187.002105; SPRADLING AC, 1981, ANNU REV GENET, V15, P219, DOI 10.1146/annurev.ge.15.120181.001251; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUZUKA I, 1989, P NATL ACAD SCI USA, V86, P3189, DOI 10.1073/pnas.86.9.3189; THOMMES P, 1990, EUR J BIOCHEM, V194, P699, DOI 10.1111/j.1432-1033.1990.tb19460.x; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEISER T, 1991, J BIOL CHEM, V266, P10420; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403	50	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6045	6050						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907087				2022-12-27	WOS:A1994MY84000086
J	SANFRIDSON, A; CULLEN, BR; DOYLE, C				SANFRIDSON, A; CULLEN, BR; DOYLE, C			THE SIMIAN IMMUNODEFICIENCY VIRUS NEF PROTEIN PROMOTES DEGRADATION OF CD4 IN HUMAN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIV-1 NEF; SERINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; HUMAN-LYMPHOCYTES; GENE-PRODUCT; TYPE-1; INTERNALIZATION; REPLICATION; ENDOCYTOSIS	Expression of the Nef protein encoded by human and simian immunodeficiency viruses results in the specific down-regulation of CD4 from dhe cell surface in both lymphoid and non lymphoid cells. In this report, we examine the biosynthesis and cell surface expression of CD4 in the human T cell line, CEM-SS, that has been stably transduced with the SIV nef gene. Quantification of CD4 in Nef-expressing cells reveals that the steady state level of CD4 is significantly reduced as compared to control transductants. The presence of Nef in these cells promotes the degradation of newly synthesized CD4 protein. The biosynthesis and oligosaccharide processing of CD4 in Nef-expressing T cells appears to be normal through the endoplasmic reticulum and Golgi compartments, suggesting that the degradation of CD4 is a late event in the biosynthetic pathway. Treatment with the lysosomotropic agents chloroquine and primaquine prevents the degradation of CD4 in Nef-expressing CEM-SS cells, indicating that the degradation of CD4 likely occurs in an acidic compartment. Thus the reduced cell surface expression observed in Nef expressing CEM-SS cells is the likely consequence of a Nef-induced sorting of CD4 into a cellular compartment where CD4 is then degraded.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Duke University; Howard Hughes Medical Institute					NATIONAL CANCER INSTITUTE [T32CA009058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046391] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09058] Funding Source: Medline; NIGMS NIH HHS [GM46391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1993, J VIROL, V67, P4923, DOI 10.1128/JVI.67.8.4923-4931.1993; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; DOYLE C, 1989, IMMUNOL REV, V109, P17, DOI 10.1111/j.1600-065X.1989.tb00018.x; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARCIA JV, 1993, J VIROL, V67, P1511, DOI 10.1128/JVI.67.3.1511-1516.1993; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; INOUE M, 1993, INT IMMUNOL, V5, P1067, DOI 10.1093/intimm/5.9.1067; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KONIG R, 1988, J BIOL CHEM, V263, P9502; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5236; MARIANI R, 1993, P NATL ACAD SCI USA, V90, P5549, DOI 10.1073/pnas.90.12.5549; NEBREDA AR, 1991, VIROLOGY, V183, P151, DOI 10.1016/0042-6822(91)90128-X; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; POULIN L, 1992, AIDS, V6, P787, DOI 10.1097/00002030-199208000-00003; REIF JS, 1991, EXP CELL RES, V192, P581, DOI 10.1016/0014-4827(91)90079-A; REPKE H, 1992, J IMMUNOL, V149, P2585; RUEGG CL, 1992, J BIOL CHEM, V267, P18837; SAGGIORO D, 1993, J BIOL CHEM, V268, P1368; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Veillette A, 1991, Semin Immunol, V3, P143; WERNER T, 1991, AIDS, V5, P1301, DOI 10.1097/00002030-199111000-00003; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WOLBER V, 1992, EUR J BIOCHEM, V205, P1115, DOI 10.1111/j.1432-1033.1992.tb16880.x; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X; ZAZOPOULOS E, 1993, VIROLOGY, V194, P20, DOI 10.1006/viro.1993.1230; ZAZOPOULOS E, 1992, P NATL ACAD SCI USA, V89, P6634, DOI 10.1073/pnas.89.14.6634	38	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3917	3920						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905875				2022-12-27	WOS:A1994MW98900004
J	CZYZYKKRZESKA, MF; FURNARI, BA; LAWSON, EE; MILLHORN, DE				CZYZYKKRZESKA, MF; FURNARI, BA; LAWSON, EE; MILLHORN, DE			HYPOXIA INCREASES RATE OF TRANSCRIPTION AND STABILITY OF TYROSINE-HYDROXYLASE MESSENGER-RNA IN PHEOCHROMOCYTOMA (PC12) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTID-BODY INVITRO; GENE-EXPRESSION; CYCLIC-AMP; CATECHOLAMINE SYNTHESIS; ERYTHROPOIETIN; OXYGEN; STIMULATION; RELEASE	Reduced arterial oxygen tension (i.e. hypoxia) is a powerful physiological stimulus that induces synthesis and release of dopamine from O2-sensitive (type I) cells in the mammalian carotid bodies. We reported recently that hypoxia stimulates gene expression for tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis in type I cells of the carotid body. Efforts to identify the mechanisms regulating TH gene expression in O2-sensitive cells during hypoxia have been hampered by the lack of an appropriate model cell culture system. Here we report that TH gene expression in the rat pheochromocytoma cell line (PC12) is regulated during hypoxia in a manner similar to that measured in carotid body type I cells. PC12 cells might therefore be useful as an experimental model for identifying the molecular mechanisms that regulate TH gene expression during hypoxia. Nuclear runoff assays revealed that transcription of the wild type TH gene was enhanced during exposures to hypoxia lasting 12 h. Chloramphenicol acetyltransferase assays with constructs that contained different fragments of TH promoter revealed that the regulatory sequences that mediate the hypoxia-induced increase in transcription are located between bases -272 and +27 of the TH gene. Findings from experiments in which transcription was inhibited either with actinomycin D or 5,6-dichloro-1-D-ribofuranosylbenzimidazole, as well as pulse-chase experiments using 4-thiouridine showed that the half-life of TH mRNA was substantially increased during hypoxia. Thus, in the present paper we show that TH gene expression in PC12 cells during hypoxia is regulated by increases in both the rate of TH gene transcription and TH mRNA stability.	UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	CZYZYKKRZESKA, MF (corresponding author), UNIV N CAROLINA, DEPT PHYSIOL, MOLEC & DEV NEUROSCI LAB, MED SCI RES BLDG 68, CHAPEL HILL, NC 27599 USA.				NHLBI NIH HHS [HL 33831, HL 34919] Funding Source: Medline; NICHD NIH HHS [HD 28948] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028948] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL034919, R01HL033831] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARVISO GL, 1992, SOC NEUR ABSTR, V18; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; FEINSILVER SH, 1987, BIOCHIM BIOPHYS ACTA, V928, P56, DOI 10.1016/0167-4889(87)90085-1; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GOLDBERG MA, 1989, CONTRIB NEPHROL, V76, P39; GOLDBERG MA, 1991, BLOOD, V77, P271; GONZALEZ C, 1992, TRENDS NEUROSCI, V15, P146, DOI 10.1016/0166-2236(92)90357-E; GONZALEZ C, 1981, AM J PHYSIOL, V240, pR38, DOI 10.1152/ajpregu.1981.240.1.R38; GONZALEZ C, 1979, J NEUROCHEM, V33, P713, DOI 10.1111/j.1471-4159.1979.tb05216.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HANBAUER I, 1977, NEUROPHARMACOLOGY, V16, P277, DOI 10.1016/0028-3908(77)90107-1; HEYMANS C, 1958, REFLEXOGENIC AREAS C, P1; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; McDonald DM., 1981, REGULATION BREATHI 1, P105; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PEREZGARCIA MT, 1990, J NEUROCHEM, V55, P1287, DOI 10.1111/j.1471-4159.1990.tb03137.x; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; SUMMERHILL EM, 1987, MOL BRAIN RES, V2, P99, DOI 10.1016/0169-328X(87)90002-7; TAMM I, 1978, ADV VIRUS RES, V22, P188; TAN CC, 1992, KIDNEY INT, V41, P1581, DOI 10.1038/ki.1992.228; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WANG WJ, 1989, NEUROSCI LETT, V105, P164, DOI 10.1016/0304-3940(89)90030-X; WANG WJ, 1991, BRAIN RES, V540, P96, DOI 10.1016/0006-8993(91)90495-H; WOODFORD TA, 1988, ANAL BIOCHEM, V171, P166, DOI 10.1016/0003-2697(88)90138-8; Zhu W. H., 1992, Society for Neuroscience Abstracts, V18, P1500	41	237	246	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					760	764						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7903970				2022-12-27	WOS:A1994MR21900119
J	RICHARME, G; KOHIYAMA, M				RICHARME, G; KOHIYAMA, M			SPECIFICITY OF THE ESCHERICHIA-COLI CHAPERONE DNAK (70-KDA HEAT-SHOCK PROTEIN) FOR HYDROPHOBIC AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN; PEPTIDE-BINDING; PREDICTION; CATALYSTS; SURFACE; GROEL	Molecular chaperones form a class of proteins that bind selectively to nascent, unfolded, misfolded, or aggregated polypeptides. This property is the basis of their implication in many cellular processes such as protein folding, protein targeting to membranes, or protein renaturation after stress. It has been suggested that the recognition of non-native proteins by chaperones is mediated by their binding to exposed hydrophobic areas, to the polypeptide backbone, or to specific secondary structures. We show in the present study that DnaK, the 70-kDa chaperone of Escherichia coli specifically recognizes hydrophobic amino acids. The peptide-dependent ATPase activity of DnaK is specifically stimulated by Ile, Phe, Leu, and Val in a manner which is consistent with an interaction of these amino acids with the polypeptide binding site of DnaK. Two classes of amino acid binding site can be distinguished, one being specific for the aliphatic amino acids and the other for the aromatic amino acids. Since the hydrophobic amino acids are buried inside the hydrophobic core of native proteins and are exposed in non-native forms, their interaction with DnaK could be the basis of the specific interaction of the chaperone with non-native proteins in protein folding, protein targeting to membranes, or protein renaturation.			RICHARME, G (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,GENET & BIOCHIM LAB,2 PL JUSSIEU,F-75221 PARIS 05,FRANCE.							BARTON GJ, 1990, J MOL BIOL, V212, P389, DOI 10.1016/0022-2836(90)90133-7; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1980, NATURE, V284, P487, DOI 10.1038/284487a0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MORIMOTO R I, 1990, P1; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PTITSYN OB, 1992, CONFORMATIONS FORCES, P155; RACKOVSKY S, 1977, P NATL ACAD SCI USA, V74, P5248, DOI 10.1073/pnas.74.12.5248; RICHARME G, 1993, FEBS LETT, V322, P277, DOI 10.1016/0014-5793(93)81585-N; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHULZ GE, 1988, ANNU REV BIOPHYS BIO, V17, P1; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	32	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24074	24077						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901212				2022-12-27	WOS:A1993MF29400056
J	SKACH, WR; LINGAPPA, VR				SKACH, WR; LINGAPPA, VR			AMINO-TERMINAL ASSEMBLY OF HUMAN P-GLYCOPROTEIN AT THE ENDOPLASMIC-RETICULUM IS DIRECTED BY COOPERATIVE ACTIONS OF 2 INTERNAL SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIZING SECRETORY PROTEIN; ONE SIGNAL SEQUENCE; MULTIDRUG-RESISTANCE; MICROSOMAL-MEMBRANES; STOP TRANSFER; TRANSMEMBRANE PROTEIN; BACTERIAL TRANSPORT; TOPOGENIC SEQUENCE; APOLIPOPROTEIN-B; CYSTIC-FIBROSIS	Transmembrane topology of polytopic integral membrane proteins is established during protein synthesis at the endoplasmic reticulum membrane. For some polytopic proteins, sequential and independent signal, stop transfer, and/or signal anchor sequences contained in the nascent chain direct this process. Here we define the topology of human P-glycoprotein (MDR1) through the first two transmembrane regions (TM1 and TM2, respectively) of the amino-terminal half of the protein. We show that unlike TM7 and TM8, which comprise homologous regions in the carboxyl half of the protein (Skach, W., Calayag, M. C., and Lingappa, V. (1993) J. Biol. Chem. 268, 6903-6908), TM1 and TM2 achieve the orientation predicted by conventional structural models. However, TM1 and TM2 appear to utilize a mechanism of biogenesis different in a key respect from that observed in multispanning proteins studied previously. TM1 and TM2, with their flanking regions, independently direct the topology observed for each of these sequences in the native protein. Each can interact with signal recognition particle to direct targetting to the endoplasmic reticulum, nascent chain translocation, and correct transmembrane orientation. Unlike the transmembrane regions of previously studied multispanning membrane proteins, neither TM1 nor TM2 alone is sufficient to integrate the chain into the membrane. However, when TM1 and TM2 are both present, as occurs in native MDR1, integration is achieved. These results suggest that cooperative interactions between TM1 and TM2 are necessary for chain integration and thus add a new complexity to the current view of polytopic integral membrane protein biogenesis.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SKACH, WR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NCI NIH HHS [CA01614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GOERLICH D, 1992, Nature (London), V357, P47; GOERLICH D, 1990, J CELL BIOL, V111, P1183; GOTTESMAN MM, 1991, BIOCH MOL ASPECTS SE, P339; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PERARA E, 1988, PROTEIN TRANSFER ORG, P3; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH W, 1992, MECHANISMS INTRACELL, P19; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	60	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23552	23561						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901209				2022-12-27	WOS:A1993MF51500091
J	BAGLIA, FA; JAMESON, BA; WALSH, PN				BAGLIA, FA; JAMESON, BA; WALSH, PN			IDENTIFICATION AND CHARACTERIZATION OF A BINDING-SITE FOR PLATELETS IN THE APPLE-3 DOMAIN OF COAGULATION-FACTOR-XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; WASHED HUMAN-PLATELETS; CONTACT ACTIVATION; PLASMA; SEQUENCE	Activated platelets expose a specific, reversible high affinity (K-dapp similar or equal to 10 nM) binding site (n similar or equal to 1500 sites/platelet platelet) for factor XI that requires the presence of high molecular weight kininogen (HK) and ZnCl2 (Greengard, J. S., Heeb, M. J., Ersdal, E., Walsh, P. N., and Griffin, J. H. (1986) Biochemistry 25, 3884-3890), Synthetic, conformationally constrained peptides from four tandem repeat (Apple) domains were tested for their capacity to inhibit I-125-factor XI binding to platelets, A peptide from the Apple 3 (A3) domain (Asn(235)-Arg(266)) inhibits factor XI binding to platelets in the presence of HK (42 nM), CaCl2, (2 mM), and ZnCl2 (25 mu M), with a K-i similar or equal to 10 nM which is identical to the K-d for factor XI binding to platelets, A peptide from the A1 domain (Phe(56)-Ser(86)) partially inhibits factor XI binding to platelets (Ki = 6 mu M) by inhibiting factor M binding to HK, whereas peptides from the A2 and A4 domains have no effect, Using computer modeling for rational design, conformationally constrained peptides were synthesized (Pro(229) Gln(233), Thr(241)-Leu(246), and Ser(248)-Ser(261)) each of which acted alone and synergistically when added together to inhibit factor XI: binding to platelets, Finally, the I-125-labeled A3 domain peptide (Asn(235)-Arg(266)) was found to bind to thrombin activated platelets in a specific, reversible, and saturable manner, Thus, the sequence of amino acids Asn(235)-Arg(266) Of the A3 domain of factor XI comprises a contact surface for interaction with a platelet receptor.	TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University					NHLBI NIH HHS [HL46213, HL25661, HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025661, P50HL045486, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FAIR BD, 1977, P SOC EXP BIOL MED, V155, P199; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFIN JH, 1979, SEMIN THROMB HEMOST, V5, P254; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; KAMP FH, 1991, ANAL CHEM, V63, pA1193; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINHA D, 1985, J BIOL CHEM, V260, P714; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; WALSH PN, 1993, METHOD ENZYMOL, V222, P65; WALSH PN, 1981, BLOOD, V57, P106	23	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6734	6740		10.1074/jbc.270.12.6734	http://dx.doi.org/10.1074/jbc.270.12.6734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896818	hybrid			2022-12-27	WOS:A1995QQ85500049
J	STAUFFER, KA				STAUFFER, KA			THE GAP JUNCTION PROTEINS BETA(1)-CONNEXIN (CONNEXIN-32) AND BETA(2)-CONNEXIN (CONNEXIN-26) CAN FORM HETEROMERIC HEMICHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER	Two different types of gap junction proteins, beta(1)- and beta(2)-connexin, were expressed in insect cells, either singly or together, using infection with recombinant baculovirus. Membrane fractions enriched in gap junction proteins were isolated, and connexons (hemichannels) were solubilized with detergent. These solubilized connexons were then run out on a gel filtration column which was capable of partially separating the two homomeric connexons. It was found that connexons from cells co-infected with both types of baculovirus ran together on this column, whereas connexons from cells infected separately and mixed before solubilization did not, suggesting that in the co-infected cells the two types of connexin are assembled into heteromeric hemichannels.	MRC,MOLEC BIOL LAB,CAMBRIDGE,ENGLAND	MRC Laboratory Molecular Biology								Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BUEHLER LK, 1995, IN PRESS BIOPHYS J; HERTZBERG EL, 1979, J BIOL CHEM, V254, P2138; HERTZBERG EL, 1984, J BIOL CHEM, V259, P9936; KISTLER J, 1994, J CELL BIOL, V126, P1047, DOI 10.1083/jcb.126.4.1047; KORDEL M, 1993, BIOPHYS J, V64, pA192; Kumar N M, 1992, Semin Cell Biol, V3, P3; Kumar Nalin M., 1991, Advances in Structural Biology, V1, P209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RUBIN JB, 1992, BIOPHYS J, V62, P183, DOI 10.1016/S0006-3495(92)81804-0; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; SUMMERS MD, 1987, TEX AGR EXP ST B, V1555; TANFORD C, 1974, BIOCHEMISTRY-US, V11, P2369; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039	16	167	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6768	6772						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896822				2022-12-27	WOS:A1995QQ85500053
J	DUCKWORTH, WC; BENNETT, RG; HAMEL, FG				DUCKWORTH, WC; BENNETT, RG; HAMEL, FG			A DIRECT INHIBITORY EFFECT OF INSULIN ON A CYTOSOLIC PROTEOLYTIC COMPLEX CONTAINING INSULIN-DEGRADING ENZYME AND MULTICATALYTIC PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; RAT HEPATOMA-CELLS; DROSOPHILA-MELANOGASTER; DEGRADATION PRODUCTS; ISOLATED HEPATOCYTES; RECEPTOR-BINDING; MAMMALIAN-CELLS; SKELETAL-MUSCLE; PROTEASE; PURIFICATION	The insulin degrading enzyme (IDE) and the multicatalytic proteinase (MCP) can be isolated as components of a cytosolic proteolytic complex. IDE is the primary enzyme involved in cellular degradation of insulin, and insulin has been shown to interact with cytosolic IDE. MCP is believed to be important in nonubiquitin pathways of cellular protein degradation. Insulin has a dose- and time-dependent inhibitory effect on MCP degradation of N-succinyl-Leu-Leu-Val-Tyr 7-amido-4-methylcoumarin (LLVY), a substrate for MCP. Proinsulin also inhibits LLVY degradation in a dose dependent manner. The effect of insulin is immediate as measured in a continuously monitored assay of LLVY degradation. purification of the IDE MCP complex using a variety of approaches, including affinity and conventional chromatography, retains the insulin effect on LLVY degradation as long as the complex remains intact. After ion-exchange chromatography, which separates IDE and MCP, insulin no longer has an inhibitory effect. Recombination of purified IDE and MCP does not restore the effect of insulin, but inclusion of additional components from the ion exchange column does. These results support the existence of a functional cytosolic complex that contains IDE and MCP. Insulin interacts with IDE and alters the activity of MCP, suggesting a functional relationship between these two components and a mechanism for an intracellular action of insulin.			DUCKWORTH, WC (corresponding author), UNIV NEBRASKA, MED CTR, VET AFFAIRS MED CTR, 600 S 42ND ST, OMAHA, NE 68198 USA.							AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; BASKIN FK, 1973, EUR J BIOCHEM, V37, P489, DOI 10.1111/j.1432-1033.1973.tb03010.x; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; BURGHEN GA, 1972, ENDOCRINOLOGY, V91, P633, DOI 10.1210/endo-91-3-633; DRAZNIN B, 1982, J BIOL CHEM, V257, P1988; DUCKWORT.WC, 1972, P NATL ACAD SCI USA, V69, P3698, DOI 10.1073/pnas.69.12.3698; DUCKWORTH WC, 1987, BIOCHEM BIOPH RES CO, V147, P615, DOI 10.1016/0006-291X(87)90975-2; DUCKWORTH WC, 1989, AM J PHYSIOL, V256, pE208, DOI 10.1152/ajpendo.1989.256.2.E208; DUCKWORTH WC, 1988, ENDOCRINOLOGY, V123, P2701, DOI 10.1210/endo-123-6-2701; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; FRANK BH, 1983, DIABETES, V32, P705, DOI 10.2337/diab.32.8.705; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GARCIA JV, 1989, J CELL BIOL, V108, P177, DOI 10.1083/jcb.108.1.177; HAMEL FG, 1991, DIABETES, V40, P436, DOI 10.2337/diabetes.40.4.436; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HARADA S, 1993, ENDOCRINOLOGY, V132, P2293, DOI 10.1210/en.132.6.2293; HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFMANN CA, 1983, J BIOL CHEM, V258, P1774; HOUGH R, 1987, J BIOL CHEM, V262, P8303; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KOLB HJ, 1980, H-S Z PHYSIOL CHEM, V361, P1029, DOI 10.1515/bchm2.1980.361.2.1029; KUEHN L, 1990, FEBS LETT, V261, P274, DOI 10.1016/0014-5793(90)80570-9; KUEHN L, 1992, ARCH BIOCHEM BIOPHYS, V295, P55, DOI 10.1016/0003-9861(92)90487-H; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LI D, 1992, J BIOL CHEM, V267, P2414; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P195, DOI 10.1016/0304-4165(88)90009-8; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MIRSKY IA, 1957, RECENT PROG HORM RES, V13, P429; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PEAVY DE, 1985, J BIOL CHEM, V260, P3989; PEAVY DE, 1984, ENDOCRINOLOGY, V114, P753, DOI 10.1210/endo-114-3-753; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1993, BIOCHEM J, V291, P1; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; YOKONO K, 1982, ENDOCRINOLOGY, V111, P1102, DOI 10.1210/endo-111-4-1102	45	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24575	24580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929129				2022-12-27	WOS:A1994PQ49000013
J	OLAH, ME; JACOBSON, KA; STILES, GL				OLAH, ME; JACOBSON, KA; STILES, GL			ROLE OF THE 2ND EXTRACELLULAR LOOP OF ADENOSINE RECEPTORS IN AGONIST AND ANTAGONIST BINDING - ANALYSIS OF CHIMERIC A(1)/A(3)-ADENOSINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; LIGAND-BINDING; HUMAN BRAIN; ADENOSINE-A1-RECEPTOR CDNA; NEUROKININ-1 RECEPTOR; HIGH-AFFINITY; RAT-BRAIN; EXPRESSION; A1	Adenosine receptor (AR) agonists and antagonists are similar to 100-fold and 100,000-fold, respectively, more potent at the bovine A(1)AR as compared to the rat A(3)AR. To determine regions of ARs involved in ligand recognition, chimeric receptors composed of bovine A(1)AR and rat A(3)AR sequence were constructed and their ligand binding properties examined following expression in COS-7 cells. Substitutions of the second extracellular loop or a region encompassing transmembrane domains 6 and 7 of the A(1)AR into the A(3)AR resulted in enhanced affinities of both agonists and antagonists compared to wild-type A(3)AR. The region of the second extracellular loop of the A(1)AR responsible for this effect was identified as the distal eleven amino acids of the loop. Replacement of this segment of the A(3)AR with that of the A(1)AR in combination with the regions encompassing transmembrane domains 6 and 7 resulted in a 50,000-fold increase in the K-d for antagonist radioligand, [H-3]1,3-dipropyl-8-cyclopentylxanthine. Agonist affinity at this chimeric was over 100-fold greater than that displayed by wild-type A(3)AR. Thus, multiple regions of ARs including a segment of the second extracellular loop are involved in ligand recognition, and considerable overlap exists in structural features required for agonist and antagonist binding.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; NIDDK, BIOORGAN CHEM LAB, BETHESDA, MD 20892 USA	Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134, P50HL017670] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999, Z01 DK031117-20] Funding Source: Medline; NHLBI NIH HHS [NHLBI RO1HL35134, NHLBI P50HL17670] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRINGTON WW, 1989, J BIOL CHEM, V264, P13157; BEAVEN MA, 1994, TRENDS PHARMACOL SCI, V15, P13, DOI 10.1016/0165-6147(94)90124-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOUDHARY MS, 1992, MOL PHARMACOL, V42, P627; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DUDLEY MW, 1993, DRUG DEVELOP RES, V28, P237, DOI 10.1002/ddr.430280309; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GETHER U, 1994, MOL PHARMACOL, V45, P500; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; IJzerman A P, 1992, Drug Des Discov, V9, P49; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LINDEN J, 1993, MOL PHARMACOL, V44, P524; MACKENZIE RG, 1993, FEBS LETT, V323, P59, DOI 10.1016/0014-5793(93)81448-9; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLAH ME, 1994, J BIOL CHEM, V269, P18016; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; SCHWABE U, 1985, N-S ARCH PHARMACOL, V330, P212, DOI 10.1007/BF00572436; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; VANGALEN PJM, 1992, MED RES REV, V12, P423, DOI 10.1002/med.2610120502; WANG CD, 1991, MOL PHARMACOL, V40, P168; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	46	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24692	24698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929142				2022-12-27	WOS:A1994PQ49000029
J	BERNSTEIN, R; DEJONG, J; ROEDER, RG				BERNSTEIN, R; DEJONG, J; ROEDER, RG			CHARACTERIZATION OF THE HIGHLY CONSERVED TFIIA SMALL-SUBUNIT FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR-IIA; TATA-BINDING PROTEIN; GENE-TRANSCRIPTION; INITIATION-FACTORS; IDENTIFICATION; ACTIVATION; PURIFICATION; COACTIVATORS; PROMOTER	TPIIA is a general transcription factor that modulates class II transcription initiation in vitro by functionally and physically interacting with TFIID or the derived TATA-binding protein (TBP). TFIIA was previously purified from human, bovine, rat, and yeast sources and has recently been identified in association with TFIID in Drosophila. Here, we report the cloning of a cDNA encoding the 12.5-kDa subunit of TFIIA from Drosophila melanogaster (dTFIIA-S) and the identification of a partial dTFIIA-S gene in Drosophila virilis. The deduced amino acid sequence of dTFIIA-S indicates a high degree of homology to the small TFIIA subunit from yeast and to a partial TFIIA-S cDNA identified in rice. A hybrid TFIIA consisting of recombinant dTFIIA-S and the recombinant human TFIIA/alpha gene product mimics natural TFIIA activity in a TBP-dependent DNA binding assay. The promoter complex formed with this hybrid TFIIA depends upon the TATA element and can be efficiently incorporated into a higher order preinitiation complex upon addition of TFIIB. The presence of dTFIIA-S within the TBP-TFIIA-promoter complex was demonstrated using anti-dTFIIA-S antiserum. Finally, the ability of recombinant dTFIIA-S to reconstitute transcriptionally active TFIIA was demonstrated in a well defined human transcription system.			BERNSTEIN, R (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.				NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI127379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Coulombe Benoit, 1992, Gene Expression, V2, P99; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, IN PRESS CELL; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1990, P NATL ACAD SCI USA, V87, P5916, DOI 10.1073/pnas.87.15.5916; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOSTROZA JA, 1992, CELL, V70, P477; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MA D, 1993, GENE DEV, V7, P2235; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENBERG AHH, 1987, GENE, V56, P155; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	39	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24361	24366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929095				2022-12-27	WOS:A1994PQ34600079
J	GARRITSEN, A; SIMONDS, WF				GARRITSEN, A; SIMONDS, WF			MULTIPLE DOMAINS OF G-PROTEIN-BETA CONFER SUBUNIT SPECIFICITY IN BETA-GAMMA-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; LIMITED PROTEOLYSIS; COILED-COIL; TRANSDUCIN; ASSOCIATION; PRENYLATION; EXPRESSION; ANTIBODIES; DIMERS; CELLS	The expression and assembly of particular combinations of beta and gamma subunit isoforms into beta gamma heterodimers may contribute to the specificity of signal transduction mediated by heterotrimeric guanine nucleotide binding regulatory proteins. Using a transient transfection paradigm to examine selectivity in beta gamma heterodimer formation, we find that gamma(1) interacts with beta(1) but not with beta(2), while both beta subunits interact with gamma(2) and that a beta(2)/beta(1) chimera containing the N-terminal 41 residues of beta(2) retained a beta(1), phenotype. These results confirm previous reports and imply that a structure or structures between residues 42 and 340 in the C-terminal region of the beta subunit imparts the ability to distinguish between gamma chains. Extending this chimeric approach to further localize the regions of beta important for selectivity between gamma subunits, we find that the region of beta(1) or beta(2) between residue 215 and the C terminus is sufficient to confer the parental phenotype. Additional mutants implicate multiple regions of beta, including discrete residues in the variable connecting segments joining conserved elements of the fifth and sixth GH-WD repeats toward the C terminus of beta. These findings suggest a multidomain interaction between beta and gamma.	NIDDK,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CLARK KL, 1993, MOL CELL BIOL, V13, P1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1993, NAT GENET, V5, P3, DOI 10.1038/ng0993-3; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Spiegel A. M., 1994, G PROTEINS; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	33	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24418	24423						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929103				2022-12-27	WOS:A1994PQ34600088
J	HAYES, G; BUSCH, A; LOTSCHER, M; WALDEGGER, S; LANG, F; VERREY, F; BIBER, J; MURER, H				HAYES, G; BUSCH, A; LOTSCHER, M; WALDEGGER, S; LANG, F; VERREY, F; BIBER, J; MURER, H			ROLE OF N-LINKED GLYCOSYLATION IN RAT RENAL NA/P-I-COTRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY PROXIMAL TUBULES; CELLULAR MECHANISMS; INORGANIC-PHOSPHATE; EXPRESSION; TRANSPORT; OLIGOSACCHARIDES; REABSORPTION; LOCALIZATION; MEMBRANE; CLONING	Our laboratory recently identified a sodium-dependent transport system for phosphate from rat kidney cortex (NaPi-2; Magagnin, S., Werner, A., Markovich, D., Sorribas, V., Stange, G., Biber, J., and Murer, H. (1993) Proc. Natl. Acad Sci. U.S.A. 90, 5979-5983). In the present study we have investigated whether or not this cotransporter is glycosylated and the role of N-glycosylation in determining its function. Glycosidase digestion of the NaPi-2 protein from rat brush border membranes, in vitro translation studies, or oocyte expression of the NaPi-2 cRNA indicate that the mature protein is glycosylated. Glycosidase treatment reduces the size of the protein from similar to 70-110 kDa to similar to 60-65 kDa. We therefore used site-directed mutagenesis to identify which of the putative consensus sites for N-linked glycosylation are utilized in the mature NaPi-2 protein. Altering the nucleotide sequences encoding both of the Asn-298 and Asn-328 residues to Gln produced mutants that are completely devoid of glycosylation, whereas mutants in which each of these sites were mutated separately are glycosylated when expressed in oocytes. These results suggest that both of these sites are modified by N-linked glycosylation in the mature protein. Surface expression of glycosylated and unglycosylated NaPi-2-related proteins was documented by biotinylation experiments. In contrast to the wild-type (fully glycosylated) transporter, immunocytochemistry provides evidence for a partial intracellular localization of mutant unglycosylated cotransporters. Na/P-i cotransport was studied in oocytes expressing wild-type or mutagenized NaPi-2 proteins using tracer or electrophysiological techniques. Although the transport rates are lower (by a factor of 2-3) after expression of the unglycosylated NaPi-2 protein, the P-i transport characteristics (pH dependence, apparent affinity for P-i or Na+) are similar in oocytes expressing either wild-type or glycosylation-deficient proteins.	UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY	University of Zurich; Eberhard Karls University of Tubingen				Verrey, Francois/0000-0003-3250-9824				BERON J, 1994, AM J PHYSIOL, V266, pC1278, DOI 10.1152/ajpcell.1994.266.5.C1278; BIBER J, 1993, PFLUG ARCH EUR J PHY, V424, P210, DOI 10.1007/BF00384344; BIBER J, 1994, CELL PHYSIOL BIOCHEM, V4, P185, DOI 10.1159/000154725; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH AE, 1994, IN PRESS P NATL ACAD; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; CUSTER M, 1993, PFLUG ARCH EUR J PHY, V424, P203, DOI 10.1007/BF00384343; FUCENTESE M, 1994, EXPERIENTIA, V50, pS15; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P554, DOI 10.1007/BF00382689; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683	23	103	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24143	24149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929070				2022-12-27	WOS:A1994PQ34600048
J	IRBY, RB; ADAIR, WL				IRBY, RB; ADAIR, WL			INTERMEDIATES IN THE FOLIC-ACID BIOSYNTHETIC-PATHWAY ARE INCORPORATED INTO MOLYBDOPTERIN THE YEAST, PICHIA-CANADENSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; NITRATE REDUCTASE; ESCHERICHIA-COLI; CONVERTING FACTOR; ENZYMATIC FORMATION; PTERINS; TETRAHYDROBIOPTERIN; PRECURSOR; ENZYMES; LIVER	Biosynthesis of molybdopterin was followed in the yeast, Pichia canadensis, using labeled precursors. High performance liquid chromatography analysis of extracts from cells labeled with [U-C-14]guanosine showed that the label was incorporated into the molybdopterin oxidation product, dephospho Form A. Dephospho Form A isolated from cells labeled with [(UC)-C-14,5'-H-3]guanosine was devoid of tritium, indicating partial loss of the ribose moiety of guanosine during the synthesis of molybdopterin. In vivo labeling of P. canadensis using [7-C-14]neopterin and [6,7,1-C-14]hydroxymethylpterin led to label from both compounds appearing in dephospho Form A as well as in folic acid in wild type cells. When these labeled precursors were incubated with P. canadensis mutants blocked in molybdopterin synthesis, only folic acid was labeled. These results suggest a shared pathway in the biosyntheses of molybdopterin and folic acid. [6-C-14]Glucose labeling experiments led to exclusive incorporation into the 4'-position of dephospho Form A but not in folic acid, It is proposed that molybdopterin synthesis branches from the folic acid biosynthetic pathway at dihydrohydroxymethylpterin and that a 5-carbon phosphorylated compound such as glyceraldehyde 3-phosphate may condense with dihydrohydroxymethylpterin to form the 4-carbon side chain precursor to molybdopterin.	UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida					NIGMS NIH HHS [GM41003] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; BURG AW, 1968, J BIOL CHEM, V243, P2349; DHONDT JL, 1990, J INHERIT METAB DIS, V13, P879, DOI 10.1007/BF01800213; DHONDT JL, 1985, J INHERIT METAB DIS, V8, P47, DOI 10.1007/BF01801660; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; ETO I, 1992, J AUTISM DEV DISORD, V22, P295, DOI 10.1007/BF01058157; FRIEDKIN M, 1962, FED PROC, V21, P176; GOLDBERG M, 1991, J VET MED A, V38, P49, DOI 10.1111/j.1439-0442.1991.tb00983.x; HAGEMAN RV, 1986, METHOD ENZYMOL, V122, P399; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HYLAND K, 1993, PEDIATR RES, V34, P10, DOI 10.1203/00006450-199307000-00003; IRBY R, 1994, ANAL BIOCHEM, V218, P413, DOI 10.1006/abio.1994.1200; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1977, J BIOL CHEM, V252, P4994; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; JOHNSON JL, 1969, METABOLIC BASIS INHE, P1463; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JONES THD, 1967, J BIOL CHEM, V242, P3989; KERLER F, 1989, BIOCHIM BIOPHYS ACTA, V990, P15, DOI 10.1016/S0304-4165(89)80005-4; KLEIN R, 1993, CHROMATOGRAPHIA, V36, P71, DOI 10.1007/BF02263840; MAILANDER B, 1976, J BIOL CHEM, V251, P3623; MANJULA S, 1993, ACTA ONCOL, V32, P29, DOI 10.3109/02841869309083881; MATHIS JB, 1970, J BIOL CHEM, V245, P3015; MURAKAMI K, 1975, BIOCHIM BIOPHYS ACTA, V384, P390, DOI 10.1016/0005-2744(75)90040-6; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIELSEN P, 1986, J BIOL CHEM, V261, P3661; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PIENKOS PT, 1977, P NATL ACAD SCI USA, V74, P5468, DOI 10.1073/pnas.74.12.5468; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; RAJAGOPALAN KV, 1988, ANNU REV NUTR, V8, P401, DOI 10.1146/annurev.nu.08.070188.002153; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; REMBOLD H, 1963, CHEM BER, V96, P1395; Rembold H., 1963, CHEM BER-RECL, V96, P1406; SEBESTA I, 1991, ADV EXP MED BIOL, V309, P261; SEO N, 1991, BIOCHIM BIOPHYS ACTA, V1074, P439, DOI 10.1016/0304-4165(91)90097-Z; SOLOMONS.LP, 1972, PLANT PHYSIOL, V50, P421, DOI 10.1104/pp.50.4.421; SOLOMONSON LP, 1986, J BIOL CHEM, V261, P1290; VAN QL, 1988, BIOCHEM BIOPH RES CO, V151, P512, DOI 10.1016/0006-291X(88)90623-7; WOLF WA, 1969, BIOCHIM BIOPHYS ACTA, V192, P468, DOI 10.1016/0304-4165(69)90396-1; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; ZAGALAK B, 1988, BIOL CHEM H-S, V369, P535	46	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23981	23987						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929047				2022-12-27	WOS:A1994PQ34600023
J	VALE, RD; COPPIN, CM; MALIK, F; KULL, FJ; MILLIGAN, RA				VALE, RD; COPPIN, CM; MALIK, F; KULL, FJ; MILLIGAN, RA			TUBULIN GTP HYDROLYSIS INFLUENCES THE STRUCTURE, MECHANICAL-PROPERTIES, AND KINESIN DRIVEN TRANSPORT OF MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; CRYOELECTRON MICROSCOPY; SURFACE LATTICE; MOVEMENT; POLYMERIZATION; MOLECULES; INVITRO; CELLS	Tubulin is a GTPase that hydrolyzes its bound nucleotide triphosphate after it becomes incorporated into a microtubule. The only known consequence of nucleotide hydrolysis is that it increases the dissociation rate of tubulin from the end of the microtubule by 2 orders of magnitude. In this study, we investigated whether microtubules composed of tubulin-GMPCPP (guanylyl alpha,beta-methylenediphosphate) (a very slowly hydrolyzed GTP analog) or tubulin-GDP exhibit additional structural or functional differences. We show that tubulin-GMPCPP microtubules are significantly stiffer than tubulin-GDP microtubules and have a 21% shallower protofilament twist angle. We also find that kinesin, a microtubule-based motor protein, transports tubulin-GMPCPP microtubules at similar to 30% faster rates than tubulin-GDP microtubules. These findings suggest that growing microtubule ends, which are thought to be composed of tubulin-GTP, may have different structural and mechanical properties from the remainder of the microtubule polymer.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Francisco; Marine Biological Laboratory - Woods Hole; Scripps Research Institute	VALE, RD (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039155] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39155] Funding Source: Medline; PHS HHS [38499] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; AMOS LA, 1991, J CELL SCI, P95; ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Cleveland Don W., 1993, P101; DYE RB, 1993, J BIOL CHEM, V268, P6847; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1991, J CELL SCI, P125; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P306; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Oosawa F., 1975, THERMODYNAMICS POLYM; SAMMAK PJ, 1988, CELL MOTIL CYTOSKEL, V10, P237, DOI 10.1002/cm.970100128; SANDOVAL IV, 1978, P NATL ACAD SCI USA, V75, P3178, DOI 10.1073/pnas.75.7.3178; SANDOVAL IV, 1977, P NATL ACAD SCI USA, V74, P4881, DOI 10.1073/pnas.74.11.4881; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; VALE RD, 1989, J CELL BIOL, V108, P2327, DOI 10.1083/jcb.108.6.2327; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WALKER RA, 1991, J CELL BIOL, V114, P73, DOI 10.1083/jcb.114.1.73; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453	38	90	90	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23769	23775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916345				2022-12-27	WOS:A1994PQ34500059
J	DEFEA, KA; NAKAHARA, DH; CALAYAG, MC; YOST, CS; MIRELS, LF; PRUSINER, SB; LINGAPPA, VR				DEFEA, KA; NAKAHARA, DH; CALAYAG, MC; YOST, CS; MIRELS, LF; PRUSINER, SB; LINGAPPA, VR			DETERMINANTS OF CARBOXYL-TERMINAL DOMAIN TRANSLOCATION DURING PRION PROTEIN BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE SIGNAL SEQUENCE; STOP-TRANSFER; TRANSMEMBRANE ORIENTATION; ENDOPLASMIC-RETICULUM; TOPOGENIC SEQUENCE; MEMBRANE-PROTEIN; APOLIPOPROTEIN-B; ER MEMBRANE; SCRAPIE; TRANSLATION	The prion protein (PrP) displays some unusual features in its biogenesis. In cell-free systems it can be synthesized as either an integral transmembrane protein spanning the membrane twice, with both amino and carboxyl domains in the lumen of the endoplasmic reticulum, or as a fully translocated polypeptide, A charged, extracytoplasmic region, termed the Stop Transfer Effector (STE) sequence, has been shown to direct the nascent translocating chain to stop at the adjoining hydrophobic domain to generate the first membrane-spanning region (TM1). However, the determinants of the second translocation event in the biogenesis of the transmembrane form have not been identified previously. Moreover, the relationship of transmembrane and fully translocated forms of PrP has not been well understood. Here, we report progress in resolving both of these issues. Using protein chimeras in cell-free translation systems and Xenopus oocytes, we identify the sequence which directs nascent PrP to span the membrane a second time, with its carboxyl-terminal domain in the endoplasmic reticulum lumen. Surprisingly, PrP carboxyl-terminal domain translocation does not appear to be directed by an internal signal or signal-anchor sequence located downstream of TM1, as would have been expected from studies of other multispanning membrane proteins. Rather, carboxyl-terminal domain translocation appears to be another consequence of the action of STE-TM1, that is, the same sequence responsible for generating the first membrane-spanning region. Studies of an STE-TM1-containing protein chimera in Xenopus oocytes demonstrate that most of these chains upon completion of their translation, initially span the membrane twice, with a topology similar to that of transmembrane PrP, but are carbonate-extractable. These chains have the transmembrane orientation only transiently and chase into a fully translocated form. These results support a model in which a metastable ''transmembrane'' intermediate, residing within the aqueous environment of the translocation channel, can be converted into either the integrated transmembrane or the fully translocated form of PrP, perhaps directed by trans-acting factor (s). Such a model may explain why stable the transmembrane isoform of PrP has not been observed in normal cells and how nascent PrP might be directed to alternate pathways of folding.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lingappa, Vishwanath R./0000-0003-0962-6571				BARRY RA, 1988, J IMMUNOL, V140, P1188; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BUELERH, 1992, NATURE, V356, P111; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; KATZ FN, 1979, J CELL BIOL, V80, P416, DOI 10.1083/jcb.80.2.416; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MEYERS RK, 1986, P NATL ACAD SCI USA, V85, P2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SIMON K, 1987, J CELL BIOL, V104, P1165, DOI 10.1083/jcb.104.5.1165; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPIESS M, 1989, J BIOL CHEM, V264, P19117; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16810	16820						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7911469				2022-12-27	WOS:A1994NR29600048
J	COLOTTA, F; RE, F; MUZIO, M; POLENTARUTTI, N; MINTY, A; CAPUT, D; FERRARA, P; MANTOVANI, A				COLOTTA, F; RE, F; MUZIO, M; POLENTARUTTI, N; MINTY, A; CAPUT, D; FERRARA, P; MANTOVANI, A			INTERLEUKIN-13 INDUCES EXPRESSION AND RELEASE OF INTERLEUKIN-1 DECOY RECEPTOR IN HUMAN POLYMORPHONUCLEAR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IL-1 RECEPTOR; SUPERFAMILY; LYMPHOKINE; RNA	The aim of this study was to examine whether interleukin-13 (IL-13), a cytokine with anti-inflammatory activities, affected expression of interleukin-1 (IL-1) receptors (R) in human polymorphonuclear cells (PMN). Treatment with IL-13 augmented both type I and type II (decoy) R transcripts, with the latter being by far the most represented. The transcriptional inhibitor actinomycin D blocked the induction of IL-1 R mRNAs by IL-13. Nuclear run-off experiments demonstrated an augmented transcriptional rate of IL-1 decoy R in IL-13-treated B lymphoblastoid cells. The protein synthesis inhibitor cycloheximide blocked type I R expression but superinduced decoy R expression. IL-13 augmented the binding of radiolabeled IL-1 beta on the PMN surface with an increased number of IL-1 receptors and no change in K-d values. IL-13 induced the surface expression of IL-1 decoy R and the release by PMN of an IL-1-binding protein identified as a soluble version of the IL-1 decoy R. These results show that PMN is an important target for IL-13 and that induction of expression and release of the IL-1 decoy R, in concert with inhibition of cytokine synthesis, may represent an important mechanism by which IL-13 blocks IL-1, a central mediator of inflammatory reactions.	SANOFI ELF BIORECH,F-31676 LABEGE,FRANCE	Sanofi-Aventis	COLOTTA, F (corresponding author), IST RIC FARMACOL MARIO NEGRI,CTR DANIELA & CATULLO BORGOMAINERIO,VIA ERITREA 62,I-20157 MILAN,ITALY.		Muzio, Marta/J-9360-2018; Mantovani, Alberto/HCI-7449-2022	Muzio, Marta/0000-0002-7761-759X; Mantovani, Alberto/0000-0001-5578-236X; Colotta, Francesco/0000-0001-8601-2309				BROWN KD, 1989, J IMMUNOL, V142, P679; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DINARELLO CA, 1991, BLOOD, V77, P1627; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSSMAN TR, 1991, IMMUNOL REV, V123, P209; MUZIO M, 1994, BLOOD, V83, P1738, DOI 10.1182/blood.V83.7.1738.bloodjournal8371738; PAUL WE, 1991, BLOOD, V77, P1859; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	19	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12403	12406						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909801				2022-12-27	WOS:A1994NH71600006
J	GESSERT, SF; KIM, JH; NARGANG, FE; WEISS, RL				GESSERT, SF; KIM, JH; NARGANG, FE; WEISS, RL			POLYPROTEIN PRECURSOR OF 2 MITOCHONDRIAL-ENZYMES IN NEUROSPORA-CRASSA - GENE STRUCTURE AND PRECURSOR PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; GAMMA-SEMIALDEHYDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ACETYLGLUTAMATE KINASE; INTERMEMBRANE SPACE; ARGC GENE; ASD GENE	N-Acetylglutamate kinase (AGK) and N-acetyl-gamma-glutamyl-phosphate reductase (AGPR) function as two separate mitochondrial enzymes, but are encoded by a single nuclear gene in several fungi. The Neurospora crassa arg-6 gene encoding these enzymes has been cloned and sequenced, and the enzymes responsible for processing the polyprotein precursor have been identified. The 871-amino acid precursor contains a normal N-terminal mitochondrial targeting sequence, an internal connecting region (approximately 200 amino acids) upstream of the distal reductase domain, and coding regions with N-terminal amino acid sequences identical with those of purified N-acetylglutamate kinase and N-acetyl-gamma-glutamyl-phosphate reductase. Sequence comparisons of the coding regions indicate high levels of conservation between prokaryotic and fungal proteins. Regions suggesting ancestral relationships to N-acetylglutamate synthase and aspartate beta-semialdehyde dehydrogenase have been identified. Both the N-terminal targeting sequence and the connecting region contain consensus sites for cleavage by the mitochondrial processing peptidase and processing enhancing protein. In vitro processing assays with intact mitochondria, solubilized mitochondria, and purified enzymes have shown that the mitochondrial processing peptidase and processing enhancing protein cleave not only the N-terminal mitochondrial targeting sequence but also process the polyprotein precursor into the two mature enzymes.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV ALBERTA,DEPT GENET,EDMONTON T6G 2E9,AB,CANADA	University of California System; University of California Los Angeles; University of Alberta					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036552] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARIL C, 1992, J GEN MICROBIOL, V138, P47, DOI 10.1099/00221287-138-1-47; BIELLMANN JF, 1980, EUR J BIOCHEM, V104, P59, DOI 10.1111/j.1432-1033.1980.tb04399.x; BIGELIS R, 1981, J BIOL CHEM, V256, P5144; BOEHNI P, 1980, ORG EXPRESSION MITOC, P423; BONNER DAVID M., 1965, P305; BONNER WM, 1983, METHOD ENZYMOL, V96, P215; BOONCHIRD C, 1991, MOL GEN GENET, V226, P154, DOI 10.1007/BF00273599; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BRANLANT G, 1985, EUR J BIOCHEM, V150, P61, DOI 10.1111/j.1432-1033.1985.tb08988.x; BROWN K, 1987, NUCLEIC ACIDS RES, V15, P10586, DOI 10.1093/nar/15.24.10586; BURNS DM, 1990, J BIOL CHEM, V265, P2060; CARDINEAU GA, 1987, J BIOL CHEM, V262, P3344; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; DAUM G, 1982, J BIOL CHEM, V257, P3075; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DAVIS RH, 1979, GENETICS, V93, P557; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DAVIS RH, 1983, MOL GEN GENET, V192, P46, DOI 10.1007/BF00327645; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, P89; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLORIANO B, 1992, MOL MICROBIOL, V6, P2085, DOI 10.1111/j.1365-2958.1992.tb01381.x; GAERTNER FH, 1970, J BIOL CHEM, V245, P595; GAERTNER FH, 1977, BIOCHEM BIOPH RES CO, V75, P259, DOI 10.1016/0006-291X(77)91037-3; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLANSDORFF N, 1987, CELLULAR MOL BIOL, V1, P321; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; GUNSALUS RP, 1979, J BACTERIOL, V140, P106, DOI 10.1128/JB.140.1.106-113.1979; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HAZIZA C, 1982, EMBO J, V1, P379, DOI 10.1002/j.1460-2075.1982.tb01178.x; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLLAND JP, 1979, J BIOL CHEM, V254, P9839; HOLLAND JP, 1980, J BIOL CHEM, V255, P2596; HOLLAND JP, 1983, J BIOL CHEM, V258, P5291; HURT EC, 1987, J BIOL CHEM, V262, P1420; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KURTZ S, 1984, P NATL ACAD SCI-BIOL, V81, P7323, DOI 10.1073/pnas.81.23.7323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Maniatis T., 1982, MOL CLONING; MCADA PC, 1982, J BIOL CHEM, V257, P3177; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; METZENBERG RL, 1984, NEUROSPORA NEWSL, V31, P35; MINET M, 1979, MOL GEN GENET, V168, P299, DOI 10.1007/BF00271500; MIURA S, 1982, EUR J BIOCHEM, V122, P641; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; OHASHI A, 1982, J BIOL CHEM, V257, P3042; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PARSOT C, 1988, GENE, V68, P275, DOI 10.1016/0378-1119(88)90030-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; REID GA, 1982, J BIOL CHEM, V257, P3068; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPP W, 1986, HEPATO-GASTROENTEROL, V33, P45; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHWEIZER M, 1981, P NATL ACAD SCI-BIOL, V78, P5086, DOI 10.1073/pnas.78.8.5086; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SMITH MCM, 1990, NUCLEIC ACIDS RES, V18, P4595, DOI 10.1093/nar/18.15.4595; SRERE PA, 1974, ANNU REV MICROBIOL, V28, P61, DOI 10.1146/annurev.mi.28.100174.000425; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; THOMAS D, 1989, MOL GEN GENET, V217, P149, DOI 10.1007/BF00330954; VANHUFFEL C, 1992, EUR J BIOCHEM, V205, P33; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANDINGERNESS AU, 1986, J BIOL CHEM, V261, P4820; WANDINGERNESS AU, 1985, J BIOL CHEM, V260, P5974; WANDINGERNESS AU, 1987, J BIOL CHEM, V262, P5823; WILLIAMS LJ, 1992, MOL CELL BIOL, V12, P347, DOI 10.1128/MCB.12.1.347; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1984, MOL BIOL EVOL, V1, P143; YOUNG JL, 1990, MOL GEN GENET, V222, P120, DOI 10.1007/BF00283032; ZIMMERMANN R, 1983, METHOD ENZYMOL, V97, P275	95	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8189	8203						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907589				2022-12-27	WOS:A1994NB40900057
J	SAIJO, T; WELCH, WJ; TANAKA, K				SAIJO, T; WELCH, WJ; TANAKA, K			INTRAMITOCHONDRIAL FOLDING AND ASSEMBLY OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE (MCAD) - DEMONSTRATION OF IMPAIRED TRANSFER OF K304E-VARIANT MCAD FROM ITS COMPLEX WITH HSP60 TO THE NATIVE TETRAMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; LIVER MITOCHONDRIA; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; ESCHERICHIA-COLI; DEFICIENCY; MATRIX; GROEL	We incubated in vitro translated precursor of medium-chain acyl-CoA dehydrogenase (MCAD) with isolated rat liver mitochondria and fractionated the solubilized mitochondria on gel filtration. After a 5-min import into mitochondria, MCAD was recovered exclusively as a high molecular weight (hM(r)) complex (700,000), while after a 10 min import, it was recovered mainly in the hM(r) complex and mature tetramer, with a small amount in monomer. Either a further 15-min chase or exposure to ATP caused a marked decrease of MCAD in the hM(r) complex and an increase in the mature tetramer in comparable amounts, suggesting that the hM(r) complex was the precursor of tetramer. No monomer was detected in either case. Using specific antibodies, we have shown that the hM(r) complex represented a complex of MCAD and heat shock protein 60 (hsp60), and, that upon import into mitochondria, unfolded MCAD first formed a transient complex with mitochondrial heat-shock protein 70 (hsp70(mit)) and then transferred to hsp60 to complete its folding into an assembly-competent conformation. We also examined the assembly of K304E MCAD, which is a prevalent variant enzyme among patients with MCAD deficiency. The assembly of the K304E into its tetrameric form was severely impaired. The binding of K304E with hsp70(mit) and its transfer from hsp70(mit) to hsp60 were normal. However, the hsp60 complex of K304E was much more stable than the wild-type counterpart upon a 15-min chase or exposure to ATP, suggesting that the folding in, or the transfer of K304E subunit to tetramer from, the complex with hsp60 was impaired.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Yale University; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK38154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; COATES PM, 1992, PEDIATR RES, V31, P34, DOI 10.1203/00006450-199201000-00006; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GREGERSEN N, 1991, HUM GENET, V86, P545; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LOEWENSTEIN J, 1970, Biochimica et Biophysica Acta, V223, P432, DOI 10.1016/0005-2728(70)90201-X; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; MIZZEN LA, 1989, J BIOL CHEM, V264; NAGAO M, 1992, J BIOL CHEM, V267, P17925; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; Tanaka K., 1992, Human Mutation, V1, P271, DOI 10.1002/humu.1380010402; Towbin H, 1979, P NATL ACAD SCI USA, V76, P4530; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YOKOTA I, 1992, J BIOL CHEM, V267, P26004; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	35	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4401	4408						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905878				2022-12-27	WOS:A1994MW98900079
J	OSHIMA, H; SIMONS, SS				OSHIMA, H; SIMONS, SS			SEQUENCE-SELECTIVE INTERACTIONS OF TRANSCRIPTION FACTOR ELEMENTS WITH TANDEM GLUCOCORTICOID-RESPONSIVE ELEMENTS AT PHYSIOLOGICAL STEROID CONCENTRATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; TISSUE-CULTURE CELLS; DEXAMETHASONE 21-MESYLATE; HORMONE RECEPTORS; SYNERGISTIC ACTIVATION; AGONIST ACTIVITY; MMTV PROMOTER; INDUCTION; MODULATION; MECHANISM	Synergism in transcription is said to occur when the combined response from two DNA elements for the binding of trans-acting factors is greater than the sum of the responses from each element in isolation. The synergism of steroid receptors with themselves or with other trans-acting factors at saturating concentrations of steroid has proved to be an important component of steroid-regulated gene transcription. We have recently described a glucocorticoid modulatory element (GME) of the rat tyrosine aminotransferase gene that, in conjunction with a trans-acting factor, modulates the transcriptional activity of receptor-glucocorticoid and -antiglucocorticoid complexes with homologous and heterologous genes and promoters (Oshima, H., and Simons, S. S., Jr. (1992) Mol. Endocrinol. 6, 416-428). We now report that, under certain circumstances, the GME displays synergistic activity with a glucocorticoid-responsive element (GRE). However, several properties of GME action are different from those previously observed for synergism. The effects of the GME were marked at subsaturating or physiological concentrations of glucocorticoids but insignificant at saturating concentrations, which are the established conditions for synergism. The GME was found to increase the agonist activity of partial antiglucocorticoids, while synergism involving antisteroids has yet to be reported. Furthermore, the GRE was active in conjunction with two tandem repeats of a GRE, which was a combination that did not support conventional synergism. Most importantly, the effects of the GME were greater than with any other trans-acting factor binding element tested, indicative of a sequence-selective activity. The efficacy of the GME was also insensitive to the spacing between elements. Thus, the GME provides a mechanism for selective transcriptional modulation by physiological concentrations of steroid, and by antisteroids, of a common class of genes that are under the control of two or more GREs.	NIDDKD,STEROID HORMONES SECT,MOLEC & CELLULAR BIOL LAB,BLDG 8,RM B2A07,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANKENBAUER W, 1988, P NATL ACAD SCI USA, V85, P7526, DOI 10.1073/pnas.85.20.7526; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADSHAW MS, 1991, J BIOL CHEM, V266, P16684; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Maniatis T., 1982, MOL CLONING; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROUSSEAU GG, 1979, GLUCOCORTICOID HORMO, P49; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1988, J STEROID BIOCHEM, V31, P1, DOI 10.1016/0022-4731(88)90198-7; SIMONS SS, 1989, CANCER RES, V49, pS2244; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SIMONS SS, 1987, STEROID STEROL HORMO, P251; SISTARE FD, 1987, MOL ENDOCRINOL, V1, P648, DOI 10.1210/mend-1-9-648; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; THOMPSON EB, 1989, GENE REGULATION STER, P63; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283	43	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26858	26865						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903299				2022-12-27	WOS:A1993MM26200008
J	IKEBE, M; MITRA, S; HARTSHORNE, DJ				IKEBE, M; MITRA, S; HARTSHORNE, DJ			CLEAVAGE AT SITE-A, GLU-642 TO SER-643, OF THE GIZZARD MYOSIN HEAVY-CHAIN DECREASES AFFINITY FOR ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; LIGHT-CHAIN; CHICKEN GIZZARD; CONFORMATION; PHOSPHORYLATION; PROTEOLYSIS; PROTEINS; SUBFRAGMENT-1; MEROMYOSIN; ACTOMYOSIN	The actin-activated ATPase activities of subfragment 1 (S1) produced from gizzard myosin by papain or Staphylococcus aureus protease are different. The activity of the latter is lower, in spite of the presence of intact 20,000-dalton light chains. To study this difference, the S. aureus protease S1 was subjected to further proteolysis by papain. This second stage of proteolysis markedly increased actin-activated ATPase, due to a decrease in K(actin) with no change in V(m) and increased the affinity of S1 for actin in the presence of ATP. Treatment with papain caused degradation of the 20-kDa light chain, a decrease in the 26-kDa C-terminal domain of S1 and the 68-kDa fragment containing the N-terminal and central domains, and in the appearance and progressive increase of a 94-kDa fragment. The increase in actin-activated ATPase activity was due to the production of the 94-kDa fragment but not due to light chain degradation. Analyses of N-terminal sequences following papain digestion showed that the 94-kDa fragment was formed from a combination of the 68- and 26-kDa fragments. The bond formed probably involved the N-terminal residue of the 26-kDa fragment (Ser-643) and a side chain carboxyl (Glu-642) or amine (Glu-636). From the sequence data site A was identified as Glu-642-Ser-643. These results confirm the importance of site A in actin-binding of gizzard myosin. It is suggested that the sequence Ser-643 and Val-659, as well as the 3 lysine residues, are important for actin binding.	UNIV ARIZONA,DEPT ANIM SCI,TUCSON,AZ 85721	University of Arizona	IKEBE, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.				NHLBI NIH HHS [HL 37117] Funding Source: Medline; NIAMS NIH HHS [AR38888, AR 41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR038888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; DRISKA S, 1975, ARCH BIOCHEM BIOPHYS, V167, P203, DOI 10.1016/0003-9861(75)90457-9; FRASER AB, 1975, BIOCHEMISTRY-US, V14, P2207, DOI 10.1021/bi00681a025; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; Higashihara M, 1989, J BIOL CHEM, V264, P5218; IKEBE M, 1988, J BIOL CHEM, V263, P10698; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1962, BIOCHEM BIOPH RES CO, V7, P457, DOI 10.1016/0006-291X(62)90335-2; MARIANNEPEPIN T, 1985, BIOCHEMISTRY-US, V24, P3024, DOI 10.1021/bi00333a033; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; ONISHI H, 1984, J BIOCHEM, V95, P899, DOI 10.1093/oxfordjournals.jbchem.a134685; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; SMITH EL, 1960, ENZYMES, V4, P156; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	24	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25948	25951						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902357				2022-12-27	WOS:A1993MK10000094
J	DASILVA, ACR; KENDRICKJONES, J; REINACH, FC				DASILVA, ACR; KENDRICKJONES, J; REINACH, FC			DETERMINANTS OF ION SPECIFICITY ON EF-HANDS SITES - CONVERSION OF THE CA2+/MG2+ SITE OF SMOOTH-MUSCLE MYOSIN REGULATORY LIGHT-CHAIN INTO A CA2+-SPECIFIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; CALCIUM-BINDING PROTEINS; SCALLOP MYOSIN; TROPONIN-C; 3-DIMENSIONAL STRUCTURE; DIRECTED MUTAGENESIS; RESOLUTION; ONCOMODULIN; DISSOCIATION; PARVALBUMIN	Calcium binding proteins mediate a large number of cellular processes. These processes respond to micromolar fluctuations of cytosolic calcium in the presence of a large excess of magnesium. The metal binding sites present in these proteins are either calcium-specific (regulatory sites) or capable of binding both calcium and magnesium (structural sites). Using site-directed mutagenesis we were able to convert the single Ca2+/Mg2+ site present in chicken smooth muscle myosin regulatory light chain (RLC) into a Ca2+-specific site. The replacement of the aspartic acid present in the 12th position (-Z coordinating position) of the metal binding loop with a glutamic acid increases calcium affinity and abolishes magnesium binding, rendering the site calcium-specific. To explain this observation, we hypothesize that restrictions on the ability of side chains to change conformation, contributing one (for Mg2+ binding) or two (for Ca2+ binding) coordinations could alter the metal specificity in EF-hands. Other mutations which decrease or abolish calcium binding have also been characterized. When used to substitute the endogenous scallop myosin RLC, these mutants were capable of restoring the Ca2+ regulation to the actin-activated myosin ATPase demonstrating that in these hybrid myosins, the regulatory function of the Ca2+-specific site (present on the essential light chain) does not the occupancy of the Ca2+/Mg2+ site (present on the regulatory light chain).	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	DASILVA, ACR (corresponding author), UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,SP,BRAZIL.							AHMED FR, 1993, J MOL BIOL, V230, P1216, DOI 10.1006/jmbi.1993.1237; AHMED FR, 1990, J MOL BIOL, V216, P127, DOI 10.1016/S0022-2836(05)80065-8; ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; DASILVA ACR, 1992, EUR J BIOCHEM, V204, P85; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; FALKE JJ, 1991, BIOCHEMISTRY-US, V30, P8690, DOI 10.1021/bi00099a029; GOODWIN EB, 1990, J MOL BIOL, V216, P85, DOI 10.1016/S0022-2836(05)80062-2; HAPAK RC, 1989, J BIOL CHEM, V264, P18751; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUMAR VD, 1990, BIOCHEMISTRY-US, V29, P1404, DOI 10.1021/bi00458a010; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MESSER N, 1991, J MOL BIOL, V218, P825, DOI 10.1016/0022-2836(91)90270-G; MESSER NG, 1988, FEBS LETT, V234, P49, DOI 10.1016/0014-5793(88)81300-0; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; RENNER M, 1993, P NATL ACAD SCI USA, V90, P6493, DOI 10.1073/pnas.90.14.6493; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; SNYDER EE, 1990, BIOCHEMISTRY-US, V29, P3937, DOI 10.1021/bi00468a021; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; VIJAYKUMAR S, 1992, J MOL BIOL, V224, P413, DOI 10.1016/0022-2836(92)91004-9; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	31	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6773	6778		10.1074/jbc.270.12.6773	http://dx.doi.org/10.1074/jbc.270.12.6773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896823	hybrid			2022-12-27	WOS:A1995QQ85500054
J	INOUE, K; TAKEUCHI, Y; MIKI, D; ODO, S				INOUE, K; TAKEUCHI, Y; MIKI, D; ODO, S			MUSSEL ADHESIVE PLAQUE PROTEIN GENE IS A NOVEL MEMBER OF EPIDERMAL GROWTH FACTOR-LIKE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF; SEQUENCE; ENCODES; DOMAINS; EXPRESSION; HOMOLOG; EMBRYO; NOTCH	A mussel (Mytilus galloprovincialis) cDNA encoding Mgfp2, a major component of the adhesive plaque that anchors mussels tightly to underwater surfaces was isolated, It encoded a protein mainly consisted of epidermal growth factor-like repeats, containing tyrosine residues that will be converted to 3,4-dihydroxyphenylalanine near C and N termini, Amino acid residues important for cell cell interaction in other epidermal growth factor-like proteins were, however, not con served in the structure of Mgfp2, RNA blot analysis on adult tissues showed foot-specific expression of this gene, while the analysis on developing larvae showed that the expression starts with formation of the foot, These results suggest that the function of Mgfp2 has been specialized to form the adhesive plaque.			INOUE, K (corresponding author), MARINE BIOTECHNOL INST,KAMAISHI LABS,3-75-1 HEITA,KAMAISHI,IWATE 026,JAPAN.							BISGROVE BW, 1993, DEV BIOL, V157, P526, DOI 10.1006/dbio.1993.1155; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FULOP C, 1993, J BIOL CHEM, V268, P17377; HOJRUP P, 1985, FEBS LETT, V184, P333, DOI 10.1016/0014-5793(85)80633-5; HONG JC, 1987, J BIOL CHEM, V262, P8367; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; HURSH DA, 1987, SCIENCE, V237, P1487, DOI 10.1126/science.3498216; INOUE K, 1994, BIOL BULL, V186, P349, DOI 10.2307/1542281; KUNST E, 1987, EMBO J, V6, P761; Laursen R.A., 1992, Results and Problems in Cell Differentiation, V19, P55; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RZEPECKI LM, 1992, BIOL BULL, V183, P123, DOI 10.2307/1542413; SUZUKI H, 1991, FEBS LETT, V283, P281, DOI 10.1016/0014-5793(91)80608-6; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Waite J.H., 1992, Results and Problems in Cell Differentiation, V19, P27; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	21	106	123	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6698	6701		10.1074/jbc.270.12.6698	http://dx.doi.org/10.1074/jbc.270.12.6698			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896812	hybrid			2022-12-27	WOS:A1995QQ85500043
J	FERNANDEZMORENO, MA; MARTINEZ, E; CABALLERO, JL; ICHINOSE, K; HOPWOOD, DA; MALPARTIDA, F				FERNANDEZMORENO, MA; MARTINEZ, E; CABALLERO, JL; ICHINOSE, K; HOPWOOD, DA; MALPARTIDA, F			DNA-SEQUENCE AND FUNCTIONS OF THE ACTVI REGION OF THE ACTINORHODIN BIOSYNTHETIC GENE-CLUSTER OF STREPTOMYCES-COELICOLOR A3(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN ALCOHOL DEHYDROGENASES; ACID BETA-OXIDATION; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ANTIBIOTIC ACTINORHODIN; MOLECULAR-CLONING; CDNA-CLONING; CLASS-I; MULTIFUNCTIONAL ENZYME; POLYKETIDE SYNTHASE	Six open reading frames (ORFs) were identified by DNA sequencing of 5.7 kilobase pairs at the left end of the act cluster (the so-called ''actVI region''), in the order: ORFB, ORFA, ORF1, ORF2, ORF3, ORF4, ORF1-4 are transcribed rightward and in the same direction as the ORFs of the actVA region which lies to the right of the actVI region, whereas ORFA and ORFB run in the opposite direction. By complementation of mutants and gene disruption of the wild type strain, the two previously genetically characterized actVI mutations were assigned to ORF1. Although disruption of ORFB and ORF4, using phi C31 derivatives, did not cause any obvious change in actinorhodin production, defects in actinorhodin synthesis were obtained by insertional inactivation of ORFA, ORF1, ORF2, or ORF3. RNA analysis within the ORF1/ORFA intergenic region showed overlapping divergent promoters, at least one of which is under the control of the actII-ORF4 gene product, the transcriptional activator of the act cluster. Data base searches with the deduced products of ORFB and ORF3 failed to show any significant similarities with other known proteins. The deduced product of ORFA strongly resembles those of genes of unknown function from Saccharopolyspora hirsuta and Streptomyces roseofulvus, located within polyketide synthase clusters. The ORF1 product strongly resembles beta-hydroxyacyl-CoA dehydrogenases of bacteria and mammals and the ORF2 and ORF4 products resemble each other and enoyl reductases from bacteria, animals, and plants, with a highly conserved cofactor-binding domain. These findings strongly suggest that the actVI region is involved in catalyzing reduction processes that determine the two stereochemical configurations at C-3/C-15 during actinorhodin biosynthesis. A scheme is proposed for the middle steps of the biosynthesis, that is formation of the pyran ring, leading to the benzoisochromanequinone structure.	UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN; JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Fernandez-Moreno, Miguel Angel/K-4425-2017; Ichinose, Koji/GON-5032-2022; Malpartida, Francisco/D-2563-2009; Caballero, José L./L-2067-2014	Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726; Ichinose, Koji/0000-0003-3734-4336; Caballero, José L./0000-0002-2678-4849				AMMENDOLA S, 1992, BIOCHEMISTRY-US, V31, P12514, DOI 10.1021/bi00164a031; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARTEL PL, 1990, J BACTERIOL, V172, P4816, DOI 10.1128/jb.172.9.4816-4826.1990; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BIBB MJ, 1986, 6TH INT S ACT BIOL, P25; BITAR KG, 1980, FEBS LETT, V116, P196, DOI 10.1016/0014-5793(80)80642-9; BROCKMAN H, 1966, LIEBIGS ANN CHEM, V698, P3575; BROWN NL, 1983, BIOCHEMISTRY-US, V22, P4089, DOI 10.1021/bi00286a015; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CABALLERO JL, 1991, MOL GEN GENET, V230, P401, DOI 10.1007/BF00280297; CHATER KF, 1982, GENE, V19, P21, DOI 10.1016/0378-1119(82)90185-8; CHATER KF, 1983, GENE, V26, P67, DOI 10.1016/0378-1119(83)90037-9; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; DANIELSSON O, 1992, BIOCHEMISTRY-US, V31, P3751, DOI 10.1021/bi00130a004; DENNIS ES, 1985, NUCLEIC ACIDS RES, V13, P727, DOI 10.1093/nar/13.3.727; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; ESTONIUS M, 1990, EUR J BIOCHEM, V194, P593, DOI 10.1111/j.1432-1033.1990.tb15657.x; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; FUJII I, 1991, BIOCHEM INT, V25, P1043; GONZALEZ P, 1993, BIOCHEM BIOPH RES CO, V191, P902, DOI 10.1006/bbrc.1993.1302; GORSTALLMAN CP, 1981, J ORG CHEM, V46, P455, DOI 10.1021/jo00315a046; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOOG JO, 1993, EUR J BIOCHEM, V213, P31, DOI 10.1111/j.1432-1033.1993.tb17731.x; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; ISHII N, 1987, J BIOL CHEM, V262, P8144; JANSSEN GR, 1993, GENE, V124, P133, DOI 10.1016/0378-1119(93)90774-W; JENDROSSEK D, 1988, J BACTERIOL, V170, P5248, DOI 10.1128/jb.170.11.5248-5256.1988; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; KAISER R, 1990, BIOCHEMISTRY-US, V29, P8365, DOI 10.1021/bi00488a024; LEGOUILL C, 1993, MOL GEN GENET, V240, P146, DOI 10.1007/BF00276894; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; Maniatis T., 1982, MOL CLONING; MATHUR M, 1992, J BIOL CHEM, V267, P19388; Maxam A M, 1980, Methods Enzymol, V65, P499; MULDERS JWM, 1988, J BIOL CHEM, V263, P15462; MURRAY MG, 1986, ANAL BIOCHEM, V158, P165, DOI 10.1016/0003-2697(86)90605-6; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; OKI T, 1981, J ANTIBIOT, V34, P783, DOI 10.7164/antibiotics.34.783; PARK DH, 1991, J BIOL CHEM, V266, P13296; PERSSON B, 1993, EUR J BIOCHEM, V216, P49, DOI 10.1111/j.1432-1033.1993.tb18115.x; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; RODICIO MR, 1985, GENE, V34, P283, DOI 10.1016/0378-1119(85)90137-4; RUDD BAM, 1979, J GEN MICROBIOL, V114, P35, DOI 10.1099/00221287-114-1-35; RUSSELL PR, 1983, J BIOL CHEM, V258, P143; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SNIPES CE, 1979, J AM CHEM SOC, V101, P701, DOI 10.1021/ja00497a036; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; SUMMERS RG, 1993, J BACTERIOL, V175, P7571, DOI 10.1128/JB.175.23.7571-7580.1993; TSUZUKI K, 1986, J ANTIBIOT, V39, P1343, DOI 10.7164/antibiotics.39.1343; VAN DER STRAETEN D, 1991, FEBS LETT, V295, P39, DOI 10.1016/0014-5793(91)81379-M; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; WRIGHT LF, 1976, J GEN MICROBIOL, V96, P289, DOI 10.1099/00221287-96-2-289; XIE Y, 1989, PLANT MOL BIOL, V13, P53, DOI 10.1007/BF00027335; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG IG, 1981, EUR J BIOCHEM, V116, P165, DOI 10.1111/j.1432-1033.1981.tb05314.x; YOUNGLESON JS, 1989, J BACTERIOL, V171, P6800, DOI 10.1128/jb.171.12.6800-6807.1989; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	79	85	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24854	24863						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929165				2022-12-27	WOS:A1994PQ49000052
J	LIN, JH; MCLEAN, K; MORSER, J; YOUNG, TA; WYDRO, RM; ANDREWS, WH; LIGHT, DR				LIN, JH; MCLEAN, K; MORSER, J; YOUNG, TA; WYDRO, RM; ANDREWS, WH; LIGHT, DR			MODULATION OF GLYCOSAMINOGLYCAN ADDITION IN NATURALLY EXPRESSED AND RECOMBINANT HUMAN THROMBOMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; HUMAN SOLUBLE THROMBOMODULIN; RABBIT THROMBOMODULIN; PROTEIN-C; COFACTOR ACTIVITY; ANTITHROMBIN-III; FACTOR-V; BINDING; SITE; IDENTIFICATION	The two major glycoforms of full-length human thrombomodulin (TM), one with (TM(CS+)) and one without (TM(CS-)) chondroitin sulfate (CS) were analyzed on Western blots of primary and transformed cells and in cells expressing recombinant TM. TM on the surface of Chinese hamster ovary and COS-7 cells is solely TM(CS-). Primary arterial endothelial cells (HAEC and HPAEC) express a greater fraction of TM with CS attached than venous cells (HUVEC). Human lung carcinoma cells (A549) express more TM(CS+) than primary cells and recombinant TM on human melanoma cells (CHL-1) occurs in two very high molecular weight forms of TM(CS+). We explored this variation in TM(CS+) with soluble recombinant TM in several cell lines and analyzed the ambiguous CS addition site in human TM by site-directed mutagenesis. Mutation of Ser(474) to Ala blocks CS addition in Chinese hamster ovary and COS-7 cells but not CHL-1 cells which add CS to Ser(472) and Ser(474). Structure of the O-link domain affects partitioning into TM(CS+) since substituting with the decorin CS addition sequence, substituting all Ser and Thr except Ser(474) with Ala, and deleting around the potential beta-turn all increase the ratio of TM(CS+) to TM(CS-). A combination of the decorin substitution and deletion of the remaining O-link domain yields the most TM(CS+).	BERLEX BIOSCI INC,DEPT PROT BIOCHEM & BIOPHYS,RICHMOND,CA 94804; BERLEX BIOSCI INC,DEPT CARDIOVASC RES,RICHMOND,CA 94804; BERLEX BIOSCI INC,DEPT MOLEC BIOL,RICHMOND,CA 94804									ARITOMI M, 1993, THROMB HAEMOSTASIS, V70, P418; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURIN MC, 1989, THROMB RES, V54, P27; BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; ENJYOJI K, 1991, J BIOCHEM-TOKYO, V109, P890, DOI 10.1093/oxfordjournals.jbchem.a123476; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1982, J BIOL CHEM, V257, P859; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; Harper J. R., 1987, BIOL PROTEOGLYCANS, P345; LIU LW, 1994, J BIOL CHEM, V269, P11807; MANN DM, 1990, J BIOL CHEM, V265, P5317; Marval E., 1992, Sangre (Saragossa), V37, P355; MORGAN AC, 1981, HYBRIDOMA, V1, P27, DOI 10.1089/hyb.1.1981.1.27; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; PREISSNER KT, 1987, BIOCHEMISTRY-US, V26, P2521, DOI 10.1021/bi00383a018; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; SPIRO RC, 1989, J BIOL CHEM, V264, P1779; SURUKI K, 1987, EMBO J, V6, P1891; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YE J, 1993, J BIOL CHEM, V268, P2373; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	32	73	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25021	25030						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929188				2022-12-27	WOS:A1994PQ49000076
J	MATTSSON, JP; SCHLESINGER, PH; KEELING, DJ; TEITELBAUM, SL; STONE, DK; XIE, XS				MATTSSON, JP; SCHLESINGER, PH; KEELING, DJ; TEITELBAUM, SL; STONE, DK; XIE, XS			ISOLATION AND RECONSTITUTION OF A VACUOLAR-TYPE PROTON PUMP OF OSTEOCLAST MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE ACIDIFICATION; H+-ATPASE; TRANSLOCATING COMPLEX; SUBUNIT; BONE; INHIBITORS; ISOFORMS	A vacuolar-type proton-translocating ATPase was extracted from ruffled membranes of chicken osteoclasts with 1% polyoxyethylene 9-lauryl ether (C(12)E(9)) and was purified 13-fold by glycerol gradient centrifugation. The isolated pump appears by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to have a subunit composition similar to that of the clathrin-coated vesicle proton pump, in that subunits of apparent molecular masses of 116, 71, 57, 40, 39, 33, and 17 kDa are present in the osteoclast pump preparation. In addition, the 116-, 71-, 57-, and 40-kDa components were shown to crossreact with specific antisera generated against the ho mologous subunits of the clathrin coated vesicle proton pump. The isolated osteoclast H+-ATPase was reconstituted into liposomes prepared from purified lipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and cholesterol) by a cholate-dilution, freeze thaw method. Proton transport catalyzed by the reconstituted pump was inhibited by bafilomycin A(1) (10 nM) and N-ethyhnaleimide (1 mM) but was insensitive to vanadate. We propose that osteoclast-mediated bone resorption is effected by a vacuolar-type proton pump with functional and structural similarities to that isolated from clathrin-coated vesicles.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235; AB HASSLE,DEPT CELL BIOL,S-43183 MOLNDAL,SWEDEN; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,JEWISH HOSP ST LOUIS,DEPT PATHOL,ST LOUIS,MO 63110	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Schlesinger, Paul H/C-6049-2012	Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 42370] Funding Source: Medline; NIDCR NIH HHS [DE 05413] Funding Source: Medline; NIDDK NIH HHS [DK 33627] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEKKER PJ, 1990, J BONE MINER RES, V5, P569, DOI 10.1002/jbmr.5650050606; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1990, BIOCHEM BIOPH RES CO, V171, P920, DOI 10.1016/0006-291X(90)90771-E; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; KANE MP, 1991, J BIOL CHEM, V267, P447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTSSON J, 1991, BIOCHIM BIOPHYS ACTA, V1146, P106; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P261; PENG SB, 1994, J BIOL CHEM, V269, P17262; PENG SB, 1993, J BIOL CHEM, V268, P23519; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1989, J BIOL CHEM, V264, P18870; XIE XS, 1983, J BIOL CHEM, V258, P4834; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859	29	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24979	24982						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929181				2022-12-27	WOS:A1994PQ49000068
J	HACKER, KJ; ALBERTS, BM				HACKER, KJ; ALBERTS, BM			THE RAPID DISSOCIATION OF THE T4 DNA-POLYMERASE HOLOENZYME WHEN STOPPED BY A DNA HAIRPIN HELIX - A MODEL FOR POLYMERASE RELEASE FOLLOWING THE TERMINATION OF EACH OKAZAKI FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; BACTERIOPHAGE T4-GENE 32-PROTEIN; REPLICATION FORK; ESCHERICHIA-COLI; III HOLOENZYME; ACCESSORY PROTEINS; INVITRO REPLICATION; MELTING PROTEINS; TEMPLATE; GENE-32	We have examined the molecular mechanism that enables the T4 bacteriophage DNA polymerase holoenzyme to synthesize DNA processively on the leading strand of the replication fork for many minutes, while allowing an identical holoenzyme on the lagging strand to recycle from one Okazaki fragment to the next in less than 4 s. We use a perfect hairpin helix of 15 base pairs to mimic the encounter of the polymerase with the end of a previously synthesized Okazaki fragment. Polymerase dissociation is monitored during the stall at the hairpin helix by the addition of excess T4 gene 32 protein (SSB protein), which rapidly melts the helix and allows a stalled polymerase molecule to continue DNA synthesis. In the accompanying paper, we show that polymerase holoenzyme dissociation is slow (half-life of 2.5 min) when this enzyme is stalled by nucleotide omission (Hacker, K. J., and Alberts, B. M. (1994) J. Biol. Chem. 269, 24209-24220). In contrast, the holoenzyme dissociates with a half-life of 1 s after hitting the hairpin helix, a rate sufficient to allow efficient polymerase recycling on the lagging strand in vivo. We conclude that, upon completing each Okazaki fragment, the holoenzyme senses an encounter with duplex DNA and then switches to a state that rapidly dissociates.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NCI NIH HHS [5 T32 CA09270] Funding Source: Medline; NIGMS NIH HHS [GM24020] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHARETTE MF, 1986, NUCLEIC ACIDS RES, V14, P3343, DOI 10.1093/nar/14.8.3343; EGLI M, 1992, P NATL ACAD SCI USA, V89, P534, DOI 10.1073/pnas.89.2.534; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GREVE J, 1978, BIOCHEMISTRY-US, V17, P893, DOI 10.1021/bi00598a023; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HACKER KJ, 1994, THESIS U CALIFORNIA; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KELLY RC, 1976, J BIOL CHEM, V251, P7240; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NEWPORT JW, 1980, THESIS U OREGON EUGE; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; PORSCHKE D, 1974, BIOPHYS CHEM, V2, P97, DOI 10.1016/0301-4622(74)80029-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELICK HE, 1987, DNA REPLICATION RECO, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	39	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24221	24228						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929078				2022-12-27	WOS:A1994PQ34600059
J	RICHARDSON, TH; JOHNSON, EF				RICHARDSON, TH; JOHNSON, EF			ALTERATIONS OF THE REGIOSPECIFICITY OF PROGESTERONE METABOLISM BY THE MUTAGENESIS OF 2 KEY AMINO-ACID-RESIDUES IN RABBIT CYTOCHROME-P450-2C3V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SEQUENCES; FORM; 3B	Ser/Thr difference at position 364 underlies a phenotypic difference between naturally occurring variants of microsomal cytochrome P450 2C3 in their capacity to catalyze the 6 beta-hydroxylation of progesterone, as well as in their sensitivity to the inhibitor 16 alpha-methyl-progesterone. Position 364 of P450 2C3 maps to a substrate contacting domain suggested by models for mammalian P450 enzymes based on the structure of P450 101. In this study, Thr 364 of P450 2C3v, a progesterone 6 beta- and 16 alpha-hydroxylase, was replaced by Gly, Asp, Asn, Val, Leu, or Ile. The latter three amino acids did not alter the resospecificity of P450 2C3v, whereas the Gly,Asp, and Asn substitutions each produced enzymes with properties that correspond closely to the Ser mutant that catalyzes 16 alpha-hydroxylation but not 6 beta-hydroxylation, The former are distinguished from the latter amino acids by their greater hydrophobicity and size. In contrast, the 16 alpha-hydroxylase activity could be greatly diminished by the introduction of an alanine replacement for Val-113. This mutation conferred progesterone 21- and 17 alpha-hydroxylase activity to P450 2C3v at the expense of 16 alpha-hydroxylase activity, leaving the 6 beta-hydroxylase activity largely unaffected. Compound mutants displayed the additive effects of the two mutations. These results are consistent with two distinct orientations for the binding of progesterone to P450 2C3v, resulting in 6 beta- and 16 alpha-hydroxylation, respectively. The binding of progesterone in these two orientations can be modulated relatively independently by modifications of the two key amino acid residues at 113 and 364.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM NX4, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIGMS NIH HHS [GM31001] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; DIETER HH, 1982, J BIOL CHEM, V257, P9315; GOTOH O, 1992, J BIOL CHEM, V267, P83; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HSU MH, 1993, J BIOL CHEM, V268, P6939; JOHNSON EF, 1982, BIOCHEM BIOPH RES CO, V109, P786, DOI 10.1016/0006-291X(82)92008-3; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; KUPFER D, 1960, J CHROMATOGR, V4, P500, DOI 10.1016/S0021-9673(01)98442-0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MCMANUS ME, 1984, CARCINOGENESIS, V5, P1717, DOI 10.1093/carcin/5.12.1717; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; SAMBROOK J, 1908, MOL CLONING LABORATO, pA2; SCHWAB GE, 1985, BIOCHEMISTRY-US, V24, P7222, DOI 10.1021/bi00346a030; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P462	19	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23937	23943						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929041				2022-12-27	WOS:A1994PQ34600016
J	GUY, HI; EVANS, DR				GUY, HI; EVANS, DR			CLONING AND EXPRESSION OF THE MAMMALIAN MULTIFUNCTIONAL PROTEIN CAD IN ESCHERICHIA-COLI - CHARACTERIZATION OF THE RECOMBINANT PROTEIN AND A DELETION MUTANT LACKING THE MAJOR INTERDOMAIN LINKER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATES PYRIMIDINE BIOSYNTHESIS; CARBAMYL-PHOSPHATE SYNTHETASE; SYRIAN-HAMSTER CELLS; ASPARTATE-TRANSCARBAMYLASE; DIHYDROOROTASE DOMAIN; NUCLEOTIDE-SEQUENCE; SUBUNIT STRUCTURE; URA2 GENE; ORGANIZATION; PURIFICATION	The multifunctional protein CAD catalyzes the first three steps in de novo pyrimidine biosynthesis in mammalian cells. Glutamine-dependent carbamyl-phosphate synthetase (CPSase), aspartate transcarbamylase, and dihydroorotase activities are carried by a 243-kDa polypeptide chain that is organized into discrete functional domains connected by interdomain linkers. One of the connecting chain segments, the DA linker bridging the dihydroorotase and aspartate transcarbamylase domains, is unusually long (109 residues) and conserved in length in all eukaryotic species. A plasmid (pCK-CAD10) that encodes the entire 243-kDa polypeptide was constructed and expressed in Escherichia coli. The recombinant protein was purified to homogeneity by ion exchange and gel filtration chromatography. The purified protein had kinetic parameters that were close to those obtained for native CAD. Moreover, the CPSase activity was allosterically regulated. Gel filtration showed that the recombinant protein had the same molecular mass as native CAD. Thus, this complex mammalian protein is expressed and folds correctly in bacterial cells and, despite its extreme protease sensitivity, can be isolated intact. A deletion mutant that lacked the DA linker was then constructed. The kinetic parameters of the mutant protein were, for the most part, unaltered showing that the DA linker is not essential for the proper folding or optimal functioning of the individual domains, However, a significant decrease in the thermal stability of the CPSase domain suggested that the linker helps to stabilize the complex. Moreover, the channeling of carbamyl phosphate, determined by measuring the extent to which the exogenously added intermediate could dilute the endogenous carbamyl phosphate pool, was appreciably reduced when the DA linker was removed. Thus, although the domains function autonomously, some of the linkers are important for interdomain interactions in CAD.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University					NIGMS NIH HHS [GM47399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIN K, 1991, J BIOL CHEM, V266, P3791; BERGH ST, 1993, P NATL ACAD SCI USA, V90, P9818, DOI 10.1073/pnas.90.21.9818; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARREY EA, 1986, BIOCHEM J, V236, P327, DOI 10.1042/bj2360327; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CARREY EA, 1988, EUR J BIOCHEM, V171, P583, DOI 10.1111/j.1432-1033.1988.tb13828.x; CHEN JJ, 1979, J BIOL CHEM, V254, P2697; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; Davis R.H., 1967, ORG BIOSYNTHESIS, P303, DOI [10.1016/b978-0-12-395658-3.50032-0, DOI 10.1016/B978-0-12-395658-3.50032-0]; EASTERBY JS, 1989, BIOCHEM J, V264, P605, DOI 10.1042/bj2640605; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KIM HS, 1992, J BIOL CHEM, V267, P7177; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACROUTE F, 1968, J BACTERIOL, V95, P824, DOI 10.1128/JB.95.3.824-832.1968; LACROUTE F, 1964, CR HEBD ACAD SCI, V259, P1357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1985, P NATL ACAD SCI USA, V82, P6802, DOI 10.1073/pnas.82.20.6802; LERNER CG, 1986, J BIOL CHEM, V261, P1156; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; LUE P F, 1970, Biochimica et Biophysica Acta, V220, P365, DOI 10.1016/0005-2744(70)90268-8; MALEY JA, 1988, BIOCHEM BIOPH RES CO, V154, P1047, DOI 10.1016/0006-291X(88)90246-X; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MUSMANNO LA, 1991, GENE, V99, P211, DOI 10.1016/0378-1119(91)90129-Y; MUSMANNO LA, 1992, SOMAT CELL MOLEC GEN, V18, P309, DOI 10.1007/BF01235754; NAGY M, 1989, J BIOL CHEM, V264, P8366; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; OTSUKI T, 1982, J BIOCHEM-TOKYO, V92, P1431, DOI 10.1093/oxfordjournals.jbchem.a134067; PADGETT RA, 1982, MOL CELL BIOL, V2, P293, DOI 10.1128/MCB.2.3.293; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; RUMSBY PC, 1984, BIOCHEM J, V217, P435, DOI 10.1042/bj2170435; SCULLY JL, 1991, PROTEINS, V9, P191, DOI 10.1002/prot.340090305; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; SIMMER JP, 1990, THESIS WAYNE STATE U; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; STARK GR, 1977, TRENDS BIOCHEM SCI, V2, P64, DOI 10.1016/0968-0004(77)90133-5; TATIBANA M, 1972, J BIOCHEM, V72, P549, DOI 10.1093/oxfordjournals.jbchem.a129934; TATIBANA M, 1967, BIOCHEM BIOPH RES CO, V26, P221, DOI 10.1016/0006-291X(67)90238-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS NK, 1993, PROTEIN ENG, V6, P333, DOI 10.1093/protein/6.3.333; WILLIAMS NK, 1990, GENE, V94, P283, DOI 10.1016/0378-1119(90)90399-C; ZIMMERMANN BH, 1993, BIOCHEMISTRY-US, V32, P1519, DOI 10.1021/bi00057a016; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	60	30	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23808	23816						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916346				2022-12-27	WOS:A1994PQ34500064
J	MCRORY, JE; SHERWOOD, NM				MCRORY, JE; SHERWOOD, NM			CATFISH EXPRESS 2 FORMS OF INSULIN-LIKE GROWTH-FACTOR-I (IGF-I) IN THE BRAIN - UBIQUITOUS IGF-I AND BRAIN-SPECIFIC IGF-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; BIOLOGICAL-ACTIVITIES; NUCLEOTIDE-SEQUENCE; FACTOR CDNA; IDENTIFICATION; PRECURSOR; RNA; EVOLUTION; RECEPTOR	Insulin-like growth factor-I (IGF-I) is expressed not only in liver, but also in brain and other tissues. This ubiquitous IGF-I has a complex pattern of expression due to multiple transcription start sites, polyadenylation sites and exon skipping. We have isolated a cDNA encoding a brain-specific IGF-I from a catfish brain cDNA library. Also, a fragment encoding ubiquitous IGF-I was amplified from brain and liver mRNA and the deduced protein shown to be distinct (66% sequence identity) from brain-specific IGF-I. Consistent with other IGF-I prepropeptides, the brain specific IGF-I has a 43-residue signal peptide followed by B, C, A, D, and E domains. Retained in the catfish brain-specific IGF-I peptide are residues predicted to be involved with the correct tertiary folding, disulfide linkages, and receptor binding. Northern blot analysis of poly(A(+))-rich mRNA from brain indicated a single 1600-base pair transcript; a band was not detected from mRNA of liver, stomach, pancreas, pituitary, blood, herring brain, or brain poly(A(-)) RNA. A sensitive reverse transcriptase/polymerase chain reaction assay also showed that brain-specific IGF-I mRNA was expressed solely in the Thai catfish brain but not liver, stomach, pancreas, pituitary, ovary, and African catfish brain.	UNIV VICTORIA,DEPT BIOL,VICTORIA V8W 2Y2,BC,CANADA	University of Victoria								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CAO QP, 1989, MOL ENDOCRINOL, V3, P2005, DOI 10.1210/mend-3-12-2005; CASELLA SJ, 1987, DNA-J MOLEC CELL BIO, V6, P325, DOI 10.1089/dna.1987.6.325; CHAN SJ, 1990, P NATL ACAD SCI USA, V87, P9319, DOI 10.1073/pnas.87.23.9319; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coe I R, 1992, DNA Seq, V3, P257, DOI 10.3109/10425179209034027; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DUGUAY SJ, 1992, MOL ENDOCRINOL, V6, P1202, DOI 10.1210/me.6.8.1202; FOYT HL, 1992, MOL ENDOCRINOL, V6, P1881, DOI 10.1210/me.6.11.1881; FRANCIS GL, 1988, BIOCHEM J, V251, P95, DOI 10.1042/bj2510095; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; KAJIMOTO Y, 1990, MOL ENDOCRINOL, V4, P217, DOI 10.1210/mend-4-2-217; KAJIMOTO Y, 1989, MOL ENDOCRINOL, V3, P1907, DOI 10.1210/mend-3-12-1907; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; NAGAMATSU S, 1991, J BIOL CHEM, V266, P2397; OGASAWARA M, 1989, BIOCHEMISTRY-US, V28, P2710, DOI 10.1021/bi00432a052; REINHARDT RR, 1993, ENDOCRINOLOGY, V133, P3, DOI 10.1210/en.133.1.3; ROMAGNOLO D, 1992, MOL ENDOCRINOL, V6, P1774, DOI 10.1210/me.6.11.1774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARA VR, 1986, P NATL ACAD SCI USA, V83, P4904, DOI 10.1073/pnas.83.13.4904; SARA VR, 1989, BIOCHEM BIOPH RES CO, V165, P766, DOI 10.1016/S0006-291X(89)80032-4; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SHAMBLOTT MJ, 1992, P NATL ACAD SCI USA, V89, P8913, DOI 10.1073/pnas.89.19.8913; SHIER P, 1989, J BIOL CHEM, V264, P14605; TAVAKKOL A, 1988, MOL ENDOCRINOL, V2, P674, DOI 10.1210/mend-2-8-674; WALLIS AE, 1993, MOL ENDOCRINOL, V7, P409, DOI 10.1210/me.7.3.409; WONG EA, 1989, DNA-J MOLEC CELL BIO, V8, P649, DOI 10.1089/dna.1.1989.8.649	31	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18588	18592						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7913463				2022-12-27	WOS:A1994NW79800057
J	ALCONADA, A; FLORES, AI; BLANCO, L; CUEZVA, JM				ALCONADA, A; FLORES, AI; BLANCO, L; CUEZVA, JM			ANTIBODIES AGAINST F1-ATPASE ALPHA-SUBUNIT RECOGNIZE MITOCHONDRIAL CHAPERONES - EVIDENCE FOR AN EVOLUTIONARY RELATIONSHIP BETWEEN CHAPERONIN AND ATPASE PROTEIN FAMILIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA VACUOLAR ATPASE; AMINO-ACID-SEQUENCE; HEAT-SHOCK PROTEIN; ION MOTIVE ATPASES; BETA-SUBUNIT; ESCHERICHIA-COLI; RAT-LIVER; NUCLEAR GENE; SULFOLOBUS-ACIDOCALDARIUS; NUCLEOTIDE-SEQUENCE	Antibodies raised against two synthetic peptides from rat liver F-1-ATPase alpha-subunit sequence recognized two main heat-shock proteins from Drosophila (p71 and p56) and rat liver (p74 and p54) cells. One of the antisera showed a 20-fold higher reactivity toward Escherichia coli GroEL chaperonin than toward the cu-subunit purified from Drosophila. Indirect immunofluorescence microscopy and subcellular fractionation experiments located both mammalian heat-shock proteins in the mitochondria. The recent findings of functional homology between chaperonins and alpha-subunits, together with the unsuspected immunological reactivity of two mitochondrial molecular chaperones toward antisera derived from two different sequence motifs of the alpha-subunit, strongly argue in favor of the existence of an evolutionary relationship between chaperonins and alpha-subunits. The complete sequence alignment of F-type ATPase alpha-subunits and chaperonins revealed the existence of eleven most conserved regions (similar to 30% of each protein sequence) with an overall amino acid identity of 20 +/- 2% and similarity of 39 +/- 4%. A search of protein data bases with three different consensus sequences derived from this alignment identified a significant proportion of proteins belonging only to these two protein families. Since the alpha-subunit protein family is evolutionary related to the other catalytic (A and beta) and regulatory (B) subunits of V- and F-type ATPases, the homology reported herein allowed us to analyze, in the chaperonin sequences, the conservation of critical residues involved in nucleotide binding. These data support the hypothesis that chaperonins and the major subunits of V- and F-type ATPases are evolutionary related.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, DEPT MOLEC BIOL, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Flores, Ana I/L-2104-2015; Cuezva, Jose M/F-8381-2011; Blanco, Luis/I-1848-2015; Cuezva, Jose M/AAR-5392-2020	Flores, Ana I/0000-0002-5019-0434; Cuezva Marcos, Jose Manuel/0000-0003-1118-248X				ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALCONADA A, 1993, TRENDS BIOCHEM SCI, V18, P81, DOI 10.1016/0968-0004(93)90158-J; AMZEL LM, 1983, ANNU REV BIOCHEM, V52, P801, DOI 10.1146/annurev.bi.52.070183.004101; ASCHENBRENNER M, 1993, FEBS LETT, V323, P27, DOI 10.1016/0014-5793(93)81441-2; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVNI A, 1991, J BIOL CHEM, V266, P7317; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRAUN CJ, 1985, PLANT PHYSIOL, V79, P571, DOI 10.1104/pp.79.2.571; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CUEZVA JM, 1990, FEBS LETT, V270, P71, DOI 10.1016/0014-5793(90)81237-I; CUEZVA JM, 1986, FEBS LETT, V194, P219, DOI 10.1016/0014-5793(86)80088-6; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P2187, DOI 10.1093/nar/9.9.2187; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GUPTA RS, 1989, BIOCHEM BIOPH RES CO, V163, P780, DOI 10.1016/0006-291X(89)92290-0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HIRST JD, 1991, PROTEIN ENG, V4, P615; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE JH, 1990, J BIOL CHEM, V265, P4664; LUIS AM, 1990, J BIOL CHEM, V265, P7713; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MORADIAMELI M, 1989, J BIOL CHEM, V264, P1361; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; OHTA S, 1988, J BIOL CHEM, V263, P11257; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PIERCE DJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P265, DOI 10.1016/0167-4781(92)90160-2; PRASAD TK, 1990, MOL CELL BIOL, V10, P3979, DOI 10.1128/MCB.10.8.3979; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SANTAREN JF, 1993, EXP CELL RES, V206, P220, DOI 10.1006/excr.1993.1141; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; Sneath PHA., 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; TOZAWA K, 1993, J BIOL CHEM, V268, P19044; VALCARCE C, 1988, J BIOL CHEM, V263, P7767; VENNER TJ, 1990, DNA CELL BIOL, V9, P545, DOI 10.1089/dna.1990.9.545; VIALE AM, 1985, J BIOL CHEM, V260, P4958; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; YUAN HB, 1992, J BIOL CHEM, V267, P14697; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	71	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13670	13679						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909811				2022-12-27	WOS:A1994NK18400089
J	YANO, S; FUKUNAGA, K; USHIO, Y; MIYAMOTO, E				YANO, S; FUKUNAGA, K; USHIO, Y; MIYAMOTO, E			ACTIVATION OF CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-II AND PHOSPHORYLATION OF INTERMEDIATE FILAMENT PROTEINS BY STIMULATION OF GLUTAMATE RECEPTORS IN CULTURED RAT CORTICAL ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLARY ACIDIC PROTEIN; AMP-DEPENDENT PHOSPHORYLATION; EXCITATORY AMINO-ACIDS; CALCIUM WAVES; HEAD DOMAIN; CALMODULIN; BRAIN; CELLS; VIMENTIN; LOCALIZATION	We investigated the activation of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) via stimulation of glutamate receptors and subsequent phosphorylation of vimentin and glial fibrillary acidic protein (GFAP) in cultured rat cortical astrocytes. The indirect immunofluorescence analysis with the anti-CaM kinase II antibody revealed that the enzyme was detected diffusely in the cytoplasm and more intensely in the nucleus. Glutamate elevated the Ca2+-independent activity of CaM kinase II through autophosphorylation, and this response was blocked by both DL-2-amino-3- phosphonopropionate and 6-cyano-7-nitroquinoxaline-2,3-dione, but not by D-2-amino-5-phosphonovalerate. In the experiments using P-32-labeled astrocytes, the phosphorylation of vimentin and GFAP as well as autophosphorylation of CaM kinase II were found to be stimulated after the exposure to glutamate. It was concluded by two dimensional phosphopeptide analysis that the increased phosphorylation of vimentin and GFAP observed in intact cells were due to the activation of CaM kinase II by glutamate. These results suggest that glutamate can activate CaM kinase II through stimulation of both the metabotropic and non-N-methyl-D-aspartate receptors, and that the concomitant phosphorylation of vimentin and GFAP may in turn regulate the functions of intermediate filament proteins in intact astrocytes.	KUMAMOTO UNIV,SCH MED,DEPT PHARMACOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT NEUROSURG,KUMAMOTO 860,JAPAN	Kumamoto University; Kumamoto University								ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; ARVIN B, 1989, BRIT J PHARMACOL, V98, P225, DOI 10.1111/j.1476-5381.1989.tb16886.x; BABCOCKATKINSON E, 1989, GLIA, V2, P112, DOI 10.1002/glia.440020207; BARRES BA, 1991, J NEUROSCI, V11, P3685; BENDER AS, 1992, J NEUROCHEM, V58, P1874, DOI 10.1111/j.1471-4159.1992.tb10064.x; BERSHADSKY AD, 1990, P NATL ACAD SCI USA, V87, P1884, DOI 10.1073/pnas.87.5.1884; BRADFORD MM, 1976, ANAL CHEM, V226, P203; BRONSTEIN J, 1988, J NEUROCHEM, V50, P45, DOI 10.1111/j.1471-4159.1988.tb13227.x; BROWNING ET, 1984, J NEUROCHEM, V42, P718, DOI 10.1111/j.1471-4159.1984.tb02742.x; CHAN PH, 1989, BRAIN RES, V487, P380, DOI 10.1016/0006-8993(89)90845-7; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; FUKUNAGA K, 1986, BIOMED RES-TOKYO, V7, P405; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRISON BC, 1991, J NEUROCHEM, V56, P1723, DOI 10.1111/j.1471-4159.1991.tb02073.x; HARRISON BC, 1992, J NEUROCHEM, V58, P320, DOI 10.1111/j.1471-4159.1992.tb09313.x; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HOUSE C, 1987, J BIOL CHEM, V262, P772; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; JENSEN AM, 1991, J NEUROSCI, V11, P1674; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KOYAMA Y, 1991, NEUROSCI LETT, V124, P235, DOI 10.1016/0304-3940(91)90102-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZBRIONES LG, 1990, EXP EYE RES, V51, P277, DOI 10.1016/0014-4835(90)90024-O; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MCCARTHY KD, 1985, J NEUROCHEM, V44, P723, DOI 10.1111/j.1471-4159.1985.tb12875.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; OHTA Y, 1988, J BIOL CHEM, V263, P11549; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; REYNOLDS IJ, 1987, P NATL ACAD SCI USA, V84, P7744, DOI 10.1073/pnas.84.21.7744; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHOEPP DD, 1989, J NEUROCHEM, V53, P1865, DOI 10.1111/j.1471-4159.1989.tb09254.x; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TANAKA E, 1984, BIOMED RES-TOKYO, V5, P239, DOI 10.2220/biomedres.5.239; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WOOTEN MW, 1987, EUR J BIOCHEM, V164, P461, DOI 10.1111/j.1432-1033.1987.tb11079.x; YAMAKAWA T, 1992, BRAIN RES, V597, P220, DOI 10.1016/0006-8993(92)91477-V; YAMAKAWA T, 1992, BIOMED RES-TOKYO, V13, P173, DOI 10.2220/biomedres.13.173; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	54	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5428	5439						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906275				2022-12-27	WOS:A1994MX57100108
J	ASTERMARK, J; SOTTILE, J; MOSHER, DF; STENFLO, J				ASTERMARK, J; SOTTILE, J; MOSHER, DF; STENFLO, J			BACULOVIRUS-MEDIATED EXPRESSION OF THE EPIDERMAL GROWTH FACTOR-LIKE MODULES OF HUMAN FACTOR-IX FUSED TO THE FACTOR-XIIIA TRANSAMIDATION SITE IN FIBRONECTIN - EVIDENCE FOR A DIRECT INTERACTION BETWEEN THE NH(2)-TERMINAL EPIDERMAL GROWTH FACTOR-LIKE MODULE OF FACTOR-IXA-BETA AND FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-X; ENDOTHELIAL-CELL BINDING; FACTOR-LIKE DOMAINS; COLD-INSOLUBLE GLOBULIN; K-DEPENDENT PROTEIN; HYDROXYASPARTIC ACID; BLOOD-COAGULATION; CALCIUM-BINDING; HUMAN-PLASMA	Factor IX is a vitamin K-dependent procoagulant zymogen of a serine protease. In the presence of Ca2+ the active form of factor IX (factor IXabeta) forms a complex with factor VIIIa on suitable phospholipid surfaces such as aggregated platelets. This macromolecular complex rapidly activates factor X. We have previously provided data that suggest an interaction between the NH2-terminal epidermal growth factor (EGF)-like module of factor IXabeta and the substrate factor X. In an alternative approach to study this protein-protein interaction, we have expressed three recombinant baculovirus constructs encoding the EGF-like modules of human factor IX and a truncated form of fibronectin in a system based on the infection of insect cells (Spodoptera frugiperda 21). This strategy allows a simple one-step purification of the recombinant proteins on a gelatin-Sepharose column, followed by removal of the gelatin-binding part derived from fibronectin by proteolytic cleavage. The fusion proteins were isolated at yields of 20-50 mug/ml culture medium. The recombinant EGF-like modules contained 0.2-0.4 mol of erythro-beta-hydroxyaspartic acid/mol of protein, i.e. similar to the amount found in factor IX from human plasma, and appeared to be glycosylated at Ser-53. The NH2-terminal EGF-like module, which contained a transamidation acceptor site derived from ribronectin, was cross-linked by factor Xllla in solution to intact and Gla-domainless factor X. There was no evidence of cross-linking to activated factor X or to factor X fragments containing only the gamma-carboxyglutamic acid module and the two EGF-like modules. The cross-linking results suggest a specific interaction between the NH2-terminal EGF-like module of factor IXabeta and the heavy chain of unactivated factor X. This interaction, albeit weak as judged by competition experiments, may be important for the targeting of factor X to the factor IXabeta-factor VIIIa complex on biological membranes and for the subsequent dissociation of factor Xa from the complex after activation.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	Lund University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; CHEN AB, 1975, FED PROC, V34, P259; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DICKSON JA, 1991, J VIROL, V65, P4006, DOI 10.1128/JVI.65.8.4006-4016.1991; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P2285; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE MB, 1980, J BIOL CHEM, V255, P3134; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HARBON S, 1968, EUR J BIOCHEM, V4, P265, DOI 10.1111/j.1432-1033.1968.tb00203.x; HARLOS K, 1987, NATURE, V330, P82, DOI 10.1038/330082a0; HARWOOD R, 1980, ENZYMOLOGY POST TRAN, P3; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; Jesty J, 1976, Methods Enzymol, V45, P95; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KNOPS J, 1991, J BIOL CHEM, V266, P7285; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LIN SW, 1990, J BIOL CHEM, V265, P144; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6; MORITA T, 1988, J BIOCHEM, V104, P368, DOI 10.1093/oxfordjournals.jbchem.a122475; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1980, VITAMIN K METABOLISM, P124; MOSESSON MW, 1975, BIOCHIM BIOPHYS ACTA, V386, P509, DOI 10.1016/0005-2795(75)90294-9; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; MOSHER DF, 1980, J BIOL CHEM, V255, P1181; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1974, J BIOL CHEM, V249, P594; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1991, J BIOL CHEM, V266, P2453; RYAN J, 1989, J BIOL CHEM, V264, P20283; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1989, P NATL ACAD SCI USA, V86, P444, DOI 10.1073/pnas.86.2.444; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUGO T, 1985, J BIOL CHEM, V260, P453; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; ZUSHI M, 1989, J BIOL CHEM, V264, P10351	62	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3690	3697						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906269				2022-12-27	WOS:A1994MV63100082
J	RAO, S; KRAUSS, NE; HEERDING, JM; SWINDELL, CS; RINGEL, I; ORR, GA; HORWITZ, SB				RAO, S; KRAUSS, NE; HEERDING, JM; SWINDELL, CS; RINGEL, I; ORR, GA; HORWITZ, SB			3'-(P-AZIDOBENZAMIDO)TAXOL PHOTOLABELS THE N-TERMINAL 31 AMINO-ACIDS OF BETA-TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MICROTUBULE ASSEMBLY INVITRO; GUANOSINE 5'-TRIPHOSPHATE; TAXOL; PROTEINS; SEQUENCE; POLYMERIZATION; CLEAVAGE; ABSENCE; PEPTIDE; FAMILY	Taxol possesses an unusual chemical structure, a unique mechanism of action, and demonstrated activity in human malignancies. It is the only antitumor agent that has a binding site on the microtubule polymer. The interaction of Taxol with the microtubule polymer results in the formation of stable bundles of cellular microtubules that are resistant to depolymerization. Although it has become evident that the microtubule, specifically beta-tubulin, is the target for Taxol, no information is available on the binding site for the drug. In this report, we demonstrate that 3'-(p-azidobenzamido)taxol, an analogue with similar biological activities as Taxol, covalently binds to the N-terminal domain of beta-tubulin after irradiation of the microtubule-drug complex. Taxol competes with [H-3]3'-(p-azidobenzamido)taxol binding, suggesting that the photoaffinity analog and Taxol are binding at the same or overlapping sites. Formic acid cleavage of [H-3]3'-(p-azidobenzamido)taxol-photolabeled beta-tubulin and subsequent protein sequence and mass analyses have identified the N-terminal 31 amino acids as the major site for [H-3]3'-(p-azidobenzamido)taxol photoincorporation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; BRYN MAWR COLL,DEPT CHEM,BRYN MAWR,PA 19010; HEBREW UNIV JERUSALEM,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL	Yeshiva University; Albert Einstein College of Medicine; Bryn Mawr College; Hebrew University of Jerusalem					NCI NIH HHS [CA39821, CA41349, CA55139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041349, R35CA039821, R01CA055139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; DEWALD DB, 1986, ANAL BIOCHEM, V154, P502, DOI 10.1016/0003-2697(86)90022-9; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HALL JL, 1983, MOL CELL BIOL, V3, P854, DOI 10.1128/MCB.3.5.854; HESSE J, 1987, J BIOL CHEM, V262, P15472; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KAPP OH, 1978, ANAL BIOCHEM, V91, P230, DOI 10.1016/0003-2697(78)90835-7; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; KUMAR N, 1981, J BIOL CHEM, V256, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1984, NUCLEIC ACIDS RES, V12, P5823, DOI 10.1093/nar/12.14.5823; LEWIS SA, 1985, J MOL BIOL, V182, P11, DOI 10.1016/0022-2836(85)90023-3; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; MAK AS, 1978, ANAL BIOCHEM, V84, P432, DOI 10.1016/0003-2697(78)90061-1; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; PARNESS J, 1982, BIOCHEM BIOPH RES CO, V105, P1082, DOI 10.1016/0006-291X(82)91080-4; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIFF PB, 1980, P NATL ACAD SCI USA, V77, P1561; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SONDEREGGER P, 1982, ANAL BIOCHEM, V122, P298, DOI 10.1016/0003-2697(82)90285-8; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045	29	262	279	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3132	3134						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906266				2022-12-27	WOS:A1994MV63100003
J	RASOLA, A; GALIETTA, LJV; GRUENERT, DC; ROMEO, G				RASOLA, A; GALIETTA, LJV; GRUENERT, DC; ROMEO, G			VOLUME-SENSITIVE CHLORIDE CURRENTS IN 4 EPITHELIAL-CELL LINES ARE NOT DIRECTLY CORRELATED TO THE EXPRESSION OF THE MDR-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; RESISTANCE P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; CHANNEL; CLONING; COMPLEMENTARY; SELECTIVITY; DOXORUBICIN; VERAPAMIL	It has been shown recently that heterologous expression of human MDR-1 gene, which is responsible for multidrug resistance during cancer therapy, causes appearance of volume-sensitive Cl- currents, thus suggesting that the product of the MDR-1 gene (the P-glycoprotein) has a Cl- channel activity (Valverde, M. A., Diaz, M., Sepulveda, M. A., Gill, D. R., Hyde, S. C., and Higgins, C, F. (1992) Nature 355, 830-833). In the present work, we have tested four epithelial cell lines both for the expression of MDR-1 gene and for the presence of volume-sensitive Cl- currents. LoVo/H and LoVo/Dx cells derive from a human colon adenocarcinoma, the latter cell line being resistant to high concentrations of the antitumoral drug doxorubicin. 9HTEo- cells were obtained by transformation of human tracheal epithelium. The 9HTEo-/Dx cell line was established from these cells by selection in doxorubicin. As expected, higher levels of P-glycoprotein expression were detected in LoVo/Dx and 9HTEo-/Dx by means of reverse transcriptase polymerase chain reaction technique, indirect immunofluorescence, and Western immunoblot assays. In contrast with these data, the size of swelling-induced Cl- current was the same in the sensitive cell line and in its drug-resistant counterpart. Actually, the Cl- conductance of 9HTEo- and 9HTEo-/Dx was 4-fold higher than that of either LoVo/H or LoVo/Dx cells. This indicates that the amplitude of this conductance is not directly related to the expression of the MDR-1 gene.	UNIV CALIF SAN FRANCISCO, CARDIOVASC & CANC RES INST, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	RASOLA, A (corresponding author), IST GIANNINA GASLINI, GENET MOLEC LAB, I-16148 GENOA, ITALY.		Galietta, Luis JV/HCG-8692-2022	Rasola, Andrea/0000-0003-4522-3008; Galietta, Luis/0000-0001-8686-3461				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BIEDLER JL, 1992, CANCER-AM CANCER SOC, V70, P1799, DOI 10.1002/1097-0142(19920915)70:4+<1799::AID-CNCR2820701623>3.0.CO;2-B; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORRIAS MV, 1992, ANTICANCER RES, V12, P1431; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GALIETTA LJV, 1991, BIOCHEM BIOPH RES CO, V179, P1155, DOI 10.1016/0006-291X(91)91692-6; GALIETTA LJV, 1991, ADV EXP MED BIOL, V290, P307; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; GRANDI M, 1986, BRIT J CANCER, V54, P515, DOI 10.1038/bjc.1986.206; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERZOG CE, 1992, J NATL CANCER I, V84, P711, DOI 10.1093/jnci/84.9.711; HORNES E, 1990, GENET ANAL-BIOMOL E, V7, P145, DOI 10.1016/0735-0651(90)90028-E; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; RASOLA A, 1992, BIOCHIM BIOPHYS ACTA, V1139, P319, DOI 10.1016/0925-4439(92)90108-Y; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SCHINKEL AH, 1991, CANCER RES, V51, P2628; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	33	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1432	1436						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904600				2022-12-27	WOS:A1994MR22000102
J	YOSHIMURA, T; ASHIUCHI, M; ESAKI, N; KOBATAKE, C; CHOI, SY; SODA, K				YOSHIMURA, T; ASHIUCHI, M; ESAKI, N; KOBATAKE, C; CHOI, SY; SODA, K			EXPRESSION OF GLR (MURI, DGA) GENE ENCODING GLUTAMATE RACEMASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; ACTIVE-SITE; SEQUENCE	The murI (dga) gene of Escherichia coli is required for the biosynthesis of D-glutamate, an essential component of bacterial peptidoglycan (Doublet, P., van Heijetnoort, J., and Mengin-Lecreulx, D. (1992) J. Bacteriol. 174, 5772-5779; Dougherty, T. J., Thanassi, J. A., and Pucci, M. J. (1993) J. Bacteriol. 175, 111-116), but its gene product has not been identified. We found that the amino acid sequence of protein deduced from the nucleotide sequence of the open reading frame of murI gene (ORF1) shows a significant homology with that of glutamate racemase of Pediococcus pentosaceus. The amino acid sequence of glutamate racemase of Lactobacillus fermenti recently reported also shows a homology with the deduced amino acid sequence of ORFI (Gallo, K. A., and Knowles, J. R. (1993) Biochemistry 32, 3981-3990). The murI (dga) gene was ligated into a plasmid, pKK223-3, with a designed ribosome binding site and expressed in E. coli JM109 cells. Glutamate racemase was produced by the transformant cells, whereas the enzyme was not found in the host cells. Accordingly, we newly termed the gene glr, which is more relevant than murI and dga. We partially purified the enzyme to characterize it. The enzyme consists of two identical subunits with a molecular weight of about 31,000 in contrast to the P. pentosaceus enzyme, a monomer protein.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN	Kyoto University								BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; Choi S Y, 1991, Protein Expr Purif, V2, P90, DOI 10.1016/1046-5928(91)90016-C; CHOI SY, 1993, J BIOCH, V112, P139; DIVEN WF, 1969, BIOCHIM BIOPHYS ACTA, V191, P702, DOI 10.1016/0005-2744(69)90364-7; DOUBLET P, 1992, J BACTERIOL, V174, P5772, DOI 10.1128/jb.174.18.5772-5779.1992; DOUGHERTY TJ, 1993, J BACTERIOL, V175, P111, DOI 10.1128/JB.175.1.111-116.1993; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GLASER L, 1960, J BIOL CHEM, V235, P2095; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HUG DH, 1957, ARCH BIOCHEM BIOPHYS, V72, P369, DOI 10.1016/0003-9861(57)90213-8; KMEADOW P, 1958, BIOCHIM BIOPHYS ACTA, V524, P60; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KURAMITSU HK, 1962, BIOCHIM BIOPHYS ACTA, V62, P114, DOI 10.1016/0006-3002(62)90496-1; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MENGINLECREULX DC, 1989, J BACTERIOL, V176, P6126; NAGATA Y, 1992, J CHROMATOGR-BIOMED, V575, P147, DOI 10.1016/0378-4347(92)80516-S; NAKAJIMA N, 1986, AGR BIOL CHEM TOKYO, V50, P2823, DOI 10.1080/00021369.1986.10867827; NARROD SA, 1952, ARCH BIOCHEM BIOPHYS, V35, P462, DOI 10.1016/S0003-9861(52)80026-8; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; TANIZAWA K, 1989, J BIOL CHEM, V264, P2445; TANIZAWA K, 1989, J BIOL CHEM, V264, P2450; TANNER ME, 1993, BIOCHEMISTRY-US, V32, P3998, DOI 10.1021/bi00066a021; THORNE CB, 1955, J BACTERIOL, V70, P420, DOI 10.1128/JB.70.4.420-426.1955; THORNE CURTIS B., 1955, JOUR BACT, V69, P357; TOYAMA H, 1991, J BIOL CHEM, V266, P13634	26	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24242	24246						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901215				2022-12-27	WOS:A1993MF29400078
J	GABELLINI, N; IWATA, T; CARAFOLI, E				GABELLINI, N; IWATA, T; CARAFOLI, E			ALTERNATIVE SPLICING SITE MODIFIES THE CARBOXYL-TERMINAL TRANS-MEMBRANE DOMAINS OF THE NA+/CA2+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; SARCOLEMMAL NA+-CA2+ EXCHANGER; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; HELA-CELLS; STIMULATION; VESICLES; ISOFORMS; PROTEIN; MGATP	The 6-kilobase (kb) cDNA of pTB11 clone and its 5' fragment of 3.7 kb encoding the canine heart Na+/Ca2+ exchanger (Nicoll, D. A., Longoni, S., and Philipson, K. D. (1990) Science 250, 562-565) were transiently expressed in 293 cells to investigate the role of the 3'-''untranslated'' region. Both fragments yielded high levels of expressed protein that were well incorporated in the membranes. Cells expressing the 6-kb cDNA produced rearranged transcripts of smaller than expected size. A 120-kDa polypeptide was produced in cells expressing the modified exchanger, and Ca2+ uptake was higher in this type of transfected cells. A constant stretch of nucleotides located at the 3' end of the 6 kb cDNA was found to be connected, by alternative RNA splicing, to four different upstream sequence positions. The deduced hydrophobic sequence of the spliced-in exon could replace the IX or the XI trans-membrane domain of the exchanger protein in two spliced isoforms. The new exon sequence was not completely included in the pTB11 insert, i.e. these two products were artificially truncated. The RNA processing of these two alternative 5'-splicing sites also occurred in tissues, as shown by RNase protection analysis. In a third type of isoform the splicing took place downstream of the originally proposed stop codon, whereas in a fourth type a stop codon was introduced after the V hydrophobic segment in the large intracellular loop.	ETH ZURICH,BIOCHEM LAB,CH-8028 ZURICH,SWITZERLAND	ETH Zurich	GABELLINI, N (corresponding author), UNIV PADUA,DIPARTIMENTO CHIM BIOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONI P, 1980, P NATL ACAD SCI-BIOL, V77, P6354, DOI 10.1073/pnas.77.11.6354; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; GABELLINI N, 1993, NEUROREPORT, V4, P531, DOI 10.1097/00001756-199305000-00017; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HOLTZ J, 1993, BASIC RES CARDIOL, V88, P183; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; REEVES JP, 1992, ARCH BIOCHEM BIOPHYS, V292, P329, DOI 10.1016/0003-9861(92)90001-D; REEVES JP, 1979, P NATL ACAD SCI USA, V76, P590, DOI 10.1073/pnas.76.2.590; TREISMAN R, 1983, NATURE, V302, P590	30	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6917	6924		10.1074/jbc.270.12.6917	http://dx.doi.org/10.1074/jbc.270.12.6917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896841	hybrid			2022-12-27	WOS:A1995QQ85500072
J	YANAGISAWA, T; LEE, JT; WU, HC; KAWAKAMI, M				YANAGISAWA, T; LEE, JT; WU, HC; KAWAKAMI, M			RELATIONSHIP OF PROTEIN-STRUCTURE OF ISOLEUCYL-TRANSFER-RNA SYNTHETASE WITH PSEUDOMONIC ACID RESISTANCE OF ESCHERICHIA-COLI - PROPOSED MODE OF ACTION OF PSEUDOMONIC ACID AS AN INHIBITOR OF ISOLEUCYL-TRANSFER-RNA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; TYROSYL-TRANSFER RNA; SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; DNA-SEQUENCE; BINDING-SITE; GENE; FLUORESCENS; CLONING	To elucidate the mode of action of pseudomonic acid, we have compared the deduced amino acid sequences of isoleucyl-tRNA synthetases (IleRS) from wild-type Escherichia coli strain MC4100, a pseudomonic acid-resistant mutant (strain PS102) of MC4100, and a pseudomonic acid-producing strain, Pseudomonas fluorescens. Compared with the wild-type enzyme, the deduced amino acid sequence of E. coli mutant ileS gene in strain PS102 shows a single amino acid substitution of leucine for phenylalanine at residue 594 of the IleRS. This mutational alteration in IleRS of an E. coli pseudomonic acid-resistant mutant resides in a region of the enzyme in close proximity to one of the consensus sequences of class I aminoacyl-tRNA synthetases, the KMSKS sequence between residues 602 and 606 of the E. coli IleRS, DNA sequence of the cloned ileS gene predicts that the P. fluorescens IleRS consists of 943 amino acids with 54% identity with the E. coli IleRS. The P. fluorescens ileS gene and the wild type and PS102 alleles of E. coli ileS were cloned into an expression vector, pEXPCR, and the sensitivities of E. coli DH5 alpha cells harboring each of these plasmids were compared. The cells harboring the P. fluorescens ileS were found to be most resistant to pseudomonic acid, while the transformants expressing the PS102 IleRS were more resistant than those containing the wild-type E. coli IleRS. IleRS purified from the wild-type E. coli was specifically cleaved by trypsin between Lys(605) and Ser(606) in the region of K(602)MSKS(606). The protection of the IleRS from the trypsin digestion was found with pseudomonic acid or ATP, but not with isoleucine or tRNA(1)(Ile). Based on these results, we propose that pseudomonic acid binds to IleRS in the vicinity of the KMSKS sequence that is an ATP-binding subsite, and that pseudomonic acid is a bifunctional inhibitor with characteristics of both isoleucine and ATP, for example, an analog of isoleucyladenylate.	NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL & IMMUNOL,BETHESDA,MD 20814	Nagoya University; Uniformed Services University of the Health Sciences - USA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28811] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RG, 1978, J CHEM SOC P1, V1, P561; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BRYAN LE, 1988, J ANTIMICROB CHEMOTH, V22, P1; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; CASSIO D, 1967, BIOCHEMISTRY-US, V6, P827, DOI 10.1021/bi00855a024; CHAIN EB, 1974, J CHEM SOC CHEM COMM, P847, DOI 10.1039/c39740000847; CHAIN SEB, 1977, J CHEM SOC P1, V1, P294; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; CLARKE ND, 1988, SCIENCE, V240, P521, DOI 10.1126/science.3282306; CSANK C, 1992, J BIOL CHEM, V267, P4592; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ENGLISCH U, 1987, BIOL CHEM H-S, V368, P971, DOI 10.1515/bchm3.1987.368.2.971; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHEMISTRY-US, V25, P16, DOI 10.1021/bi00349a003; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; HUGHES J, 1980, FEBS LETT, V122, P322, DOI 10.1016/0014-5793(80)80465-0; ISAKI L, 1990, J BACTERIOL, V172, P469, DOI 10.1128/JB.172.1.469-472.1990; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; JENAL U, 1991, J BIOL CHEM, V266, P10570; KAWAKAMI M, 1985, FEBS LETT, V185, P162, DOI 10.1016/0014-5793(85)80762-6; KLEIN LL, 1989, J MED CHEM, V32, P151, DOI 10.1021/jm00121a028; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; MILLER JH, 1972, EXPT MOL GENETICS, P93; MILLER KW, 1987, J BIOL CHEM, V262, P7391; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PARENTI MA, 1987, CLIN PHARMACY, V6, P761; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SNIDER BB, 1983, J ORG CHEM, V48, P3003, DOI 10.1021/jo00166a013; SNIDER BB, 1982, J AM CHEM SOC, V104, P1113, DOI 10.1021/ja00368a042; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023	44	69	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24304	24309						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929087				2022-12-27	WOS:A1994PQ34600070
J	SENOGLES, SE				SENOGLES, SE			THE D2 DOPAMINE-RECEPTOR ISOFORMS SIGNAL THROUGH DISTINCT G(I-ALPHA)ADENYLYL CYCLASE - A STUDY WITH SITE-DIRECTED MUTANT G(I-ALPHA) PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; CYCLIC-AMP ACCUMULATION; ADENYLATE-CYCLASE; SOMATOSTATIN RECEPTORS; MESSENGER-RNA; RAT-BRAIN; INHIBITION; BINDING; IDENTIFICATION; GI2	Site-directed mutations of the cDNA for G(i1 alpha), G(i2 alpha), G(i3 alpha) were constructed which changed the cysteine residue at the C terminus to a glycine residue (G(i alpha)PT). This mutation of the G(i alpha) would not permit the subsequent covalent modification by pertussis toxin, which requires the cysteine moiety. The cDNA for each of the mutant G(i alpha) subunits was transfected into GH4C1 cells with either of the alternative splice forms of the D2 dopamine receptor and clonal lines were generated. After treatment with pertussis toxin to remove the contribution from endogenous G(i) proteins, the receptor-mediated inhibition of adenylyl cyclase was examined. The D2 dopamine receptor, short form (D2s) signaled through the G(i2 alpha)PT mutant in these cells with an affinity for agonist which was comparable to that observed in cells transfected with the cDNA for D2s alone or the signaling observed in the absence of pertussis toxin. The long form of the D2 dopamine receptor (D21) signaled through the G(i3 alpha)PT mutant to inhibit forskolin-stimulated adenylyl cyclase, with an affinity for agonist comparable to that observed in cells transfected with the cDNA for D21 alone. The receptor for somatostatin (somatotropin release inhibiting factor) was used as an endogenous control receptor in these cell lines. The somatotropin release inhibiting factor was able to signal through both G(i1 alpha)PT and G(i3 alpha)PT to inhibit forskolin-stimulated adenylyl cyclase. These results indicated that receptors use distinct G(i) proteins to signal to a common effector.			SENOGLES, SE (corresponding author), UNIV TENNESSEE, DEPT BIOCHEM, 858 MADISON AVE G01, MEMPHIS, TN 38163 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [S15NS028111] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28111] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COTE TE, 1982, MOL PHARMACOL, V22, P290; CRONIN MJ, 1980, ENDOCRINOLOGY, V106, P718, DOI 10.1210/endo-106-3-718; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; EINHORN LC, 1991, J NEUROSCI, V11, P3727; GIANNATTASIO G, 1981, LIFE SCI, V28, P1605, DOI 10.1016/0024-3205(81)90315-5; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; MALARKEY WB, 1977, NATURE, V266, P640, DOI 10.1038/266640a0; MANSOUR A, 1990, J NEUROSCI, V10, P2587; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCDONALD WM, 1984, MOL CELL ENDOCRINOL, V36, P201, DOI 10.1016/0303-7207(84)90037-6; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; RAYNOR K, 1993, J PHARMACOL EXP THER, V264, P110; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TAM SW, 1981, ENDOCRINOLOGY, V109, P403; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WEINER DM, 1989, FEBS LETT, V253, P207, DOI 10.1016/0014-5793(89)80960-3; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	32	168	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23120	23127						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916015				2022-12-27	WOS:A1994PQ16400036
J	DICKSON, PW; JENNINGS, IG; COTTON, RGH				DICKSON, PW; JENNINGS, IG; COTTON, RGH			DELINEATION OF THE CATALYTIC CORE OF PHENYLALANINE-HYDROXYLASE AND IDENTIFICATION OF GLUTAMATE-286 AS A CRITICAL RESIDUE FOR PTERIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID HYDROXYLASES; SITE-DIRECTED MUTAGENESIS; RAT-LIVER; ESCHERICHIA-COLI; BINDING-SITES; TYROSINE-HYDROXYLASE; PURIFICATION; ACTIVATION; EXPRESSION; PHENYLKETONURIA	Rat phenylalanine hydroxylase was expressed in Escherichia coli. High level expression was achieved when the transformed E. coli were incubated at 27 degrees C for 24 h. A series of truncated fragments were expressed. The smallest fragment that gave an active soluble protein was from Leu(142) to Phe(410). This fragment corresponds closely to the region where there is highest homology between the three aromatic amino acid hydroxylases. The circular dichroism spectra of the phenylalanine hydroxylase catalytic core suggested that it contains around 50% alpha-helix. The core fragment is monomeric in dilute solutions but self-associates at higher concentrations. The E. coli expression system was used to generate a number of mutations in phenylalanine hydroxylase from position 264 to 290. This region had been previously shown to be important for pterin binding. Characterization of the mutant phenylalanine hydroxylase molecules identified Glu(286) as an amino acid critical for pterin function in phenylalanine hydroxylase.	ROYAL CHILDRENS HOSP, MURDOCH INST, OLIVE MILLER PROT LAB, PARKVILLE, VIC 3052, AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	DICKSON, PW (corresponding author), UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM, RUSSELL GRIMWADE LAB PROT ENGN, GRATTAN ST, PARKVILLE, VIC 3052, AUSTRALIA.			Jennings, Ian/0000-0002-4781-9465				ABITA JP, 1984, J BIOL CHEM, V259, P4560; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOO KH, 1979, BIOCHEM GENET, V17, P921, DOI 10.1007/BF00504313; COTTON RGH, 1988, BIOCHEM J, V255, P193, DOI 10.1042/bj2550193; COTTON RGH, 1978, EUR J BIOCHEM, V85, P357, DOI 10.1111/j.1432-1033.1978.tb12247.x; DAHL HHM, 1986, J BIOL CHEM, V261, P4148; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5839, DOI 10.1021/bi00342a022; FISHER DB, 1973, J BIOL CHEM, V248, P4345; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; GIBBS BS, 1993, J BIOL CHEM, V268, P8046; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; Guttler Flemming, 1993, Developmental Brain Dysfunction, V6, P92; HOWELLS DW, 1994, IN PRESS J INHERITED; IWAKI M, 1986, J BIOL CHEM, V261, P2051; JENNINGS I, 1990, J BIOL CHEM, V265, P1885; JENNINGS IG, 1991, P NATL ACAD SCI USA, V88, P5734, DOI 10.1073/pnas.88.13.5734; KAUFMAN S, 1987, METHOD ENZYMOL, V142, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; NIELSEN KH, 1969, EUR J BIOCHEM, V7, P360, DOI 10.1111/j.1432-1033.1969.tb19617.x; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; ONISHI A, 1991, J BIOL CHEM, V266, P18454; RAMUS SJ, 1993, J MED GENET, V30, P401, DOI 10.1136/jmg.30.5.401; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOURIAN A, 1971, BIOCHIM BIOPHYS ACTA, V242, P345, DOI 10.1016/0005-2744(71)90226-9	30	61	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20369	20375						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914195				2022-12-27	WOS:A1994PB31700027
J	KOHNO, K; TANIMURA, H; SATO, S; NAKAYAMA, Y; MAKINO, Y; WADA, M; FOJO, AT; KUWANO, M				KOHNO, K; TANIMURA, H; SATO, S; NAKAYAMA, Y; MAKINO, Y; WADA, M; FOJO, AT; KUWANO, M			CELLULAR CONTROL OF HUMAN MULTIDRUG-RESISTANCE-1 (MDR-1) GENE-EXPRESSION IN ABSENCE AND PRESENCE OF GENE AMPLIFICATION IN HUMAN CANCER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-RESISTANCE; CARCINOMA-CELLS; HEAT-SHOCK; DNA; PROMOTER; LINES; ACTIVATION; MODULATION; SEQUENCE; AGENTS	The Kst-6 cell line is a human KB carcinoma cell line that has a stably integrated chloramphenicol acetyltransferase (CAT) reporter gene under the control of the human mdr-1 promoter. Using Kst-6 cells as the parental cell line, five vincristine resistant sublines, designated Kst-V5, -V25, V50, -V75, and -V100, were isolated by exposure to increasing concentrations of drug. These sublines showed increased resistance to vincristine when compared with parental Kst-6 cells. Two sublines, V25-1 and V25-2, were further isolated from Kst-V25 after culture in the presence of vincristine, and V100-1 and V100-2 were also isolated from Kst-V100. Southern analysis demonstrated mdr-1 gene amplification in Kst-V50, Kst-V75, Kst-V100, V100-1, and V100-2 cells, respectively, but not in Kst-V5, Kst-V25, V25-1, and V25-2 cells. In contrast, increased mdr-1 expression was documented by Northern analysis in Kst-V25, V25-1, and V25-2 cells and five cell lines with mdr-1 amplification. Southern blot analysis utilizing a CAT probe demonstrated a stable copy number in all vincristine-resistant sublines. However, Northern analysis documented increased CAT expression in Kst-V5, Kst-V25, V25-1, and V25-2 cells but reduced mRNA levels in the cell line with amplification of the endogenous mdr-1 gene. Expression of the CAT gene was increased along with the endogenous mdr-1 gene in the early steps of the selection but decreased with the onset of gene amplification. There appeared almost similar mRNA levels of two trans-acting factor genes, SP-1 and MDR-NF1/YB-1, which are supposed to be involved in mdr-1 gene promoter activation, among all cell lines used in this study. These findings suggest that transcription of both the CAT gene fused to the mdr-1 promoter and the endogenous mdr-1 gene is enhanced through activation by trans-acting factors in the early steps of drug selection. However, the quantity of trans-activating factor is limiting, and with the onset of gene amplification, less is available for activation of the CAT gene, resulting in decreased expression.	NCI, MED BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KOHNO, K (corresponding author), KYUSHU UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 812, JAPAN.							ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; KOHNO K, 1988, JPN J CANCER RES, V79, P1238, DOI 10.1111/j.1349-7006.1988.tb01550.x; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; KOHNO K, 1992, INT J ONCOL, V1, P73; KOHNO K, 1993, INT CONGR SER, V1026, P21; KOHNO K, 1992, MOL BIOL DNA TOPOISO, P247; Maniatis T., 1982, MOL CLONING; MARINO PA, 1990, CELL GROWTH DIFFER, V1, P57; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1358, DOI 10.1016/0006-291X(90)91016-L; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SUGIMOTO Y, 1987, MOL CELL BIOL, V7, P4549, DOI 10.1128/MCB.7.12.4549; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UCHIUMI T, 1993, INT CONGR SER, V1026, P71; UEDA K, 1987, J BIOL CHEM, V262, P17432; VANDERBLIEK AM, 1989, ADV CANCER RES, V52, P165	37	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20503	20508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914196				2022-12-27	WOS:A1994PB31700047
J	REITER, Y; BRINKMANN, U; JUNG, SH; LEE, BK; KASPRZYK, PG; KING, CR; PASTAN, I				REITER, Y; BRINKMANN, U; JUNG, SH; LEE, BK; KASPRZYK, PG; KING, CR; PASTAN, I			IMPROVED BINDING AND ANTITUMOR-ACTIVITY OF A RECOMBINANT ANTI-ERBB2 IMMUNOTOXIN BY DISULFIDE STABILIZATION OF THE FV FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; PSEUDOMONAS EXOTOXIN; PROTEINS; TOXINS; FORMS	e23(dsFv)-PE38KDEL is a recombinant immunotoxin composed of the Pv region of anti-erbB2 monoclonal antibody e23 connected to a truncated form of Pseudomonas exotoxin (PE38KDEL), in which the inherently unstable Fv heterodimer (composed of V-H and V-L) is stabilized by a disulfide bond engineered between structurally conserved framework positions of V-H and V-L. We have now found that e23(dsFv)-PE38KDEL is considerably more cytotoxic to antigen-positive cell lines than the corresponding single-chain immunotoxin. The basis for the enhanced cytotoxic activity is that the e23 dsFv-immunotoxin binds to erbB2 with greater affinity than the single-chain counterpart. The dsFv-immunotoxin had 4-fold increased binding compared to the scFv and almost identical to the binding affinity of e23 Fab. e23(dsFv)-PE38KDEL was also considerably more stable at 37 degrees C than the single-chain immunotoxin. The therapeutic potential of the disulfide-stabilized immunotoxin was compared with its single-chain counterpart using two animal models of immunodeficient mice bearing subcutaneous tumor xenografts of human gastric tumor N87 cells or human A431 epidermoid carcinoma cells. The antitumor effect of e23(dsFv)-PE38KDEL was significantly better than that of the single-chain immunotoxin. e23(dsFv)-PE38KDEL caused complete regression of tumors at doses which caused no toxic effects in mice, whereas the single-chain immunotoxin did not cause complete regressions at the same doses.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892; ONCOLOGIX INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Brinkmann, Ulrich/AAF-8216-2019; Lee, Byungkook/E-4564-2011; pastan, ira/P-9319-2019	Brinkmann, Ulrich/0000-0002-5558-0212; Lee, Byungkook/0000-0002-3339-4582; pastan, ira/0000-0002-9223-0270				BATRA JK, 1992, P NATL ACAD SCI USA, V89, P5867, DOI 10.1073/pnas.89.13.5867; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JUNG SH, 1994, PROTEINS, V19, P35, DOI 10.1002/prot.340190106; MILENIC DE, 1991, CANCER RES, V51, P6363; PAI LH, 1991, P NATL ACAD SCI USA, V88, P3358, DOI 10.1073/pnas.88.8.3358; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; REITER Y, 1994, PROTEIN ENG, V7, P697, DOI 10.1093/protein/7.5.697; REITER Y, 1994, CANCER RES, V54, P2714; REITER Y, 1994, BIOCHEMISTRY-US, V33, P5454; REITER Y, 1994, IN PRESS INT J CANCE; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; YOKOTA T, 1992, CANCER RES, V52, P3402	18	92	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18327	18331						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7913461				2022-12-27	WOS:A1994NW79800017
J	ZHANG, SH; LAWTON, MA; HUNTER, T; LAMB, CJ				ZHANG, SH; LAWTON, MA; HUNTER, T; LAMB, CJ			ATPK1, A NOVEL RIBOSOMAL-PROTEIN KINASE GENE FROM ARABIDOPSIS .1. ISOLATION, CHARACTERIZATION, AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FAMILY; THALIANA; SEQUENCE; PLANTS; RNA; PHOSPHORYLATION; TRANSCRIPTION; TRANSDUCTION; POLYMERASE	Two protein kinase genes (atpk1 and atpk2) were isolated from Arabidopsis thaliana genomic DNA with a probe generated by polymerase chain reaction (PCR) using oligonucleotide primers encoding conserved eukaryotic protein kinase sequences. atpk1 and atpk2 are organized in a head-to-tail tandem array on chromosome 3 and have about 80% nucleotide sequence identity. atpk1 encodes a hydrophilic polypeptide of 465 amino acids, M(r)=52,554. The centrally located catalytic domain contains all the conserved residues characteristic of eukaryotic protein kinases, with greatest similarity to the catalytic domains of 70-kDa ribosomal S6 protein kinase, protein kinase C, and protein kinase A. The C-terminal 75 residues also show homology to protein kinase C and S6 protein kinase. In contrast, the N-terminal 130 residues have no homology to any known protein, and thus may represent a new class of protein kinase regulatory domain. Other motifs found in the Atpk1 protein include two putative autophosphorylation sites, a pseudosubstrate site, two acidic domains, a lysine-rich domain, and two putative PEST sequences, which may contribute to the regulation of protein kinase activity. RNA-blot hybridization showed that atpk1 encoded a 1.8-kb mRNA Analysis of atpk1 promoter/beta-glucuronidase reporter gene fusions in transgenic plants showed that atpk1 was expressed in all tissues and at all developmental stages, with the strongest expression observed in metabolically active tissues, suggesting that atpk1 is involved in the control of plant growth and development. The first intron of atpk1 functions as an enhancer in atpk1 expression.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, GRAD PROGRAM CHEM, LA JOLLA, CA 92093 USA	Salk Institute; Salk Institute; University of California System; University of California San Diego								BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUDDE RJA, 1990, PLANT BIOL, V9, P351; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HUANG SH, 1990, NUCLEIC ACIDS RES, V18, P1922, DOI 10.1093/nar/18.7.1922; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAWTON MA, 1989, P NATL ACAD SCI USA, V86, P3140, DOI 10.1073/pnas.86.9.3140; MA H, 1993, TRENDS GENET, V9, P228, DOI 10.1016/0168-9525(93)90075-S; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; Maniatis T., 1982, MOL CLONING; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHL S, 1990, PLANT CELL, V2, P837, DOI 10.1105/tpc.2.9.837; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RANJEVA R, 1987, ANNU REV PLANT PHYS, V38, P73, DOI 10.1146/annurev.pp.38.060187.000445; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; VOYTAS DF, 1990, GENETICS, V126, P713; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; ZHANG SH, 1994, J BIOL CHEM, V269, P17593; ZHANG SH, 1993, THESIS U CALIFORNIA	40	55	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17586	17592						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7912697				2022-12-27	WOS:A1994NU12800040
J	GOVEZENSKY, D; BOCHKAREVA, ES; ZAMIR, A; GIRSHOVICH, AS				GOVEZENSKY, D; BOCHKAREVA, ES; ZAMIR, A; GIRSHOVICH, AS			CHAPERONINS AS POTENTIAL GENE REGULATORY FACTORS - IN-VITRO INTERACTION AND SOLUBILIZATION OF NIFA, THE NIF TRANSCRIPTIONAL ACTIVATOR, WITH GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; BACTERIAL PROTEINS; ESCHERICHIA-COLI; INVITRO; PURIFICATION; PROMOTERS	A previous study (Govezensky, D., Greener, T., and Zamir, A. (1991) J. Bacteriol, 20, 6339-6346) indicated that the chaperonin GroEL was required for maximal expression from nif promoters in Klebsiella pneumoniae and nif-transformed Escherichia coli. That this requirement stemmed from the ability of GroEL to properly fold NifA, the nif transcriptional activator, was first supported by co-immunoprecipitation of NifA in K. pneumoniae extracts with anti-GroEL antibodies. In the present in vitro study, NifA, partially purified from E. coli overexpressing the protein, was diluted from a 6 M urea solution into a refolding buffer in the presence or absence of GroEL. Dilution in the absence of GroEL caused the complete precipitation of NifA. When present in the dilution buffer, GroEL bound NifA and maintained it in a soluble state. GroEL was also found to bind NifA newly synthesized in an in vitro translation system. For both NifA preparations, cochaperonin GroES and ATP promoted release of NifA from GroEL. These results provide evidence for the association of NifA with GroEL and for the role of both GroEL and GroES in the solubilization and thereby folding of the nif transcriptional activator.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								AUSTIN S, 1990, EUR J BIOCHEM, V187, P353, DOI 10.1111/j.1432-1033.1990.tb15312.x; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCK M, 1986, NATURE, V294, P776; CANNON W, 1991, J MOL BIOL, V220, P915, DOI 10.1016/0022-2836(91)90363-B; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FISCHER HM, 1993, EMBO J, V12, P2901, DOI 10.1002/j.1460-2075.1993.tb05952.x; GOVEZENSKY D, 1991, J BACTERIOL, V173, P6339, DOI 10.1128/jb.173.20.6339-6346.1991; GREENER T, 1993, EMBO J, V12, P889, DOI 10.1002/j.1460-2075.1993.tb05729.x; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; LONG SR, 1991, ADV MOL GENETICS PLA, V1, P127; MERRICK MJ, 1993, NEW HORIZONS NITROGE, P43; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; ROBERTS GP, 1980, J BACTERIOL, V144, P210, DOI 10.1128/JB.144.1.210-216.1980; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346	24	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14003	14006						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910608				2022-12-27	WOS:A1994NL60600044
J	ZHANG, Y; OLDENBURG, M; FILLINGAME, RH				ZHANG, Y; OLDENBURG, M; FILLINGAME, RH			SUPPRESSOR MUTATIONS IN F1 SUBUNIT-EPSILON RECOUPLE ATP-DRIVEN H+ TRANSLOCATION IN UNCOUPLED Q42E SUBUNIT C-MUTANT OF ESCHERICHIA-COLI F1F0 ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OXIDATIVE-PHOSPHORYLATION; CRYOELECTRON MICROSCOPY; NUCLEOTIDE-SEQUENCE; CATALYTIC SITE; GAMMA-SUBUNIT; ALPHA-SUBUNIT; IDENTIFICATION; F1-ATPASE; RESIDUES; COMPLEX	The Q42E mutation in the polar loop of subunit c of the Escherichia coli F1F0 ATP synthase leads to an uncoupling of H+ translocation through F-0 and ATP synthesis/hydrolysis in F-1. We have isolated four second-site suppressor mutants in which the coupling defect is corrected. Substitutions for Glu(31) in F-1 subunit epsilon were found in each suppressor mutant, where the substitutitions were E31G, E31V, and E31K (the last being found twice). The different substitutions vary in effectiveness in restoring wild type growth properties in the order epsilon E31G > epsilon E31V > epsilon E31K. Biochemical properties of epsilon E31G/cQ42E and epsilon E31K/cQ42E membranes were compared. In epsilon E31G/cQ42E mutant membranes, ATP-driven H+ translocation by F1F0 and the binding and coupling of F-1 to F-0 showed a striking pH dependence. Near normal function was observed at pH 7.0, but function was lost at pH 7.8. The function of epsilon E31K/cQ42E membranes was much less affected by changes in pH. Relative to epsilon E31G/cQ42E membranes, the ATP-driven H+ transport function of epsilon E31K/cQ42E membranes was approximately the same at pH 7.5, greater at pH 7.8, and less at pH 7.0. The differences between mutants could be explained if cGlu(42) ionized at pH 7.8 with loss of function in epsilon E31G/cQ42E membrane and a similar ionization were compensated for by the positively charged Lys in the epsilon E31K/cQ42E membrane.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1992, J BIOENERG BIOMEMBR, V24, P435, DOI 10.1007/BF00762359; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNN SD, 1982, J BIOL CHEM, V257, P7354; FELTON J, 1980, J BACTERIOL, V142, P221, DOI 10.1128/JB.142.1.221-228.1980; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAROE DJ, 1992, J BACTERIOL, V174, P633, DOI 10.1128/jb.174.2.633-637.1992; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P11097; Miller J.H., 1972, EXPT MOL GENETICS; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MITRA B, 1990, BIOCHEMISTRY-US, V29, P9879, DOI 10.1021/bi00494a018; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P272, DOI 10.1006/abbi.1993.1210; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P279, DOI 10.1006/abbi.1993.1211; STANLOTTER H, 1986, FEBS LETT, V197, P121, DOI 10.1016/0014-5793(86)80310-6; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZHANG Y, 1994, J BIOL CHEM, V269, P5473	31	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10221	10224						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908291				2022-12-27	WOS:A1994NF01700010
J	DEGIOIA, L; SELVAGGINI, C; GHIBAUDI, E; DIOMEDE, L; BUGIANI, O; FORLONI, G; TAGLIAVINI, F; SALMONA, M				DEGIOIA, L; SELVAGGINI, C; GHIBAUDI, E; DIOMEDE, L; BUGIANI, O; FORLONI, G; TAGLIAVINI, F; SALMONA, M			CONFORMATIONAL POLYMORPHISM OF THE AMYLOIDOGENIC AND NEUROTOXIC PEPTIDE HOMOLOGOUS TO RESIDUES-106-126 OF THE PRION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INFECTED CULTURED-CELLS; CIRCULAR-DICHROISM; FORM	Prion-related encephalopathies are characterized by cerebral accumulation of a post translationally modified form of the cellular prion protein (PrPC), designated PrPSc. Evidence suggests that the conversion from PrPC to PrPSc involves changes in the secondary structure leading to an increase in beta-sheet content. We have previously shown that a synthetic peptide homologous to residues 106-126 of human PrP, belonging to a predicted alpha-helical domain, exhibits a beta-sheet conformation, forms amyloid like fibrils, and is neurotoxic in vitro. The present study investigated how different chemicophysical conditions such as pH and ionic strength or a membrane-like environment influenced the secondary structure of this peptide. PrP 106-126 exhibited a predominantly beta-sheet structure in 200 mM phosphate buffer, pH 5.0, but a combination of beta-sheet and random coil structure in 200 mM phosphate buffer, pH 7.0, or in deionized water. The addition of trifluoroethanol (50% final concentration) to solutions of peptide in deionized water induced the appearance of an alpha-helical secondary structure, but did not modify the beta-sheet conformation of the peptide dissolved in 200 mM phosphate buffer, pH 5.0. In the presence of micelles formed by a 5% solution of sodium dodecyl sulfate, PrP 106-126 showed a high content of alpha-helix. When the peptide was dissolved in 5 mm phosphate buffer, pH 7.4, and incubated with liposomes, it changed from a prevalently random coil structure to a beta sheet conformation. The environment-dependent conformational polymorphism of PrP 106-126 and its marked tendency to form stable beta-sheet structures at acidic pH could account for the shift from alpha-helix to beta-sheet associated with the conversion of PrPC to PrPSc, which occurs most likely in the endosomal-lysosomal compartment.	IST RIC FARMACOL MARIO NEGRI,ENZYME RES LAB,I-20157 MILAN,ITALY; IST NEUROL CARLO BESTA,I-20133 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Neurologico Besta			salmona, mario/AAA-7116-2020; Tagliavini, Fabrizio/AAO-7891-2021; Forloni, Gianluigi/AAB-2115-2020; salmona, mario/ABI-4066-2020; De Gioia, Luca/K-6439-2016	salmona, mario/0000-0002-9098-9873; Tagliavini, Fabrizio/0000-0003-1039-7315; Forloni, Gianluigi/0000-0001-5374-3914; Diomede, Luisa/0000-0002-2258-0531				BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; LASZLO L, 1992, J PATHOL, V166, P333, DOI 10.1002/path.1711660404; MCKINLEY MP, 1991, LAB INVEST, V65, P622; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; RAPOPORT TA, 1985, CRIT REV BIOCH, V20, P73; REDDY GL, 1989, J BIOL CHEM, V264, P16591; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; SITARAM N, 1993, BIOCHEMISTRY-US, V32, P3124, DOI 10.1021/bi00063a026; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YANG JT, 1986, METHOD ENZYMOL, V130, P208	22	176	188	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7859	7862						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907586				2022-12-27	WOS:A1994NB40900007
J	MOHNEY, RP; KNEZ, JJ; RAVI, L; SEVLEVER, D; ROSENBERRY, TL; HIROSE, S; MEDOF, ME				MOHNEY, RP; KNEZ, JJ; RAVI, L; SEVLEVER, D; ROSENBERRY, TL; HIROSE, S; MEDOF, ME			GLYCOINOSITOL PHOSPHOLIPID ANCHOR-DEFECTIVE K562 MUTANTS WITH BIOCHEMICAL LESIONS DISTINCT FROM THOSE IN THY-1(-) MURINE LYMPHOMA MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; DECAY-ACCELERATING FACTOR; STRUCTURAL CHARACTERIZATION; MEMBRANE ANCHOR; GLYCOPHOSPHATIDYLINOSITOL ANCHORS; TRYPANOSOMA-BRUCEI; MASS-SPECTROMETRY; MAMMALIAN-CELLS; BIOSYNTHESIS	Deficient expression of glycoinositol phospholipid (GPI)-anchored surface proteins has been linked to six different genetic defects in Thy-1(-) murine lymphoma mutants. In this study, human K562 cell mutants defective in GPI anchoring were derived by anti-decay-accelerating factor (CD55) based negative fluorescent cell sorting of N-methyl-N'-nitro-N-nitrosoguanidine pretreated cells. Homologous cell fusions of six clones that complemented a previously described K562 mutant corresponding to one of the Thy-1(-) mutant classes (Hirose, S., Mohney, R. P., Mutka, S. C., Ravi, L., Singleton, D, R., Perry, G., Tartakoff, A., and Medof, M. E, (1992) J. Biol. Chem. 267, 5272-5278) showed that they segregated into two complementation groups. In heterologous cell fusions, representative clones of each group complemented Thy-1 expression by all of the previously described GPI anchor pathway defective Thy-1(-) murine lymphoma classes (A, B, C, E, F, and H) but not class(es) D (and I) defective in the Thy-1 structural gene. Analyses of putative GPI anchor precursors synthesized by the two lines revealed that one mutant exhibited a complete block in deacetylation of N-acetyl-D-glucosamine-inositol phospholipid to glucosamine (GlcN)-inositol phospholipid, whereas the other mutant assembled GlcN-inositol phospholipid and subsequent mannose (Man)-containing intermediates but showed markedly increased amounts of the terminal ethanolamine (EthN)-phosphate (P)-substituted putative anchor precursors, EthN-P-6ManMan(EthN-P-->)ManGlcN- and EthN-P-6Man(EthN-P-6) Man(EthN-P-->)ManGlcN-acylinositol phospholipid (H7 and H8). We designate these new complementation classes J, harboring a defect in N-acetyl-D-glucosamine-inositol phospholipid deacetylation, and K, deficient in a step preliminary to or associated with protein transfer of assembled anchor precursors, The availability of these new mutant classes should aid in characterization of the GPI anchor pathway enzymes providing for these reactions.	CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; CAMP LA, 1993, J BIOL CHEM, V268, P6721; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HIROSE S, 1991, FASEB J, V5, P2459; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1978, COLD SPRING HARBOR C, V5, P741; KAMITANI T, 1992, J BIOL CHEM, V267, P16968; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1992, J BIOL CHEM, V267, P22673; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHUBERT J, 1993, J BIOL CHEM, V268, P6281; SEGA GA, 1984, MUTAT RES, V134, P113, DOI 10.1016/0165-1110(84)90007-1; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; SLONINA AE, 1993, J BIOL CHEM, V268, P6729; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; UEDA E, 1993, J BIOL CHEM, V268, P9998; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VARKI A, 1980, J BIOL CHEM, V255, P847	41	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6536	6542						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907094				2022-12-27	WOS:A1994MZ50300044
J	RAWLINGS, SR; DEMAUREX, N; SCHLEGEL, W				RAWLINGS, SR; DEMAUREX, N; SCHLEGEL, W			PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE INCREASES [CA2+](I) IN RAT GONADOTROPHS THROUGH AN INOSITOL TRISPHOSPHATE-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; HORMONE-RELEASING HORMONE; HYPOTHALAMIC PEPTIDE; CYCLIC-AMP; SARCOPLASMIC-RETICULUM; CALCIUM MOBILIZATION; CYTOSOLIC CALCIUM; CELLS; OSCILLATIONS; PACAP	Pituitary adenylate cyclase-activating polypeptide (PACAP) increases cAMP production and stimulates hormone release from a variety of anterior pituitary cells. However, in anterior pituitary gonadotrophs PACAP stimulates oscillations in cytosolic free Ca2+ concentration ([Ca2+](i)) that appear to be independent of cAMP. To study the mechanisms involved in this response, we used the patch-clamp technique to microperfuse various agents into single rat gonadotrophs while monitoring [Ca2+](i) with microfluorometry. Extracellular application of PACAP to single gonadotrophs stimulated high amplitude (>1 mu M) oscillations in [Ca2+](i), which were blocked by intracellular application of GDP beta S (guanosine 5'-O-2-thiodiphosphate), indicating the involvement of a G-protein. To identify the intracellular messenger(s) involved, we microperfused gonadotrophs with cAMP, inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3), or heparin, an antagonist of the Ins(1,4,5)P-3 receptor. A high concentration of cAMP (100 mu m) had no significant effect on basal [Ca2+](i) and did not alter the PACAP-stimulated Ca2+ response. Heparin, but not its inactive isoform, completely blocked the PACAP-stimulated increase in [Ca2+](i), while Ins(1,4,5)P-3 stimulated oscillations in [Ca2+](i) very similar to those observed in response to PACAP. These results strongly suggest that PACAP mobilizes Ca2+ through an Ins(1,4,5)P-3-dependent mechanism. The fact that PACAP stimulates two signaling pathways in pituitary cells could substantially enhance the signaling potential of this hypothalamic peptide.	UNIV HOSP GENEVA,DIV INFECT DIS,GENEVA,SWITZERLAND	University of Geneva	RAWLINGS, SR (corresponding author), UNIV GENEVA,FDN RECH MED,CH-1211 GENEVA 4,SWITZERLAND.			Demaurex, Nicolas/0000-0002-9933-6772				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANNY BJ, 1992, ENDOCRINOLOGY, V130, P211, DOI 10.1210/en.130.1.211; CAPIOD T, 1991, BIOCHEM J, V275, P277, DOI 10.1042/bj2750277; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CONN PM, 1987, RECENT PROG HORM RES, V43, P29; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DEMAUREX N, 1993, IN PRESS METHODS ENZ; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GALIONE A, 1993, NATURE, V259, P325; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GOTH MI, 1992, ENDOCRINOLOGY, V130, P939, DOI 10.1210/en.130.2.939; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GRACIANAVARRO F, 1992, ENDOCRINOLOGY, V131, P1069, DOI 10.1210/en.131.3.1069; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HART GR, 1992, J ENDOCRINOL, V134, P33, DOI 10.1677/joe.0.1340033; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; JARRY H, 1992, LIFE SCI, V51, P823, DOI 10.1016/0024-3205(92)90609-S; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH B, 1992, REGUL PEPTIDES, V38, P45, DOI 10.1016/0167-0115(92)90071-2; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; LEONG DA, 1991, J BIOL CHEM, V266, P9016; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NAOR Z, 1986, J BIOL CHEM, V261, P2506; OSUGA Y, 1992, ENDOCRINOL JAPON, V39, P153; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PAPE PC, 1988, FEBS LETT, V235, P57, DOI 10.1016/0014-5793(88)81233-X; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1993, ENDOCRINOLOGY, V132, P1447, DOI 10.1210/en.132.4.1447; RAWLINGS SR, 1991, J BIOL CHEM, V266, P22755; SCHAFER H, 1991, EUR J BIOCHEM, V202, P951, DOI 10.1111/j.1432-1033.1991.tb16455.x; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; VIGH S, 1992, REGUL PEPTIDES, V37, P315, DOI 10.1016/0167-0115(92)90630-D	55	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5680	5686						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907085				2022-12-27	WOS:A1994MY84000033
J	PATEL, YC; PANETTA, R; ESCHER, E; GREENWOOD, M; SRIKANT, CB				PATEL, YC; PANETTA, R; ESCHER, E; GREENWOOD, M; SRIKANT, CB			EXPRESSION OF MULTIPLE SOMATOSTATIN RECEPTOR GENES IN ATT-20 CELLS - EVIDENCE FOR A NOVEL SOMATOSTATIN-28 SELECTIVE RECEPTOR SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-INDEPENDENT ACTIONS; PITUITARY-TUMOR CELLS; RAT-BRAIN; MOLECULAR CHARACTERIZATION; POTASSIUM CONDUCTANCE; GH CELLS; CLONING; BINDING; IDENTIFICATION; INHIBITION	The pattern of expression of somatostatin receptor (SSTR) genes and gene products in AtT-20 cells was characterized in an attempt to explain the SST-28 binding selectivity that typifies these cells. AtT-20 cells expressed multiple SSTR mRNAs. Paradoxically, this included mRNA for three of the four SST-14 selective receptors: SSTR2 (++++), SSTR1 (+), SSTR4 (+). The SST-28 selective SSTR5 was expressed as a 3.8-kilobase (kb) transcript of reLatively Low abundance (+) in contrast to normal mouse pituitary which dispLayed high Levels (+++) of a 2.4-kb SSTR5 MRNA. Immunoblot analysis of solubilized membranes with an antipeptide SSTR2 antibody revealed a single SSTR2 protein of 72 +/- 2 kDa. Preincubation of AtT-20 cell membranes with SSTR2 antibody reduced I-125-[Leu8,D-Trp22,Tyr25]SST-28 binding sites by 38%. Residual binding sites exhibited a 4.9-fold increase in affinity for SST-28, a 2.6-fold decrease in affinity for SST-14, and an SST-28:SST-14 potency ratio of 40:1 compared with a potency ratio of 3.5:1 in control membranes. These results demonstrate the expression of four SSTR genes in AtT-20 cells of which SSTR2 predominates. Blockade of SSTR2 with antibody exposes high affinity SST-28 selective sites with comparable binding characteristics to those reported for cloned SSTR5. These SST-28 binding sites may arise from a SSTR5 variant encoded by a high molecular weight 3.8-kb transcript or more likely from another as yet undiscovered member of the SST-28 selective SSTR subfamily.	ROYAL VICTORIA HOSP,DEPT NEUROL & NEUROSURG,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,FRASER LABS,MONTREAL H3A 2T5,QUEBEC,CANADA; MONTREAL NEUROL HOSP & INST,MONTREAL H3A 2B4,QUEBEC,CANADA; UNIV SHERBROOKE,DEPT PHARMACOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; University of Sherbrooke	PATEL, YC (corresponding author), ROYAL VICTORIA HOSP,DEPT MED,RM M3-15,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA.			Greenwood, Michael/0000-0003-0890-3434; Escher, Emanuel/0000-0001-6601-987X				AMHERDT M, 1987, J CLIN INVEST, V80, P1455, DOI 10.1172/JCI113225; BROWN PJ, 1990, J BIOL CHEM, V265, P17995; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNESS JD, 1993, FEBS LETT, V321, P279, DOI 10.1016/0014-5793(93)80124-D; DEMCHYSHYN LL, 1993, MOL PHARMACOL, V43, P894; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1988, J BIOL CHEM, V263, P226; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LI XJ, 1992, J BIOL CHEM, V267, P21307; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; MOREL G, 1985, ENDOCRINOLOGY, V116, P1615, DOI 10.1210/endo-116-4-1615; MURTHY KK, 1989, ENDOCRINOLOGY, V125, P948, DOI 10.1210/endo-125-2-948; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PANETTA R, 1993, 75TH ANN M US END SO, P411; PATEL YC, 1993, BIOCHEM BIOPH RES CO, V192, P288, DOI 10.1006/bbrc.1993.1412; PATEL YC, 1990, METABOLISM, V39, P63, DOI 10.1016/0026-0495(90)90214-W; PATEL YC, 1988, J BIOL CHEM, V263, P7455; PATEL YC, 1992, RLE SOMATOSTATIN BAS, V5, P1; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; SCHONBRUNN A, 1983, ENDOCRINOLOGY, V113, P1559, DOI 10.1210/endo-113-5-1559; SCHONBRUNN A, 1993, 75TH AN M US END SOC, V3, P476; SRIKANT CB, 1992, ENDOCRINOLOGY, V130, P2937, DOI 10.1210/en.130.5.2937; SRIKANT CB, 1981, P NATL ACAD SCI-BIOL, V78, P3930, DOI 10.1073/pnas.78.6.3930; SRIKANT CB, 1981, NATURE, V294, P259, DOI 10.1038/294259a0; SRIKANT CB, 1985, ENDOCRINOLOGY, V117, P271, DOI 10.1210/endo-117-1-271; SRIKANT CB, 1987, SOMATOSTATIN BASIC C, P89; STRNAD J, 1993, BIOCHEM BIOPH RES CO, V191, P968, DOI 10.1006/bbrc.1993.1312; THEVENIAU M, 1992, P NATL ACAD SCI USA, V89, P4314, DOI 10.1073/pnas.89.10.4314; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1993, GENOMICS, V15, P449, DOI 10.1006/geno.1993.1088; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YASUDA K, 1992, J BIOL CHEM, V267, P20422	39	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1506	1509						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904601				2022-12-27	WOS:A1994MR22000111
J	HAMRICK, M; RENAUD, KJ; FAMBROUGH, DM				HAMRICK, M; RENAUD, KJ; FAMBROUGH, DM			ASSEMBLY OF THE EXTRACELLULAR DOMAIN OF THE NA,K-ATPASE BETA-SUBUNIT WITH THE ALPHA-SUBUNIT - ANALYSIS OF BETA-SUBUNIT CHIMERAS AND CARBOXYL-TERMINAL DELETIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; XENOPUS-OOCYTES; INTRACELLULAR-TRANSPORT; DISULFIDE BONDS; SODIUM-PUMP; ENDOPLASMIC-RETICULUM; ADHESION MOLECULE; RNA-POLYMERASE; NA+/K+-ATPASE; EXPRESSION	The role of the extracellular domain of the Na,K-ATPase beta subunit in assembly with the alpha subunit was investigated. A chimeric protein consisting of the extracellular domain of the beta subunit fused with the transmembrane and cytoplasmic domains of dipeptidyl peptidase IV assembles with the alpha subunit. An inverse chimera consisting of the cytoplasmic and transmembrane domains of the beta subunit fused with the extracellular domain of dipeptidyl peptidase IV does not assemble with the alpha subunit. The assembly data from these chimeras demonstrate that the extracellular domain of the beta subunit is both necessary and sufficient for assembly with the alpha subunit. Deletions of up to 146 extracellular amino acids from the carboxyl terminus of the beta subunit appear to result in misfolding of the subunit, but do allow reduced assembly with the alpha subunit. Together, the assembly data from chimeras and carboxyl-terminal deletions have identified a 96-residue extracellular domain which contains sequences involved in subunit assembly. While the chimeric subunits properly localize to the plasma membrane, deletion of as few as 4 amino acids from the carboxyl terminus impairs the ability of the beta subunit to be transported to the plasma membrane.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University					NINDS NIH HHS [NS-23241] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023241] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1991, SODIUM PUMP RECENT D, P125; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAWAKAMI K, 1988, J BIOCHEM-TOKYO, V103, P54, DOI 10.1093/oxfordjournals.jbchem.a122239; KAWAMURA M, 1984, BIOCHIM BIOPHYS ACTA, V774, P188, DOI 10.1016/0005-2736(84)90290-6; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; Kone BC., 1991, SODIUM PUMP RECENT D, P265; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OGATA S, 1989, J BIOL CHEM, V264, P3596; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009	42	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24367	24373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901216				2022-12-27	WOS:A1993MF29400097
J	CHEUNG, PP; KUNAPULI, SP; SCOTT, CF; WACHTFOGEL, YT; COLMAN, RW				CHEUNG, PP; KUNAPULI, SP; SCOTT, CF; WACHTFOGEL, YT; COLMAN, RW			GENETIC-BASIS OF TOTAL KININOGEN DEFICIENCY IN WILLIAMS TRAIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; HUMAN-PLASMA; IDENTIFICATION; PREKALLIKREIN; INHIBITORS; ACTIVATION; PLATELETS; THROMBIN; CLEAVAGE	High and low molecular weight kininogens (HK and LK) modulate inflammatory responses, serve as precursors of kinins, inhibit cysteine proteinases, and modulate thrombin activation of platelets. Differential splicing yields two different mRNAs for HK and LK. We report the first molecular characterization of a kininogen gene mutation in a patient lacking LK and HK. No gross DNA deletion or insertion was detected by Southern blots, and LK and HK mRNAs were normal size on Northern blots. Exon sequences amplified by polymerase chain reaction showed a C --> T transition at nucleotide 587, resulting in a CGA (Arg) --> TGA (Stop) mutation in exon 5 before the splice site in exon 10, thus preventing synthesis of both HK and LK. The mutation eliminated the recognition site of the restriction enyzme Csp45I. Results of Csp45I digestion of the polymerase chain reaction-amplified exon 5 DNA fragment of the patient (lacking kininogens), three daughters (approximately 50% HK), and 1 granddaughter (normal HK) revealed that the patient was homozygous, while the three daughters were heterozygous, and the granddaughter was normal. We conclude that a single base mutation in the kininogen gene exon 5 was responsible for kininogen deficiency in the Williams family.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,SOL SHERRY THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005417] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7 RR05417] Funding Source: Medline; NHLBI NIH HHS [HL45486] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; CHEUNG P, 1984, P NATL ACAD SCI-BIOL, V81, P508, DOI 10.1073/pnas.81.2.508; CHEUNG PP, 1992, CYTOGENET CELL GENET, V59, P24, DOI 10.1159/000133192; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; DONALDSON VH, 1976, J LAB CLIN MED, V87, P327; EXNER T, 1987, MED J AUSTRALIA, V146, P545, DOI 10.5694/j.1326-5377.1987.tb120397.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORREST S, 1990, MOL BIOL MED, V7, P451; HAYASHI H, 1990, BLOOD, V75, P1296; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KAN YW, 1977, NEW ENGL J MED, V297, P1081, DOI 10.1056/NEJM197711172972002; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; LACOMBE MJ, 1975, BLOOD, V46, P761; LEFRERE JJ, 1986, AM J HEMATOL, V22, P415, DOI 10.1002/ajh.2830220411; LUTCHER CL, 1976, CLIN RES, V24, pA47; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MULLERESTERL W, 1989, THROMB HAEMOSTASIS, V61, P2; PURI RN, 1991, BLOOD, V77, P500; REGOLI D, 1980, PHARMACOL REV, V32, P1; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT CF, 1992, J LAB CLIN MED, V119, P77; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; STORMORKEN H, 1990, THROMB RES, V60, P457, DOI 10.1016/0049-3848(90)90230-A; SUEYOSHI T, 1985, FEBS LETT, V182, P193, DOI 10.1016/0014-5793(85)81182-0; WILLIAMS JG, 1987, NUCL ACID HYBRIDISAT, P139	31	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23361	23365						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901207				2022-12-27	WOS:A1993MF51500064
J	HIREMAGALUR, B; NANKOVA, B; NITAHARA, J; ZEMAN, R; SABBAN, EL				HIREMAGALUR, B; NANKOVA, B; NITAHARA, J; ZEMAN, R; SABBAN, EL			NICOTINE INCREASES EXPRESSION OF TYROSINE-HYDROXYLASE GENE - INVOLVEMENT OF PROTEIN KINASE-A-MEDIATED PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; NERVE GROWTH-FACTOR; ADRENAL CHROMAFFIN CELLS; PC12 PHEOCHROMOCYTOMA CELLS; CYCLIC-AMP; MESSENGER-RNAS; MEMBRANE DEPOLARIZATION; CHOLINERGIC AGONISTS; MEDULLARY CELLS; RAT-BRAIN	Nicotine, a major component of tobacco smoke, stimulates catecholamine secretion and activates catecholamine biosynthetic enzymes such as tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) in adrenal medullary cells. We investigated the effect of long term treatment with nicotine on TH and DBH gene expression in rat PC12 pheochromocytoma cells. Nicotine treatment for 1-2 days increased both the TH and DBH mRNA levels. The effect of nicotine on TH mRNA seems to be transcriptionally mediated. Deletion analysis of the 5' promoter region of the TH gene showed that the region containing a cyclic AMP/calcium regulatory element is sufficient for the nicotinic induction of TH. Nicotine did not induce TH mRNA or chloramphenicol acetyltransferase reporter activity in mutant PC12 cells deficient in protein kinase A activity. However, the deficiency in protein kinase A activity did not affect the elevation in intracellular calcium concentration caused by nicotine, indicating normal receptor function. These results suggest that a cAMP-mediated pathway plays a crucial role in the long term nicotine-induced activation of the TH gene.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595	New York Medical College; New York Medical College			Zeman, Richard/A-9295-2009	Nankova, Bistra/0000-0002-3997-4369	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON K, 1992, BRIT J PHARMACOL, V106, P360, DOI 10.1111/j.1476-5381.1992.tb14341.x; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADOYANNIS HC, 1991, MOL BRAIN RES, V11, P79, DOI 10.1016/0169-328X(91)90024-R; BAIZER L, 1985, J NEUROSCI, V5, P1176; BLACK IB, 1985, BRAIN RES, V339, P151, DOI 10.1016/0006-8993(85)90635-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVISO GL, 1992, J NEUROCHEM, V59, P2285; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAS B, 1992, J NEUROCHEM, V59, P2263; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FOSSOM LH, 1991, J NEUROCHEM, V57, P2070, DOI 10.1111/j.1471-4159.1991.tb06424.x; FOSSOM LH, 1991, MOL PHARMACOL, V40, P193; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUIDOTTI A, 1974, J PHARMACOL EXP THER, V189, P665; GUIDOTTI A, 1975, P NATL ACAD SCI USA, V72, P1152, DOI 10.1073/pnas.72.3.1152; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KVETNANSKY R, 1971, MOL PHARMACOL, V7, P81; KVETNANSKY R, 1973, FRONTIERS CATECHOLAM, P223; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MACNICOL M, 1992, FEBS LETT, V304, P237, DOI 10.1016/0014-5793(92)80627-S; Martin W., 1987, TOBACCO SMOKING NICO, P1; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1992, J NEUROCHEM, V59, P2040; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MESSING RO, 1989, J NEUROSCI, V9, P507; MINER LL, 1992, J NEUROSCI RES, V33, P10, DOI 10.1002/jnr.490330103; OLASMAA M, 1992, MOL PHARMACOL, V41, P456; RAYNAUD B, 1987, DEV BIOL, V119, P305, DOI 10.1016/0012-1606(87)90036-4; REIS DJ, 1975, J PHARMACOL EXP THER, V193, P775; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SANDS SB, 1991, BRAIN RES, V560, P38, DOI 10.1016/0006-8993(91)91211-I; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SLOTKIN TA, 1976, LIFE SCI, V16, P1613; SMITH KM, 1991, J NEUROCHEM, V57, P1750, DOI 10.1111/j.1471-4159.1991.tb06377.x; STACHOWIAK M K, 1990, Molecular and Cellular Neuroscience, V1, P202, DOI 10.1016/1044-7431(90)90003-M; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; STACHOWIAK MK, 1986, J NEUROSCI RES, V16, P13, DOI 10.1002/jnr.490160104; TANK AW, 1986, MOL PHARMACOL, V30, P497; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; THOENEN H, 1969, J PHARMACOL EXP THER, V169, P249; TOUMINEN RK, 1992, J NEUROCHEM, V58, P1652; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WESSELSREIKER M, 1991, J BIOL CHEM, V266, P9347; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	61	119	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23704	23711						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901211				2022-12-27	WOS:A1993MF51500111
J	BUURMAN, ET; KIM, KT; EPSTEIN, W				BUURMAN, ET; KIM, KT; EPSTEIN, W			GENETIC-EVIDENCE FOR 2 SEQUENTIALLY OCCUPIED K+ BINDING-SITES IN THE KDP TRANSPORT ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE H+-ATPASE; DRIVEN POTASSIUM-TRANSPORT; ESCHERICHIA-COLI; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; MOLECULAR-CLONING; TRANSMEMBRANE DOMAIN; ALKALINE-PHOSPHATASE; COMPLEMENTARY-DNA	Substrate binding sites in Kdp, a P-type ATPase of Escherichia coli, were identified by the isolation and characterization of mutants with reduced affinity for K+, its cation substrate, Most of the mutants have an altered KdpA subunit, a hydrophobic subunit not found in other P-type ATPases. Topological analysis of KdpA and the locations of the residues changed in the mutants suggest that KdpA has 10 membrane-spanning segments and forms two separate and distinct sites where K+ is bound. One site is formed by three periplasmic loops of the protein and is inferred to be the site of initial binding, The other site is cytoplasmic. We believe K+ moves from the periplasmic site through the membrane to the cytoplasmic site where it becomes ''occluded,'' i.e. inexchangeable with K+ outside the membrane, Membrane-spanning parts of KdpA probably form the path for transmembrane movement of K+, The kinetics of cation transport in the mutants indicate that each of the two binding sites contributes to the observed K-m for cations as well as to the marked discrimination between K+ and Rb+ characteristic of wild type Kdp, Energy coupling in Kdp, mediated by the KdpB subunit, is performed by a different subunit from the one that mediates transport.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022323] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22323] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; BAKKER EP, 1992, ALKALI CATION TRANSP, P205; BOSSEMEYER D, 1989, J BACTERIOL, V171, P2219, DOI 10.1128/jb.171.4.2219-2221.1989; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BROER S, 1993, J BACTERIOL, V175, P3480, DOI 10.1128/jb.175.11.3480-3485.1993; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; EPSTEIN W, 1978, J BIOL CHEM, V253, P6666; EPSTEIN W, 1990, PHIL T R SOC LOND B, V316, P479; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GLYNN IM, 1970, J PHYSIOL-LONDON, V207, P393, DOI 10.1113/jphysiol.1970.sp009068; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GROISMAN EA, 1986, J BACTERIOL, V168, P357, DOI 10.1128/jb.168.1.357-364.1986; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KEPES A, 1962, BACTERIA, V4, P179; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIMINS LA, 1978, P NATL ACAD SCI USA, V75, P3216, DOI 10.1073/pnas.75.7.3216; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LEE KS, 1992, J BACTERIOL, V174, P2501, DOI 10.1128/jb.174.8.2501-2510.1992; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANOIL C, 1988, TRENDS GENET, V4, P23; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; NAVARRE C, 1994, J BIOL CHEM, V269, P21269; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POLAREK JW, 1988, METHOD ENZYMOL, V157, P655; RABON EC, 1993, J BIOL CHEM, V268, P8012; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SERRANO R, 1986, NATURE, V319, P698; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SIEBERS A, 1992, J BIOL CHEM, V267, P12717; SIEBERS A, 1988, THESIS U OSNABRUCK; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	68	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6678	6685		10.1074/jbc.270.12.6678	http://dx.doi.org/10.1074/jbc.270.12.6678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896809	hybrid			2022-12-27	WOS:A1995QQ85500040
J	HONG, YS; MA, GT; IVES, DH				HONG, YS; MA, GT; IVES, DH			DIRECTED MUTAGENESIS OF DEOXYGUANOSINE SITE AT ARGININE-79 UP-REGULATES TURNOVER ON DEOXYADENOSINE KINASE SUBUNIT OF HETERODIMERIC ENZYME FROM LACTOBACILLUS-ACIDOPHILUS R26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS THYMIDINE KINASE; DEOXYCYTIDINE KINASE; ADENYLATE KINASE; BINDING-SITE; SECONDARY STRUCTURE; PROTEINS; PREDICTIONS; SELECTION	Examination of conserved motifs on the cloned subunits of the deoxyguanosine kinase/deoxyadenosine kinase (dGK/dAK) of Lactobacillus acidophilus R-26 has begun with the Asp-Arg-Ser (DRS) motif. Replacement of Asp-78 of both subunits with Glu, Ala, or Asn reduced dGK and dAK activities to less than 0.2%, whereas replacement of Arg-79 with Lys, either on both subunits in tandem (R79K), or on the dGK subunit only (R79K:dGK), yielded active but kinetically modified enzymes. These were partially purified, and their kinetic and regulatory properties were analyzed, For dAK activity, the V-max of the R79K:dGK enzyme was increased 28-fold, with no change in the limiting K-m, for dAdo, but with a slightly reduced K-m for MgATP, The V/K efficiency ratio of dAK was also increased 29-fold, but that of dGK was decreased to 5-10% due to a 10-fold increase in K-m, for dGuo and a reduced V-max. Therefore, the R79K substitution seems to have a greater effect on dGuo binding than on that of dAdo, but dGK modification appears to produce a stimulatory conformational effect on the opposite subunit, resembling the known unidirectional activation of dAK by either dGuo or dGTP.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL CANCER INSTITUTE [R01CA047828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049635] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47828] Funding Source: Medline; NIGMS NIH HHS [GM49635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; CHAKRAVARTY R, 1984, BIOCHEMISTRY-US, V23, P6235, DOI 10.1021/bi00320a053; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRETTON EM, 1992, BIOCHEM PHARMACOL, V44, P973, DOI 10.1016/0006-2952(92)90130-B; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DATTA NS, 1989, BIOCHEMISTRY-US, V28, P114, DOI 10.1021/bi00427a017; Deibel M R Jr, 1978, Methods Enzymol, V51, P346, DOI 10.1016/S0076-6879(78)51046-X; DEIBEL MR, 1977, J BIOL CHEM, V252, P8240; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAO WY, 1990, J BIOL CHEM, V265, P20172; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENTRY GA, 1992, PHARMACOL THERAPEUT, V54, P319, DOI 10.1016/0163-7258(92)90006-L; IKEDA S, 1986, J BIOL CHEM, V261, P5836; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; IKEDA S, 1988, BIOCHEMISTRY-US, V27, P8648, DOI 10.1021/bi00423a021; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P13373, DOI 10.1021/bi00249a025; Ives D H, 1978, Methods Enzymol, V51, P337; IVES DH, 1984, ANAL BIOCHEM, V136, P416, DOI 10.1016/0003-2697(84)90237-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA GT, 1994, J BIOL CHEM, V270, P6595; MUNIR KM, 1994, PROTEIN ENG, V7, P83, DOI 10.1093/protein/7.1.83; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I. H., 1975, ENZYME KINETICS, P273; SUZUTANI T, 1993, J GEN VIROL, V74, P1011, DOI 10.1099/0022-1317-74-6-1011; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002	29	6	8	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6602	6606		10.1074/jbc.270.12.6602	http://dx.doi.org/10.1074/jbc.270.12.6602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896799				2022-12-27	WOS:A1995QQ85500029
J	HSU, YS; TANG, FM; LIU, WL; CHUANG, JY; LAI, MY; LIN, YS				HSU, YS; TANG, FM; LIU, WL; CHUANG, JY; LAI, MY; LIN, YS			TRANSCRIPTIONAL REGULATION BY P53 - FUNCTIONAL INTERACTIONS AMONG MULTIPLE REGULATORY DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DNA-BINDING; GENE-EXPRESSION; MUTANT P53; SYNERGISTIC ACTIVATION; RESPONSIVE ELEMENT; PROTEIN; SEQUENCE; SUPPRESSOR; IDENTIFICATION	The tumor suppressor p53 protein possesses activities typical of eukaryotic transcriptional activators; p53 binds to specific DNA sequences and stimulates transcription of the target genes. By a series of deletion and domain-swapping studies, we report here that (i) p53 has two auxiliary domains, which have little effect on the DNA binding activity of its core domain but are capable of modulating its transactivation activity in a target site dependent manner; (ii) p53 contains two cell-specific transcriptional inhibitory domains, I1 and I2, which are active in Saos-2 and HeLa cells but not in HepG2 and Hep3B cells; and (iii) I1 inhibits the activity of several structurally different activating regions. These results demonstrate that the apparent transcrip tional activity of p53 is determined by collaborations among its regulatory domains, its target sites, and the cellular environment.	ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN; NATL TAIWAN UNIV,COLL MED,GRAD INST CLIN MED,TAIPEI 11529,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PATHOL,TAIPEI 11529,TAIWAN	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University								AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM KS, 1990, P NATL ACAD SCI USA, V87, P4524, DOI 10.1073/pnas.87.12.4524; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; LIN YS, 1989, P NATL ACAD SCI USA, V86, P109, DOI 10.1073/pnas.86.1.109; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAKOS M, 1993, CANCER RES, V53, P2719; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; PTASHNE M, 1992, GENETIC SWITCH GENE; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6966	6974		10.1074/jbc.270.12.6966	http://dx.doi.org/10.1074/jbc.270.12.6966			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896847	hybrid			2022-12-27	WOS:A1995QQ85500078
J	RAO, P; MUFSON, RA				RAO, P; MUFSON, RA			A MEMBRANE PROXIMAL DOMAIN OF THE HUMAN INTERLEUKIN-3 RECEPTOR BETA(C) SUBUNIT THAT SIGNALS DNA-SYNTHESIS IN NIH 3T3 CELLS SPECIFICALLY BINDS A COMPLEX OF SRC AND JANUS FAMILY TYROSINE KINASES AND PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GTPASE-ACTIVATING PROTEIN; FACTOR-I RECEPTOR; CYTOPLASMIC DOMAINS; GM-CSF; TRANSDUCTION; PHOSPHORYLATION; ASSOCIATION; IDENTIFICATION; JAK2	The high affinity human interleukin 3 receptor is a heterodimeric protein consisting of alpha and beta(c) subunit. The beta(c) subunit is responsible for receptor signal transduction. We have shown that a membrane proximal domain of the cytoplasmic tail of the human beta(c) subunit (amino acids 451-517) is minimally required for human IL-3 to signal DNA synthesis in quiescent transfected NIH 3T3 cells. Glutathione S-transferase (GST) fusion proteins of this 451-517 region and another region 451-562 that includes an acidic domain previously shown in other receptors to bind Src family kinases were constructed. Purified Lyn and Lck kinase, but not Fes, could phosphorylate tyrosines in both domains. Adsorption with lysates from the human IL-3-dependent hematopoietic cell line (TF-1) or 3T3 cells and in vitro phosphorylation showed that both these domains were intensely phosphorylated. Phosphoamino acid analysis, however, revealed that the majority of phosphorylation was on serine and threonine rather than tyrosine. Adsorption of these domains with 3T3 or TF-1 cell lysates, followed by immunoblotting, showed that cytoplasmic tyrosine kinases Lyn, Fes, and JAK-2 could also stably associate with both domains; however, Src family kinases are more strongly recognized by both regions than JAK-2 kinase. In addition, phosphatidylinositol 3-kinase from cell lysates was also found stably associated with these domains, but GTPase activating protein, Vav, Sos1, or Grb2 were not.	AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,DEPT IMMUNOL,ROCKVILLE,MD 20855	American Red Cross					NCI NIH HHS [CA 53609] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053609] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI KI, 1990, ANN REV BIOCH, V56, P783; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLEAVELAND JL, 1989, MOL CELL BIOL, V9, P5685; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GESNER T, 1989, BLOOD, V74, P2652; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHIDA K, 1989, P NATL ACAD SCI USA, V87, P9655; KANAKURA Y, 1990, BLOOD, V76, P706; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P85; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; METCALF D, 1986, BLOOD, V67, P257; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; OCONNOR R, 1991, BLOOD, V80, P1017; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; QUELLE FW, 1994, MOL CELL BIOL, P4335; RAO P, 1995, J IMMUNOL, V154, P1664; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1992, P NATL ACAD SCI USA, V87, P5993; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TORIGOE T, 1992, BLOOD, V80, P617; TOYO A, 1987, EXP CELL RES, V171, P16; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6886	6893		10.1074/jbc.270.12.6886	http://dx.doi.org/10.1074/jbc.270.12.6886			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896837	hybrid			2022-12-27	WOS:A1995QQ85500068
J	YERUSHALMI, H; LEBENDIKER, M; SCHULDINER, S				YERUSHALMI, H; LEBENDIKER, M; SCHULDINER, S			EMRE, AN ESCHERICHIA-COLI 12-KDA MULTIDRUG TRANSPORTER, EXCHANGES TOXIC CATIONS AND H+ AND IS SOLUBLE IN ORGANIC-SOLVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHIDIUM EFFLUX GENE; NA+/H+ ANTIPORTER; BACILLUS-SUBTILIS; RESISTANCE GENE; CLONING; PROTEINS; SEQUENCE; SYSTEM; CDNA; PURIFICATION	The smallest membrane protein shown to catalyze ion-coupled transport is documented in this report. A gene coding for a small 110-amino acid membrane protein (emrE or mvrC) has been previously identified and cloned and shown to render Escherichia coli cells resistant to methyl viologen and to ethidium. In this report, it is shown that the resistance is due to extrusion of the toxic compounds in a process that requires a proton electrochemical gradient rather than ATP. For this purpose, cells in which the unc gene was inactivated were used so that the interconversion between the proton gradient and ATP is not possible, and the effect of agents, which specifically affect either of them, was tested on transport of ethidium in the intact cell. In addition, EmrE has been overexpressed and metabolically labeled with [S-35]methionine. Strikingly, the protein can be quantitatively extracted with a mixture of organic solvents such as chloroform:methanol and is practically pure after this extraction. Moreover, after addition of E. coli lipids to the chloroform:methanol extract, EmrE has been reconstituted in proteoliposomes loaded with ammonium chloride. Upon dilution of the proteoliposomes in ammonium-free medium, a pH gradient was formed that drove transport of ethidium and methyl viologen into the proteoliposome. Both substrates compete with each other and exchange with previously transported solute. EmrE is a multidrug transporter of a novel type, and, because of its size and its solubility properties, it provides a unique model to study structure-function aspects of transport reactions in ion-coupled processes.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				AHMED M, 1993, J BIOL CHEM, V268, P11086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; GITLER C, 1977, BIOCHEM BIOPH RES CO, V74, P178; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HARELBRONSTEIN M, 1995, J BIOL CHEM, V270, P3816, DOI 10.1074/jbc.270.8.3816; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; LAMBERT B, 1984, BIOCHEMISTRY-US, V23, P166, DOI 10.1021/bi00296a027; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MIDGLEY M, 1987, MICROBIOL SCI, V4, P125; MORIMYO M, 1992, NUCLEIC ACIDS RES, V20, P3159, DOI 10.1093/nar/20.12.3159; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; PEARCE HL, 1989, P NATL ACAD SCI USA, V86, P5128, DOI 10.1073/pnas.86.13.5128; PINNER E, 1992, J BIOL CHEM, V267, P11064; PUREWAL AS, 1990, FEMS MICROBIOL LETT, V68, P73; PUREWAL AS, 1991, FEMS MICROBIOL LETT, V82, P229, DOI 10.1111/j.1574-6968.1991.tb04870.x; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1995, IN PRESS PHYSL REV; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	242	255	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6856	6863		10.1074/jbc.270.12.6856	http://dx.doi.org/10.1074/jbc.270.12.6856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896833	hybrid			2022-12-27	WOS:A1995QQ85500064
J	TACHIBANA, T; IMAMOTO, N; SEINO, H; NISHIMOTO, T; YONEDA, Y				TACHIBANA, T; IMAMOTO, N; SEINO, H; NISHIMOTO, T; YONEDA, Y			LOSS OF RCC1 LEADS TO SUPPRESSION OF NUCLEAR-PROTEIN IMPORT IN LIVING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; CHROMOSOME CONDENSATION; KARYOPHILIC PROTEINS; SYNTHETIC PEPTIDES; DNA-REPLICATION; 2 STEPS; TRANSPORT; REGULATOR; MITOSIS; TRANSLOCATION	The role of RCC1-Ran/TC4 in nuclear protein import was examined in living cells using a temperature-sensitive RCC1 mutant cell line, tsBN2, and tsBN2 transformed with a RCC1 cDNA lacking the nuclear localization sequence domain, Delta 8-29. Substrate, containing a small number of SV40 T antigen nuclear localization sequence peptides, injected into the cytoplasm of tsBN2 cells cultured at the non-permissive temperature of 39.5 degrees C did not accumulate efficiently in the nucleus. When the same substrate was injected into the cytoplasm of heterokaryons of tsBN2 and wild type BHK21 cells, import efficiency into the tsBN2 nuclei was not restored. Import into the BHK21 nuclei gradually decreased after fusion. In contrast, import efficiency into tsBN2 nuclei gradually recovered after fusion with tsBN2 cells transformed with Delta 8-29 in which functional RCC1 was diffusely distributed in both the nuclei and cytoplasm. Substrate did not accumulate in the nuclei of digitonin-permeabilized tsBN2 cells cultured at 39.5 degrees C even in the presence of normal cytosol. These results suggest that loss of RCC1 function leads to the decline of import competence of the nucleus and accumulation of a factor in the cytoplasm that suppresses nuclear import. These results indicate that the RCC1-Ran/TC4 system may regulate nuclear import.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; KYUSHU UNIV, GRAD SCH MED SCI, DEPT BIOL MOLEC, MAIDASHI, FUKUOKA 812, JAPAN	Osaka University; Kyushu University			Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OKADA Y, 1993, METHOD ENZYMOL, V221, P18, DOI 10.1016/0076-6879(93)21005-S; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SEINO H, 1992, J CELL SCI, V102, P393; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3	32	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24542	24545						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929123				2022-12-27	WOS:A1994PQ49000007
J	WILLUHN, J; SCHMITTWREDE, HP; GREVEN, H; WUNDERLICH, F				WILLUHN, J; SCHMITTWREDE, HP; GREVEN, H; WUNDERLICH, F			CDNA CLONING OF A CADMIUM-INDUCIBLE MESSENGER-RNA ENCODING A NOVEL CYSTEINE-RICH, NONMETALLOTHIONEIN 25-KDA PROTEIN IN AN ENCHYTRAEID EARTHWORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; ELECTROPHORESIS; TRANSLATION; SEQUENCE	Cadmium accumulation and its effect on gene expression have been investigated at sublethal cadmium concentrations in the soil oligochaete Enchytraeus buch-holzi. This worm is capable of accumulating cadmium to large amounts, which coincides with the induction of a mRNA isolated as a cDNA clone by differential screening of a cDNA library constructed from cadmium-treated enchytraeids. The cDNA clone designated CRP1 is 1474 base pairs in length and contains a 753-base pair open reading frame, encoding a novel Cys-rich non-metallothionein protein. In vitro translation of the in vitro transcribed CRP1 results in a protein with a molecular mass of 25 kDa and an pi of approximately 7.5. These values are consistent with those predicted from the deduced amino acid sequence. The CRP protein contains 27% Cys, most of them arranged in Cys-X-Cys and Cys-Cys segments. The sequence is also characterized by a 31-amino-acid motif, which is tandemly repeated along the sequence. Northern blot analysis reveals that the CRP gene is not constitutively expressed in untreated worms, but rather it is rapidly induced by cadmium. The CRP gene may be a promising candidate gene for monitoring bioavailable cadmium at subtoxic levels in terrestric environments.	UNIV DUSSELDORF, INST ZOOL, DIV PARASITOL, D-40225 DUSSELDORF, GERMANY; UNIV DUSSELDORF, BIOL MED FORSCHUNGSZENTRUM, D-40225 DUSSELDORF, GERMANY; UNIV DUSSELDORF, INST ZOOL, DIV MORPHOL & CELL BIOL, D-40225 DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf			Schmitt-Wrede, Hans-Peter/ABD-6206-2021					ATWATER JA, 1990, ANNU REV GENET, V24, P519; BRADY FO, 1982, TRENDS BIOCHEM SCI, V7, P143, DOI 10.1016/0968-0004(82)90206-7; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FRAZIER JM, 1985, COMP BIOCHEM PHYS C, V80, P257, DOI 10.1016/0742-8413(85)90052-0; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KASPRZAK K, 1982, PEDOBIOLOGIA, V23, P217; KIMURA M, 1991, METHOD ENZYMOL, V205, P114; KOJIMA Y, 1991, METHOD ENZYMOL, V205, P8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASTOWSKIPERRY D, 1985, J BIOL CHEM, V260, P1527; LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99; MENZER RE, 1991, TOXICOLOGY, P890; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POSTHUMA L, 1993, COMP BIOCHEM PHYS C, V106, P11, DOI 10.1016/0742-8413(93)90251-F; RAMSEIER S, 1990, MOL CELL BIOCHEM, V97, P137; ROEMBKE J, 1989, HYDROBIOLOGIA, V180, P235, DOI 10.1007/BF00027556; Ruther U., 1990, Acta Biologica Benrodis, V2, P125; Sambrook J, 1989, MOL CLONING LABORATO; STONE H, 1985, COMP BIOCHEM PHYS C, V80, P9, DOI 10.1016/0742-8413(85)90126-4; WEIGMANN G, 1991, WATER AIR SOIL POLL, V57-8, P655, DOI 10.1007/BF00282929; Westheide W., 1991, P497	28	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24688	24691						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929141				2022-12-27	WOS:A1994PQ49000028
J	ELICEIRI, BP; BROWN, DD				ELICEIRI, BP; BROWN, DD			QUANTITATION OF ENDOGENOUS THYROID-HORMONE RECEPTOR-ALPHA AND RECEPTOR-BETA DURING EMBRYOGENESIS AND METAMORPHOSIS IN XENOPUS-LAEVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRIIODOTHYRONINE RECEPTORS; AMPHIBIAN METAMORPHOSIS; BINDING-CAPACITY; TRANSLATIONAL CONTROL; TADPOLE ERYTHROCYTES; GENE-EXPRESSION; ASSAY PROCEDURE; RAT; PROTEINS; CELLS	Greater than 90% of the endogenous thyroid hormone receptor proteins TR alpha and TR beta in tissues of Xenopus laevis comigrate with their respective in vitro synthesized counterparts, and these major components are not phosphorylated detectably. Maternally inherited TR alpha protein is stable through early embryogenesis during a time in which there is no detectable TR alpha mRNA synthesis. At stage 35 when TR alpha mRNA is first detectable, the inherited TR alpha protein is present at about 100 molecules/cell. TR alpha protein subsequently increases to levels of about 1500 and 6000 molecules/cell in tail and head regions, respectively, in stage 52 tadpoles. Even though TR alpha mRNA gradually increases during metamorphosis (from stage 52 to 62), TR alpha protein remains constant, suggesting strongly that post-transcriptional events control the ultimate levels of TR alpha protein. In contrast, there is no detectable TR beta protein (less than 100 molecules/cell) throughout embryogenesis until stage 52. Both TR beta mRNA and protein rise along with the increase in endogenous thyroid hormone, reaching a maximum at the climax of metamorphosis, when TR beta protein exceeds TR alpha protein in concentration. As with TR alpha protein, TR beta protein in tail is consistently about one-fourth that of TR beta protein in the head region. The number of TR alpha protein molecules in extracts of premetamorphic tadpoles and cultured cells grown in the absence of thyroid hormone fully accounts for all of the sites to which I-125-T-3 bind. We interpret this to mean that TR alpha protein must be a necessary, if not sufficient, component in the pathway toward metamorphosis triggered by thyroid hormone and required for the phenomenon of competence in tissues and cells.			ELICEIRI, BP (corresponding author), CARNEGIE INST WASHINGTON,BALTIMORE,MD 21210, USA.			Eliceiri, Brian/0000-0003-1811-1916				BANKER DE, 1993, MOL CELL BIOL, V13, P7540, DOI 10.1128/MCB.13.12.7540; BENOIT R, 1982, P NATL ACAD SCI-BIOL, V79, P917, DOI 10.1073/pnas.79.3.917; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BROWN TA, 1990, J BIOL CHEM, V265, P10025; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; DAWID IB, 1965, J MOL BIOL, V12, P581, DOI 10.1016/S0022-2836(65)80313-8; DENNER LA, 1990, J BIOL CHEM, V265, P16458; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALTON VA, 1985, ENDOCRINOLOGY, V116, P99, DOI 10.1210/endo-116-1-99; GALTON VA, 1984, ENDOCRINOLOGY, V114, P735, DOI 10.1210/endo-114-3-735; GALTON VA, 1983, THYROID  HORMONE ACT, P445; GLINEUR C, 1989, ONCOGENE, V4, P1247; Gudernatsch JF, 1912, ARCH ENTWICKLUNG ORG, V35, P457, DOI 10.1007/BF02277051; HARLOW E, 1988, ANTIBODIES LABORATOR; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOROWITZ ZD, 1988, PHOTOAFFINITY LABELI, P212; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; KANAMORI A, 1993, P NATL ACAD SCI USA, V90, P6013, DOI 10.1073/pnas.90.13.6013; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KIKUYAMA S, 1993, INT REV CYTOL, V145, P105, DOI 10.1016/S0074-7696(08)60426-X; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MACHUCA I, 1992, MOL CELL ENDOCRINOL, V87, P105, DOI 10.1016/0303-7207(92)90238-2; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OPPENHEIMER JH, 1972, J CLIN ENDOCR METAB, V35, P330, DOI 10.1210/jcem-35-2-330; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SHI YB, 1992, J BIOL CHEM, V267, P733; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; TAGAMI T, 1993, ENDOCRINOLOGY, V132, P275, DOI 10.1210/en.132.1.275; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WANG Z, 1993, J BIOL CHEM, V268, P16270; Weber R, 1967, BIOCH ANIMAL DEV, P227; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEISS RE, 1992, ANNU REV MED, V43, P363, DOI 10.1146/annurev.med.43.1.363; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YOSHIZATO K, 1975, NATURE, V254, P705, DOI 10.1038/254705a0	58	126	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24459	24465						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929109				2022-12-27	WOS:A1994PQ34600094
J	SNYDER, PM; MCDONALD, FJ; STOKES, JB; WELSH, MJ				SNYDER, PM; MCDONALD, FJ; STOKES, JB; WELSH, MJ			MEMBRANE TOPOLOGY OF THE AMILORIDE-SENSITIVE EPITHELIAL SODIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; POTASSIUM CHANNEL; NA+ CHANNEL; EXPRESSION; NEURODEGENERATION; PROTEINS; CLONING	The amiloride-sensitive epithelial sodium channel (ENaC) is involved in fluid and electrolyte absorption across a number of epithelia, and cloning of several ENaC subunits has begun to facilitate investigation of the structure, function, and regulation of this channel. Analysis of the amino acid sequence has revealed two potential membrane-spanning domains, but little else is known about the structure of ENaC. To investigate the membrane topology of one subunit, alpha rENaC, we used in vitro transcription, translation, and translocation into microsomal membranes. This generated a glycosylated protein of 93 kDa. Sequence analysis also revealed eight potential sites for N-glycosylation, six of which were found to be glycosylated (Asn(190), Asn(259), Asn(320), Asn(339) Asn(424), and Asn(538)), indicating that they are extracellular. The C terminus was localized as intracellular based on antibody recognition and protease sensitivity of a tagged epitope at the C terminus. The N terminus was also found to be intracellular, based on its protease sensitivity. Similar results were obtained by expression in Xenopus oocytes. Together, these results support a model of alpha rENaC consisting of an intracellular N terminus and C terminus, a large N-glycosylated extracellular domain, and two membrane-spanning domains that each pass once through the plasma membrane. Because of their sequence similarity, it is likely that this structure is shared by other ENaC subunits and possibly the degenerins of Caenorhabditis elegans as well.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DIV NEPHROL,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07344] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Canessa C. M., 1993, Journal of the American Society of Nephrology, V4, P864; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247	20	194	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24379	24383						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929098				2022-12-27	WOS:A1994PQ34600082
J	VARNUM, JM; THAKUR, ML; SCHALLY, AV; JANSEN, S; MAYO, KH				VARNUM, JM; THAKUR, ML; SCHALLY, AV; JANSEN, S; MAYO, KH			RHENIUM-LABELED SOMATOSTATIN ANALOG RC-160 - H-1-NMR AND COMPUTER MODELING CONFORMATIONAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SPECTROSCOPY; SECRETION; PROTEINS; HORMONE; H-1-NMR; TUMORS; CANCER	The solution conformations of RC-160, cyclic D-Phe(1)-Cys(2)-Tyr(3)-D-Trp(4)-Lys(5)-Val(6)-Cys(7)-Trp(8)-NH2, an analog of the tumor antiproliferatory neuropeptide somatostatin, and RC-160 labeled with rhenium (Re-RC-160), have been determined by using two-dimensional H-1 NMR spectroscopy (600 MHz) and restrained molecular dynamics simulations. Re-RC-160 yields the same average solution conformation as does the apo form with an antiparallel P-sheet fold and a type II' beta-turn centered at D-Trp(4)-Lys(5). These results indicate that the spatial topography of the side chains essential for somatostatin receptor binding is maintained in Re-RC-160.	UNIV MINNESOTA,CTR BIOMED ENGN,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,STRUCT BIOL GRP,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19107; TULANE UNIV,VET ADM MED CTR,SCH MED,INST ENDOCRINE POLYPEPTIDE & CANC,NEW ORLEANS,LA 70146; TEMPLE UNIV,DEPT CHEM,PHILADELPHIA,PA 19122	University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; Jefferson University; Tulane University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Thakur, Mathew/0000-0003-2409-039X; Schally, Andrew/0000-0003-1273-6747				AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BYSTROV VF, 1973, TETRAHEDRON, V29, P873, DOI 10.1016/0040-4020(73)80031-6; CAI RZ, 1986, P NATL ACAD SCI USA, V83, P1896, DOI 10.1073/pnas.83.6.1896; COLES M, 1993, J MED CHEM, V36, P2658, DOI 10.1021/jm00070a009; CUNG MT, 1974, MACROMOLECULES, V7, P606, DOI 10.1021/ma60041a012; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; ELSEVIERS M, 1989, PEPTIDES CHEM STRUCT, P198; GIANNIS A, 1993, ANGEW CHEM INT EDIT, V32, P1244, DOI 10.1002/anie.199312441; HUANG ZW, 1992, J AM CHEM SOC, V114, P9390, DOI 10.1021/ja00050a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KVOLS LK, 1993, RADIOLOGY, V187, P129, DOI 10.1148/radiology.187.1.8383865; KVOLS LK, 1986, NEW ENGL J MED, V315, P702; LAMBERTS SWJ, 1990, BAILLIERE CLIN ENDOC, V4, P29, DOI 10.1016/S0950-351X(05)80314-3; LAMBERTS SWJ, 1988, ENDOCR REV, V9, P417, DOI 10.1210/edrv-9-4-417; LAMBERTS SWJ, 1987, EUR J CLIN INVEST, V17, P281, DOI 10.1111/j.1365-2362.1987.tb02188.x; NUTT RF, 1987, SOMATOSTATIN, P83; SCHALLY AV, 1988, CANCER RES, V48, P6977; SEYBOLD VS, 1982, PEPTIDES, V3, P49, DOI 10.1016/0196-9781(82)90141-3; SOUDAH HC, 1991, NEW ENGL J MED, V325, P1508; SRKALOVIC G, 1990, J CLIN ENDOCR METAB, V70, P661, DOI 10.1210/jcem-70-3-661; Stewart JM, 1984, SOLID PHASE PEPTIDE; THAKUR ML, 1992, J LABELLED COMPD, P365; VEBER DF, 1981, PEPTIDES SYNTHESIS S, P685; VEBER DF, 1992, PEPTIDES CHEM BIOL, P3; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAMORA PO, 1992, BIOCONJUGATE CHEM, V3, P493, DOI 10.1021/bc00018a005	29	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12583	12588						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909804				2022-12-27	WOS:A1994NH71600035
J	MORROW, CS; NAKAGAWA, M; GOLDSMITH, ME; MADDEN, MJ; COWAN, KH				MORROW, CS; NAKAGAWA, M; GOLDSMITH, ME; MADDEN, MJ; COWAN, KH			REVERSIBLE TRANSCRIPTIONAL ACTIVATION OF MDR1 BY SODIUM-BUTYRATE TREATMENT OF HUMAN COLON-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; TUMOR VIRUS PROMOTER; S-TRANSFERASE-PI; HISTONE ACETYLATION; MAMMALIAN-CELLS; HEAT-SHOCK; DRUG-RESISTANCE; MESSENGER-RNA; RAT-LIVER; EXPRESSION	We investigated the mechanism of sodium butyrate (NaB)-mediated induction of mdr1 mRNA in parental (wild type) and multidrug-resistant (Ad1000) SW620 colon cancer cell lines. NaB treatment resulted in reversible, time-dependent increases in nuclear run-on transcription of endogenous mdr1 in these cell lines that paralleled the reversible increases of mdr1 mRNA in both timing and magnitude. In contrast, NaB treatment had no effect on mdr1 mRNA stability. Thus, the effects of NaB on mdr1 mRNA levels are fully attributable to altered mdr1 transcription. Furthermore, NaB induces the expression of transiently transfected chloramphenicol acetyltransferase reporter plasmids that are under the transcriptional control of the mdr1 promoter (mdrCAT vectors). Transfections using mdrCAT vectors modified by deletion and site-directed mutagenesis of the mdr1 promoter indicate that NaB-mediated induction of these vectors is at least partially dependent upon sequences present in the basal mdr1 promoter between -89 and +11 relative to the start site of transcription. The Y-box moth located between -82 and -73 contributes to NaB inducibility of mdrCAT vector expression in Ad1000 SW620 cells.	NCI,MED BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MORROW, CS (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.				NCI NIH HHS [CA-12197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; BOHAN CA, 1989, VIROLOGY, V172, P573, DOI 10.1016/0042-6822(89)90200-6; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COOK JR, 1990, CELL BIOL INT REP, V14, P629; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FREGEAU CJ, 1992, NUCLEIC ACIDS RES, V20, P3113, DOI 10.1093/nar/20.12.3113; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GUILD BC, 1988, P NATL ACAD SCI USA, V85, P1595, DOI 10.1073/pnas.85.5.1595; HILL BT, 1990, J NATL CANCER I, V82, P607, DOI 10.1093/jnci/82.7.607; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; MORROW CS, 1992, J BIOL CHEM, V267, P10544; NAKAGAWA M, 1992, CANCER RES, V52, P6175; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; SAINI K, 1990, BIOCHEM J, V272, P541, DOI 10.1042/bj2720541; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHIBATA H, 1990, JPN J CANCER RES, V81, P1214, DOI 10.1111/j.1349-7006.1990.tb02681.x; SIMPSON RT, 1990, PROG NUCLEIC ACID RE, V64, P2907; TANG DC, 1990, J VIROL, V64, P2907, DOI 10.1128/JVI.64.6.2907-2911.1990; TANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1048, P59, DOI 10.1016/0167-4781(90)90022-T; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; TURNER BM, 1991, J CELL SCI, V99, P13; VANGROENIGEN M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P138, DOI 10.1016/0167-4781(93)90280-Q; WOLFFE AP, 1992, FASEB J, V6, P3354, DOI 10.1096/fasebj.6.15.1464369; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	53	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10739	10746						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908296				2022-12-27	WOS:A1994NF01700082
J	SHAPIRO, AB; LING, V				SHAPIRO, AB; LING, V			ATPASE ACTIVITY OF PURIFIED AND RECONSTITUTED P-GLYCOPROTEIN FROM CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; PURIFICATION; EXPRESSION; TRANSPORT; PROTEINS; COLCHICINE; HYDROLYSIS	P-glycoprotein was purified from multidrug-resistant Chinese hamster ovary CH(R)B30 cells by a combination of anion exchange and immunoaffinity chromatography. The P-glycoprotein was about 90% pure and had a V(max) for ATP hydrolysis in detergent solution of 321 nmol/min/mg with a K(m) of 0.94 mM. The ATPase activity was inhibited by low concentrations of vanadate and N-ethylmaleimide, but unaffected by azide or ouabain. When the purified P-glycoprotein was reconstituted into phospholipid bilayer membranes, the ATPase activity became highly stimulated by several chemosensitizers and drugs involved with multidrug resistance. Verapamil, a potent chemosensitizer, increased the V(max) for ATP hydrolysis by 22-fold and the K(m) for ATP by 5.4-fold. This effect of verapamil on P-glycoprotein has not previously been observed. These results demonstrate that purified P-glycoprotein has an intrinsic ATPase activity with unique properties. This activity appears sufficient to account for the ATP-dependent reduction in intracellular drug accumulation of P-glycoprotein-expressing multidrug-resistant cells.	ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto					NCI NIH HHS [CA37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHIN KV, 1993, ADV CANCER RES, V60, P157; DEUCHARS KL, 1992, THESIS U TORONTO; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, CANCER RES, V48, P4926; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SPOELSTRA EC, 1992, EUR J BIOCHEM, V207, P567, DOI 10.1111/j.1432-1033.1992.tb17083.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WEST IC, 1990, TRENDS BIOCHEM SCI, V15, P42, DOI 10.1016/0968-0004(90)90171-7; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	35	238	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3745	3754						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906270				2022-12-27	WOS:A1994MV63100090
J	HIROSE, F; YAMAGUCHI, M; MATSUKAGE, A				HIROSE, F; YAMAGUCHI, M; MATSUKAGE, A			REPRESSION OF REGULATORY FACTOR FOR DROSOPHILA DNA REPLICATION-RELATED GENE PROMOTERS BY ZERKNULLT HOMEODOMAIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; POLYMERASE-ALPHA; BUDDING YEAST; TRANSCRIPTION; EXPRESSION; BINDING; EMBRYOS; CDC10+; SWI6	The expression of the chloramphenicol acetyltransferase gene under control of the 1152-base pair 5'-flanking region (-1107 to +45 nucleotide positions with respect to the major transcription initiation site) of the Drosophila DNA polymerase alpha gene was repressed by cotransfection into Drosophila Kc cells with a zerknullt (zen)-expressing plasmid as previously observed with the proliferating cell nuclear antigen (PCNA) gene promoter. The expression of the zen resulted in reduction of the abundance of mRNA for the transfected chloramphenicol acetyltransferase gene and also mRNAs for both DNA polymerase alpha and PCNA. Results obtained using various deletion derivatives of the promoter region and chemically synthesized oligonucleotides of the DNA replication-related element (DRE), a positive cis-acting element found in both DNA polymerase alpha and PCNA genes, revealed that the DRE sequences are responsible to repression by Zen protein. The nuclear extract of Kc cells transfected by the zen-expressing plasmid contained lesser amounts of the DRE-binding factor (DREF) than that of untransfected or mutant zen-transfected cells. These results suggest that the Zen protein represses expression of DNA replication-related genes by reducing DREF, although the detailed mechanism of the repression remains to be elucidated.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center								ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP, P210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOE VE, 1989, DEVELOPMENT, V107, P1; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; Johnston Leland H., 1992, Trends in Cell Biology, V2, P353, DOI 10.1016/0962-8924(92)90041-K; LEWIS RA, 1980, GENETICS, V295, P383; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; Sambrook J, 1989, MOL CLONING LABORATO; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	28	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2937	2942						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905482				2022-12-27	WOS:A1994MV43200084
J	SAUNDERS, NA; JETTEN, AM				SAUNDERS, NA; JETTEN, AM			CONTROL OF GROWTH-REGULATORY AND DIFFERENTIATION-SPECIFIC GENES IN HUMAN EPIDERMAL-KERATINOCYTES BY INTERFERON-GAMMA - ANTAGONISM BY RETINOIC ACID AND TRANSFORMING GROWTH-FACTOR-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; NECROSIS-FACTOR-ALPHA; CORNIFIED ENVELOPE; BINDING-PROTEIN; CELLS; TRANSGLUTAMINASE; EXPRESSION; ACTIVATION; INDUCTION; RECEPTOR	Interferon gamma (IFN-gamma) is a potent inducer of squamous differentiation in normal human epidermal keratinocytes. This induction is characterized by a greater-than-or-equal-to 95% decrease in the mRNA level of two growth regulatory genes, cdc2 and E2F-1, and a 7-15-fold increase in the expression of two squamous cell-specific genes, transglutaminase type I and cornifin. In contrast to the decrease in cdc2 and E2F-1 expression, the increase in transglutaminase type I and cornifin mRNAs by IFN-gamma occurs after a lagtime of more than 12 h. These results are consistent with the hypothesis that in normal human epidermal keratinocyte cells irreversible growth arrest precedes the expression of the squamous-differentiated phenotype. The action of IFN-gamma on the expression of squamous cell-specific genes is antagonized by retinoic acid and transforming growth factor beta1. Both factors are potent suppressors of the induction of transglutaminase type I and, cornifin; however, they do not prevent the commitment to irreversible growth arrest. Several squamous cell carcinoma cell lines do not show a detectable decrease in cdc2 or increase in transglutaminase type I mRNA levels after IFN-gamma treatment and appear to be altered in their control of squamous differentiation.			SAUNDERS, NA (corresponding author), NIEHS,PULM PATHOBIOL LAB,CELL BIOL SECT,RES TRIANGLE PK,NC 27709, USA.		Jetten, Anton/C-3736-2019; McTaggart, Jill/G-4696-2010; saunders, nicholas/E-1544-2014	Jetten, Anton/0000-0003-0954-4445; McTaggart, Jill/0000-0002-9000-8529; saunders, nicholas/0000-0002-2478-3420				BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DAWSON MM, 1991, LYMPHOKINES INTERLEU, P190; DECKER T, 1991, EMBO J, V10, P97; DEMAEYER E, 1988, IFNS OTHER REGULATOR, P93; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HALL PA, 1989, DEVELOPMENT, V106, P619; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOLBROOK KA, 1983, J INVEST DERMATOL, V81, P125; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; KIM MY, 1991, J BIOL CHEM, V266, P484; LIAN JB, 1992, MOL CELLULAR APPROAC, P165; MARGOLISNUNNO H, 1990, J INTERFERON RES, V10, P309, DOI 10.1089/jir.1990.10.309; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; NICKOLOFF BJ, 1991, ARCH DERMATOL, V127, P871, DOI 10.1001/archderm.127.6.871; NICKOLOFF BJ, 1986, ULTRASTRUCT PATHOL, V10, P17, DOI 10.3109/01913128609015559; PHIHKAJANIEMI T, 1991, J BIOL CHEM, V260, P7618; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RICHTER KH, 1991, CANCER RES, V51, P6010; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SCHEYNIUS A, 1992, J INVEST DERMATOL, V98, P255, DOI 10.1111/1523-1747.ep12556086; SHIPLEY GD, 1986, CANCER RES, V46, P2068; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; VOLLBERG TM, 1991, EXP CELL RES, V193, P93, DOI 10.1016/0014-4827(91)90542-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	46	144	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2016	2022						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7904998				2022-12-27	WOS:A1994MR98800072
J	NAUSEEF, WM; BRIGHAM, S; COGLEY, M				NAUSEEF, WM; BRIGHAM, S; COGLEY, M			HEREDITARY MYELOPEROXIDASE DEFICIENCY DUE TO A MISSENSE MUTATION OF ARGININE-569 TO TRYPTOPHAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; MYELOID LYSOSOMAL-ENZYME; PROMYELOCYTIC LEUKEMIA; INTRACELLULAR-TRANSPORT; MESSENGER-RNA; DIFFERENTIATION; GENE; EXPRESSION; BIOSYNTHESIS; LINE	Hereditary deficiency of myeloperoxidase (MPO) is a common disorder but its genetic basis is unknown. We have reported that neutrophils from individuals with MPO deficiency lack enzymatic and immunochemical evidence for mature MPO but have a 90-kDa precursor protein. We have thus hypothesized that hereditary MPO deficiency reflects a defect in processing of a mutated primary translation product. Genomic DNA's from normal subjects digested with BglII and probed with radiolabeled cDNA for MPO have a 2.6-kilobase (kb) band. Previously we described the presence of an aberrant 2.1-kb fragment in BglII digests from most individuals with either partial or complete MPO deficiency. We describe here the responsible mutation. The substitution of thymidine for cytosine in exon 10 at nucleotide 8,089 of the genomic sequence results in generation of a recognition site for BglII not present normally and converts the normal 2.6-kb BglII fragment to the 2.1-kb fragment associated with MPO deficiency. At the amino acid level this mutation would replace arginine at codon 569 with tryptophan. Six of seven patients with complete MPO deficiency had this mutation. One subject was homozygous for this mutation whereas five others were heterozygous at this locus. The seventh patient was the only completely deficient subject without this mutation. Thus, at least two mutations and three genotypes can produce the phenotype of MPO deficiency.	VET ADM MED CTR, DEPT MED, IOWA CITY, IA USA; UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	NAUSEEF, WM (corresponding author), UNIV IOWA, DEPT MED, 200 HAWKINS DR, IOWA CITY, IA 52242 USA.			Nauseef, William/0000-0003-4032-757X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28412] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V255, P428, DOI 10.1016/0003-9861(87)90411-5; AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V257, P451, DOI 10.1016/0003-9861(87)90590-X; AKIN DT, 1986, J BIOL CHEM, V261, P8370; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; Johnson K. R., 1991, PEROXIDASES CHEM BIO, P63; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LUBBERT M, 1991, BLOOD, V78, P345; LUBBERT M, 1991, BLOOD, V77, P909; MEIER RW, 1991, BIOCHEM BIOPH RES CO, V176, P1345, DOI 10.1016/0006-291X(91)90434-9; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; NAUSEEF W M, 1990, Hematologic Pathology, V4, P165; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NAUSEEF WM, 1986, BLOOD, V68, P442; NAUSEEF WM, 1989, BLOOD, V73, P290; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; ROSMARIN AG, 1989, BLOOD, V73, P131; STROMBERG K, 1986, EUR J CELL BIOL, V39, P424; TOBLER A, 1989, BLOOD, V73, P1980; VANTUINEN P, 1987, ONCOGENE, V1, P319; WEIL SC, 1987, P NATL ACAD SCI USA, V84, P2057, DOI 10.1073/pnas.84.7.2057; YAMADA M, 1984, J BIOL CHEM, V259, P3021; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	32	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1212	1216						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904599				2022-12-27	WOS:A1994MR22000070
J	WEISEL, JW; FRANCIS, CW; NAGASWAMI, C; MARDER, VJ				WEISEL, JW; FRANCIS, CW; NAGASWAMI, C; MARDER, VJ			DETERMINATION OF THE TOPOLOGY OF FACTOR-XIIIA-INDUCED FIBRIN GAMMA-CHAIN CROSS-LINKS BY ELECTRON-MICROSCOPY OF LIGATED FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSSLINKED FIBRIN; PLASMIC DEGRADATION; MODEL; MODULUS; CLOTS; COMPLEXES; POLYMERS; RHEOLOGY; DOMAINS; FIBERS	After fibrin polymerizes to form a clot, the transglutaminase Factor XIIIa cross-links the gamma and alpha chains to stabilize the clot. There has been conflicting evidence on whether the gamma chain isopeptide bonds occur between molecules that are interacting in a longitudinal (end-to-end) manner or transverse (half-staggered) manner between the two strands of the protofibril. Since the topology of the cross-links has important consequences for fibrin structure, as well as for its stability and susceptibility to and pattern of fibrinolysis, cross-linked fibrin fragments were examined by electron microscopy to distinguish between these two possibilities for the arrangement of the ligated molecules. Cross-linked fibrin clots were produced by prolonged incubation of fibrinogen with thrombin and Factor XIII, and then digested with plasmin. The resulting soluble cross-linked fibrin complexes were rotary-shadowed with tungsten and examined by electron microscopy, revealing protofibril-like structures consisting of clusters of globular domains with a repeat of 22.5 nm. Longer plasmin digestion times yielded increasingly shorter structures. Rotary-shadowed cross-linked fibrin fragments, produced by dilution of the complexes into 0.125% acetic acid at pH 3.5 to dissociate all non-covalently linked fragments, showed uniformly single-stranded structures with a characteristic spacing of nodules, consistent with longitudinal cross-linking. Long, thin strands were seen at short digestion times, while shorter strands appeared with longer digestion. The smallest structures observed included two nodules together, and two such nodules with another nodule at a short distance from one or both ends, compatible with fragments DD, DY, and YY. Longer strands had the appearance of fibrin molecules that were linked end-to-end, usually with a fragment D or Y at each end. In conclusion, these results are consistent with previously proposed structures of these derivatives and clearly demonstrate that the interactions between cross-linked gamma chains are longitudinal (end-to-end) and not transverse.	UNIV ROCHESTER, SCH MED & DENT, DEPT MED, HEMATOL UNIT, ROCHESTER, NY 14642 USA	University of Rochester	WEISEL, JW (corresponding author), UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30616, HL30954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALE MD, 1988, THROMB RES, V52, P565, DOI 10.1016/0049-3848(88)90129-6; BELITSER VA, 1968, BIOCHIM BIOPHYS ACTA, V154, P367, DOI 10.1016/0005-2795(68)90051-2; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FOWLER WE, 1981, SCIENCE, V211, P287, DOI 10.1126/science.6108612; FRANCIS CW, 1979, BLOOD, V54, P1282; FRANCIS CW, 1982, SEMIN THROMB HEMOST, V8, P25, DOI 10.1055/s-2007-1005040; FRANCIS CW, 1980, J CLIN INVEST, V66, P1033, DOI 10.1172/JCI109931; Henschen A., 1986, BLOOD COAGULATION, V171, P241; JANMEY PA, 1983, J RHEOL, V27, P135, DOI 10.1122/1.549722; LORAND L, 1983, ANN NY ACAD SCI, V408, P226, DOI 10.1111/j.1749-6632.1983.tb23247.x; Lorand L, 1980, Prog Hemost Thromb, V5, P245; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MARDER VJ, 1975, THROMB DIATH HAEMOST, V33, P199, DOI 10.1055/s-0038-1647872; MEDVED L, 1990, J MOL BIOL, V216, P503, DOI 10.1016/0022-2836(90)90376-W; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; NELB GW, 1981, BIOPHYS CHEM, V13, P15, DOI 10.1016/0301-4622(81)80020-8; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; SELMAYR E, 1985, THROMB RES, V39, P467, DOI 10.1016/0049-3848(85)90170-7; SELMAYR E, 1988, BIOPOLYMERS, V27, P1733, DOI 10.1002/bip.360271104; SELMAYR E, 1985, THROMB RES, V39, P459, DOI 10.1016/0049-3848(85)90169-0; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	28	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26618	26624						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7902838				2022-12-27	WOS:A1993MK42500088
J	ORR, GA; HAN, EKH; BROWNE, PC; NIEVES, E; OCONNOR, BM; YANG, CPH; HORWITZ, SB				ORR, GA; HAN, EKH; BROWNE, PC; NIEVES, E; OCONNOR, BM; YANG, CPH; HORWITZ, SB			IDENTIFICATION OF THE MAJOR PHOSPHORYLATION DOMAIN OF MURINE MDR1B P-GLYCOPROTEIN - ANALYSIS OF THE PROTEIN KINASE-A AND PROTEIN-KINASE-C PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG-RESISTANCE GENE; DRUG ACCUMULATION; CYSTIC-FIBROSIS; J774.2 CELLS; KB CELLS; MEMBRANE GLYCOPROTEIN; CHLORIDE CHANNEL; HL60 CELLS; R-DOMAIN	P-glycoprotein is phosphorylated in cells, and it has been suggested that phosphorylation may regulate the drug transport activity of P-glycoprotein. Domain mapping, utilizing a combination of cyanogen bromide digestion and immunoblot analysis, was used to reveal the major phosphorylation sites in murine mdr1b P-glycoprotein. After labeling of J7.V1-1 cells with [P-32]P(i), or labeling membranes with [gamma-P-32]ATP and either protein kinase A or protein kinase C, it was found that the majority of the label was contained within a single cyanogen bromide fragment (amino acid 627-682) that encompassed the majority of the linker region. The in vitro protein kinase C phosphorylation sites within this fragment were analyzed by a combination of fast atom bombardment mass spectrometry (FABMS) and two-dimensional phosphopeptide mapping. FABMS analysis of a protein kinase C-phosphorylated synthetic peptide, corresponding to a segment of the linker region of P-glycoprotein, identified serine 669 as the single site of phosphorylation. Comparison of two-dimensional tryptic phosphopeptide maps prepared from synthetic peptide and P-glycoprotein, both of which were phosphorylated in vitro with protein kinase C, revealed that serine 669 was also the major phosphorylation site in the intact glycoprotein. The in vitro protein kinase A phosphorylation site was identified as serine 681 by site-directed mutagenesis. Inspection of the gene organization and the deduced amino acid sequence of mdr1b P-glycoprotein revealed that the linker region, although shorter than the R domain (55 versus 241 amino acids), fits the operational definition of the R domain of cystic fibrosis conductance regulator. Like the R domain, the linker region is encoded by a single exon, is highly charged with alternating acidic and basic side chains, and contains several protein kinase A/protein kinase C consensus phosphorylation sites. Since the R domain is believed to be involved in the regulation of cystic fibrosis conductance regulator function by phosphorylation, it is possible that the linker region plays a similar regulatory role in P-glycoprotein function.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, MACROMOLEC ANAL LAB, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	ORR, GA (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330, R35CA039821, R01CA056677] Funding Source: NIH RePORTER; NCI NIH HHS [CA56677, 5P30 CA13330, CA39821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CENTER MS, 1985, BIOCHEM PHARMACOL, V34, P1471, DOI 10.1016/0006-2952(85)90686-0; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; ENDICOTT JA, 1987, MOL CELL BIOL, V7, P4075, DOI 10.1128/MCB.7.11.4075; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1987, CANCER RES, V47, P2860; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HSU SIH, 1989, J BIOL CHEM, V264, P12053; KIRSCHNER LS, 1992, BIOCHEM PHARMACOL, V43, P77, DOI 10.1016/0006-2952(92)90664-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MA LD, 1991, J BIOL CHEM, V266, P5593; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; PAPAYANNOPOULOU.IA, 1991, AM SOC MASS SPECTROM, V2, P176; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROY SN, 1985, CANCER RES, V45, P3856; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; STAATS J, 1990, J BIOL CHEM, V265, P4084; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; YANG CPH, 1988, BIOCHEM PHARMACOL, V37, P1417; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; ZEHEB R, 1987, BIOCHEM BIOPH RES CO, V143, P732, DOI 10.1016/0006-291X(87)91415-X	51	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25054	25062						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901220				2022-12-27	WOS:A1993MG67300079
J	TAXMAN, DJ; WOJCHOWSKI, DM				TAXMAN, DJ; WOJCHOWSKI, DM			ERYTHROPOIETIN-INDUCED TRANSCRIPTION AT THE MURINE BETA(MAJ)-GLOBIN PROMOTER - A CENTRAL ROLE FOR GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-TRANSCRIPTION; MOUSE ERYTHROLEUKEMIA-CELLS; ERYTHROID PROGENITOR CELLS; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; DNA-SEQUENCES; DIFFERENTIATION; BINDING; EXPRESSION; RECEPTOR	Using J2E cells and the murine beta(maj)-globin promoter as a model, we have performed the first direct analyses of erythropoietin (EPO)-activated transcription from defined templates. The -348 to +26 beta(maj) promoter was shown to comprise a target for maximal activation. This included a positive role for a -346 to -107-base pair (bp) domain in J2E cells, but not in F-MEL cells, Mutagenesis of a -215 bp AGATAA element within this domain showed that this effect did not require GATA-1 binding, In contrast, a critical role for GATA-1 at a -60-bp (G)GATAG element was defined by mutagenesis (GGg-TAG and TGATAG), complementation with a synthetic TGATAA element, and the demonstrated specific binding of GATA-1. Proximal CCAAT (-75) and CACCC (-90) elements also were shown to contribute to transcriptional activation in J2E cells, yet exerted quantitatively distinct effects in the F-MEL system, Based on these results, minimal [TGATAA](4)-TATA and TGATAA-CACCC-TATA promoters were constructed and assayed in each system, Remarkably, the [TGATAA],-TATA promoter, but not the TGATAA-CACCC-TATA promoter, was induced efficiently by EPO in J2E cells, whereas the TGATAA-CACCC-TATA promoter was highly induced by Me,SO in F-MEL cells, These findings suggest that mechanisms of EPO-induced transcription in J2E cells involve GATA-1 and differ from chemically activated mechanisms studied previously in F-MEL cells, Globin induction in J2E cells was not associated with effects of EPO on levels or nuclear translocation of GATA-1, However, hemoglobinization was induced by okadaic acid, 8-Br-cAMP, and forskolin, a finding consistent with induction mechanisms that may involve modulated serine/threonine threonine phosphorylation.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT PATHOL & VET SCI, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NHLBI NIH HHS [HL44491, KO4HL203042] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; BRANCH DR, 1987, BLOOD, V69, P1782; BUSFIELD SJ, 1992, BLOOD, V80, P412; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENVER T, 1988, P NATL ACAD SCI USA, V85, P9091, DOI 10.1073/pnas.85.23.9091; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FANTONI A, 1979, NUCLEIC ACIDS RES, V6, P3505, DOI 10.1093/nar/6.11.3505; FENG WC, 1994, J BIOL CHEM, V269, P1493; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FRASER JK, 1988, BLOOD, V71, P104; FUKUMOTO H, 1989, DEVELOPMENT, V105, P109; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARDISON RC, 1983, J BIOL CHEM, V258, P8739; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HE TC, 1993, BLOOD, V82, P3530; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; KITAMURA T, 1989, BLOOD, V73, P375; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOMATSU N, 1993, BLOOD, V82, P456; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; KURAMOCHI S, 1990, EUR J BIOCHEM, V193, P163, DOI 10.1111/j.1432-1033.1990.tb19318.x; LEONARD M, 1993, BLOOD, V82, P1071; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; ORKIN SH, 1992, BLOOD, V80, P575; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAY FA, 1992, BIOTECHNIQUES, V13, P342; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; ROCHAIX JD, 1978, GENE, V3, P9, DOI 10.1016/0378-1119(78)90003-3; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STUVE LL, 1990, MOL CELL BIOL, V10, P972, DOI 10.1128/MCB.10.3.972; STUVE LL, 1993, MOL CELL BIOL, V13, P4311, DOI 10.1128/MCB.13.7.4311; TAXMAN DJ, 1993, ANAL BIOCHEM, V213, P97, DOI 10.1006/abio.1993.1391; TAXMAN DJ, 1994, PROTEIN EXPRES PURIF, V5, P587, DOI 10.1006/prep.1994.1081; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YOST SE, 1991, JH S CONT M, P220; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	59	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6619	6627		10.1074/jbc.270.12.6619	http://dx.doi.org/10.1074/jbc.270.12.6619			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896801	hybrid			2022-12-27	WOS:A1995QQ85500032
J	AOTA, S; NOMIZU, M; YAMADA, KM				AOTA, S; NOMIZU, M; YAMADA, KM			THE SHORT AMINO-ACID-SEQUENCE PRO-HIS-SER-ARG-ASN IN HUMAN FIBRONECTIN ENHANCES CELL-ADHESIVE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BINDING DOMAIN; III MODULE; POLYMERASE; REGIONS; PROTEIN; RGD	Synergistic sites in the central cell-adhesive domain of fibronectin (FN) substantially enhance cell adhesion mediated by the alpha(5) beta(1) integrin receptor for fibronectin. We characterized a critical minimal sequence needed for synergistic activity using site directed mutagenesis and homology scanning using intramolecular chimeras. The minimal cell-binding domain of FN consisting of the 9th and 10th type III FN repeat was expressed in an Escherichia coli expression system. This protein retained high biological activity when assayed using a competitive inhibition assay for FN-mediated adhesion of baby hamster kidney or HT-1080 cells. In contrast, a construct consisting of the 8th and 10th repeat displayed very low biological activity. By replacing various portions of the 8th repeat with homologous 9th repeat segments, we mapped the synergistic region to the center of the 9th repeat. When a very short peptide sequence, Pro-His-Ser-Arg-Asn (PHSRN), from the 9th repeat was substituted for the homologous pentapeptide site in the 8th repeat sequence, the recombinant protein showed markedly enhanced activity. Further mutagenesis analysis suggested that the arginine residue of this pentapeptide sequence is important for function. We also identified a weaker adjacent synergy region other than the PHSRN region, Epitope mapping of an anti-FN monoclonal antibody that inhibits FN-mediated adhesion identified the same critical regions. A synthetic peptide containing the PHSRN sequence showed neither competitive inhibitory activity in solution nor synergy with a soluble RGD-containing peptide. However, when the same synthetic peptide was positioned via a covalent bond at the corresponding site of the normally inactive 8th repeat, it mediated an enhancement of adhesive activity. These results identify a pentapeptide site that synergistically enhances the cell-adhesive activity of the FN RGD sequence.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				AOTA S, 1991, J BIOL CHEM, V266, P15938; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Mosher DF, 1989, FIBRONECTIN; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3	22	528	536	1	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24756	24761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929152				2022-12-27	WOS:A1994PQ49000039
J	IYPE, LE; WOOD, EA; INMAN, RB; COX, MM				IYPE, LE; WOOD, EA; INMAN, RB; COX, MM			RUVA AND RUVB PROTEINS FACILITATE THE BYPASS OF HETEROLOGOUS DNA INSERTIONS DURING RECA PROTEIN-MEDIATED DNA STRAND EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; BINDING-PROTEIN; NUCLEOSIDE TRIPHOSPHATE; PARTIAL DENATURATION; ATP HYDROLYSIS; M13 VECTORS; RECOMBINATION; REPAIR	RecA protein mediated DNA strand exchange between circular single stranded DNA and linear duplex DNA readily bypasses short (up to 100 base pairs) heterologous inserts in one of the DNA substrates. Larger heterologous inserts are bypassed with decreasing efficiency, and inserts larger than 200 base pairs substantially block RecA-mediated DNA strand exchange. The RuvA and RuvB proteins dramatically facilitate the bypass of larger heterologous inserts. When the RuvA and RuvB proteins are added to an ongoing RecA protein-mediated strand exchange reaction, interior heterologous inserts of 1 kilobase pair are bypassed at significant frequencies. The RuvA, RuvB, and RecA proteins are all required for this activity. Bypass occurs only when homologous sequences are present on both sides of the insert. When the heterologous insert is positioned at either end of the linear duplex substrate, the RuvA and RuvB proteins do not significantly increase product formation in RecA protein-mediated DNA strand exchange reactions. The results suggest an important role for RuvA and RuvB in the bypass of DNA structural barriers during recombinational DNA repair.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison								BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; COX MM, 1987, DNA REPLICATION RECO, P597; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; Davis R., 1980, ADV BACTERIAL GENETI; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HAHN TR, 1988, J BIOL CHEM, V263, P7431; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1989, MOL GEN GENET, V219, P328, DOI 10.1007/BF00261196; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LICHTEN M, 1984, P NATL ACAD SCI-BIOL, V81, P7180, DOI 10.1073/pnas.81.22.7180; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHINAGAWA H, 1991, BIOCHIMIE, V73, P505, DOI 10.1016/0300-9084(91)90120-P; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR AF, 1992, CELL, V69, P1063, DOI 10.1016/0092-8674(92)90626-N; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1992, MOL MICROBIOL, V6, P2755, DOI 10.1111/j.1365-2958.1992.tb01454.x; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149	68	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24967	24978						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929180				2022-12-27	WOS:A1994PQ49000067
J	LEMBERGER, T; STAELS, B; SALADIN, R; DESVERGNE, B; AUWERX, J; WAHLI, W				LEMBERGER, T; STAELS, B; SALADIN, R; DESVERGNE, B; AUWERX, J; WAHLI, W			REGULATION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA GENE BY GLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACYL-COA OXIDASE; FATTY-ACIDS; RESPONSE ELEMENT; CLOFIBRIC ACID; ENZYME GENE; IDENTIFICATION; INDUCTION; DEXAMETHASONE; SUPERFAMILY; EXPRESSION	This study demonstrates that the expression of the peroxisome proliferator-activated receptor alpha (PPAR alpha) is regulated by glucocorticoid hormones in hepatocytes. Hydrocortisone, dexamethasone, and triamcinolone stimulated PPAR alpha mRNA synthesis in a dose-dependent manner in primary rat hepatocyte cultures. This glucocorticoid stimulation was inhibited by RU 486, a specific glucocorticoid antagonist. Moreover, in contrast to glucocorticoid hormones, the mineralocorticoid aldosterone had only a weak effect, suggesting that the hormonal stimulation of PPAR alpha was mediated by the glucocorticoid receptor. The induction was not prevented by cycloheximide treatment of the hepatocytes, indicating that it was mediated by preexisting glucocorticoid receptor. Finally, the RNA synthesis inhibitor actinomycin D abolished the stimulatory effect of dexamethasone, and nuclear run-on analysis showed an increase of PPAR alpha transcripts after hormonal induction. Thus, the PPAR alpha gene is an early response gene of glucocorticoids that control its expression at the transcriptional level.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND; INST PASTEUR,DEPT ATHEROSCLEROSE,BIOL REGULAT EUCARYOTES LAB,F-59019 LILLE,FRANCE	University of Lausanne; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Staels, Bart/N-9497-2016; Wahli, Walter/I-3194-2019; Lemberger, Thomas/A-7301-2008; Wahli, Walter/B-1398-2009; Auwerx, Johan/ABE-9307-2021; Desvergne, Beatrice/C-8892-2016	Staels, Bart/0000-0002-3784-1503; Lemberger, Thomas/0000-0002-2499-4025; Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X; Auwerx, Johan/0000-0002-5065-5393				AMRI EZ, 1991, J LIPID RES, V32, P1457; AUWERX J, 1992, HORM RES, V38, P269, DOI 10.1159/000182557; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DESVERGNE B, 1994, INDUCIBLE GENE EXPRE, V1, P142; DIVERTIE GD, 1991, DIABETES, V40, P1228, DOI 10.2337/diabetes.40.10.1228; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FAIN JN, 1965, J BIOL CHEM, V240, P3522; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RODRIGUEZ JC, 1994, IN PRESS J BIOL CHEM, V269; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SORENSEN HN, 1993, BIOCHIM BIOPHYS ACTA, V1171, P263, DOI 10.1016/0167-4781(93)90064-K; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZHU Y, 1993, J BIOL CHEM, V258, P26817	28	210	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24527	24530						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929119				2022-12-27	WOS:A1994PQ49000003
J	SCHIRCH, D; VILLAR, E; MARAS, B; BARRA, D; SCHIRCH, V				SCHIRCH, D; VILLAR, E; MARAS, B; BARRA, D; SCHIRCH, V			DOMAIN-STRUCTURE AND FUNCTION OF 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE BINDING-PROTEIN; RAT-LIVER; PURIFICATION; HYDROLASE; METABOLISM; RESOLUTION; CYTOSOL	10-Formyltetrahydrofolate dehydrogenase catalyzes the NADP(+)-dependent oxidation of 10-formyltetrahydrofolate to CO2 and tetrahydrofolate. Previous studies have shown that the enzyme binds the physiological pentaglutamate form of tetrahydrofolate product so tightly that it remains bound during size exclusion chromatography (Cook, R. J., and Wagner, C. (1982) Biochemistry 21, 4427-4434). In addition to the dehydrogenase activity, the enzyme from rat liver has been reported to exhibit both 10-formyltetrahydrofolate hydrolase and aldehyde dehydrogenase activities (Cook, R. J., Lloyd, R. S., and Wagner, C. (1991) J. Biol. Chem. 266, 4965-4973). We have purified the enzyme from rabbit liver and found that it catalyzes the same three reactions with similar kinetic constants and that it is a 99-kDa homotetramer, as reported previously for the rat and pig enzymes. Previous studies have suggested that the enzyme is composed of three domains and has separate folate binding sites for the dehydrogenase and hydrolase activities. We have investigated the domain structure of the rabbit enzyme. Differential scanning calorimetry reveals two thermal transitions, indicating the presence of two independently folded domains. The pentaglutamate form of tetrahydrofolate and NADP(+) each stabilize one of the thermal transitions, showing that these ligands bind to separate domains. Limited proteolytic digestions by several proteases cleave the enzyme in a linker region between the two domains. After proteolytic cleavage, the domains no longer remain associated and do not catalyze the 10-formyltetrahydrofolate dehydrogenase reaction. Isolation and characterization of the intact domains revealed that the N-terminal domain only catalyzes the NADP(+)-independent 10-formyltetrahydrofolate hydrolase activity and the C-terminal domain only catalyzes the NADP(+)-dependent aldehyde dehydrogenase activity. The kinetic constants of these isolated domains are similar to those of the intact enzyme. Binding studies on the native enzyme using fluorescence and isothermal titration calorimetry indicated that the enzyme binds one molecule of tetrahydrofolate and two molecules of NADP(+) per tetramer. Dissociation constants for both ligands were also determined by these methods.	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA; UNIV SALAMANCA, DEPT BIOQUIM & BIOL MOLEC, E-37007 SALAMANCA, SPAIN; UNIV ROMA LA SAPIENZA, CNR, DIPARTIMENTO SCI BIOCHIM, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR BIOL MOLEC, I-00185 ROME, ITALY	Virginia Commonwealth University; University of Salamanca; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Maras, Bruno/A-2020-2010; Barra, Donatella/D-1236-2011		NIGMS NIH HHS [GM 28143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagshaw C. R., 1987, SPECTROPHOTOMETRY SP, P91; BARLOWE C K, 1988, Biofactors, V1, P171; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; CASE GL, 1988, J BIOL CHEM, V263, P10204; CHEN MS, 1973, J BIOL CHEM, V248, P3631; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; Dawson R.M., 1986, DATA BIOCH RES, P130; ECKFELDT J, 1976, J BIOL CHEM, V251, P236; KREBS HA, 1976, BIOCHEM J, V158, P341, DOI 10.1042/bj1580341; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REAM JE, 1992, BIOCHEMISTRY-US, V31, P5528, DOI 10.1021/bi00139a015; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; RYAN LD, 1974, ARCH BIOCHEM BIOPHYS, V160, P279, DOI 10.1016/S0003-9861(74)80035-4; SANNY CG, 1985, ALCOHOL CLIN EXP RES, V9, P255, DOI 10.1111/j.1530-0277.1985.tb05746.x; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; TEMPLE C, 1980, CHEM BIOCH FOLATES, V1, P61; WEBB JL, 1963, ENZYMES METABOL INH, V1, P71	25	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24728	24735						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929148				2022-12-27	WOS:A1994PQ49000035
J	TAKEUCHI, A; MIYAMOTO, T; HAYASHI, H; TOMITA, M; ONOZAKI, K				TAKEUCHI, A; MIYAMOTO, T; HAYASHI, H; TOMITA, M; ONOZAKI, K			PURIFICATION AND CHARACTERIZATION OF A HUMAN ERYTHROCYTE-DERIVED GROWTH-FACTOR WITH A WIDE TARGET-CELL SPECTRUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; GRADIENT GEL-ELECTROPHORESIS; NON-DENATURED PROTEINS; POTENTIATING ACTIVITY; PROMOTING ACTIVITY; MOLECULAR-WEIGHTS; TISSUE INHIBITOR; STOKES RADII; LINES; PLATELETS	A cell extract from human erythrocytes promoted the growth of a wide variety of cell types, namely human and mouse myeloid cells, human and mouse T cells, human B cells, human melanoma cells, mouse transformed fibroblast cells, mouse mastocytoma cells, human lung fibroblast cells, and mouse bone marrow fibroblast/stroma-like cells. The growth-promoting activity was acid- and heat labile and sensitive to proteases, indicating the proteinaceous nature of the molecule. The activity was also lost upon exposure to 2-mercaptoethanol. The novel growth-promoting factor, termed basic growth factor because of its fundamental effect and a wide target cell spectrum, was purified by sequential anion-exchange, hydrophobic, gel filtration, hydroxylapatite, and reverse-phase high performance liquid chromatographies. The purified factor has an apparent molecular mass of 53 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions. The factor migrated at 270 kDa on native gradient polyacrylamide gel electrophoresis. Therefore, the factor consists of a homopolymer of a single polypeptide chain. The purified factor promoted the growth of the same cell types as the cell extract, except for bone marrow cells.	NAGOYA CITY UNIV,FAC PHARMACEUT SCI,DEPT HYG CHEM,MIZUHO KU,NAGOYA,AICHI 467,JAPAN; SHOWA UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SHINAGAWA KU,TOKYO 143,JAPAN	Nagoya City University; Showa University								ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; AVALOS BR, 1988, BLOOD, V71, P1720; BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; FRAEFEL W, 1986, 2ND P S CYT KYOT, V2, P293; GAFFNEY EV, 1986, J LEUKOCYTE BIOL, V39, P409, DOI 10.1002/jlb.39.4.409; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; JAEGER KH, 1958, KLIN WOCHENSCHR, V36, P441, DOI 10.1007/BF01478732; KODAMA S, 1989, MATRIX, V9, P1; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; MIYAMOTO T, 1994, IN PRESS BIOCH MOL B; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; ONOZAKI K, 1988, J IMMUNOL, V140, P112; Riede U N, 1975, Med Welt, V26, P122; ROTHE GM, 1982, ELECTROPHORESIS, V3, P43, DOI 10.1002/elps.1150030108; ROTHE GM, 1982, ELECTROPHORESIS, V3, P33, DOI 10.1002/elps.1150030107; RUFF MR, 1980, J IMMUNOL, V125, P1671; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; STANLEY ER, 1980, MONONUCLEAR PHAGOCYT, P417; TAKEUCHI A, 1993, CANCER RES, V53, P1871; TAMATANI T, 1989, J BIOCHEM-TOKYO, V105, P55, DOI 10.1093/oxfordjournals.jbchem.a122619; TSUTSUI T, 1984, JPN J PHARMACOL, V34, P471, DOI 10.1254/jjp.34.471; WELUGUS HG, 1983, J BIOL CHEM, V258, P12259; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992	36	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24935	24940						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929176				2022-12-27	WOS:A1994PQ49000063
J	TIELENS, AGM; VANDENHEUVEL, JM; VANMAZIJK, HJ; WILSON, JE; SHOEMAKER, CB				TIELENS, AGM; VANDENHEUVEL, JM; VANMAZIJK, HJ; WILSON, JE; SHOEMAKER, CB			THE 50-KDA GLUCOSE 6-PHOSPHATE-SENSITIVE HEXOKINASE OF SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN HEXOKINASE; C-TERMINAL HALVES; FRUCTOSE 2,6-BISPHOSPHATE; ENERGY-METABOLISM; SUGAR KINASES; PROTEINS; ENZYME; SITE; PHOSPHOFRUCTOKINASE; BINDING	Hexokinase has been purified from adult Schistosoma mansoni worms and the activity shown to be associated with a single protein species having an M(r) about 50,000. This protein is recognized on Western blots probed with antisera against rat Type I hexokinase or against a recombinant S. mansoni hexokinase that had been expressed in Escherichia coli using a previously cloned cDNA. An 18-residue N-terminal sequence determined for the purified S. mansoni hexokinase is identical to that deduced from the nucleotide sequence of the cDNA, consistent with the view that the cloned cDNA encodes the hexokinase characterized in the present study. The S. mansoni enzyme has a relatively low K-m (approximate to 60 mu M) for glucose and is sensitive to inhibition (competitive versus ATP, K-i approximate to 50 mu M) by its product, glucose 6-phosphate (Glc-6-P). With these kinetic properties and 50 kDa molecular mass, S. mansoni hexokinase resembles the ancestral hexokinase predicted to have given rise, by gene duplication and fusion, to the present day 100-kDa Glc-6-P-sensitive mammalian hexokinases. The schistosomal hexokinase represents the first 50-kDa Glc-6-P-sensitive hexokinase whose sequence has been obtained. The schistosomal hexokinase does not bind to mitochondria, consistent with its lack of a hydrophobic segment at the N terminus which is required for binding of the mammalian Type I and II isoenzymes to mitochondria. The marked Crabtree effect exhibited by S. mansoni cercariae may be at least partly attributed to the expression of rather high levels of a hexokinase having a high affinity for glucose but only a moderate sensitivity to product inhibition by Glc-6-P.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Michigan State University; Harvard University; Harvard T.H. Chan School of Public Health	TIELENS, AGM (corresponding author), UNIV UTRECHT,VET BIOCHEM LAB,POB 80176,3508 TD UTRECHT,NETHERLANDS.			Tielens, Aloysius/0000-0002-5485-1105	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI028499, R01AI028499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009910] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28499] Funding Source: Medline; NINDS NIH HHS [NS09910] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BAIJAL M, 1992, ARCH BIOCHEM BIOPHYS, V298, P271, DOI 10.1016/0003-9861(92)90123-E; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BORK P, 1993, PROTEIN SCI, V2, P31; BUEDING E, 1950, J GEN PHYSIOL, V33, P475, DOI 10.1085/jgp.33.5.475; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CHOU AC, 1974, ARCH BIOCHEM BIOPHYS, V165, P628, DOI 10.1016/0003-9861(74)90290-2; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; ELLISON WR, 1975, J BIOL CHEM, V250, P1864; ELLISON WR, 1974, BIOCHEM BIOPH RES CO, V57, P1214, DOI 10.1016/0006-291X(74)90826-2; GRIFFIN LD, 1991, GENOMICS, V11, P1014, DOI 10.1016/0888-7543(91)90027-C; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HARRISON RW, 1985, THESIS YALE U NEW HA; HOREMANS AMC, 1991, PARASITOLOGY, V102, P259, DOI 10.1017/S0031182000062570; HOREMANS AMC, 1992, MOL BIOCHEM PARASIT, V51, P73, DOI 10.1016/0166-6851(92)90202-U; HUE L, 1993, ADV ENZYME REGUL, V33, P97; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOCHIZUKI Y, 1981, COMP BIOCHEM PHYS B, V70, P745, DOI 10.1016/0305-0491(81)90011-0; MOCHIZUKI Y, 1977, J BIOCHEM, V81, P1849, DOI 10.1093/oxfordjournals.jbchem.a131646; PAYNE MA, 1991, J BIOL CHEM, V266, P8891; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; REES BB, 1989, J BIOL CHEM, V264, P15410; ROSE IA, 1974, ARCH BIOCHEM BIOPHYS, V164, P729, DOI 10.1016/0003-9861(74)90086-1; SANGSTER NC, 1987, COMP BIOCHEM PHYS B, V88, P317, DOI 10.1016/0305-0491(87)90122-2; SENER A, 1988, J BIOL CHEM, V263, P1904; SKELLY PJ, 1993, MOL BIOCHEM PARASIT, V60, P93, DOI 10.1016/0166-6851(93)90032-S; SOLS A, 1954, J BIOL CHEM, V210, P581; SRINIVASAN NG, 1990, MOL BIOCHEM PARASIT, V38, P151, DOI 10.1016/0166-6851(90)90215-8; VANOORDT BEP, 1985, MOL BIOCHEM PARASIT, V16, P117, DOI 10.1016/0166-6851(85)90080-5; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; WILKIN JP, 1977, J NEUROCHEM, V24, P1034; WILSON JE, 1994, IN PRESS REV PHYSL B; YANAGAWA HA, 1978, INSECT BIOCHEM, V8, P293, DOI 10.1016/0020-1790(78)90040-9	42	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24736	24741						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929149				2022-12-27	WOS:A1994PQ49000036
J	HARRISON, PT; DAVIS, W; NORMAN, JC; HOCKADAY, AR; ALLEN, JM				HARRISON, PT; DAVIS, W; NORMAN, JC; HOCKADAY, AR; ALLEN, JM			BINDING OF MONOMERIC IMMUNOGLOBULIN-G TRIGGERS FC-GAMMA-RI-MEDIATED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CROSS-LINKING; HIGH-AFFINITY; TYROSINE PHOSPHORYLATION; CELL-LINE; ASIALOGLYCOPROTEIN RECEPTOR; LYSOSOMOTROPIC AMINES; HEPATOMA-CELLS; IGE RECEPTOR; U937 CELLS; INTERNALIZATION	Cross-linking of leukocyte Fe receptors specific for IgG (Fc gamma Rs) by multivalent IgG complexes triggers a wide range of immune functions. Many of these responses can also be stimulated in vitro using anti-Fc gamma R monoclonal antibody-containing complexes. This observation has suggested that cross-linking is the key event and that binding of IgG, which in itself does not elicit a response, is functionally passive. However, in this study we show that binding of monomeric IgG to the human high affinity receptor, Fc gamma RI, is itself sufficient to permit the receptor to enter an internalization-recycling pathway, which has a small intracellular pool. Unoccupied Fc gamma RI is not internalized and recycled in this manner. This finding may be explained by the previous observation that there is a physical association between Fc gamma RI and the cytoskeletal component, actin-binding protein (non-muscle filamin; ABP-280), which is disrupted upon IgG binding. Thus, in the absence of IgG, Fc gamma RI may be physically excluded from the endocytic pathway by tethering to the cytoskeleton. The role of cross-linking is to divert Fc gamma RI-IgG complexes from the recycling pathway, causing their retention and subsequent degradation within the cell. In contrast to Fc gamma RII-mediated endocytosis, intracellular accumulation of cross-linked Fc gamma RI-IgG complexes is not sensitive to inhibition by genistein, suggesting that the process is independent of tyrosine kinase activity.	UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND	University of Cambridge				Harrison, Patrick/0000-0002-2319-0949; NORMAN, Jim/0000-0002-0098-3014				AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; JONES DH, 1985, J CELL BIOL, V100, P558, DOI 10.1083/jcb.100.2.558; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KRUTMANN J, 1990, J IMMUNOL, V145, P1337; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; RANKIN BM, 1993, J IMMUNOL, V150, P605; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	27	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24396	24402						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929100				2022-12-27	WOS:A1994PQ34600085
J	SCHWEERS, O; SCHONBRUNNHANEBECK, E; MARX, A; MANDELKOW, E				SCHWEERS, O; SCHONBRUNNHANEBECK, E; MARX, A; MANDELKOW, E			STRUCTURAL STUDIES OF TAU-PROTEIN AND ALZHEIMER PAIRED HELICAL FILAMENTS SHOW NO EVIDENCE FOR BETA-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; MICROTUBULE-ASSOCIATED PROTEINS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; INFRARED-SPECTROSCOPY; BINDING DOMAINS; AMYLOID PROTEIN; DISEASE; BRAIN; PHOSPHORYLATION	We have studied the conformation of tau protein and Alzheimer paired helical filaments (PHF) by several spectroscopic, scattering, and imaging methods revealing the overall shape and the conformation of the polypeptide backbone. Tau protein behaves in solution as if it were denatured; no evidence for compact folding was detected. The protein is highly extended, there is no defined radius of gyration, and the scattering is best described by that of a random (''Gaussian'') polymer. CD and Fourier transform infrared spectroscopy show only a minimal content of ordered secondary structure (alpha-helix or beta-sheet). Similarly, PHFs from Alzheimer brain tissue show no detectable secondary structure by x-ray diffraction or spectroscopy. It is thus unlikely that the aggregation of tau into Alzheimer PHFs is based on interactions between strands of beta-sheets (a model currently favored for other disease-related polymers such as beta-amyloid fibers of Alzheimer's disease).	DESY, MAX PLANCK UNIT STRUCT MOLEC BIOL, D-22603 HAMBURG, GERMANY	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society				Schonbrunn, Ernst/0000-0002-3589-3510				BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CLORE GM, 1986, J MOL BIOL, V191, P553, DOI 10.1016/0022-2836(86)90147-6; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1985, EMBO J, V4, P3661, DOI 10.1002/j.1460-2075.1985.tb04132.x; DAMASCHUN G, 1993, BIOCHEMISTRY-US, V32, P7739, DOI 10.1021/bi00081a019; DOWNING KH, 1992, J STRUCT BIOL, V109, P152, DOI 10.1016/1047-8477(92)90046-D; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GEISLER N, 1993, J STRUCT BIOL, V110, P205, DOI 10.1006/jsbi.1993.1023; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARVIS JA, 1993, BIOCHEM BIOPH RES CO, V192, P991, DOI 10.1006/bbrc.1993.1514; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Kirste R. G., 1982, SMALL ANGLE XRAY SCA, P387; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KOSIK KS, 1989, ANN NY ACAD SCI, V568, P125; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Kratky O., 1982, SMALL ANGLE XRAY SCA, P361; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANDELKOW E, 1977, P NATL ACAD SCI USA, V74, P3370, DOI 10.1073/pnas.74.8.3370; MANDELKOW E, 1986, METHOD ENZYMOL, V134, P633; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Siakotos A N, 1974, Methods Enzymol, V31, P478; SPANN U, 1987, BIOCHEMISTRY-US, V26, P1123, DOI 10.1021/bi00378a021; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TAUBOLD RD, 1975, LIPIDS, V10, P383, DOI 10.1007/BF02532441; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VOTER WA, 1982, J ULTRA MOL STRUCT R, V80, P374, DOI 10.1016/S0022-5320(82)80051-8; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; WOODY RW, 1983, BIOCHEMISTRY-US, V22, P2186, DOI 10.1021/bi00278a020; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZINGSHEIM HP, 1979, EUR J CELL BIOL, V19, P175	58	460	475	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24290	24297						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929085				2022-12-27	WOS:A1994PQ34600068
J	YOSHIDA, T; WILLARDSON, BM; WILKINS, JF; JENSEN, GJ; THORNTON, BD; BITENSKY, MW				YOSHIDA, T; WILLARDSON, BM; WILKINS, JF; JENSEN, GJ; THORNTON, BD; BITENSKY, MW			THE PHOSPHORYLATION STATE OF PHOSDUCIN DETERMINES ITS ABILITY TO BLOCK TRANSDUCIN SUBUNIT INTERACTIONS AND INHIBIT TRANSDUCIN BINDING TO ACTIVATED RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ROD OUTER SEGMENTS; G-PROTEIN; PHOTORECEPTOR CELLS; PHOSPHOLIPASE-C; CYCLIC-GMP; BOVINE; LIGHT; RETINA; KINASE	Heterotrimeric GTP-binding proteins (G-proteins) serve many different signal transduction pathways. Phosducin, a 28-kDa phosphoprotein, is expressed in a variety of mammalian cell types and blocks activation of several classes of G-proteins. Phosphorylation of phosducin by cyclic AMP-dependent protein kinase prevents phosducin-mediated inhibition of G-protein GTPase activity (Bauer, P. H., Muller, S., Puzicha, M., Pippig, S., Obermaier, B., Helmreich, E. J. M., and Lohse, M. J. (1992) Nature 358, 73-76). In retinal rods, phosducin inhibits transducin (G(t)) activation by binding its beta gamma subunits. While rod phosducin is phosphorylated in the dark and dephosphorylated after illumination (Lee, R.H., Brown, B. M., and Lolley, R. N. (1984) Biochemistry 23, 1972-1977), the significance of these reactions is still unclear. The data presented here permit a more precise characterization of phosducin function and the consequences of its phosphorylation. Dephosphophosducin blocked binding of the G(t) alpha(1) subunit to activated rhodopsin in the presence of stoichiometric amounts of G(t) beta gamma, whereas phosphophosducin did not. Surprisingly, the binding affinity of phosphophosducin for G(t) beta gamma was not significantly reduced compared with the binding affinity of dephosphophosducin. However, the association of phosducin with G(t) beta gamma in a size exclusion column matrix was dependent on the phosphorylation state of phosducin. Moreover, the ability of phosducin to compete with G(t) alpha for binding to G(t) beta gamma was also dependent on the phosphorylation state of phosducin. No interaction was found between phosducin and G(t) alpha. These data indicate that phosducin decreases rod responsiveness by binding to the beta gamma subunits of G(t) and preventing their interaction with G(t) alpha, thereby inhibiting G(t) alpha activation by the activated receptor. Moreover phosphorylation of phosducin blocks its ability to compete with G(t) alpha for binding to G(t) beta gamma.	LOS ALAMOS NATL LAB,DIV PHYS,BIOPHYS GRP,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory			Wilkins, Jon/A-4984-2009	Wilkins, Jon/0000-0001-6405-6538; Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY 06816] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLAZYNSKI C, 1986, J BIOL CHEM, V261, P14142; BLAZYNSKI C, 1984, EXP EYE RES, V38, P279, DOI 10.1016/0014-4835(84)90166-0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COHEN AI, 1982, J NEUROCHEM, V38, P781, DOI 10.1111/j.1471-4159.1982.tb08699.x; COTE RH, 1984, J BIOL CHEM, V259, P9635; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUO CH, 1986, MOL BRAIN RES, V1, P251, DOI 10.1016/0169-328X(86)90031-8; KUO CH, 1993, BIOCHEM BIOPH RES CO, V191, P1097, DOI 10.1006/bbrc.1993.1329; KUO CH, 1989, BIOCHEM BIOPH RES CO, V162, P1063, DOI 10.1016/0006-291X(89)90781-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1991, INVEST OPHTH VIS SCI, V32, P1054; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; LEE RH, 1981, BIOCHEMISTRY-US, V20, P7532, DOI 10.1021/bi00529a031; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; ORR HT, 1976, P NATL ACAD SCI USA, V73, P4442, DOI 10.1073/pnas.73.12.4442; PARK DG, 1993, J BIOL CHEM, V268, P4573; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316	35	116	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24050	24057						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929057				2022-12-27	WOS:A1994PQ34600034
J	WHATLEY, VJ; MIHIC, SJ; ALLAN, AM; MCQUILKIN, SJ; HARRIS, RA				WHATLEY, VJ; MIHIC, SJ; ALLAN, AM; MCQUILKIN, SJ; HARRIS, RA			GAMMA-AMINOBUTYRIC ACID(A) RECEPTOR FUNCTION IS INHIBITED BY MICROTUBULE DEPOLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BENZODIAZEPINE RECEPTORS; ACETYLCHOLINE-RECEPTOR; XENOPUS OOCYTES; PHOSPHORYLATION; BRAIN; INVOLVEMENT; BINDING; TUBULIN; CELLS	Microtubules are present at postsynaptic densities in brain and are proposed to be involved in anchoring neurotransmitter receptor clusters at postsynaptic membranes. However, the influence of microtubules on gamma-aminobutyric acid(A) (GABA(A)) receptors has not been studied. Microtubule-affecting agents were tested for their actions on GABA(A) receptor function, by measuring muscimol-stimulated chloride uptake into cerebral cortical microsacs and proteoliposomes and GABA-mediated currents in Xenopus laevis oocytes expressing GABA(A) receptors. Colchicine, nocodazole, vinblastine, and taxol inhibited muscimol-stimulated chloride uptake. beta- and gamma-lumicolchicine did not inhibit GABA(A)ergic function. Colchicine decreased the potency of muscimol, a GABA agonist, to stimulate chloride uptake without affecting the specific binding of [H-3]flunitrazepam or t-[S-35]butylbicyclophosphorothionate to the GABA(A) receptor, or the allosteric modulation of binding of these ligands by muscimol. The function of purified GABA(A) receptors reconstituted in proteoliposomes, a preparation not containing microtubule components, was not affected by colchicine. In contrast to the results seen in human monocytes by other investigators, we found that colchicine decreased, rather than increased, protein kinase A activity in cortical microsacs. Thus, protein kinase A modulation of the GABA(A) receptor is not a likely mechanism for the actions of colchicine. We propose that microtubule-depolymerizing agents inhibit GABA(A)ergic function by disrupting the interaction of GABA(A) receptors with microtubules.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80262; UNIV NEW MEXICO,DEPT PHARMACOL,ALBUQUERQUE,NM 87131	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico			Allan, Andrea M/L-8919-2015	Allan, Andrea/0000-0002-6745-4352	NIAAA NIH HHS [AA06399] Funding Source: Medline; NIGMS NIH HHS [GM14855] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM014855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAAS PW, 1991, J NEUROSCI RES, V30, P134, DOI 10.1002/jnr.490300115; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BORISY GG, 1974, FED PROC, V33, P167; BURNS RG, 1984, EUR J BIOCHEM, V141, P609, DOI 10.1111/j.1432-1033.1984.tb08236.x; CORNET M, 1993, J MEMBRANE BIOL, V133, P161; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DUNN SMJ, 1989, BIOCHEMISTRY-US, V28, P2545, DOI 10.1021/bi00432a030; FROEHNER SC, 1993, NATURE, V366, P719, DOI 10.1038/366719a0; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GORDONWEEKS PR, 1982, NEUROSCIENCE, V7, P739, DOI 10.1016/0306-4522(82)90079-3; HADINGHAM KL, 1993, MOL PHARMACOL, V43, P970; HARRIS RA, 1989, BRAIN RES, V490, P26; IQBAL K, 1986, LANCET, V2, P421; JALILIANTEHRANI MH, 1986, J NEUROCHEM, V46, P1542; JONSON BD, 1993, NEURON, V10, P797; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; LEIDENHEIMER NJ, 1991, J NEUROCHEM, V57, P722, DOI 10.1111/j.1471-4159.1991.tb03806.x; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LO MMS, 1982, P NATL ACAD SCI-BIOL, V79, P680, DOI 10.1073/pnas.79.2.680; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MANIE S, 1993, J BIOL CHEM, V268, P13675; MATSUMOTO G, 1984, J MEMBRANE BIOL, V77, P77; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENDELKOW EM, 1992, FEBS LETT, V314, P315; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; RAJAN VP, 1985, ENDOCRINOLOGY, V117, P2408, DOI 10.1210/endo-117-6-2408; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VELAZQUEZ JL, 1989, J NEUROSCI, V9, P2163; WALKER JH, 1984, EMBO J, V3, P2287, DOI 10.1002/j.1460-2075.1984.tb02127.x; WANDOSELL F, 1986, J BIOL CHEM, V261, P332; WHITE WF, 1981, BRAIN RES, V215, P162, DOI 10.1016/0006-8993(81)90499-6; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WILSON L, 1967, BIOCHEMISTRY-US, V6, P3126, DOI 10.1021/bi00862a021; WILSON L, 1974, FED PROC, V33, P158	40	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19546	19552						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7913471				2022-12-27	WOS:A1994NY33200054
J	WOODS, A; MUNDAY, MR; SCOTT, J; YANG, XL; CARLSON, M; CARLING, D				WOODS, A; MUNDAY, MR; SCOTT, J; YANG, XL; CARLSON, M; CARLING, D			YEAST SNF1 IS FUNCTIONALLY RELATED TO MAMMALIAN AMP-ACTIVATED PROTEIN-KINASE AND REGULATES ACETYL-COA CARBOXYLASE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE KINASE; SACCHAROMYCES-CEREVISIAE; RAT-LIVER; PHOSPHORYLATION SITES; FATTY-ACID; IDENTIFICATION; GENE; METABOLISM; ASSOCIATION; REPRESSION	The product of the SNF1 gene is a protein kinase whose activity is essential for transcriptional activation of glucose repressed genes in Saccharomyces cerevisiae. We have cloned a mammalian AMP-activated protein kinase (AMPK) that is 46% identical to the deduced amino acid sequence of SNF1 (Carling, D., Aguan, K., Woods, A, Verhoeven, A. J. M., Beri, R., Brennan, C. H., Sidebottom, C., Davison, M. D., and Scott, J. (1994) J. Biol. Chem. 269, 11442-11448). Mammalian AMPK plays a major role in the control of lipid metabolism and phosphorylating, thereby inactivating both acetyl-CoA carboxylase and 3-hydroxy-3-methylglutaryl-CoA reductase, key regulatory enzymes in the synthesis of fatty acids and cholesterol, respectively. We present evidence indicating that, in common with its mammalian homologue, SNF1 forms part of a protein kinase cascade. SNF1 is inactivated in vitro by treatment with protein phosphatase 2A and can be reactivated using a partially purified preparation of mammalian AMPK kinase. SNF1 undergoes a time-dependent increase in activity during growth in glucose-derepressing conditions, providing the first evidence that SNF1 activity is regulated by the level of available glucose. In wild-type yeast, but not in a snf1 deletion mutant, acetyl-CoA carboxylase shows a reciprocal change in activity compared with SNF1 under glucose derepressing conditions, indicating that SNF1 regulates acetyl-CoA carboxylase in vivo. These results suggest that, in addition to their structural similarity, the role of SNF1 and AMPK in the regulation of fatty acid synthesis has been highly conserved throughout evolution.	ROYAL POSTGRAD MED SCH, MRC MOLEC MED, LONDON W12 0NN, ENGLAND; UNIV LONDON, SCH PHARM, DEPT PHARMACEUT CHEM, LONDON WC1, ENGLAND; COLUMBIA UNIV, COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Imperial College London; University of London; Columbia University			Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830				ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; CARLING D, 1986, BIOCHEM SOC T, V14, P1076, DOI 10.1042/bst0141076; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CARLSON M, 1981, GENETICS, V98, P25; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; ESTRUCH F, 1992, GENETICS, V132, P639; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HARLOW E, 1985, ANTIBODIES LABORATOR; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MACKINTOSH RW, 1992, EUR J BIOCHEM, V209, P923, DOI 10.1111/j.1432-1033.1992.tb17364.x; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MUNDAY MR, 1984, EUR J BIOCHEM, V141, P617, DOI 10.1111/j.1432-1033.1984.tb08237.x; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; WITTERS LA, 1990, BIOCHEM BIOPH RES CO, V169, P369, DOI 10.1016/0006-291X(90)90341-J; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	38	324	328	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19509	19515						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7913470				2022-12-27	WOS:A1994NY33200049
J	BAUDE, EJ; DIGNAM, SS; OLSEN, SR; REIMANN, EM; UHLER, MD				BAUDE, EJ; DIGNAM, SS; OLSEN, SR; REIMANN, EM; UHLER, MD			GLUTAMIC ACID-203 OF THE CAMP-DEPENDENT PROTEIN-KINASE CATALYTIC SUBUNIT PARTICIPATES IN THE INHIBITION BY 2 ISOFORMS OF THE PROTEIN-KINASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; RABBIT SKELETAL-MUSCLE; PEPTIDE INHIBITOR; ESCHERICHIA-COLI; IDENTIFICATION; EXPRESSION; CELLS; OVEREXPRESSION; MOBILITY; BINDING	Although the protein kinase inhibitors (PKIs) are known to be potent and specific inhibitors of the catalytic (C) subunit of cAMP-dependent protein kinase, little is known about their physiological roles. Glutamate 203 of the Calpha isoform (CalphaE203) has been implicated in the binding of the arginine 15 residue of the skeletal isoform of PKI (PKIalphaR15) (Knighton, D. R., Zheng, J., Ten Eyck, L. F., Xuong, N., Taylor, S. S., and Sowadski, J. M. (1991) Science 253, 414-420). To investigate the role of CalphaE203 in the binding of PKI and in vivo C-PKI interactions, in vitro mutagenesis was used to change the CalphaE203 codon of the murine Calpha cDNA to alanine and glutamine codons. Initially, the CalphaE203 mutant proteins were expressed and purified from Escherichia coli. CalphaE203 is not essential for catalysis as all of the C subunit mutants were enzymatically active. The mutation of Glu203 did increase the apparent K(m) for Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) severalfold but did not affect the apparent K(m) for ATP. The V(max(app)) was not affected by the mutation of CalphaE203. The mutation of CalphaE203 compromised the ability of PKIalpha(5-24), PKIalpha, and PKIbeta to inhibit phosphotransferase activity. PKIalpha was altered using in vitro mutagenesis to probe the role of Arg15 in interacting with CalphaE203. The PKIalphaR15A mutant was reduced in its inhibition of Calpha. Preliminary studies of the expression of these Calpha mutants in COS cells gave similar results. These results suggest that the CalphaE203 mutants may be useful in assessing the role of PKI in vivo.	UNIV MICHIGAN, MENTAL HLTH RES INST, 205 ZINA PITCHER PL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, GRAD PROGRAM CELLULAR & MOLEC BIOL, ANN ARBOR, MI 48109 USA; MED COLL OHIO, DEPT BIOCHEM, TOLEDO, OH 43699 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005700] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038788, R29GM038788] Funding Source: NIH RePORTER; NCRR NIH HHS [S07-RR05700] Funding Source: Medline; NHLBI NIH HHS [HL36573] Funding Source: Medline; NIGMS NIH HHS [GM38788] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MH, 1992, J AM SOC MASS SPECTR, V3, P18, DOI 10.1016/1044-0305(92)85014-B; Andrews PC, 1992, TECHNIQUES PROTEIN C, VIII, P515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1990, CURR OPIN CELL BIOL, V2, P221, DOI 10.1016/0955-0674(90)90010-C; BROWN NA, 1990, J BIOL CHEM, V265, P13181; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG HC, 1985, BIOCHEM J, V231, P665; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DEJONG WW, 1978, BIOCHEM BIOPH RES CO, V82, P532, DOI 10.1016/0006-291X(78)90907-5; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; EDMONDS CG, 1990, METHOD ENZYMOL, V193, P412, DOI 10.1016/0076-6879(90)93430-S; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GLASS DB, 1989, J BIOL CHEM, V264, P8802; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; JARDINE I, 1990, METHOD ENZYMOL, V193, P441, DOI 10.1016/0076-6879(90)93432-K; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STEINBERG RA, 1991, MOL CELL BIOL, V11, P705, DOI 10.1128/MCB.11.2.705; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2232; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONERWEBB J, 1992, J BIOL CHEM, V267, P25174; TONERWEBB J, 1987, BIOCHEMISTRY-US, V26, P7371, DOI 10.1021/bi00397a026; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581	52	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2316	2323						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7905001				2022-12-27	WOS:A1994MR98800113
J	YAMAGUCHI, A; OYAUCHI, R; SOMEYA, Y; AKASAKA, T; SAWAI, T				YAMAGUCHI, A; OYAUCHI, R; SOMEYA, Y; AKASAKA, T; SAWAI, T			2ND-SITE MUTATION OF ALA-220 TO GLU OR ASP SUPPRESSES THE MUTATION OF ASP-285 TO ASN IN THE TRANSPOSON TN10-ENCODED METAL-TETRACYCLINE/H(+) ANTIPORTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRACYCLINE RESISTANCE PROTEIN; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; MEMBRANE-PROTEIN; LACTOSE PERMEASE; H+ ANTIPORTER; TN10; GENE; CARRIER; DETERMINANTS	A carboxyl group of Asp-285 is essential for tetracycline/H+ antiport mediated by the transposon Tn10-encoded metal-tetracycline/H+ antiporter (TetA) of Escherichia coli (Yamaguchi, A., Akasaka, T., Ono, N., Someya, Y., Nakatani, M., and Sawai, T. (1992) J. Biol. Chem. 267, 7490-7498). Spontaneous tetracycline resistance revertants were isolated from E. coli cells carrying the Asn-285 mutant tetA gene. All of the revertants were due to the second-site mutation at codon 220 of GCG (Ala) to GAG (Glu). The K(m) value of the tetracycline transport mediated by the revertant TetA protein was about 4-fold higher than that of the wild-type, indicating that the revertant is a low affinity mutant. A Glu-220 and Asn-285 double mutant constructed by site-directed mutagenesis showed the same properties as the revertants, confirming that the mutation of Ala-220 is solely responsible for the suppression. The Asp-220 mutation of the Asn-285 mutant resulted in a lower level of restoration of the tetracycline resistance and the transport activity than in the case of the Glu-220 mutation. A single mutation replacing Ala-220 with Glu or Asp caused about a 2-4-fold decrease in the tetracycline resistance, but no crucial change in the transport activity. It is not likely that Glu-220 is required for a charge-neutralizing salt bridge because an unpaired negative charge in a Glu-220 or Asp-220 single mutant did not cause a serious change in the activity. An alternative explanation is reasonable; Asp-285 directly contributes to the binding of a cationic substrate, metal-tetracycline chelation complex, or proton, and an acidic residue at position 220 can take over the role of Asp-285.			YAMAGUCHI, A (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,DIV MICROBIAL CHEM,CHIBA 263,JAPAN.							ALLARD JD, 1992, J BIOL CHEM, V267, P17809; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; ECKERT B, 1989, J BIOL CHEM, V264, P11663; FOSTER DL, 1983, J BIOL CHEM, V258, P31; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LEE JI, 1992, J BIOL CHEM, V267, P20758; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAGUCHI A, 1993, IN PRESS BIOCHEMISTR, V32; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	36	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26990	26995						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903301				2022-12-27	WOS:A1993MM26200026
J	MYERS, LC; JACKOW, F; VERDINE, GL				MYERS, LC; JACKOW, F; VERDINE, GL			METAL DEPENDENCE OF TRANSCRIPTIONAL SWITCHING IN ESCHERICHIA-COLI ADA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; REGULATORY PROTEIN; ALKYLATING-AGENTS; ADAPTIVE RESPONSE; METHYLTRANSFERASE; REPAIR; GENE; PHOSPHOTRIESTERS; EXPRESSION; RESISTANCE	The Escherichia coli Ada protein repairs methylphos photriesters in DNA by direct, irreversible methyl transfer to one of its own cysteine residues. The methyl transfer process is autocatalyzed by coordination of the acceptor residue, Cys(69), to, a tightly bound zinc ion. Kinetic data reveal a 4-fold reduction in the methylphosphotriester repair activity for the Cd(II) form of Ada versus the native Zn(II)-bound form, thus confirming a direct role for the metal in autocatalysis. Quantitative electrophoretic mobility shift assays reveal that the specific DNA affinity of the protein is increased 10(3)-fold by transfer of a methyl group to Cys(69); the Cd(II) and the Zn(II) forms of the protein behave similarly in this respect, This methylation-sensitive stimulation of binding underlies the ability of Ada to activate inducibly the transcription of a methylation-dependent regulon, We conclude that the chemical properties of the bound metal influence the transition state for autocatalytic methyl transfer, but not the structure that ultimately results from this process.	HARVARD UNIV,PROGRAM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard University								AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAUER R, 1976, BIOCHEMISTRY-US, V15, P334, DOI 10.1021/bi00647a015; COATES JH, 1974, NATURE, V249, P773, DOI 10.1038/249773a0; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COTTON FA, 1988, ADV INORG CHEM RAD, P597; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P3167, DOI 10.1093/nar/20.12.3167; EZAZNIKPAY K, 1994, PROTEIN SCI, V3, P132; HAKURA A, 1991, J BACTERIOL, V173, P3663, DOI 10.1128/JB.173.12.3663-3672.1991; HAMBLIN MR, 1985, FEBS LETT, V189, P315, DOI 10.1016/0014-5793(85)81047-4; KUIJPERS WHA, 1990, NUCLEIC ACIDS RES, V18, P5197, DOI 10.1093/nar/18.17.5197; LANIR A, 1975, BIOCHEMISTRY-US, V14, P242, DOI 10.1021/bi00673a008; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MCCARTHY JG, 1983, P NATL ACAD SCI-BIOL, V80, P7380, DOI 10.1073/pnas.80.24.7380; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; Myers L C, 1994, Chem Biol, V1, P91, DOI 10.1016/1074-5521(94)90046-9; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; MYERS LC, 1993, BIOCHEMISTRY-US, V32, P14089, DOI 10.1021/bi00214a003; MYERS LC, 1992, BIOCHEMISTRY-US, V31, P4541, DOI 10.1021/bi00134a002; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; OHKUBO T, 1984, J AM CHEM SOC, V116, P6035; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; SAKASHITA H, 1993, FEBS LETT, V323, P252, DOI 10.1016/0014-5793(93)81351-Y; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SEDGWICK B, 1988, J BIOL CHEM, V263, P4430; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TEO I, 1984, EMBO J, V3, P2151, DOI 10.1002/j.1460-2075.1984.tb02105.x; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996	32	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6664	6670		10.1074/jbc.270.12.6664	http://dx.doi.org/10.1074/jbc.270.12.6664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896807	Green Submitted, hybrid			2022-12-27	WOS:A1995QQ85500038
J	RYBA, NJP; TIRINDELLI, R				RYBA, NJP; TIRINDELLI, R			A NOVEL GTP-BINDING PROTEIN GAMMA-SUBUNIT, G-GAMMA-8, IS EXPRESSED DURING NEUROGENESIS IN THE OLFACTORY AND VOMERONASAL NEUROEPITHELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; CENTRAL-NERVOUS-SYSTEM; BETA-GAMMA; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; ADENYLYL CYCLASE; TYROSINE-PHOSPHATASE; ODORANT RECEPTORS; GENE-EXPRESSION	A novel heterotrimeric G-protein gamma-subunit has been cloned, and its function has been confirmed by expression and purification. This gamma-subunit is only detected in the olfactory epithelium, the vomeronasal epithelium and, to a lesser extent, the olfactory bulb. It is absent from all other tissues studied including the nasal respiratory epithelium, During development, expression of G gamma 8 in the olfactory epithelium parallels neurogenesis, peaking shortly after birth and declining in the adult. In situ hybridization studies localize expression of this novel gamma-subunit to the sensory neurons; hybridization is strongest in the region of the epithelium that contains immature neurons, Unlike proteins that are expressed only in mature olfactory neurons (e.g. olfactory marker protein or Golf alpha), expression of G gamma 8 in the olfactory epithelium is relatively unaffected by olfactory bulbectomy. In the vomeronasal epithelium expression of G gamma 8 is also highest in the developing neurons. Taken together, these findings are consistent with a very specific role for G gamma 8 in the development and turnover of olfactory and vomeronasal neurons.	UNIV PARMA,I-43100 PARMA,ITALY	University of Parma	RYBA, NJP (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM 1A09,BETHESDA,MD 20892, USA.			Ryba, Nicholas/0000-0002-2060-8393				ASANO T, 1993, J BIOL CHEM, V268, P20512; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BARBER PC, 1978, BRAIN RES, V147, P297, DOI 10.1016/0006-8993(78)90841-7; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COSTANZO RM, 1983, J COMP NEUROL, V215, P370, DOI 10.1002/cne.902150403; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIADEI PP, 1973, TISSUE CELL, V5, P113, DOI 10.1016/S0040-8166(73)80010-2; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MEISAMI E, 1989, DEV BRAIN RES, V46, P9, DOI 10.1016/0165-3806(89)90139-9; MENCO BPM, 1988, J CELL SCI, V89, P495; Meredith M., 1983, P199; Moulton D. G, 1970, P227; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RAY K, 1992, J BIOL CHEM, V267, P6086; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; VUKICEVIC S, 1994, J HISTOCHEM CYTOCHEM, V42, P869, DOI 10.1177/42.7.8014470; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WILSON KCP, 1980, BRAIN RES, V185, P103, DOI 10.1016/0006-8993(80)90675-7; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; ZIGMAN JM, 1993, ENDOCRINOLOGY, V133, P2508, DOI 10.1210/en.133.6.2508	60	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6757	6767		10.1074/jbc.270.12.6757	http://dx.doi.org/10.1074/jbc.270.12.6757			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896821	hybrid			2022-12-27	WOS:A1995QQ85500052
J	WANG, ZM; CHOUDHARY, A; LEDVINA, PS; QUIOCHO, FA				WANG, ZM; CHOUDHARY, A; LEDVINA, PS; QUIOCHO, FA			FINE-TUNING THE SPECIFICITY OF THE PERIPLASMIC PHOSPHATE-TRANSPORT RECEPTOR - SITE-DIRECTED MUTAGENESIS, LIGAND-BINDING, AND CRYSTALLOGRAPHIC STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; PROTEIN-STRUCTURE; ACTIVE-TRANSPORT; HYDROGEN-BONDS; PHOS-GENE; REFINEMENT; DIPOLES; CHARGES	Phosphorous, primarily in the form of phosphate, is a critical nutrient for the life of a cell. We have previously determined the 1.7-Angstrom resolution structure of the phosphate-binding protein, an initial receptor for the high-affinity phosphate active transport system or permease in Escherichia coli (Luecke, H., and Quiocho, F.A. (1990) Nature 347, 402-406). This structure is the first to reveal the key role of hydrogen bonding interactions in conferring the high specificity of the permease, a specificity also shared by other phosphate transport systems. Both monobasic and dibasic phosphates are recognized by the phosphate-binding protein with Asp(56) playing a key role. Here we report site-directed mutagenesis, ligand binding, and crystallographic studies of the binding protein which show that introduction of one additional Asp by mutagenesis of the Thr(141) in the ligand-binding site restricts binding to only the monobasic phosphate.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, STRUCT & COMPUTAT BIOL & MOLEC BIOPHYS PROGRAM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine								ANDERSEN AB, 1989, INFECT IMMUN, V57, P2481, DOI 10.1128/IAI.57.8.2481-2488.1989; AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; Brunger A.T., 1992, XPLOR VERSION 31; CHANG ZY, 1994, J BIOL CHEM, V269, P1956; Clare Speakman J., 1972, STRUCTURE BONDING, P141; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; HE JJ, 1993, PROTEIN SCI, V2, P1643, DOI 10.1002/pro.5560021010; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JACOBSON BL, 1988, J MOL BIOL, V204, P783, DOI 10.1016/0022-2836(88)90369-5; KUBENA BD, 1986, J BIOL CHEM, V261, P7995; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MAGOTA K, 1984, J BACTERIOL, V157, P909, DOI 10.1128/JB.157.3.909-917.1984; MEDVECZKY N, 1970, BIOCHIM BIOPHYS ACTA, V211, P158, DOI 10.1016/0005-2736(70)90090-8; MEDVECZKY N, 1971, BIOCHIM BIOPHYS ACTA, V241, P494, DOI 10.1016/0005-2736(71)90048-4; NEU HC, 1965, J BIOL CHEM, V240, P3685; PARDEE AB, 1966, J BIOL CHEM, V241, P5886; PARDEE AB, 1966, J BIOL CHEM, V241, P3962; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SHARMA SD, 1992, MICROELECTRON RELIAB, V32, P1657, DOI 10.1016/0026-2714(92)90261-I; SURIN BP, 1984, J BACTERIOL, V157, P772, DOI 10.1128/JB.157.3.772-778.1984; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	29	61	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25091	25094						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929197				2022-12-27	WOS:A1994PQ49000086
J	XIA, T; GRAY, DW; SHIMAN, R				XIA, T; GRAY, DW; SHIMAN, R			REGULATION OF RAT-LIVER PHENYLALANINE-HYDROXYLASE .3. CONTROL OF CATALYSIS BY (6R)-TETRAHYDROBIOPTERIN AND PHENYLALANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; ACTIVATION; 4-MONOOXYGENASE; PURIFICATION; METABOLISM; MECHANISM; INVITRO; PTERINS; INVIVO	Effects of phenylalanine and di and tetrahydropterins on presteady-state and steady-state catalytic behavior of rat liver phenylalanine hydroxylase are analyzed. From this and previous work (Shiman, R, Xia, T., Hill, M., and Gray, D. (1994) J. Biol. Chem. 269, 24647-24656), which analyzed binding of the same compounds to the enzyme in the absence of catalysis, a model of phenylalanine hydroxylase regulation is proposed. The mechanism appears novel in that 1) one substrate, phenylalanine, is a positive effector (activator), 2) a second substrate, (6R)-tetrahydrobiopterin (BH4), is a negative effector that blocks phenylalanine activation by forming an inactive BH4 enzyme complex, and 3) the BH4-enzyme complex sequesters BH4 and controls its metabolic availability. Reaction progress curves showing regulatory effects of BH4, 7,8-dihydrobiopterin (BH2), and phenylalanine are fit by the model with high precision. Data are presented that the high affinity pterin-binding site on unactivated phenylalanine hydroxylase is the pterin site that regulates catalysis. Occupancy of this site by BH4 or BH2 causes non-cooperative, linear inhibition of phenylalanine activation of the enzyme. All inhibitory effects of BH4 appear due to its binding at the pterin regulatory site on unactivated enzyme. BH2 inhibits by binding at the active site as well as the pterin regulatory site. 6-Methyltetrahydropterin also appears to bind at the pterin regulatory site, but its effect is only seen at high phenylalanine concentrations. Using kinetic constants measured in this and earlier work, quantitative effects of phenylalanine and BH4 regulation on the rate of the phenylalanine hydroxylase reaction in vitro and in vivo are calculated. The effects of formation of the BH4 enzyme complex on free BH4 concentration, on enzyme activity, and on regulation of the rate of phenylalanine hydroxylation in liver are discussed.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOCHEM & MOLEC BIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ABITA JP, 1976, J BIOL CHEM, V251, P5310; BLAU N, 1988, ANNU REV NUTR, V8, P185; DONLON J, 1978, J BIOL CHEM, V253, P6657; DOSKELAND AP, 1987, BIOCHEM J, V242, P867, DOI 10.1042/bj2420867; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P562; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; LAZARUS RA, 1983, J BIOL CHEM, V258, P960; LAZARUS RA, 1981, BIOCHEMISTRY-US, V20, P6834, DOI 10.1021/bi00527a015; LAZARUS RA, 1982, J AM CHEM SOC, V104, P6871, DOI 10.1021/ja00388a106; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIELSEN KH, 1969, EUR J BIOCHEM, V9, P497, DOI 10.1111/j.1432-1033.1969.tb00636.x; PARNIAK MA, 1988, J BIOL CHEM, V263, P1223; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; Press W., 1986, NUMERICAL RECIPES; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1985, CHEM BIOCH PTERINS, V2, P179; SMITH GK, 1991, J NUTR BIOCH, V2, P411; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STORM CB, 1971, J ORG CHEM, V36, P3925; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	28	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24657	24665						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929137				2022-12-27	WOS:A1994PQ49000024
J	DUDEN, R; HOSOBUCHI, M; HAMAMOTO, S; WINEY, M; BYERS, B; SCHEKMAN, R				DUDEN, R; HOSOBUCHI, M; HAMAMOTO, S; WINEY, M; BYERS, B; SCHEKMAN, R			YEAST BETA-COAT AND BETA'-COAT PROTEINS (COP) - 2 COATOMER SUBUNITS ESSENTIAL FOR ENDOPLASMIC RETICULUM-TO-GOLGI PROTEIN TRAFFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; TRANSPORT VESICLE FORMATION; INTEGRAL MEMBRANE-PROTEIN; CLATHRIN-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; VESICULAR TRANSPORT; SHOWS HOMOLOGY; SEC13P COMPLEX	To understand better the role of non-clathrin coat proteins in membrane traffic, we have cloned and characterized two essential genes encoding subunits of the yeast coatomer, SEC26 and SEC27. Sec26p is a 109-kDa protein that shares 43% sequence identity with mammalian beta-coat protein (beta-COP). Sec26p depleted cells accumulate endoplasmic reticulum (ER) forms of secretory precursor proteins, and growth ceases after a dramatic accumulation of ER membranes. Sec26p overproduction partially suppresses sec27-1, a new mutant that shows a temperature-sensitive defect in ER-to-Golgi transport. The SEC27 gene was cloned, and the sequence predicts a 99.4-kDa protein with 45% sequence identity to mammalian beta'-COP. Our sequence data support a two-domain model for the SEC27 protein: a conserved amino-terminal domain, composed of five WD-40 repeats similar to those found in beta-subunits of trimeric G proteins, and a less conserved carboxyl-terminal domain. Genetic interactions connect sec27-1 and sec21-1 (coatomer gamma subunit) with the ARF1 and ARF2 genes and with the SEC22, BET1, and BOS1 genes, which encode membrane proteins involved in ER-to-Golgi transport.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; UNIV WASHINGTON, DEPT GENET SK-50, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Colorado System; University of Colorado Boulder; University of Washington; University of Washington Seattle			Duden, Rainer/C-8917-2011					BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; REXACH M, 1994, IN PRESS J CELL BIOL; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RIPOCHE J, 1994, P NATL ACAD SCI USA, V91, P1878, DOI 10.1073/pnas.91.5.1878; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1993, MOL BIOL CELL S, V4, pA455; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	56	120	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24486	24495						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929113				2022-12-27	WOS:A1994PQ34600098
J	ILG, T; OVERATH, P; FERGUSON, MAJ; RUTHERFORD, T; CAMPBELL, DG; MCCONVILLE, MJ				ILG, T; OVERATH, P; FERGUSON, MAJ; RUTHERFORD, T; CAMPBELL, DG; MCCONVILLE, MJ			O-GLYCOSYLATION AND N-GLYCOSYLATION OF THE LEISHMANIA-MEXICANA SECRETED ACID-PHOSPHATASE - CHARACTERIZATION OF A NEW CLASS OF PHOSPHOSERINE-LINKED GLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOVANI PROMASTIGOTES; MONOCLONAL-ANTIBODIES; INTRALYSOSOMAL ACCUMULATION; VIRULENCE FACTORS; LIPOPHOSPHOGLYCAN; MACROPHAGES; EPITOPES; PHOSPHATIDYLINOSITOLS; IDENTIFICATION; PHOSPHOGLYCAN	The protozoan parasite Leishmania mexicana secretes a heavily glycosylated 100-kDa acid phosphatase (sAP) which is associated with one or more polydisperse proteophosphoglycans. Most of the glycans in this complex were released using mild acid hydrolysis conditions that preferentially cleave phosphodiester linkages. The released saccharides were shown to consist of monomeric mannose and a series of neutral and phosphorylated glycans by Dionex high performance liquid chromatography, methylation analysis, exoglycosidase digestions, and one-dimensional H-1 NMR spectroscopy. The neutral species comprised a linear series of oligosaccharides with the structures [Man alpha 1-2](1-5)Man. The phosphorylated oligosaccharides were characterized as PO4-6Gal beta 1-4Man and PO4-6[Glc beta 1-3]Gal beta 4Man. The attachment of these glycans to the polypeptide backbone via the linkage, Man alpha 1-PO4-Ser, is suggested by: 1) the finding that more than 60% of the serine residues in the polypeptide are phosphorylated and 2) the resistance of the phosphoserine residues to alkaline phosphatase digestion unless the sAP was first treated with either mild acid (to release all glycans) or jack bean alpha-mannosidase (to release neutral mannose glycans). Analysis of the partially resolved components of the complex indicated that the most of the O-linked glycans on the 100-kDa phosphoglycoprotein comprised mannose and the mannoseoligosaccharides. In contrast the major O-linked glycans on the proteophosphoglycan were short phosphoglycan chains, containing on average two repeat units per chain. In addition to the O-linked glycans, both components in the sAP complex contained N-linked glycans. The N-glycanase F-released glycans were characterized by Bio-Gel P4 chromatography and exoglycosidase digestions to be the biantennary oligomannose type with the structures Glc(1)Man(6)GlcNAc(2) and Man(6)GlcNAc(2). The O-linked glycans of the sAP complex are similar to those found in the phosphoglycan chains of the abundant surface lipophosphoglycan, but differ in having much shorter phosphoglycan chains and a more diverse series of mannose cap oligosaccharides. These data suggest that there are marked differences in the ability of different glycosyltransferases to utilize peptide-linked versus glycolipid-linked accepters.	UNIV MELBOURNE,DEPT BIOCHEM,PARKVILLE,VIC 3052,AUSTRALIA; MAX PLANCK INST BIOL,MEMBRANBIOCHEM ABT,D-72076 TUBINGEN,GERMANY; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Melbourne; Max Planck Society; University of Dundee			Ferguson, Michael A. J./F-7829-2010; Campbell, David G/K-1874-2015	Ferguson, Michael A. J./0000-0003-1321-8714; Campbell, David G/0000-0003-2278-2149	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; ANTOINE JC, 1987, EXP PARASITOL, V64, P485, DOI 10.1016/0014-4894(87)90063-4; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; BATES PA, 1989, EXP PARASITOL, V68, P335, DOI 10.1016/0014-4894(89)90115-X; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; BATES PA, 1987, EXP PARASITOL, V64, P157, DOI 10.1016/0014-4894(87)90139-1; BATES PA, 1988, EXP PARASITOL, V67, P199, DOI 10.1016/0014-4894(88)90067-7; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; FINN DJ, 1987, BIOCHEM BIOPH RES CO, V148, P834, DOI 10.1016/0006-291X(87)90951-X; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; GREIS KD, 1992, J BIOL CHEM, V267, P5876; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HELANDER A, 1992, CARBOHYD RES, V230, P299; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; ILG T, 1992, J BIOL CHEM, V267, P6834; ILG T, 1994, IN PRESS PARASITOLOG; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; JANSSON PE, 1989, CARBOHYD RES, V188, P169, DOI 10.1016/0008-6215(89)84069-8; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KIELIAN MC, 1982, J CELL BIOL, V93, P866, DOI 10.1083/jcb.93.3.866; KING DL, 1987, MOL BIOCHEM PARASIT, V24, P47, DOI 10.1016/0166-6851(87)90114-9; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LEYVACOBIAN F, 1988, J IMMUNOL, V141, P1445; LOVELACE JK, 1987, J PROTOZOOL, V34, P78, DOI 10.1111/j.1550-7408.1987.tb03136.x; LOVELACE JK, 1987, MOL BIOCHEM PARASIT, V22, P19, DOI 10.1016/0166-6851(87)90065-X; LOVELACE JK, 1986, AM J TROP MED HYG, V35, P1121, DOI 10.4269/ajtmh.1986.35.1121; LOVELACE JK, 1986, MOL BIOCHEM PARASIT, V20, P243, DOI 10.1016/0166-6851(86)90105-2; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1993, PARASITOL TODAY, V9, P316, DOI 10.1016/0169-4758(93)90225-5; MEDINAACOSTA E, 1993, INFECT AGENT DIS, V2, P25; NIKOLAEV AV, 1989, BIOORG KHIM+, V15, P1649; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433	43	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24073	24081						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929059				2022-12-27	WOS:A1994PQ34600037
J	KANG, C; SUN, N; HONZATKO, RB; FROMM, HJ				KANG, C; SUN, N; HONZATKO, RB; FROMM, HJ			REPLACEMENT OF ASP(333) WITH ASN BY SITE-DIRECTED MUTAGENESIS CHANGES THE SUBSTRATE-SPECIFICITY OF ESCHERICHIA-COLI ADENYLOSUCCINATE SYNTHETASE FROM GUANOSINE 5'-TRIPHOSPHATE TO XANTHOSINE 5'-TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSENSUS SEQUENCE; MOLECULAR-CLONING; DEHYDROGENASE; PURIFICATION; REDESIGN; PROTEIN; MUSCLE; PURA	The aspartate residue of the (N/T)KXD concensus sequence for GTP-binding proteins is present in the eight available sequences of adenylosuccinate synthetase. Reported here is a comprehensive analysis of the substrate specificity of mutant enzymes, where the conserved Asp(333) of the synthetase from Escherichia coli is changed to asparagine, glutamate, and glutamine by site-directed mutagenesis. The mutants D333N, D333E, and D333Q generally show deceased k(cat) values and increased K-m values for GTP. The decreased values of k(cat) exhibited by the mutants indicate that the interactions between Asp(333) and the guanine are relayed by some mechanism to the catalytic residues around the gamma-phosphate of GTP, and that the energy provided by the interaction between Asp(333) and the guanine moiety of GTP is utilized for rearrangement of the catalytic residues. The three mutants each have higher affinity for xanthosine 5'-triphosphate (XTP) and ITP than does the wild-type enzyme. In fact, the D333N mutant uses XTP more effectively than the wild-type enzyme employs GTP as a substrate. The side-chain of Asp(333) forms hydrogen bonds with the N-1 and the exocyclic amino group of the guanine base of GTP. In the D333N mutant, this interaction is probably replaced by hydrogen bonds between the amide side chain of Asn(333) and N-1 and the 2-oxo group of XTP. The D333Q mutant can use UTP as a substrate more effectively than the wild-type enzyme. The longer side chain of glutamine at residue 333 favors pyrimidine nucleotides over the purine nucleotides, GTP, XTP, and ITP. These results demonstrate that Asp(333) in the (N/T)KXD consensus sequence of adenylosuccinate synthetase from E. coli is a determinant for GTP-specificity.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50010	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNARA AS, 1974, EUR J BIOCHEM, V41, P421; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HARDY LW, 1992, P NATL ACAD SCI USA, V89, P9725, DOI 10.1073/pnas.89.20.9725; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LIU F, 1992, J BIOL CHEM, V267, P2388; MANTSALA P, 1992, J BACTERIOL, V174, P1883; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; Sambrook J, 1989, MOL CLONING LABORATO; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; TORNHEIM K, 1972, J BIOL CHEM, V247, P162; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WENG G, 1994, PROTEIN SCI, V3, P22; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	30	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24046	24049						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929056				2022-12-27	WOS:A1994PQ34600033
J	APODACA, G; ENRICH, C; MOSTOV, KE				APODACA, G; ENRICH, C; MOSTOV, KE			THE CALMODULIN ANTAGONIST, W-13, ALTERS TRANSCYTOSIS, RECYCLING, AND THE MORPHOLOGY OF THE ENDOCYTIC PATHWAY IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; DEPENDENT PROTEIN-KINASE; NAPHTHALENESULFONAMIDE DERIVATIVES; CALCIUM-CALMODULIN; PLATELET SECRETION; TRANSFERRIN; TRIFLUOPERAZINE; PHOSPHORYLATION; INHIBITORS; EXOCYTOSIS	The effect of the calmodulin antagonist N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide (W-13) on the endosomal system of Madin-Darby canine kidney cells was assessed. W-13 inhibited receptor-mediated IgA. transcytosis, recycling of transferrin, and caused all material endocytosed from both surfaces of the cell to be delivered to exceptionally large, novel endosomal structures, which appear to be derived from early endosomes. Treatment with other calmodulin antagonists similarly inhibited transcytosis and caused large endosomes to form. These observations raise the possibility that calmodulin may be involved in regulating membrane trafficking through the endosomes of polarized epithelial cells.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV BARCELONA, FAC MED, DEPT BIOL CELULAR & ANAT PATOL, BARCELONA 7, SPAIN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Barcelona	APODACA, G (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, S-1372, SAN FRANCISCO, CA 94143 USA.		Apodaca, Gerard/HCJ-0048-2022	mostov, keith/0000-0002-8123-6247; Enrich, Carlos/0000-0003-0382-2993	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID RO1 AI25144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CARDONE M, 1993, J CELL BIOCH C S, V17; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DIPAOLA M, 1984, J CELL PHYSIOL, V118, P193, DOI 10.1002/jcp.1041180212; GRASSO JA, 1990, BIOCHEM J, V266, P261, DOI 10.1042/bj2660261; HENQUIN JC, 1981, BIOCHEM J, V196, P771, DOI 10.1042/bj1960771; HIDAKA H, 1981, MOL PHARMACOL, V20, P571; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORWITZ SB, 1981, J CELL BIOL, V91, P798, DOI 10.1083/jcb.91.3.798; HUNT RC, 1986, J BIOL CHEM, V261, P3681; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KRETSINGER RH, 1992, CELL CALCIUM, V13, P363, DOI 10.1016/0143-4160(92)90050-3; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; REDDY GPV, 1992, BIOCHEMISTRY-US, V31, P10426, DOI 10.1021/bi00158a002; SCHETTINI G, 1983, NEUROENDOCRINOLOGY, V37, P229, DOI 10.1159/000123548; SCHETTINI G, 1983, ENDOCRINOLOGY, V112, P64, DOI 10.1210/endo-112-1-64; STEINHARDT RA, 1982, NATURE, V295, P154, DOI 10.1038/295154a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TANAKA T, 1988, BIOCHEM PHARMACOL, V37, P2537; TANAKA T, 1982, MOL PHARMACOL, V22, P403; TANAKA T, 1985, CALMODULIN ANTAGONIS, P524; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	40	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19005	19013						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913467				2022-12-27	WOS:A1994NX32700047
J	LORET, EP; DELVALLE, RMS; MANSUELLE, P; SAMPIERI, F; ROCHAT, H				LORET, EP; DELVALLE, RMS; MANSUELLE, P; SAMPIERI, F; ROCHAT, H			POSITIVELY CHARGED AMINO-ACID-RESIDUES LOCATED SIMILARLY IN SEA-ANEMONE AND SCORPION TOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS HECTOR; NUCLEAR MAGNETIC-RESONANCE; SODIUM-CHANNEL; CIRCULAR-DICHROISM; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; POTASSIUM CHANNEL; NEUROTOXINS; RECEPTORS; PROTEINS	Specific groups of sea anemone and scorpion toxins compete on the same pharmacological site, on the voltage-gated sodium channel of mammal excitable membranes, However, these scorpion and sea anemone toxins are two distinct protein families, Here we purified and sequenced a new sea anemone toxin, Bg II, highly toxic to mammals and also a less toxic mutant, Bg III. Two Bg II models were determined from sequence homologies with two sea anemone toxin two-dimensional NMR structures. Only one model conformed to circular dichroism data obtained from Bg II and was compared with an x-ray structure of a scorpion toxin. The comparison of the two structures shows that 5 amino acid residues are located similarly in the sea anemone toxin and the scorpion toxin. From these 5 residues, 4 are basic residues, constituting two distinct positively charged poles on the surface of these toxins. In the sea anemone mutant isolated, a negative charge beside one of the positive poles decreases the toxicity. These results show that positively charged amino acid residues could be essential for the activity of these toxins and outline the role of electrostatic bonds in the interaction of sea anemone and scorpion toxins with their receptor.	CTR NACL INVEST CIENT, 68806990 HAVANA, CUBA		LORET, EP (corresponding author), FAC MED MARSEILLE, BIOCHIM LAB, CNRS, URA 1455, F-13916 MARSEILLE 20, FRANCE.			mansuelle, pascal/0000-0002-4504-6809				BERESS L, 1988, POISONOUS VENOMOUS M, P152; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COURAUD F, 1984, HDB NATURAL TOXINS, V2, P513; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2188, DOI 10.1021/bi00431a033; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; GOULD AR, 1990, EUR J BIOCHEM, V189, P145, DOI 10.1111/j.1432-1033.1990.tb15471.x; HILLE B, 1991, IONIC CHANNELS EXCIT, P236; Kem W.R., 1988, P375; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LLEWELLYN LE, 1991, BIOCHEM INT, V24, P937; LORET EP, 1991, BIOCHEMISTRY-US, V30, P633, DOI 10.1021/bi00217a007; LORET EP, 1990, BIOCHEMISTRY-US, V29, P1492, DOI 10.1021/bi00458a021; LORET EP, 1994, IN PRESS SCORPION BI; MACKINNON R, 1989, BIOCHEMISTRY-US, V28, P8092, DOI 10.1021/bi00446a020; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MATHEWS CK, 1990, BIOCHEMISTRY-US, P190; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; NUMA S, 1989, HARVEY LECT, V83, P121; Possani L. D., 1984, HDB NATURAL TOXINS, V2, P513; Rochat H, 1979, Adv Cytopharmacol, V3, P325; SALGADO VL, 1992, TOXICON, V30, P1365, DOI 10.1016/0041-0101(92)90512-4; SAMPIERI F, 1987, INT J PEPT PROT RES, V29, P231; SCHWEITZ H, 1985, BIOCHEMISTRY-US, V24, P3554, DOI 10.1021/bi00335a025; SIMARD M, 1990, BIOL SCORPION, P415; WIDMER H, 1989, PROTEINS, V6, P357, DOI 10.1002/prot.340060403	30	55	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	1994	269	24					16785	16788						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NR296	7911468				2022-12-27	WOS:A1994NR29600044
J	DEAN, NM; MCKAY, R; CONDON, TP; BENNETT, CF				DEAN, NM; MCKAY, R; CONDON, TP; BENNETT, CF			INHIBITION OF PROTEIN-KINASE C-ALPHA EXPRESSION IN HUMAN A549 CELLS BY ANTISENSE OLIGONUCLEOTIDES INHIBITS INDUCTION OF INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) MESSENGER-RNA BY PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; HUMAN-BREAST-CANCER; GENE-EXPRESSION; DOWN-REGULATION; RNASE-H; POTENT; HYDROLYSIS; AGENTS; MYC; DNA	We have identified 20-mer phosphorothioate oligodeoxynucleotides which potently (IC50 values of 100-200 nM) and specifically inhibit protein kinase C (PKC)-(alpha mRNA and protein expression in human lung carcinoma (A549) cells. These oligonucleotides target multiple, diverse sites on PKC-alpha mRNA including the AUG translation codon and 3'-untranslated sequences. 2'-O-Methyl phosphorothioate analogs of these oligonucleotides were without effect on PKC-alpha( )mRNA levels, suggesting that the reduction in targeted PKC-alpha mRNA is through RNase H-mediated cleavage. One oligonucleotide, however, was effective at inhibiting PKC-alpha protein levels as a 2'-O-methyl phosphorothioate at concentrations 2-3-fold greater than its phosphorothioate/deoxy homolog. These results suggest that the ability to serve as an RNase H substrate, although not required for all oligonucleotides, certainly increases their potency. These oligonucleotides have been used to examine the role played by PKC-alpha in mediating the phorbol ester-induced changes in mRNA levels of the cell adhesion molecule ICAM-1. In A549 cells, ICAM-1 mRNA is increased 10-20-fold by treatment of cells with the phorbol ester phorbol 12-myristate 13-acetate. When PKC-alpha protein levels are depleted by oligonucleotide treatment of A549 cells, the increase in ICAM-1 expression in response to phorbol 12-myristate 13-acetate is greatly reduced, demonstrating that PKC-alpha plays a major role in this process.			DEAN, NM (corresponding author), ISIS PHARMACEUT,DEPT MOLEC & CELLULAR BIOL,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.							AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CROOKE ST, 1993, ANTISENSE RES APPLIC; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229; ECKSTEIN F, 1989, TRENDS BIOCHEM SCI, V14, P97, DOI 10.1016/0968-0004(89)90130-8; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; GODSON C, 1990, J BIOL CHEM, V265, P8369; HANNUN YA, 1988, J BIOL CHEM, V263, P5124; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIER JAM, 1993, EXP CELL RES, V205, P52, DOI 10.1006/excr.1993.1057; MARKUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MYERS CL, 1992, AM J PHYSIOL, V262, pC365, DOI 10.1152/ajpcell.1992.262.2.C365; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SHAKIN SH, 1986, J BIOL CHEM, V261, P6018; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STRAUSS M, 1992, ONCOGENE, V7, P769; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WATSON PH, 1991, CANCER RES, V51, P3996; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	44	294	314	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					16416	16424						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	7911467				2022-12-27	WOS:A1994NQ72900070
J	MORELOCK, MM; ROTHLEIN, R; BRIGHT, SM; ROBINSON, MK; GRAHAM, ET; SABO, JP; OWENS, R; KING, DJ; NORRIS, SH; SCHER, DS; WRIGHT, JL; ADAIR, JR				MORELOCK, MM; ROTHLEIN, R; BRIGHT, SM; ROBINSON, MK; GRAHAM, ET; SABO, JP; OWENS, R; KING, DJ; NORRIS, SH; SCHER, DS; WRIGHT, JL; ADAIR, JR			ISOTYPE CHOICE FOR CHIMERIC ANTIBODIES AFFECTS BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Construction of a series of chimeric antibodies (murine variable region and human constant region) derived from the murine antibody BIRR1, which recognizes intercellular adhesion molecule 1 (ICAM-1), has revealed differences in the relative binding abilities of the chimeric antibody to antigen. The chimeric antibodies show a ranking of their ability to compete with BIRR1 for antigen on the surface of cells with the order BIRR1 = cIgG(1) (100%) > cIgG(4) (30%) > cIgG(2) (10%) as demonstrated by solid-phase competitive enzyme-linked immunosorbent assay. Papain digestion yielded Fab fragments that were purified to homogeneity. Competitive enzyme-linked immunosorbent assay showed that the chimeric and murine Fab binding constants were equivalent. A solution-phase binding assay (analyzed by size exclusion high performance liquid chromatography) between the intact mAbs and recombinant soluble ICAM-1 further established that the binding constants involving the Fab arms of the two antibodies were equivalent. In summary, the murine and chimeric anti-ICAM-1 antibodies bind cellular ICAM-1 with equivalent affinities but with differing avidities.	BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT IMMUNOL, RIDGEFIELD, CT 06877 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT MANAGEMENT INFORMAT SYST, RIDGEFIELD, CT 06877 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT DRUG METAB & PHARMACOKINET, RIDGEFIELD, CT 06877 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT PHARMACEUT, RIDGEFIELD, CT 06877 USA; CELLTECH LTD, CELLTECH RES, SLOUGH SL1 4EN, BERKS, ENGLAND	Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Celltech Group Ltd	MORELOCK, MM (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC, CTR RES & DEV, DEPT BIOCHEM, 900 RIDGEBURY RD, POB 368, RIDGEFIELD, CT 06877 USA.			Owens, Ray/0000-0002-3705-2993				ADAIR JR, 1992, IMMUNOL REV, V130, P5, DOI 10.1111/j.1600-065X.1992.tb01519.x; ANGAL S, 1993, MOL IMMUNOL, V30, P105, DOI 10.1016/0161-5890(93)90432-B; BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; BENJAMIN RJ, 1986, J EXP MED, V163, P1539, DOI 10.1084/jem.163.6.1539; Blottiere H M, 1991, Hum Antibodies Hybridomas, V2, P16; BORREBAECK CA, 1992, ANTIBODY ENG, P69; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CHATENOUD L, 1986, J IMMUNOL, V137, P830; CHATENOUD L, 1986, IMMUNOL TODAY, V7, P367, DOI 10.1016/0167-5699(86)90028-9; COLCHER D, 1989, CANCER RES, V49, P1738; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DILLMAN RO, 1990, ANTIBODY IMMUNOCONJ, V3, P1; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GODING JW, 1980, J IMMUNOL METHODS, V39, P285, DOI 10.1016/0022-1759(80)90230-6; HARDMAN N, 1989, INT J CANCER, V44, P424, DOI 10.1002/ijc.2910440308; HORGAN C, 1993, J IMMUNOL, V150, P5400; HUTZELL P, 1991, CANCER RES, V51, P181; JACKSON AP, 1983, BIOCHEM J, V215, P505, DOI 10.1042/bj2150505; JIN FS, 1991, J IMMUNOL, V146, P1806; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JONKER M, 1987, EUR J IMMUNOL, V17, P1547, DOI 10.1002/eji.1830171104; KHAZAELI MB, 1988, JNCI-J NATL CANCER I, V80, P937, DOI 10.1093/jnci/80.12.937; KING DJ, 1992, BIOCHEM J, V281, P317, DOI 10.1042/bj2810317; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MASON DW, 1980, BIOCHEM J, V187, P1; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; Nezlin R, 1990, Adv Immunol, V48, P1, DOI 10.1016/S0065-2776(08)60750-6; NORRIS SH, 1991, J PHARMACEUT BIOMED, V9, P211, DOI 10.1016/0731-7085(91)80149-4; NYGREN H, 1989, IMMUNOLOGY, V66, P321; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; PINCUS MR, 1981, P NATL ACAD SCI USA, V78, P5924, DOI 10.1073/pnas.78.10.5924; REYNOLDS JC, 1989, NUCL MED BIOL, V16, P121, DOI 10.1016/0883-2897(89)90182-7; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; ROMANS DG, 1977, P NATL ACAD SCI USA, V74, P2531, DOI 10.1073/pnas.74.6.2531; ROTHLEIN R, 1993, INT ARCH ALLERGY IMM, V100, P121, DOI 10.1159/000236398; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SCHUMAKER VN, 1991, MOL IMMUNOL, V28, P1347, DOI 10.1016/0161-5890(91)90037-K; SEARS HF, 1984, J BIOL RESP MODIF, V3, P138; SHAW DR, 1988, J NATL CANCER I, V80, P1553, DOI 10.1093/jnci/80.19.1553; SHEARMAN CW, 1991, J IMMUNOL, V146, P928; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STEPLEWSKI Z, 1988, P NATL ACAD SCI USA, V85, P4852, DOI 10.1073/pnas.85.13.4852; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499	59	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13048	13055						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909805				2022-12-27	WOS:A1994NH71600102
J	CARLING, D; AGUAN, K; WOODS, A; VERHOEVEN, AJM; BERI, RK; BRENNAN, CH; SIDEBOTTOM, C; DAVISON, MD; SCOTT, J				CARLING, D; AGUAN, K; WOODS, A; VERHOEVEN, AJM; BERI, RK; BRENNAN, CH; SIDEBOTTOM, C; DAVISON, MD; SCOTT, J			MAMMALIAN AMP-ACTIVATED PROTEIN-KINASE IS HOMOLOGOUS TO YEAST AND PLANT PROTEIN-KINASES INVOLVED IN THE REGULATION OF CARBON METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE KINASE; SODIUM DODECYL-SULFATE; RAT-LIVER; PHOSPHORYLATION SITES; GEL-ELECTROPHORESIS; MESSENGER-RNAS; IDENTIFICATION; SNF1; ACID	In mammals, an AMP-activated protein kinase (AMPK) phosphorylates both acetyl-CoA carboxylase and 3-hydroxy-3-methylglutaryl-CoA reductase in vitro and has been proposed to play a major role in the regulation of lipid metabolism in vivo. We report here the primary sequence of rat AMPK and show that antibodies raised against synthetic peptides based on the deduced sequence of AMPK immunoprecipitate AMPK activity from rat liver extracts. AMPK has a remarkable degree of sequence identity to the proteins encoded by the yeast SNF1 gene and the plant RKIN1 gene. SNF1 protein kinase activity is essential for release of genes from glucose repression in Saccharomyces cerevisiae. Expression of cRKIN1 in yeast snf1 mutants restores SNF1 function. These results indicate that AMPK, SNF1, and RKIN1 form part of a family of protein kinases that have been highly conserved throughout evolution. Our results suggest that AMPK may be involved in the regulation of a wide range of metabolic pathways.	ZENECA PHARMACEUT, DEPT CARDIOVASC, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND; UNILEVER RES, BEDFORD MK44 1LQ, ENGLAND; ERASMUS UNIV ROTTERDAM, DEPT BIOCHEM, 3000 DR ROTTERDAM, NETHERLANDS	Unilever; Erasmus University Rotterdam	CARLING, D (corresponding author), ROYAL POSTGRAD MED SCH, MRC MOLEC MED, DUCANE RD, LONDON W12 0NN, ENGLAND.		Verhoeven, Adrie J/H-4612-2011; Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830				ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1991, METHOD ENZYMOL, V200, P362; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; FORDER RA, 1983, PROSTA LEUKOTR MED, V12, P323, DOI 10.1016/0262-1746(83)90011-2; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; MACKINTOSH RW, 1992, EUR J BIOCHEM, V209, P923, DOI 10.1111/j.1432-1033.1992.tb17364.x; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; THOMPSONJAEGER S, 1991, GENETICS, V129, P697	36	200	209	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11442	11448						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7908907				2022-12-27	WOS:A1994NF96600069
J	YUEN, PST; DOOLITTLE, LK; GARBERS, DL				YUEN, PST; DOOLITTLE, LK; GARBERS, DL			DOMINANT-NEGATIVE MUTANTS OF NITRIC OXIDE-SENSITIVE GUANYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NATRIURETIC-PEPTIDE RECEPTOR; CATALYTIC ACTIVITY; ADENYLYL CYCLASE; BOVINE LUNG; RAT LUNG; EXPRESSION; CLONING; ENZYME	Since a nitric oxide-sensitive form of guanylyl cyclase exists as a heterodimer, mutations disrupting catalysis but not heterodimer formation could serve as dominant negative mutations. Two mutations within the catalytic region of the a subunit (alpha1D513A, alpha1D529A) caused complete losses of basal and sodium nitroprusside-stimulated guanylyl cyclase activity; however, the mutant alpha subunits continued to form heterodimers with wild-type beta-subunit. Rat insulinoma cells, which contain the alpha1beta1 form of guanylyl cyclase, were stably transfected with alpha1D513A or alpha1D529A. The response to sodium nitroprusside, which exceeded 200-fold in the presence of wild-type alpha1, was markedly reduced by the expression of either mutant subunit. In contrast, the mutant subunits failed to inhibit heat-stable enterotoxin-induced cGMP elevations; the bacterial peptide elevated insulinoma cell cGMP approximately 100-fold. The two point mutations, therefore, result in dominant negative proteins that can effectively and specifically block the NO/cGMP signaling pathway. These are also the first studies to show that, although both the alpha and beta subunits contain regions homologous to putative cyclase catalytic regions, a point mutation in just one of the subunits can completely inhibit cyclase activity.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			ST Yuen, Peter/B-1954-2008	ST Yuen, Peter/0000-0001-9557-3909				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEBENEK K, 1989, NUCLEIC ACIDS RES, V17, P5408, DOI 10.1093/nar/17.13.5408; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GARBERS DL, 1992, CELL, V71, P1; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KATSUSHIKA S, 1993, J BIOL CHEM, V268, P2273; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V156, P1000; RAPOPORT RM, 1983, J CYCLIC NUCL PROT, V9, P281; RETTORI V, 1992, P NATL ACAD SCI USA, V89, P11543, DOI 10.1073/pnas.89.23.11543; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THORPE DS, 1991, BIOCHEM BIOPH RES CO, V180, P538, DOI 10.1016/S0006-291X(05)81098-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WALSETH TF, 1991, METHOD ENZYMOL, V195, P29; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	32	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					791	793						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904602				2022-12-27	WOS:A1994MR22000002
J	ERIJMAN, L; PALADINI, AA; LORIMER, GH; WEBER, G				ERIJMAN, L; PALADINI, AA; LORIMER, GH; WEBER, G			PLURALITY OF PROTEIN CONFORMATIONS OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE MONOMERS PROBED BY HIGH-PRESSURE ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; GEL-ELECTROPHORESIS; HYDROSTATIC-PRESSURE; STATE	We used hydrostatic pressure in the range of 1 to 2 kbar, coupled with polyacrylamide gel electrophoresis, to investigate the properties of monomers of dimeric ribulose bisphosphate carboxylase/oxygenase. At temperatures below -5-degrees-C or pressures above 1.5 kbar, only a diffuse band with low electrophoretic mobility was observed, which is assigned to a denatured monomer. In gels run at 1.0 kbar and temperatures above 0-degrees-C, both the wild type and a mutant in which a positively charged Lys at the dimer interface is replaced by a negatively charged glutamic acid displayed several discrete bands with retardation coefficients larger than that of the dimer. Cross-linking due to oxidation of cysteines was not the reason for the multiplicity of bands, which in addition were independent on the length of the electrophoretic run in the range of 1-3 h. Binding of 1,1'-bis(4-anilino) naphthalene-5,5'-disulfonic acid to the pressure dissociated monomers stabilized the unfolded conformations. We propose that the dissociated monomers adopt various expanded conformations, which, under the experimental conditions, are stabilized to the extent necessary to be considered as distinct chemical species. Gel filtration high performance liquid chromatography analysis of bands eluted from nonstained gels run at 1 kbar (15-degrees-C) and 1.5 kbar (-5-degrees-C), respectively, was performed. In both cases the dimeric structure was fully recovered, along with the spectroscopic properties and catalytic activity characteristic of the native dimer, indicating that the unresolved unfolded conformers that appear at -5-degrees-C, as well as the set of discrete conformers obtained at 15-degrees-C, are able to reconstitute a single active conformation on reassociation.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; DUPONT CO INC,EXPTL STN,CENT RES & DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880; CONSEJO NACL INVEST CIENT & TECN,INGEBI,RA-1428 BUENOS AIRES,ARGENTINA	University of Illinois System; University of Illinois Urbana-Champaign; DuPont; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)			Erijman, Leonardo/AAI-1359-2020	Erijman, Leonardo/0000-0001-7525-2112	NIGMS NIH HHS [GM-11223] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; ERIJMAN L, 1991, BIOCHEMISTRY-US, V30, P1595, DOI 10.1021/bi00220a022; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRIKO YV, 1988, P NATL ACAD SCI USA, V85, P3343, DOI 10.1073/pnas.85.10.3343; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; Jaenicke R, 1986, Methods Enzymol, V131, P218; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LILLEY RM, 1974, BIOCHIM BIOPHYS ACTA, V358, P226, DOI 10.1016/0005-2744(74)90274-5; MULLER K, 1981, BIOPHYS CHEM, V14, P101, DOI 10.1016/0301-4622(81)85011-9; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; PALADINI AA, 1987, ANAL BIOCHEM, V161, P358, DOI 10.1016/0003-2697(87)90463-5; PIERCE J, 1986, APPL ENVIRON MICROB, V49, P1094; PRIVALOV P, 1990, CRC CRIT REV BIOCH M, V25, P287; RODBARD D, 1970, P NATL ACAD SCI USA, V65, P970, DOI 10.1073/pnas.65.4.970; RODBARD D, 1971, ANAL BIOCHEM, V40, P95, DOI 10.1016/0003-2697(71)90086-8; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WEBER G, 1991, NEW TRENDS BIOL CHEM, P225	25	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25914	25919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902356				2022-12-27	WOS:A1993MK10000090
J	SOGAARD, M; KADZIOLA, A; HASER, R; SVENSSON, B				SOGAARD, M; KADZIOLA, A; HASER, R; SVENSSON, B			SITE-DIRECTED MUTAGENESIS OF HISTIDINE-93, ASPARTIC ACID-180, GLUTAMIC ACID-205, HISTIDINE-290, AND ASPARTIC ACID-291 AT THE ACTIVE-SITE AND TRYPTOPHAN-279 AT THE RAW STARCH BINDING-SITE IN BARLEY ALPHA-AMYLASE 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIGER; TAKA-AMYLASE; BACILLUS-STEAROTHERMOPHILUS; RESIDUES; SEQUENCE; MALT; ALPHA-AMYLASE-1; GLUCOAMYLASE-G2; IDENTIFICATION; RESOLUTION	The pseudotetrasaccharide acarbose has high affinity for the active site (K(i,app) = 1 muM) and low affinity for a secondary site (K(d) = 2.3 mM) in barley alpha-amylase 1, distinguished by inhibition kinetics and spectral perturbation. Mutants of putative catalytic residues, D180N, E205Q, and D291N, are inactive and display low affinity for acarbose-Sepharose. H93N and H290N mutants, at invariant residues, have k(cat)/K(m) for p-nitrophenylmaltoheptaoside of 0.3 and 1.2% of wild-type. A corresponding 370- and 85-fold increased K(i,app) for acarbose and a lack of shifts in pH activity profiles indicate that these histidines participate in transition state stabilization but not directly in catalysis. This finding agrees with H bonding to OH groups of the valienamine ring of acarbose in the three-dimensional structure. Loss of inhibition above pH 6 supports that acarbose is most potent in protonated form. The low affinity site contains Trp278 and Trp279, known to bind cyclomaltoheptaose. While the W279A mutant has 10-fold decreased affinity for starch granules, production of Trp278 mutants failed. The invariant Trp278 is perhaps critical for stability or folding in cereal alpha-amylases.	CARLSBERG LAB,DEPT CHEM,GAMLE CARLSBERG VEJ 10,DK-2500 VALBY,DENMARK; FAC MED MARSEILLE,CRISTALLOG & CRISTALLISAT MACROMOLEC BIOL LAB,CNRS,F-13326 MARSEILLE 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite				Svensson, Birte/0000-0002-2993-8196				AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; [Anonymous], 1960, ENZYMES; BAULCOMBE DC, 1987, MOL GEN GENET, V209, P33, DOI 10.1007/BF00329833; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BRAUN PJ, 1985, ARCH BIOCHEM BIOPHYS, V242, P231, DOI 10.1016/0003-9861(85)90497-7; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CHAN YC, 1984, BIOCHEMISTRY-US, V23, P5795, DOI 10.1021/bi00319a019; CHIBA S, 1990, 15TH INT CARB S YOK; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P559, DOI 10.1007/BF02908684; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P111, DOI 10.1007/BF02913970; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; GIBSON RM, 1987, CARLSBERG RES COMMUN, V52, P373, DOI 10.1007/BF02907525; GIBSON RM, 1986, CARLSBERG RES COMMUN, V51, P295, DOI 10.1007/BF02907163; HANOZET G, 1981, J BIOL CHEM, V256, P3703; HUANG N, 1990, NUCLEIC ACIDS RES, V18, P7007, DOI 10.1093/nar/18.23.7007; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V183, P286, DOI 10.1016/0006-291X(92)91641-3; ISODA Y, 1992, J BIOCHEM-TOKYO, V111, P204, DOI 10.1093/oxfordjournals.jbchem.a123738; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MACGREGOR AW, 1979, CEREAL CHEM, V56, P430; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MacGregor E. A., 1985, In 'New approaches to research on cereal carbohydrates' [see FSTA (1986) 18 9M38]., P149; MACGREGOR EA, 1985, CARBOHYD RES, V142, P223, DOI 10.1016/0008-6215(85)85025-4; MACGREGOR EA, 1988, J PROTEIN CHEM, V7, P399, DOI 10.1007/BF01024888; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; MISAKI A, 1982, CARBOHYD RES, V109, P207, DOI 10.1016/0008-6215(82)84039-1; MOOSER G, 1991, J BIOL CHEM, V266, P8916; NAGASHIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P207, DOI 10.1271/bbb.56.207; NAKAJIMA R, 1986, APPL MICROBIOL BIOT, V23, P355; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; RAUSCHER E, 1982, FRESEN Z ANAL CHEM, V311, P454, DOI 10.1007/BF00481820; ROGERS JC, 1983, J BIOL CHEM, V258, P8169; Sambrook J, 1989, MOL CLONING LABORATO; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; SOGAARD M, 1991, P NATL ACAD SCI USA, V88, P8140, DOI 10.1073/pnas.88.18.8140; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TAKASE K, 1992, BIOCHIM BIOPHYS ACTA, V1120, P281, DOI 10.1016/0167-4838(92)90249-D; TAKEDA Y, 1983, BIOCHIM BIOPHYS ACTA, V749, P302, DOI 10.1016/0167-4838(83)90240-6; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; TRUSCHEIT E, 1981, ANGEW CHEM, V93, P738; VERNON CA, 1967, PROC R SOC SER B-BIO, V167, P389, DOI 10.1098/rspb.1967.0036; VIHINEN M, 1990, J BIOCHEM-TOKYO, V107, P267, DOI 10.1093/oxfordjournals.jbchem.a123037; Vihinen M, 1991, MOL ENG, V1, P267; WESELAKE RJ, 1983, CEREAL CHEM, V60, P98; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	51	138	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22480	22484						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901200				2022-12-27	WOS:A1993MD34800046
J	CORRETTEBENNETT, SE; LOVETT, ST				CORRETTEBENNETT, SE; LOVETT, ST			ENHANCEMENT OF RECA STRAND-TRANSFER ACTIVITY BY THE RECJ EXONUCLEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; BRANCH MIGRATION; PROTEIN; DNA; EXCHANGE; PURIFICATION; MECHANISM; POLARITY; BINDING; GENE	We have examined coupled reactions with the RecA protein of Escherichia coli, which can mediate DNA strand exchange in vitro between homologous DNA molecules, and the RecJ exonuclease, a 5' to 3' single-stranded DNA exonuclease. In RecA-mediated strand-transfer reactions between circular single-stranded and duplex linear DNA, we have found that RecJ stimulates the rate of heteroduplex product formation. Because RecJ must be present concurrent with strand transfer and RecJ does not detectably stimulate the synapsis stage of the reaction, we believe that RecJ stimulates specifically the branch migration phase of the RecA strand-transfer reaction. RecJ also dramatically enhances the efficiency with which RecA is able to traverse regions of non-homology in the substrates. We propose a model where RecJ degrades the displaced strand produced by strand exchange which competes for pairing with the transferred strand, thus driving forward the unidirectional branch migration mediated by RecA protein. This suggests a new role for exonucleases in genetic recombination, facilitating the strand-transfer reaction itself.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University; Brandeis University			Lovett, Susan/AAC-1810-2021	Lovett, Susan/0000-0003-2792-1857	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043889] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43889] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASE JW, 1974, J BIOL CHEM, V249, P4553; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LOVETT ST, 1991, J BACTERIOL, V173, P353, DOI 10.1128/jb.173.1.353-364.1991; LOVETT ST, 1988, GENETICS, V120, P37; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; PRASHER DC, 1983, J BIOL CHEM, V258, P6340; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; Sambrook J, 1989, MOL CLONING LABORATO; SHIBATA T, 1983, METHOD ENZYMOL, V100, P197; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	27	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6881	6885		10.1074/jbc.270.12.6881	http://dx.doi.org/10.1074/jbc.270.12.6881			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896836	hybrid			2022-12-27	WOS:A1995QQ85500067
J	JONES, KT; CARROLL, J; WHITTINGHAM, DG				JONES, KT; CARROLL, J; WHITTINGHAM, DG			IONOMYCIN, THAPSIGARGIN, RYANODINE, AND SPERM INDUCED CA2+ RELEASE INCREASE DURING MEIOTIC MATURATION OF MOUSE OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; ADRENAL CHROMAFFIN CELLS; FERTILIZED HAMSTER EGGS; PAROTID ACINAR-CELLS; INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; SENSITIVE STORES; RAT HEPATOCYTES; CHANNEL; OSCILLATIONS	Fertilization of mature mouse oocytes triggered highly repetitive Ca2+ oscillations lasting 2-3 h, However, immature oocytes generated only two or three oscillations, which ceased within 1 h. Development of repetitive Ca2+ transients to sperm occurred late in oocyte maturation and was dependent on cytoplasmic modifications that were independent of cell cycle progression from metaphase I to metaphase II, Immature oocytes released significantly less Ca2+ from stores than mature oocytes in response to ionomycin and thapsigargin Ryanodine had no effect on intracellular Ca2+ in maturing oocytes but stimulated an increase in Ca2+ in mature oocytes, The ability of ryanodine to increase Ca2+ levels was, however, strain-dependent. Preincubation of oocytes with thapsigargin or ryanodine significantly attenuated the normal fertilization Ca2+ response, causing a decrease in the number and the rate of rise of the transients, The inhibition of sperm-induced Ca2+ transients by ryanodine was independent of its ability to cause an immediate Ca2+ in crease. Low concentrations of ryanodine had no effect on resting Ca2+ levels but inhibited Ca2+ oscillations at fertilization. Similarly Ca2+ oscillations were blocked in oocytes from a strain of mouse that showed no immediate Ca2+ increase with ryanodine, These results suggest that modifications in Ca2+ stores and ryanodine-sensitive Ca2+ release mechanisms during oocyte maturation play an important role in Ca2+ oscillations at fertilization.			JONES, KT (corresponding author), ST GEORGE HOSP,SCH MED,MRC,EXPTL EMBRYOL & TERATOL UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Jones, Keith/AAA-3479-2021; Jones, Keith/C-9821-2013	Jones, Keith/0000-0002-0294-0851; Jones, Keith/0000-0002-0294-0851; Carroll, John/0000-0001-9644-5861				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARROLL J, 1992, J BIOL CHEM, V267, P11196; CARROLL J, 1994, DEVELOPMENT, V120, P3507; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; CUTHBERTSON KSR, 1981, NATURE, V294, P754, DOI 10.1038/294754a0; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DUCIBELLA T, 1990, BIOL REPROD, V43, P870, DOI 10.1095/biolreprod43.5.870; DUCIBELLA T, 1994, DEV BIOL, V165, P95, DOI 10.1006/dbio.1994.1237; DUCIBELLA T, 1993, BIOL REPROD, V48, P1251, DOI 10.1095/biolreprod48.6.1251; EDWARDS RG, 1965, NATURE, V208, P349, DOI 10.1038/208349a0; EPPIG JJ, 1994, DEV BIOL, V164, P1, DOI 10.1006/dbio.1994.1175; FOSKETT JK, 1992, AM J PHYSIOL, V262, pC656, DOI 10.1152/ajpcell.1992.262.3.C656; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FUJIWARA T, 1993, DEV BIOL, V156, P69, DOI 10.1006/dbio.1993.1059; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GLENISTER PH, 1967, GAMETE RES, V16, P205; HERRMANNFRANK A, 1993, FEBS LETT, V332, P237, DOI 10.1016/0014-5793(93)80640-G; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; IGUSA Y, 1986, J PHYSIOL-LONDON, V377, P193, DOI 10.1113/jphysiol.1986.sp016181; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; KLINE D, 1988, DEV BIOL, V126, P346, DOI 10.1016/0012-1606(88)90145-5; KLINE D, 1992, J BIOL CHEM, V267, P17624; KLINE JT, 1994, BIOL REPROD, V50, P193, DOI 10.1095/biolreprod50.1.193; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KUBIAK JZ, 1989, DEV BIOL, V136, P537, DOI 10.1016/0012-1606(89)90279-0; LYNN S, 1993, FEBS LETT, V330, P227, DOI 10.1016/0014-5793(93)80279-4; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; QUINN P, 1982, J REPROD FERTIL, V66, P161; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SWANN K, 1992, BIOCHEM J, V287, P79, DOI 10.1042/bj2870079; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; TAYLOR CT, 1993, HUM REPROD, V8, P2174, DOI 10.1093/oxfordjournals.humrep.a137999; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; USUI N, 1976, J ULTRA MOL STRUCT R, V57, P276, DOI 10.1016/S0022-5320(76)80117-7; Wassarman P.M., 1988, P69; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	51	164	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6671	6677		10.1074/jbc.270.12.6671	http://dx.doi.org/10.1074/jbc.270.12.6671			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896808	hybrid			2022-12-27	WOS:A1995QQ85500039
J	MANI, RS; KAY, CM				MANI, RS; KAY, CM			EFFECT OF CALTROPIN ON CALDESMON-ACTIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT REGULATION; MUSCLE THIN-FILAMENTS; SMOOTH-MUSCLE; ATPASE ACTIVITY; MYOSIN SUBFRAGMENTS; HEAVY-MEROMYOSIN; BINDING PROTEIN; ACTOMYOSIN; TROPOMYOSIN; PURIFICATION	The binding of chicken gizzard caldesmon to actin was studied both in the presence and the absence of caltropin using Airfuge centrifugation experiments, disulfide cross-linking studies, and the fluorescent probe acrylodan (6-acryloyl-2-(dimethylamino)napththalene). In co-sedimentation studies most of the caldesmon pelleted along with actin. However, when caldesmon in the presence of caltropin was mixed with actin, caldesmon did not pellet along with actin following high speed centrifugation, suggesting that caltropin has significantly weakened its binding to actin. The caltropin effect was noticed even when tropomyosin was included in the reaction mixture. Acrylodan-labeled caldesmon, when excited at 375 nm, had an emission maximum at 515 +/- 2 nm. The addition of actin produced a nearly 70% increase in fluorescent intensity, accompanied by a blue shift in the emission maximum (i.e. lambda(em (max)) = 505 +/- 2 nm), suggesting that the probe now occupies a more nonpolar environment. Titration of labeled caldesmon with actin indicated a strong affinity (K-alpha = similar to 6 x 10(7) M(-1)). When actin was titrated with labeled caldesmon in the presence of caltropin in a 0.2 mM Ca2+ medium, its affinity for caldesmon was lowered (K-alpha = similar to 2 x 10(7) M(-1)). Caltropin, which is very effective in reversing caldesmon's inhibition of the actin-activated myosin ATPase (Mani, R. S., McCubbin, W. D., and Kay, C. M. (1992) Biochemistry 31, 11896-11901), is shown in the present study to have a pronounced effect on its binding to actin, suggesting a major role for caltropin in regulating caldesmon in smooth muscle.	UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1993, PHARMACOL THERAPEUT, V55, P95; CROSBIE RH, 1994, BIOCHEMISTRY-US, V33, P3210, DOI 10.1021/bi00177a010; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HILL TL, 1981, BIOPHYS J, V35, P99, DOI 10.1016/S0006-3495(81)84777-7; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEHMAN W, 1987, BIOCHIM BIOPHYS ACTA, V914, P35, DOI 10.1016/0167-4838(87)90158-0; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; Lehrer S S, 1978, Methods Enzymol, V49, P222; MANI RS, 1993, BIOCHEMISTRY-US, V32, P11217, DOI 10.1021/bi00092a035; MANI RS, 1992, BIOCHEMISTRY-US, V31, P11896, DOI 10.1021/bi00162a031; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MOODY CJ, 1985, FEBS LETT, V191, P107, DOI 10.1016/0014-5793(85)81003-6; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PFITZER G, 1994, MECHANISM MYOFILAMEN, P195; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBIESZEK A, 1975, EUR J BIOCHEM, V55, P49, DOI 10.1111/j.1432-1033.1975.tb02137.x; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1989, J BIOL CHEM, V264, P9602; Walsh M P, 1989, Adv Exp Med Biol, V255, P337; ZHUANG S, 1994, BIOPHYS J, V66, P196	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6658	6663		10.1074/jbc.270.12.6658	http://dx.doi.org/10.1074/jbc.270.12.6658			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896806	hybrid			2022-12-27	WOS:A1995QQ85500037
J	BOOTMAN, MD; CHEEK, TR; MORETON, RB; BENNETT, DL; BERRIDGE, MJ				BOOTMAN, MD; CHEEK, TR; MORETON, RB; BENNETT, DL; BERRIDGE, MJ			SMOOTHLY GRADED CA2+ RELEASE FROM INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE CA2+ STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; ADRENAL CHROMAFFIN CELLS; CALCIUM RELEASE; HELA-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; PERMEABILIZED HEPATOCYTES; INTRACELLULAR STORES; NONEXCITABLE CELLS; POSSIBLE MECHANISM; CA-2+ RELEASE	Stimulation of cells with Ca2+-mobilizing hormones often leads to the generation of temporally and spatially complex changes in the intracellular Ca2+ ion concentration ([Ca2+](i)). To understand the mechanisms regulating Ca2+ release from intracellular stores more clearly, we investigated the ability of histamine to release Ca2+ stores under different experimental conditions, using video imaging of single Fura-2-loaded HeLa cells. In Ca2+-free medium, stepwise increases in histamine concentration released an increasing proportion of the intracellular Ca2+ pool. This pattern of Ca2+-release is analogous to the ''quantal'' release of Ca2+ previously observed using permeabilized cells. Quantal Ca2+ release was observed at both 20 and 37 degrees C and was not due to inactivation or desensitization of the Ca2+ release mechanism, since application of histamine in a pulsatile manner, which avoided desensitization of the Ca2+-release mechanism, still produced a quantal response. In Ca2+-containing medium at both 20 and 37 degrees C, stepwise increases in histamine concentration evoked [Ca2+](i) responses where the amplitude was smoothly graded in direct proportion to the histamine concentration. Similar smoothly graded responses were observed from HeLa cells in Ca2+-free medium. These data indicate that hormone-evoked Ca2+ release from intracellular stores is limited by the hormone concentration, and that the mechanisms underlying complex [Ca2+](i) signals do not lead to an all-or-none release of Ca2+ from the entire intracellular Ca2+ pool. We suggest that the hormone-sensitive intracellular Ca2+ pool is composed of functionally discrete units that are recruited by agonists in a concentration-dependent manner.			BOOTMAN, MD (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, BABRAHAM INST, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BIZZARRI C, 1994, EUR J BIOCHEM, V219, P837, DOI 10.1111/j.1432-1033.1994.tb18565.x; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; BOOTMAN MD, 1994, MOL CELL ENDOCRINOL, V98, P157, DOI 10.1016/0303-7207(94)90134-1; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GIOVANNARDI S, 1992, EXP CELL RES, V202, P398, DOI 10.1016/0014-4827(92)90092-M; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KALTHOF B, 1993, J PHYSIOL-LONDON, V466, P245; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; MACGLASHAN D, 1989, J CELL BIOL, V109, P123, DOI 10.1083/jcb.109.1.123; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1994, MOL CELL ENDOCRINOL, V98, P147, DOI 10.1016/0303-7207(94)90133-3; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; OLDERSHAW KA, 1992, J BIOL CHEM, V267, P16312; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SAUVE R, 1987, J MEMBRANE BIOL, V96, P199, DOI 10.1007/BF01869302; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SITSAPESAN R, 1994, J MEMBRANE BIOL, V137, P215; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	58	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24783	24791						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929156				2022-12-27	WOS:A1994PQ49000043
J	FITZPATRICK, VD; VANDLEN, RL				FITZPATRICK, VD; VANDLEN, RL			AGONIST SELECTIVITY DETERMINANTS IN SOMATOSTATIN RECEPTOR SUBTYPE-I AND SUBTYPE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; PROTEIN-COUPLED RECEPTORS; DELTA-OPIOID RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AMINO TERMINUS; BRAIN; BINDING; IDENTIFICATION; SPECIFICITY	The biological activities of the peptide hormone somatostatin are mediated through a recently identified family of G-protein-linked receptors. A number of somatostatin analogs have been characterized with selective affinities for particular somatostatin receptor subtypes. Using one such molecule (MK-678), we have delineated receptor regions that determine analog selectivity in the murine Type 1 and Type 2 somatostatin receptors. We find that the regions about the second and third extracellular loops of these two receptors contain the determinants for MK-678 selectivity and affinity	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BREDER CD, 1992, J NEUROSCI, V12, P3920; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHAPMAN V, 1992, NEUROPEPTIDES, V23, P147, DOI 10.1016/0143-4179(92)90115-D; CHEN Y, 1993, MOL PHARMACOL, V44, P8; DENOBLE VJ, 1989, BRAIN RES, V482, P42, DOI 10.1016/0006-8993(89)90540-4; ENGLAND BP, 1991, FEBS LETT, V279, P87, DOI 10.1016/0014-5793(91)80257-4; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FITZGERALD LW, 1989, BRAIN RES, V505, P246, DOI 10.1016/0006-8993(89)91450-9; FONG TM, 1992, J BIOL CHEM, V267, P25664; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GETHER U, 1993, J BIOL CHEM, V268, P7893; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HULME EC, 1993, CELL SIGNAL, V5, P687, DOI 10.1016/0898-6568(93)90030-P; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KAUPMANN K, 1993, FEBS LETT, V331, P53, DOI 10.1016/0014-5793(93)80296-7; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MANNI A, 1992, BIOTHERAPY, V4, P31, DOI 10.1007/BF02171707; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAYNOR K, 1993, J PHARMACOL EXP THER, V265, P67; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; ROSSOWSKI WJ, 1993, BIOCHEM BIOPH RES CO, V197, P366, DOI 10.1006/bbrc.1993.2488; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; VEBER DF, 1984, LIFE SCI, V34, P1371, DOI 10.1016/0024-3205(84)90009-2; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; YASUDA K, 1992, J BIOL CHEM, V267, P20422	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24621	24626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929134				2022-12-27	WOS:A1994PQ49000020
J	KACA, W; ROTH, RI; LEVIN, J				KACA, W; ROTH, RI; LEVIN, J			HEMOGLOBIN, A NEWLY RECOGNIZED LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN THAT ENHANCES LPS BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMA-FREE HEMOGLOBIN; LIPID-A; BIS(3,5-DIBROMOSALICYL) FUMARATE; BACTERIAL LIPOPOLYSACCHARIDES; ALPHA-CHAINS; POLYMYXIN-B; TOXICITY; BINDING; SUBSTITUTE; COMPLEMENT	Cell-free hemoglobin (Hb) is a purified preparation of human hemoglobin that is being developed as a resuscitation fluid. In vivo administration of hemoglobin has resulted in significant toxicity, due in part to contamination with bacterial endotoxin (lipopolysaccharide (LPS)). To better understand this toxicity, we have studied the interaction between Hb and LPS. Mixtures of each of three different Hb preparations (cross-linked alpha alpha Hb, cross-linked carbon monoxy-alpha alpha HbCO, and noncross-linked (native) HbA(o)) and LPS (Escherichia coli O26:B6 or Proteus mirabilis S1959) were examined by several independent methods for evidence of Hb.LPS complex formation, Binding assays in microtiter plates demonstrated saturable binding of LPS to immobilized Hb, with a k(D) of 3.1 x 10(-8) M. finding of LPS to Hb also was demonstrated with a radiolabeled LPS photoaffinity probe. Ultrafiltration of Hb/LPS mixtures by 300- and 100-kDa cut-off membranes showed that the majority of LPS in these mixtures (87-97 and 64-72%, respectively) was detected in the filtrates, in contrast to the lack of filterability of LPS in the absence of Rb. Density centrifugation demonstrated that LPS co-migrated with each of the three Hbs, whereas unbound LPS had a distinctly greater sedimentation velocity than Hb or Hb.LPS complexes. Nondenaturing polyacrylamide gel electrophoresis demonstrated that in the presence of Bb, LPS migrated into the gel and co-electrophoresed with Hb, whereas LPS alone did not appreciably enter the gel. Finally, precipitation by ethanol of each of the three Hb preparations was increased in the presence of LPS compared with precipitation in the absence of LPS. Interaction of LPS with each of the three Hb preparations was also associated with altered biological activity of LPS, as shown by enhancement of LPS activation of Limulus amebocyte lysate. Therefore, our data provide several lines of independent evidence for Hb.LPS complex formation and indicated that LPS exhibited altered physical characteristics and enhanced biological activity in the presence of Hb.	VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco				Kaca, Wieslaw/0000-0002-8734-7191	NIDDK NIH HHS [NIDDK DK 43102] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043102] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKHREM AA, 1989, BIOCHIM BIOPHYS ACTA, V992, P191, DOI 10.1016/0304-4165(89)90009-3; AMBERSON WR, 1949, J APPL PHYSIOL, V1, P469, DOI 10.1152/jappl.1949.1.7.469; BRANDT JL, 1951, BLOOD, V6, P1152, DOI 10.1182/blood.V6.11.1152.1152; CHAPMAN KW, 1992, BIOMAT ARTIF CELL IM, V20, P415, DOI 10.3109/10731199209119661; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P145; DAVID SA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P269, DOI 10.1016/0005-2760(92)90006-H; DAWIDSON I, 1988, CRIT CARE MED, V16, P606, DOI 10.1097/00003246-198806000-00008; DEVENUTO F, 1982, SURG GYNECOL OBSTET, V155, P342; FEOLA M, 1988, CIRC SHOCK, V25, P275; FEOLA M, 1988, SURG GYNECOL OBSTET, V166, P211; FREUDENBERG MA, 1980, INFECT IMMUN, V28, P373; GALANOS C, 1971, EUR J BIOCHEM, V19, P143, DOI 10.1111/j.1432-1033.1971.tb01298.x; GALANOS C, 1972, EUR J BIOCHEM, V31, P230, DOI 10.1111/j.1432-1033.1972.tb02524.x; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HESS JR, 1991, J APPL PHYSIOL, V70, P1639, DOI 10.1152/jappl.1991.70.4.1639; HOMMA R, 1982, ENDOTOXINS THEIR DET, P310; KACA W, 1987, ARCH IMMUNOL THER EX, V35, P431; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LITWIN MS, 1963, ANN SURG, V157, P485, DOI 10.1097/00000658-196304000-00001; MARKS DH, 1989, MIL MED, V154, P180; MARRA MN, 1992, J IMMUNOL, V148, P532; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; Nowotny A., 1979, BASIC EXERCISES IMMU, P171; OHNO N, 1989, J BIOL CHEM, V264, P4434; RADZIEJEWSKALEB.J, 1989, EUR J BIOCHEM, V193, P573; REMILLARD JF, 1987, DETECTION BACTERIAL, P197; ROTH RI, 1994, METHOD ENZYMOL, V231, P75; ROTH RI, 1994, BLOOD, V83, P2860, DOI 10.1182/blood.V83.10.2860.2860; ROTH RI, 1993, INFECT IMMUN, V61, P1033, DOI 10.1128/IAI.61.3.1033-1039.1993; ROTH RI, 1993, TRANSFUSION, V33, P919, DOI 10.1046/j.1537-2995.1993.331194082383.x; SAVITSKY JP, 1978, CLIN PHARMACOL THER, V23, P73; SEHGAL LR, 1984, SURGERY, V95, P433; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; SMITH CD, 1990, BIOMATER ARTIF CELL, V18, P251, DOI 10.3109/10731199009117305; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; ULEVITCH RJ, 1978, J CLIN INVEST, V62, P1313, DOI 10.1172/JCI109252; VANDEGRIFF KD, 1989, J BIOL CHEM, V264, P17824; WAINWRIGHT NR, 1990, INT CONGR SER, V923, P315; WEBER G, 1992, INFECT IMMUN, V60, P1062; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WHITE CT, 1986, J LAB CLIN MED, V108, P121; WHITE CT, 1986, J LAB CLIN MED, V108, P132; WINSLOW R M, 1991, Biomaterials Artificial Cells and Immobilization Biotechnology, V19, P503; WINSLOW RM, 1989, RED CELL, P305; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068	49	121	126	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25078	25084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929195				2022-12-27	WOS:A1994PQ49000084
J	KIMURA, K; NOZAKI, N; SAIJO, M; KIKUCHI, A; UI, M; ENOMOTO, T				KIMURA, K; NOZAKI, N; SAIJO, M; KIKUCHI, A; UI, M; ENOMOTO, T			IDENTIFICATION OF THE NATURE OF MODIFICATION THAT CAUSES THE SHIFT OF DNA TOPOISOMERASE-II-BETA TO APPARENT HIGHER MOLECULAR-WEIGHT FORMS IN THE M-PHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CASEIN KINASE-II; MITOTIC CHROMOSOMES; PHORBOL ESTER; PHOSPHORYLATION; CONDENSATION; CELLS; LOCALIZATION; EXPRESSION; ISOFORMS; EXTRACTS	Human cell lines express two genetically distinct isoforms of DNA topoisomerase (topo II) II: topo II alpha (p170) and topo II beta (p180). We detected a higher molecular weight form with an apparent molecular mass of about 190 kDa in M phase-arrested HeLa cells (Kimura, K., Saijo, M., Ui, M., and Enomoto, T. (1994) J. Biol, Chem. 269, 1173-1176). In this study we confirmed, using anti-topo II alpha and topo II beta monoclonal antibodies, that this higher molecular weight form is topo II beta and consists of doublet bands around 190 kDa. We confirmed that the doublet bands constituted an M phase-specific phenomenon and were not an artifact of the procedure used to accumulate mitotic cells. Digesting the immunoprecipitated materials from mitotic cell extracts with alkaline phosphatase resulted in the disappearance of the doublet bands and the appearance of the 180-kDa band with the concomitant disappearance of P-32 label in the region of the doublet bands. Neither heat-inactivated alkaline phosphatase nor phosphodiesterase affected the doublet bands and the P-32 label. Topo II beta in interphase cells was also phosphorylated, but the shift in apparent molecular weight was very slight after alkaline phosphatase digestion. Analysis of the labeled phosphoamino acids present in topo II beta from M phase and logarithmically growing cells indicated that phosphorylation occurred mainly on serine and fairly on threonine residues in both topo II beta isoforms. These results indicated that topo II beta is phosphorylated at specific sites in M phase, resulting in the formation of the doublet bands.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	University of Tokyo			Saijo, Masayuki/L-2697-2019					ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KIMURA K, 1994, J BIOL CHEM, V269, P1173; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TSUTSUI K, 1993, J BIOL CHEM, V268, P19076; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	35	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24523	24526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929118				2022-12-27	WOS:A1994PQ49000002
J	PRUSS, D; REEVES, R; BUSHMAN, FD; WOLFFE, AP				PRUSS, D; REEVES, R; BUSHMAN, FD; WOLFFE, AP			THE INFLUENCE OF DNA AND NUCLEOSOME STRUCTURE ON INTEGRATION EVENTS DIRECTED BY HIV INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-HYPERSENSITIVE SITES; TRANSFER-RNA GENE; RETROVIRAL INTEGRATION; ESCHERICHIA-COLI; B-DNA; TRANSCRIPTION COMPLEXES; PREFERRED TARGETS; KINETOPLAST DNA; SEQUENCE; CHROMATIN	DNA copies of the human immunodeficiency virus (HIV) genome integrate nonrandomly into the chromosomal DNA of the host cell. In this report, we investigate the molecular basis of this selectivity using the virus-encoded HIV integrase to direct integration of a synthetic HIV long terminal repeat substrate into either DNA molecules of known structure or previously defined nucleosomal complexes. We find that the structure of the target greatly influences the site of integration, and, moreover, DNA curvature, flexibility, and rigidity in solution all influence the frequency of integration. Importantly, for DNA with all of these properties, the distortion of the double helix directed by association with the histone proteins promotes the integration reaction and alters the distribution of sites that are selected for integration. We suggest that both intrinsic DNA structure and the folding of DNA into chromosomal structures will exert a major influence on target site selection for integration of the viral genome.	SALK INST BIOL STUDIES,INFECT DIS LAB,LA JOLLA,CA 92014	Salk Institute	PRUSS, D (corresponding author), NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892, USA.							AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; BOSSI L, 1984, CELL, V39, P643, DOI 10.1016/0092-8674(84)90471-9; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P445; BUSHMAN FD, 1992, P NATL ACAD SCI USA, V89, P3458, DOI 10.1073/pnas.89.8.3458; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHUPRINA VP, 1985, FEBS LETT, V186, P98, DOI 10.1016/0014-5793(85)81347-8; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; HUIBREGTSE JM, 1987, MOL CELL BIOL, V7, P3212, DOI 10.1128/MCB.7.9.3212; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KUNKEL GR, 1981, NUCLEIC ACIDS RES, V9, P6869, DOI 10.1093/nar/9.24.6869; LAMOND AI, 1983, NATURE, V305, P248, DOI 10.1038/305248a0; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LOSA R, 1990, NUCLEIC ACIDS RES, V18, P3495, DOI 10.1093/nar/18.12.3495; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, P NATL ACAD SCI USA, V89, P9237, DOI 10.1073/pnas.89.19.9237; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; RAMSAY N, 1984, EMBO J, V3, P2605, DOI 10.1002/j.1460-2075.1984.tb02181.x; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDMEYER SB, 1990, ANNU REV GENET, V24, P1499; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5293; THOMAS GH, 1988, EMBO J, V7, P7291; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; TRAVERS AA, 1993, CURR BIOL, V3, P898, DOI 10.1016/0960-9822(93)90231-C; VALENZUELA P, 1977, NATURE, V267, P641, DOI 10.1038/267641a0; VARMUS HE, 1985, RNA TUMOR VIRUSES, V1; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603	65	150	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25031	25041						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929189				2022-12-27	WOS:A1994PQ49000077
J	GRAVEN, KK; TROXLER, RF; KORNFELD, H; PANCHENKO, MV; FARBER, HW				GRAVEN, KK; TROXLER, RF; KORNFELD, H; PANCHENKO, MV; FARBER, HW			REGULATION OF ENDOTHELIAL-CELL GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE EXPRESSION BY HYPOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; NITRIC-OXIDE; TRANSCRIPTIONAL ENHANCER; DNA GLYCOSYLASE; SKELETAL-MUSCLE; PROTEIN; BINDING; IDENTIFICATION; STRESS; INDUCTION	Exposure of endothelial cells (EC) to hypoxia results in the increased expression of a distinct set of proteins with molecular masses of 56, 47, 39, 36, and 34 kDa. Their induction appears to be unique to EC and the stress of decreased oxygen tension. To understand the mechanism(s) and significance of the up-regulation of these proteins we have identified the 36-kDa protein by limited amino-terminal amino acid sequencing. The 21-amino acid sequence from the bovine protein exhibited 90.5% identity with the human sequence of the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Northern blot analysis showed that the time course and extent of EC GAPDH mRNA up-regulation correlated with the increase in 36-kDa protein synthesis. Nuclear runoff analysis demonstrated that this increase in GAPDH expression is regulated, in part, at the transcriptional level; however, the increase in the rate of transcription did not account for the entire mRNA accumulation, suggesting that GAPDH, like other hypoxia-regulated proteins, is posttranscriptionally regulated. Subcellular fractionation of hypoxic EC showed up-regulation of the 36-kDa protein in the cytoplasmic fraction and, to a lesser extent, in the nuclear fraction. The up-regulation of GAPDH in EC may be related to their relative hypoxia tolerance. Alternatively, the upregulation of GAPDH in EC during hypoxia may be related to the potential nonglycolytic functions of this enzyme.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University	GRAVEN, KK (corresponding author), BOSTON UNIV,SCH MED,CTR PULM,80 E CONCORD ST,K-603,BOSTON,MA 02118, USA.		Kornfeld, Hardy/AAS-2903-2021	Farber, Harrison/0000-0002-0297-7902; Panchenko, Maria/0000-0001-6247-6598	NHLBI NIH HHS [HL-44846, HL-45537] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045537, R01HL044846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN RW, 1987, J BIOL CHEM, V262, P649; ANDERSON GR, 1989, J BIOL CHEM, V264, P14885; BECK I, 1991, J BIOL CHEM, V266, P15563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T, 1993, CURRENT PROTOCOLS MO; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN DB, 1993, J BIOL CHEM, V268, P26904; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P200; FARBER HW, 1991, CIRC RES, V68, P1446, DOI 10.1161/01.RES.68.5.1446; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GRAVEN KK, 1993, J CELL PHYSIOL, V157, P544, DOI 10.1002/jcp.1041570314; GREENBERG ME, 1993, CURRENT PROTOCOLS MO; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HODOR P, 1989, MICROCIRC ENDOTH LYM, V5, P485; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; LAUNAY JF, 1989, BIOCHIM BIOPHYS ACTA, V996, P103, DOI 10.1016/0167-4838(89)90101-5; LEE SL, 1987, CIRC RES, V60, P653, DOI 10.1161/01.RES.60.5.653; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MANSUR NR, 1993, NUCLEIC ACIDS RES, V21, P993, DOI 10.1093/nar/21.4.993; MCDONALD B, 1993, P NATL ACAD SCI USA, V90, P11122, DOI 10.1073/pnas.90.23.11122; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MERTENS S, 1990, AM J PHYSIOL, V258, pH689, DOI 10.1152/ajpheart.1990.258.3.H689; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; OGAWA S, 1991, P NATL ACAD SCI USA, V88, P9897, DOI 10.1073/pnas.88.21.9897; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PERUCHO M, 1977, EUR J BIOCHEM, V81, P557, DOI 10.1111/j.1432-1033.1977.tb11982.x; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; RYAZANOV AG, 1988, EUR J BIOCHEM, V171, P301, DOI 10.1111/j.1432-1033.1988.tb13790.x; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SULLIVAN DT, 1985, J BIOL CHEM, V260, P4345; TABOR S, 1993, CURRENT PROTOCOLS MO; TSAI IH, 1982, J BIOL CHEM, V257, P1438; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; WANG CS, 1980, ARCH BIOCHEM BIOPHYS, V205, P136, DOI 10.1016/0003-9861(80)90092-2; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZIMMERMAN LH, 1991, J CLIN INVEST, V87, P908, DOI 10.1172/JCI115097	53	134	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24446	24453						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929107				2022-12-27	WOS:A1994PQ34600092
J	HATAKEYAMA, H; MIYAMORI, I; FUJITA, T; TAKEDA, Y; TAKEDA, R; YAMAMOTO, H				HATAKEYAMA, H; MIYAMORI, I; FUJITA, T; TAKEDA, Y; TAKEDA, R; YAMAMOTO, H			VASCULAR ALDOSTERONE - BIOSYNTHESIS AND A LINK TO ANGIOTENSIN-II-INDUCED HYPERTROPHY OF VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; STEROID 11-BETA-HYDROXYLASE; MINERALOCORTICOID RECEPTOR; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; DNA; BINDING; CLONING; TISSUES	Mineralocorticoids have been suggested to act on blood vessels, leading to increased vasoreactivity and peripheral resistance. However, the site of their production has so far been believed to be only the adrenal cortex. Here, we show direct evidence that vascular cells per se are aldosteronogenic, possessing their own system that responds to the steroid. Using polymerase chain reaction after reverse transcription, the CYP11B2 mRNA encoding the key enzyme for the biosynthesis of aldosterone was detected in both endothelial cells and smooth muscle cells cultivated from human pulmonary artery. The aldosterone receptor (type 1 mineralocorticoid receptor) gene was also found to be expressed in smooth muscle cells and, to a lesser extent, in endothelial cells. CYP11B2 gene expression in smooth muscle cells was stimulated by angiotensin II, the effector peptide of the renin-angiotensin system. Furthermore, the angiotensin II-induced increase in [H-3]leucine incorporation in smooth muscle cells was significantly enhanced by aldosterone but inhibited by ZK 91587, a type 1 mineralocorticoid receptor antagonist. This may indicate that vascular aldosterone participates in the angiotensin II-induced hypertrophy of vascular smooth muscle cells. The present study therefore provides the starting point for a novel understanding of the molecular basis of vascular remodeling and hypertension.	KKR HOKURIKU HOSP,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 2,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT BIOCHEM,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University								ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BRILLA CG, 1992, J HYPERTENS, V10, pS75; BUNKENBURG B, 1992, HYPERTENSION, V20, P746, DOI 10.1161/01.HYP.20.6.746; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DZAU VJ, 1988, CIRCULATION, V77, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNDER JW, 1989, ENDOCRINOLOGY, V125, P2224, DOI 10.1210/endo-125-4-2224; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRILL HJ, 1985, J STEROID BIOCH S9, V23; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KAWAMOTO T, 1990, FEBS LETT, V269, P345, DOI 10.1016/0014-5793(90)81190-Y; KAWAMOTO T, 1992, P NATL ACAD SCI USA, V89, P1458, DOI 10.1073/pnas.89.4.1458; KORNEL L, 1982, CLIN EXP HYPERTENS A, V4, P1561, DOI 10.3109/10641968209061625; LOMBES M, 1992, CIRC RES, V71, P503, DOI 10.1161/01.RES.71.3.503; MCKENNA TJ, 1978, J STEROID BIOCHEM, V9, P967, DOI 10.1016/0022-4731(78)90059-6; MORNET E, 1989, J BIOL CHEM, V264, P20961; NAFTILAN AJ, 1991, J CLIN INVEST, V87, P1300, DOI 10.1172/JCI115133; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428; RAKUGI H, 1993, CIRCULATION, V87, P283, DOI 10.1161/01.CIR.87.1.283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT BA, 1987, J HYPERTENS, V5, P739, DOI 10.1097/00004872-198712000-00018; TAKEDA Y, 1993, STEROIDS, V58, P282, DOI 10.1016/0039-128X(93)90074-W; ULLIAN ME, 1992, HYPERTENSION, V20, P67, DOI 10.1161/01.HYP.20.1.67; ULLIAN ME, 1993, AM J PHYSIOL, V264, pC1525, DOI 10.1152/ajpcell.1993.264.6.C1525; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	29	285	292	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24316	24320						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929089				2022-12-27	WOS:A1994PQ34600072
J	RICHIERI, GV; OGATA, RT; KLEINFELD, AM				RICHIERI, GV; OGATA, RT; KLEINFELD, AM			EQUILIBRIUM-CONSTANTS FOR THE BINDING OF FATTY-ACIDS WITH FATTY-ACID-BINDING PROTEINS FROM ADIPOCYTE, INTESTINE, HEART, AND LIVER MEASURED WITH THE FLUORESCENT-PROBE ADIFAB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RAT-HEART; 3-DIMENSIONAL STRUCTURE; COMPLEMENTARY-DNA; CRYSTAL-STRUCTURE; BOUND PALMITATE; BOVINE LIVER; PURIFICATION; CLONING; REFINEMENT	Affinities of long chain fatty acids (FA) for fatty acid-binding proteins (FABPs) have been measured by monitoring the concentrations of the unbound or free fatty acids (FFA) in equilibrium with the FABPs using the fluorescent probe ADIFAB. This probe allows the measurement of the concentration of FFA in equilibrium with FABPs, without physical separation of any of the reactants. Equilibrium characteristics were measured at 37 degrees C for palmitate, stearate, oleate, linoleate, linolenate, and arachidonate binding to six FABPs from intestine, heart, adipose, and liver from different species. Equilibrium constants for each FA were found to be extremely sensitive to the tissue origin of the FABP but largely independent of species differences. The measured values of the dissociation constants (K-d) ranged from about 2 to 1000 nM, depending upon the tissue origin of the FABP and the FA. Binding constants for some FABPs varied considerably with different FA, as much as 80-fold in the case of the intestinal FABP. In contrast, K-d values for adipocyte FABPs exhibited less than 4-fold variation with FA type and are generally larger (lower affinities) than for the other FABPs. For all FABPs, K-d values for fatty acids with the same chain length were considerably lower for saturated as compared to polyunsaturated FA. This characteristic likely reflects the lower aqueous solubilities of the saturated fatty acids. In contrast to the other FABPs, rat liver FABP was found to have two FA-binding sites/ monomer. Each of these two sites had similar high affinities for the saturated FA,while for the unsaturated FA the two sites exhibited affinities that differ by more than 7-fold. This study disagrees with earlier investigations in finding that equilibrium binding of FA to FABPs is a sensitive function of FA type and FABP tissue origin and that FA-FABP dissociation constants are submicromolar. These results provide a framework with which to understand better the biological function of FABPs and the FA-FABP interaction.	MED BIOL INST,LA JOLLA,CA 92037						NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, J BIOL CHEM, V260, P1432; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BRECHER P, 1984, J BIOL CHEM, V259, P3395; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P852; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; CLAFFEY KP, 1987, BIOCHEMISTRY-US, V26, P7900, DOI 10.1021/bi00398a054; DUTTAROY AK, 1993, BIOCHIM BIOPHYS ACTA, V1169, P73, DOI 10.1016/0005-2760(93)90084-M; EADS J, 1993, J BIOL CHEM, V268, P26375; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FOURNIER NC, 1983, BIOCHEMISTRY-US, V22, P1863, DOI 10.1021/bi00277a019; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KEUPER HJK, 1985, CHEM PHYS LIPIDS, V38, P159, DOI 10.1016/0009-3084(85)90064-7; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; LOWE JB, 1985, J BIOL CHEM, V260, P3413; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; OFFNER GD, 1986, J BIOL CHEM, V261, P5584; PAULUSSEN RJA, 1988, ARCH BIOCHEM BIOPHYS, V264, P533, DOI 10.1016/0003-9861(88)90319-0; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SHA RS, 1993, J BIOL CHEM, V268, P7885; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P288; STORCH J, 1989, J BIOL CHEM, V264, P8706; Tanford C, 1973, HYDROPHOBIC EFFECT, P6; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; VEERKAMP JH, 1992, BIOCHEM SOC T, V20, P801, DOI 10.1042/bst0200801; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VORK MM, 1990, MOL CELL BIOCHEM, V98, P111, DOI 10.1007/BF00231374; WILKINSON TCI, 1987, BIOCHEM J, V247, P485, DOI 10.1042/bj2470485; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; YOUNG ACM, 1994, IN PRESS STRUCTURE; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	54	232	246	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23918	23930						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929039				2022-12-27	WOS:A1994PQ34600014
J	SHISHEVA, A; BUXTON, J; CZECH, MP				SHISHEVA, A; BUXTON, J; CZECH, MP			DIFFERENTIAL INTRACELLULAR LOCALIZATIONS OF GDP DISSOCIATION INHIBITOR ISOFORMS - INSULIN-DEPENDENT REDISTRIBUTION OF GDP DISSOCIATION INHIBITOR-2 IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RESPONSIVE GLUCOSE TRANSPORTER; GTP-BINDING PROTEIN; RAT ADIPOSE-CELLS; MOLECULAR-CLONING; PLASMA-MEMBRANE; SMG P25A; GLUT4; STIMULATION; TRANSLOCATION; KINETICS	Insulin action on fat cell/skeletal muscle glucose transporter (GLUT4) redistribution to cell surface membranes appears to involve small GTP-binding proteins. It has been recently recognized that at least two GDP dissociation inhibitor (GDI) isoforms, GDI-1 and GDI-2, can bind and release GDP-bound Rab proteins from membranes (Shisheva, A., Sudhof, T. C., and Czech, M. P. (1994) Mol. Cell. Biol. 14, 3459-3468). The present studies show that a strikingly higher level of GDI-2 fractionates with total membranes of COS-1 cells, Chinese hamster ovary cells, and 3T3-L1 adipocytes compared to GDI-1, which is virtually totally cytosolic. In 3T3-L1 adipocytes, most of the membrane-bound GDI-2 was present in a low density, intracellular membrane fraction. Immunodepletion of GLUT4-enriched vesicles from this membrane fraction also depleted significant amounts of GDI-2 proteins. Localization of both GDI-2 and GLUT4 in the same perinuclear regions of these cells was established by immunofluorescence microscopy, whereas GDI-1 displayed a diffuse, cytoplasmic distribution. Insulin acutely decreased both GLUT4 and GDI-2 protein levels in the low density microsomes by about 50%. Concomitantly, GLUT4 but not GDI-2 protein content of plasma membranes increased, suggesting release of GDI-2 into the cytoplasm in response to insulin. Taken together, these data suggest functional differences for the GDI-1 and GDI-2 protein isoforms, as well as a potential role of GDI-2 in the action of insulin on membrane movements.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	SHISHEVA, A (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BELL GI, 1993, J BIOL CHEM, V268, P19161; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; HARLOW E, 1988, ANTIBODIES LABORATOR, P311; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PESSINO A, 1991, J BIOL CHEM, V266, P20213; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHISHEVA A, 1993, ENDOCRINOLOGY, V133, P1562, DOI 10.1210/en.133.4.1562; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD F, 1994, TRENDS BIOCHEM SCI, V19, P164; YANG J, 1993, J BIOL CHEM, V268, P4600; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	36	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23865	23868						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929030				2022-12-27	WOS:A1994PQ34600004
J	SHUCK, ME; BOCK, JH; BENJAMIN, CW; TSAI, TD; LEE, KS; SLIGHTOM, JL; BIENKOWSKI, MJ				SHUCK, ME; BOCK, JH; BENJAMIN, CW; TSAI, TD; LEE, KS; SLIGHTOM, JL; BIENKOWSKI, MJ			CLONING SAD CHARACTERIZATION OF MULTIPLE FORMS OF THE HUMAN KIDNEY ROM-K POTASSIUM CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; FUNCTIONAL EXPRESSION; INWARD RECTIFICATION; SEQUENCE-ANALYSIS; MEMBRANE; INACTIVATION; DIVERSITY; PROTEIN; MOUSE; GENE	The rat kidney ROM-K1 potassium channel cDNA was used to clone the homolog from human kidney using a combination of cDNA cloning, reverse transcriptase-polymerase chain reaction (RT-PCR), and primer extension cloning methods. In addition to the human species homolog of ROM-K1, four additional transcripts that are formed by alternative splicing of a single human gene were also characterized (hROM-K2 to hROM-K5). All five transcripts share a common 3' exon that encodes the majority of the channel protein and in three of the isoforms translation is initiated at a start codon contained within this exon (hROM-K2, hROM-K4, and hROM-K5). The two other transcripts contain additional exons that potentially extend the open reading frame by either 19 amino acid residues (hROM-K1) or by 17 amino acid residues (hROM-K3). Comparison of the translation products from the three representative transcripts (hROM-K1, hROM-K2, and hROM-K3) confirmed that hROM-K1 gave the largest product (41.6 kDa) and was translated more efficiently than either hROM-K2 or hROM-K3. Also, despite the presence of several additional canonical acceptor sites for Asn-linked glycosylation relative to rat ROM-K1, all three channel polypeptides were glycosylated to a similar extent in the in vitro translation reactions when canine pancreatic microsomes were included. A survey of the tissue distribution of expression of the various forms in selected human tissues showed that the core-exon linked to all four possible 5' exons are detected almost exclusively in kidney. The core-exon was also detected in human kidney and lower amounts were detected in skeletal muscle > pancreas > spleen > brain = heart > liver RNAs by RT-PCR. Alternatively, Northern blot analysis of poly(A)(+) RNAs from these same tissues revealed a 2.8-kilobase transcript only in kidney. Heterologous expression of either the hROM-K1, hROM-K2, or hROM-K3 channel transcripts in Xenopus oocytes led to the expression of K+-selective, Ba2+-sensitive inwardly rectifying channels as measured by whole cell currents. At this level of analysis, the channel properties of the individual forms could not be distinguished.	UPJOHN LABS, DEPT CELL BIOL, KALAMAZOO, MI 49007 USA; UPJOHN LABS, DEPT BIOL MOLEC, KALAMAZOO, MI 49007 USA; UPJOHN LABS, DEPT CARDIOVASC DIS RES, KALAMAZOO, MI 49007 USA									BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHANDY KG, 1990, BIOPHYS J, V57, pA110; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GHANSHANI S, 1992, GENOMICS, V12, P190, DOI 10.1016/0888-7543(92)90365-Y; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HALL AE, 1963, J PHYSIOL-LONDON, V166, P225, DOI 10.1113/jphysiol.1963.sp007102; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KACZMAREK LK, 1991, NEW BIOL, V3, P315; KANDEL ER, 1966, J PHYSIOL-LONDON, V183, P287, DOI 10.1113/jphysiol.1966.sp007867; KOZAK M, 1994, J MOL BIOL, V235, P95, DOI 10.1016/S0022-2836(05)80019-1; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUNEAU C, 1991, FEBS LETT, V288, P163, DOI 10.1016/0014-5793(91)81026-5; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PERNEY T M, 1991, Current Opinion in Cell Biology, V3, P663, DOI 10.1016/0955-0674(91)90039-2; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; Pongs O., 1993, SEMIN NEUROSCI, V5, P93; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SAKAMANN B, 1984, J PHYSL, V347, P641; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SLIGHTOM JL, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P18; STANDEN NB, 1978, J PHYSIOL-LONDON, V280, P169, DOI 10.1113/jphysiol.1978.sp012379; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	39	103	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24261	24270						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929082				2022-12-27	WOS:A1994PQ34600064
J	SUGIMOTO, K; HAGISHITA, Y; HIMENO, M				SUGIMOTO, K; HAGISHITA, Y; HIMENO, M			FUNCTIONAL DOMAIN-STRUCTURE OF HUMAN CENTROMERE PROTEIN-B - IMPLICATION OF THE INTERNAL AND C-TERMINAL SELF-ASSOCIATION DOMAINS IN CENTROMERIC HETEROCHROMATIN CONDENSATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENP-B; DNA-BINDING; ANTICENTROMERE ANTIBODIES; SATELLITE DNA; CELL; IMMUNOPRECIPITATION; KINETOCHORE; SEQUENCE; RECEPTOR; ANTIGEN	Centromere protein B (CENP-B) is a common centromere DNA binding protein among mammalian centromeres, CENP-B possesses the specific DNA binding activity to the 17-base pair sequence dispersed in centromeric repetitive DNA sequences. In the previous study, we have shown that its DNA-binding domain exists within the N-terminal 134 amino acid residues. Here, to clarify the whole domain structure, another functional unit required for CENP-B self association was examined. Recombinant CENP-B was expressed in Escherichia coli. First, a chemical cross linking reagent, disuccinimidyl suberate, was used to fix the physical association without losing the DNA-binding activity. The complexes with the same molecular weight as homodimer and trimer were identified after a separation by SDS-polyacrylamide gel electrophoresis. With a series of CENP-B deletion constructs, the area responsible for this oligomer formation was located at the internal region. Second, an electrophoretic mobility shift assay was also used to survey the minimum regions required for the CENP-B self-association. Three separate elements were identified by assaying the capacity to form the additional slow-migrating complex, two in the internal region and one in the C terminus. These results suggest that CENP-B molecules interact with each other at the multiple sites to fold the centromeric DNA repeats into a heterochromatin structure.			SUGIMOTO, K (corresponding author), UNIV OSAKA PREFECTURE, DEPT APPL BIOCHEM, APPL MOLEC BIOL LAB, SAKAI, OSAKA 593, JAPAN.							CHEN JD, 1992, MOL CELL BIOL, V12, P598, DOI 10.1128/MCB.12.2.598; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; CORNELL R, 1989, J BIOL CHEM, V264, P9077; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; MURO Y, 1990, J RHEUMATOL, V17, P1042; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PILCH PF, 1980, J BIOL CHEM, V255, P1722; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; Sambrook J, 1989, MOL CLONING LABORATO; SUGIMOTO K, 1992, BIOSCI BIOTECH BIOCH, V56, P1174, DOI 10.1271/bbb.56.1174; SUGIMOTO K, 1992, CELL STRUCT FUNCT, V17, P129, DOI 10.1247/csf.17.129; SUGIMOTO K, 1992, J BIOCHEM, V111, P478, DOI 10.1093/oxfordjournals.jbchem.a123783; SUGIMOTO K, 1992, ANAL BIOCHEM, V207, P114, DOI 10.1016/0003-2697(92)90511-5; SULLIVAN KF, 1991, CHROMOSOMA, V100, P360, DOI 10.1007/BF00337514; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; WRIGHT BS, 1987, P NATL ACAD SCI USA, V84, P26, DOI 10.1073/pnas.84.1.26; YODA K, 1992, J CELL BIOL, V119, P1413, DOI 10.1083/jcb.119.6.1413	23	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24271	24276						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929083				2022-12-27	WOS:A1994PQ34600065
J	CAMP, LA; VERKRUYSE, LA; AFENDIS, SJ; SLAUGHTER, CA; HOFMANN, SL				CAMP, LA; VERKRUYSE, LA; AFENDIS, SJ; SLAUGHTER, CA; HOFMANN, SL			MOLECULAR-CLONING AND EXPRESSION OF PALMITOYL-PROTEIN THIOESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; SEQUENCE; IDENTIFICATION; RECEPTOR; ENZYME; DOMAIN; CELLS; CDNA; GENE; RAS	We have previously reported the purification of a palmitoyl-protein thioesterase (PPT) from bovine brain that removes palmitate from Ha-Ras (Camp, L. A., and Hofmann, S. L. (1993) J. Biol. Chem. 268, 22566-22574). In the current paper, we have isolated bovine and rat cDNA clones encoding PPT. The deduced amino acid sequence of PPT predicts a protein of 306 amino acids that contains amino acid motifs characteristic of thioesterases: ''Gly-X-Ser-X-Gly'' positioned near the NH, terminus and ''Gly-Asp-His'' positioned near the COOH terminus of the protein. The identity of the PPT cDNA was further confirmed by expression in simian COS cells and insect Sf9 cells. Comparison of the DNA and protein sequence data suggests that a hydrophobic NH2-terminal sequence of 27 amino acid residues is removed from the primary translation product. Furthermore, the recombinant protein and the native protein purified from bovine brain contain complex asparagine-linked oligosaccharides and a large proportion of the expressed PPT is secreted from COS and Sf9 cells. Thus, while the palmitoyl-protein thioesterase will deacylate intracellular palmitoylated proteins such as Ha-Ras and the alpha subunits of heterotrimeric G proteins, the physiologic substrates are likely to be externally oriented or secreted proteins.	UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA061823] Funding Source: NIH RePORTER; NCI NIH HHS [CA61823-01] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CHO HS, 1993, J BIOL CHEM, V268, P9238; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOEG JM, 1986, J BIOL CHEM, V261, P3911; HOFMANN SL, 1987, P NATL ACAD SCI USA, V84, P6312, DOI 10.1073/pnas.84.17.6312; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; HWANG CS, 1993, J BIOL CHEM, V268, P14278; Knudsen J, 1981, Methods Enzymol, V71 Pt C, P200, DOI 10.1016/0076-6879(81)71028-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; PATHAK RK, 1992, J MUSCLE RES CELL M, V13, P366, DOI 10.1007/BF01766464; PEARCE EJ, 1991, EMBO J, V10, P2741, DOI 10.1002/j.1460-2075.1991.tb07822.x; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RANDALL WR, 1994, J BIOL CHEM, V269, P12367; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; YANG CY, 1988, BIOCHEMISTRY-US, V27, P7773, DOI 10.1021/bi00420a028	30	203	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 16	1994	269	37					23212	23219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ164	7916016				2022-12-27	WOS:A1994PQ16400049
J	STOLE, E; SMITH, TK; MANNING, JM; MEISTER, A				STOLE, E; SMITH, TK; MANNING, JM; MEISTER, A			INTERACTION OF GAMMA-GLUTAMYL-TRANSPEPTIDASE WITH ACIVICIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE TRANSPEPTIDASE; ACID AT-125; AMINO-ACIDS; GLUTATHIONE; INHIBITION	Inactivation of gamma-glutamyl transpeptidase by acivicin (L(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazole acetic acid) is rapid, thought to be irreversible, and associated with binding of close to 1 mol of inhibitor/mol of enzyme. Previous studies with [3-C-14]acivicin indicated binding (prevented by substrate) to a specific hydroxyl group (threonine 523) of the rat kidney enzyme. In the present work, we found that such inactivation can be reversed by treating the inhibited enzyme with hydroxylamine. Reactivation (more than 85% complete) is associated with release from the inactivated enzyme of compounds that exhibit the properties of threo-beta-hydroxy-L-gamma-glutamyl hydroxamate and 3-hydroxypyrrolidone-2-carboxylate. We found that the enzyme acts very slowly on acivicin, at a rate that is about 10(-9) that of its normal catalytic rate with glutathione, to form threo-beta-hydroxy-L-glutamate and hydroxylamine. The findings indicate that inhibition by acivicin involves its transformation on the enzyme to an inhibitory species which is attached, apparently by ester linkage, to a specific hydroxyl group of the enzyme. The very slow rate of release of this intermediate appears to account for the observed inhibition.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University	STOLE, E (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021, USA.				NIDDK NIH HHS [2 R37 DK12034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN L, 1980, RES COMMUN CHEM PATH, V27, P175; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; GARDELL SJ, 1979, J BIOL CHEM, V254, P4942; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P1934; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P2419; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P927; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; GRIFFITH OW, 1980, P NATL ACAD SCI-BIOL, V77, P3384, DOI 10.1073/pnas.77.6.3384; HAMILTON PB, 1945, J BIOL CHEM, V158, P375; IKEDA Y, 1994, FASEB J, V8, P571; LAPERCHE Y, 1989, P NATL ACAD SCI USA, V86, P3159; LEANZA WJ, 1953, J BIOL CHEM, V201, P377; LEVINTOW L, 1955, J AM CHEM SOC, V77, P5304, DOI 10.1021/ja01625a031; MANNING JM, 1969, BIOCHEMISTRY-US, V8, P2681, DOI 10.1021/bi00834a066; MCCARTY CG, 1970, CHEM CARBON NITROGEN, P403; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A, 1976, ENZYMES BIOL MEMBR, Vv3, P315; Meister A, 1989, GLUTATHIONE CHEM BIO, P367; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ORLOWSKI M, 1965, J BIOL CHEM, V240, P338; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STOLE E, 1990, P NATL ACAD SCI USA, V87, P1706, DOI 10.1073/pnas.87.5.1706; Tate S.S., 1980, ENZYMATIC BASIS DETO, VII, P95; TATE SS, 1974, J BIOL CHEM, V249, P7593; TATE SS, 1974, P NATL ACAD SCI USA, V71, P3329, DOI 10.1073/pnas.71.9.3329; TATE SS, 1985, METHOD ENZYMOL, V113, P400; TSO JY, 1980, J BIOL CHEM, V255, P6734; Wilson H, 1937, J BIOL CHEM, V119, P309	30	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 26	1994	269	34					21435	21439						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PK973	7914892				2022-12-27	WOS:A1994PK97300010
J	KANAI, Y; STELZNER, M; NUSSBERGER, S; KHAWAJA, S; HEBERT, SC; SMITH, CP; HEDIGER, MA				KANAI, Y; STELZNER, M; NUSSBERGER, S; KHAWAJA, S; HEBERT, SC; SMITH, CP; HEDIGER, MA			THE NEURONAL AND EPITHELIAL HUMAN HIGH-AFFINITY GLUTAMATE TRANSPORTER - INSIGHTS INTO STRUCTURE AND MECHANISM OF TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; LONG-TERM POTENTIATION; PROTEIN-KINASE-C; DICARBOXYLIC AMINOACIDURIA; RAT-BRAIN; GLUCOSE COTRANSPORTER; EXPRESSION CLONING; MEMBRANE-VESICLES; GABA TRANSPORTER; INBORN ERROR	High affinity transport of glutamate across plasma membranes of brain neurons and epithelia is mediated by a Na+- and K+-coupled electrogenic transporter. Here we report the primary structure and functional characterization of the human high affinity glutamate transporter (HEAAC1). A unique characteristic of HEAAC1-mediated transport is that the affinity for glutamate and the maximal transport rate are strongly dependent on membrane potential. Our data provide new insights into individual steps of high affinity glutamate transport and show that the transport mechanism is distinct from that of the gamma-aminobutyric acid transporter GAT-1 and the Na+/glucose transporter SGLT1. Under voltage clamp condition, HEAAC1 mediated large substrate-evoked inward currents (up to 1 mu A). The substrate specificity, stereospecificity, the K-m value (30 +/- 3 mu M at -60 mV) of the L-glutamate-evoked current, and Northern analysis all agree with previously reported characteristics of high affinity glutamate transport in brain. In contrast to SGLT1 and GAT-1, voltage jump studies of HEAAC1 yielded only minor relaxation currents. Classic inhibitors of brain glutamate uptake such as DL-threo-beta-hydroxyaspartate, L-trans-pyrrolidine 2,4,-dicarboxylic acid (PDC), and dihydrokainate were found to be either transport substrates or to have no significant effect on glutamate transport. We also found that the maximal transport rate for PDC was markedly reduced compared to that for L-glutamate. We propose that PDC most likely reduces the turnover rate of the transporter. A search of the sequence data bases revealed weak homology of HEAAC1 to the H+- coupled vesicular monoamine transporter, suggesting an evolutionary link between plasma membrane and vesicular transporters.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X; Nussberger, Stephan/0000-0003-3619-4452	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BALLATORI N, 1986, J BIOL CHEM, V261, P6216; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P259; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FUKUHARA Y, 1985, AM J PHYSIOL, V248, pF869, DOI 10.1152/ajprenal.1985.248.6.F869; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARIG JM, 1987, BIOCHIM BIOPHYS ACTA, V903, P358, DOI 10.1016/0005-2736(87)90226-4; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HEINZ E, 1988, BIOCHIM BIOPHYS ACTA, V937, P300, DOI 10.1016/0005-2736(88)90252-0; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; LEE WS, 1994, IN PRESS J BIOL CHEM, V269; LERNER J, 1987, COMP BIOCHEM PHYS B, V87, P443, DOI 10.1016/0305-0491(87)90035-6; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MELANCON SB, 1977, J PEDIATR-US, V91, P422, DOI 10.1016/S0022-3476(77)81312-7; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; REITHMEIER R, 1993, MOL BIOL FUNCTIONS C, V46, P161; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SMITH CP, 1994, GENOMICS, V20, P335, DOI 10.1006/geno.1994.1183; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SWARNA M, 1989, HUM GENET, V82, P299, DOI 10.1007/BF00291178; TEIJEMA HL, 1974, METABOLISM, V23, P115, DOI 10.1016/0026-0495(74)90108-5; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459	44	116	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20599	20606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914198				2022-12-27	WOS:A1994PB31700061
J	BROUILLET, A; DARBOUY, M; OKAMOTO, T; CHOBERT, MN; LAHUNA, O; GARLATTI, M; GOODSPEED, D; LAPERCHE, Y				BROUILLET, A; DARBOUY, M; OKAMOTO, T; CHOBERT, MN; LAHUNA, O; GARLATTI, M; GOODSPEED, D; LAPERCHE, Y			FUNCTIONAL-CHARACTERIZATION OF THE RAT BETA-GLUTAMYL TRANSPEPTIDASE PROMOTER THAT IS EXPRESSED AND REGULATED IN THE LIVER AND HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE COPY GENE; TRANSFERASE TRANSPEPTIDASE; BINDING PROTEIN; GLUTATHIONE METABOLISM; HETEROLOGOUS SUBUNITS; MESSENGER-RNAS; 5' ENDS; TRANSCRIPTION; DNA; SEQUENCE	gamma-Gylutamyl transpeptidase (GGT) is an enzyme encoded by multiple mRNAs (mRNA(I) to mRNA(IV)) that, in the rat, are transcribed from a single copy gene in a tissue specific manner. In the liver, GGT expression is up-regulated in transformed cells, and this induction is the most widely used marker of liver cell transformation. We characterized the GGT mRNA species expressed in the liver (mRNA(III)), and we report that this mRNA differs from the other GGT mRNA species by a 275-base alternate 5'-end sequence. Its transcription occurs on a specific promoter (promoter III) that maps on the GGT gene upstream of the two promoters coding for the GGT mRNA(I) and mRNA(II). In hepatoma cells, mRNA(III) expression is related to the differentiation state of the cells. We have shown that, in Reuber H-35-derived cell lines, the GGT mRNA(III) is transcribed in cells that express a differentiated phenotype (Fao), but not in the dedifferentiated C2 and H5 variants. Moreover, we observed a reexpression of the GGT mRNA(III) species in the C2 Rev7 variant, which has reverted from C2 toward a differentiated hepatocyte phenotype. In the proximal promoter III region, we identified a sequence that strongly enhances transcriptional activity in Fao and C2 Rev7 cells, but not in the dedifferentiated C2 variant. This motif interacts with nuclear proteins belonging to the NF-1 and NF-Y families that govern GGT promoter III expression in differentiated hepatoma cells.	HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Brouillet, Arthur/S-4499-2018; lahuna, olivier/O-7840-2017	lahuna, olivier/0000-0002-6286-3923				CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DARBOUY M, 1991, AM J PHYSIOL, V261, pC1130, DOI 10.1152/ajpcell.1991.261.6.C1130; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; ELMORE LW, 1991, CANCER RES, V51, P5752; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FINIDORI J, 1984, J BIOL CHEM, V259, P4687; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GERMAIN L, 1988, CANCER RES, V48, P4909; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; HANIGAN M, 1983, CARCINOGENESIS, V6, P165; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KURAUCHI O, 1991, BIOCHEMISTRY-US, V30, P1618, DOI 10.1021/bi00220a025; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LI XY, 1992, J BIOL CHEM, V267, P8984; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEISTER A, 1984, HEPATOLOGY, V4, P739, DOI 10.1002/hep.1840040431; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MITCHEL PJ, 1991, CELL, V50, P847; MULLER WH, 1985, BIOL CHEM H-S, V366, P375, DOI 10.1515/bchm3.1985.366.1.375; NASH B, 1982, J BIOL CHEM, V257, P585; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PALLARDO FV, 1991, BIOCHEM J, V274, P891, DOI 10.1042/bj2740891; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; RAJAGOPALAN S, 1990, J BIOL CHEM, V265, P11721; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; REUBER MD, 1961, J NATL CANCER I, V26, P891; SELL S, 1990, CANCER RES, V50, P3811; SIEGRIST S, 1990, BIOCHEM J, V267, P621, DOI 10.1042/bj2670621; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TEMPLETON NS, 1991, CANCER RES, V51, P6190; THOMPSON EB, 1966, P NATL ACAD SCI USA, V56, P296, DOI 10.1073/pnas.56.1.296; TSUJI A, 1990, CLIN CHIM ACTA, V104, P361; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x	42	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14878	14884						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910821				2022-12-27	WOS:A1994NP73800008
J	SHIMIZU, T; MURAKAMI, Y; HATANO, M				SHIMIZU, T; MURAKAMI, Y; HATANO, M			GLU(318) AND THR(319) MUTATIONS OF CYTOCHROME-P450 1A2 REMARKABLY ENHANCE HOMOLYTIC O-O CLEAVAGE OF ALKYL HYDROPEROXIDES - AN OPTICAL-ABSORPTION SPECTRAL STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; PUTATIVE DISTAL SITE; SUBSTRATE HYDROXYLATION; PROTEIN ADDUCTS; LIGAND TRANS; COMPOUND-I; HEME; OXYGEN; ENZYME; DEGRADATION	Interactions of putative distal mutants of cytochrome P450 1A2 (P450 1A2) with hydroperoxides were studied with optical absorption spectroscopy. The Soret absorption at 393 nm of the wild-type P450 1A2 decreased by adding H2O2, tert-butyl hydroperoxide (TBHP), and cumyl hydroperoxide (CHP), whereas the absorption decrease was accompanied by the appearance of a new band around 423 nm for Glu(318) and Thr(319) mutants with similar treatments. Spectral simulation based on Gaussian analyses and visible bands indicate that H2O2- and TBHP-induced intermediates' spectra of the wild type are close to that of Compound I of horseradish peroxidase, whereas TBHP- and CHP induced intermediates' spectra of the mutants are close to that of Compound II of horseradish peroxidase. Based on kinetic parameters of the spectral changes, it is suggested that: 1) TBHP and CHP mainly form porphyrin(+.)Fe(IV)=O due to heterolytic O-O scission in the wild type, while forming porphyrinFe(IV)=O for the mutants owing to homolytic O-O scission; and 2) heterolytic O-O scission of H2O2 is not changed by the mutations. Heterolytic/homolytic cleavage ratios for the P450 1A2 reactions with CHP obtained from product analysis were consistent with those obtained from spectral changes.			SHIMIZU, T (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,SENDAI 98077,JAPAN.							ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BLAKE RC, 1981, J BIOL CHEM, V256, P2127; BRAIN WR, 1990, BIOCHEMISTRY-US, V29, P11280; CORREIA MA, 1987, ARCH BIOCHEM BIOPHYS, V258, P436, DOI 10.1016/0003-9861(87)90365-1; DAVIES HW, 1986, ARCH BIOCHEM BIOPHYS, V244, P387, DOI 10.1016/0003-9861(86)90128-1; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; EGAWA T, 1992, FEBS LETT, V305, P206, DOI 10.1016/0014-5793(92)80668-7; FUNAE Y, 1987, BIOCHIM BIOPHYS ACTA, V926, P349, DOI 10.1016/0304-4165(87)90221-2; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HIGUCHI T, 1993, J AM CHEM SOC, V115, P7551, DOI 10.1021/ja00069a084; HIROYA K, 1994, IN PRESS ARCH BIOCH; HRYCAY EG, 1975, BIOCHEM BIOPH RES CO, V66, P209, DOI 10.1016/S0006-291X(75)80315-9; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KRAINEV AG, 1991, BIOCHEMISTRY-US, V30, P11206, DOI 10.1021/bi00111a003; KRAINEV AG, 1993, BIOCHEMISTRY-US, V32, P1951, DOI 10.1021/bi00059a011; LAU SMC, 1993, BIOCHEMISTRY-US, V32, P1945, DOI 10.1021/bi00059a010; MANSUY D, 1982, TETRAHEDRON LETT, V23, P2781, DOI 10.1016/S0040-4039(00)87457-2; MANSUY D, 1989, EUR J BIOCHEM, V184, P267, DOI 10.1111/j.1432-1033.1989.tb15017.x; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; MAYUZUMI H, 1993, BIOCHEMISTRY-US, V32, P5622, DOI 10.1021/bi00072a018; MCCARTHY MB, 1983, J BIOL CHEM, V258, P9153; MURAKAMI Y, 1993, 2ND INT S CYT P450 M, P21; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PERRIN DD, 1988, LABORATORY CHEM, P129; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P4659, DOI 10.1021/bi00233a004; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P1490, DOI 10.1021/bi00220a007; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SONG WC, 1993, J BIOL CHEM, V268, P6293; TAJIMA K, 1989, INORG CHEM, V28, P709, DOI 10.1021/ic00303a020; TAJIMA K, 1993, BIOCHEM BIOPH RES CO, V191, P157, DOI 10.1006/bbrc.1993.1197; TAMURA M, 1978, HEMOPROTEIN CHEM, P53; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; WAGNER GC, 1983, FEBS LETT, V156, P244, DOI 10.1016/0014-5793(83)80505-5; WHITE RE, 1982, J BIOL CHEM, V257, P3073; YAMAGUCHI K, 1993, J AM CHEM SOC, V115, P4058, DOI 10.1021/ja00063a026; YAO KQ, 1993, J BIOL CHEM, V268, P59	47	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13296	13304						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	7909807				2022-12-27	WOS:A1994NK18400039
J	MOORE, M; WANG, XH; LU, YF; WORMKE, M; CRAIG, A; GERLACH, JH; BURGHARDT, R; BARHOUMI, R; SAFE, S				MOORE, M; WANG, XH; LU, YF; WORMKE, M; CRAIG, A; GERLACH, JH; BURGHARDT, R; BARHOUMI, R; SAFE, S			BENZO[A]PYRENE-RESISTANT MCF-7 HUMAN BREAST-CANCER CELLS - A UNIQUE ARYL HYDROCARBON-NONRESPONSIVE CLONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR CONTENT; PROTEIN-DNA INTERACTIONS; MOUSE HEPATOMA LINE; AH-RECEPTOR; GENE-EXPRESSION; MULTIDRUG RESISTANCE; RESPONSIVE ELEMENT; P-GLYCOPROTEIN; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN TCDD; DEPENDENT INDUCTION	Wild-type MCF-7 human breast cancer cells were cultured for 3 months in 1 mu M benzo[a]pyrene (BaP), and resistant clones were screened for inducibility of CYP1A1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). One of the BaP-resistant (BaPR) clones exhibited unique genotypic expression which distinguished it from both wild type and drug-resistant (Adr(R)) variant MCF-7 cells. Glutathione levels, glutathione S-transferase activities, estrogen receptor levels, estrogen responsiveness, and expression of the multidrug-resistant MDR1 and MRP mRNA levels were similar in the wild-type and BaPR cells, whereas these parameters were reported to be altered in Adr(R) cells. In contrast, TCDD induced CYP1A1 gene expression and inhibited selected estrogen-induced responses in wild-type but not BaPR MCF-7 cells. Treatment of wild-type and BaPR cells with [H-3]TCDD resulted in formation of the radio-labeled aryl hydrocarbon (Ah) 6 S nuclear receptor complex in both cell lines, The loss of Ah responsiveness in the BaPR variant cells correlated with the failure of the nuclear or transformed cytosolic Ah receptor complex to bind genomic dioxin-responsive elements as determined in gel retardation assays.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON K7L 3N6, ON, CANADA; QUEENS UNIV, CANC RES LAB, KINGSTON K7L 3N6, ON, CANADA; TEXAS A&M UNIV, DEPT VET ANAT & PUBL HLTH, COLLEGE STN, TX 77843 USA	Queens University - Canada; Queens University - Canada; Texas A&M University System; Texas A&M University College Station	MOORE, M (corresponding author), TEXAS A&M UNIV, DEPT VET PHYSIOL & PHARMACOL, COLLEGE STN, TX 77843 USA.		Burghardt, Robert C./AAF-4847-2021	Burghardt, Robert C./0000-0003-1021-8444	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004176, R01ES003843] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04176, ES03843] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKMAN SA, 1990, CANCER RES, V50, P1397; BATIST G, 1986, J BIOL CHEM, V261, P5544; BIEGEL L, 1990, J STEROID BIOCHEM, V37, P725, DOI 10.1016/0960-0760(90)90357-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409; BRUNNER N, 1989, CANCER CELL-MON REV, V1, P81; BRUNNER N, 1993, CANCER RES, V53, P283; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BUTLER WB, 1992, CANCER RES, V52, P6164; BUTLER WB, 1986, CANCER RES, V46, P6339; CHEN YN, 1990, J BIOL CHEM, V265, P10073; CHO HS, 1991, MOL ENDOCRINOL, V5, P1323, DOI 10.1210/mend-5-9-1323; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; CLARKE R, 1990, ANN ONCOL, V1, P401, DOI 10.1093/oxfordjournals.annonc.a057790; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; CRESTEIL T, 1987, ARCH BIOCHEM BIOPHYS, V253, P233, DOI 10.1016/0003-9861(87)90656-4; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DALTON WS, 1986, CANCER RES, V46, P5125; DARBON JM, 1990, BIOCHEM PHARMACOL, V40, P1785, DOI 10.1016/0006-2952(90)90357-Q; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DENISON MS, 1990, MOL CELL ENDOCRINOL, V69, P51, DOI 10.1016/0303-7207(90)90088-P; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; FOLDES RL, 1989, BIOCHEM PHARMACOL, V38, P1017, DOI 10.1016/0006-2952(89)90295-5; GERLACH JH, 1986, CANCER SURV, V5, P25; GIERTHY JF, 1987, CANCER RES, V47, P6198; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRADIN K, 1993, J BIOL CHEM, V268, P4061; HANKINSON O, 1981, SOMAT CELL GENET, V7, P373, DOI 10.1007/BF01542983; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARPER N, 1992, TOXICOLOGIST, V12, P474; HARRIS M, 1990, CANCER RES, V50, P3579; HARRIS M, 1989, CANCER RES, V49, P4531; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; IVY SP, 1988, J BIOL CHEM, V263, P19119; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; JIANG SY, 1992, MOL CELL ENDOCRINOL, V90, P77, DOI 10.1016/0303-7207(92)90104-E; JORDAN VC, 1988, BREAST CANCER RES TR, V11, P197, DOI 10.1007/BF01807278; JORDAN VC, 1987, DRUG RESISTANCE, P403; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRISHNAN V, 1992, ANAL BIOCHEM, V204, P137, DOI 10.1016/0003-2697(92)90152-W; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; LERNER LJ, 1990, CANCER RES, V50, P4177; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MILLER AG, 1981, J BIOL CHEM, V256, P2433; MIMNAUGH EG, 1989, CANCER RES, V49, P8; MORGAN TL, 1986, IN VITRO CELL DEV B, V22, P317, DOI 10.1007/BF02623404; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; NEMOTO N, 1991, CARCINOGENESIS, V12, P2115, DOI 10.1093/carcin/12.11.2115; NIELSEN D, 1992, BIOCHIM BIOPHYS ACTA, V1139, P169, DOI 10.1016/0925-4439(92)90131-6; PASANEN M, 1988, CHEM-BIOL INTERACT, V66, P223, DOI 10.1016/0009-2797(88)90073-7; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; POOT M, 1991, CYTOMETRY, V12, P184, DOI 10.1002/cyto.990120214; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RICE GC, 1986, CANCER RES, V46, P6105; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400, DOI 10.1111/j.1600-0773.1991.tb01321.x; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; THOMSEN JS, 1991, EUR J BIOCHEM, V197, P577, DOI 10.1111/j.1432-1033.1991.tb15946.x; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; WANG XH, 1992, BIOCHEM PHARMACOL, V43, P1635; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; YEH GC, 1992, CANCER RES, V52, P6692; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P; ZAMAN GJR, 1993, CANCER RES, V53, P1747	78	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11751	11759						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909315				2022-12-27	WOS:A1994NG37700015
J	PAPADOPOULOU, B; ROY, G; DEY, S; ROSEN, BP; OUELLETTE, M				PAPADOPOULOU, B; ROY, G; DEY, S; ROSEN, BP; OUELLETTE, M			CONTRIBUTION OF THE LEISHMANIA P-GLYCOPROTEIN-RELATED GENE LTPGPA TO OXYANION RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING SITE; AMPLIFIED H-CIRCLE; CANCER CELL-LINE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; PLASMODIUM-FALCIPARUM; CARCINOMA-CELLS; MDR1 GENE	Oxyanions in the form of pentavalent antimony compounds are currently the drug of choice for treating leishmaniasis. Leishmania mutants resistant to high concentrations of the oxyanion arsenite were obtained in a stepwise selection procedure. Amplification of the H locus P-glycoprotein related gene ltpgpA, as part of extrachromosomal circles, is a frequent event in arsenite-resistant cells, but was observed only in cells resistant to high concentrations of the metalloid salts. Revertants grown in the absence of the drug lost their ltpgpA-containing amplicon and part of their resistance. The results of previous transfection experiments in Leishmania had suggested that ltpgpA is only involved in low level resistance to arsenite and antimonite. The results of this study using transfection of ltpgpA alleles isolated from arsenite resistant mutants or of whole circular amplicons containing ltpgpA demonstrate clearly that this P-glycoprotein-related gene is involved in low level resistance to oxyanions, including the pentavalent antimony-containing drug Pentostam. By site-directed mutagenesis, the LtpgpA protein was shown to require an intact nucleotide-binding site to confer arsenite resistance. Under the experimental conditions used, decreased accumulation of the (AsO2-)-As-73 drug was not observed in the ltpgpA transfectants. One possibility is that LtpgpA-mediated arsenite resistance could result from sequestration of the toxic anion in an intracellular compartment. The results indicate that despite the fact that ltpgpA amplification is a frequent event in oxyanion-resistant mutants, it contributes only slightly to the overall resistance.	CHU LAVAL,CTR RECH,SERV INFECTIOL,QUEBEC CITY G1V 4G2,PQ,CANADA; UNIV LAVAL,FAC MED,DEPT MICROBIOL,QUEBEC CITY G1V 4G2,PQ,CANADA; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	Laval University; Laval University; Wayne State University			Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646; Rosen, Barry P./0000-0002-5230-4271	NATIONAL CANCER INSTITUTE [R01CA054141] Funding Source: NIH RePORTER; NCI NIH HHS [CA54141] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; BERMAN JD, 1988, REV INFECT DIS, V10, P560; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; COLE SPC, 1991, CANCER RES, V51, P3345; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; DETKE S, 1989, EXP CELL RES, V180, P161, DOI 10.1016/0014-4827(89)90220-6; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DOU DX, 1992, J BIOL CHEM, V267, P25768; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; GROGL M, 1991, AM J TROP MED HYG, V45, P98, DOI 10.4269/ajtmh.1991.45.98; GRONDIN K, 1993, NUCLEIC ACIDS RES, V21, P1895, DOI 10.1093/nar/21.8.1895; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JACKSON JE, 1990, AM J TROP MED HYG, V43, P464, DOI 10.4269/ajtmh.1990.43.464; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1992, J BIOL CHEM, V267, P19272; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; MA LD, 1991, J BIOL CHEM, V266, P5593; OKOROKOV LA, 1977, EUR J BIOCHEM, V75, P373, DOI 10.1111/j.1432-1033.1977.tb11538.x; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3; OWOLABI JB, 1990, J BACTERIOL, V172, P2367, DOI 10.1128/jb.172.5.2367-2371.1990; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; PAPADOPOULOU B, 1994, IN PRESS MOL BIOCH P; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; Sambrook J, 1989, MOL CLONING LABORATO; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE C, 1986, FEMS MICROBIOL ECOL, V38, P277, DOI 10.1111/j.1574-6968.1986.tb01738.x; WHITE C, 1987, J GEN MICROBIOL, V133, P727; WHITE TC, 1988, J BIOL CHEM, V263, P16977; ZAMAN GJR, 1993, CANCER RES, V53, P1747	55	102	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11980	11986						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909316				2022-12-27	WOS:A1994NG37700049
J	STRIKER, R; JACOBDUBUISSON, F; FRIEDEN, C; HULTGREN, SJ				STRIKER, R; JACOBDUBUISSON, F; FRIEDEN, C; HULTGREN, SJ			STABLE FIBER-FORMING AND NONFIBER-FORMING CHAPERONE-SUBUNIT COMPLEXES IN PILUS BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; PAPD; PROTEIN; BACTERIA; SURFACES; BINDING	The P pilus is a composite fiber consisting of a thin adhesive tip fibrillum joined to the pilus rod that mediates specific adherence of uropathogenic Escherichia coli to human uroepithelial cells via the PapG tip adhesin. P pilus assembly depends upon the periplasmic chaperone PapD. The interaction of PapD with different pilus subunits was investigated to gain further insight into pilus assembly PapA, the major subunit of the pilus rod, formed two periplasmic complexes (DA(2) and DA) with PapD. PapK, an adaptor protein that joins the tip fibrillum to the pilus rod, formed only one complex with PapD (DK). Only ''fiber forming'' or homopolymeric subunits, PapA in the rod and PapE in the tip fibrillum, were able to form subunit-subunit interactions in the periplasm. Subunits that are present in single or low copy in the pilus (PapK and PapG) did not form periplasmic intersubunit interactions. A pulse-chase analysis revealed that a chaperone-PapA complex is a true periplasmic intermediate in pilus assembly.	ST LOUIS UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63130	Saint Louis University; Washington University (WUSTL)			; Jacob-Dubuisson, Francoise/F-1610-2018	Striker, Rob/0000-0002-0454-895X; Jacob-Dubuisson, Francoise/0000-0002-5102-1704	NIAID NIH HHS [1RO1AI29549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKKER D, 1991, MOL MICROBIOL, V5, P875, DOI 10.1111/j.1365-2958.1991.tb00761.x; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BOCK K, 1985, J BIOL CHEM, V260, P8545; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; ESHDAT Y, 1981, J BACTERIOL, V148, P308, DOI 10.1128/JB.148.1.308-314.1981; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; GRANT GA, 1992, SYNTHETIC PEPTIDES U, P185; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; Jacob-Dubuisson Francoise, 1993, Trends in Microbiology, V1, P50, DOI 10.1016/0966-842X(93)90032-M; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LUND B, 1985, J BACTERIOL, V162, P1293, DOI 10.1128/JB.162.3.1293-1301.1985; SIMONS BL, 1990, FEMS MICROBIOL LETT, V67, P107, DOI 10.1111/j.1574-6968.1990.tb13845.x; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x	22	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12233	12239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909317				2022-12-27	WOS:A1994NG37700085
J	ALSHAWI, MK; URBATSCH, IL; SENIOR, AE				ALSHAWI, MK; URBATSCH, IL; SENIOR, AE			COVALENT INHIBITORS OF P-GLYCOPROTEIN ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; PLASMA-MEMBRANE VESICLES; HAMSTER OVARY CELLS; AMINO-ACID-SEQUENCE; MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODIES; PYRIDOXAL 5'-DIPHOSPHO-5'-ADENOSINE; BETA-SUBUNIT; TRANSPORT; FLUORESCEIN	Verapamil stimulated ATP hydrolysis by Chinese hamster P-glycoprotein in plasma membranes was shown to occur at a site(s) which is conformationally flexible and of relatively low affinity and specificity. Such properties distinguish P glycoprotein from other transport ATPases. 8-Azido-ATP and a-azido-ATP were excellent substrates, confirming that both analogs are suitable photoaffinity labels for investigating the catalytic site(s). Inactivation of ATPase activity occurred coincident with covalent incorporation of approximately two 8-azido-ATP/P-glycoprotein, with the incorporated analog distributed equally between N- and C-terminal halves of the molecule. N-Ethylmaleimide potently inactivated in an ATP protected, dithiothreitol-irreversible manner, with maximal inactivation occurring coincident with incorporation of approximately two N-ethylmaleimide/P-glycoprotein. The critical catalytic site sulfhydryls were shown to be located equally in N- and C-terminal halves of the molecule. Sulfhydryl-substituted purines also gave substantial inhibition of P-glycoprotein ATPase activity, which was dithiothreitol reversible. The data provide guidelines for beginning investigation of catalytic site architecture by protein chemistry approaches.			ALSHAWI, MK (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.							ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; COLMAN RF, 1990, ENZYMES, V19, P283; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P94; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FENG Y, 1992, J BIOL CHEM, V267, P5817; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GROS P, 1992, BIOCHEMISTRY-US, V31, P1992, DOI 10.1021/bi00122a014; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO R, 1988, J BIOL CHEM, V263, P5640; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RONINSON IB, 1990, PEDIATR PULM, V5, P138; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHURR E, 1989, CANCER RES, V49, P2729; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TAMURA JK, 1986, J BIOL CHEM, V261, P4126; TSOU C, 1962, SCI SINICA, V11, P1535; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	45	158	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8986	8992						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7907596				2022-12-27	WOS:A1994NB41100056
J	ARGUELLO, JM; KAPLAN, JH				ARGUELLO, JM; KAPLAN, JH			GLUTAMATE-779, AN INTRAMEMBRANE CARBOXYL, IS ESSENTIAL FOR MONOVALENT CATION-BINDING BY THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; ALPHA-SUBUNIT; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; CDNA SEQUENCE; NA/K-ATPASE; INACTIVATION; NA+	Incubation of purified renal Na,K-ATPase with the fluorescent carboxyl-selective reagent, 4-(diazomethyl)7-(diethylamino)-coumarin (DEAC), results in enzyme inactivation via disruption of the monovalent cation binding sites and loss of K+ and Na+ binding capacity. Modification of 1 or 2 carboxyl residues in the alpha-subunit in a K+ or Na+-preventable manner leaves the ATP binding unaltered, and the enzyme is still able to undergo the major conformational transitions (Arguello, J. M., and Kaplan, J. H. (1991) J. Biol. Chem. 266, 14627-14635). Labeled alpha-subunits of Na,K-ATPase were isolated by gel electrophoresis and digested using V-8 protease. The digests contained two bands which were fluorescently labeIed in a cation-protectable fashion. Four peptides were identified in these bands. Peptides I (apparent molecular mass similar to 17 kDa), II (similar to 15 kDa), and IIIa (similar to 5 kDa) start at Gly(758) while Peptide IIIb (similar to 5 kDa) starts at Gly(561). Subsequent proteolysis of peptides IIIa and IIIb with thermolysin followed by electrophoresis revealed a single smaller fluorescent peptide which passed through 3-kDa cut-off membrane filters but was retained by 1-kDa cut off filters. N-terminal sequence analysis of this peptide gave the sequence (773)Leu-Thr-Ser-Asn-Ile-Pro-GIu Ile-Thr-Pro-Phe-Leu. The length of this peptide was also examined in labeling experiments with cysteine-reactive probes which indicated that the peptide did not extend to the next carboxyl-containing amino acid residue in the cu-subunit sequence (Asp(804)). The site of attachment of DEAC is thus GlU(779), an intramembrane carboxyl residue present in all known sequences of alpha-subunit isoforms of the Na,K-ATPase. This glutamate is essential for Na+ and K+ binding and active transport by the sodium pump. Its location in the fifth transmembrane segment provides a way in which information about ATP binding and phosphorylation in the major cytoplasmic loop of the enzyme is transmitted to intramembrane cation sites during the reaction cycle.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297; Kaplan, Jack/0000-0002-7048-6574	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1993, BIOPHYS J, V64, pA352; ARGUELLO JM, 1991, SODIUM PUMP RECENT D, P199; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; BURK SE, 1989, J BIOL CHEM, V264, P18561; CANFIELD VA, 1992, NEW BIOL, V4, P339; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; ELLISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GORGA FR, 1985, BIOCHEMISTRY-US, V24, P6783, DOI 10.1021/bi00345a009; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; ITO K, 1983, CHEM PHARM BULL, V31, P3014; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KAPLAN JH, 1991, SOC GEN PHY, V46, P117; KAPLAN JH, 1989, RED BLOOD CELL MEMBR, P455; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1992, ACTA PHYSIOL SCAND, V146, P69; KARLISH SJD, 1991, SODIUM PUMP STRUCTUR, P129; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MAGYAR A, 1990, BIOCHEM BIOPH RES CO, V173, P872, DOI 10.1016/S0006-291X(05)80867-8; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MATSUEDA GR, 1981, BIOCHEMISTRY-US, V20, P2571, DOI 10.1021/bi00512a032; MODYANOV N, 1991, SOC GEN PHY, V46, P99; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MOOS M, 1988, J BIOL CHEM, V263, P6005; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P3632; PEDEMONTE CH, 1992, FEBS LETT, V314, P97, DOI 10.1016/0014-5793(92)81470-7; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P6660; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; ROBINSON JD, 1974, FEBS LETT, V38, P325, DOI 10.1016/0014-5793(74)80083-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONER W, 1971, ANGEW CHEM INT EDIT, V10, P882, DOI 10.1002/anie.197108821; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; STEIMAN DM, 1985, ANAL BIOCHEM, V145, P91, DOI 10.1016/0003-2697(85)90331-8; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; TAYLOR KL, 1992, J BIOL CHEM, V267, P25282; THIBAULT D, 1993, BIOCHEMISTRY-US, V32, P2813, DOI 10.1021/bi00062a012; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; YAMAGUCHI M, 1983, CURR TOP MEMBR TRANS, V19, P203	60	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6892	6899						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907096				2022-12-27	WOS:A1994MZ50300098
J	VANDESTOLPE, A; CALDENHOVEN, E; STADE, BG; KOENDERMAN, L; RAAIJMAKER, JAM; JOHNSON, JP; VANDERSAAG, PT				VANDESTOLPE, A; CALDENHOVEN, E; STADE, BG; KOENDERMAN, L; RAAIJMAKER, JAM; JOHNSON, JP; VANDERSAAG, PT			12-O-TETRADECANOYLPHORBOL-13-ACETATE- AND TUMOR-NECROSIS-FACTOR ALPHA-MEDIATED INDUCTION OF INTERCELLULAR-ADHESION MOLECULE-1 IS INHIBITED BY DEXAMETHASONE - FUNCTIONAL-ANALYSIS OF THE HUMAN INTERCELLULAR-ADHESION MOLECULE-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; DNA-BINDING; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; PHORBOL ESTERS; REPORTER GENE; CELL-LINES; JUN; ACTIVATION	Transcription regulation of the human intercellular adhesion molecule-1 gene by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), tumor necrosis factor alpha (TNF alpha), and the glucocorticoid dexamethasone was studied using transient transfections in 293 cells with intercellular adhesion molecule-1 promoter-luciferase constructs (together with a glucocorticoid receptor expression vector). TPA and TNF alpha induced promoter activity, which was repressed by dexamethasone. Four TPA-responsive DNA regions were identified, each containing a potential TPA-responsive enhancer sequence: 1) -677/-340 an AP3-like sequence; 2) -290/278 a TPA-response element (TRE); 3) -227/-175 an NF kappa B-like sequence; 4) -105/-38 an AP2-like sequence. TNF alpha enhanced transcription only through region 3. The TRE in region 2 appeared to be functionally coupled to a distal TATA box at -313 and differed from the consensus TRE with respect to binding characteristics for members of the AP1 family. The newly identified NF kappa B enhancer (TGGAAATTCC) is bound by a TNF alpha-induced nuclear protein and appears to be the key element in rapid transcription induction by TNF alpha (and TPA), while transactivation of this element is repressed by the ligand-bound glucocorticoid receptor, We propose a negative cross-talk between the NF kappa B transcription factor and the glucocorticoid receptor.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; UNIV HOSP UTRECHT,DEPT PULM DIS,UTRECHT,NETHERLANDS; UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH,GERMANY	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; University of Munich				Koenderman, Leo/0000-0002-5636-6453				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALLANTYNE CM, 1992, GENOMICS, V14, P1076, DOI 10.1016/S0888-7543(05)80132-6; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUSSO N, 1987, EXP CELL RES, V173, P425, DOI 10.1016/0014-4827(87)90282-5; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; FRIED M, 1981, NUCLEIC ACIDS RES, V13, P1431; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KRESS C, 1990, DEVELOPMENT, V109, P775; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; MYERS CL, 1992, AM J PHYSIOL, V263, pC767, DOI 10.1152/ajpcell.1992.263.4.C767; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PUCH BF, 1990, CELL, V61, P1187; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; ROTHLEIN R, 1986, J IMMUNOL, V137, P1279; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZABEL U, 1991, J BIOL CHEM, V266, P252	47	247	253	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6185	6192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907090				2022-12-27	WOS:A1994MY84000105
J	WILCOX, GR; FOGH, RH; NORTON, RS				WILCOX, GR; FOGH, RH; NORTON, RS			REFINED STRUCTURE IN SOLUTION OF THE SEA-ANEMONE NEUROTOXIN SHI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; POLYPEPTIDE CARDIAC STIMULANT; DISTANCE GEOMETRY CALCULATIONS; RESTRAINED MOLECULAR-DYNAMICS; OVERHAUSER EFFECT SPECTRA; STICHODACTYLA-HELIANTHUS; PROTEIN CONFORMATIONS; ANTHOPLEURIN-A; SECONDARY STRUCTURE; DNA OCTAMER	A high resolution structure in solution has been determined for the polypeptide neurotoxin I, from the sea anemone Stichodactyla helianthus, using NMR data, distance geometry calculations, and refinement by back-calculation of two-dimensional nuclear Overhauser enhancement (NOE) spectra. A set of 913 distance constraints derived from NOEs was used, together with a large set of lower distance bounds based on the absence of NOEs in the spectrum. Eight published structures for neurotoxin I were refined independently to give structures which agree better with the experimental data, as reflected in reduced R factors calculated over well resolved cross-peaks of the two-dimensional NOE spectra and a lower total volume of peaks in back-calculated spectra that are absent from experimental spectra. The refined structures are also more precisely defined, with mean pairwise root mean square differences over backbone heavy atoms of 0.62 angstrom for well defined residues and 1.14 angstrom for all residues, compared with previous values of 1.09 and 2.41 angstrom, respectively. The consensus constraint set from the 8 refined structures was also used to generate 12 new structures, with corresponding root mean square differences of 0.76 and 1.26 angstrom. In all 20 structures the loop linking the first and second strands of the beta-sheet is considerably better defined than before. A type I beta-turn encompassing the functionally important residues Asp6, Asp7, and Glu8 is evident in the refined structures.	NMR LAB,BIOMOLEC RES INST,381 ROYAL PARADE,PARKVILLE 3052,AUSTRALIA; UNIV NEW S WALES,SCH BIOCHEM & MOLEC GENET,KENSINGTON,NSW 2033,AUSTRALIA	University of New South Wales Sydney								BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; BANKS KM, 1989, BIOCHEMISTRY-US, V28, P6996, DOI 10.1021/bi00443a033; BOELENS R, 1989, J MAGN RESON, V82, P290, DOI 10.1016/0022-2364(89)90032-2; BONVIN A M J J, 1991, Journal of Biomolecular NMR, V1, P305, DOI 10.1007/BF01875523; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; DEVLIEG J, 1986, ISRAEL J CHEM, V27, P181; ERNST RR, 1987, PRINCIPLES NUCL MAGN, P516; FOGH RH, 1989, BIOCHEMISTRY-US, V28, P1826, DOI 10.1021/bi00430a060; FOGH RH, 1990, J BIOL CHEM, V265, P13016; GOULD AR, 1990, EUR J BIOCHEM, V189, P145, DOI 10.1111/j.1432-1033.1990.tb15471.x; GOULD AR, 1992, EUR J BIOCHEM, V206, P641, DOI 10.1111/j.1432-1033.1992.tb16969.x; GUESNET JL, 1990, BIOCHEMISTRY-US, V29, P4982, DOI 10.1021/bi00472a031; HAVEL TF, 1985, J MOL BIOL, V182, P281, DOI 10.1016/0022-2836(85)90346-8; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEEPERS JW, 1984, J MAGN RESON, V57, P404, DOI 10.1016/0022-2364(84)90257-9; Kem W.R., 1988, P375; KEM WR, 1989, BIOCHEMISTRY-US, V28, P3483, DOI 10.1021/bi00434a050; KIM SG, 1992, J MAGN RESON, V100, P382, DOI 10.1016/0022-2364(92)90271-8; KONING TMG, 1991, BIOCHEMISTRY-US, V30, P3787, DOI 10.1021/bi00229a028; LEFEVRE JF, 1987, BIOCHEMISTRY-US, V26, P5076, DOI 10.1021/bi00390a029; MANOLERAS N, 1992, J BIOMOL NMR, V2, P485, DOI 10.1007/BF02192811; MARION D, 1987, BIOPHYS CHEM, V28, P235, DOI 10.1016/0301-4622(87)80094-7; NEUHAUS D, 1989, NUCLEAR OVERHAUSER E, P358; NIKONOWICZ EP, 1990, BIOCHEMISTRY-US, V29, P4193, DOI 10.1021/bi00469a024; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; Norton R S, 1990, Aust J Biotechnol, V4, P114; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; OLEJNICZAK ET, 1986, J MAGN RESON, V67, P28, DOI 10.1016/0022-2364(86)90406-3; PALLAGHY PK, 1993, IN PRESS J MOL BIOL; PENNINGTON M W, 1990, Peptide Research, V3, P228; SMITH JA, 1980, CRC CR REV BIOCH MOL, V8, P315, DOI 10.3109/10409238009105470; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; THOMAS PD, 1991, P NATL ACAD SCI USA, V88, P1237, DOI 10.1073/pnas.88.4.1237; TORDA AE, 1988, FEBS LETT, V239, P266, DOI 10.1016/0014-5793(88)80931-1; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; VANGUNSTEREN WF, 1987, GROMOS MANUAL; WEBER PL, 1988, J MOL BIOL, V204, P483, DOI 10.1016/0022-2836(88)90589-X; WIDMER H, 1989, PROTEINS, V6, P357, DOI 10.1002/prot.340060403; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YIP P, 1989, J MAGN RESON, V83, P643, DOI 10.1016/0022-2364(89)90360-0	43	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24707	24719						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901218				2022-12-27	WOS:A1993MG67300032
J	ANDERSEN, B; SCHONEMANN, MD; PEARSE, RV; JENNE, K; SUGARMAN, J; ROSENFELD, MG				ANDERSEN, B; SCHONEMANN, MD; PEARSE, RV; JENNE, K; SUGARMAN, J; ROSENFELD, MG			BRN-5 IS A DIVERGENT POU DOMAIN FACTOR HIGHLY EXPRESSED IN LAYER-IV OF THE NEOCORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN GENES; ACTIVATOR PROTEIN; RESPONSE ELEMENTS; EMBRYONIC-CELLS; MESSENGER-RNAS; STEM-CELLS; C-ELEGANS; DROSOPHILA	We have identified rat cDNA clones that encode a POU domain protein, referred to as brain-5 (Brn-5). During embryogenesis in the rat, Brn-5 is widely expressed with highest levels in the developing brain and spinal cord from embryonic day 12.5. In the adult, Brn-5 mRNA is most abundant in the brain, where it is diffusely expressed with the exception of an enrichment in layer IV of the neocortex. However, Brn-5 is also found in multiple adult tissues outside the central nervous system, including kidney, lung, heart, adrenal, skin, testis, and anterior pituitary. This expression pattern contrasts with that of most other POU domain genes that are expressed predominantly in the developing nervous system and are progressively restricted to discrete regions of the brain. The predicted amino acid sequence of Brn-5 is considerably divergent from previously described POU domains and thus defines a new POU domain subclass (class VI). Consistent with its divergent sequence, the DNA-binding characteristics of Brn-5 overlap with, but are clearly distinct from, that of Oct-2. Although Brn-5 can bind to non-octamer sites, a random site selection indicates that its preferred binding site contains a variant octamer core motif. Finally, we show that the amino terminus of Brn-5 contains a transactivation domain.	UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego				Pearse, Richard/0000-0003-3972-1457	NIMH NIH HHS [MH47137] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047137] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGARWAL VR, 1991, DEV BIOL, V147, P363, DOI 10.1016/0012-1606(91)90294-D; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BILLIN AN, 1991, MECH DEVELOP, V34, P75, DOI 10.1016/0925-4773(91)90045-8; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORNCORAN LM, 1993, GENES, V7, P570; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DICK T, 1991, P NATL ACAD SCI USA, V88, P7645, DOI 10.1073/pnas.88.17.7645; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRANK D, 1992, DEVELOPMENT, V115, P439; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GERRERO R, 1993, IN PRESS P NATL ACAD; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4503, DOI 10.1093/nar/19.16.4503; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHANSEN T, 1993, NUCLEIC ACIDS RES, V21, P475, DOI 10.1093/nar/21.3.475; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KAMBE F, 1993, BIOCHIM BIOPHYS ACTA, V1171, P307, DOI 10.1016/0167-4781(93)90071-K; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LLOYD A, 1991, MECH DEVELOP, V36, P87, DOI 10.1016/0925-4773(91)90075-H; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MATSUZAKI T, 1992, BIOCHEM BIOPH RES CO, V187, P1446, DOI 10.1016/0006-291X(92)90464-V; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAMOTO K, 1993, J BIOL CHEM, V268, P7449; PETRYNIAK B, 1990, P NATL ACAD SCI USA, V87, P1099, DOI 10.1073/pnas.87.3.1099; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PRAKASH K, 1992, P NATL ACAD SCI USA, V89, P7080, DOI 10.1073/pnas.89.15.7080; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; Schmitt F. O., 1981, ORG CEREBRAL CORTEX; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1992, ANNU REV NEUROSCI, V15, P139, DOI 10.1146/annurev.ne.15.030192.001035; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; VERRIJZER CP, 1992, NUCLEIC ACIDS RES, V20, P6369, DOI 10.1093/nar/20.23.6369; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WHITFIELD T, 1993, DEV BIOL, V155, P361, DOI 10.1006/dbio.1993.1035; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIA YR, 1993, IN PRESS GENOMICS; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	88	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23390	23398						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901208				2022-12-27	WOS:A1993MF51500068
J	MORRISON, DF; TING, TD; VALLURY, V; HO, YK; CROUCH, RK; CORSON, DW; MANGINI, NJ; PEPPERBERG, DR				MORRISON, DF; TING, TD; VALLURY, V; HO, YK; CROUCH, RK; CORSON, DW; MANGINI, NJ; PEPPERBERG, DR			REDUCED LIGHT-DEPENDENT PHOSPHORYLATION OF AN ANALOG VISUAL PIGMENT CONTAINING 9-DEMETHYLRETINAL AS ITS CHROMOPHORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; RHODOPSIN KINASE; 48-KDA PROTEIN; PHOSPHODIESTERASE ACTIVATION; PHOTOEXCITED RHODOPSIN; 9-DESMETHYL RHODOPSIN; AMPLIFICATION; SITES; EXCITATION; KINETICS	9-Demethyl rhodopsin (9dR), an analog of vertebrate rhodopsin, consists of opsin and a covalently attached chromophore of 11-cis 9-demthylretinal. Electrophysiological evidence that photoactivated 9dR (9dR*) undergoes abnormally slow deactivation in salamander rods (Corson, D. W., Cornwall, M. C., and Pepperberg, D. R. (1994) Visual Neurosci, 11, 91-98) raises the possibility that opsin phosphorylation, a reaction involved in visual pigment deactivation, operates abnormally on 9dR*. This possibility was tested by measuring the light-dependent phosphorylation of 9dR in preparations obtained from bovine rod outer segments. Outer segment membranes containing 9dR or regenerated rhodopsin were flash-illuminated in the presence of [gamma-P-32]ATP and rhodopsin kinase, further incubated in darkness, and then analyzed for opsin-bound [P-32]P-i. [P-32]P-i incorporation by 9dR* increased with both incubation period and bleaching extent but, under all conditions tested, was less than that measured in rhodopsin controls. Results obtained with 30-s incubation periods indicated that the maximal initial rate of incorporation by 9dR* is about 25% of that by photoactivated rhodopsin, The results imply that the low incorporation of P-i by 9dR* results from a reduced rate of phosphorylation by rhodopsin kinase and are consistent with the prolonged lifetime of 9dR* determined electrophysiologically.	UNIV ILLINOIS,DEPT OPHTHALMOL & VISUAL SCI,LIONS ILLINOIS EYE RES INST,CHICAGO,IL 60612; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612; MED UNIV S CAROLINA,DEPT OPHTHALMOL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University of South Carolina; Medical University of South Carolina					NATIONAL EYE INSTITUTE [R01EY005494, P30EY001792] Funding Source: NIH RePORTER; NEI NIH HHS [EY-05494, EY-06038, EY-01792] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BLATZ PE, 1969, J AM CHEM SOC, V91, P5930, DOI 10.1021/ja01049a069; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CORSON DW, 1994, VISUAL NEUROSCI, V11, P91, DOI 10.1017/S0952523800011135; CORSON DW, 1994, P NATL ACAD SCI USA, V91, P6958, DOI 10.1073/pnas.91.15.6958; DOWLING JE, 1971, J GEN PHYSIOL, V58, P163, DOI 10.1085/jgp.58.2.163; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; KAHLERT M, 1990, NATURE, V345, P537, DOI 10.1038/345537a0; KROPF A, 1973, EXP EYE RES, V17, P591, DOI 10.1016/0014-4835(73)90088-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MORRISON DF, 1993, INVEST OPHTH VIS SCI, V34, P1324; MORRISON DF, 1993, BIOPHYS J, V64, pA211; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAULSEN R, 1984, NATURE, V302, P417; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; PEPPERBERG DR, 1988, P NATL ACAD SCI USA, V85, P5531, DOI 10.1073/pnas.85.15.5531; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SECKLER B, 1989, BIOCHEM J, V264, P489, DOI 10.1042/bj2640489; STRYER L, 1991, J BIOL CHEM, V266, P10711; WALD G, 1954, J GEN PHYSIOL, V37, P189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702	36	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6718	6721		10.1074/jbc.270.12.6718	http://dx.doi.org/10.1074/jbc.270.12.6718			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896815	hybrid			2022-12-27	WOS:A1995QQ85500046
J	KURATA, S				KURATA, S			POTENTIAL OF AZIDOTHYMIDINE TO ACTIVATE THE HIV-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; INVITRO; 2',3'-DIDEOXYNUCLEOSIDES; INFECTIVITY; INHIBITION; TRIAL; DNA	Azidothymidine (AZT) has been used for treatment of acquired immunodeficiency syndrome (AIDS), but a recent concord trial showed that it is ineffective for suppressing the development of AIDS. In this study, the effects of AZT on three cell lines transformed by pCD12 plasmid (human immunodeficiency virus-1 (HIV-1) promoter-chloramphenicol acetyltransferase) were examined. Results showed that AZT has the potential to activate the HIV-1 promoter.			KURATA, S (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT BIOCHEM GENET,TOKYO 113,JAPAN.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V176, P87, DOI 10.1016/0006-291X(91)90893-C; KURATA SI, 1993, FEBS LETT, V320, P201; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RICKMAN DD, 1987, NEW ENGL J MED, V317, P192; SANDRIGOLDIN RM, 1981, MOL CELL BIOL, V1, P743, DOI 10.1128/MCB.1.8.743; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327	17	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24553	24556						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929126				2022-12-27	WOS:A1994PQ49000010
J	SANTOS, MJ; KAWADA, ME; ESPEEL, M; FIGUEROA, C; ALVAREZ, A; HIDALGO, U; METZ, C				SANTOS, MJ; KAWADA, ME; ESPEEL, M; FIGUEROA, C; ALVAREZ, A; HIDALGO, U; METZ, C			CHARACTERIZATION OF HUMAN PEROXISOMAL MEMBRANE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; ACYL-COA OXIDASE; ZELLWEGER SYNDROME; BINDING PROTEINS; TARGETING SIGNAL; BIOGENESIS; MEMBER; POLYPEPTIDES; LOCALIZATION; FIBROBLASTS	The peroxisomal membrane appears to play a crucial role in transporting proteins into the organelle. Some human genetic disorders involving peroxisome biogenesis, such as Zellweger syndrome, may be caused by genetic defects of the import machinery located in the peroxisomal membrane. In order to characterize the proteins of the human peroxisomal membrane, we isolated peroxisomes from human liver. We obtained their membranes using various procedures and analyzed their proteins by SDS-polyacrylamide gel electrophoresis and silver staining. We compared the protein composition of peroxisomal membranes with membranes derived from mitochondria and microsomes. The main peroxisomal membrane proteins (PMPs) have apparent molecular masses of 147, 112, 95, 87, 81, 79, 74, 69(70), 53-52 (double band), 47, 45, 43, 37, 31, 28, 22, and 17 kDa. The following PMPs of 147, 112, 79, 69(70), 53-52 (double band), 47, 43, 31, 28, 22, and 17 kDa fit the criteria for integral membrane proteins. We then produced rabbit polyclonal and mouse monoclonal antibodies that recognized some human PMPs. One of these antibodies detected mainly PMP43. We used this antiserum to evaluate the presence and subcellular distribution of the PMP43 in fibroblasts derived from patients affected by Zellweger syndrome. These results represent new information about the protein composition of the human peroxisomal membrane and provide biological tools for further characterization of the human PMPs and their genes in normal and pathological conditions.	STATE UNIV GHENT,DEPT ANAT HISTOL & EMBRYOL,B-9000 GHENT,BELGIUM	Ghent University	SANTOS, MJ (corresponding author), PONTIFICIA UNIV CATOLICA CHILE,FAC BIOL SCI & MED,DEPT CELL & MOLEC BIOL,CASILLA 114-D,SANTIAGO,CHILE.		Figueroa, Christian C./A-1170-2008	Figueroa, Christian C./0000-0001-9218-5564; Alvarez Rojas, Alejandra/0000-0002-8129-9280; Metz, Claudia/0000-0002-5093-3066				ALVAREZ A, 1992, ANAL BIOCHEM, V206, P147, DOI 10.1016/S0003-2697(05)80025-9; BALFE A, 1990, PEDIATR RES, V27, P304, DOI 10.1203/00006450-199003000-00023; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BERGMEYER HU, 1963, METHDOS ENZYMATIC AN, P452; BERTHET J, 1951, BIOCHEM J, V50, P174, DOI 10.1042/bj0500174; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BOWERS WE, 1967, J CELL BIOL, V32, P339, DOI 10.1083/jcb.32.2.339; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUL S, 1988, J CLIN INVEST, V81, P1702; CAUSERET C, 1993, BIOL CELL, V77, P89, DOI 10.1016/S0248-4900(05)80178-9; DELVALLE R, 1988, BIOCHEM BIOPH RES CO, V156, P1353, DOI 10.1016/S0006-291X(88)80781-2; DUDUVA C, 1967, ENZYME CYTOLOGY, P1; FUJIKI Y, 1989, AGR BIOL CHEM TOKYO, V53, P591; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOODMAN JM, 1986, J BIOL CHEM, V261, P3464; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; HARTL FU, 1987, ARCH BIOCHEM BIOPHYS, V255, P109, DOI 10.1016/0003-9861(87)90300-6; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; KALDI K, 1993, FEBS LETT, V315, P217, DOI 10.1016/0014-5793(93)81167-X; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; LABARCA P, 1986, J MEMBRANE BIOL, V94, P285, DOI 10.1007/BF01869724; Lazarow PB, 1989, CURR OPIN CELL BIOL, V1, P630, DOI 10.1016/0955-0674(89)90026-4; Lazarow Paul B., 1993, Trends in Cell Biology, V3, P89, DOI 10.1016/0962-8924(93)90079-G; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1989, METABOLIC BASIS INHE, P1470; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEIGHTON F, 1969, J CELL BIOL, V41, P521, DOI 10.1083/jcb.41.2.521; LEMMENS M, 1989, BIOCHIM BIOPHYS ACTA, V984, P351, DOI 10.1016/0005-2736(89)90302-7; MAKITA T, 1990, ACTA HISTOCHEM CYTOC, V23, P601, DOI 10.1267/ahc.23.601; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; ROELS F, 1979, J HISTOCHEM CYTOCHEM, V27, P1471, DOI 10.1177/27.11.92501; ROSCHER AA, 1989, PEDIATR RES, V26, P67, DOI 10.1203/00006450-198907000-00019; SANTOS MJ, 1992, J CELL PHYSIOL, V151, P103, DOI 10.1002/jcp.1041510115; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SELLINGER OZ, 1960, BIOCHEM J, V74, P450, DOI 10.1042/bj0740450; SHIMIZU S, 1992, J BIOCHEM-TOKYO, V112, P733, DOI 10.1093/oxfordjournals.jbchem.a123967; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SMALL GM, 1988, J INHERIT METAB DIS, V11, P358, DOI 10.1007/BF01800425; SMALL GM, 1985, BIOCHEM J, V227, P205, DOI 10.1042/bj2270205; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; WILSON GN, 1991, BIOCHEM MED METAB B, V46, P235, DOI 10.1016/0885-4505(91)90071-R; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	57	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24890	24896						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929170				2022-12-27	WOS:A1994PQ49000057
J	SCHWARTZ, HL; LAZAR, MA; OPPENHEIMER, JH				SCHWARTZ, HL; LAZAR, MA; OPPENHEIMER, JH			WIDESPREAD DISTRIBUTION OF IMMUNOREACTIVE THYROID-HORMONE BETA-2 RECEPTOR (TR-BETA-2) IN THE NUCLEI OF EXTRAPITUITARY RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 MESSENGER-RNA; BINDING-CAPACITY; LYMPHOID-TISSUES; NERVOUS-SYSTEM; EXPRESSION; PROTEIN; LOCALIZATION; OCT-2	Messenger RNA for thyroid hormone receptor (TR) isoforms alpha 1 and beta 1 are widely distributed in rat tissues. Until recently, TR beta 2 mRNA was believed to be limited to the pituitary and the assumption was made that TR beta 2 protein was similarly restricted. We determined the distribution of TR beta 2 protein in selected adult and fetal rat tissues using three anti-TR beta 2 antisera directed to different amino acid sequences of the distinctive A/B domain of TR beta 2. The proportion of total nuclear binding capacity cleared by each antiserum was determined by saturation analysis. 10-20% of total binding capacity in adult brain, liver, kidney, and heart was immunoprecipitated by each antiserum. Use of specific antibodies to TR beta 1 and TR alpha 1 showed these isoforms accounted for the remainder of total T-3 binding. Fetal liver and brain, however, contained only TR alpha 1. Immunohistochemical analysis of the adult tissues showed TR beta 2 present in nuclei. Reverse transcription polymerase chain reaction detected low levels of TR beta 2 mRNA in the adult tissues. We infer that TR beta 2 accounts for a significant fraction of TR in adult rat tissues despite the low levels of its mRNA.	UNIV MINNESOTA,CTR HLTH,DEPT MED,DIABET ENDOCRINOL & METAB SECT,TYROID RES UNIT,MINNEAPOLIS,MN 55455; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NIADDK NIH HHS [AM19-812] Funding Source: Medline; NIDDK NIH HHS [DK43806] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043806, R37DK043806] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; COOK CB, 1992, ENDOCRINOLOGY, V130, P1077, DOI 10.1210/en.130.2.1077; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KONDO E, 1992, BLOOD, V80, P2044; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; SUZUKI N, 1993, NUCLEIC ACIDS RES, V21, P245, DOI 10.1093/nar/21.2.245; WOOD JN, 1992, J BIOL CHEM, V267, P17787; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539	18	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24777	24782						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929155				2022-12-27	WOS:A1994PQ49000042
J	CHEADLE, C; IVASHCHENKO, Y; SOUTH, V; SEARFOSS, GH; FRENCH, S; HOWK, R; RICCA, GA; JAYE, M				CHEADLE, C; IVASHCHENKO, Y; SOUTH, V; SEARFOSS, GH; FRENCH, S; HOWK, R; RICCA, GA; JAYE, M			IDENTIFICATION OF A SRC SH3 DOMAIN BINDING MOTIF BY SCREENING A RANDOM PHAGE DISPLAY LIBRARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE COMBINATORIAL LIBRARIES; EPITOPE LIBRARY; PHOSPHATIDYLINOSITOL 3-KINASE; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; PROTEIN; LIGANDS; SELECTION; FAMILY; SITE	A phage display library was constructed in the filamentous bacteriophage fuse5. The library was made by inserting a degenerate oligonucleotide which encodes 15 variable amino acids into the NH,(2)-terminal region of the phage gene III protein. This library containing over 10(7) different phage, was screened with a glutathione S-transferase (GST) fusion protein containing the Src homology 3 (Src SH3) domain and a protein kinase A phosphorylation site (GST/PKA/Src SH3). A family of proline-rich sequences was isolated following four cycles of enrichment and amplification. Phage containing these sequences were shown to specifically bind to the GST/PHA/Src SH3 protein but not to GST/PKA only. A comparison of the inferred amino acid sequence of the different phage clones revealed a consensus sequence, RPLPXXP, which conforms to a Src SH3 domain binding motif identified independently during an affinity screen of a lambda-lox mouse embryo cDNA library using a P-32-labeled Src SH3 protein fragment as the probe (Y. Ivashchenko, manuscript in preparation). Peptides based upon the 7-amino acid SH3 binding domain core motif displayed strong binding to both the Src and to the Fyn SH3 do mains, but failed to bind to the SH3 domain of p21Ras-GTPase-activating protein (Ras GAP) and other proteins. We anticipate that further screening of the phage display library will be a useful tool for the rapid identification of additional SH3 domain binding sequences and will also help to establish the essential core motifs that define the specificity of interactions among the diverse proteins containing SH3 domains and those containing SH3 binding motifs.	RHONE POULENC RORER CENT RES,DEPT BIOL MOLEC,COLLEGEVILLE,PA 19426									BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FIELDS C G, 1991, Peptide Research, V4, P95; FLYNN DC, 1993, MOL CELL BIOL, V13, P7862; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1992, BIOTECHNIQUES, V13, P412; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LENSTRA JA, 1992, J IMMUNOL METHODS, V152, P149, DOI 10.1016/0022-1759(92)90136-H; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RON D, 1992, BIOTECHNIQUES, V13, P866; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	41	118	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24034	24039						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929055				2022-12-27	WOS:A1994PQ34600031
J	YAHI, N; SABATIER, JM; NICKEL, P; MABROUK, K; GONZALEZSCARANO, F; FANTINI, J				YAHI, N; SABATIER, JM; NICKEL, P; MABROUK, K; GONZALEZSCARANO, F; FANTINI, J			SURAMIN INHIBITS BINDING OF THE V3 REGION OF HIV-1 ENVELOPE GLYCOPROTEIN GP120 TO GALACTOSYLCERAMIDE, THE RECEPTOR FOR HIV-1 GP120 ON HUMAN COLON EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; SURFACE EXPRESSION; INFECTION; TYPE-1; LINES; CERAMIDE; INVITRO; GLYCOSPHINGOLIPIDS; LYMPHOCYTES	The infection of human colonic epithelial cells HT-29 by human immunodeficiency virus type 1 (HIV-1) occurs independently of CD4, the main HIV-1 receptor ex pressed on lymphocytes and macrophages. Recent studies from our group have shown that HT-29 cells express the glycosphingolipid galactosylceramide (GalCer), a potential alternative receptor for the HIV-1 envelope glycoprotein gp120. The binding of recombinant gp120 to GalCer was blocked by monoclonal antibodies directed against the third variable region (V3) of gp120 suggesting that the V3 domain was implicated in GalCer recognition. In the present report, we show that suramin, a polysulfonyl naphtylurea known to inhibit retroviral reverse transcriptases in vitro, blocks HIV-1 infection in HT-29 cells. The effect is dose dependent, with a half-maximal inhibition (IC50) achieved for a suramin concentration of 54 mu g/ml. Since [H-3]suramin was not significantly internalized into HT-29 cells during our infection assay (i.e. 2 h), we have considered the possibility that the drug could act at an extracellular step of the HIV-1 cycle. Using a high performance thin layer chromatography binding assay, we show that suramin inhibits binding of HIV-1 gp120 to purified GalCer with an IC50 of 25 mu g/ml. Suramin does not bind to GalCer, since preincubation of GalCer with suramin did not prevent the subsequent attachment of gp120. Using a solid-phase assay, we show that [SH]suramin specifically binds to recombinant gp120 and that this binding could be blocked by a monoclonal antibody specific for the conserved GPGRAF motif of the V3 domain of gp120. We also demonstrate that [H-3]suramin binds to multibranched synthetic GPGRAF peptides that block HIV-1 infection in HT-29 cells. Binding of [H-3]suramin to V3 peptides is specific and inhibited by unlabeled suramin (IC50 of 28 mu g/ml). In contrast, the suramin derivative NF036, that is unable to bleak HIV-1 infection in HT-29 cells, does not inhibit the binding of [H-3]suramin to V3 peptides. Taken together, these results suggest that suramin blocks HIV-1 infection in HT-29 cells because it binds to the V3 domain of gp120 and hence prevents the interaction between gp120 and the GalCer receptor.	UNIV BONN,INST PHARMAZEUT,W-5300 BONN 1,GERMANY; UNIV PENN,MED CTR,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of Bonn; University of Pennsylvania; University of Pennsylvania	YAHI, N (corresponding author), FAC MED NORD,CNRS,URA 1455,BD PIERRE DRAMARD,F-13916 MARSEILLE 20,FRANCE.			SABATIER, Jean-Marc/0000-0002-9040-5647; Fantini, Jacques/0000-0001-8653-5521				ADACHI A, 1987, J VIROL, V61, P209, DOI 10.1128/JVI.61.1.209-213.1987; AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; ASMUTH DM, 1994, AIDS, V8, P205, DOI 10.1097/00002030-199402000-00008; BAGHDIGUIAN S, 1993, CANCER LETT, V75, P151, DOI 10.1016/0304-3835(93)90057-G; BAGHDIGUIAN S, 1991, CANCER LETT, V60, P213, DOI 10.1016/0304-3835(91)90116-Y; BARNETT SW, 1991, VIROLOGY, V182, P902; BATINIC D, 1992, J BIOL CHEM, V267, P6664; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; BJORK S, 1987, J BIOL CHEM, V262, P6758; BOURINBAIAR AS, 1993, EUR J PHARMACOL, V230, P15, DOI 10.1016/0014-2999(93)90404-6; COOK DG, 1994, VIROLOGY, V201, P206, DOI 10.1006/viro.1994.1287; COOK DG, 1994, METHODS MOL GENET, V4, P86; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; FANTINI J, 1993, CR ACAD SCI III-VIE, V316, P1381; FANTINI J, 1990, INT J CANCER, V45, P554, DOI 10.1002/ijc.2910450330; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HARROP HA, 1994, AIDS, V8, P183, DOI 10.1097/00002030-199402000-00005; HEISE C, 1991, GASTROENTEROLOGY, V100, P1521, DOI 10.1016/0016-5085(91)90648-5; HOLGERSSON J, 1991, J BIOCHEM-TOKYO, V110, P120, DOI 10.1093/oxfordjournals.jbchem.a123530; JENTSCH KD, 1987, J GEN VIROL, V68, P2183, DOI 10.1099/0022-1317-68-8-2183; KOTLER DP, 1991, AM J PATHOL, V139, P823; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEVY JA, 1989, AM J GASTROENTEROL, V84, P787; MAYER KH, 1986, AM J MED, V80, P357, DOI 10.1016/0002-9343(86)90706-0; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; MOYER MP, 1991, J LEUKOCYTE BIOL, V49, P499, DOI 10.1002/jlb.49.5.499; OMARY MB, 1991, AIDS, V5, P275, DOI 10.1097/00002030-199103000-00005; PHILLIPS DM, 1992, VIROLOGY, V186, P261, DOI 10.1016/0042-6822(92)90080-9; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; SMITH PD, 1992, GASTROENTEROL CLIN N, V21, P331; STEIN CA, 1993, CANCER RES, V53, P2239; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TUCKER SP, 1993, ADV VIRUS RES, V42, P187, DOI 10.1016/S0065-3527(08)60086-X; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; YAHI N, 1992, EUR J IMMUNOL, V22, P2495, DOI 10.1002/eji.1830221005	40	75	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24349	24353						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929093				2022-12-27	WOS:A1994PQ34600077
J	NAGAN, N; KAGAN, HM				NAGAN, N; KAGAN, HM			MODULATION OF LYSYL OXIDASE ACTIVITY TOWARD PEPTIDYL LYSINE BY VICINAL DICARBOXYLIC AMINO-ACID-RESIDUES - IMPLICATIONS FOR COLLAGEN CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; III COLLAGEN; I PROCOLLAGEN; CDNA CLONE; CHAIN; PROPEPTIDE; REGION; GENE; IDENTIFICATION; BIOSYNTHESIS	The substrate specificity of lysyl oxidase has been explored with synthetic oligopeptides. k(cat)/K-m increased with increasing peptide length in Ac-(Gly)(n)-Lys-(Gly)(n)- CONH2 (n = 1-5). Using 11-mers as the standard peptide length, Glu immediately N-terminal to Lys increased k(cat)/K-m 8.8-fold over that for the -Lys-Glu- sequence and 4.9-fold over the glutamate-free control. Kinetic constants were significantly less perturbed when Glu was 2 or more residues distant from Lys. Replacement of Glu in -Glu-Lys- with Gln significantly increased K-m and lowered k(cat)/K-m. Asp rather than Glu N-terminal to Lys decreased K-m similar to that of the -Glu-Lys- 11-mer, although the k(cat) decreased considerably, indicating that lysyl oxidase responds to the side chain length of vicinal Asp or Glu at this position. -Asp-Glu-Lys- within an 11-mer was not oxidized, although this sequence is oxidized within the N-terminal telopeptide of the alpha 1(I) chain in type I collagen fibrils. Thus, lysyl oxidase exhibits distinct preferences for sequences vicinal to lysine. These results are discussed with respect to a model requiring collagen fibril formation prior to oxidation of lysine in collagen by lysyl oxidase.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, P01HL046902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 13262, HL 46902] Funding Source: Medline; NIAMS NIH HHS [R37 AR 18880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Atherton E., 1990, SOLID PHASE PEPTIDE; BERGOT BJ, 1985, USER B PEPTIDE SYNTH, V3; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BODANSZKY M, 1989, PEPTIDE CHEM PRACTIC; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; BORNSTEIN P, 1969, BIOCHEMISTRY-US, V8, P63, DOI 10.1021/bi00829a010; CHANDA VB, 1989, GENE, V78, P255; CLICK EM, 1970, BIOCHEMISTRY-US, V9, P4699; DEAK F, 1985, BIOCHEM J, V229, P189, DOI 10.1042/bj2290189; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; FIETZEK PP, 1979, H-S Z PHYSIOL CHEM, V360, P809, DOI 10.1515/bchm2.1979.360.2.809; FIETZEK PP, 1974, BIOCHIM BIOPHYS ACTA, V365, P305, DOI 10.1016/0005-2795(74)90001-4; FRANKEL FR, 1988, DNA-J MOLEC CELL BIO, V7, P347, DOI 10.1089/dna.1.1988.7.347; FUKAE M, 1980, J BIOL CHEM, V255, P6511; FULLER F, 1981, BIOCHEMISTRY-US, V20, P996, DOI 10.1021/bi00507a054; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; JANECZKO RA, 1989, NUCLEIC ACIDS RES, V17, P6742, DOI 10.1093/nar/17.16.6742; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1980, J BIOL CHEM, V255, P3656; KAGAN HM, 1981, J BIOL CHEM, V256, P5417; KAGAN HM, 1982, METHOD ENZYMOL, V82, P637; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KANG AH, 1970, BIOCHEMISTRY-US, V9, P796, DOI 10.1021/bi00806a012; KANG AH, 1967, BIOCHEMISTRY-US, V6, P788, DOI 10.1021/bi00855a019; KOHNO K, 1984, J BIOL CHEM, V259, P3668; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; RAUTERBERG J, 1972, EUR J BIOCHEM, V27, P231, DOI 10.1111/j.1432-1033.1972.tb01831.x; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SOLE NA, 1992, J ORG CHEM, V57, P5339; STOLTZ TR, 1972, FEBS LETT, V26, P61; SU MW, 1989, GENOMICS, V4, P438, DOI 10.1016/0888-7543(89)90353-4; TANG SS, 1983, J BIOL CHEM, V258, P4331; THOMPSON RC, 1970, P NATL ACAD SCI USA, V67, P1734, DOI 10.1073/pnas.67.4.1734; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; TRACKMAN PC, 1979, J BIOL CHEM, V254, P7831; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; WOOD L, 1987, GENE, V61, P225, DOI 10.1016/0378-1119(87)90117-X; WU JJ, 1992, J BIOL CHEM, V267, P23007; YAMADA Y, 1983, NUCLEIC ACIDS RES, V11, P2733, DOI 10.1093/nar/11.9.2733	50	33	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22366	22371						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915281				2022-12-27	WOS:A1994PE09800066
J	GADDA, G; NEGRI, A; PILONE, MS				GADDA, G; NEGRI, A; PILONE, MS			REACTION OF PHENYLGLYOXAL WITH ARGININE GROUPS IN D-AMINO-ACID OXIDASE FROM RHODOTORULA-GRACILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE ARGININE; D-ASPARTATE OXIDASE; CHEMICAL MODIFICATION; BEEF KIDNEY; PIG-KIDNEY; INACTIVATION; RESOLUTION; SEQUENCE; FLAVOCYTOCHROME-B2; 8-MERCAPTOFLAVINS	D-Amino-acid oxidase from Rhodotorula gracilis was irreversibly inactivated by phenylglyoxal in a biphasic process. The fast phase was completed in less than 1 min. Its extent was linearly dependent on phenylglyoxal concentration and was not influenced by the presence of FAD or benzoate, a pseudo substrate. The second phase of inactivation was due to a simple second-order reaction. The presence of FAD exerted only partial protection; the second-order rate constants of inactivation were 8.3 M(-1) min(-1) for holoprotein and 18.0 M(-1) min(-1) for apoprotein. The addition of benzoate completely protected against this second phase of inactivation. Efforts to isolate the enzyme modified at a single arginine residue at the end of the fast phase were unsuccessful, but analysis of the enzyme isolated at the end of the slow phase identified an arginine residue, protected by benzoate, that is highly conserved in all D-amino-acid oxidases and corresponds to Arg(283) in the pig kidney enzyme. Modification of this residue is directly involved in the inactivation process during the slow phase. This arginine may represent the basic residue ion pairing with the carboxylate group of the substrate or the residue interacting with the flavin N-1-C-2 = O locus.	UNIV MILAN,DEPT GEN PHYSIOL & BIOCHEM,I-20133 MILAN,ITALY; UNIV MILAN,INST VET PHYSIOL & BIOCHEM,I-20133 MILAN,ITALY; UNIV MILAN,CTR INTERUNIV STUDIO MACROMOLEC INFORMAZ,I-20133 MILAN,ITALY	University of Milan; University of Milan; University of Milan			Gadda, Giovanni/M-2354-2016; Negri, Armando/H-7914-2017	Gadda, Giovanni/0000-0002-7508-4195; Negri, Armando/0000-0002-8401-7437				BORDERS CL, 1975, BIOCHEMISTRY-US, V14, P4699, DOI 10.1021/bi00692a021; CASALIN P, 1991, EUR J BIOCHEM, V197, P513, DOI 10.1111/j.1432-1033.1991.tb15939.x; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; FAOTTO L, 1994, IN PRESS FLAVINS FLA; FERTI C, 1981, EUR J BIOCHEM, V199, P553; FITZPATRICK PF, 1983, J BIOL CHEM, V258, P9700; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GHRIR R, 1984, BIOCHEMISTRY-US, V23, P5202, DOI 10.1021/bi00317a018; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; ISOGAI T, 1990, J BIOCHEM-TOKYO, V108, P1063, DOI 10.1093/oxfordjournals.jbchem.a123306; KOHLBRENNER WE, 1978, J BIOL CHEM, V253, P7609; KOMATSU K, 1988, CHEM ABSTR 49619S, V108; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIM LW, 1986, J BIOL CHEM, V261, P5140; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; MIYAKE Y, 1991, FLAVINS AND FLAVOPROTEINS 1990, P135; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; MUKHERJEE JJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P147, DOI 10.1016/0003-9861(92)90256-V; NEGRI A, 1992, J BIOL CHEM, V267, P11865; NISHINO T, 1980, J BIOL CHEM, V255, P3610; PETERS RG, 1981, BIOCHEMISTRY-US, V20, P2564, DOI 10.1021/bi00512a031; PILONE MS, 1992, BIOTECHNOL APPL BIOC, V16, P252; POLLEGIONI L, 1992, BIOCHEM J, V286, P389, DOI 10.1042/bj2860389; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; POLLEGIONI L, 1992, PROTEIN EXPRES PURIF, V3, P165, DOI 10.1016/S1046-5928(05)80034-8; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; RAMAKRISHNA S, 1981, BIOCHEM J, V195, P735, DOI 10.1042/bj1950735; RONCHI S, 1982, J BIOL CHEM, V257, P8824; SIMONETTA MP, 1987, BIOCHIM BIOPHYS ACTA, V914, P136, DOI 10.1016/0167-4838(87)90056-2; SIMONETTA MP, 1989, EUR J BIOCHEM, V180, P199; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TEDESCHI G, 1992, EUR J BIOCHEM, V205, P127, DOI 10.1111/j.1432-1033.1992.tb16759.x; VANBERKEL WJH, 1984, EUR J BIOCHEM, V145, P245; VANDENBERGHESNOREK S, 1985, J BIOL CHEM, V260, P3373; VANONI MA, 1987, EUR J BIOCHEM, V167, P261, DOI 10.1111/j.1432-1033.1987.tb13332.x; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	39	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	1994	269	27					17809	17814						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NV422	7913089				2022-12-27	WOS:A1994NV42200011
J	LOOK, DC; PELLETIER, MR; HOLTZMAN, MJ				LOOK, DC; PELLETIER, MR; HOLTZMAN, MJ			SELECTIVE INTERACTION OF A SUBSET OF INTERFERON-GAMMA RESPONSE ELEMENT-BINDING PROTEINS WITH THE INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1) GENE PROMOTER CONTROLS THE PATTERN OF EXPRESSION ON EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTIONAL INDUCTION; DEVELOPMENTAL REGULATION; ENHANCER ELEMENT; SYNTHETASE GENE; NUCLEAR FACTORS; REGION; IDENTIFICATION; RECEPTOR; MEDIATE	Intercellular adhesion molecule-1 (ICAM-1) modulates epithelial and endothelial leukocyte adherence, but epithelial cell ICAM-1 levels (unlike endothelial cell levels) are selectively sensitive to interferon-gamma (IFN-gamma). Nuclear run off assays indicated that IFN gamma regulation of epithelial ICAM-1 levels occurs at a transcriptional level, so the basis for selective cytokine control of ICAM-1 expression was investigated using the ICAM-1 gene promoter region. A plasmid construct containing 5.0 kilobases of ICAM-1 gene 5'-flanking region fused to a reporter gene was selectively responsive to IFN-gamma in (human tracheal) epithelial cells but not in (human umbilical vein) endothelial cells, indicating that this region is sufficient to mediate proper cell specific expression. An IFN-gamma response element (IRE) was localized to a DNA segment (nucleotides -130 to -94) in the ICAM-1 gene by comparisons of nested 5'-deletional constructs and by demonstrating that this segment confers IFN-gamma responsiveness on heterologous promoters. This same IRE formed a single major binding complex (IRE-BC) in gel retardation assays with nuclear proteins from IFN-gamma-stimulated but not unstimulated epithelial cells, and mutation of the IRE consensus motif (TTTCCGGGAAA at -116 to -106) resulted in loss of IRE-protein binding and abolished IFN-gamma responsiveness, indicating that this sequence is required for ICAM-1 IRE function. Comparison of the ICAM-1 IRE to DNA elements that confer IFN responsiveness in other human genes indicated similarity only to response regions in the Fc gamma RI and IRF-1 genes. The findings provide evidence for a distinct IRE subset that combines a DNA element common to all IFN-responsive genes (GAAA) with a distinct flanking sequence (the inverted repeat GAAA) in order to fine-tune IFN responses and activate a subset of immune response genes (ICAM-1, Fc gamma RI, and IRF-1).	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NHLBI NIH HHS [HL-02920, HL-07317, HL-40078] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317, R01HL040078, K08HL002920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLANTYNE CM, 1992, GENOMICS, V14, P1076, DOI 10.1016/S0888-7543(05)80132-6; BARR CL, 1991, J BIOL CHEM, V266, P3475; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DAI W, 1990, J BIOL CHEM, V265, P19871; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; HAKEM R, 1991, INT J CANCER, P2; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1990, MOL CELL BIOL, V10, P5150, DOI 10.1128/MCB.10.10.5150; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LUSTER AD, 1987, MOL CELL BIOL, V7, P3723, DOI 10.1128/MCB.7.10.3723; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; NAKAJIMA S, 1993, J CELL BIOCHEM, P351; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORNICK LP, 1993, J BIOL CHEM, V268, P371; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; ZINN K, 1986, CELL, V45, P611, DOI 10.1016/0092-8674(86)90293-X	57	124	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8952	8958						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7907595				2022-12-27	WOS:A1994NB41100051
J	REZAIE, AR; MATHER, T; SUSSMAN, F; ESMON, CT				REZAIE, AR; MATHER, T; SUSSMAN, F; ESMON, CT			MUTATION OF GLU-80 -] LYS RESULTS IN A PROTEIN-C MUTANT THAT NO LONGER REQUIRES CA2+ FOR RAPID ACTIVATION BY THE THROMBIN-THROMBOMODULIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; CALCIUM-BINDING SITE; CRYSTAL-STRUCTURE; FACTOR-X; DOMAIN; COAGULATION; RESOLUTION; CHAIN	Binding Ca2+ to a high affinity site in protein C and Gla-domainless protein C (protein C lacking residues 1-44) results in a conformational change that is required for activation by the thrombin-thrombomodulin complex, the natural activator of protein C. Protein C modeling studies suggested the single high affinity Ca2+ binding-site might be present in a loop in the protease domain and involve Glu-70 and -80 (chymotrypsin numbering system). This loop, which is a known Ca2+-binding site in trypsin, is also conserved in other coagulation proteases, including factors VII, IX and X. In thrombin, which does not bind Ca2+, Glu-70 is replaced by Lys, creating an internal salt bridge with Glu-80. We constructed and expressed a Gla-domainless protein C mutant in which Glu-80 is replaced with Lys. The activation of the resultant mutant is accelerated by thrombomodulin in a Ca2+-independent fashion. Unlike wild type Gla-domainless protein C, Ca2+ no longer inhibits activation of the mutant by free thrombin, and Ca2+ stimulation of chromogenic activity is also absent. The characteristic Ca2+-dependent quenching of Gla-domainless protein C intrinsic fluorescence is also absent in the mutant. We conclude that the high affinity Ca2+-binding site in protein C critical for zymogen activation involves Glu-80. The Glu-80 to Lys mutation probably results in a salt bridge with Glu-70 that stabilizes protein C zymogen in a conformation similar, if not identical, to the Ca2+-stabilized conformation favorable for rapid activation by the thrombin-thrombomodulin complex.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT CHEM & BIOCHEM,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT RES & EDUC COMP,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center				Sussman, Fredy/0000-0003-0189-6307				BADMANABHAN K, 1993, J MOL BIOL, V232, P947; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GREER J, 1990, PROTEIN-STRUCT FUNCT, V7, P312; GRINNELL BW, 1991, PROTEIN C RELATED AN, V11, P29; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KIMURA S, 1989, J BIOCHEM-TOKYO, V105, P478, DOI 10.1093/oxfordjournals.jbchem.a122690; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; MOMANY FA, 1992, J COMPUT CHEM, V13, P888, DOI 10.1002/jcc.540130714; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1991, J BIOL CHEM, V266, P2444; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SUGO T, 1985, J BIOL CHEM, V130, P841; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016	28	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3151	3154						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7906267				2022-12-27	WOS:A1994MV63100008
J	MERY, PF; PAVOINE, C; BELHASSEN, L; PECKER, F; FISCHMEISTER, R				MERY, PF; PAVOINE, C; BELHASSEN, L; PECKER, F; FISCHMEISTER, R			NITRIC-OXIDE REGULATES CARDIAC CA2+ CURRENT - INVOLVEMENT OF CGMP-INHIBITED AND CGMP-STIMULATED PHOSPHODIESTERASES THROUGH GUANYLYL CYCLASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PIG VENTRICULAR MYOCYTES; DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; CALCIUM CURRENT; AMP PHOSPHODIESTERASES; SELECTIVE INHIBITORS; FROG VENTRICLE; CA-2+ CURRENT; SINGLE CELLS	The effects of the nitric oxide (NO) donor 3-morpholino-sydnonimine (SIN-1) on the L-type Ca2+ current (I(Ca)) were examined in frog ventricular myocytes under basal and phosphorylated conditions. SIN-1 was found to exert insignificant effects on basal I(Ca) but to induce a biphasic action on stimulated I(Ca). Indeed, in the nanomolar range of concentrations (0.1-10 nM), SIN-1 induced a pronounced (almost-equal-to 40%) stimulation of I(Ca) elevated by a non-maximal concentration of forskolin (0.3 muM). However, the stimulatory effects of SIN-1 on I(Ca) were not additive with those of maximal concentrations (10 muM) of forskolin or intracellular cAMP. In contrast, at higher concentrations (100 nM to 1 mM), SIN-1 strongly reduced I(Ca) (by up to 85%) which had been previously stimulated by cAMP, forskolin, or isoprenaline. All the effects of SIN-1 appeared to be mediated by the liberation of NO since they were suppressed by methylene blue and LY83583 and were not mimicked by SIN-1C, a metabolite of SIN-1. The stimulatory or inhibitory effects of SIN-1 were absent, respectively, in the presence of milrinone (10 muM) or when the hydrolysis-resistant cAMP analog 8-bromo-cAMP was used instead of cAMP to stimulate I(Ca). In addition to its effects on I(Ca), SIN-1 induced a dose-dependent stimulation of guanylyl cyclase activity in the cytosolic and membrane fractions of frog ventricle. The membrane form of guanylyl cyclase displayed a higher sensitivity to SIN-1 than the cytosolic form, which correlated with SIN-1 sensitivity of I(Ca). Our data suggest that the activatory and inhibitory effects of NO donors on I(Ca). result from an inhibition of the cGMP-inhibited cAMP-phosphodiesterase and an activation of the cGMP-stimulated cAMP-phosphodiesterase, respectively, both linked to the activation of guanylyl cyclase, possibly a membrane form of the enzyme.	UNIV PARIS SUD, FAC PHARM,INSERM,CARDIOL CELLULAIRE & MOLEC LAB, CJF 92-11, F-92296 CHATENAY MALABRY, FRANCE; HOP HENRI MONDOR, INSERM, F-94010 CRETEIL, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Pavoine, Catherine/N-4405-2018; Fischmeister, Rodolphe/L-6061-2018; MERY, Pierre-François/C-5903-2019	Pavoine, Catherine/0000-0002-0598-5545; Fischmeister, Rodolphe/0000-0003-2086-9865; Mery, Pierre-Francois/0000-0001-6214-5422				ALLOATTI G, 1991, J MOL CELL CARDIOL, V23, P851, DOI 10.1016/0022-2828(91)90218-B; ARGIBAY JA, 1988, J PHYSIOL-LONDON, V401, P201, DOI 10.1113/jphysiol.1988.sp017158; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BARBIER AJM, 1992, EUR J PHARMACOL, V219, P331, DOI 10.1016/0014-2999(92)90315-U; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BRECHLER V, 1992, J BIOL CHEM, V267, P15496; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUTSAERT DL, 1993, NEWS PHYSIOL SCI, V8, P82; BUXTON ILO, 1993, CIRC RES, V72, P387, DOI 10.1161/01.RES.72.2.387; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; FACH WA, 1984, Z KARDIOL, V73, P613; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; FISCHMEISTER R, 1991, LIFE SCI, V48, P2365, DOI 10.1016/0024-3205(91)90369-M; FISCHMEISTER R, 1990, MOL PHARMACOL, V38, P426; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; GARBERS DL, 1992, CELL, V71, P1; GARCIA JL, 1992, BRIT J PHARMACOL, V106, P563, DOI 10.1111/j.1476-5381.1992.tb14375.x; GISBERT MP, 1988, CIRC RES, V62, P660, DOI 10.1161/01.RES.62.4.660; Goldberg N D, 1975, Adv Cyclic Nucleotide Res, V5, P307; HARTZELL HC, 1992, TRENDS PHARMACOL SCI, V13, P380, DOI 10.1016/0165-6147(92)90117-O; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HARTZELL HC, 1987, MOL PHARMACOL, V32, P639; HONGO K, 1993, J PHYSIOL-LONDON, V461, P185, DOI 10.1113/jphysiol.1993.sp019508; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KLABUNDE RE, 1992, EUR J PHARMACOL, V223, P1, DOI 10.1016/0014-2999(92)90810-Q; KLIMASCHEWSKI L, 1992, CIRC RES, V71, P1533, DOI 10.1161/01.RES.71.6.1533; KONTOS HA, 1993, STROKE, V24, P427, DOI 10.1161/01.STR.24.3.427; LACOMBE ML, 1983, BIOCHEM BIOPH RES CO, V116, P47, DOI 10.1016/0006-291X(83)90378-9; LAMONTAGNE D, 1991, J CARDIOVASC PHARM, V17, pS89, DOI 10.1097/00005344-199117003-00016; LEGRAND B, 1992, PFLUG ARCH EUR J PHY, V421, P486, DOI 10.1007/BF00370260; LEVI RC, 1989, PFLUG ARCH EUR J PHY, V413, P685, DOI 10.1007/BF00581823; LEVI RC, 1988, J PHARMACOL EXP THER, V246, P377; LINCOLN TM, 1981, BIOCHIM BIOPHYS ACTA, V676, P230, DOI 10.1016/0304-4165(81)90192-6; LINDEMANN JP, 1989, PHYSL PATHOPHYSIOLOG, P423; LOHMANN SM, 1991, BASIC RES CARDIOL, V86, P503, DOI 10.1007/BF02190700; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MARCZIN N, 1992, J PHARMACOL EXP THER, V263, P170; MCCALL D, 1990, J MOL CELL CARDIOL, V22, P201, DOI 10.1016/0022-2828(90)91116-O; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MERY PF, 1990, NATURE, V345, P158, DOI 10.1038/345158a0; MERY PF, 1993, J PHYSIOL-LONDON, V459, pP420; NICHOLSON CD, 1991, TRENDS PHARMACOL SCI, V12, P19, DOI 10.1016/0165-6147(91)90484-A; ONO K, 1991, J PHYSIOL-LONDON, V443, P387, DOI 10.1113/jphysiol.1991.sp018839; OUADID H, 1992, MOL PHARMACOL, V41, P346; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; RAMACIOTTI C, 1992, P NATL ACAD SCI USA, V89, P4033, DOI 10.1073/pnas.89.9.4033; REDEN J, 1990, BLOOD VESSELS, V27, P282; RUGG EL, 1989, BIOCHEM BIOPH RES CO, V162, P1339, DOI 10.1016/0006-291X(89)90820-6; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHULZ R, 1991, BRIT J PHARMACOL, V104, P21, DOI 10.1111/j.1476-5381.1991.tb12378.x; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SIMMONS MA, 1988, MOL PHARMACOL, V33, P664; SMITH JA, 1992, TRENDS PHARMACOL SCI, V13, P113, DOI 10.1016/0165-6147(92)90040-D; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SORBERA LA, 1990, SCIENCE, V247, P969, DOI 10.1126/science.2154853; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; THELEN KI, 1992, N-S ARCH PHARMACOL, V345, P93; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WANG R, 1991, FEBS LETT, V282, P331, DOI 10.1016/0014-5793(91)80507-Y; WEBER KT, 1992, HEART CARDIOVASCULAR, P1465; WHITE DG, 1993, BRIT J PHARMACOL, V108, P763, DOI 10.1111/j.1476-5381.1993.tb12875.x; YAMAZAKI J, 1991, J PHARMACOL EXP THER, V259, P52	69	422	429	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26286	26295						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7902837				2022-12-27	WOS:A1993MK42500044
J	WANG, LY; KARLSSON, A; ARNER, ESJ; ERIKSSON, S				WANG, LY; KARLSSON, A; ARNER, ESJ; ERIKSSON, S			SUBSTRATE-SPECIFICITY OF MITOCHONDRIAL 2'-DEOXYGUANOSINE KINASE - EFFICIENT PHOSPHORYLATION OF 2-CHLORODEOXYADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; VARICELLA-ZOSTER VIRUS; DEOXYCYTIDINE KINASE; DEOXYGUANOSINE KINASE; NUCLEOSIDE ANALOGS; THYMIDINE KINASE-1; LEUKEMIC CELLS; METABOLISM; TOXICITY; DNA	Mitochondrial deoxyguanosine kinase (dGK) (EC 2.7.1.113) was purified to apparent homogeneity from bovine brain. The molecular mass of the native protein was 56 kDa, as judged by gel filtration, and one single band of 28 kDa was seen in sodium dodecyl sulfate-gel electrophoresis. 2'-Deoxyguanosine (dGuo) (K(m), 7.6 muM), 2'-deoxyinosine, and 2'-deoxyadenosine (K(m), 60 muM) were substrates for the enzyme as well as several dGuo analogs containing a lipophilic substituent at C-2'. Carbocyclic dGuo, 9-beta-D-arabinofuranosylguanine, 9-beta-D-arabinofuranosylhypoxanthine, and 9-beta-D-arabinofuranosyladenine were substrates for the enzyme, whereas no 3'-modified dGuo analogs were effective. Interestingly, 2-chloro-2'-deoxyadenosine (CdA) was found to be an efficient substrate for dGK (K(m), 85 muM). Subcellular fractionation of human CEM lymphoblasts showed that extracts of mitochondria contain significant CdA phosphorylating activity (71.5 pmol/mg/min) that is not inhibited by excess of 2'-deoxycytidine (dCyd). This contrasts with the CdA phosphorylating activity found in cytosolic extracts, which is carried out by dCyd kinase and strongly inhibited by excess of dCyd. The efficient CdA phosphorylation by mitochondrial dGK is a novel finding that may have far reaching implications for the clinical use of this potent cytostatic drug.	KAROLINSKA INST,MED NOBEL INST,DEPT BIOCHEM 1,BOX 60 400,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Arnér, Elias/K-6737-2019; Karlsson, Anna/E-7945-2018; Arnér, Elias S.J./J-5832-2012	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Karlsson, Anna/0000-0001-6843-6685				ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; AVERETT DR, 1991, ANTIMICROB AGENTS CH, V35, P851, DOI 10.1128/AAC.35.5.851; BARKER J, 1981, BIOCHIM BIOPHYS ACTA, V658, P111, DOI 10.1016/0005-2744(81)90254-0; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CHEN CH, 1989, J BIOL CHEM, V264, P11934; COHEN A, 1983, BLOOD, V61, P660; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; FAIRBANKS LD, 1990, J IMMUNOL, V144, P485; GOWER WR, 1979, J BIOL CHEM, V254, P2180; GREEN FJ, 1979, BIOCHEM J, V183, P547, DOI 10.1042/bj1830547; HERSHFIELD MS, 1982, J BIOL CHEM, V257, P6380; Ives D H, 1978, Methods Enzymol, V51, P337; LAMBE CU, 1992, ANTIMICROB AGENTS CH, V36, P353, DOI 10.1128/AAC.36.2.353; LEWIS RA, 1991, PURINE PYRIMIDINE ME, V7, P181; PARK I, 1988, ARCH BIOCHEM BIOPHYS, V266, P51, DOI 10.1016/0003-9861(88)90235-4; PLUNKETT W, 1991, PHARMACOL THERAPEUT, V49, P239, DOI 10.1016/0163-7258(91)90057-S; SHEWACH DS, 1989, CANCER RES, V49, P6498; STARNES MC, 1987, J BIOL CHEM, V262, P988; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; YAMADA Y, 1982, BIOCHIM BIOPHYS ACTA, V709, P265, DOI 10.1016/0167-4838(82)90469-1	24	124	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22847	22852						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901204				2022-12-27	WOS:A1993MD34800097
J	IWASAKI, S; HOMMA, T; MATSUDA, Y; KON, V				IWASAKI, S; HOMMA, T; MATSUDA, Y; KON, V			ENDOTHELIN RECEPTOR SUBTYPE-B MEDIATES AUTOINDUCTION OF ENDOTHELIN-1 IN RAT MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; TRANSFORMING GROWTH FACTOR-BETA-1; MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; NITRIC-OXIDE; PREPROENDOTHELIN-1 GENE; SECRETION; CLONING; SEQUENCE; KIDNEY	Autoinduction of endothelin-1 (ET-1) has been suggested to be involved in the profound and long-lasting effects of ET-1. We examined mechanisms that underlie autoinduction of ET-1 in cultured rat glomerular mesangial cells. Incubation of mesangial cells with ET-1 resulted in an immediate and dose-dependent stimulation of preproET-1 mRNA expression as assessed by polymerase chain reaction coupled with reverse transcription. Within 1 h of exposure to ET-1 (10(-7) M), preproET-1 mRNA expression was increased to a maximal level of 465 +/- 43% of the control value (p < 0.01), which was accompanied by significant stimulation of production of the immunoreactive ET-1 peptide. Nuclear run-off analysis revealed increases in the transcriptional rate of preproET-1 mRNA to 239 and 175% above the control values at 1 and 3 h of ET-1 stimulation, respectively. ET-1 also increased the stability of preproET-1 mRNA, resulting in an mRNA half-life of 60 min from 20 min seen in non-stimulated cells. Addition of an ET(B)-specific antagonist, RES701-1, at > 10(-9) M abolished ET-1 stimulation of preproET-1 mRNA (p < 0.001), whereas an ET(A)-specific antagonist, BQ123, was without effects (up to 10(-5) M). The ET(B) agonist, sarafotoxin S6c (10(-7) M), significantly stimulated preproET-1 mRNA expression to 201 +/- 14% above controls (p < 0.01), an effect that was lessened significantly by RES701-1 (p < 0.05). RES701-1 abolished the ET-1-induced production of the ET-1 peptide (p < 0.001). Taken together, we demonstrates that in mesangial cells, autoinduction of ET-1 occurs through the ET(B) receptor subtype via increases in both preproET-1 transcription and mRNA stability.	VANDERBILT UNIV,MED CTR N C4204,SCH MED,DEPT PEDIAT,DIV PEDIAT NEPHROL,NASHVILLE,TN 37232; KYOWA HAKKO KOGYO CO LTD,TOKYO 194,JAPAN	Vanderbilt University; Kyowa Kirin Ltd					NIDDK NIH HHS [DK42159, DK44757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK044757, R01DK042159] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS GF, 1994, J BIOL CHEM, V269, P10112; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; AWAZU M, 1991, J AM SOC NEPHROL, V1, P1253; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FIRTH JD, 1992, J CLIN INVEST, V90, P1023, DOI 10.1172/JCI115915; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOLIGORSKY MS, 1994, J CELL PHYSIOL, V158, P485, DOI 10.1002/jcp.1041580313; GOTO K, 1989, P NATL ACAD SCI USA, V86, P3915, DOI 10.1073/pnas.86.10.3915; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAHN AWA, 1990, CELL REGUL, V1, P649, DOI 10.1091/mbc.1.9.649; HEXUM TD, 1990, BIOCHEM BIOPH RES CO, V167, P294, DOI 10.1016/0006-291X(90)91764-J; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; HORIE M, 1991, J CARDIOVASC PHARM, V17, pS222, DOI 10.1097/00005344-199100177-00064; HU RM, 1992, J BIOL CHEM, V267, P17384; HUGGINS JP, 1993, PHARMACOL THERAPEUT, V59, P55, DOI 10.1016/0163-7258(93)90041-B; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; IMAI T, 1992, HYPERTENSION, V19, P753, DOI 10.1161/01.HYP.19.6.753; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; ISHIMURA E, 1991, Journal of the American Society of Nephrology, V2, P546; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWASAKI S, 1994, KIDNEY INT, V45, P592, DOI 10.1038/ki.1994.77; Iwasaki Shigeki, 1992, Journal of the American Society of Nephrology, V3, P760; KARNE S, 1993, J BIOL CHEM, V268, P19126; KOHAN DE, 1993, AM J KIDNEY DIS, V22, P493, DOI 10.1016/S0272-6386(12)80920-6; KOHNO M, 1994, AM J PHYSIOL, V266, pF894, DOI 10.1152/ajprenal.1994.266.6.F894; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KRAPF R, 1991, J CLIN INVEST, V88, P783, DOI 10.1172/JCI115377; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; MARTIN ER, 1990, J BIOL CHEM, V4265, P14044; MORISHITA Y, 1994, J ANTIBIOT, V47, P269, DOI 10.7164/antibiotics.47.269; OWADA A, 1994, J CLIN INVEST, V93, P556, DOI 10.1172/JCI117007; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; SAIJONMAA O, 1992, BIOCHEM BIOPH RES CO, V188, P286, DOI 10.1016/0006-291X(92)92382-8; SAKAMOTO H, 1992, KIDNEY INT, V41, P350, DOI 10.1038/ki.1992.48; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; TAKEDA M, 1994, AM J PATHOL, V144, P473; TAKEDA M, 1992, KIDNEY INT, V42, P1713; TANAKA T, 1994, MOL PHARMACOL, V45, P724; VANOBBERGHENSCH.E, 1988, J BIOL CHEM, V263, P7741; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; WARMER S, 1987, J EXP MED, V165, P1316; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOKAWA K, 1991, HYPERTENSION, V18, P304, DOI 10.1161/01.HYP.18.3.304; Yoshimura Ashio, 1992, Journal of the American Society of Nephrology, V3, P624; ZOJA C, 1991, LAB INVEST, V64, P16	64	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6997	7003		10.1074/jbc.270.12.6997	http://dx.doi.org/10.1074/jbc.270.12.6997			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896851	hybrid			2022-12-27	WOS:A1995QQ85500082
J	NAO, SQ; HINCAPIE, M; MCCUSKER, JH; HABER, JE				NAO, SQ; HINCAPIE, M; MCCUSKER, JH; HABER, JE			MOP2 (SLA2) AFFECTS THE ABUNDANCE OF THE PLASMA-MEMBRANE H+-ATPASE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; (NA+ + K+)ATPASE; INTRACELLULAR-TRANSPORT; YEAST-CELLS; FUNCTIONAL EXPRESSION; SECRETORY VESICLES; ALPHA-SUBUNIT; GENE; NA,K-ATPASE; IDENTIFICATION	The abundance of yeast plasma membrane H+-ATPase on the cell surface is tightly regulated. Modifier of pma1 (mop) mutants were isolated as enhancers of the mutant phenotypes of pma1 mutants, mop2 mutations reduce the abundance and activity of Pma1 protein on the plasma membrane without affecting the abundance of other prominent plasma membrane proteins. The MOP2 gene encodes a 108-kDa protein that has previously been identified both as a gene affecting the yeast cytoskeleton (SLA2) (Holtzman, D.A., Yang, S., and Drubin, D. G. (1993) J. Cell Biol. 122, 635-644) and as a gene affecting endocytosis (END4) (Raths, S., Roher, J., Crausaz, F., and Riezman, H. (1993) J. Cell Biol. 120, 55-65). In some strains, MOP2 (SLA2) is essential for cell viability; in others, a deletion mutant is temperature sensitive for growth. mop2 mutations do not reduce the transcription of PMA1 nor do they lead to the accumulation of Pma1 protein in any intracellular compartment. An epitope-tagged MOP2 protein behaves as a plasma membrane-associated protein whose abundance is proportional to its level of gene expression. Over-expression of MOP2 relieved the toxicity caused by the over-expression of PMA1 from a high copy plasmid; conversely, the growth of mop2 strains was inhibited by the presence of a single extra copy of PMA1. We conclude that MOP2 (SLA2) encodes a plasma membrane-associated protein that is required for the accumulation and/or maintenance of plasma membrane H+-ATPase on the cell surface.	BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA; BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610; McCusker, John/0000-0002-8803-9131	NIGMS NIH HHS [GM39739, GM07596] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1016/S0022-2836(05)80360-2; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BOWMAN BJ, 1981, J BIOL CHEM, V256, P2343; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARONI P, 1981, J BIOL CHEM, V256, P9371; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CHANG A, 1993, P NATL ACAD SCI USA, V90, P5808, DOI 10.1073/pnas.90.12.5808; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS LS, 1994, P NATL ACAD SCI USA, V91, P10531; HIRATA R, 1993, J BIOL CHEM, V268, P961; HOLCOMB CL, 1988, J CELL BIOL, V106, P641, DOI 10.1083/jcb.106.3.641; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MacLennan D H, 1987, Soc Gen Physiol Ser, V41, P287; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MCCUSKER JH, 1988, GENETICS, V119, P317; MCCUSKER JH, 1986, THESIS BRANDEIS U; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PANARETOU B, 1992, EUR J BIOCHEM, V206, P635, DOI 10.1111/j.1432-1033.1992.tb16968.x; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REED DJG, 1990, NATURE, V347, P685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERRANO R, 1980, EUR J BIOCHEM, V105, P419, DOI 10.1111/j.1432-1033.1980.tb04516.x; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1991, BIOCHIM BIOPHYS ACTA, V1062, P157, DOI 10.1016/0005-2736(91)90387-N; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SLAYMAN CL, 1986, J BIOENERG BIOMEMBR, V19, P1; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; TAKEYASU K, 1989, SEIKAGAKU, V61, P394; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; VAI M, 1986, FEBS LETT, V206, P135, DOI 10.1016/0014-5793(86)81355-2; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WUYTACK F, 1992, J BIOENERG BIOMEMBR, V24, P285	65	46	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6815	6823		10.1074/jbc.270.12.6815	http://dx.doi.org/10.1074/jbc.270.12.6815			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896828	hybrid			2022-12-27	WOS:A1995QQ85500059
J	XIE, T; BELINSKY, M; XU, YH; JAISWAL, AK				XIE, T; BELINSKY, M; XU, YH; JAISWAL, AK			ARE-MEDIATED AND TRE-MEDIATED REGULATION OF GENE-EXPRESSION - RESPONSE TO XENOBIOTICS AND ANTIOXIDANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; NAD(P)H-QUINONE REDUCTASE GENE; GLUTATHIONE S-TRANSFERASES; PLANAR AROMATIC-COMPOUNDS; DNA-PROTEIN INTERACTION; TRANSCRIPTIONAL REGULATION; OXIDATIVE STRESS; PHENOLIC ANTIOXIDANTS; BIOLOGICAL FUNCTION	Antioxidant response elements (AREs) containing 12-O- tetradecanoylphorbol-13-acetate response element (TRE) (perfect AP1) and TRE-like (imperfect AP1) elements mediate high basal transcription of the NAD-(P)H:quinone oxidoreductase(1) (NQO(1)) and glutathione S-transferase Ya genes in tumor cells and its induction in response to xenobiotics and antioxidants. Mutations in the human NQO(1) gene ARE (hARE) revealed the requirement for two TRE or TRE-like elements arranged in inverse orientation at the interval of three base pairs and a GC box for optimal expression and beta-naphthoflavone induction of the NQO(1) gene. A single TRE element from the human collagenase gene failed to respond to beta-naphthoflavone. These results demonstrate that ARE (2 x TRE or TRE-like elements)-containing detoxifying enzyme genes and not genes that contain 1 x TRE are responsive to xenobiotics and antioxidants. Bandshift assays showed shifting of a complex of more or less similar mobility with hARE and TRE that could be competed by each other. Mutations in the 3'-TRE of the NQO(1) gene hARE eliminated binding of nuclear proteins to the hARE and resulted in the loss of basal and induced expression, indicating that 3'-TRE is the most important element within the hARE. 5'-TRE-like element within the NQO(1) gene hARE is required for xenobiotic response but may not bind to the nuclear proteins by itself. The GC box located immmediately following the 3'-TRE is required for optimal expression and induction of the NQO(1) gene. The comparison of AREs from several different genes indicated the requirement for specific arrangement and spacing of two TRE and TRE-like elements within the AREs.	FOX CHASE CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-09035] Funding Source: Medline; NIGMS NIH HHS [GM 47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; DAVIES LG, 1980, BASIC METHODS MOL BI, P298; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARRIS CC, 1991, CANCER RES, V51, P5025; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1993, J BIOL CHEM, V268, P21454; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TALALAY P, 1987, CANCER BIOL THERAPEU, P197; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WATTENBERG LW, 1985, CANCER RES, V45, P1	35	129	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6894	6900		10.1074/jbc.270.12.6894	http://dx.doi.org/10.1074/jbc.270.12.6894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896838	hybrid			2022-12-27	WOS:A1995QQ85500069
J	CHANG, HCJ; LINDQUIST, S				CHANG, HCJ; LINDQUIST, S			CONSERVATION OF HSP90 MACROMOLECULAR COMPLEXES IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; STEROID-RECEPTORS; POLYACRYLAMIDE GELS; CELLULAR PROTEINS; INDUCIBLE GENE; PEP4 GENE; YEAST; COMPONENT; BINDING; KINASE	In higher eukaryotic cells, the Hsp90 chaperone protein is found in complexes with other proteins, in addition to the substrate protein. These other proteins include Hsp70, p60, and several peptidyl-prolyl cis trans isomerases (immunophilins). We utilized affinity chromatography to investigate whether Hsp82, the Hsp90 of Saccharomyces cerevisiae, is found in similar complexes in that organism. Six histidine residues were fused to the N terminus of Hsp82 to yield a fusion protein (Hsp82(FP)) with affinity for a nickel-ion matrix. Hsp82(FP) was shown to have wild type function. In addition, when mammalian substrates of Hsp90 (glucocorticoid receptor and p60(v-src)) were expressed in yeast cells, these proteins bound to the affinity matrix only when isolated from cells containing Hsp82(FP). Yeast homologs of Hsp70 (in particular, members of the Ssa subfamily), p60 (Sti1), and a 45-kDa immunophilin homolog were also isolated; in this manner, by virtue of their specific, stable association with Hsp82. Thus, Hsp90 functions as part of a highly conserved macromolecular complex in eukaryotes.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago			Foreman, Hui-Chen (Jane)/GMW-4448-2022	Foreman, Hui-Chen (Jane)/0000-0001-9640-9780				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CRAIG EA, 1990, STRESS PROTEINS BIOL; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; INGOLIA TD, 1982, MOL CELL BIOL, V2, P1388, DOI 10.1128/MCB.2.11.1388; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; PRATT WB, 1992, J STEROID BIOCHEM, V41, P223, DOI 10.1016/0960-0760(92)90348-M; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RICKEY C, 1990, MOL BIOL REP, V9, P2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOELLMY R, 1983, J BIOL CHEM, V258, P3516; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	48	139	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24983	24988						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929182				2022-12-27	WOS:A1994PQ49000069
J	KRUTH, HS; SKARLATOS, SI; GAYNOR, PM; GAMBLE, W				KRUTH, HS; SKARLATOS, SI; GAYNOR, PM; GAMBLE, W			PRODUCTION OF CHOLESTEROL-ENRICHED NASCENT HIGH-DENSITY-LIPOPROTEINS BY HUMAN MONOCYTE-DERIVED MACROPHAGES IS A MECHANISM THAT CONTRIBUTES TO MACROPHAGE CHOLESTEROL EFFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; HYPERLIPIDEMIC RABBIT; A-I; ATHEROSCLEROSIS; METABOLISM; TRANSPORT; SECRETION; VESICLES; PLAQUES; ATHEROGENESIS	Atherosclerotic lesions have a lipid core containing crystals and liposomes enriched in unesterified cholesterol as well as numerous monocyte-macrophages enriched in cholesteryl ester. Sufficient amounts of plasma-derived high density lipoproteins (HDL) may not reach and efficiently remove the cholesterol deposited in lesion macrophages or in the lipid core of lesions. We examined the potential of human monocyte-macrophages to produce nascent HDL and to solubilize cholesterol derived from interaction of monocyte-macrophages with lipoprotein and non-lipoprotein sources of cholesterol. Monocyte-macrophages produced discoidal (25 +/- 6 nm long and 6 +/- 1 nm wide (mean +/- S.D.)) and vesicular (89 +/- 41 nm in diameter) lipoprotein particles following and during enrichment of macrophages with cholesterol from acetylated low density lipoprotein (AcLDL) or cholesterol crystals. During cholesterol enrichment, discoidal particles progressively accumulated in the medium for up to 6 days. In contrast, vesicles did not increase past 2 days of incubation. Both the discoidal and vesicular lipoprotein particles had a peak density of about 1.09-1.10 g/ml, The discoidal particles contained apolipoprotein E (apoE), whereas the vesicles contained a major protein constituent with a molecular mass of 22,000 daltons. The vesicles did not contain detectable apoE and the 22,000-dalton protein was not the 22,000-dalton thrombolytic fragment of apoE. Following cholesterol enrichment of macrophages with AcLDL or cholesterol crystals, macrophages excreted much of their accumulated cholesterol, even in the absence of exogenously added cholesterol accepters. Most of this excreted cholesterol was recovered from the culture medium and was carried in the apoE discoidal particles that showed cholesterol enrichment up to a 2:1 unesterified cholesterol to phospholipid molar ratio. The findings suggest that sufficient production of these nascent HDL by macrophages within atherosclerotic lesions should facilitate removal of cellular and extracellular cholesterol, even in the absence of plasma-derived HDL.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Oregon State University	KRUTH, HS (corresponding author), NHLBI, EXPTL ATHEROSCLEROSIS SECT, BLDG 10, RM 5N-113, BETHESDA, MD 20892 USA.							BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; CHAO FF, 1994, J LIPID RES, V35, P71; CHAO FF, 1990, AM J PATHOL, V136, P169; DORY L, 1985, J LIPID RES, V26, P519; FALK E, 1992, CIRCULATION, V86, P30; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUSTER V, 1992, CIRCULATION, V86, P1; GAMBLE W, 1978, J LIPID RES, V19, P1068; GERRITY RG, 1981, AM J PATHOL, V103, P181; GUO LSS, 1982, J LIPID RES, V23, P543; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1989, AM J PATHOL, V134, P705; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; KATZ SS, 1980, J BIOL CHEM, V255, P9753; KOO C, 1985, J BIOL CHEM, V260, P1934; KRUL ES, 1982, FEBS LETT, V139, P259, DOI 10.1016/0014-5793(82)80865-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENICH C, 1988, J LIPID RES, V29, P755; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1984, CHEM PHYS LIPIDS, V34, P307, DOI 10.1016/0009-3084(84)90004-5; MATSUURA JE, 1991, J LIPID RES, V32, P581; MORA R, 1990, J LIPID RES, V31, P1793; NAKAMURA H, 1992, ELECTRON MICROSC REV, V5, P129, DOI 10.1016/0892-0354(92)90008-E; PITAS RE, 1987, J BIOL CHEM, V262, P14352; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; ROHEIM PS, 1986, AM J CARDIOL, V57, pC3, DOI 10.1016/0002-9149(86)91020-9; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P46, DOI 10.1161/01.ATV.8.1.46; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; Skarlatos S.I., 1992, J TISSUE CULT METHOD, V14, P113, DOI [10.1007/BF01409100, DOI 10.1007/BF01409100]; SOMJEN GJ, 1986, BIOCHIM BIOPHYS ACTA, V879, P14, DOI 10.1016/0005-2760(86)90260-2; SWANEY JB, 1985, CHEM PHYS LIPIDS, V37, P317, DOI 10.1016/0009-3084(85)90086-6; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WOLF AV, 1979, HDB CHEM PHYSICS, P227	44	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24511	24518						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929116				2022-12-27	WOS:A1994PQ34600101
J	LEES, JF; BULLEID, NJ				LEES, JF; BULLEID, NJ			THE ROLE OF CYSTEINE RESIDUES IN THE FOLDING AND ASSOCIATION OF THE COOH-TERMINAL PROPEPTIDE OF TYPE-I AND TYPE-III PROCOLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYNTHESIS; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; TRIPLE HELICES; COLLAGEN; PROTEIN; CHAIN; MUTATIONS; CONSERVATION; BIOSYNTHESIS	Procollagen chains assemble in a type-specific manner forming either homo- or heterotrimers. The molecular mechanisms underlying procollagen chain selectivity are unknown, although it is thought that the C-propeptide (COOH-terminal propeptide) is responsible for directing chain recognition and assembly. To define the processes involved in chain selection we reconstituted the initial stages of procollagen folding and assembly in a cell-free system. Using human pro-alpha 1(III) and pro-alpha 2(I) chains as prototypes of chains that are either capable or incapable of forming homotrimeric molecules, respectively, we constructed two minigenes p alpha 1(III)Delta 1 and p(alpha 2(I)Delta 1) that lacked most of the triple helical domains. The minigenes were transcribed in vitro and translated in a rabbit reticulocyte lysate supplemented with microsomal membranes under conditions that favored disulfide bond formation. Both pro-alpha 1(III)Delta 1 and pro-alpha 2(I)Delta 1 chains formed intrachain disulfide bonds within the C-propeptide. However, only pro-alpha 1(III)Delta 1 chains were able to self-associate forming homotrimers stabilized by interchain disulfide bonds. The C-propeptide of the pro-alpha 1(III) chain contains 8 cysteine residues (Cys-1-8). We used a site-directed mutagenesis to investigate the role of specific cysteine residues in trimer formation and found that substitution of serine for Cys-1, Cys-2, Cys-3, and Cys-4 prevented interchain disulfide bonding and trimerization. Furthermore, mutations in Cys-1 and Cys-4 also prevented intrachain disulfide bond formation within the C-propeptide. The C-propeptide of the pro-alpha 2(I) chain contains only 7 cysteine residues, lacking cysteine at position 2. Substitution of the existing Ser residue with Cys did not produce a homotrimeric phenotype, indicating that additional recognition signals are required to determine chain selection.			LEES, JF (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,2205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.			Bulleid, Neil/0000-0002-9839-5279	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; BULLEID NJ, 1988, BIOCHEM J, V254, P805, DOI 10.1042/bj2540805; BYERS PH, 1975, P NATL ACAD SCI USA, V72, P3009, DOI 10.1073/pnas.72.8.3009; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHUNG E, 1974, SCIENCE, V183, P1200, DOI 10.1126/science.183.4130.1200; COPELAND CS, 1988, CELL, V53, P167; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; Kielty Cay M., 1993, P103; KOIVU J, 1987, FEBS LETT, V212, P229, DOI 10.1016/0014-5793(87)81350-9; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKENS LN, 1976, J BIOL CHEM, V251, P3530; MADRI JA, 1979, AM J PATHOL, V94, P323; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MILLER EJ, 1971, BIOCHEM BIOPH RES CO, V42, P1024, DOI 10.1016/0006-291X(71)90006-4; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; OLSEN BR, 1982, NEW TRENDS BASEMENT, P225; PETERS T, 1982, J BIOL CHEM, V257, P8847; PROCKOP DJ, 1990, ANN NY ACAD SCI, V580, P330, DOI 10.1111/j.1749-6632.1990.tb17942.x; RAMIREZ F, 1989, COLLAGEN, V4, P22; SCHEELE G, 1982, J BIOL CHEM, V257, P1227; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181	38	58	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24354	24360						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929094				2022-12-27	WOS:A1994PQ34600078
J	PEDONE, PV; COSMA, MP; UNGARO, P; COLANTUONI, V; BRUNI, CB; ZARRILLI, R; RICCIO, A				PEDONE, PV; COSMA, MP; UNGARO, P; COLANTUONI, V; BRUNI, CB; ZARRILLI, R; RICCIO, A			PARENTAL IMPRINTING OF RAT INSULIN-LIKE GROWTH-FACTOR-II GENE PROMOTERS IS COORDINATELY REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 PROMOTERS; IGF2 GENE; MOUSE; EXPRESSION; METHYLATION; RELAXATION; CANCER; ALLELE	The insulin-like growth factor II (IGF-II) gene is parentally imprinted in the mouse and human species. By following the inheritance of natural polymorphisms of IGF-II mRNA, we demonstrated that the tissue-specific parental imprinting of the IGF-II gene is conserved in the rat. The expression of the paternal IGF-II allele exceeded by more than 3 orders of magnitude that of the maternal allele in livers of 3-day-old Wistar x Fisher interstrain rat crosses. In contrast, the two alleles were both expressed in the rat central nervous system, which is also the only district of the organism where this gene is active in adult rodents. We also analyzed the allelic usage of the three IGF-II promoters, which generate alternatively spliced transcripts, and showed that parental imprinting of all transcription starts sites is coordinately regulated since P1, P2, and P3 are all repressed on the maternal allele in neonatal rat liver, and all of them are activated on both alleles in the choroid plexus of the central nervous system. RNase protection assays demonstrated that the activity ratio of the three IGF-II promoters can be different in tissues that show the same imprinting mode.	CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II			Riccio, Andrea/A-4991-2015; Cosma, Maria Pia/E-8731-2015; Cerrato, Flavia/O-8315-2015; Riccio, Andrea/AAY-7571-2020; Zarrilli, Raffaele/F-5067-2012	Riccio, Andrea/0000-0001-7990-3576; Cosma, Maria Pia/0000-0003-4207-5097; Cerrato, Flavia/0000-0003-3794-3021; Riccio, Andrea/0000-0001-7990-3576; Zarrilli, Raffaele/0000-0003-4191-9032; Pedone, Paolo Vincenzo/0000-0002-0828-5843				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; HAUGE XY, 1993, HUM MOL GENET, V2, P411, DOI 10.1093/hmg/2.4.411; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Rechler M. M., 1990, PEPTIDE GROWTH FACTO, P263; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; UENO T, 1987, BIOCHEM BIOPH RES CO, V148, P344, DOI 10.1016/0006-291X(87)91116-8; UENO T, 1988, BIOCHIM BIOPHYS ACTA, V950, P411, DOI 10.1016/0167-4781(88)90138-8; ZARRILLI R, 1992, EUR J BIOCHEM, V209, P445, DOI 10.1111/j.1432-1033.1992.tb17308.x; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	31	44	44	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23970	23975						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929045				2022-12-27	WOS:A1994PQ34600021
J	SETOYOUNG, D; NA, SQ; MONK, BC; HABER, JE; PERLIN, DS				SETOYOUNG, D; NA, SQ; MONK, BC; HABER, JE; PERLIN, DS			MUTATIONAL ANALYSIS OF THE FIRST EXTRACELLULAR LOOP REGION OF THE H+-ATPASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; COMPETITIVE PHOTOAFFINITY INHIBITOR; SITE-DIRECTED MUTAGENESIS; RESISTANT PMA1 MUTANTS; P-TYPE ATPASE; SARCOPLASMIC-RETICULUM; NEUROSPORA-CRASSA; SALMONELLA-TYPHIMURIUM; OUABAIN SENSITIVITY; GASTRIC H,K-ATPASE	Transmembrane segments 1 and 2 of the yeast plasma membrane H+-ATPase are believed to form a helical hairpin structure that is joined by a short extracytoplasmic loop. The hairpin head region (Ala(135)-Phe(144)) was probed using site-directed mutagenesis, Scanning alanine mutagenesis produced functional H+-ATPase at all positions except Leu(138), Asp(143), and Phe(144). D140A and V142A gave strong hygromycin B resistance and low pH sensitivity suggesting a major kinetic defect in these mutant enzymes. Other amino acid substitutions, such as L138Y, were highly perturbing, while mutations S139E and D140E produced minor effects on phenotype. Small uncharged residues Gly and Ala, which were inserted between Leu(138) and Ser(139) to examine the importance of loop length on Ht-ATPase function, were well tolerated, while the insertion of a polar Ser residue was highly perturbing. Other additions were not tolerated by the enzyme. These results suggest that the turn region has limited structural flexibility. The conserved Phe(144) residue could be changed to Trp with a minor effect on phenotype. However, neither Tyr,Arg, nor small hydrophobic residues could substitute, suggesting that this region is closely packed and hydrophobic. ATP hydrolysis measurements showed that V-max was significantly reduced in nearly all. mutant enzymes, except D140E; whereas, K-m values were nearly normal. Vanadate-sensitivity and pH profiles for ATP hydrolysis were nearly normal for all mutant enzymes except insertion mutant S138+. Mutants with extreme phenotypes (S138+, Tyr(138)) showed significantly altered medium acidification profiles. These results support the notion that the hairpin head region linking transmembrane segments 1 and 2 forms a tightly packed conformationally sensitive domain that is coupled to the catalytic ATP hydrolysis domain.	PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, DEPT BIOL, WALTHAM, MA 02254 USA; UNIV OTAGO, FAC DENT, EXPTL ORAL BIOL UNIT, DUNEDIN, NEW ZEALAND	Brandeis University; University of Otago				Monk, Brian/0000-0003-2264-3480; Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM39737, GM38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BARTS PWJ, 1980, BIOCHIM BIOPHYS ACTA, V597, P195; BIGELOW DJ, 1991, BIOCHEMISTRY-US, V30, P2113, DOI 10.1021/bi00222a016; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CID A, 1988, J BIOL CHEM, V263, P14134; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13528; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; LAUGER P, 1987, PHYSIOL REV, V67, P1296, DOI 10.1152/physrev.1987.67.4.1296; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MATA AM, 1992, BIOCHEM J, V286, P567, DOI 10.1042/bj2860567; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MEWES HW, 1981, FEBS LETT, V131, P7, DOI 10.1016/0014-5793(81)80875-7; MIDGLEY M, 1986, FEMS MICROBIOL LETT, V34, P187; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; MONK BC, 1991, J BIOL CHEM, V266, P18097; MONK BC, 1994, J BIOENERG BIOMEMBR, V26, P101, DOI 10.1007/BF00763222; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; MUNSON KB, 1988, BIOCHEMISTRY-US, V27, P3932, DOI 10.1021/bi00411a007; NA SQ, 1993, J BIOL CHEM, V268, P11792; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1990, J BIOL CHEM, V265, P6638; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RAO US, 1991, J BIOL CHEM, V266, P14740; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROSE MD, 1990, METHODS YEAST GENETI, P126; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; SLAYMAN CL, 1973, J MEMBRANE BIOL, V14, P305, DOI 10.1007/BF01868083; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; STOCK JB, 1992, J BIOL CHEM, V267, P19753; TRAMONTANO A, 1989, PROTEINS, V6, P382, DOI 10.1002/prot.340060405; VANDEMORTEL JBJ, 1990, BIOCHIM BIOPHYS ACTA, V1026, P220, DOI 10.1016/0005-2736(90)90067-X; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309	62	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23988	23995						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929048				2022-12-27	WOS:A1994PQ34600024
J	FLANAGAN, CA; BECKER, II; DAVIDSON, JS; WAKEFIELD, IK; ZHOU, W; SEALFON, SC; MILLAR, RP				FLANAGAN, CA; BECKER, II; DAVIDSON, JS; WAKEFIELD, IK; ZHOU, W; SEALFON, SC; MILLAR, RP			GLUTAMATE-301 OF THE MOUSE GONADOTROPIN-RELEASING-HORMONE RECEPTOR CONFERS SPECIFICITY FOR ARGININE-8 OF MAMMALIAN GONADOTROPIN-RELEASING-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MOLECULAR-CLONING; RAT PITUITARY; GNRH RECEPTOR; FUNCTIONAL-CHARACTERIZATION; NEUROKININ-1 RECEPTOR; BINDING; EXPRESSION; AFFINITY; PEPTIDES	The Arg residue at position 8 of mammalian GnRH is necessary for high affinity binding to mammalian GnRH receptors. This requirement has been postulated to derive from an electrostatic interaction of Arg(8) with a negatively charged receptor residue. In order to identify such a residue, 8 conserved acidic residues of the mouse GnRH receptor were mutated to isosteric Asn or Gin. Mutant receptors were tested for decreased preference for Arg(8)-containing Ligands by ligand binding and inositol phosphate production. One of the mutants, in which the Glu(301) residue was mutated to Gin, exhibited a 56-fold decrease in apparent affinity for mammalian GnRH. The mutant receptor also exhibited decreased affinity for [Lys(8)]GnRH, but its affinity for [Gln(8)]GnRH was unchanged compared with the wild type receptor. The apparent affinity of the mutant receptor for the acidic analogue, [Glu(8)]GnRH, was increased more than 10-fold. The mutant receptor did not, therefore, distinguish mammalian GnRH from analogues with amino acid substitutions at position 8 as effectively as the wild type receptor. This loss of discrimination was specific for the residue at position 8, because the mutant receptor did distinguish mammalian GnRH from analogues with favorable substitutions at positions 5, 6, and 7. These findings show that Glu(301) Of the GnRH receptor plays a role in receptor recognition of Arg(8) in the ligand and are consistent with an electrostatic interaction between these 2 residues.	UNIV CAPE TOWN, SCH MED, DEPT MED, ENDOCRINE LAB, CAPE TOWN 7925, SOUTH AFRICA; CUNY MT SINAI SCH MED, DEPT NEUROL, NEW YORK, NY 10029 USA	University of Cape Town; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	FLANAGAN, CA (corresponding author), UNIV CAPE TOWN, SCH MED, DEPT CHEM PATHOL, MRC, REGULATORY PEPTIDES RES UNIT, CAPE TOWN 7925, SOUTH AFRICA.		Flanagan, Colleen/ABG-2109-2020; Hitzeroth, Inga I./I-6042-2019	Hitzeroth, Inga I./0000-0002-8515-9525; SEALFON, Stuart/0000-0001-5791-1217; Millar, Robert P/0000-0003-3606-2708; Flanagan, Colleen A./0000-0003-2803-8986	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 46943] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EIDNE KA, 1992, MOL CELL ENDOCRINOL, V90, pR5, DOI 10.1016/0303-7207(92)90116-N; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FREIDINGER RM, 1980, SCIENCE, V210, P656, DOI 10.1126/science.7001627; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; HAZUM E, 1977, FEBS LETT, V76, P187, DOI 10.1016/0014-5793(77)80148-8; HAZUM E, 1987, BIOCHEMISTRY-US, V26, P7011, DOI 10.1021/bi00396a023; ILLING N, 1993, BIOCHEM BIOPH RES CO, V196, P745, DOI 10.1006/bbrc.1993.2312; KAISER UB, 1992, BIOCHEM BIOPH RES CO, V189, P1645, DOI 10.1016/0006-291X(92)90266-N; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; KEINAN D, 1985, BIOCHEMISTRY-US, V24, P7728, DOI 10.1021/bi00347a034; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KING JA, 1992, TRENDS ENDOCRIN MET, V3, P339, DOI 10.1016/1043-2760(92)90113-F; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MILLAR RP, 1989, J BIOL CHEM, V264, P21007; MILTON RCD, 1983, BIOCHEM BIOPH RES CO, V111, P1082, DOI 10.1016/0006-291X(83)91410-9; MOMANY FA, 1976, J AM CHEM SOC, V98, P2990, DOI 10.1021/ja00426a052; MONAHAN MW, 1973, BIOCHEMISTRY-US, V12, P4616, DOI 10.1021/bi00747a012; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; PERRIN MH, 1993, BIOCHEM BIOPH RES CO, V191, P1139, DOI 10.1006/bbrc.1993.1335; Sandow J., 1978, Control of ovulation., P49; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V453, P553, DOI 10.1016/0005-2795(76)90152-5; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V434, P137, DOI 10.1016/0005-2795(76)90043-X; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; ZHU GC, 1992, J CELL BIOCHEM, V50, P159	34	119	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	1994	269	36					22636	22641						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ163	7915716				2022-12-27	WOS:A1994PQ16300030
J	DENU, JM; FITZPATRICK, PF				DENU, JM; FITZPATRICK, PF			PH AND KINETIC ISOTOPE EFFECTS ON THE OXIDATIVE HALF-REACTION OF D-AMINO-ACID OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATION MODE; HOG KIDNEY; SUBSTRATE; FEATURES; PROTON	D Amino-acid oxidase catalyzes the oxidation of D-amino acids to imino acids. In the oxidative half-reaction, oxygen reacts with the reduced enzyme-imino acid complex to reoxidize the bound FAD. This is then followed by dissociation of the imino acid. The effects of pH and D2O on the kinetics of the oxidative half-reaction of D-amino-acid oxidase have been determined with glycine, D-alanine, and D-serine as substrates. Reaction of the reduced enzyme with oxygen requires that a group with a pK(alpha) value of about 10.5 be protonated and a group with a pK(alpha) value of 8.5 be deprotonated. The former value is not seen with D-alanine as substrate; the latter is only seen with glycine. No solvent isotope effects are seen on the V/K-O2, value with D-alanine, consistent with rate-limiting electron transfer. Product release involves a pH-dependent conformational change. This is rate-limiting at all pH values with D-alanine as substrate. Significant solvent isotope effects are seen on the V-max value with D-alanine. The proton inventory at high pH is linear, consistent with release of a single proton in the slow step; at pH 6 the solvent inventory is bowl-shaped, consistent with a solvent isotope effect on the conformation of the protein. With glycine the V-D value increases to the intrinsic value at pH 10.5; this establishes that CH bond cleavage becomes rate-limiting with this substrate above pH 10.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station								ANTONINI E, 1966, J BIOL CHEM, V241, P2358; Bright H.B., 1975, ENZYMES, V12B, P421; BRUMBY PE, 1968, BIOCHEM PREP, V12, P29; Cleland W W, 1979, Methods Enzymol, V63, P103; DENU JM, 1992, BIOCHEMISTRY-US, V31, P8207, DOI 10.1021/bi00150a013; DENU JM, 1994, IN PRESS BIOCHEMISTR, V33; EBERLEIN G, 1983, J AM CHEM SOC, V105, P6685, DOI 10.1021/ja00360a024; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P9958; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P2916; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P1166; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; Ghisla S., 1982, FLAVINS FLAVOPROTEIN, P133; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MASSEY V, 1966, J BIOL CHEM, V241, P2347; Massey V, 1988, Prog Clin Biol Res, V274, P147; MASSEY V, 1980, FLAVINS FLAVOPROTEIN, P1; Palmer G, 1968, BIOL OXIDATIONS, P263; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; PURDY DE, 1982, THESIS U PENNSYLVANI; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; RICARD J, 1985, EUR J BIOCHEM, V152, P557, DOI 10.1111/j.1432-1033.1985.tb09231.x; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHIGA K, 1972, BIOCHIM BIOPHYS ACTA, V263, P294, DOI 10.1016/0005-2795(72)90082-7; TOJO H, 1985, J BIOL CHEM, V260, P2607; TOJO H, 1985, J BIOL CHEM, V260, P2615; YAGI K, 1973, J BIOCHEM-TOKYO, V73, P909, DOI 10.1093/oxfordjournals.jbchem.a130173	27	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15054	15059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910822				2022-12-27	WOS:A1994NP73800034
J	MCLAGGAN, D; NAPRSTEK, J; BUURMAN, ET; EPSTEIN, W				MCLAGGAN, D; NAPRSTEK, J; BUURMAN, ET; EPSTEIN, W			INTERDEPENDENCE OF K+ AND GLUTAMATE ACCUMULATION DURING OSMOTIC ADAPTATION OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; PROLINE TRANSPORT; CATION-TRANSPORT; GENE-EXPRESSION; OSMOREGULATION; BACTERIA; TREHALOSE; PRESSURE; MEMBRANE; BETAINE	Escherichia coli responds to an increase in medium osmolarity by accumulating K+ and glutamate. At low osmolarity a large fraction of cytoplasmic K+ serves to balance charge on macromolecular anions. That fraction of K+ is here referred to as ''bound,'' as distinguished from ''free'' K+ that serves to balance charge of small anions. At higher osmolarity where cytoplasmic K+ increases markedly, the bound fraction decreases but the absolute amount of bound K+ expressed per unit of dry weight increases. The increase in bound K+ can be explained largely by the reduction of cytoplasmic putrescine at high osmolarity. At high osmolarity, glutamate is the major cytoplasmic anion, equal to at least 70% of free cytoplasmic K+. A sudden increase in the osmolarity of the medium stimulates glutamate synthesis with a lag of only about a minute; glutamate synthesis is almost totally dependent on K+ uptake. The high rate of flow of nitrogen through the glutamate pool under control conditions of growth at low osmolarity indicates that glutamate accumulation immediately after shift to high osmolarity must be due to inhibition of utilization of glutamate in the synthesis of other nitrogen-containing compounds rather than stimulation of glutamate synthesis. In agreement with this reasoning we find the kinetics of glutamate accumulation to be independent of the specific path of synthesis, whether, by glutamate dehydrogenase or by glutamate synthase. Synthesis of glutamate appears to be required to attain normal values of the electrical membrane potential after shift to high osmolarity.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago				McLaggan, Debbie/0000-0003-3044-7287				ALEXANDROWICZ Z, 1962, J POLYM SCI, V56, P115, DOI 10.1002/pol.1962.1205616311; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BAKKER EP, 1990, FEMS MICROBIOL LETT, V75, P319, DOI 10.1111/j.1574-6968.1990.tb04105.x; BAKKER EP, 1987, J BACTERIOL, V169, P3743, DOI 10.1128/jb.169.8.3743-3749.1987; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BOLTON ET, 1957, YB 1956, P122; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; BROWN AD, 1972, J GEN MICROBIOL, V72, P589, DOI 10.1099/00221287-72-3-589; CAIRNEY J, 1985, J BACTERIOL, V164, P1218, DOI 10.1128/JB.164.3.1218-1223.1985; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; CAYLEY DS, 1990, J MOL BIOL, V222, P281; CAYLEY S, 1992, J BACTERIOL, V174, P1586, DOI 10.1128/jb.174.5.1586-1595.1992; CAYLEY S, 1989, J BACTERIOL, V171, P3597, DOI 10.1128/jb.171.7.3597-3602.1989; COHN EJ, 1943, PROTEINS AMINO ACIDS, P111; COLLINS SH, 1976, J BACTERIOL, V126, P1224, DOI 10.1128/JB.126.3.1224-1231.1976; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CSONKA LN, 1982, J BACTERIOL, V151, P1433, DOI 10.1128/JB.151.3.1433-1443.1982; DAVSON H, 1964, TXB GENERAL PHYSL, P376; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; KIM SY, 1990, J BACTERIOL, V172, P6127, DOI 10.1128/jb.172.10.6127-6128.1990; KRULWICH TA, 1985, J BACTERIOL, V162, P768, DOI 10.1128/JB.162.2.768-772.1985; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LARSEN PI, 1987, ARCH MICROBIOL, V147, P1, DOI 10.1007/BF00492896; LUND P, 1984, METHOD ENZYMAT AN, V8, P357; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MCLAGGAN D, 1990, J BACTERIOL, V172, P3631, DOI 10.1128/jb.172.7.3631-3636.1990; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MILNER JL, 1988, J BIOL CHEM, V263, P14900; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; OHWADA T, 1987, ARCH BIOCHEM BIOPHYS, V259, P157, DOI 10.1016/0003-9861(87)90481-4; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PAHEL G, 1978, J BACTERIOL, V133, P139, DOI 10.1128/JB.133.1.139-148.1978; REIZER LJ, 1987, ESCHERICHIA COLI SAL, V1, P302; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; RICHEY B, 1987, J BIOL CHEM, V262, P7157; Rottenberg H, 1979, Methods Enzymol, V55, P547; SINGER M, 1989, MICROBIOL REV, V53, P1; SLONCZEWSKI JL, 1982, J BACTERIOL, V152, P384; STORTS DR, 1988, J BACTERIOL, V170, P1541, DOI 10.1128/jb.170.4.1541-1547.1988; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; WELSH DT, 1991, J GEN MICROBIOL, V137, P745, DOI 10.1099/00221287-137-4-745	51	166	182	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1911	1917						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7904996				2022-12-27	WOS:A1994MR98800056
J	FLINK, IL; MORKIN, E				FLINK, IL; MORKIN, E			ALTERNATIVELY PROCESSED ISOFORMS OF CELLULAR NUCLEIC ACID-BINDING PROTEIN INTERACT WITH A SUPPRESSOR REGION OF THE HUMAN BETA-MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENT; MESSENGER-RNA; VENTRICULAR MYOCARDIUM; FINGER PROTEIN; CARDIAC-MUSCLE; ALPHA-MYOSIN; DNA; EXPRESSION; HEART; IDENTIFICATION	Analysis of a series of human beta-myosin heavy chain (MHC) constructs with progressive deletions in the 5'-flanking region has localized a strong positive element at positions -298/-277 with a repressor region located immediately upstream at -332/-300 (FLink, I. L., Edwards, J. G., Bahl, J. J., Liew, C.-C., Sole, M., and Morkin, E. (1992) J. Biol. Chem. 267, 9917-9924). A 49-base pair restriction fragment containing the suppressor element was used to screen a cardiac expression library. The 0.65-kilobase pair cDNA identified by this procedure was similar in sequence, except for the absence of a 21-base pair region encoding seven amino acids, to cellular nucleic acid-binding protein (CNBP), a 19-kDa zinc finger DNA-binding protein isolated earlier from liver, which may be involved in negative regulation of cholesterol biosynthesis (Rajavashisth, T. B., Taylor, A. K., Andalibi, A., Svenson, K. L., and Lusis, A. J. (1989) Science 245, 640-643). An additional clone identical to the one originally found in liver, referred to as CNBP alpha, was isolated from the cardiac library by hybridization screening. Gel mobility shift analysis indicated that CNBP alpha and CNBP beta isoforms preferentially interact with single-stranded DNA corresponding to the proximal and distal regions of the suppressor. When cotransfected with a beta-MHC reporter construct, CNBP alpha repressed activity in a dosage-dependent manner, whereas repression was not observed with the shorter construct (CNBP beta). Cotransfection of a combination of CNBP alpha and CNBP beta repressed reporter activity to an extent similar to cotransfection with CNBP alpha alone, suggesting that CNBP beta is not translationally active under these conditions. The results of RNase protection assays and genomic sequencing indicated that the alpha and beta isoforms are formed by alternative use of 5' donor sites within a single exon. These results suggest that CNBP isoforms may modulate the activity of the beta-MHC gene by interaction with a repressor region.	UNIV ARIZONA,CTR HEART,TUCSON,AZ 85724; UNIV ARIZONA,DEPT INTERNAL MED,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHARMACOL,TUCSON,AZ 85724	University of Arizona; University of Arizona; University of Arizona; University of Arizona					NHLBI NIH HHS [P01 HL20984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUVAGNET P, 1984, CIRC RES, V55, P794, DOI 10.1161/01.RES.55.6.794; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; EDWARDS JG, 1994, BIOCHEM BIOPH RES CO, V199, P1482, DOI 10.1006/bbrc.1994.1398; EDWARDS JG, 1992, BIOCHEM BIOPH RES CO, V189, P504, DOI 10.1016/0006-291X(92)91586-F; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; EVANS SM, 1991, J CELL BIOCHEM     S, V15, P194; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORZA L, 1984, CIRC RES, V54, P694, DOI 10.1161/01.RES.54.6.694; GREEN M, 1992, ANN REV CELL BIOL, V7, P559; KOTHEKAR V, 1990, FEBS LETT, V274, P217, DOI 10.1016/0014-5793(90)81367-W; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LUSIS AJ, 1990, GENOMICS, V8, P411, DOI 10.1016/0888-7543(90)90303-C; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1986, UCLA S MOL CELL BIOL, V29, P345; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SATO SM, 1991, DEVELOPMENT, V112, P747; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TAKECHI H, 1994, MOL CELL BIOL, V14, P567, DOI 10.1128/MCB.14.1.567; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU HP, 1992, MOL BIOL CELL, V3, P721, DOI 10.1091/mbc.3.7.721; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839	41	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6959	6965		10.1074/jbc.270.12.6959	http://dx.doi.org/10.1074/jbc.270.12.6959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896846				2022-12-27	WOS:A1995QQ85500077
J	CACCIAPUOTI, G; PORCELLI, M; BERTOLDO, C; DEROSA, M; ZAPPIA, V				CACCIAPUOTI, G; PORCELLI, M; BERTOLDO, C; DEROSA, M; ZAPPIA, V			PURIFICATION AND CHARACTERIZATION OF EXTREMELY THERMOPHILIC AND THERMOSTABLE 5'-METHYLTHIOADENOSINE PHOSPHORYLASE FROM THE ARCHAEON SULFOLOBUS-SOLFATARICUS - PURINE NUCLEOSIDE PHOSPHORYLASE-ACTIVITY AND EVIDENCE FOR INTERSUBUNIT DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; LIQUID-CHROMATOGRAPHIC ANALYSIS; HYPERTHERMOPHILIC ARCHAEBACTERIUM; 2ND-DERIVATIVE SPECTROSCOPY; PROPYLAMINE TRANSFERASE; MOLECULAR-PROPERTIES; ESCHERICHIA-COLI; DEHYDROGENASE; BACTERIA; PROTEINS	5'-Methylthioadenosine phosphorylase from Sulfolobus solfataricus, a thermoacidophilic archaeon optimally growing at 87 degrees C, has been purified to homogeneity. Reducing agents are not required for catalytic activity. The enzyme has a molecular mass of 160 kDa and is composed of six apparently identical subunits of 27 kDa. The NH2-terminal sequence shows high homology (50%) with the NH2-terminal sequence of Escherichia coli purine nucleoside phosphorylase. Physicochemical and kinetic features are reported. 5'-Methylthioadenosine phosphorylase is highly thermophilic, with an optimum temperature of 120 degrees C. The enzyme is characterized by extreme thermal stability, remaining completely active after 2 h at 100 degrees C and showing half-inactivation times of 15 and 5 min when incubated at 130 and 140 degrees C, respectively. An apparent melting temperature of 132 degrees C has been calculated. After 24 h of incubation at room temperature no loss of activity is detected in the presence of 9 M urea, 4 M guanidine hydrochloride, 0.075% SDS, 50% methanol, 50% ethanol, 50% dimethylformamide, 1 M NaCl, and 1% Triton X-100. Data are also reported on the enzyme's resistance to proteolysis and on the effect of salts, detergents, solvents, and reducing agents on enzyme thermostability. Labeling experiments with iodo[2-C-14]acetic acid resulted in the incorporation of approximately 12 mol of labeled iodoacetate/mol of protein, indicating the presence of six disulfide bonds that, on the basis of SDS-polyacrylamide gel electrophoresis, are probably positioned intersubunits, resulting in the organization of the enzyme into two trimers. 5'-Methylthioadenosine (MTA) phosphorylase is endowed with a broad substrate specificity, being able to phosphorolytically cleave inosine, guanosine, and adenosine with a better efficiency than MTA, allowing us to hypothesize that in S. solfataricus the same enzyme is responsible for the catabo lism of MTA and of these purine nucleosides.			CACCIAPUOTI, G (corresponding author), UNIV NAPLES 2, FAC MED, INST BIOCHEM MACROMOLEC, VIA COSTANTINOPOLI 16, I-80138 NAPLES, ITALY.			De Rosa, Mario/0000-0002-2976-0818				BALESTRIERI C, 1978, EUR J BIOCHEM, V90, P433, DOI 10.1111/j.1432-1033.1978.tb12622.x; BIGELOW CC, 1967, J THEOR BIOL, V16, P187, DOI 10.1016/0022-5193(67)90004-5; BOSE R, 1974, BIOCHEMISTRY-US, V13, P2051, DOI 10.1021/bi00707a008; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLINI N, 1992, BIOCHIM BIOPHYS ACTA, V1122, P283, DOI 10.1016/0167-4838(92)90406-4; CACCIAPUOTI G, 1978, INT J BIOCHEM, V9, P35, DOI 10.1016/0020-711X(78)90135-0; CACCIAPUOTI G, 1986, EUR J BIOCHEM, V161, P263, DOI 10.1111/j.1432-1033.1986.tb10442.x; CACCIAPUOTI G, 1991, EUR J BIOCHEM, V199, P395, DOI 10.1111/j.1432-1033.1991.tb16136.x; CACCIAPUOTI G, 1989, PHYSL POLYAMINES, V2, P47; COLOMBO S, 1992, EUR J BIOCHEM, V206, P349, DOI 10.1111/j.1432-1033.1992.tb16934.x; CONSALVI V, 1991, EUR J BIOCHEM, V196, P459, DOI 10.1111/j.1432-1033.1991.tb15837.x; COSTANTINO HR, 1990, J BACTERIOL, V172, P3654, DOI 10.1128/jb.172.7.3654-3660.1990; DALESSIO G, 1975, BIOCHEMISTRY-US, V14, P1116, DOI 10.1021/bi00677a004; DANIEL RM, 1966, PROTEIN STRUCTURE FO, P291; DELLARAGIONE F, 1986, J BIOL CHEM, V261, P2324; DELLARAGIONE F, 1990, J BIOL CHEM, V265, P6241; DELLARAGIONE F, 1981, J CHROMATOGR, V226, P243, DOI 10.1016/S0378-4347(00)84229-2; DELLARAGIONE F, 1989, PHYSL POLYAMINES, V1, P231; DELLARAGIONE F, 1985, RECENT PROGR POLYAMI, P481; DEROSA M, 1984, BIOCHEM J, V224, P407, DOI 10.1042/bj2240407; DEROSA M, 1975, J GEN MICROBIOL, V86, P156, DOI 10.1099/00221287-86-1-156; DEROSA M, 1978, BIOCHEM J, V176, P1; EALICK SE, 1990, J BIOL CHEM, V265, P1812; FONTANA A, 1993, STUD ORG CHEM, V47, P101; FONTANA A, 1991, LIFE EXTREME CONDITI, P89; GOMI T, 1986, J BIOL CHEM, V261, P3422; GUAGLIARDI A, 1989, EUR J BIOCHEM, V183, P25, DOI 10.1111/j.1432-1033.1989.tb14891.x; GURANOWSKI AB, 1981, EUR J BIOCHEM, V114, P293, DOI 10.1111/j.1432-1033.1981.tb05148.x; HERSHFIELD MS, 1991, P NATL ACAD SCI USA, V88, P7185, DOI 10.1073/pnas.88.16.7185; JENSEN KF, 1975, EUR J BIOCHEM, V51, P253, DOI 10.1111/j.1432-1033.1975.tb03925.x; KIM S, 1978, ANAL BIOCHEM, V84, P415, DOI 10.1016/0003-2697(78)90059-3; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; MARINO G, 1988, J BIOL CHEM, V263, P12305; MATSUBARA H, 1970, METHOD ENZYMOL, V19, P642; MENENDEZARIAS L, 1988, COMPUT APPL BIOSCI, V4, P479; NELSON DM, 1992, GENE, V113, P215, DOI 10.1016/0378-1119(92)90398-9; PANTOLIANO MW, 1987, BIOCHEMISTRY-US, V26, P2077, DOI 10.1021/bi00382a002; PEGG AE, 1969, BIOCHEM J, V115, P241, DOI 10.1042/bj1150241; PORCELLI M, 1993, BIOCHIM BIOPHYS ACTA, V1164, P179, DOI 10.1016/0167-4838(93)90246-N; PORCELLI M, 1988, EUR J BIOCHEM, V177, P273, DOI 10.1111/j.1432-1033.1988.tb14373.x; RAGIONE ED, 1985, BIOCHEM J, V232, P335, DOI 10.1042/bj2320335; RAGONE R, 1992, EUR J BIOCHEM, V204, P483, DOI 10.1111/j.1432-1033.1992.tb16658.x; SAVARESE TM, 1979, BIOCHEM PHARMACOL, V28, P2227, DOI 10.1016/0006-2952(79)90211-9; SCHLENK F, 1964, ARCH BIOCHEM BIOPHYS, V106, P95, DOI 10.1016/0003-9861(64)90161-4; SHAPIRO SK, 1966, ANAL BIOCHEM, V15, P323, DOI 10.1016/0003-2697(66)90038-8; SHUGART L, 1979, INT J BIOCHEM, V10, P901, DOI 10.1016/0020-711X(79)90121-6; STELLWAGEN E, 1976, ENZYMES PROTEINS THE, P223; SUGIMOTO Y, 1976, ARCH MICROBIOL, V108, P175, DOI 10.1007/BF00428948; SUNDARAM TK, 1980, BIOCHEMISTRY-US, V19, P2017, DOI 10.1021/bi00551a002; UELAND PM, 1982, PHARMACOL REV, V34, P223; WEBER K, 1972, METHOD ENZYMOL, V260, P3; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1985, BACTERIA, V8; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; ZAPPIA V, 1983, METHOD ENZYMOL, V94, P57; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	58	66	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24762	24769						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929153				2022-12-27	WOS:A1994PQ49000040
J	LAI, TS; ACHYUTHAN, KE; SANTIAGO, MA; GREENBERG, CS				LAI, TS; ACHYUTHAN, KE; SANTIAGO, MA; GREENBERG, CS			CARBOXYL-TERMINAL TRUNCATION OF RECOMBINANT FACTOR-XIII A-CHAINS - CHARACTERIZATION OF MINIMUM STRUCTURAL REQUIREMENT FOR TRANSGLUTAMINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; ESCHERICHIA-COLI; HUMAN-PLASMA; BINDING; FIBRIN; SITES; EXPRESSION; PURIFICATION; SUBSTRATE; SEQUENCE	A series of truncation mutants lacking 218, 229, 250, and 269 amino acid residues from the carboxyl terminus of blood coagulation factor XIII A-chains (FXIII A), designated as Delta K513, Delta A502, Delta Y481, and Delta K462, respectively, were expressed in Escherichia coli to define the minimum structure required for transglutaminase activity. Delta K513 and Delta A502 displayed a 3.8-4.7 fold reduction in the K-cat with no change in the K-m for the glutamine substrate and a 2-fold increase in the K-m of the primary amine substrate. There was no detectable transglutaminase activity for either thrombin-activated Delta Y481 or Delta K462. The rate of ammonia release of thrombin-activated Delta K513 and Delta A502 was reduced 6- and 4-fold, respectively, whereas ammonia release was not detected for the Delta Y481 and Delta 462 mutants. The K-act for calcium ions of the Delta K513 mutant was similar to recombinant FXIIIa, whereas, it was increased by similar to 3-fold for the Delta A502 mutant. The rate of fibrin gamma-chain dimer formation for the Delta K513 and Delta A502 mutants was reduced by similar to 19-fold. Delta K462 did not bind to fibrin, while all of the other thrombin-cleaved mutants were bound. In conclusion, these results documented that the carboxyl-terminal calcium binding domain (Asp(468)-Glu(495)) was important for FXIIIa to adopt the correct conformation to ensure that efficient catalysis occurred.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University				, Thung-Shen/0000-0002-8791-9698	NHLBI NIH HHS [HL28391, HL38245] Funding Source: Medline; NIAMS NIH HHS [AR39162] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P60HL028391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; ACHYUTHAN KE, 1994, ANAL BIOCHEM, V219, P43, DOI 10.1006/abio.1994.1229; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BOARD PG, 1990, THROMB HAEMOSTASIS, V63, P235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1972, J BIOL CHEM, V247, P2798; FICKENSCHER K, 1991, THROMB HAEMOSTASIS, V65, P535; FOLK JE, 1967, J BIOL CHEM, V242, P1838; FOLK JE, 1967, J BIOL CHEM, V242, P2615; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HETTASCH JM, 1993, BLOOD, V82, P276; HORNYAK TJ, 1991, BIOCHEMISTRY-US, V30, P6175, DOI 10.1021/bi00239a014; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LAI TS, 1994, PROTEIN EXPRES PURIF, V5, P125, DOI 10.1006/prep.1994.1019; LAI TS, 1992, CIRCULATION, V86, P465; LEWIS BA, 1978, BIOCHEM J, V169, P397, DOI 10.1042/bj1690397; LORAND L, 1962, NATURE, V194, P1148, DOI 10.1038/1941148a0; Lorand L, 1980, Prog Hemost Thromb, V5, P245; MARY A, 1988, ARCH BIOCHEM BIOPHYS, V216, P112; McDonagh J, 1987, HEMOSTASIS THROMBOSI, P289; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; SCHWARTZ ML, 1971, J BIOL CHEM, V246, P5851; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019	38	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24596	24601						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929131				2022-12-27	WOS:A1994PQ49000016
J	CHOI, KY; LU, F; ZALKIN, H				CHOI, KY; LU, F; ZALKIN, H			MUTAGENESIS OF AMINO-ACID-RESIDUES REQUIRED FOR BINDING OF COREPRESSORS TO THE PURINE REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL SIMILARITY; REGULON REPRESSOR; GENE-EXPRESSION; LAC REPRESSOR; D-GALACTOSE; L-ARABINOSE; D-RIBOSE; PROTEIN; SEQUENCE	The corepressor binding domain of the Escherichia coli purine repressor (PurR) is homologous with several periplasmic sugar-binding proteins. Four amino acids in PurR were investigated for a role in binding of corepressors. Three of the residues, Asp(146), Arg(196), and Asp(275) conserved in periplasmic binding proteins for ribose, glucose/galactose, and arabinose and function to bind sugars. A fourth amino acid, Trp(147), required for corepressor binding to PurR, corresponds to residues in glucose/galactose, ribose, and arabinose that also have a role in sugar binding. The four mutations that were constructed perturbed the binding of both hypoxanthine and guanine thus providing evidence for a single corepressor site/PurR subunit, The decreased corepressor binding affinity resulted in reduced affinity of mutant repressors for operator DNA in vitro and decreased capacity for repression in vivo. The corepressor-binding site in PurR appears to be similar to the conserved ligand-binding sites in the three periplasmic sugar-binding proteins and in the LacI family of repressors.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024658, R01GM024658] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60DK20542] Funding Source: Medline; NIGMS NIH HHS [GM24658] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIN H, 1993, J BACTERIOL, V175, P3598, DOI 10.1128/jb.175.11.3598-3606.1993; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1990, J BACTERIOL, V172, P3201, DOI 10.1128/jb.172.6.3201-3207.1990; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; HE B, 1990, J BACTERIOL, V172, P4555, DOI 10.1128/jb.172.8.4555-4562.1990; HE B, 1992, J BACTERIOL, V174, P7121, DOI 10.1128/jb.174.22.7121-7127.1992; HOULBERG U, 1983, J BACTERIOL, V153, P837, DOI 10.1128/JB.153.2.837-845.1983; KILSTRUP M, 1989, J BACTERIOL, V171, P2124, DOI 10.1128/jb.171.4.2124-2127.1989; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LIU YC, 1993, J BIOL CHEM, V268, P23239; LIU YC, 1994, J BIOL CHEM, V269, P1692; MAHONEY WC, 1981, J BIOL CHEM, V256, P4350; MANIATIS T, 1982, MOL CLONING LABORATO, P464; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MENG LM, 1990, MOL MICROBIOL, V4, P2187, DOI 10.1111/j.1365-2958.1990.tb00580.x; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; ROLFES RJ, 1988, J BIOL CHEM, V263, P19649; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SAMS CF, 1984, NATURE, V310, P429, DOI 10.1038/310429a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCRIPTURE JB, 1987, J MOL BIOL, V197, P37, DOI 10.1016/0022-2836(87)90607-3; SPOTTS RO, 1991, J BIOL CHEM, V266, P22998; STEIERT JG, 1990, J BACTERIOL, V172, P3799, DOI 10.1128/jb.172.7.3799-3803.1990; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WILSON HR, 1990, J BACTERIOL, V172, P3208, DOI 10.1128/jb.172.6.3208-3213.1990	36	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24066	24072						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929058				2022-12-27	WOS:A1994PQ34600036
J	CHU, KT; LITTMAN, DR				CHU, KT; LITTMAN, DR			REQUIREMENT FOR KINASE-ACTIVITY OF CD4-ASSOCIATED P56(LCK) IN ANTIBODY-TRIGGERED T-CELL SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RECEPTOR ZETA-CHAIN; ANTIGEN RECEPTOR; ALPHA-3 DOMAIN; PHOSPHOLIPASE C-GAMMA-1; THYMOCYTE DEVELOPMENT; NEGATIVE SELECTION; BINDING-SITE; CD4; ACTIVATION	The lymphoid-specific Src family protein tyrosine kinase p56(lck) (Lck) is non-covalently associated with the cytoplasmic tail of CD4 and has an essential role in T cell activation. Engagement of ligand by the T cell antigen receptor (TCR) is followed by rapid tyrosine phosphorylation of several cellular proteins, including phospholipase C gamma 1 (PLC) and the TCR-associated CD3 zeta polypeptides. Tyrosine phosphorylation of PLC gamma 1 results in activation of PLC and subsequent phosphatidylinositol turnover, We have studied the effects of the CD4-associated Lck molecule on TCR-mediated activation of the protein tyrosine kinase (PTK) pathway in a murine T cell hybridoma. Antibodies against CD3 elicited the expected PTK activation, which was enhanced upon co-cross-linking of CD4. In contrast, anti-TCR-alpha beta antibodies had no effect on the PTK pathway unless CD4 was co-cross-linked. Antibody cross-linking of CD4 alone failed to induce the same pattern of tyrosine phosphorylation. Similar results were obtained when a chimeric protein consisting of the extracellular and transmembrane domains of CD4 linked to the intracellular Lck molecule was used in place of CD4. The tyrosine kinase activity of Lck was essential for the activity of the chimeric protein. Cross-linking of the CD4/Lck chimera to a CD8/zeta chimeric molecule also facilitated induction of the PTK pathway with anti-CD8 antibodies. Moreover, the interaction of the two chimeric proteins, either in vitro or in vivo, resulted in tyrosine phosphorylation of CD8/zeta. The effects of CD4/Lck on tyrosine phosphorylation and activation of PLC correlated well with the effects on PTK activation. Our results suggest that the Lck molecule positively regulates the TCR-coupled PTK pathway by phosphorylating tyrosines on the TCR-associated CD3 zeta polypeptides.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	CHU, KT (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; DIEZOREJAS R, 1994, EMBO J, V13, P90, DOI 10.1002/j.1460-2075.1994.tb06238.x; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1991, CURR OPIN IMMUNOL, V3, P287, DOI 10.1016/0952-7915(91)90026-W; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, PHILOS T ROY SOC B, V342, P25, DOI 10.1098/rstb.1993.0131; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVIN SD, 1993, J EXP MED, V178, P245, DOI 10.1084/jem.178.1.245; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LUO KX, 1990, MOL CELL BIOL, V10, P5304; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PENNINGER J, 1993, SCIENCE, V260, P358, DOI 10.1126/science.8469988; POTTER TA, 1987, J EXP MED, V166, P956, DOI 10.1084/jem.166.4.956; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANCHO J, 1992, J BIOL CHEM, V267, P7871; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; Siegel J N, 1991, Semin Immunol, V3, P325; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	52	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24095	24101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929062				2022-12-27	WOS:A1994PQ34600040
J	LEEBLUNDBERG, LMF; SONG, XH; MATHIS, SA				LEEBLUNDBERG, LMF; SONG, XH; MATHIS, SA			FOCAL ADHESION-ASSOCIATED PROTEINS P125(FAK) AND PAXILLIN ARE SUBSTRATES FOR BRADYKININ-STIMULATED TYROSINE PHOSPHORYLATION IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; FREE CA-2+; BOMBESIN; VASOPRESSIN; FIBROBLASTS; CALCIUM; IDENTIFICATION	In this study we examined the involvement of the focal adhesion-associated proteins p125(FAK) and paxillin as substrates for bradykinin (BK)-stimulated tyrosine phosphorylation in Swiss 3T3 cells and the potential role of protein kinase C and Ca2+ in these events. BK (1 mu M) stimulated tyrosine phosphorylation of p125(FAK) and paxillin. In addition, BK also increased the phosphotyrosine content of the src transformation-associated protein p130. The responses were rapid and transient and peaked at similar to 1 min after BK addition. Furthermore, the responses were dose-dependent with half-maximal effects occurring at 1-10 nM BK. The phosphotyrosine content of p125(FAK), paxillin, and p130 was also increased following stimulation with phorbol 12-myristate 13-acetate (PMA) (0.1 mu M). In contrast, PMA had no effect on the phosphotyrosine content of p125, a Ras-GAP-associated tyrosine phosphoprotein that we recently identified. Long term pretreatment (18 h) of cells with 0.3 mu M PMA partially attenuated BK-stimulated phosphorylation of p125(FAK) but was without effect on phosphorylation of paxillin and Ras-GAP-associated p125. Furthermore, only a small inhibition of BK- and PMA-stimulated phosphorylation of p125(FAK) was observed following pretreatment with 25 mu M BAPTA/AM. In all, these results show that multiple mechanisms are involved in BK-stimulated tyrosine phosphorylation of p1Z5(FAK), paxillin, Ras-GAP-associated p125, and are transformation-associated p130.			LEEBLUNDBERG, LMF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; FORCE T, 1991, J BIOL CHEM, V266, P6650; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MCALLISTER BS, 1993, ARCH BIOCHEM BIOPHYS, V304, P294, DOI 10.1006/abbi.1993.1352; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MONCK JR, 1988, J BIOL CHEM, V263, P4569; MUNOZ CM, 1992, ARCH BIOCHEM BIOPHYS, V301, P336; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OLSEN R, 1988, J BIOL CHEM, V263, P18030; PANDIELLA A, 1989, J BIOL CHEM, V264, P3122; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	52	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24328	24334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929090				2022-12-27	WOS:A1994PQ34600074
J	PERLMAN, KL; PRAHL, JM; SMITH, C; KUTNER, A; DELUCA, HF				PERLMAN, KL; PRAHL, JM; SMITH, C; KUTNER, A; DELUCA, HF			26,27-DIHOMO-1-ALPHA-HYDROXY-VITAMIN-D-2 AND 26,27-DIHOMO-24-EPI-1-ALPHA,25-DIHYDROXYVITAMIN-D-2 ANALOGS THAT DIFFER MARKEDLY IN BIOLOGICAL-ACTIVITY IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D; METABOLISM; RATS; 1,25-DIHYDROXYCHOLECALCIFEROL; RECEPTOR; CALCIUM	26,27-Dihomo-1 alpha-hydroxyvitamin D-2, 26,27-dihomo-24-epi-1 alpha-hydroxyvitamin D-2, and 26,27-dihomo-24-epi-1 alpha,25-dihydroxyvitamin D-2 have been synthesized. In contrast to 1 alpha-hydroxyvitamin D-2 and 24-epi-1 alpha-hydroxyvitamin D-2, 26,27-dihomo-1 alpha-hydroxyvitamin D-2 (1) and the 24-epi analog (2) have no activity in intestinal calcium transport, bone calcium mobilization, or skeleton mineralization. On the other hand, 26,27-dihomo-24-epi-1 alpha,25-dihydroxyvitamin D-2 is equal to 1,25-dihydroxyvitamin D-3 in biological activity. Vitamin D 25-hydroxylase readily converts 1 alpha-hydroxyvitamin D-2 to 1,25-dihydroxyvitamin D-2. In contrast, the same preparations fail to hydroxylate 26,27-dihomo-1 alpha-hydroxyvitamin D-2 and 26,27-dihomo-24-epi-1 alpha-hydroxyvitamin D-2 on carbon 25. Thus, homologation of carbons 26 and 27 of the vitamin D compound likely sterically hinders vitamin D 25-hydroxylase.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			KUTNER, ANDRZEJ/P-8823-2015; Kutner, Andrzej/AAB-6213-2020	Kutner, Andrzej/0000-0002-9518-4142	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DELUCA HF, 1988, AM J PHYSIOL, V254, pE402, DOI 10.1152/ajpendo.1988.254.4.E402; HOLICK MF, 1975, SCIENCE, V190, P576, DOI 10.1126/science.1188356; KUTNER A, 1988, J ORG CHEM, V53, P3450, DOI 10.1021/jo00250a009; KUTNER A, 1987, TETRAHEDRON LETT, V28, P6129, DOI 10.1016/S0040-4039(00)61826-9; LAM HYP, 1974, SCIENCE, V186, P1038; MADHOK TC, 1979, BIOCHEM J, V184, P491, DOI 10.1042/bj1840491; NAPOLI JL, 1979, ARCH BIOCHEM BIOPHYS, V197, P193, DOI 10.1016/0003-9861(79)90236-4; PERLMAN K, 1990, BIOCHEMISTRY-US, V29, P190, DOI 10.1021/bi00453a026; PERLMAN KL, 1992, TETRAHEDRON LETT, V33, P2937, DOI 10.1016/S0040-4039(00)79565-7; PERLMAN KL, 1989, J CHEM SOC CHEM COMM, P1113, DOI 10.1039/c39890001113; PINAZZI CP, 1975, B SOC CHIM FR II-CH, P201; REEVE LE, 1978, ARCH BIOCHEM BIOPHYS, V186, P164, DOI 10.1016/0003-9861(78)90475-7; SICINSKI RR, 1985, BIOORG CHEM, V13, P158, DOI 10.1016/0045-2068(85)90018-5; Snedecor G.W., 1980, STAT METHODS, V7; SOLLADIE G, 1981, SYNTHESIS-STUTTGART, P185; SORENSEN H, 1990, BIOCHEM PHARMACOL, V39, P391, DOI 10.1016/0006-2952(90)90039-N; SUDA T, 1970, J NUTR, V100, P1049, DOI 10.1093/jn/100.9.1049; TANAKA Y, 1973, ENDOCRINOLOGY, V92, P417, DOI 10.1210/endo-92-2-417; UHLANDSMITH A, 1993, J NUTR, V123, P1777, DOI 10.1093/jn/123.11.1777; UHLANDSMITH A, 1992, J NUTR, V122, P2316, DOI 10.1093/jn/122.12.2316; 1955, US PHARMACOPOEIA, P889	21	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24014	24019						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929052				2022-12-27	WOS:A1994PQ34600028
J	SARAS, J; CLAESSONWELSH, L; HELDIN, CH; GONEZ, LJ				SARAS, J; CLAESSONWELSH, L; HELDIN, CH; GONEZ, LJ			CLONING AND CHARACTERIZATION OF PTPL1, A PROTEIN-TYROSINE-PHOSPHATASE WITH SIMILARITIES TO CYTOSKELETAL-ASSOCIATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; TUMOR SUPPRESSOR GENE; GROWTH-FACTOR; FOCAL ADHESIONS; SEQUENCE HOMOLOGY; HUMAN-PLATELETS; MESSENGER-RNAS; CDNA CLONING; SH3 DOMAINS; CELL-LINES	A novel cytoplasmic protein tyrosine phosphatase (PTP), PTPL1, was identified and cloned using a polymerase chain reaction-based approach. Overlapping cDNA clones encompass an open reading frame of 7398 base pairs, predicting a protein of 2466 amino acid residues with a molecular mass of 275 kDa. PTPL1 has a wide tissue distribution, a 9.5-kilobase transcript being expressed in most tissues. Peptide antisera against PTPL1 specifically precipitate a protein with an apparent mass of 250 kDa. PTPL1 has a PTP domain located in the COOP terminus, and the protein was shown to dephosphorylate P-32-labeled myelin basic protein. In the non-enzymatic part of PTPL1, three different structural motifs can be identified. Two of these are often found in proteins at the interface between the plasma membrane and the cytoskeleton, i.e. a 300-amino acid domain with similarity to the band 4.1 superfamily, and a region consisting of five GLGF repeats, an 80-amino acid repeat found in a variety of cytoskeleton associated proteins. In addition to these structures PTPL1 has a region that fulfills the criteria for a leucine zipper motif. PTPL1 is the hitherto largest PTP identified and the only one known which contains a leucine zipper motif.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUCKLAND R, 1989, NATURE, V338, P547, DOI 10.1038/338547a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P8512; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FU YH, 1989, MOL CELL BIOL, V9, P1120, DOI 10.1128/MCB.9.3.1120; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HONDA H, 1993, LEUKEMIA, V7, P742; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEG J, 1992, J BIOL CHEM, V267, P19258; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; NISTER M, 1988, CANCER RES, V48, P3910; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHARMA S, 1989, ONCOGENE RES, V5, P91; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1991, COLD SH Q B, V56, P265; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	72	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24082	24089						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929060				2022-12-27	WOS:A1994PQ34600038
J	YAMAGUCHI, T; KOMODA, Y; NAKAJIMA, H				YAMAGUCHI, T; KOMODA, Y; NAKAJIMA, H			BILIVERDIN-IX-ALPHA REDUCTASE AND BILIVERDIN-IX-BETA REDUCTASE FROM HUMAN LIVER - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; HEME OXYGENASE; MOLECULAR-FORMS; MULTIPLE FORMS; PATTERN; KIDNEY; EXPRESSION; BROMOBENZENE; VARIANTS	This report describes for the first time the identification of four forms of biliverdin reductase including two biliverdin-Mg reductases and two biliverdin-IX alpha reductases, designated isozymes I and II and isozymes III and IV, respectively, in human liver cytosolic fractions. The four forms of biliverdin reductase were purified to homogeneity. There was a 7,800-15,000-fold increase in specific activity when compared with the crude preparation, and the recovery was 8-26%. The purified enzymes were monomers with a molecular weight of about 21,000 (isozymes I and II) and 34,000 (isozymes III and IV). The enzymes were strictly specific for biliverdin, and no other oxidoreductase activities were detected in the purified preparations. The purified enzymes used NADPH and NADH as electron donors for the reduction of biliverdin. The apparent K-m values of isozymes I, II, III, and IV for NADPH were 35.9, 13.1, 10.9, and 34.1 mu M, respectively, whereas those for NADH were 5.6, 8.2, 7.9, and 23.4 mM, respectively. It was assumed that NADPH rather than NADH was the physiological electron donor in the intracellular reduction of biliverdin. The apparent K-m value of isozymes I and II for biliverdin-IX beta in the NADPH system was 0.3 mu M whereas those of isozymes III and IV for biliverdin-IX alpha were 1.0 and 0.8 mu M, respectively. Isozymes I and II used biliverdin-IX beta, -IX gamma, and -IX delta as substrates but not biliverdin-IX alpha and isozymes III and IV preferred biliverdin-IX alpha as the most effective substrate among the four biliverdin isomers. The NADPH-dependent enzyme activities were inhibited by substrate concentrations in excess of 3-4 mu M. The NADPH-dependent enzyme activities, especially isozymes III and IV, were sensitive to SH reagents including iodoacetamide, p-chloromercuribenzoic acid, and N-ethylmaleimide. The optimum pH of the reaction with NADPH for isozymes I and II was 8.2 whereas that for isozymes III and IV was 7.4. The proportion of the total activity of isozymes I and II to that of isozymes III and IV was considerably higher in the fetal than in the adult liver.	TOKYO MED & DENT UNIV, INST MED & DENT ENGN, DIV MED CHEM, TOKYO 113, JAPAN	Tokyo Medical & Dental University (TMDU)	YAMAGUCHI, T (corresponding author), TOKYO MED & DENT UNIV, MED RES INST, DEPT BIOCHEM GENET, TOKYO 113, JAPAN.							BELL JE, 1988, ARCH BIOCHEM BIOPHYS, V263, P1, DOI 10.1016/0003-9861(88)90607-8; BLANCKAERT N, 1976, BIOCHEM J, V155, P405, DOI 10.1042/bj1550405; BRINDLE NJM, 1986, BIOCHEM J, V236, P303, DOI 10.1042/bj2360303; CASCONE O, 1989, EUR J BIOCHEM, V179, P123, DOI 10.1111/j.1432-1033.1989.tb14529.x; COLLERAN E, 1977, CHEM PHYSL BILE PIGM, P69; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; FRYDMAN RB, 1983, BIOCHIM BIOPHYS ACTA, V759, P257, DOI 10.1016/0304-4165(83)90321-5; FRYDMAN RB, 1987, BIOCHIM BIOPHYS ACTA, V916, P500, DOI 10.1016/0167-4838(87)90197-X; FRYDMAN RB, 1982, BIOCHEM BIOPH RES CO, V105, P752, DOI 10.1016/0006-291X(82)91498-X; HUANG TJ, 1989, ARCH BIOCHEM BIOPHYS, V270, P513, DOI 10.1016/0003-9861(89)90533-X; HUANG TJ, 1990, MOL PHARMACOL, V37, P25; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; KUTTY RK, 1983, BIOCHEM PHARMACOL, V32, P2095, DOI 10.1016/0006-2952(83)90432-X; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LEMBERG R, 1949, HEMATIN COMPOUNDS BI, P114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1990, MOL PHARMACOL, V38, P481; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; MAINES MD, 1977, J BIOL CHEM, V252, P5900; MAINES MD, 1986, J BIOL CHEM, V261, P411; NAKAJIMA H, 1963, J BIOL CHEM, V238, P3784; NOGUCHI M, 1979, J BIOCHEM, V86, P833, DOI 10.1093/oxfordjournals.jbchem.a132615; O'CARRA P, 1971, Biochemical Journal, V125, p110P; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; Sols A., 1970, CURRENT TOPICS CELLU, V2, P227; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; WATT J, 1976, BIOCHEM SOC T, V4, P866, DOI 10.1042/bst0040866; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAGUCHI T, 1979, P JPN ACAD B-PHYS, V55, P84, DOI 10.2183/pjab.55.84; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778	32	73	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24343	24348						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929092				2022-12-27	WOS:A1994PQ34600076
J	YOON, SO; CHIKARAISHI, DM				YOON, SO; CHIKARAISHI, DM			ISOLATION OF 2 E-BOX BINDING-FACTORS THAT INTERACT WITH THE RAT TYROSINE-HYDROXYLASE ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN-DNA INTERACTIONS; CCAAT DISPLACEMENT PROTEIN; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GENE PROMOTER; DROSOPHILA; SEQUENCE; HOMEOBOX; DOMAIN	The enhancer of the rat tyrosine hydroxylase gene (TH) in PC8b cells is composed of the AP1 motif (TCAT-TCA, -205 to -199) and an overlapping 20-base pair dyad symmetry element (TCAGAGGCAGGTGCCTGTGA, -201 to -182) whose core is an E-box. We have isolated two partial cDNA clones that encode factors which bind the TH dyad. One is rITF2 with a basic helix-loop-helix motif and the other is CDP2 with a homeodomain. rITF2 is a rat homolog of human ITF2 (or E2-2), and CDP2 is a member of a new family of homeoproteins defined by histidine as the 9th residue of the recognition helix and by unique 64 amino acid repeats related to those of the Drosophila cut gene. The binding affinity of CDP2 alone is relatively weak, but it enhances the binding of rITF2 to the TH-dyad. In transfected F9 cells, activation of a TH-driven reporter requires both rITF2 and CDP2, suggesting that the proteins may functionally interact. However, rITF2 and CDP2 are not restricted to TH-expressing tissues; hence they may not be involved in the tissue-specific expression of TH. In addition, CDP2 is phosphorylated in vitro and in vivo.	TUFTS UNIV,SCH MED,NEUROSCI PROGRAM,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111	Tufts University; Tufts University			Yoon, Sung Ok/C-5992-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022675] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22675] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; BAHLER M, 1991, J NEUROCHEM, V57, P423, DOI 10.1111/j.1471-4159.1991.tb03769.x; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1993, ANNU REV GENET, V24, P387; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; HARLOW E, 1988, ANTIBODY LABORATORY; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; JAVAUX F, 1991, NUCLEIC ACIDS RES, V19, P1121, DOI 10.1093/nar/19.5.1121; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RIDDIHOUGH G, 1992, NATURE, V357, P643, DOI 10.1038/357643a0; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; VALARCHE I, 1993, DEVELOPMENT, V119, P881; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	42	95	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1994	269	28					18453	18462						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NW798	7913462				2022-12-27	WOS:A1994NW79800037
J	FARRES, J; WANG, XP; TAKAHASHI, K; CUNNINGHAM, SJ; WANG, TT; WEINER, H				FARRES, J; WANG, XP; TAKAHASHI, K; CUNNINGHAM, SJ; WANG, TT; WEINER, H			EFFECTS OF CHANGING GLUTAMATE-487 TO LYSINE IN RAT AND HUMAN LIVER MITOCHONDRIAL ALDEHYDE DEHYDROGENASE - A MODEL TO STUDY HUMAN (ORIENTAL TYPE) CLASS-2 ALDEHYDE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE; HORSE LIVER; ESCHERICHIA-COLI; MOLECULAR-CLONING; CYTOPLASMIC ISOENZYME; ALCOHOL-DEHYDROGENASE; CATALYTIC ACTIVITY; MESSENGER-RNA; CDNA; GENE	Many Oriental people possess a liver mitochondrial aldehyde dehydrogenase where glutamate at position 487 has been replaced by a lysine, and they have very low levels of mitochondrial aldehyde dehydrogenase activity. To investigate the cause of the lack of activity of this aldehyde dehydrogenase, we mutated residue 487 of rat and human liver mitochondrial aldehyde dehydrogenase to a lysine and expressed the mutant and native enzyme forms in Escherichia coli. Both rat and human recombinant aldehyde dehydrogenases showed the same molecular and kinetic properties as the enzyme isolated from liver mitochondria. The E487K mutants were found to be active but possessed altered kinetic properties when compared to the glutamate enzyme. The K-m for NAD(+) at pH 7.4 increased more than 150-fold, whereas k(cat) decreased 2-10-fold with respect to the recombinant native enzymes. Detailed steady-state kinetic analysis showed that the binding of NAD(+) to the mutant enzyme was impaired, and it could be calculated that this resulted in a decreased nucleophilicity of the active site cysteine residue. The rate-limiting step for the rat E487K mutant was also different from that of the recombinant rat liver aldehyde dehydrogenase in that no pre-steady state burst of NADH formation was found with the mutant enzyme. Both the rat native enzyme and the E487K mutant oxidized chloroacetaldehyde twice as fast as acetaldehyde, indicating that the rate limiting step was not hydride transfer or coenzyme dissociation but depended upon nucleophilic attack. Each enzyme form showed a 2-fold activation upon the addition of Mg2+ ions. Substituting a glutamine for the glutamate did not grossly affect the properties of the enzyme. Glutamate 487 may interact directly with the positive nicotinamide ring of NAD(+) for the K-i of NADH was the same in the lysine enzyme as it was in the glutamate form. Because of the altered NAD(+) binding properties and k(cat) of the E487K variant, it is assumed that people possessing this form will not have a functional mitochondrial aldehyde dehydrogenase.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; UNIV AUTONOMA BARCELONA,DEPT BIOQUIM & BIOL MOLEC,UNITAT CIENCIES,BARCELONA,SPAIN; OKAYAMA UNIV,SCH DENT,DEPT BIOCHEM,OKAYAMA 700,JAPAN; NCI,NUTR & MOLEC REGULAT LAB,FREDERICK,MD 21702	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Autonomous University of Barcelona; Okayama University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Farrés, Jaume/F-8648-2016	Farrés, Jaume/0000-0001-9069-3987	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005812, R37AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00028, AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABRIOLA DP, 1990, BIOCHEM J, V266, P179, DOI 10.1042/bj2660179; AMBROZIAK W, 1989, BIOCHEMISTRY-US, V28, P5367, DOI 10.1021/bi00439a008; BLACKWELL LF, 1987, BIOCHEM J, V242, P803, DOI 10.1042/bj2420803; BOYD LA, 1991, GENE, V103, P45, DOI 10.1016/0378-1119(91)90389-S; BRAUN T, 1987, FEBS LETT, V215, P233, DOI 10.1016/0014-5793(87)80152-7; BURNELL JC, 1987, BIOCHEM BIOPH RES CO, V146, P1227, DOI 10.1016/0006-291X(87)90779-0; CHRISTENSEN EL, 1979, BIOCH PHARMACOLOGY E, V1, P191; COOK RJ, 1991, J BIOL CHEM, V266, P4965; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; EKLUND H, 1987, BIOL MACROMOL, V3, P74; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FERENCZBIRO K, 1984, BIOCHEM BIOPH RES CO, V118, P97, DOI 10.1016/0006-291X(84)91072-6; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GOEDDE HW, 1979, HUM GENET, V51, P331; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; GUAN K, 1990, ARCH BIOCHEM BIOPHYS, V277, P351, DOI 10.1016/0003-9861(90)90590-U; GUAN KL, 1988, ALCOHOL CLIN EXP RES, V12, P713, DOI 10.1111/j.1530-0277.1988.tb00270.x; HEIM R, 1991, GENE, V99, P15, DOI 10.1016/0378-1119(91)90028-A; HEMPEL J, 1984, FEBS LETT, V173, P367, DOI 10.1016/0014-5793(84)80807-8; HEMPEL J, 1985, EUR J BIOCHEM, V153, P13, DOI 10.1111/j.1432-1033.1985.tb09260.x; HEMPEL J, 1991, PROTEINS, V11, P176, DOI 10.1002/prot.340110303; HEMPEL J, 1984, EUR J BIOCHEM, V141, P21, DOI 10.1111/j.1432-1033.1984.tb08150.x; HEMPEL J, 1987, ENZYMOLOGY MOL BIOL, P1; HEMPEL JD, 1982, ALCOHOL CLIN EXP RES, V6, P417, DOI 10.1111/j.1530-0277.1982.tb05001.x; HIDALGO E, 1991, J BACTERIOL, V173, P6118, DOI 10.1128/jb.173.19.6118-6123.1991; HSU LC, 1991, J BIOL CHEM, V266, P12257; Hsu LC, 1988, GENOMICS, V2, P57, DOI 10.1016/0888-7543(88)90109-7; HURLEY TD, 1992, J MOL BIOL, V227, P1255, DOI 10.1016/0022-2836(92)90536-S; IKAWA M, 1983, J BIOL CHEM, V258, P6282; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; JOHANSSON J, 1988, EUR J BIOCHEM, V172, P527, DOI 10.1111/j.1432-1033.1988.tb13920.x; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; KOK M, 1989, J BIOL CHEM, V264, P5442; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; LINDROS KO, 1982, ARCH BIOCHEM BIOPHYS, V218, P429, DOI 10.1016/0003-9861(82)90364-2; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MIZOI Y, 1979, PHARMACOL BIOCHEM BE, V10, P303, DOI 10.1016/0091-3057(79)90105-9; NORDLUND I, 1990, BIOCHIM BIOPHYS ACTA, V1049, P227, DOI 10.1016/0167-4781(90)90046-5; OHLSSON I, 1974, J MOL BIOL, V89, P339, DOI 10.1016/0022-2836(74)90523-3; PARSOT C, 1991, J BACTERIOL, V173, P2842, DOI 10.1128/JB.173.9.2842-2851.1991; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; PIETRUSZKO R, 1981, ALCOHOL CLIN EXP RES, V5, P78; PLOWMAN KM, 1972, ENZYME KINETICS, P40; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH S, 1989, HUM GENET, V83, P119, DOI 10.1007/BF00286702; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SRIDHARA S, 1969, J BIOL CHEM, V244, P5233; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P2720, DOI 10.1021/bi00513a003; TAKAHASHI K, 1980, ARCH BIOCHEM BIOPHYS, V205, P571, DOI 10.1016/0003-9861(80)90140-X; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; VALLARI RC, 1981, ARCH BIOCHEM BIOPHYS, V212, P9, DOI 10.1016/0003-9861(81)90338-6; VALLARI RC, 1984, J BIOL CHEM, V259, P4922; VONBAHRLINDSTROM H, 1985, BIOCHEMISTRY-US, V24, P5847, DOI 10.1021/bi00342a023; VONBAHRLINDSTROM H, 1984, EUR J BIOCHEM, V141, P37; WEINER H, 1976, J BIOL CHEM, V251, P3853; WEINER H, 1982, ENZYMOLOGY CARBONYL, P1; WERETILNYK EA, 1989, ARCH BIOCHEM BIOPHYS, V271, P56, DOI 10.1016/0003-9861(89)90255-5; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	66	120	123	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13854	13860						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	7910607				2022-12-27	WOS:A1994NL60600023
J	MANN, SS; HAMMARBACK, JA				MANN, SS; HAMMARBACK, JA			MOLECULAR CHARACTERIZATION OF LIGHT CHAIN-3 - A MICROTUBULE-BINDING SUBUNIT OF MAP1A AND MAP1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-1 MAP-1; NERVOUS-SYSTEM; MESSENGER-RNA; IDENTIFICATION; SEQUENCE; TUBULIN; LOCALIZATION; PURIFICATION; POLYPEPTIDE; COMPONENT	Light chain 3 (LC3) is a subunit of the neuronal microtubule-associated proteins (MAPs), MAP1A and MAP1B. Recent findings show that the cDNAs for MAP1A and MAP1B encode polyproteins that contain the MAP1A or MAP1B heavy chain and a LC2 or LC1 subunit, respectively. We have sequenced a cDNA encoding rat LC3, and its sequence is not found in the MAP1A/LC2 or MAP1B/LC1 polyprotein cDNAs. The deduced amino acid sequence of LC3 is highly conserved between rat and mouse. Rat LC3 is a 16.4-kDa protein with a predicted pI of 9.2. It is encoded on a 1.7-kilobase mRNA. Our anti-LC3 antiserum shows that LC3 is abundant only in neurons and that the majority of LC3 in brain co-purifies with microtubules. Purified recombinant rat LC3 retains the ability to associate with microtubules assembled in the presence of brain MAPs and with microtubules assembled from purified tubulin. We propose that LC3 functions primarily as a MAP1A and MAP1B subunit and that its expression could regulate the microtubule binding activity of MAP1A and MAP1B.	BOWMAN GRAY SCH MED, DEPT NEUROBIOL & ANAT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030985] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30985] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Ausubel FM, 1988, MOL REPROD DEV; BATTEY JF, 1986, BASIC METHODS MOL BI, P143; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; CALVERT RA, 1987, NEUROSCIENCE, V23, P131, DOI 10.1016/0306-4522(87)90277-6; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIBSON CA, 1990, J VIROL METHODS, V29, P167, DOI 10.1016/0166-0934(90)90110-2; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; KIRSCH J, 1990, FEBS LETT, V262, P259, DOI 10.1016/0014-5793(90)80205-W; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUZNETSOV SA, 1986, J CELL BIOL, V102, P1060, DOI 10.1083/jcb.102.3.1060; KUZNETSOV SA, 1987, FEBS LETT, V212, P145, DOI 10.1016/0014-5793(87)81574-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RIEDERER B, 1986, J NEUROCYTOL, V15, P763, DOI 10.1007/BF01625193; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; TUCKER RP, 1988, J COMP NEUROL, V271, P44, DOI 10.1002/cne.902710106; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P1342, DOI 10.1073/pnas.80.5.1342; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; [No title captured]	34	244	255	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11492	11497						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7908909				2022-12-27	WOS:A1994NF96600076
J	SCHMIDT, M; BUCHNER, J; TODD, MJ; LORIMER, GH; VIITANEN, PV				SCHMIDT, M; BUCHNER, J; TODD, MJ; LORIMER, GH; VIITANEN, PV			ON THE ROLE OF GROES IN THE CHAPERONIN-ASSISTED FOLDING REACTION - 3 CASE-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; RIBULOSEBISPHOSPHATE CARBOXYLASE; ATP HYDROLYSIS; BETA-LACTAMASE; GENE-PRODUCTS; PROTEIN; IDENTIFICATION; INVITRO	The mechanism by which correctly folded proteins are recovered from stable complexes with groEL is not well understood. Certain target proteins require ATP and groES, while others seemingly dispense with the co-chaperonin. Here, we examine the chaperonin-assisted folding of ribulose-1,5-bisphosphate carboxylase, malate dehydrogenase, and citrate synthase, three proteins that are believed to require both chaperonin components for successful reactivation. Surprisingly, in all cases, the need for groES depended on the folding environment. Under ''non-permissive'' conditions, where unassisted spontaneous folding could not occur, reactivation to the native state required the complete chaperonin system (e.g. groEL, groES, and MgATP). However, under ''permissive'' conditions where spontaneous folding could occur groES was no longer mandatory. Instead, upon the addition of ATP alone, all three target proteins could be released from groEL, in a form that was capable of reaching the native state. In the permissive setting, groES merely accelerated the rate of the ATP dependent release process. The results suggest that the incompletely folded protein species that are released from groEL, in the absence of groES, are not necessarily committed to the native state. Similar to the unassisted folding reaction, they still partition between productive and unproductive folding pathways in an environment-dependent manner. It follows that the mechanistic contribution of the co-chaperonin, groES, and its physiological significance in cellular protein folding, could be entirely missed in a permissive in vitro environment.	DUPONT CO INC, DEPT CENT RES & DEV, DIV MOLEC BIOL, EXPTL STN, WILMINGTON, DE 19880 USA; UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, W-8400 REGENSBURG, GERMANY	DuPont; University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; GRIMM R, 1993, J BIOL CHEM, V268, P5220; GUTTERIDGE S, 1989, BIOCHEM J, V260, P711, DOI 10.1042/bj2600711; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUBBS AE, 1993, J BIOL CHEM, V268, P13519; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KERN G, 1992, FEBS LETT, V305, P203, DOI 10.1016/0014-5793(92)80667-6; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522; WEAVER AJ, 1993, BIOPHYS J, V64, pA350; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	59	156	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10304	10311						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908292				2022-12-27	WOS:A1994NF01700022
J	SAUK, JJ; SMITH, T; NORRIS, K; FERREIRA, L				SAUK, JJ; SMITH, T; NORRIS, K; FERREIRA, L			HSP47 AND THE TRANSLATION-TRANSLOCATION MACHINERY COOPERATE IN THE PRODUCTION OF ALPHA-1(I) CHAINS OF TYPE-I PROCOLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; COLLAGEN-BINDING PROTEIN; HEAT-SHOCK PROTEIN; POLYPEPTIDE TRANSLOCATION; MICROSOMAL-MEMBRANES; NASCENT POLYPEPTIDES; POLYACRYLAMIDE GELS; CROSS-LINKING	Hsp47, an endoplasmic reticulum resident protein, has gelatin-binding and procollagen binding properties and has been hypothesized to function as a molecular chaperone in regulating procollagen folding and/or assembly. In this report, we further investigate the interaction of Hsp47 with polysome associated alpha 1(I) procollagen chains following antisense treatment of 3T6 cells. For these studies, we employed phosphorothioate oligo-deoxynucleotides directed to the first five codons of Hsp47 that straddle the predicted translation initiation site of mouse Hsp47. Cells depleted of Hsp47 in this manner were observed to produce diminished amounts of fully elongated nascent alpha 1(I) procollagen while accumulating shorter procollagen peptides associated with peptidyl-tRNA. Pulse-labeling of cells with [S-35]methionine followed by treatment with puromycin and immunoprecipitation with anti-Hsp47 and anti-procollagen antibodies revealed that Hsp47 is associated with alpha 1(I) procollagen at a very early point during translocation of the nascent procollagen chains. Although Hsp47 appears to possess properties similar to grp78/BiP, Hsp47 binding early during translocation favors a more specialized specific function relative to chain selection or completion of stable folding in type I procollagen.			SAUK, JJ (corresponding author), UNIV MARYLAND, SCH DENT, DEPT PATHOL, BALTIMORE, MD 21201 USA.			Sauk, John/0000-0002-9208-5739	NIAMS NIH HHS [AR41572] Funding Source: Medline; NIDCR NIH HHS [DE08648] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008648] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERGMAN LW, 1977, BIOCHEMISTRY-US, V16, P4490, DOI 10.1021/bi00639a025; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CLARKE EP, 1992, BIOCHIM BIOPHYS ACTA, V1129, P246, DOI 10.1016/0167-4781(92)90498-O; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FOELLMER HG, 1983, EUR J BIOCHEM, V134, P183, DOI 10.1111/j.1432-1033.1983.tb07549.x; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KANG PJ, 1990, NATURE, V333, P330; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KIRK TZ, 1987, J BIOL CHEM, V262, P5540; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KURKINEN M, 1984, J BIOL CHEM, V259, P5915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIYAISHI O, 1992, J HISTOCHEM CYTOCHEM, V40, P1021, DOI 10.1177/40.7.1607635; NAGATA K, 1986, J BIOL CHEM, V261, P7531; NAKAI A, 1990, J BIOL CHEM, V265, P992; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NANDAN D, 1990, ARCH BIOCHEM BIOPHYS, V278, P291, DOI 10.1016/0003-9861(90)90263-X; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; REED JC, 1990, CANCER RES, V50, P6565; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAUK JJ, 1990, BIOCHEM BIOPH RES CO, V172, P135, DOI 10.1016/S0006-291X(05)80183-4; SHROFF B, 1993, CONNECT TISSUE RES, V29, P273, DOI 10.3109/03008209309016833; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEDELER A, 1991, MOL CELL BIOCHEM, V100, P183; VEIS A, 1985, P NATL ACAD SCI USA, V82, P3693, DOI 10.1073/pnas.82.11.3693; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1992, NATURE, V357, P22, DOI 10.1038/357022a0	49	119	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3941	3946						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7905876				2022-12-27	WOS:A1994MW98900009
J	BOCHKAREVA, ES; HOROVITZ, A; GIRSHOVICH, AS				BOCHKAREVA, ES; HOROVITZ, A; GIRSHOVICH, AS			DIRECT DEMONSTRATION THAT ATP IS IN CONTACT WITH CYS-137 IN CHAPERONIN GROEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BACTERIOPHAGE-T7 DNA-POLYMERASE; ESCHERICHIA-COLI; PROTEIN; COOPERATIVITY; PURIFICATION; MUTAGENESIS	The nonhydrolyzable ATP analogue ATPgammaS (adenosine 5'-3-O-(thio)triphosphate) is affinity cross-linked to GroEL by formation of a disulfide bridge in a peroxide-promoted reaction. By replacing with serine each of 3 cysteine residues in GroEL, it is shown that ATpgammaS specifically cross-links to Cys-137. It is thus demonstrated that the ATP bound to GroEL is in direct contact with Cys-137.			BOCHKAREVA, ES (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.							BANEYX F, 1992, J BIOL CHEM, V267, P11637; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BROCKLEHURST K, 1982, METHOD ENZYMOL, V87, P427; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIRSHOVICH AS, 1981, J MOL BIOL, V151, P229, DOI 10.1016/0022-2836(81)90513-1; GONEK T, 1992, INT J BIOCHEM, V24, P1533; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Kenny J W, 1979, Methods Enzymol, V59, P534; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MENDOZA JA, 1992, J PROTEIN CHEM, V11, P589, DOI 10.1007/BF01024958; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447	26	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					44	46						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7903969				2022-12-27	WOS:A1994MR21900012
J	MORII, N; KUMAGAI, N; NUREKAMAL, MSA; NARUMIYA, S; MARUTA, H				MORII, N; KUMAGAI, N; NUREKAMAL, MSA; NARUMIYA, S; MARUTA, H			RHO GAP OF 28 KDA (GAP2), BUT NOT OF 190 KDA (P190), REQUIRES ASP(65) AND ASP(67) OF RHO GTPASE FOR ITS ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; GENE-PRODUCT; SUPPRESSOR ACTIVITY; BINDING PROTEIN; RAS P21; PURIFICATION; SEQUENCE; CLONING; DOMAIN; SUBSTRATE	Two distinct GTPase-activating proteins (GAPs), i.e. rho GAPs of 28 kDa (GAP2) and of 190 kDa (p190), stimulate the intrinsic GTPase activity of the rho protein. The rho GAP activity of p190 resides in its C-terminal domain (p190C). Neither GAP2 nor p190C activates the ras GTPase. We replaced Asp65 and Asp67 residues of rho GTPase with the corresponding ras residues and examined whether the domain containing them is involved in its activation by rho GAPs. Mutation of either Asp65 to Glu or Asp67 to Ser did not change the K(d) value for GTPgammaS of the rho protein. The Ser67 mutation reduced the intrinsic GTPase activity of the rho protein, while no change was observed with the Glu65 mutation. Both mutations abolished activation of rho GTPase by GAP2. The GAP2-dependent activation of rho GTPase was inhibited by the addition of GTPgammaS-bound wild type rho but not by either GTPgammaS-bound Glu65- or Ser67-rho, indicating that both Asp65 and Asp67 are essential for interaction of rho protein with GAP2. On the contrary, p190C activated both Glu65- and Ser67-rho GTPases to the extent and in a dose dependence to those seen in the wild GTPase. These results suggest that GAP2 and p190 interact with different residues or domains of the rho GTPase for their activation.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	MORII, N (corresponding author), KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN.							ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1988, J BIOL CHEM, V263, P12420; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NICE E, 1991, J BIOL CHEM, V267, P1546; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27160	27163						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903304				2022-12-27	WOS:A1993MM26200049
J	COLLIECJOUAULT, S; SHWORAK, NW; LIU, J; DEAGOSTINI, AI; ROSENBERG, RD				COLLIECJOUAULT, S; SHWORAK, NW; LIU, J; DEAGOSTINI, AI; ROSENBERG, RD			CHARACTERIZATION OF A CELL MUTANT SPECIFICALLY DEFECTIVE IN THE SYNTHESIS OF ANTICOAGULANTLY ACTIVE HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PROTEOGLYCANS; GROWTH	We have investigated the characteristics of clonal L cell mutant VI-7 that has previously been demonstrated to exhibit reduced levels of cell surface proteoglycans containing heparan sulfate (HS) with regions of defined monosaccharide sequence that interact with antithrombin (HSact) (de Agostini, A. L., Lau, H. K., Leone, C., Youssoufian, H., and Rosenberg, R. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9784-9788). Pulse labeling revealed that the synthesis of HSact in mutant cells, as compared to wild-type cells, was reduced by 5-7-fold, which is identical to the previously observed reduction in cell surface-bound antithrombin. This alteration is independent of growth state since production of HSact by mutant cells, as compared to wild type cells, is decreased to a similar extent in exponentially growing and post-confluent cultures. The synthetic defect was specific for HSact since production of total HS and chondroitin sulfate by mutant cells, as compared to wild-type cells, was identical in magnitude. The synthetic abnormality is not due to an alteration in core protein since complementation was not observed when mutant cells were stably transfected with the epitope-tagged ryudocan cDNA which can initiate HSact production. Structural analyses revealed that HS from mutant cells, as compared to wild-type cells, exhibited normal molecular weight, extent and distribution of sulfate, and disaccharide composition, which indicate that the mutation did not affect HS biosynthetic enzymes. Together, the data suggest that mutant VI-7 is defective in a regulatory component which directly or indirectly coordinates HS biosynthetic enzymes to specifically generate the defined monosaccharide sequence of HSact.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215; UNIV HOSP GENEVA,DEPT OBSTET & GYNAECOL,CH-1211 GENEVA 14,SWITZERLAND	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Geneva			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634; Colliec-Jouault, Sylvia/0000-0002-2449-5410	NHLBI NIH HHS [HL-33014, HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; Esko J D, 1986, Methods Enzymol, V129, P237; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	16	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24953	24958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929178				2022-12-27	WOS:A1994PQ49000065
J	CURRIE, PD; SULLIVAN, DT				CURRIE, PD; SULLIVAN, DT			STRUCTURE AND EXPRESSION OF THE GENE ENCODING PHOSPHOFRUCTOKINASE (PFK) IN DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE GENE; FLIGHT-MUSCLE; DNA; SEQUENCE; 6-PHOSPHOFRUCTO-1-KINASE; DUPLICATION; TRANSCRIPTS; ISOZYMES; CLONING; INTRONS	The gene from Drosophila melanogaster that encodes phosphofructokinase has been isolated and its structure and expression characterized. Southern blots of genomic DNA, comparison of multiple clones, and in situ hybridization to salivary gland chromosomes indicate that the Drosophila genome contains a single copy of the gene which encodes phosphofructokinase (PFK) that is located at cytogenetic position 46D/E on the polytene map. Analysis of the gene structure reveals a single coding region that spans 6.5 kilobase pairs and is composed of eight exons and seven introns. Three developmentally regulated transcripts are generated through the use of alternative polyadenylation sites. Transcription initiation occurs at a single site. The pattern of transcript accumulation during development is similar to other genes of Drosophila which encode enzymes of the glycolytic pathway. Deficiency analysis of the 46D/E region has identified a lethal complementation group associated with reduced PFK activity, thereby establishing the vital role of PFK function in Drosophila.	SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244; UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,OXFORD OX1 3PS,ENGLAND	Syracuse University; University of Oxford				Currie, Peter/0000-0001-8874-8862	NIGMS NIH HHS [GM26830] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026830] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CURRIE P, 1994, IN PRESS GENETICS; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; DUNAWAY GA, 1974, ARCH BIOCHEM BIOPHYS, V162, P620, DOI 10.1016/0003-9861(74)90224-0; ENGELS WR, 1986, FOCUS, V8, P6; FRIEDMAN S, 1985, COMPREHENSIVE INSECT, V10, P53; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P229; GOLDSTEIN ES, 1993, 34TH ANN DROS RES C; HEINISCH J, 1989, GENE, V78, P309; HEINISCH J, 1991, CURR GENET, V20, P167, DOI 10.1007/BF00312781; HONG GF, 1982, J MOL BIOL, V158, P539, DOI 10.1016/0022-2836(82)90213-3; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KHOJA SM, 1990, INSECT BIOCHEM, V20, P443, DOI 10.1016/0020-1790(90)90025-P; KIM J, 1992, MOL CELL BIOL, V12, P773, DOI 10.1128/MCB.12.2.773; KOPPERSCHLAGER G, 1977, EUR J BIOCHEM, V81, P317, DOI 10.1111/j.1432-1033.1977.tb11954.x; LEITE A, 1988, J BIOL CHEM, V263, P17527; LISSEMORE JL, 1987, PLANT MOL BIOL, V8, P485, DOI 10.1007/BF00017994; Maniatis T, 1989, DECONTAMINATION DILU; MARCHIONNI M, 1986, CELL, V46, P133, DOI 10.1016/0092-8674(86)90867-6; MCKNIGHT GL, 1986, CELL, V46, P143, DOI 10.1016/0092-8674(86)90868-8; MORELLE G, 1988, FOCUS, V11, P7; MUNNEKE LR, 1985, BIOCHEM GENET, V23, P847, DOI 10.1007/BF00499933; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; ROSELLIREHFUSS L, 1992, MOL GEN GENET, V235, P213, DOI 10.1007/BF00279363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHAWLEE R, 1992, J BIOL CHEM, V267, P3959; SHAWLEE RL, 1991, MOL GEN GENET, V230, P225, DOI 10.1007/BF00290672; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOREY KB, 1985, INSECT BIOCHEM, V15, P663, DOI 10.1016/0020-1790(85)90130-1; UYEDA K, 1979, ADV ENZYMOL, V48, P192; VAISANEN PA, 1992, DNA CELL BIOL, V11, P461, DOI 10.1089/dna.1992.11.461; VALAITIS AP, 1992, INSECT BIOCHEM MOLEC, V22, P481, DOI 10.1016/0965-1748(92)90144-4; VONKALM L, 1989, P NATL ACAD SCI USA, V86, P5021; WALKER PR, 1969, BIOCHEM J, V111, P365, DOI 10.1042/bj1110365; WEGENER G, 1986, BIOCHEM J, V236, P925, DOI 10.1042/bj2360925; WINTERROWD CA, 1991, MOL BIOCHEM PARASIT, V48, P17	40	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24679	24687						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929140				2022-12-27	WOS:A1994PQ49000027
J	KAWABE, J; EBINA, T; ISMAIL, S; KITCHEN, DB; HOMCY, CJ; ISHIKAWA, Y				KAWABE, J; EBINA, T; ISMAIL, S; KITCHEN, DB; HOMCY, CJ; ISHIKAWA, Y			A NOVEL PEPTIDE INHIBITOR OF ADENYLYL-CYCLASE (AC) - A PEPTIDE FROM TYPE-V AC DIRECTLY INHIBITS AC CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC CHOLINERGIC RECEPTOR; SYNTHETIC PEPTIDES; PROTEIN; EXPRESSION; CLONING; RHODOPSIN; TRANSDUCIN; SEQUENCE; CHANNEL; BINDING	Peptides derived from various regions of type V adenylyl cyclase (AC) were studied to determine their effect on AC catalytic activity. Out of 10 examined, only one peptide, peptide 2 (Lys(425)-Cys(444)), significantly inhibited both basal and stimulated (forskolin or GTP gamma S (guanosine 5'-O-thiotriphosphate)) type VAC catalytic activity overexpressed in CMT cells. The sequence of this peptide was taken from the first cytoplasmic domain of type VAC, which has a high sequence homology to other AC isoforms. Competition studies performed between the peptide and the substrate ATP showed that the inhibition was noncompetitive. Mutation or truncation of the peptide designed to destroy its secondary structure totally negated the inhibitory effect. This peptide also inhibited the catalytic activity of purified types II and VAC, as well as that of various cells, including S49 cyc(-) cells. Our data indicate that the peptide directly interacts with AC to inhibit catalytic activity; this provides new information regarding regions of the enzyme involved in its catalytic activation.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965	Columbia University; Columbia University				Kitchen, Douglas/0000-0001-8988-759X	NHLBI NIH HHS [HL38070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARBERS DL, 1992, CELL, V71, P1; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; ISHIKAWA Y, 1992, NUCLEIC ACIDS RES, V20, P4367, DOI 10.1093/nar/20.16.4367; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KATSUSHIKA S, 1993, J BIOL CHEM, V268, P2273; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MONTAL MO, 1993, FEBS LETT, V320, P261, DOI 10.1016/0014-5793(93)80599-P; OBLATTMONTAL M, 1993, J BIOL CHEM, V268, P14601; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; RARICK HM, 1992, SCIENCE, V256, P1033; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; TAKEMOTO DJ, 1986, BIOCHEM J, V235, P309, DOI 10.1042/bj2350309; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	31	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24906	24911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929172				2022-12-27	WOS:A1994PQ49000059
J	LEMKUIL, DC; NETTESHEIM, D; SHAW, CF; PETERING, DH				LEMKUIL, DC; NETTESHEIM, D; SHAW, CF; PETERING, DH			REACTION OF CD-7-METALLOTHIONEIN WITH CIS-DICHLORODIAMINE PLATINUM(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULE CELLS; METALLOTHIONEIN; RESISTANCE; CISPLATIN; SENSITIVITY; BINDING	The reaction of Cd-7-metallothionein with cis-dichlorodiammine platinum (II) has been examined in titration and kinetic experiments. Titrations followed by Cd-111 MMR spectroscopy and analysis of cadmium and platinum in the products indicated that platinum displaced cadmium in approximate 1:1 fashion, producing Pt-7-metallothionein. According to NMR analysis, the overall reaction involved cooperative exchange of platinum for Cd-111 in each domain of the protein. There was a modest preference for the reaction of the drug with the Cd,containing P-domain of the protein. The product had an apparent molecular weight that was nearly the same as that of Cd-7-metallothionein as determined by Sephadex G-75 chromatography. Kinetic analysis also supported a cooperative displacement mechanism. The reaction was biphasic; neither step could be identified solely with the reaction of one cluster as indicated by the biphasic reaction of the Cd-4-containing alpha-domain with the platinum complex.	UNIV WISCONSIN, DEPT CHEM, MILWAUKEE, WI 53201 USA	University of Wisconsin System; University of Wisconsin Milwaukee					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004026] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-04026] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149; ARMITAGE IM, 1982, FED PROC, V41, P2974; BAKKA A, 1981, TOXICOL APPL PHARM, V61, P215, DOI 10.1016/0041-008X(81)90411-7; BLUMENTHAL SS, 1990, AM J PHYSIOL, V258, pF1625, DOI 10.1152/ajprenal.1990.258.6.F1625; BONGERS J, 1988, J INORG BIOCHEM, V34, P55, DOI 10.1016/0162-0134(88)85017-7; BONGERS J, 1991, INORG CHEM, V30, P515, DOI 10.1021/ic00003a032; BUHLER RHO, 1974, FEBS LETT, V39, P229, DOI 10.1016/0014-5793(74)80057-8; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; KAEGI JH, 1961, J BIOL CHEM, V236, P2435; KASAHARA K, 1991, CANCER RES, V51, P3237; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KOROPATNICK J, 1990, SOMAT CELL MOLEC GEN, V16, P529, DOI 10.1007/BF01233093; KRAKER A, 1985, BIOCHEM BIOPH RES CO, V130, P786, DOI 10.1016/0006-291X(85)90485-1; LEMKUIL D, 1991, J INORG BIOCHEM, V43, P604; LI TY, 1981, BIOCHEM J, V193, P441, DOI 10.1042/bj1930441; MCPARTLIN EM, 1969, ACTA CRYSTALL B-STRU, VB 25, P1659, DOI 10.1107/S0567740869004481; MINKEL DT, 1980, BIOCHEM J, V191, P475, DOI 10.1042/bj1910475; Otvos J. D., 1989, COMMENTS INORG CHEM, V9, P1, DOI DOI 10.1080/02603598908035801; PATTANAIK A, 1992, J BIOL CHEM, V267, P16121; Petering D. H., 1984, ANTICANCER INTERFERO, P203; PETERING DH, 1993, METALLOTHIONEIN, V3, P329; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; SAFIRSTEIN R, 1987, INT J ANDROL, V10, P325, DOI 10.1111/j.1365-2605.1987.tb00200.x; SAVAS MM, 1991, INORG CHEM, V30, P581, DOI 10.1021/ic00003a049; SHAW CF, 1990, INORG CHEM, V29, P403, DOI 10.1021/ic00328a012; TAY LK, 1988, CANCER RES, V48, P2538	26	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24792	24797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929157				2022-12-27	WOS:A1994PQ49000044
J	LI, JZ; ROBERTS, RM				LI, JZ; ROBERTS, RM			STRUCTURE-FUNCTION-RELATIONSHIPS IN THE INTERFERON-TAU (IFN-TAU) - CHANGES IN RECEPTOR-BINDING AND IN ANTIVIRAL AND ANTIPROLIFERATIVE ACTIVITIES RESULTING FROM SITE-DIRECTED MUTAGENESIS PERFORMED NEAR THE CARBOXYL-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE TROPHOBLAST PROTEIN-1; HUMAN-LEUKOCYTE INTERFERON; 3-DIMENSIONAL CRYSTAL-STRUCTURE; ALPHA RECEPTOR; GAMMA-CHAIN; ENDOMETRIAL RECEPTORS; INTERESTROUS INTERVAL; ESTROUS-CYCLE; PREGNANCY; SHEEP	The interferons-tau (IFN-tau) are Type I IFN, 172 amino acids in length, which are produced by the trophoblast of ruminant ungulate species and whose only known function is in triggering maternal responses to pregnancy. These IFN have the normal antiviral and antiproliferative activities exhibited by other Type I IFN, such as IFN-alpha and -beta, and are predicted to have similar structures based on five alpha-helices (A-E). A series of ovine IFN-tau variants was prepared with alterations in the carboxyl terminal region in residues not expected to interact directly with the Type I receptor. Replacement of IIe(143) with Thr in helix E significantly lowered receptor binding affinity to about 5% of control values, reduced antiviral activity to about 13% of control values, and abolished antiproliferative activity completely. Deletion of the terminal 11 residues from the carboxyl termini of these 172 amino acid IFN also reduced antiviral activities (similar to 5% of control) and antiproliferative proteins (1-2% of control), but had only slight negative influence on receptor binding. Deletion of Lys(160), but not its replacement with Ala, had similar consequences to deleting the entire 11-amino acid carboxyl terminus. These studies show that mutations can be introduced into IFN-tau that influence antiviral and antiproliferative activities differentially and that the carboxyl tail of the molecule is important for signal transduction but not for primary receptor binding.	UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DEPT ANIM SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021896, R01HD021896] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21896] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAZER FW, 1992, P SOC EXP BIOL MED, V199, P373, DOI 10.3181/00379727-199-43371A; BOSVELD J, 1989, BIOCHEM BIOPH RES CO, V164, P22, DOI 10.1016/0006-291X(89)91677-X; BRENNAN GL, 1983, BIOTECHNIQUES, V1, P78; CHANG NT, 1983, ARCH BIOCHEM BIOPHYS, V221, P585, DOI 10.1016/0003-9861(83)90179-0; CHEETHAM BF, 1991, ANTIVIR RES, V15, P27, DOI 10.1016/0166-3542(91)90038-S; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; FLORES I, 1991, J BIOL CHEM, V266, P19875; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GODKIN JD, 1984, ENDOCRINOLOGY, V114, P120, DOI 10.1210/endo-114-1-120; HANSEN TR, 1989, J INTERFERON RES, V9, P215, DOI 10.1089/jir.1989.9.215; Hertzog P. J., 1993, Journal of Interferon Research, V13, pS140; HU RQ, 1993, J BIOL CHEM, V268, P12591; KLEMANN SW, 1990, MOL ENDOCRINOL, V4, P1506, DOI 10.1210/mend-4-10-1506; KNICKERBOCKER JJ, 1989, BIOL REPROD, V40, P361, DOI 10.1095/biolreprod40.2.361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEVY WP, 1981, P NATL ACAD SCI-BIOL, V78, P6186, DOI 10.1073/pnas.78.10.6186; LI JZ, 1994, J BIOL CHEM, V269, P13544; MARTAL J, 1990, J ENDOCRINOL, V127, pR5, DOI 10.1677/joe.0.127R005; MITSUI Y, 1993, PHARMACOL THERAPEUT, V58, P93, DOI 10.1016/0163-7258(93)90068-O; MURGOLO NJ, 1993, PROTEINS, V17, P62, DOI 10.1002/prot.340170109; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OLSEN MK, 1989, J BIOTECHNOL, V9, P179, DOI 10.1016/0168-1656(89)90107-7; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; OTT TL, 1993, THERIOGENOLOGY, V40, P757, DOI 10.1016/0093-691X(93)90211-M; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PONTZER CH, 1990, P NATL ACAD SCI USA, V87, P5945, DOI 10.1073/pnas.87.15.5945; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SATTAYASAI N, 1991, J INTERFERON RES, V11, P41, DOI 10.1089/jir.1991.11.41; SCHALUEFRANCIS TK, 1991, J REPROD FERTIL, V91, P347, DOI 10.1530/jrf.0.0910347; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SHAFFERMAN A, 1987, J BIOL CHEM, V262, P6227; SHARROCKS AD, 1992, NUCLEIC ACIDS RES, V20, P1147, DOI 10.1093/nar/20.5.1147; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Stewart H J, 1989, J Reprod Fertil Suppl, V37, P127; STEWART HJ, 1987, J ENDOCRINOL, V115, pR13, DOI 10.1677/joe.0.115R013; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VALLET JL, 1988, J REPROD FERTIL, V84, P493, DOI 10.1530/jrf.0.0840493; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; ZAVYALOV VP, 1989, IMMUNOL LETT, V22, P173, DOI 10.1016/0165-2478(89)90186-7	53	27	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24826	24833						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929162				2022-12-27	WOS:A1994PQ49000049
J	VANRENTERGHEM, B; BROWNING, MD; MALLER, JL				VANRENTERGHEM, B; BROWNING, MD; MALLER, JL			REGULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION BY PROTEIN KINASE-A AND KINASE-C IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE THREONINE KINASE; MAP KINASE; XENOPUS-OOCYTES; P34CDC2 KINASE; S6 KINASE; SIGNAL-TRANSDUCTION; MEIOTIC MATURATION; RAPID STIMULATION; CATALYTIC SUBUNIT	Previously pp(60v-src), cyclin A, p39(mos), and maturation-promoting factor (composed of Cdc2 and cyclin B) have been shown to activate mitogen-activated protein kinase (MAPK) and MAPK kinase (MEK) in cell-free extracts of Xenopus oocytes. The pp60(v-src) pathway is dependent on a functional Pas signal whereas the cyclin/ maturation promoting factor pathway is not. Here we show that protein kinase C (PKC) is also able to stimulate MAPK in a Pas-dependent manner, but PKC is not necessary for signaling by pp60(v-src). In addition, preincubation of extracts with cAMP-dependent protein kinase (PKA) blocks stimulation of MAPK by cyclin, p21(V12ras) PKC, or pp60(v-src), by at least 50%, but stimulation by c-Mos is unaffected. Furthermore, inhibition of endogenous PKA by the heat-stable PKA inhibitor is sufficient to stimulate MAPK activity in these extracts in the absence of protein synthesis and without dependence on a functional Pas protein. These results suggest that independent pp60(v-src) and PKC pathways converge at Pas and that PKA acts to block MAPK activation by both Ras-dependent and -independent signals.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIAAA NIH HHS [AA03527] Funding Source: Medline; NIA NIH HHS [AG04418] Funding Source: Medline; NIDDK NIH HHS [DK28353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003527] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ALEXANDROPOULOS K, 1993, ONCOGENE, V8, P803; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNSLAEGER EA, 1986, DEV BIOL, V114, P453, DOI 10.1016/0012-1606(86)90209-5; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CAROLL MP, 1994, J BIOL CHEM, V269, P1249; CONRAD KE, 1992, ONCOGENE, V7, P1279; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOHMANN P, 1993, CELL PROLIFERAT, V26, P195, DOI 10.1111/j.1365-2184.1993.tb00019.x; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; HUCHON D, 1981, MOL CELL ENDOCRINOL, V22, P211, DOI 10.1016/0303-7207(81)90092-7; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KASAKO H, 1992, EMBO J, V11, P2903; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KROOK A, 1993, MOL CELL BIOL, V13, P1471, DOI 10.1128/MCB.13.3.1471; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; Maller J L, 1980, Curr Top Cell Regul, V16, P271; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEIJER L, 1989, DEV BIOL, V133, P58, DOI 10.1016/0012-1606(89)90296-0; MOLLOY S, 1992, EXP CELL RES, V201, P494, DOI 10.1016/0014-4827(92)90299-N; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; ORI M, 1992, MOL CELL BIOL, V12, P939; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAHARA S, 1992, BIOCHEM BIOPH RES CO, V182, P105, DOI 10.1016/S0006-291X(05)80118-4; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SMITH MR, 1992, J IMMUNOL, V149, P1304; SOZERI O, 1992, ONCOGENE, V7, P2259; SPIVACK JG, 1985, MOL CELL BIOL, V5, P3629, DOI 10.1128/MCB.5.12.3629; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS J, 1991, J BIOL CHEM, V266, P10906; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; WOODROW MA, 1993, J IMMUNOL, V150, P3853; WOTTON D, 1993, J BIOL CHEM, V268, P17975; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	82	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24666	24672						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929138				2022-12-27	WOS:A1994PQ49000025
J	ZHI, G; HERRING, BP; STULL, JT				ZHI, G; HERRING, BP; STULL, JT			STRUCTURAL REQUIREMENTS FOR PHOSPHORYLATION OF MYOSIN REGULATORY LIGHT-CHAIN FROM SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SUBSTRATE-SPECIFICITY; SYNTHETIC PEPTIDES; BASIC RESIDUES; SEQUENCE; BINDING; SITE	Site-directed and chimeric mutations of myosin regulatory light chains were used to identify residues important for phosphorylation of Ser(19) by smooth muscle myosin light chain kinase. Arg(16) and hydrophobic residues C-terminal of Ser(19) in smooth muscle light chain were important substrate determinants in the intact protein. However, changes in the kinetic properties with mutations in the light chain were substantially smaller than results reported with structurally similar synthetic peptide substrates. These results together with the low V-max value for short peptide substrates containing the consensus phosphorylation sequence suggest that there may be additional sites of interactions between the kinase and protein substrate. Chimeras of skeletal and smooth muscle light chains were constructed with exchanges at the N terminus and subdomains I, II, III, and IV. Analysis of results obtained on the kinetic properties for phosphorylation showed that subdomains I and II contribute to high V-max values. Thus, a region distant from the consensus phosphorylation sequence in smooth muscle light chain is also an important substrate determinant for myosin light chain kinase.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296, R01HL026043, R37HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26043, HL 06296] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HERRING BP, 1990, J BIOL CHEM, V265, P16588; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KUMAR CC, 1989, BIOCHEMISTRY-US, V28, P4027, DOI 10.1021/bi00435a059; MAEDA K, 1990, NUCLEIC ACIDS RES, V18, P6687, DOI 10.1093/nar/18.22.6687; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SELLERS JR, 1987, ENZYMES, P381; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STULL JT, 1986, ENZYMES, V17, P113; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24723	24727						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929147				2022-12-27	WOS:A1994PQ49000034
J	MICHNOFF, CH; PARIKH, VS; LELSZ, DL; TUCKER, PW				MICHNOFF, CH; PARIKH, VS; LELSZ, DL; TUCKER, PW			MUTATIONS WITHIN THE NH2-TERMINAL TRANSMEMBRANE DOMAIN OF MEMBRANE IMMUNOGLOBULIN (IG)-M ALTERS IG-ALPHA AND IG-BETA ASSOCIATION AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASES; MOLECULAR-COMPONENTS; LYMPHOCYTES-B; SRC FAMILY; COMPLEX; ACTIVATION; EXPRESSION; ANTIBODIES; SURFACE	Potentiation of initial signal transduction events through the cross-linking of the B cell antigen receptor complex appears to be dependent upon the association of membrane immunoglobulin (mIg) with Ig alpha and Ig beta. We made two groups of mutations within the COOH terminus of mIgM substituting: 1) the spacer, transmembrane, and cytoplasmic domains and 2) the NH2-terminal 2-8 amino acids within the transmembrane domain (NL-WTTAST). We then evaluated the ability of the mutated receptors to associate with Ig alpha and Ig beta and to initiate signal transduction events (Ca2+ mobilization and phosphorylation by tyrosine protein kinases) after crosslinking mIgM receptors. Mutant mIgM receptors containing substitutions of gamma 2b (spacer, transmembrane, and cytoplasmic domains), AA for TT, and AAAAA for TTAST bound Ig alpha and Ig beta and initiated signal transduction events after mIgM receptor cross-linking. However, substitutions of I-A alpha (spacer, transmembrane, and cytoplasmic domains) or TTVVCALGL for NLWTTAST blocked association of Ig alpha and Ig beta and initiation of signal transduction events. Results indicate that residues within the first 8 amino acids of the transmembrane domain other than TTAST are necessary for receptor function and association with Ig alpha and Ig beta.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIAID NIH HHS [AI18016] Funding Source: Medline; NIGMS NIH HHS [GM 31689] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018016, R01AI018016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM JH, 1993, J BIOL CHEM, V268, P27236; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DAS C, 1992, P NATL ACAD SCI USA, V89, P9749, DOI 10.1073/pnas.89.20.9749; DESIDERIO SV, 1992, CURR OPIN IMMUNOL, V4, P252, DOI 10.1016/0952-7915(92)90073-N; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRONOWICZ ES, 1980, J IMMUNOL, V125, P976; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KIM KJ, 1979, J IMMUNOL, V122, P549; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM PL, 1986, MOL IMMUNOL, V23, P909; LIN JJ, 1992, J IMMUNOL, V149, P1548; NEUBERGER MS, 1993, IMMUNOL REV, V132, P147, DOI 10.1111/j.1600-065X.1993.tb00841.x; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PARIKH VS, 1991, J EXP MED, V174, P1103, DOI 10.1084/jem.174.5.1103; PARIKH VS, 1992, J EXP MED, V176, P1025, DOI 10.1084/jem.176.4.1025; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; STEVENS TL, 1994, J IMMUNOL, V152, P4397; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEBB CF, 1989, P NATL ACAD SCI USA, V86, P1977, DOI 10.1073/pnas.86.6.1977; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947	41	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24237	24244						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929080				2022-12-27	WOS:A1994PQ34600061
J	REIFELMILLER, AE; CALNEK, DS; GRINNELL, BW				REIFELMILLER, AE; CALNEK, DS; GRINNELL, BW			TYROSINE PHOSPHORYLATION REGULATES THE DNA-BINDING ACTIVITY OF A NUCLEAR FACTOR 1-LIKE REPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; ENHANCER ACTIVITY; GENE-EXPRESSION; ADENOVIRUS; PHOSPHATASE; CELLS; ACTIVATION; INHIBITOR; VANADATE	We have previously identified an ubiquitous repressor binding site that binds a nuclear factor 1 (NF-1)-like transcription factor designated BEF-1. The DNA binding activity of BEF-1, a 98-kDa protein, is increased by the oncoproteins of adenovirus, the early region la proteins (E1a), which results in the induction of further repression. Using the prototype repressor sequence, first identified in the enhancer of the human polyoma virus BKV-P2, we have shown that phosphorylation of BEF-1 is required for its DNA binding activity. We demonstrate here that the inhibition of DNA binding by BEF-1 dephosphorylated with potato acid phosphatase or calf intestinal alkaline phosphatase was reversed by sodium orthovanadate, a specific inhibitor of phosphotyrosyl-protein phosphatases, In addition, BEF-1 binding activity, but not the binding of related factor NF-1, could be inhibited by dephosphorylation with a specific phosphotyrosine phosphatase. We found that both polyclonal and monoclonal phosphotyrosine-specific antibodies blocked binding of the repressor protein to the BEF-1 site. Moreover, BEF-1 activity could be adsorbed on an anti-phosphotyrosine antibody column and specially eluted with phosphotyrosine. In transfection studies in HeLa cells, which contain high levels of BEF-1, we show that E1a-induced repression mediated by BEF-1 was relieved with the tyrosine kinase inhibitors genistein and tyrphostin. Together, these results demonstrate that a phosphotyrosine on the BEF-1 repressor protein regulates DNA binding activity and thus regulates repression of the BKV-P2 enhancer. This report represents the first demonstration that the phosphorylated state of a tyrosine can control gene expression by altering the DNA binding activity of a transcription factor.	ELI LILLY & CO,LILLY CORP CTR,LILLY RES LABS,DEPT CARDIOVASC RES 0522,INDIANAPOLIS,IN 46285; ELI LILLY & CO,LILLY RES LAB,DEPT DIABET,INDIANAPOLIS,IN 46285	Eli Lilly; Eli Lilly								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERG DT, 1989, MOL CELL BIOL, V9, P5248, DOI 10.1128/MCB.9.11.5248; BERG DT, 1988, NUCLEIC ACIDS RES, V16, P9057, DOI 10.1093/nar/16.18.9057; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GRINNELL BW, 1988, MOL CELL BIOL, V8, P3448, DOI 10.1128/MCB.8.8.3448; GRINNELL BW, 1986, MOL CELL BIOL, V6, P3596, DOI 10.1128/MCB.6.11.3596; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MONTESANO R, 1988, J CELL PHYSIOL, V134, P460, DOI 10.1002/jcp.1041340318; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; REIFELMILLER AE, 1991, J BIOL CHEM, V266, P13873; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1982, J BIOL CHEM, V257, P7298; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHONG XH, 1990, MOL CELL BIOL, V10, P770, DOI 10.1128/MCB.10.2.770	26	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23861	23864						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929029				2022-12-27	WOS:A1994PQ34600003
J	ZAIDI, SHE; MALTER, JS				ZAIDI, SHE; MALTER, JS			AMYLOID PRECURSOR PROTEIN MESSENGER-RNA STABILITY IS CONTROLLED BY A 29-BASE ELEMENT IN THE 3'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; T-CELL ACTIVATION; ALZHEIMERS-DISEASE; PHORBOL ESTER; GM-CSF; EXPRESSION; DEGRADATION; SEQUENCE	In the accompanying paper (Zaidi, S. H. E., Denman, R., and Malter, J. S. (1994) J. Biol. Chem. 269, 24000-24006) we demonstrate that in tumor and normal cells, multiple cytosolic proteins interact with a 29-base sequence in the 3'-untranslated region of amyloid precursor protein (APP) mRNA. These data suggested that APP gene expression may be modulated by regulated APP mRNA decay. We have investigated this prediction by measuring the decay rates of APP mRNA in resting and mitogen-treated peripheral blood mononuclear cells and H4 and K562 tumor cell lines. In resting peripheral blood mononuclear cells, APP mRNA decayed with a half-life of 4 h. Under these conditions, the activity of APP mRNA-binding proteins was not detectable. After activation, binding protein activities were induced, and APP mRNA decay was blocked with a half-life of >12 h. In log phase neuronal or lymphoid tumor cell lines, binding activity was constitutively present and APP mRNA displayed a half-life of >12 h. Protein synthesis inhibition by cycloheximide had no effect on APP mRNA decay in normal or tumor cells. Transfected wild type or mutant APP mRNAs that lacked the 29-base region were stable (t(1/2) > 10 h) in K562 tumor cells. Therefore, we conclude that the 29-base region functions in cis to destabilize APP mRNA in resting, normal cells. Upon activation APP mRNA-binding proteins are induced, interact with the 29-base region, and likely participate in stabilization of the mRNA.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,NEUROSCI PROGRAM,MADISON,WI 53792; UNIV WISCONSIN,INST AGING,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIA NIH HHS [R01-AG 10675] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P986, DOI 10.1016/0006-291X(92)92301-D; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CHANG L, 1993, P NATL ACAD SCI USA, V90, P4455; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUVAL C, 1990, MOL CELL BIOL, V10, P4123, DOI 10.1128/MCB.10.8.4123; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MONNING U, 1992, J BIOL CHEM, V267, P23950; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSS HJ, 1991, BLOOD, V77, P1787; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHARMA N, 1991, GLIA, V4, P572, DOI 10.1002/glia.440040604; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILJANDER P, 1993, FEBS LETT, V315, P81, DOI 10.1016/0014-5793(93)81138-P; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WALZ G, 1991, CELL IMMUNOL, V134, P511, DOI 10.1016/0008-8749(91)90322-3; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	35	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24007	24013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929051				2022-12-27	WOS:A1994PQ34600027
J	SAITOU, M; NARUMIYA, S; KAKIZUKA, A				SAITOU, M; NARUMIYA, S; KAKIZUKA, A			ALTERATION OF A SINGLE AMINO-ACID RESIDUE IN RETINOIC ACID RECEPTOR CAUSES DOMINANT-NEGATIVE PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; VITAMIN-D RECEPTOR; GENERALIZED RESISTANCE; RESPONSE ELEMENT; BETA-GENE; RAR-ALPHA; C-ERBA; NUCLEAR RECEPTORS; KININOGEN GENES; POINT MUTATION	Thyroid hormone receptor (TR) and retinoic acid receptor (RAR) are closely related not only in their structures but also in their modes of action. TR and RAR share many amino acids in the functionally important DNA binding domain, ligand binding domain, and heterodimeric interface. To function, both receptors dimerize with retinoid X receptor, recognize their cognate hormone response elements, and then respond to the ligand, leading to the activation of the target genes. Genetic analysis has revealed mutated TRs in thyroid hormone resistance syndrome, which displays autosomal dominant inheritance. Eventually, the mutated TRs show the dominant-negative phenotype on the wild-type TR. The mutations have been observed mostly in conserved amino acids between TR and RAR in the ligand binding domain and produce hormone-insensitive receptors. In this report, we demonstrate that the dominant-negative phenotype is transferable to RAR by a single amino acid substitution identified in the syndromes of thyroid hormone resistance. The mutated RAR can suppress the wild-type RAR function, especially at the physiological concentration of retinoic acid. Consistently, the mutated RAR is an absolute requirement of intact dimeric and DNA binding capacities for the dominant-negative phenotype, indicating the necessity of the maintenance of a machinery for correct recognition of the targets. Thus, the hormone-insensitive receptor may be interfering with the access of functional receptors to the hormone response elements. The dominant-negative RAR will serve as a molecular tool to elucidate physiological roles of RAR by blocking RAR-mediated signaling pathways.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 60601,JAPAN	Kyoto University								ADAMS M, 1992, CLIN ENDOCRINOL, V36, P281, DOI 10.1111/j.1365-2265.1992.tb01444.x; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; Blaner William S., 1994, P229; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROOKS MH, 1978, NEW ENGL J MED, V298, P996, DOI 10.1056/NEJM197805042981804; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DOKOH S, 1981, ANAL BIOCHEM, V116, P211, DOI 10.1016/0003-2697(81)90346-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAKIZUKA A, 1988, J BIOL CHEM, V263, P3884; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MIXSON AJ, 1992, J CLIN ENDOCR METAB, V75, P1039, DOI 10.1210/jc.75.4.1039; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; REFETOFF S, 1982, AM J PHYSIOL, V243, pE88, DOI 10.1152/ajpendo.1982.243.2.E88; REFETOFF S, 1972, METABOLISM, V21, P723, DOI 10.1016/0026-0495(72)90121-7; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; REFETOFF S, 1990, THYROID TODAY, V13, P1; REFETOFF S, 1992, ENDOCRINOLOGIST, V2, P261; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SASAKI S, 1992, MOL CELL ENDOCRINOL, V84, P159, DOI 10.1016/0303-7207(92)90026-3; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USALA SJ, 1991, J CLIN ENDOCR METAB, V72, P32, DOI 10.1210/jcem-72-1-32; USALA SJ, 1991, TRENDS ENDOCRIN MET, V2, P140, DOI 10.1016/1043-2760(91)90004-7; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEISS RE, 1992, ANNU REV MED, V43, P363, DOI 10.1146/annurev.med.43.1.363; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	64	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					19101	19107						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913468				2022-12-27	WOS:A1994NX32700061
J	GOHDA, K; OKA, K; TOMITA, K; HAKOSHIMA, T				GOHDA, K; OKA, K; TOMITA, K; HAKOSHIMA, T			CRYSTAL-STRUCTURE OF RNASE T1 COMPLEXED WITH THE PRODUCT 3'-GMP - STRUCTURAL EVIDENCE FOR DIRECT INTERACTION OF HISTIDINE-40 AND GLUTAMIC-ACID-58 WITH THE 2'-HYDROXYL GROUP OF THE RIBOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REFINEMENT; 3-DIMENSIONAL STRUCTURE; SUBSITE INTERACTIONS; X-RAY; FURANOSE RING; GPN TRANSESTERIFICATION; SUBSTRATE-BINDING; 1.9-A RESOLUTION; RIBONUCLEASE-T1; PHOSPHATE	The crystal structure of RNase T1 complexed with 3'-GMP has been determined. The glycosyl conformation of 3'-GMP is in the syn conformation, and the ribose adopts the O4'-endo pucker. This observed pucker is different from that in any complex structures of RNase T1. In the present complex, this energetically unfavorable conformation is stabilized by the water molecule with the bridged hydrogen bonds between the O2' and the O3' atoms of the ribose. The guanine base is recognized in the same manner as observed in the complex of 2'-GMP. The 2'-hydroxyl group of the ribose shows a tight hydrogen bond to both His-40 and Glu-58 with the suitable geometry for the proton transfer. These hydrogen bonds suggest that the two residues can participate directly in the proton transfer. His-92 is hydrogen banded to two oxygen atoms of the phosphate group. Based on the geometry in the active site, the O1P atom may correspond to the O5' atom of the leaving nucleotide in the phosphoryl transfer or a water molecule as a nucleophile in the hydrolysis reaction. In the present complex, the conformations of the 3'-GMP molecule and the side chains of the catalytic residues would be represented as the conformation before the phosphoryl transfer reaction and/or after the hydrolysis reaction.	OSAKA UNIV,FAC PHARMACEUT SCI,SUITA,OSAKA 565,JAPAN	Osaka University				Gohda, Keigo/0000-0002-9345-2377				ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARNI R, 1988, J BIOL CHEM, V263, P15358; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMBILLOU C, 1989, SILICON GRAPHICS GEO, P1; COULTER CL, 1973, J AM CHEM SOC, V95, P570, DOI 10.1021/ja00783a042; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; Egami F, 1980, Mol Biol Biochem Biophys, V32, P250; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HAKOSHIMA T, 1992, J MOL BIOL, V223, P1013, DOI 10.1016/0022-2836(92)90259-M; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; INAGAKI F, 1985, BIOCHEMISTRY-US, V24, P1013, DOI 10.1021/bi00325a031; IRIE M, 1967, J BIOCHEM-TOKYO, V61, P550, DOI 10.1093/oxfordjournals.jbchem.a128585; ITOH T, 1991, J BIOCHEM-TOKYO, V110, P677, DOI 10.1093/oxfordjournals.jbchem.a123639; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOELLNER G, 1992, J MOL BIOL, V224, P701, DOI 10.1016/0022-2836(92)90554-W; KOEPKE J, 1989, J MOL BIOL, V206, P475, DOI 10.1016/0022-2836(89)90495-6; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; LENZ A, 1991, J BIOL CHEM, V266, P7661; LEVITT M, 1978, J AM CHEM SOC, V100, P2607, DOI 10.1021/ja00477a004; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALIN R, 1991, J BIOL CHEM, V266, P4848; MARTINEZOYANEDEL J, 1991, J MOL BIOL, V222, P335, DOI 10.1016/0022-2836(91)90215-R; MEIERING EM, 1993, BIOCHEMISTRY-US, V32, P10975, DOI 10.1021/bi00092a006; MORIOKA H, 1989, THESIS OSAKA U JAPAN; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; NISHIKAWA S, 1986, BIOCHEM BIOPH RES CO, V138, P789, DOI 10.1016/S0006-291X(86)80566-6; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; OLSON WK, 1982, J AM CHEM SOC, V104, P270, DOI 10.1021/ja00365a049; OLSON WK, 1982, J AM CHEM SOC, V104, P278, DOI 10.1021/ja00365a050; OSTERMAN HL, 1978, BIOCHEMISTRY-US, V17, P4124, DOI 10.1021/bi00613a003; OSTERMAN HL, 1979, BIOCHEMISTRY-US, V18, P1984, DOI 10.1021/bi00577a021; PAVLOVSKII AG, 1987, DOKL AKAD NAUK SSSR+, V292, P1253; SATO K, 1957, J BIOCHEM-TOKYO, V44, P753, DOI 10.1093/oxfordjournals.jbchem.a126717; SEVCIK J, 1991, ACTA CRYSTALLOGR B, V47, P240, DOI 10.1107/S0108768190009569; SHIMADA I, 1990, BIOCHEMISTRY-US, V29, P757, DOI 10.1021/bi00455a024; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8661, DOI 10.1021/bi00099a024; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8666, DOI 10.1021/bi00099a025; STEYAERT J, 1993, J MOL BIOL, V229, P770, DOI 10.1006/jmbi.1993.1078; STORER JW, 1991, J AM CHEM SOC, V113, P5216, DOI 10.1021/ja00014a012; SUGIO S, 1985, FEBS LETT, V183, P115, DOI 10.1016/0014-5793(85)80966-2; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P2747, DOI 10.1093/nar/19.10.2747; TAKAHASHI K, 1972, J BIOCHEM-TOKYO, V67, P833; Takahashi K., 1982, ENZYMES, V15, p435 468; WALZ FG, 1976, BIOCHEMISTRY-US, V15, P2837, DOI 10.1021/bi00658a021	52	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 1	1994	269	26					17531	17536						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NU128	7912696				2022-12-27	WOS:A1994NU12800032
J	JAMES, R; ERLER, T; KAZENWADEL, J				JAMES, R; ERLER, T; KAZENWADEL, J			STRUCTURE OF THE MURINE HOMEOBOX GENE CDX-2 - EXPRESSION IN EMBRYONIC AND ADULT INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA HOMEODOMAIN PROTEINS; MOUSE SMALL-INTESTINE; DNA-BINDING; MESSENGER-RNA; DISTAL COLON; CELL-TYPES; RAT COLON; DIFFERENTIATION; SEQUENCE; DOMAIN	To gain insight into the mechanisms which govern cellular identity in the intestinal epithelium we have begun a detailed study of the murine cdx-2 homeobox gene, We isolated and sequenced both cDNA and genomic clones in order to define the open reading frame and mature transcript. A detailed analysis of cdx-2 transcript levels late in embryogenesis showed that they increased 6-7-fold at a time when the gut undergoes a major develop mental transition. In the adult, cdx-2 was expressed in colon in a region-specific manner with transcripts some 5-fold more abundant in the cecum as compared with the rectum. In situ hybridization and immunohistochemical experiments showed cdx-2 transcripts and protein were present in all epithelial cells in the proximal colon irrespective of their degree of differentiation. In distal colon, however, transcripts were most abundant in undifferentiated cells at the bottom of crypts, whereas the highest protein levels were present in mature cells in the upper half of crypts. We conclude that cdx-2 is expressed specifically in gut epithelium where it is not restricted to a particular cell lineage. Rather, the rostrocaudal expression gradient suggests that it may play a role in specifying positional identity.	UNIV MELBOURNE,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA	University of Melbourne	JAMES, R (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,DEPT MED,MELBOURNE TUMOR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Kazenwadel, Jan/E-6620-2012	Kazenwadel, Jan/0000-0001-6216-3444				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHANG WWL, 1975, AM J ANAT, V144, P39, DOI 10.1002/aja.1001440104; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1982, ANAT REC, V203, P251, DOI 10.1002/ar.1092030207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLONY PC, 1985, GASTROENTEROLOGY, V89, P294, DOI 10.1016/0016-5085(85)90329-4; COLONY PC, 1983, DEV BIOL, V97, P349, DOI 10.1016/0012-1606(83)90092-1; COLONY PC, 1989, CELLULAR MOL BIOL CO, P2; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DAUCA M, 1990, International Journal of Developmental Biology, V34, P205; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GAVIS ER, 1991, DEVELOPMENT, V112, P1077; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAN HY, 1993, P NATL ACAD SCI USA, V90, P3806, DOI 10.1073/pnas.90.9.3806; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HU YL, 1993, J BIOL CHEM, V268, P27214; JAMES R, 1991, J BIOL CHEM, V266, P3246; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KROZOWSKI Z, 1992, MOL CELL ENDOCRINOL, V85, P21, DOI 10.1016/0303-7207(92)90121-L; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MORITA T, 1988, GENE, V68, P109; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; PAN LX, 1993, HISTOCHEM J, V25, P57, DOI 10.1007/BF00161045; PEREZTOMAS R, 1993, GASTROENTEROLOGY, V104, P789, DOI 10.1016/0016-5085(93)91014-9; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; ROTH KA, 1992, AM J PHYSIOL, V263, pG174, DOI 10.1152/ajpgi.1992.263.2.G174; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STURZL M, 1990, ANAL BIOCHEM, V185, P164, DOI 10.1016/0003-2697(90)90274-D; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WRIGHT EM, 1990, DEVELOPMENT CAMB, V110, P477	51	263	275	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15229	15237						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910823				2022-12-27	WOS:A1994NP73800057
J	SCHWARTZ, BS				SCHWARTZ, BS			DIFFERENTIAL INHIBITION OF SOLUBLE AND CELL-SURFACE RECEPTOR-BOUND SINGLE-CHAIN UROKINASE BY PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-2 - A POTENTIAL REGULATORY MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MONOCYTES; HUMAN-PLACENTA; LIPOPOLYSACCHARIDE; PURIFICATION; PROUROKINASE; INACTIVATION; PROTEIN	Urokinase (u-PA)-mediated cell surface plasminogen activation is required for cellular tissue invasion. This invasion occurs in environments rich in plasminogen activator inhibitors (PAIs), which efficiently inhibit receptor-bound two-chain u-PA. Single-chain u-PA (scu-PA) was recently found to efficiently initiate cell surface plasminogen activation, and we herein describe the interaction of scu-PA with PAI type 2 (PAI-2). In the fluid phase (no cells) the plasminogen-activating activities of both scu-PA and Glu(158)-scu-PA (a plasmin non-activatable variant of scu-PA) were inhibited in a concentration-dependent manner by recombinant human PAI-2. This inhibition occurred with both forms of scu-PA remaining as single-chain molecules throughout the interactions. Although scu-PA did not form SDS-stable complexes with PAI-2, preincubation of scu-PA with I-125-PAI-2 demonstrated a dose dependent inhibition of SDS-stable complex formation between I-125-PAI-2 and subsequently added two-chain u-PA. This indicates that although a ''stable intermediate'' type complex between scu-PA and PAI-2 was not detected, there was a physical association between the two molecules that shared at least some determinants with the two-chain u-PA-PAI-2 complex. In contrast, Glu(158)-scu-PA bound to u-PA receptors on monocytes was only minimally inhibited by a large molar excess of PAI-2. These data suggest that the initiation of cell surface plasminogen activation may involve the partitioning of scu-PA between PAI-2 (a ''negative modulator'') and the u-PA receptor (a ''positive modulator'') and that the enzymatic activity of receptor-bound scu-PA may allow initiation of cell surface proteolysis even in PAI-2-rich environments. A model along these lines is presented.	UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; WILLIAM A MIDDLETON VET ADM HOSP, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	SCHWARTZ, BS (corresponding author), UNIV WISCONSIN, DEPT MED, 1300 UNIV AVE, MADISON, WI 53706 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043506] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43506] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P233; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANCHANDA N, 1990, J IMMUNOL, V145, P4174; MUSSONI L, 1984, THROMB RES, V34, P241, DOI 10.1016/0049-3848(84)90008-2; OLSON D, 1992, J BIOL CHEM, V267, P9129; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; POLLANEN J, 1991, ADV CANCER RES, V57, P273; SCHWARTZ BS, 1992, J BIOL CHEM, V267, P7089; SCHWARTZ BS, 1988, BLOOD, V71, P734; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; WUN TC, 1987, J BIOL CHEM, V262, P3646; YE RD, 1987, J BIOL CHEM, V262, P3718	22	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8319	8323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907591				2022-12-27	WOS:A1994NB40900074
J	VERNET, T; ZIOMEK, E; RECKTENWALD, A; SCHRAG, JD; DEMONTIGNY, C; TESSIER, DC; THOMAS, DY; CYGLER, M				VERNET, T; ZIOMEK, E; RECKTENWALD, A; SCHRAG, JD; DEMONTIGNY, C; TESSIER, DC; THOMAS, DY; CYGLER, M			CLONING AND EXPRESSION OF GEOTRICHUM-CANDIDUM LIPASE-II GENE IN YEAST - PROBING OF THE ENZYME ACTIVE-SITE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASE; SACCHAROMYCES-CEREVISIAE; ALPHA-FACTOR; TRIAD FORMS; ACETYLCHOLINESTERASE; PROTEINS; DNA; EFFICIENT; VECTORS; IDENTIFICATION	The three-dimensional structure of lipase II of Geotrichum candidum strain ATCC34614 (GCL II) has provided insights with respect to the nature of the catalytic machinery of lipases. To support these structural observations, we have carried out an analysis of GCL II by mutagenesis. The gene encoding lipase II of Geotrichum candidum strain ATCC34614 (GCL II) was amplified using the polymerase chain reaction, cloned, and sequenced. The intronless lipase gene was expressed and secreted from Saccharomyces cerevisiae at approximately 5 mg/liter of culture. Recombinant GCL II was purified by immunoaffinity chromatography and characterized using a combination of substrates and independent analytical methods. The recombinant enzyme and the enzyme isolated from its natural source have comparable specific activities against triolein of about 1000 mumol of oleic acid released/min/mg of protein. The putative catalytic triad Ser217-His463-Glu354 was probed by site-directed mutagenesis. The substitution of Ser217 by either Cys or Thr and of His463 by Ala led to a complete elimination of the activity against both triolein and tributyrin. Substitution of Glu354 by either Ser, Ala or Gln renders the enzyme inactive and also perturbs the enzyme stability. However, the enzyme with the conservative replacement Glu354Asp is stable and displays only a small decrease of triolein activity but a 10-fold decrease in activity against tributyrin. There was no appreciable difference in esterase activity between the native, recombinant wild type, and Glu354 Asp mutant. These results confirm that the triad formed by Ser217-Glu354-His463 is essential for catalytic activity. They also show that the active site of GCL II is more tolerant to a conservative change of the carboxylic side chain within the triad than are other hydrolases with similar catalytic triads.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, 6100 AVE ROYALMOUNT, MONTREAL H4P 2R2, PQ, CANADA	National Research Council Canada			Vernet, Thierry/G-1118-2012; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				[Anonymous], 1972, ENZYMES; ARENDS J, 1979, J IMMUNOL METHODS, V25, P171, DOI 10.1016/0022-1759(79)90052-8; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BAILLARGEON MW, 1991, LIPIDS, V26, P831, DOI 10.1007/BF02536165; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRAKE AJ, 1989, YEAST GENETIC ENG, P269; BROMME D, 1993, J BIOL CHEM, V268, P4832; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CARTER P, 1988, NATURE, V332, P561; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4988, DOI 10.1021/bi00668a007; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; CYGLER M, 1993, PROTEIN SCI, V2, P366; CYGLER M, 1992, BIOTECHNOL GENET REV, V10, P141; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1993, J BIOL CHEM, V268, P300; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; ERGAN F, 1989, LIPIDS, V24, P76, DOI 10.1007/BF02535268; ERNST JF, 1988, DNA-J MOLEC CELL BIO, V7, P355, DOI 10.1089/dna.1.1988.7.355; ERNST JF, 1986, DNA CELL BIOL, V5, P8; FOURNIER D, 1992, J BIOL CHEM, V267, P14270; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN RG, 1965, J AM OIL CHEM SOC, V42, P1029, DOI 10.1007/BF02636897; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; JULIUS D, 1983, CELL, V32, P837; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livingston D M, 1974, Methods Enzymol, V34, P723; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; NEVILLE LF, 1990, J BIOL CHEM, V265, P20735; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; SAMAD MYA, 1989, J MICROBIOL METH, V9, P51, DOI 10.1016/0167-7012(89)90030-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; Sherman F., 1982, METHODS YEAST GENETI; SHIMADA Y, 1989, J BIOCHEM-TOKYO, V106, P383, DOI 10.1093/oxfordjournals.jbchem.a122862; SHIMADA Y, 1990, J BIOCHEM-TOKYO, V107, P703, DOI 10.1093/oxfordjournals.jbchem.a123112; SIDEBOTTOM CM, 1991, EUR J BIOCHEM, V202, P485, DOI 10.1111/j.1432-1033.1991.tb16398.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SZEWCZUK A, 1985, AFFINITY CHROMATOGR, P117; TSAI PK, 1984, J BIOL CHEM, V259, P3805; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YAMAGUCHI S, 1992, BIOSCI BIOTECH BIOCH, V56, P315, DOI 10.1271/bbb.56.315; ZIOMEK E, 1984, CAN J MICROBIOL, V30, P1197, DOI 10.1139/m84-190; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	60	35	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26212	26219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7902836				2022-12-27	WOS:A1993MK42500033
J	LEGRANDPOELS, S; BOURS, V; PIRET, B; PFLAUM, M; EPE, B; RENTIER, B; PIETTE, J				LEGRANDPOELS, S; BOURS, V; PIRET, B; PFLAUM, M; EPE, B; RENTIER, B; PIETTE, J			TRANSCRIPTION FACTOR NF-KAPPA-B IS ACTIVATED BY PHOTOSENSITIZATION GENERATING OXIDATIVE DNA DAMAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; T-CELL CLONE; PROTEIN-KINASE; NUCLEIC-ACIDS; INTACT-CELLS; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; MAMMALIAN-CELLS; SINGLET-OXYGEN	Reactive oxygen intermediates like hydrogen peroxide (H2O2) have been shown to serve as messengers in the induction of NF-kappa B and, then, in the activation and replication of human immunodeficiency virus (HIV)-1 in human cells. Because H2O2 can be converted into the highly reactive OH. at various locations inside the cells, we started to investigate the generation of Reactive oxygen intermediates by photosensitization. This technique is based on the use of a photosensitizer which is a molecule absorbing visible light and which can be located at various sites inside the cell depending on its physicochemical properties. In this work, we used proflavine (PF), a cationic molecule having a high affinity for DNA, capable of intercalating between DNA base pairs. Upon visible light irradiation, intercalated PF molecules oxidize guanine residues and generate DNA single-strand breaks. In lymphocytes or monocytes latently infected with HIV-1 (ACH-2 or U1, respectively), this photosensitizing treatment induced a cytotoxicity, an induction of NF-kappa B, and a reactivation of HIV-1 in cells surviving the treatment. NF-kappa B induction by PF-mediated photosensitization was not affected by the presence of N-acetyl-L-cysteine while strong inhibition was recorded when the induction was triggered by H2O2 or by phorbol 12-myristate 13-acetate. Another transcription factor like AP-1 is less activated by this photosensitizing treatment. In comparison with other inducing treatments, such as phorbol 12-myristate 13-acetate or tumor necrosis factor alpha, the activation of NF-kappa B is slow, being optimal 120 min after treatment. These kinetic data were obtained by following, on the same samples, both the appearance of NF-kappa B in the nucleus and the disappearance of I kappa B-alpha in cytoplasmic extracts. These data allow us to postulate that signaling events, initiated by DNA oxidative damages, are transmitted into the cytoplasm where the inactive NF-kappa B factor is resident and allow the translocation of p50/p65 subunits of NF-kappa B to the nucleus leading to HIV-1 gene expression.	UNIV LIEGE, INST PATHOL B23, MED CHEM LAB, B-4000 LIEGE, BELGIUM; UNIV WURZBURG, INST TOXICOL, D-97078 WURZBURG, GERMANY	University of Liege; University of Wurzburg	LEGRANDPOELS, S (corresponding author), UNIV LIEGE, INST PATHOL B23, VIROL LAB, B-4000 LIEGE, BELGIUM.							ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERMAN HM, 1981, ANNU REV BIOPHYS BIO, V10, P87, DOI 10.1146/annurev.bb.10.060181.000511; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CADET J, 1983, ISRAEL J CHEM, V23, P420; Cadet J., 1990, BIOORGANIC PHOTOCHEM, V1, P1; CLOUSE KA, 1989, J IMMUNOL, V142, P431; Davies K.J.A., 1991, OXIDATIVE DAMAGE REP; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1992, CHEM IMMUNOL, V51, P1; EPE B, 1994, METHOD ENZYMOL, V234, P122; EPE B, 1993, MUTAT RES, V299, P135, DOI 10.1016/0165-1218(93)90091-Q; FLOYD RA, 1989, ARCH BIOCHEM BIOPHYS, V273, P106, DOI 10.1016/0003-9861(89)90167-7; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOOTE CS, 1988, PHOTOSENSITIZATION M, P125; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GENEST D, 1981, BIOPHYS CHEM, V13, P89, DOI 10.1016/0301-4622(81)80028-2; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HASELTINE W, 1988, CONTROL HUMAN RETROV; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOFF SF, 1983, J HISTOCHEM CYTOCHEM, V31, P613, DOI 10.1177/31.5.6841967; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOLBROOK NJ, 1993, FREE RADICAL BIO MED, V15, P543, DOI 10.1016/0891-5849(93)90454-3; HORVAT RT, 1989, J IMMUNOL, V143, P2745; ISRAEL N, 1989, J IMMUNOL, V143, P3956; KANOFSKY JR, 1993, FREE RADICAL BIO MED, V15, P527, DOI 10.1016/0891-5849(93)90397-D; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; KESSEL D, 1993, SPECTRUM-J STATE GOV, V6, P1; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; LEE PCC, 1987, PHOTOCHEM PHOTOBIOL, V45, P79, DOI 10.1111/j.1751-1097.1987.tb08407.x; LEGRANDPOELS S, 1990, AIDS RES HUM RETROV, V6, P1389, DOI 10.1089/aid.1990.6.1389; LEMAY P, 1983, BIOCHEM BIOPH RES CO, V111, P1074, DOI 10.1016/0006-291X(83)91409-2; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LERMAN LS, 1961, J MOL BIOL, V3, P18, DOI 10.1016/S0022-2836(61)80004-1; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LUETHY JD, 1992, CANCER RES, V52, P5; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEIDLE S, 1988, NUCLEIC ACIDS RES, V16, P8999, DOI 10.1093/nar/16.18.8999; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PIETTE J, 1982, PHOTOCHEM PHOTOBIOL, V35, P705, DOI 10.1111/j.1751-1097.1982.tb02633.x; PIETTE J, 1986, PHOTOCHEM PHOTOBIOL, V44, P793, DOI 10.1111/j.1751-1097.1986.tb05539.x; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RUCK A, 1992, J PHOTOCH PHOTOBIO B, V12, P403, DOI 10.1016/1011-1344(92)85044-U; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TONGSTARKSEN S, 1989, P NATL ACAD SCI USA, V87, P7861; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VALERIE K, 1990, New Biologist, V2, P712; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VIRELIZIER JL, 1990, CURR OPIN IMMUNOL, V2, P409, DOI 10.1016/0952-7915(89)90151-9; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	81	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6925	6934		10.1074/jbc.270.12.6925	http://dx.doi.org/10.1074/jbc.270.12.6925			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896842	hybrid, Green Submitted			2022-12-27	WOS:A1995QQ85500073
J	LIN, JL; ADDISON, R				LIN, JL; ADDISON, R			A NOVEL INTEGRATION SIGNAL THAT IS COMPOSED OF 2 TRANSMEMBRANE SEGMENTS IS REQUIRED TO INTEGRATE THE NEUROSPORA PLASMA-MEMBRANE H+-ATPASE INTO MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RECOGNITION PARTICLE; SEQUENCE; PROTEIN; CRASSA; INSERTION; CONFORMATION; ENVIRONMENTS; INVERTASE; BEHAVIOR	The Neurospora plasma membrane H+-ATPase belongs to a family of cation-motive porters called P-type ATPases. Putative transmembrane segments of these enzymes contain one or more charged residues. Conditions were determined by which a transmembrane segment with charged residues is integrated into its cognate membrane. We constructed fusion proteins flanked by the hydrophilic domains of the amino and carboxyl termini of the H+-ATPase that contained either one or two transmembrane segments. Neurospora in vitro translation system supplemented with homologous microsomes was programmed with RNA transcripts of these constructs. When transmembrane segment number one (M1) or number two (M2) of the H+-ATPase was engineered into the construct, the resultant protein did not integrate into microsomes. When M1 and M2 were placed in tandem, the resultant protein integrated into microsomes as judged by the criteria of resistance to extraction at pH 11.5 and protection from protease digestion. The integration event depended on ATP and GTP and on microsomal protein(s). We posited that membrane topology of the amino terminal third of the H+-ATPase, and perhaps of other P-type ATPases is achieved by inserting transmembrane segments into membrane in pairs.			LIN, JL (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163, USA.							ADDISON R, 1990, BIOCHIM BIOPHYS ACTA, V1030, P127, DOI 10.1016/0005-2736(90)90247-L; ADDISON R, 1987, J BIOL CHEM, V262, P17031; ADDISON R, 1986, J BIOL CHEM, V261, P4896; ADDISON R, 1981, J BIOL CHEM, V256, P3165; ADDISON R, 1993, BIOCHIM BIOPHYS ACTA, V1152, P119, DOI 10.1016/0005-2736(93)90238-U; ADDISON R, 1991, BIOCHIM BIOPHYS ACTA, V1065, P130, DOI 10.1016/0005-2736(91)90222-T; ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BURR FA, 1983, METHOD ENZYMOL, V96, P239; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EMR SD, 1980, NATURE, V285, P82, DOI 10.1038/285082a0; EMR SD, 1993, P NATL ACAD SCI USA, V80, P4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; LI SC, 1993, J BIOL CHEM, V268, P22975; LIN J, 1994, J BIOL CHEM, V269, P3887; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; MITCHELL P, 1967, ADV ENZYMOL RAMB, V29, P33; NOUWEN N, 1994, J BIOL CHEM, V269, P16029; RAO US, 1991, J BIOL CHEM, V266, P14740; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SKACH WR, 1993, J BIOL CHEM, V268, P23552; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8	32	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6935	6941		10.1074/jbc.270.12.6935	http://dx.doi.org/10.1074/jbc.270.12.6935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896843	hybrid			2022-12-27	WOS:A1995QQ85500074
J	GORDON, MK; FOLEY, JW; BIRK, DE; FITCH, JM; LINSENMAYER, TF				GORDON, MK; FOLEY, JW; BIRK, DE; FITCH, JM; LINSENMAYER, TF			TYPE-V COLLAGEN AND BOWMANS MEMBRANE - QUANTITATION OF MESSENGER-RNA IN CORNEAL EPITHELIUM AND STROMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; EMBRYONIC CHICKEN CORNEA; MONOCLONAL-ANTIBODIES; EXTRACELLULAR MATRICES; MESSENGER-RNA; XII COLLAGEN; I COLLAGEN; INVITRO; LOCALIZATION; ORGANIZATION	Bowman's membrane is an acellular matrix of the cornea which lies between the epithelial basal lamina and the corneal stroma. By immunoelectron microscopy, we have determined that types I and V collagen are components of the collagen fibrils in Bowman's membrane of the chick cornea. Although these same components are found in the fibrils of the stroma, the fibrils of Bowman's membrane are smaller in diameter and less uniform than those of the stroma. At early stages of development, the corneal epithelium synthesizes the types I and II collagen of the primary stroma. We therefore asked whether it might also be capable of synthesizing the type V collagen found in Bowman's membrane at later stages of development. Our results, using competitive polymerase chain reaction to quantitate mRNA from avian corneal cells, indicate that the amount of alpha 1(V) collagen mRNA present in epithelia, relative to alpha 2(I) collagen mRNA, is greater than that in stromal fibroblasts. We postulate that this enables the epithelium to synthesize a higher ratio of type V to type I collagen than the stroma and that this proportionally higher amount of type V might account for the ultrastructural appearance of the fibrils in Bowman's membrane.			GORDON, MK (corresponding author), TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.		Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088	NATIONAL EYE INSTITUTE [R01EY005191, R01EY009056, R37EY005191, R01EY005129] Funding Source: NIH RePORTER; NEI NIH HHS [EY05129, EY05191, EY09056] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIRK DE, 1986, INVEST OPHTH VIS SCI, V27, P1470; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chomczynski P, 1993, BIOTECHNIQUES, V15, P536; DUBLET B, 1991, J BIOL CHEM, V266, P6853; FITCH JM, 1988, INVEST OPHTH VIS SCI, V29, P1125; FITCH JM, 1984, P NATL ACAD SCI-BIOL, V81, P2791, DOI 10.1073/pnas.81.9.2791; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; HAY ED, 1969, MONOGRAPHS DEV BIOL, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; LINSENMAYER TF, 1990, INVEST OPHTH VIS SCI, V31, P1271; LINSENMAYER TF, 1979, P NATL ACAD SCI USA, V76, P3703, DOI 10.1073/pnas.76.8.3703; LINSENMAYER TF, 1984, INVEST OPHTH VIS SCI, V25, P41; LINSENMAYER TF, 1983, J CELL BIOL, V96, P124, DOI 10.1083/jcb.96.1.124; LINSENMAYER TF, 1977, P NATL ACAD SCI USA, V74, P39, DOI 10.1073/pnas.74.1.39; Maniatis T, 1989, DECONTAMINATION DILU; MARCHANT JK, 1991, P NATL ACAD SCI USA, V88, P1560, DOI 10.1073/pnas.88.4.1560; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; MIRSKY AE, 1949, NATURE, V163, P666, DOI 10.1038/163666a0; MODESTI A, 1984, EUR J CELL BIOL, V35, P246; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; PANABIERES F, 1984, BIOCHEM BIOPH RES CO, V118, P767, DOI 10.1016/0006-291X(84)91461-X; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; SWASDISON S, 1992, MATRIX, V11, P56; TSENG SCG, 1982, J BIOL CHEM, V257, P2627; VANDERREST M, 1982, EUR J BIOCHEM, V125, P491, DOI 10.1111/j.1432-1033.1982.tb06709.x; VONDERMARK K, 1982, COLLAGEN REL RES, V2, P541	34	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24959	24966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929179				2022-12-27	WOS:A1994PQ49000066
J	KAO, J; HOUCK, K; FAN, Y; HAEHNEL, I; LIBUTTI, SK; KAYTON, ML; GRIKSCHEIT, T; CHABOT, J; NOWYGROD, R; GREENBERG, S; KUANG, WJ; LEUNG, DW; HAYWARD, JR; KISIEL, W; HEATH, M; BRETT, J; STERN, DM				KAO, J; HOUCK, K; FAN, Y; HAEHNEL, I; LIBUTTI, SK; KAYTON, ML; GRIKSCHEIT, T; CHABOT, J; NOWYGROD, R; GREENBERG, S; KUANG, WJ; LEUNG, DW; HAYWARD, JR; KISIEL, W; HEATH, M; BRETT, J; STERN, DM			CHARACTERIZATION OF A NOVEL TUMOR-DERIVED CYTOKINE - ENDOTHELIAL-MONOCYTE ACTIVATING POLYPEPTIDE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; NEUTROPHIL CHEMOTACTIC FACTOR; NECROSIS-FACTOR CACHECTIN; VONWILLEBRAND ANTIGEN-II; MONONUCLEAR PHAGOCYTES; STIMULATED SECRETION; INTERLEUKIN 1-ALPHA; MOLECULAR-CLONING; MAMMARY-TUMOR; TISSUE FACTOR	Endothelial-monocyte activating polypeptide II (EMAP II) was initially identified in the supernatant of murine methylcholanthrene A-induced fibrosarcomas (Meth A) by its capacity to activate host effector cells (Kao, J., Ryan, J., Brett, J., Chen, J., Shen, H., Fan, Y-G., Godman, G., Familletti, P., Wang, F., Pan, Y-C., Stern, D., and Clauss, M. (1992) J. Biol. Chem. 267, 20239-20247). Based on the NH2-terminal protein sequence, a full-length cDNA has been cloned which indicates that the precursor of EMAP II is a unique, leaderless, single polypeptide chain with predicted molecular mass approximate to 34 kDa and that the mature form released by Meth A cells corresponds to approximate to 20 kDa. Purified recombinant mature EMAP II (EMAP II, approximate to 20 kDa form) activated endothelial cells with resulting elevation of cytosolic free calcium concentration, release of von Willebrand factor, induction of tissue factor, and expression of the adhesion molecules E-selectin and P-selectin. Neutrophils exposed to EMAP II demonstrated elevated cytosolic free calcium concentration, peroxidase generation, and chemotaxis. EMAP II also activated mononuclear phagocytes elevating cytosolic free calcium concentration, inducing tumor necrosis factor-alpha (TNF) and tissue factor, and stimulating chemotaxis. Systemic infusion of EMAP II into C3H/HeJ or Balb/c mice was associated with systemic toxicity, pulmonary congestion, and the appearance of TNF, interleukin-1 and -6 in the plasma. A single intratumor injection of EMAP II into Meth A sarcomas induced acute thrombohemorrhage and partial tumor regression. Local injection of EMAP II into a tumor resistant to the effects of TNF murine mammary carcinoma, rendered it sensitive to subsequently administered TNF, which resulted in acute thrombohemorrhage and partial regression. These data suggest that recombinant EMAP II, a tumor-derived cytokine, has properties of a proinflammatory mediator with the capacity to prime the tumor vasculature for a locally destructive process.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANESTHESIA,NEW YORK,NY 10032; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT RECOVERY SCI,S SAN FRANCISCO,CA 94080; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,BLOOD SYST RES FDN LAB,ALBUQUERQUE,NM 87131	Columbia University; Columbia University; Columbia University; Roche Holding; Genentech; Roche Holding; Genentech; University of New Mexico	KAO, J (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL,P&S 11-518,630 W 168TH ST,NEW YORK,NY 10032, USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249	NHLBI NIH HHS [HL42507, HL42833, HL02641] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042833, K08HL002641, R01HL042507] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHER A, 1987, J IMMUNOL, V138, P963; BIBBY MC, 1989, J NATL CANCER I, V81, P216, DOI 10.1093/jnci/81.3.216; BIRCH KA, 1992, J CELL BIOL, V118, P1501, DOI 10.1083/jcb.118.6.1501; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BRAUNSCHWEIGER PG, 1990, CANCER RES, V50, P4709; BRETT J, 1993, AM J PATHOL, V143, P1699; BROZNA JP, 1990, SEMIN THROMB HEMOST, V16, P326, DOI 10.1055/s-2007-1002685; CARRE P, 1991, J CLIN INVEST, V68, P1802; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHENSUE SW, 1991, AM J PATHOL, V138, P395; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONSTANTINIDIS I, 1989, CANCER RES, V49, P6379; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P9774; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KARPATI RM, 1991, J IMMUNOL, V146, P2043; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOGA S, 1992, J CLIN INVEST, V90, P1007, DOI 10.1172/JCI115913; KONDO S, 1987, BLOOD, V70, P1947; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LO SK, 1992, J CLIN INVEST, V89, P981, DOI 10.1172/JCI115681; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MENEGAZZI R, 1992, J LEUKOCYTE BIOL, V52, P619, DOI 10.1002/jlb.52.6.619; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MOVAT HZ, 1987, AM J PATHOL, V129, P463; NAWROTH P, 1988, J EXP MED, V168, P637, DOI 10.1084/jem.168.2.637; OLD LJ, 1961, CANCER RES, V21, P1281; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OUTZEN HC, 1985, J NATL CANCER I, V75, P917, DOI 10.1093/jnci/75.5.917; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REGEHR WG, 1992, J NEUROSCI, V12, P4202; RETROSEN D, 1986, J CELL BIOL, V103, P2379; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; Sambrook J, 1989, MOL CLONING LABORATO; SAUDER DN, 1984, J IMMUNOL, V132, P828; SCHMIDT JA, 1990, PEPTIDE GROWTH FACTO, P473; SCOTT JP, 1981, BLOOD, V58, P1075; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHEN H, 1993, BLOOD, V81, P2767; STRIETER RM, 1992, AM J PATHOL, V141, P1279; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TIJBURG P, 1992, CIRCULATION S1, V86, P1627; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; TWENTYMAN PR, 1980, JNCI-J NATL CANCER I, V64, P595; VAAGE J, 1985, CANCER RES, V45, P659; WAGNER DD, 1991, MAYO CLIN PROC, V66, P621, DOI 10.1016/S0025-6196(12)60522-9; WATANABE N, 1988, CANCER RES, V48, P2179; WEAST RC, 1966, HDB CHEM PHYSICS; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	74	152	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25106	25119						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929199				2022-12-27	WOS:A1994PQ49000088
J	OMURA, TH; NOGUCHI, A; JOHANNS, CA; JEFFREY, JJ; PARTRIDGE, NC				OMURA, TH; NOGUCHI, A; JOHANNS, CA; JEFFREY, JJ; PARTRIDGE, NC			IDENTIFICATION OF A SPECIFIC RECEPTOR FOR INTERSTITIAL COLLAGENASE ON OSTEOBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; BONE-RESORBING AGENTS; PLASMINOGEN-ACTIVATOR; PARATHYROID-HORMONE; UROKINASE RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; FIBROBLAST COLLAGENASE; MEDIATED ENDOCYTOSIS; BINDING-SITE; PROTEIN	We have previously shown that the rat osteoblastic cell line UMR 106-01 responds to parathyroid hormone treatment by secreting interstitial collagenase. Secreted collagenase reaches a maximal concentration 12-24 h after parathyroid hormone stimulation, but then declines to undetectable levels by 96 h. Neither spontaneous nor cell-mediated extracellular degradation could account for this disappearance, since the enzyme maintained stability in both fresh and conditioned media. Instead, a cell-mediated binding mechanism was suggested by the rapid and saturable removal of exogenous purified rat collagenase at 37 degrees C. Binding studies using I-125-collagenase at 4 degrees C indicated a saturable receptor of a single class and 12,000 receptors per cell (K-d = 5 x 10(-9) M). A time course revealed specific receptor-mediated binding within 10 min and equilibrium by 60 min, while dissociation experiments further demonstrated reversibility, The kinetics of I-125-collagenase binding are characterized by the association (k(1) = 4 x 10(6) M(-1) min(-1)) and dissociation (k(-1) = 2 x 10(-3) min(-1)) rate constants. The receptor was shown to be specific for rat collagenase since a host of related and unrelated proteins failed to compete for binding. Internalization studies revealed maximal intracellular accumulation at 30 min and complete degradation by 90 min, suggesting this receptor functions in these osteoblastic cells to eliminate extracellular collagenase.	ST LOUIS UNIV, MED CTR, SCH MED, DEPT PHARMACOL & PHYSIOL SCI, ST LOUIS, MO 63104 USA; CARDINAL GLENNON MEM HOSP CHILDREN, PEDIAT RES INST, ST LOUIS, MO 63110 USA; ALBANY MED COLL, DEPT MED, DIV HEMATOL, ALBANY, NY 12208 USA	Saint Louis University; Albany Medical College				Partridge, Nicola/0000-0002-5406-4814	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040661] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40661] Funding Source: Medline; NICHD NIH HHS [HD05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1993, J BIOL CHEM, V268, P13002; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; CIVITELLI R, 1989, ENDOCRINOLOGY, V124, P2928, DOI 10.1210/endo-124-6-2928; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DELAISSE JM, 1988, ENDOCRINOLOGY, V123, P264, DOI 10.1210/endo-123-1-264; DIETRICH JW, 1976, ENDOCRINOLOGY, V98, P943, DOI 10.1210/endo-98-4-943; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; EMONARD HP, 1992, CANCER RES, V52, P5845; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; KRISTENSEN T, 1989, FEBS LETT, V255, P275; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MOLL UM, 1990, CANCER RES, V50, P6995; MONSKY WL, 1993, CANCER RES, V53, P3159; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; PARTRIDGE NC, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P269; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PUCCINELLI JM, 1991, J CELL PHYSIOL, V147, P505, DOI 10.1002/jcp.1041470317; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; THOMSON BM, 1989, BIOCHIM BIOPHYS ACTA, V1014, P125, DOI 10.1016/0167-4889(89)90024-4; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801	44	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24994	24998						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929184				2022-12-27	WOS:A1994PQ49000071
J	RAVICHANDRAN, V; SERES, T; MORIGUCHI, T; THOMAS, JA; JOHNSTON, RB				RAVICHANDRAN, V; SERES, T; MORIGUCHI, T; THOMAS, JA; JOHNSTON, RB			S-THIOLATION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE INDUCED BY THE PHAGOCYTOSIS-ASSOCIATED RESPIRATORY BURST IN BLOOD MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; AUTO-ADP-RIBOSYLATION; DISULFIDE EXCHANGE; HYDROGEN-PEROXIDE; HUMAN-NEUTROPHILS; SUPEROXIDE ANION; OXIDATIVE-METABOLISM; REVERSIBLE OXIDATION; CREATINE-KINASE; SKELETAL-MUSCLE	Chemical oxidants can induce the covalent binding of low molecular weight thiols to reactive sulfhydryls on proteins (S-thiolation), We found that stimulation of the respiratory burst of human blood monocytes resulted in S-thiolation of several proteins, most prominently one of 38 kDa. This purified protein was identified as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by enzyme activity, immunoblotting, and amino acid analysis. After stimulation of the respiratory burst, S-thiolation of GAPDH gradually increased, and cytosol GAPDH activity decreased; so that at 60 min, GAPDH activity was reduced by similar to 40%, Activity was restored by the addition of the sulfhydryl-reducing agent dithioerythritol. H2O2 appeared to be particularly important in mediating S-thiolation during the respiratory burst. Exposure of monocytes to H2O2 induced concentration-dependent S-thiolation of GAPDH and a concomitant decrease in enzyme activity. The addition of respiratory burst stimuli to lymphocytes, which lack a full respiratory burst, had no effect on GAPDH S-thiolation or activity; but H2O2 induced S-thiolation of lymphocyte GAPDH and inhibition of enzyme activity. Stimulation of monocytes from three patients with chronic granulomatous disease resulted in no respiratory burst, S-thiolation of GAPDH, or inactivation of GAPDH activity. The thiols covalently bound to purified S-thiolated GAPDH were removed by dithioerythritol and were identified as glutathione and cysteine; glutathione was predominant. These results indicate that during the respiratory burst in monocytes, low molecular weight thiols can bind to specific cytosolic proteins, including GAPDH. It is possible that S-thiolation of cytosolic proteins serves to modulate cellular metabolic events during phagocytosis.	YALE UNIV,SCH MED,DEPT PEDIAT IMMUNOL,NEW HAVEN,CT 06520; IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Yale University; Iowa State University					NIAID NIH HHS [AI 24782] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024782] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RW, 1987, J BIOL CHEM, V262, P649; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BAEHNER RL, 1977, BLOOD, V50, P327; BIRKETT DJ, 1973, MOL PHARMACOL, V9, P209; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; CAPPEL RE, 1989, J BIOL CHEM, V264, P9180; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; CONSTANTINIDES SM, 1969, J BIOL CHEM, V244, P5695; DIMMELER S, 1993, J IMMUNOL, V150, P2964; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; ERNEST MJ, 1974, J BIOL CHEM, V249, P5011; ERNST V, 1978, P NATL ACAD SCI USA, V75, P4110, DOI 10.1073/pnas.75.9.4110; FINKEL TH, 1987, J BIOL CHEM, V262, P12589; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; HARRIS JI, 1976, ENZYMES, V13, P1; HARRIS JJ, 1963, BIOCHEM J, V89, P60; HAZUM E, 1979, NATURE, V282, P626, DOI 10.1038/282626a0; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JOHNSTON RB, 1976, J EXP MED, V143, P1551, DOI 10.1084/jem.143.6.1551; JOHNSTON RB, 1978, J EXP MED, V148, P115; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P283; MAKINEN AL, 1989, J BIOL CHEM, V264, P12148; MARZULLO G, 1980, SCIENCE, V208, P1171, DOI 10.1126/science.6246583; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEREDITH MJ, 1983, ANAL BIOCHEM, V131, P504, DOI 10.1016/0003-2697(83)90205-1; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MILLER RM, 1990, ARCH BIOCHEM BIOPHYS, V276, P355, DOI 10.1016/0003-9861(90)90732-E; MUKHERJEE SP, 1979, BIOCHIM BIOPHYS ACTA, V568, P224, DOI 10.1016/0005-2744(79)90289-4; NAMBOODIRI MAA, 1979, BIOCHEM BIOPH RES CO, V91, P1166, DOI 10.1016/0006-291X(79)92002-3; NATHAN CF, 1979, J EXP MED, V149, P100, DOI 10.1084/jem.149.1.100; NELSON RD, 1979, INFECT IMMUN, V23, P282, DOI 10.1128/IAI.23.2.282-286.1979; OHNO Y, 1985, J BIOL CHEM, V260, P8438; OLIVER CN, 1985, CELLULAR REGULATION, P320; PABST MJ, 1982, J IMMUNOL, V128, P123; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; Pontremoli S, 1970, CURRENT TOPICS CELLU, V2, P173; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; REED PW, 1969, J BIOL CHEM, V244, P2459; ROKUTAN K, 1991, J IMMUNOL, V147, P260; ROOS D, 1980, AGENTS ACTIONS, V10, P528, DOI 10.1007/BF02024158; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SASADA M, 1980, J EXP MED, V152, P85, DOI 10.1084/jem.152.1.85; SHIMAZU T, 1978, J BIOL CHEM, V253, P7376; Sies H., 1985, OXIDATIVE STRESS, V1, P73, DOI DOI 10.1016/B978-0-12-642760-8.50008-9; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SMIT MJ, 1992, AGENTS ACTIONS, V36, P58, DOI 10.1007/BF01991229; THOMAS JA, 1990, ADV EXP MED BIOL, V283, P95; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	57	152	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25010	25015						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929187				2022-12-27	WOS:A1994PQ49000074
J	SHIMAN, R; XIA, T; HILL, MA; GRAY, DW				SHIMAN, R; XIA, T; HILL, MA; GRAY, DW			REGULATION OF RAT-LIVER PHENYLALANINE-HYDROXYLASE .2. SUBSTRATE-BINDING AND THE ROLE OF ACTIVATION IN THE CONTROL OF ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHETASE; FILTER ASSAY; AMINO-ACIDS; MECHANISM; SITE; 4-MONOOXYGENASE; PURIFICATION; IRON	Activation by phenylalanine and reduction by the cofactor (GR)-tetrahydrobiopterin (BH4) are required for formation of active liver phenylalanine hydroxylase. This work describes effects of the activation and redox state on substrate and effector recognition of this enzyme, it establishes relationships among the pterin and phenylalanine binding sites on the different forms of the enzyme, and it provides a quantitative description of the enzyme's presumptive regulatory and catalytic sites. BH4, 7,8-dihydrobiopterin (BH2), 6-methyltetrahydropterin, and 5-deaza-6-methyltetrahydropterin were found to bind to unactivated phenylalanine hydroxylase with a stoichiometry of 1/enzyme subunit and with hyperbolic kinetics; all appear to compete for the same binding site on the enzyme, and all appear to bind in the proximity of, but not to, the enzyme's non-heme iron. In the transition from unactivated to activated enzyme, phenylalanine and pterin binding is modified, a new site for phenylalanine is formed, and the pterin site is replaced by a site of greatly decreased affinity for BH4 and BH2, one which does not appear to recognize the dihydroxypropyl side chain of BH4 and BH2. The pterin- and phenylalanine binding sites on activated phenylalanine hydroxylase appear to be part of the enzyme's active site. Despite large effects on substrate binding, neither chelator binding ability nor solvent accessibility of the iron are affected by activation; activation appears to affect the nearby environment of the enzyme's iron but not the iron itself. Studies of oxidized and reduced phenylalanine hydroxylase indicate that the redox state is not a major determinant of pterin and phenylalanine association with enzyme.			SHIMAN, R (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOCHEM & MOLEC BIOL, HERSHEY, PA 17033 USA.							ABITA JP, 1984, J BIOL CHEM, V259, P4560; AHMED F, 1985, ANAL BIOCHEM, V145, P151, DOI 10.1016/0003-2697(85)90341-0; BAILEY SW, 1978, J BIOL CHEM, V253, P1598; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5839, DOI 10.1021/bi00342a022; HAAVIK J, 1986, EUR J BIOCHEM, V160, P1, DOI 10.1111/j.1432-1033.1986.tb09932.x; HILL MA, 1988, J BIOL CHEM, V263, P5646; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; KAUFMAN S, 1982, J BIOL CHEM, V257, P4667; LFEIDERER W, 1985, CHEM BIOCH PTERINS, V2, P88; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; MARTINEZ A, 1991, EUR J BIOCHEM, V198, P675, DOI 10.1111/j.1432-1033.1991.tb16066.x; MILLER MR, 1976, J BIOL CHEM, V251, P3671; MOAD G, 1979, J AM CHEM SOC, V101, P6068, DOI 10.1021/ja00514a033; NAKATA H, 1980, BIOCHIM BIOPHYS ACTA, V614, P313, DOI 10.1016/0005-2744(80)90221-1; Parsons S M, 1979, Methods Enzymol, V59, P322; PEMBER SO, 1987, BIOCHEMISTRY-US, V26, P4477, DOI 10.1021/bi00388a045; PHILLIPS RS, 1984, J BIOL CHEM, V259, P271; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; PRESS WH, 1986, NUMERICAL RECIPES AR, P523; RENSON J, 1961, BIOCHEM BIOPH RES CO, V6, P20, DOI 10.1016/0006-291X(61)90177-2; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P467, DOI 10.1021/bi00700a011; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1994, J BIOL CHEM, V269, P24637; SHIMAN R, 1980, J BIOL CHEM, V255, P29; SHIMAN R, 1985, CHEM BIOCH PTERINS, V2, P179; STORM CB, 1971, J ORG CHEM, V36, P3925; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; XIA T, 1994, J BIOL CHEM, V269, P24657	34	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24647	24656						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929136				2022-12-27	WOS:A1994PQ49000023
J	STAHL, B; VONMOLLARD, GF; WALCHSOLIMENA, C; JAHN, R				STAHL, B; VONMOLLARD, GF; WALCHSOLIMENA, C; JAHN, R			GTP CLEAVAGE BY THE SMALL GTP-BINDING PROTEIN RAB3A IS ASSOCIATED WITH EXOCYTOSIS OF SYNAPTIC VESICLES INDUCED BY ALPHA-LATROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; SMG P25A; GLUTAMATE RELEASE; SECRETORY PATHWAY; MEMBRANE-PROTEIN; EXCHANGE PROTEIN; SEC4 PROTEIN; RAS; TRANSPORT; SYNAPTOSOMES	Neurotransmitter release from presynaptic nerve terminals is a highly regulated form of exocytosis. Small GTP-binding proteins of the Rab family have been proposed to act as central regulators in this process that cycle between a GTP- and GDP-bound form. Previous work has shown that the synaptic vesicle protein Rab3A undergoes a membrane association-dissociation cycle that is associated with neurotransmitter release. Using isolated nerve terminals as our model system, we have now analyzed the GDP/GTP status of Rab3A. Synaptic vesicle-bound Rab3A was almost exclusively in the GTP form whereas cytosolic Rab3A contained only GDP. Approximately equal amounts of GTP and GDP were found in the pool of Rab3A localized to a membrane fraction containing plasma membrane-synaptic vesicle complexes. In contrast to Rab3A, Rab5 (an endosomal G-protein) was predominantly GDP-bound in all analyzed compartments. To analyze whether Rab3A-bound GTP is cleaved during exocytosis, synaptosomes were stimulated with alpha-latrotoxin, the active component of black widow spider venom. This resulted in massive exocytosis. A significant increase of the GDP/GTP ratio of Rab3A was observed under these conditions that was not due to a nonspecific loss of high energy nucleotides. Our findings suggest that cleavage of Rab3A-bound GTP is a crucial step in regulated exocytosis of synaptic vesicles.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06504; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Jahn, Reinhard/0000-0003-1542-3498	NCI NIH HHS [P01 CA 46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NANBERG E, 1993, J BIOL CHEM, V268, P18187; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SCOTT ID, 1980, BIOCHEM J, V192, P873, DOI 10.1042/bj1920873; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	45	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24770	24776						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929154				2022-12-27	WOS:A1994PQ49000041
J	JENSEN, PH; SCHULER, E; WOODROW, G; RICHARDSON, M; GOSS, N; HOJRUP, P; PETERSEN, TE; RASMUSSEN, LK				JENSEN, PH; SCHULER, E; WOODROW, G; RICHARDSON, M; GOSS, N; HOJRUP, P; PETERSEN, TE; RASMUSSEN, LK			A UNIQUE INTERHELICAL INSERTION IN PLASMINOGEN-ACTIVATOR INHIBITOR-2 CONTAINS 3 GLUTAMINES, GLN(83), GLN(84), GLN(86), ESSENTIAL FOR TRANSGLUTAMINASE-MEDIATED CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIN-STABILIZING FACTOR; HUMAN-PLACENTA; SEQUENCE; SITE; OVALBUMIN; VITRONECTIN; EXPRESSION; COMPLEXES; SUBSTRATE; ACCEPTOR	Plasminogen activator inhibitor type 2 (PAI-2) prevents fibrinolysis by blocking plasminogen activators. It is expressed principally by trophoblast cells and macrophages. PAI-2 in trophoblast membranes has been found cross-linked to large complexes apparently catalyzed by trophoblast transglutaminase (Jensen, P. H., Lorand, L., Ebbesen, P., and Gliemann, J. (1993) Eur. J. Biochem. 214, 141-146). Recombinant human PAI-2 was labeled with [C-14]putrescine catalyzedby guinea pig liver transglutaminase. The [C-14]putrescine-labeled PAI-2 was digested with cyanogen bromide and trypsin, and the peptides were purified by reverse-phase high performance chromatography. Amino acid sequencing and plasma desorption mass spectrometry of the labeled peptides revealed [C-14]putrescine incorporation at Gln(83), Gln(84), and Gln(86). These residues are present in a PAI-2-specific region of 33 amino acids that is inserted between helices C and D and which probably represents a unique solvent-exposed domain. A PAI-2 mutant lacking this insertion was determined not to be a substrate for transglutaminase by [C-14]putrescine incorporation and could not form transglutaminase catalyzed polymers. Thus, the unique PAI-2 insertion represents a functional domain that, by virtue of its transglutaminase acceptor sites, allows participation in binding reactions without affecting the inhibitory function of PAI-2.	AARHUS UNIV,DEPT MOLEC BIOL,PROT CHEM LAB,DK-8000 AARHUS,DENMARK; AARHUS UNIV,DEPT MED BIOCHEM,DK-8000 AARHUS,DENMARK; ODENSE UNIV,DEPT MOLEC BIOL,ODENSE,DENMARK; BEHRINGWERKE AG,MARBURG,GERMANY; BIOTECH AUSTRALIA,ROSEVILLE,NSW,AUSTRALIA	Aarhus University; Aarhus University; University of Southern Denmark			Højrup, Peter/ABG-8477-2020	Jensen, Poul Henning/0000-0002-4439-9020				AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; ANTALIS TM, 1988, P NATL ACAD SCI USA, V85, P985, DOI 10.1073/pnas.85.4.985; ASTEDT B, 1986, THROMB HAEMOSTASIS, V56, P63; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; CHRISTENSEN S, 1992, FEBS LETT, V312, P100, DOI 10.1016/0014-5793(92)81419-M; FEINBERG RF, 1989, LAB INVEST, V61, P20; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; JENSEN PH, 1993, EUR J BIOCHEM, V214, P141, DOI 10.1111/j.1432-1033.1993.tb17906.x; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; JENSEN PH, 1989, BIOCHIM BIOPHYS ACTA, V986, P135, DOI 10.1016/0005-2736(89)90282-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MORTENSEN SB, 1981, FEBS LETT, V129, P314, DOI 10.1016/0014-5793(81)80191-3; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P137, DOI 10.1002/bms.1200170212; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; RADTKE KP, 1990, BIOL CHEM H-S, V371, P1119, DOI 10.1515/bchm3.1990.371.2.1119; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SKORSTENGAARD K, 1990, FEBS LETT, V262, P269, DOI 10.1016/0014-5793(90)80208-Z; SPRANG SR, 1992, TRENDS BIOCHEM SCI, V17, P49, DOI 10.1016/0968-0004(92)90495-U; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; WUN TC, 1987, J BIOL CHEM, V262, P3646; YE RD, 1987, J BIOL CHEM, V262, P3718; YE RD, 1989, J BIOL CHEM, V264, P5495	32	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15394	15398						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	7910824				2022-12-27	WOS:A1994NP73800080
J	BARKER, EL; WESTPHAL, RS; SCHMIDT, D; SANDERSBUSH, E				BARKER, EL; WESTPHAL, RS; SCHMIDT, D; SANDERSBUSH, E			CONSTITUTIVELY ACTIVE 5-HYDROXYTRYPTAMINE(2C) RECEPTORS REVEAL NOVEL INVERSE AGONIST ACTIVITY OF RECEPTOR LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEROTONIN 1C RECEPTOR; CHOROID-PLEXUS; INTRINSIC ACTIVITY; ANTAGONISTS; BINDING; 5-HT1C; ACTIVATION; TRANSFORMATION; CELLS	5-HT2C receptor antagonists, such as mianserin and mesulergine, exhibit negative intrinsic activity, defined as a decrease in agonist-independent, receptor mediated, phosphoinositide hydrolysis in cells transfected with the 5-HT2C receptor cDNA These drugs are classified as inverse agonists. Guanine nucleotides reciprocally modulate the binding of an agonist and inverse agonist, suggesting that an inverse agonist binds preferentially to the G protein uncoupled form of the 5-HT2C receptor. Another 5 HT2C receptor antagonist, 2-bromolysergic acid diethylamide, functions as a neutral antagonist with no intrinsic activity, but is able to block both agonist and inverse agonist. Chronic treatment of choroid plexus cells with an inverse agonist, but not with the neutral antagonist, causes 5-HT2C receptor down-regulation, suggesting that the biological effects of 5-HT2C receptor antagonists are not solely due to antagonism of endogenous agonist. These results provide evidence that constitutively active 5-HT2C receptors are biologically significant. The functionally distinct properties of inverse agonists and neutral antagonists may elucidate the mechanisms controlling basal receptor activity states and lead to novel approaches in the development of therapeutic agents.	VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT PSYCHIAT, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NIMH NIH HHS [MH 34007] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH034007, R37MH034007] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARKER EL, 1991, BRAIN RES, V552, P330, DOI 10.1016/0006-8993(91)90099-H; BARKER EL, 1993, MOL PHARMACOL, V44, P725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; CANTON H, 1990, EUR J PHARMACOL, V191, P93, DOI 10.1016/0014-2999(90)94100-C; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONN PJ, 1987, PSYCHOPHARMACOLOGY, V92, P267, DOI 10.1007/BF00210830; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; ESTERLE TM, 1992, J NEUROSCI, V12, P4775; HOYER D, 1989, N-S ARCH PHARMACOL, V339, P252; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KENNETT GA, 1989, EUR J PHARMACOL, V164, P445, DOI 10.1016/0014-2999(89)90252-5; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MOREAU JL, 1993, PSYCHOPHARMACOLOGY, V110, P140, DOI 10.1007/BF02246963; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PRANZATELLI MR, 1993, EUR J PHARM-MOLEC PH, V244, P1, DOI 10.1016/0922-4106(93)90052-B; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANDERSBUSH E, 1991, PSYCHOPHARMACOLOGY, V105, P340, DOI 10.1007/BF02244428; SANDERSBUSH E, 1988, J PHARMACOL EXP THER, V247, P169; SCHMIDT D, 1990, BIOMED CHROMATOGR, V4, P215, DOI 10.1002/bmc.1130040509; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N	27	254	265	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11687	11690						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909313				2022-12-27	WOS:A1994NG37700004
J	RUETZ, S; GROS, P				RUETZ, S; GROS, P			FUNCTIONAL EXPRESSION OF P-GLYCOPROTEINS IN SECRETORY VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; CONFER MULTIDRUG RESISTANCE; MDR GENE FAMILY; MONOCLONAL-ANTIBODIES; MEMBRANE-VESICLES; HUMAN-CELLS; YEAST; CDNA; PURIFICATION; HOMOLOGY	We expressed P glycoproteins (P-gps) encoded by the three mouse mdr genes in the membranes of secretory vesicles (SV) accumulating in the yeast mutant strain sec 6-4. Expression of the Mdr1 and Mdr3 isoforms in SV membranes caused a significant increased accumulation of the drug vinblastine (VBL) over background levels measured in control SV. The Mdr1/Mdr3-mediated increased drug accumulation could be completely abolished by the P gp modulator verapamil. By contrast, overexpression of Mdr2 in these vesicles failed to increase intravesicular VBL accumulation over background levels. Mdr3-mediated VBL transport was not affected by changes in the membrane potential, since identical rates of VBL uptake were measured in the presence or absence of the endogenous proton-translocating PMA1 H+-ATPase responsible for the strong electrochemical membrane potential across SV membranes. Moreover, in the presence of a Delta<(mu)over bar>(H+) across the SV membranes (inside positive) of almost 90 mV, we detected in Mdr3-expressing SV an enhanced accumulation of the lipophilic cation and P-gp substrate tetraphenylphosphonium, suggesting that P gp-mediated uptake of this cation occurs against an intravesicular depolarized membrane. Likewise, VBL transport in Mdr3-expressing SV was not affected by the presence or absence of a steep proton gradient (inside acid) and was independent of any proton movements, excluding a proton synport or antiport mechanism for P-gp-mediated drug transport. Finally, we could demonstrate that colchicine accumulation in Mdr3-expressing SV occurred against a significant substrate concentration gradient, reaching a 7-fold increase in intravesicular colchicine concentration above the extravesicular medium drug concentration. Our studies show that SV isolated from the temperature-sensitive yeast sec 6-4 mutants are an ideal tool to express and to functionally characterize heterologous membrane proteins, in general and P-gps, in particular.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA	McGill University								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALTENBERG GA, 1993, P NATL ACAD SCI USA, V90, P9735, DOI 10.1073/pnas.90.20.9735; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BECK WT, 1990, EUR J CANCER, V26, P513, DOI 10.1016/0277-5379(90)90028-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DELAPENA P, 1982, EUR J BIOCHEM, V123, P447; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1992, BIOCHEMISTRY-US, V31, P1992, DOI 10.1021/bi00122a014; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; RAMOS S, 1976, P NATL ACAD SCI USA, V73, P1892, DOI 10.1073/pnas.73.6.1892; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; SAFA AR, 1992, CANCER INVEST, V10, P295, DOI 10.3109/07357909209032754; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHURR E, 1989, CANCER RES, V49, P2729; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163	38	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12277	12284						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909318				2022-12-27	WOS:A1994NG37700091
J	SARKAR, FH; SMITH, MR; HOOVER, T; PRINCLER, G; CRISSMAN, JD; VISSCHER, DW; LONGO, DL; KUNG, HF; RAZIUDDIN				SARKAR, FH; SMITH, MR; HOOVER, T; PRINCLER, G; CRISSMAN, JD; VISSCHER, DW; LONGO, DL; KUNG, HF; RAZIUDDIN			C-ERBB-2 PROMOTER-SPECIFIC DNA-BINDING PROTEIN ISOLATED FROM HUMAN BREAST-CANCER TISSUES DISPLAYS MITOGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; LONG TERMINAL REPEAT; HUMAN MAMMARY-TUMORS; NEU PROTOONCOGENE; EGF RECEPTOR; CELL-LINE; ONCOGENE; TRANSFORMATION; REGION; GENE	Amplification and overexpression of the c-erbB-2 gene appears to play a role in the pathogenesis of human breast and other cancers. Frequent amplification (20-30%) of the c-erbB-2 gene was observed in human adenocarcinomas of kidney, pancreas, lung, ovarian, and breast cancer. The gene product is a 185-kDa glycoprotein that has intrinsic tyrosine kinase activity and is believed to be a receptor. Several candidate ligands have been described. In the present study we have identified and purified a novel DNA-binding protein from malignant human breast tissues. The protein binds to a core element (-22 to +9, +1 being the transcription start site) of the c-erbB-2 promoter region in a sequence-specific manner. The affinity-purified protein has the ability to induce DNA synthesis in quiescent NIH/3T3 cells, suggesting that the factor has mitogenic activity. The purified protein induces c-erbB-2 expression on the surface of microinjected NIH/3T3 cells. This DNA-binding protein is a sequence-specific cellular factor that is associated with high level expression of the c-erbB-2 gene and appears to play a role in cell transformation. Understanding the control and expression of this DNA-binding protein may shed light on the mechanism(s) of c-erbB-2 gene regulation and its potential role in the pathogenesis of human adenocarcinomas.	NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Wayne State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Longo, Dan L./F-6022-2011					BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CALVERT I, 1991, GENE, V101, P171, DOI 10.1016/0378-1119(91)90408-4; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HENRY JL, 1993, CANCER RES, V53, P1403; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAGUIRE HC, 1989, J INVEST DERMATOL, V92, P786, DOI 10.1111/1523-1747.ep12696796; MIKOVITS JAR, 1991, P NATL ACAD SCI USA, V88, P9426; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; RUSSELL KS, 1992, CANCER RES, V52, P6624; SALMON DJ, 1987, SCIENCE, V235, P177; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; WEST M, 1992, J BIOL CHEM, V267, P24948; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YOKOTA J, 1986, LANCET, V1, P765	39	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12285	12289						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909319				2022-12-27	WOS:A1994NG37700092
J	JACKLE, S; BEISIEGEL, U; RINNINGER, F; BUCK, F; GRIGOLEIT, A; BLOCK, A; GROGER, I; GRETEN, H; WINDLER, E				JACKLE, S; BEISIEGEL, U; RINNINGER, F; BUCK, F; GRIGOLEIT, A; BLOCK, A; GROGER, I; GRETEN, H; WINDLER, E			ANNEXIN-VI, A MARKER PROTEIN OF HEPATOCYTIC ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED PHOSPHOLIPID-BINDING; RECEPTOR-MEDIATED ENDOCYTOSIS; LIPOPROTEIN RECEPTORS; CELLULAR-DISTRIBUTION; RAT HEPATOCYTES; PLASMA-MEMBRANE; COATED PITS; CALCIUM; LIVER; P68	Three highly purified endosomal fractions from rat liver were used to purify and characterize a major protein of endosomal membranes. Intravenously injected ligands, which are taken up via receptor-mediated endocytosis, accumulate first in the fraction of intermediate density, the compartment of uncoupling of receptors and ligands. The high density membranous fraction is highly enriched in a receptor recycling compartment. The endosomal fraction of lowest density is composed of multivesicular bodies, which appear to be the immediate prelysosomal compartment. The most prominent membrane protein of these endosomes is one of 68 kDa, as revealed by silver and Coomassie Brilliant Blue staining of SDS-gel electrophoretograms. This protein dominates profiles obtained from purified membranes of the compartment of uncoupling of receptors and ligands, multivesicular bodies, and receptor recycling compartment, but is greatly reduced in those obtained from plasma membranes and lysosomes. The 68-kDa protein was purified from endosomes and digested with trypsin, and cleavage products were analyzed by protein sequencing. The tryptic fragments of the endosomal 68-kDa protein share 96% identity with corresponding sequences of mouse annexin VI and 91% identity with sequences of human annexin VI. Using immunoblots, high concentrations of annexin VI with an apparent molecular mass of 68 kDa were detected in endosomal membranes by specific antiserum to annexin VI. Significant amounts of annexin VI were also detected in Golgi membranes. Yet, the concentration was substantially lower than that of the three endosomal fractions. The association of annexin VI with endosomal membranes is calcium-dependent, as revealed by the complete solubilization from endosomal membranes by EGTA. Incubation of intact endosomes with Pronase leads to a complete degradation of annexin VI without any detectable disintegration of proteins localized on the luminal surface of endosomal membranes. Evidently, annexin VI is localized on the cytoplasmatic leaflet of the membrane of endosomes and may be of significance for their intracellular trafficking.	UNIV KRANKENHAUS EPPENDORF,INST ZELLBIOCHEM & KLIN NEUROBIOL,D-20246 HAMBURG,GERMANY	University of Hamburg; University Medical Center Hamburg-Eppendorf	BEISIEGEL, U (corresponding author), UNIV KRANKENHAUS EPPENDORF,MED KERNKLIN & POLIKLIN,MARTINISTR 52,D-20246 HAMBURG,GERMANY.							ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BAENZIGER JU, 1986, J BIOL CHEM, V261, P7445; BANDOROWICZ J, 1992, BIOCHIM BIOPHYS ACTA, V1105, P201, DOI 10.1016/0005-2736(92)90195-R; BAREL M, 1991, J IMMUNOL, V147, P1286; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BIANCHI R, 1992, FEBS LETT, V296, P158, DOI 10.1016/0014-5793(92)80369-R; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; CASCIOLAROSEN LA, 1992, J BIOL CHEM, V267, P11856; CHAO Y, 1979, J BIOL CHEM, V254, P1360; CLARK DM, 1991, HISTOCHEMISTRY, V96, P405, DOI 10.1007/BF00315998; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EDWARDS HC, 1987, J CELL BIOL, V105, P303, DOI 10.1083/jcb.105.1.303; EDWARDS HC, 1991, EUR J BIOCHEM, V198, P121, DOI 10.1111/j.1432-1033.1991.tb15994.x; ENRICH C, 1990, BIOCHEM J, V271, P171, DOI 10.1042/bj2710171; GASSAMADIAGNE A, 1990, J BIOL CHEM, V265, P4309; GEISOW M, 1984, EMBO J, V3, P2969, DOI 10.1002/j.1460-2075.1984.tb02242.x; GEISOW MJ, 1987, BIOCHEM SOC T, V15, P800, DOI 10.1042/bst0150800; GERKE V, 1990, BIOCHEM SOC T, V18, P1106, DOI 10.1042/bst0181106; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GOLDBERG M, 1991, CELL TISSUE RES, V263, P81, DOI 10.1007/BF00318402; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HAMILTON RL, 1991, J LIPID RES, V32, P529; HAVEL RJ, 1988, HEPATOLOGY, V8, P1689, DOI 10.1002/hep.1840080637; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P78, DOI 10.1002/jcb.240460112; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HULLIN F, 1989, J BIOL CHEM, V264, P3506; JACKLE S, 1991, J LIPID RES, V32, P485; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JACKLE S, 1989, P NATL ACAD SCI USA, V86, P1880; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; JOSTVU E, 1986, HISTOCHEMISTRY, V85, P457, DOI 10.1007/BF00508427; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KRETSINGER RH, 1986, NATURE, V320, P573, DOI 10.1038/320573a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; MOSS SE, 1988, EUR J BIOCHEM, V177, P21, DOI 10.1111/j.1432-1033.1988.tb14340.x; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; NEWMAN R, 1989, J MOL BIOL, V206, P213, DOI 10.1016/0022-2836(89)90534-2; OWENS RJ, 1984, EMBO J, V3, P945, DOI 10.1002/j.1460-2075.1984.tb01912.x; OWENS RJ, 1984, BIOCHEM J, V219, P309, DOI 10.1042/bj2190309; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SEKIMOTO S, 1991, J NEUROCHEM, V56, P1774, DOI 10.1111/j.1471-4159.1991.tb02080.x; SILVA FG, 1986, DIFFERENTIATION, V33, P175, DOI 10.1111/j.1432-0436.1986.tb00423.x; SMALLWOOD M, 1990, BIOCHEM J, V270, P157, DOI 10.1042/bj2700157; SMITH VL, 1986, J BIOL CHEM, V261, P5815; STOEHR SJ, 1990, J IMMUNOL, V144, P3936; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WEISIGER R, 1981, SCIENCE, V211, P1048, DOI 10.1126/science.6258226; YOSHIZAKI H, 1991, CHEM PHARM BULL, V39, P2617	66	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1026	1032						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904597				2022-12-27	WOS:A1994MR22000041
J	YEN, PM; IKEDA, M; BRUBAKER, JH; FORGIONE, M; SUGAWARA, A; CHIN, WW				YEN, PM; IKEDA, M; BRUBAKER, JH; FORGIONE, M; SUGAWARA, A; CHIN, WW			ROLES OF V-ERBA HOMODIMERS AND HETERODIMERS IN MEDIATING DOMINANT-NEGATIVE ACTIVITY BY V-ERBA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; RESPONSE ELEMENTS; GENERALIZED RESISTANCE; DNA-BINDING; NUCLEAR RECEPTORS; AUXILIARY PROTEIN; ONCOGENE PROTEIN; ACID RECEPTORS	v-erbA, a viral oncogenic homolog of thyroid hormone receptor (TR), blocks the effect of T3 in TR-mediated transcription. The mechanism(s) for this dominant negative effect by v-erbA on TRs is unknown but may involve competition between v-erbA and TR-containing complexes for binding to thyroid hormone response elements (TREs) and/or protein-protein interactions between v-erbA and TR. To investigate these potential mechanisms, we used the electrophoretic mobility shift assay to compare in vitro translated v-erbA and TRalpha binding to two TREs-chick lysozyme TRE (F2) and direct repeat TRE (DR4). v-erbA bound as a homodimer to these TREs, whereas TRalpha bound as a homodimer and monomer. T3 decreased TRalpha homodimer binding to the TREs as we reported previously; however, surprisingly, high concentrations of T3 (10(-6) M) also decreased v-erbA homodimer binding to the TREs. Additionally, v-erbA formed heterodimers with nuclear proteins such as retinoid X receptor and T3 receptor auxiliary protein as well as with TRalpha. These dimers remained bound to DNA in the presence of T3. Finally, v-erbA could not mediate ligand-dependent transcriptional activation even at 10(-6) M T3 but could block ligand-dependent TR-mediated transactivation in co-transfection experiments. v-erbA also exhibited differential dominant negative activity on F2 and DR4 suggesting that half-site sequence and/or orientation may influence v-erbA-dominant negative activity. In sum, there are multiple v-erbA complexes that bind to TREs in the presence of T3, which all may contribute to v-erbA's dominant negative effect on TR-mediated transcription by competing with TR-containing complexes for binding to TREs.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,GW THORN RES BLDG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114; Sugawara, Akira/0000-0003-4511-8101				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FORREST D, 1990, ONCOGENE, V5, P309; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HERMANN T, 1993, ONCOGENE, V8, P55; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; RIBIERO RCJ, 1992, MOL ENDOCRINOL, V6, P142; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SELMI S, 1991, J BIOL CHEM, V266, P11589; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539; YEN PM, 1992, J CLIN INVEST, V90, P1825, DOI 10.1172/JCI116058; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	50	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					903	909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904604				2022-12-27	WOS:A1994MR22000023
J	ZIERE, GJ; BIJSTERBOSCH, MK; VANBERKEL, TJC				ZIERE, GJ; BIJSTERBOSCH, MK; VANBERKEL, TJC			REMOVAL OF 14 N-TERMINAL AMINO-ACIDS OF LACTOFERRIN ENHANCES ITS AFFINITY FOR PARENCHYMAL LIVER-CELLS AND POTENTIATES THE INHIBITION OF BETA-VERY LOW-DENSITY-LIPOPROTEIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CHYLOMICRON REMNANTS; ARGININE RESIDUES; KUPFFER CELLS; SEQUENCE; PROTEIN; INVIVO; RECOGNITION; DEGRADATION; SITE	Lactoferrin inhibits the hepatic uptake of lipoprotein remnants, and we showed earlier that arginine residues of lactoferrin are involved. In this study, lactoferrin was treated with aminopeptidase M (APM), which resulted in removal of 14 N-terminal amino acids, including 4 clustered arginine residues at positions 2-5 (APM-lactoferrin). After intravenous injection into rats, I-125-labeled APM-lactoferrin was cleared within 10 min by the liver parenchymal cells (74.7% of the dose). In contrast to native lactoferrin, APM-lactoferrin was rapidly internalized after liver association (>80% of the liver-associated radioactivity was internalized within 10 min). Binding of APM-lactoferrin to isolated parenchymal liver cells was saturable with a K(d) of 186 nm (750,000 sites/cell). This is in striking contrast to the binding of native lactoferrin (K(d) 10 muM; 20 x 10(6) sites/cell). Preinjection of rats with 20 mg of APM-lactoferrin/kg of body weight reduced the liver association of beta-very low density lipoprotein (beta-VLDL) by 50%, whereas lactoferrin had no effect at this dose. With isolated parenchymal liver cells, APM-lactoferrin was a more effective competitor for beta-VLDL binding than native lactoferrin (50% inhibition at 0.5 mg/ml versus 8.0 mg/ml). Selective modification of the arginines of APM-lactoferrin with 1,2-cyclohexanedione reduced the liver association by approximately 60% and abolished the capacity of APM-lactoferrin to inhibit the binding of I-125-labeled beta-VLDL in vitro. In conclusion, our data indicate that the four-arginine cluster of lactoferrin at positions 2-5 is involved in its massive, low affinity association of lactoferrin with the liver, possibly to proteoglycans, but is not essential for the inhibition of lipoprotein remnant uptake. The Arg-Lys sequence at positions 25-31, which resembles the binding site of apolipoprotein E, may mediate the high affinity binding of lactoferrin and block the binding of beta-VLDL to the remnant receptor with high efficiency.	LEIDEN UNIV,SYLVIUS LAB,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021					BENNETT RM, 1979, CLIN SCI, V57, P453, DOI 10.1042/cs0570453; BENSADOUM A, 1991, ANN REV NUTR, V1, P217; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BLUARDDECONINCK JM, 1978, BIOCHEM J, V171, P321, DOI 10.1042/bj1710321; CASTELEIJN E, 1986, FEBS LETT, V201, P1193; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; DEWATER R, 1990, EUR J BIOCHEM, V192, P419, DOI 10.1111/j.1432-1033.1990.tb19243.x; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GORIUS JB, 1980, AM J PATHOL, V99, P413; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P259, DOI 10.1042/bj1990259; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; IMBER MJ, 1983, BIOCHEM J, V212, P249, DOI 10.1042/bj2120249; KARLE H, 1979, SCAND J HAEMATOL, V23, P303; LEE BR, 1991, J LIPID RES, V32, P165; LEGER D, 1977, ANN BIOL ANIM BIOCH, V17, P737, DOI 10.1051/rnd:19770609; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MASSON PL, 1986, PROTIDES BIOL FLUIDS, V14, P115; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MOGUILEVSKY N, 1984, LAB INVEST, V50, P335; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAKANISHI M, 1989, J BIOCHEM, V106, P818, DOI 10.1093/oxfordjournals.jbchem.a122937; PATTHY L, 1975, J BIOL CHEM, V250, P557; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PRIEELS JP, 1978, P NATL ACAD SCI USA, V75, P2215, DOI 10.1073/pnas.75.5.2215; QUERINJE.P, 1971, EUR J BIOCHEM, V20, P420, DOI 10.1111/j.1432-1033.1971.tb01408.x; RECOECZI E, 1985, AM J PHYSIOL, V248, pG8; RETEGUI LA, 1984, LAB INVEST, V50, P323; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPIK G, 1966, CR ACAD SCI D NAT, V263, P893; SPITZNAGEL JK, 1972, J CLIN INVEST, V51, pA93; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; VANDIJK MCM, 1992, EUR J BIOCHEM, V205, P775, DOI 10.1111/j.1432-1033.1992.tb16842.x; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANTOL A, 1978, ATHEROSCLEROSIS, V29, P449, DOI 10.1016/0021-9150(78)90173-9; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	44	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27069	27075						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903302				2022-12-27	WOS:A1993MM26200037
J	GREENE, NM; WILLIAMS, DS; NEWTON, AC				GREENE, NM; WILLIAMS, DS; NEWTON, AC			KINETICS AND LOCALIZATION OF THE PHOSPHORYLATION OF RHODOPSIN BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; LIGHT-MEDIATED BREAKDOWN; PHOSPHOLIPASE-C; PHOTORECEPTOR CELLS; BOVINE RHODOPSIN; RECEPTOR; SITES; DESENSITIZATION; SPECIFICITY; RETINA	Protein kinase C isolated from retina catalyzes the stoichiometric phosphorylation of bovine rhodopsin, Enzymological studies using receptor in rod outer segment membranes stripped of peripheral proteins reveal that the phosphorylation is independent of receptor conformation or liganded state; the half-time for phosphorylation of unbleached (dark-adapted) rhodopsin, bleached (light-activated) rhodopsin, and opsin (chromophore removed) is the same. The phosphorylation by protein kinase C is Ca2+ and lipid regulated; the K-m for Ca2+ decreases with increasing concentrations of membrane, consistent with known properties of Ca2+-regulated protein kinase Cs. The K-m for ATP is 27 mu M, with an optimal concentration for MgCl2 of approximately 1 mM. The phosphorylation of rhodopsin by protein kinase C is inhibited by the protein kinase C-selective inhibitor sangivamycin. Proteolysis by Asp-N reveals that all the protein kinase C phosphorylation sites are on the carboxyl terminus of the receptor. Cleavage with trypsin indicates that Ser(338), the primary phosphorylation site of rhodopsin kinase, is not phosphorylated significantly; rather, the primary phosphorylation site of protein kinase C is on the membrane proximal half of the carboxyl terminus. The protein kinase C catalyzed phosphorylation of rhodopsin is analogous to the ligand-independent phosphorylation of other G protein-coupled receptors that is catalyzed by second messenger-regulated kinases.	INDIANA UNIV, DEPT CHEM, BLOOMINGTON, IN 47405 USA; INDIANA UNIV, SCH OPTOMETRY, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NATIONAL EYE INSTITUTE [R01EY008820] Funding Source: NIH RePORTER; NEI NIH HHS [EY08820] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AZARIAN SM, 1993, J CELL SCI, V105, P787; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DAS ND, 1987, CELL STRUCT FUNCT, V12, P471, DOI 10.1247/csf.12.471; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HONG K, 1972, P NATL ACAD SCI USA, V69, P2617, DOI 10.1073/pnas.69.9.2617; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JEAN T, 1986, J BIOL CHEM, V261, P6414; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KHOVRATOVICH VI, 1991, BIOL MEMBR, V4, P1392; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MILLAR FA, 1988, BIOCHIM BIOPHYS ACTA, V970, P205, DOI 10.1016/0167-4889(88)90180-2; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NEWTON AC, 1993, METH NEUROSCI, V15, P261; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; THORPE GHG, 1985, CLIN CHEM, V31, P1335; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WILLIAMS DS, 1993, INVEST OPHTH VIS SCI, V34, P1361	55	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6710	6717		10.1074/jbc.270.12.6710	http://dx.doi.org/10.1074/jbc.270.12.6710			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896814	hybrid			2022-12-27	WOS:A1995QQ85500045
J	LIN, JL; ADDISON, R				LIN, JL; ADDISON, R			THE MEMBRANE TOPOLOGY OF THE CARBOXYL-TERMINAL 3RD OF THE NEUROSPORA PLASMA-MEMBRANE H(+)ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM MEMBRANE; H+-ATPASE; PROTEIN; SEQUENCE; SURFACE; CRASSA; AMINO; CA-2+-ATPASE; GENE	To localize transmembrane segments in the carboxyl-terminal third of the Neurospora plasma membrane H+-ATPase, we constructed fusion proteins on the cDNA level. These contained DNA fragments encoding hydrophilic residues of the amino and carboxyl termini of the H+-ATPase with a DNA fragment encoding the putative transmembrane segment. To report translocation into microsomes, a DNA fragment encoding three consensus N-linked glycosylation sites was engineered carboxyl-terminal to the putative transmembrane segment. Fusion proteins were synthesized in a Neurospora in vitro translation system supplemented with homologous microsomes. By the criteria of glycosylation of fusion proteins by microsomes, sedimentation of products with microsomes after alkaline extraction, and analysis of protected fragments generated from proteinase K digestion of integrated products, we localized six transmembrane segments in the carboxyl-terminal third of the H+-ATPase. These results support a 10-segment model of the Neurospora H+-ATPase.			LIN, JL (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163, USA.							ADDISON R, 1987, J BIOL CHEM, V262, P17031; ADDISON R, 1986, J BIOL CHEM, V261, P4896; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EBELE BE, 1987, MOL CELL BIOL, V7, P3591; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; LIN J, 1994, J BIOL CHEM, V269, P3887; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; RAO US, 1991, J BIOL CHEM, V266, P14740; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SMITH DL, 1993, J BIOL CHEM, V268, P22469; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; TAYLOR KA, 1994, J BIOL CHEM, V269, P10107; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0	24	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6942	6948		10.1074/jbc.270.12.6942	http://dx.doi.org/10.1074/jbc.270.12.6942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896844	hybrid			2022-12-27	WOS:A1995QQ85500075
J	CUI, Z; HOUWELING, M; VANCE, DE				CUI, Z; HOUWELING, M; VANCE, DE			SUPPRESSION OF RAT HEPATOMA-CELL GROWTH BY EXPRESSION OF PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIVER; PHOSPHATIDYLCHOLINE; METHYLTRANSFERASE; PROTEINS	The expression of rat liver phosphatidylethanolamine N-methyltransferase-2 (PEMT2) in McA-RH7777 rat hepatoma cells resulted in the unexpected inhibition of cell growth. There was a strict correlation (r = 0.973) between the level of expression of the enzyme activity and the generation time for hepatoma cell division. Expression of other foreign proteins via the same vector did not inhibit McA-RH7777 cell growth; thus, retardation of cell division was specific for the methyltransferase. Addition of 1 mu M 3-deazaadenosine, which causes inhibition of phosphatidylethanolamine methylation, reversed the PEMT2-mediated inhibition of cell division. Transfection of a line of Chinese hamster ovary cells with PEMT2 had no effect on the division of these cells. Induction of hepatic tumors in rats with N-nitrosodiethylamine coincided with a striking decrease in methyltransferase activity and immunoreactive protein in the tumor nodules. Thus, data from studies in cell culture and intact rats suggest a regulatory role for PEMT2 in hepatocyte cell growth and possibly in the development of liver cancer.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta								BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; CUI Z, 1993, J BIOL CHEM, V268, P16655; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRISHAM JW, 1962, CANCER RES, V22, P842; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PELECH SL, 1983, CAN J BIOCHEM CELL B, V61, P1147, DOI 10.1139/o83-147; PRITCHARD PH, 1982, J BIOL CHEM, V257, P6362; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TANG H, 1992, MOL CELL BIOCHEM, V109, P83; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vance D E, 1981, Methods Enzymol, V71 Pt C, P576; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; YAO ZM, 1991, J BIOL CHEM, V266, P3300	18	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24531	24533						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929120				2022-12-27	WOS:A1994PQ49000004
J	ARNIS, S; FAHMY, K; HOFMANN, KP; SAKMAR, TP				ARNIS, S; FAHMY, K; HOFMANN, KP; SAKMAR, TP			A CONSERVED CARBOXYLIC-ACID GROUP MEDIATES LIGHT-DEPENDENT PROTON UPTAKE AND SIGNALING BY RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METARHODOPSIN-II; BOVINE RHODOPSIN; CONFORMATIONAL-CHANGES; TRANSDUCIN; MUTANTS; GENE	A carboxylic acid residue is conserved at the cytoplasmic border of the third transmembrane segment among nearly all G protein-coupled receptors. In the visual receptor rhodopsin, replacement of the conserved Glu(134) by a neutral glutamine results in enhanced transducin activation. Here we show that a key event in forming the active state of rhodopsin is proton uptake by Glu(134) in the metarhodopsin II (MII) photoproduct. Site-directed mutants E134D and E134Q were studied by flash photolysis, where formation rates of their photoproducts and rates of pH change could be monitored simultaneously. Both mutants showed normal MII formation rates. However, E134D displayed a slowed rate of proton uptake and E134Q displayed a loss of light-induced uptake of two protons from the aqueous phase. Thus, Glu(134) mediates light-dependent proton uptake by MII. We propose that receptor activation requires a light-induced conformational change that allows protonation of Glu(134) and subsequent protonation of a second group. The strong conservation of Glu(134) in G protein-coupled receptors implies a general requirement for a proton acceptor group at this position to allow light- or ligand-dependent receptor activation.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, MOLEC BIOL & BIOCHEM LAB, NEW YORK, NY 10021 USA; UNIV FREIBURG, INST BIOPHYS & STRAHLENBIOL, W-7800 FREIBURG, GERMANY	Howard Hughes Medical Institute; Rockefeller University; University of Freiburg			Sakmar, Thomas P/D-1833-2015; Fahmy, Karim/B-2708-2017	Sakmar, Thomas P/0000-0002-2836-8953; Fahmy, Karim/0000-0002-8752-5824				ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BENNETT N, 1980, EUR J BIOCHEM, V111, P99; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; KIBELBEIS J, 1991, BIOCHEMISTRY-US, V36, P6761; KOENIG B, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P6878; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; RADDING CR, 1965, GEN PHYSL, V30, P909; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176, DOI 10.1021/bi00214a016	23	186	188	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23879	23881						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929034				2022-12-27	WOS:A1994PQ34600008
J	NUNOKI, K; ISHII, K; OKADA, H; YAMAGISHI, T; MURAKOSHI, H; TAIRA, N				NUNOKI, K; ISHII, K; OKADA, H; YAMAGISHI, T; MURAKOSHI, H; TAIRA, N			HYBRID POTASSIUM CHANNELS BY TANDEM LINKAGE OF INACTIVATING AND NONINACTIVATING SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; CARDIAC PURKINJE-FIBERS; SHAKER K+ CHANNEL; STOICHIOMETRY; CELLS; MODULATION; NEURONS; BINDING; REGION; HEART	We constructed tandem cDNA by linking the 5' end of a delayed rectifier-type (Kv1.2) clone to the 3' end of a transient-type (Kv1.4) K+ channel clone. Fusion genes were also constructed, consisting of Kv1.4 and mutants of Kv1.2, which have a single amino acid substitution in the S4-S5 loop. From electrophysiolog;ical characterization, it is likely that two pairs of tandem heterodimer constructs can form hybrid channels. In addition, it has been revealed that the wild-type hybrid channel shows a time constant of inactivation very similar to that observed in the homotetrameric Kv1.4 channel. Difference of inactivation kinetics between wild-type and mutant hybrid K+ channels suggests that not only the S4-S5 loop of Kv1.4 but also that of Kv1.2 can serve as the acceptor sites for the inactivation gates, and that all of four sets of loops should be functional for rapid inactivation. From these results, in the hybrid channels the structure and composition of the acceptor sites could be important factors for determining the rate of inactivation.			NUNOKI, K (corresponding author), TOHOKU UNIV,SCH MED,DEPT PHARMACOL,2-1 SEIRYO MACHI,SENDAI,MIYAGI 980,JAPAN.							CHRISTIE MJ, 1990, NEURON, V2, P405; CORABOEUF E, 1982, PFLUG ARCH EUR J PHY, V392, P352, DOI 10.1007/BF00581631; ESCANDE D, 1987, AM J PHYSIOL, V252, pH142, DOI 10.1152/ajpheart.1987.252.1.H142; GILES WR, 1985, J PHYSIOL-LONDON, V368, P243, DOI 10.1113/jphysiol.1985.sp015856; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ISHII K, 1992, BIOCHEM BIOPH RES CO, V184, P1484, DOI 10.1016/S0006-291X(05)80050-6; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JOSEPHSON IR, 1984, CIRC RES, V54, P157, DOI 10.1161/01.RES.54.2.157; KACZMAREK LK, 1984, J NEUROPHYSIOL, V52, P340, DOI 10.1152/jn.1984.52.2.340; KENYON JL, 1987, J GEN PHYSIOL, V89, P921, DOI 10.1085/jgp.89.6.921; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; NAKAYAMA T, 1985, CIRC RES, V57, P65, DOI 10.1161/01.RES.57.1.65; OKADA H, 1992, BIOCHEM BIOPH RES CO, V189, P430, DOI 10.1016/0006-291X(92)91576-C; PEROZO E, 1992, BIOPHYS J, V62, P160, DOI 10.1016/S0006-3495(92)81802-7; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SEGAL M, 1984, J NEUROSCI, V4, P604; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHIBATA EF, 1989, AM J PHYSIOL, V257, pH1773, DOI 10.1152/ajpheart.1989.257.6.H1773; TSENG GN, 1989, CIRC RES, V64, P633, DOI 10.1161/01.RES.64.4.633; YAO JA, 1992, CIRCULATION, V86, P77; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	32	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24138	24142						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929069				2022-12-27	WOS:A1994PQ34600047
J	PORTER, DJT				PORTER, DJT			DEHALOGENATING AND NADPH-MODIFYING ACTIVITIES OF DIHYDROPYRIMIDINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PIG-LIVER; ANTITUMOR-ACTIVITY; 5-FLUOROURACIL; PURIFICATION; MECHANISM; INACTIVATION; 5-ETHYNYLURACIL; OXIDATION; ACID	Dihydropyrimidine dehydrogenase (DPDase) catalyzed the debromination of 8-bromo-5,6-dihydrouracil (BrUH2) to uracil at pH 7.7 and 37 degrees C. The debrominating activity of DPDase was increased 5-fold by treatment with H2O2, whereas the dehydrogenating activity was inhibited by this treatment. The time course for increasing the debrominating activity by H2O2 was similar to that for decreasing the dehydrogenating activity. Thus, the relative amounts of debrominating and dehydrogenating activities of DPDase were reciprocally related. H2O2 treatment of DPDase decreased the number of thiol groups reactive with 5,5'-dithiobis(2-nitrobenzoate) from eight/subunit to less than one. The k(cat) for debromination of BrUH2 by H2O2-treated DPDase (OxDPDase) was 1.9 s(-1), which was comparable with k(cat) for reduction of thymine (2.1 s(-1)) by DPDase. Even though the debromination of BrUH2 to uracil does not involve a net reduction of BrUH2, NADPH was required for this activity. The reaction of OxDPDase with 5-iodo-5,6 dihydrouracil (IUH2) was more complicated than that with BrUH2. Aerobically, OxDPDase catalyzed the deiodination of IUH2 to uracil and the iodination of NADPH to 5-iodo-6-hydroxy-1,4,6-trihydronicotinamide adenine dinucleotide phosphate. The turnover number for the iodination reaction was enhanced by NaI and had a value of 3.5 s(-1) in the presence of 4 mM IUH2 and 50 mM NaI. Anaerobically, OxDPDase catalyzed the above reactions, the deiodination of IUH2 to 5,6-dihydrouracil, and the hydration of NADPH to 6-hydroxy-1,2,3,4-tetrahydronicotinamide adenine dinucleotide phosphate. The turnover number for the anaerobic hydration of NADPH was similar to that for the aerobic iodination of NADPH.			PORTER, DJT (corresponding author), WELLCOME RES LABS, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							ACHESON SA, 1988, BIOCHEMISTRY-US, V27, P7371, DOI 10.1021/bi00419a030; BACCANARI DP, 1993, P NATL ACAD SCI USA, V90, P11064, DOI 10.1073/pnas.90.23.11064; CHAYKIN S, 1956, J BIOL CHEM, V220, P811; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DESGRANGES C, 1986, CANCER RES, V46, P1094; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GELDERMANN AH, 1985, BIOCHEMISTRY-US, V4, P1511; HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F; HILVERS AG, 1966, BIOCHIM BIOPHYS ACTA, V128, P74, DOI 10.1016/0926-6593(66)90143-3; HUENNEKENS FM, 1955, J BIOL CHEM, V213, P951; IIGO M, 1988, BIOCHEM PHARMACOL, V37, P1609; LESKOVAC V, 1987, MONATSH CHEM, V118, P1119, DOI 10.1007/BF00811285; LU ZH, 1992, J BIOL CHEM, V267, P17102; MARGOLIS SA, 1978, J LIQ CHROMATOGR, V1, P669, DOI 10.1080/01483917808060026; MIKSIC JR, 1978, BIOCHEMISTRY-US, V17, P2234, DOI 10.1021/bi00604a034; MIKSIC JR, 1977, J CHROMATOGR, V142, P641, DOI 10.1016/S0021-9673(01)92074-6; NAGUIB FNM, 1989, BIOCHEM PHARMACOL, V38, P1471, DOI 10.1016/0006-2952(89)90187-1; OPPENHEIMER NJ, 1974, BIOCHEMISTRY-US, V13, P4675, DOI 10.1021/bi00720a001; OPPENHEIMER NJ, 1974, BIOCHEMISTRY-US, V13, P4685, DOI 10.1021/bi00720a002; PODSCHUN B, 1993, J BIOL CHEM, V268, P3407; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; PODSCHUN B, 1990, J BIOL CHEM, V265, P12966; PODSCHUN B, 1992, BIOCHEM BIOPH RES CO, V182, P609, DOI 10.1016/0006-291X(92)91776-M; PORTER DJT, 1991, J BIOL CHEM, V266, P19988; PORTER DJT, 1992, J BIOL CHEM, V267, P5236; RAFTER GW, 1954, J BIOL CHEM, V208, P799; REGUEIRO B, 1970, PHYSIOL CHEM PHYS M, V2, P445; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; RORK GS, 1975, J AM CHEM SOC, V97, P5566, DOI 10.1021/ja00852a041; SANDER EG, 1976, BIOORG CHEM, V5, P231, DOI 10.1016/0045-2068(76)90032-8; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; SHIOTANI T, 1981, J BIOL CHEM, V256, P219; STOCK A, 1961, LIEBIGS ANN CHEM, V647, P188; TATSUMI K, 1987, JPN J CANCER RES, V78, P748; VELICK SF, 1955, METHOD ENZYMOL, V1, P401, DOI 10.1016/0076-6879(55)01065-3; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6	36	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24177	24182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929074				2022-12-27	WOS:A1994PQ34600053
J	HA, J; DANIEL, S; BROYLES, SS; KIM, KH				HA, J; DANIEL, S; BROYLES, SS; KIM, KH			CRITICAL PHOSPHORYLATION SITES FOR ACETYL-COA CARBOXYLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; BACTERIOPHAGE-T7 RNA-POLYMERASE; ACTIVATED PROTEIN-KINASE; FATTY-ACID SYNTHESIS; MESSENGER-RNA; 5' END; ISOLATED ADIPOCYTES; CODING SEQUENCE; MALONYL-COA; EXPRESSION	Acetyl CoA carboxylase (ACC) is rapidly regulated by reversible phosphorylation; phosphorylation inactivates ACC, whereas dephosphorylation activates the enzyme. Among protein kinases only cAMP-dependent protein kinase and 5'-AMP-dependent protein kinase can inactivate ACC; cAMP-dependent protein kinase phosphorylates Ser-77 and -1200; 5'-AMP-dependent protein kinase phosphorylates Ser-79, -1200, and -1215. In this report, the construction and expression of ACC cDNA containing the entire coding region (7.2 kilobase pairs) is described. In order to identify the critical phosphorylation site(s) for each protein kinase, we introduced site-specific mutations at Ser-77, -79, -1200, and -1215 of ACC cDNA and a series of mutated ACCs containing various combinations of these four mutated sites was expressed. By examination of the various mutant ACCs, we provided evidence that the effect of cAMP-dependent protein kinase is entirely mediated by the phosphorylation of Ser-1200 and that Ser-79 is important for 5'-AMP-dependent protein kinase action in vitro.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA 46882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIVARAM P, 1990, J BIOL CHEM, V265, P5774; BEATY NB, 1983, J BIOL CHEM, V258, P3043; CARSON CA, 1979, ARCH BIOCHEM BIOPHYS, V164, P490; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOODRIDGE AG, 1972, J BIOL CHEM, V247, P6946; GURDON JB, 1977, METHOD CELL BIOL, V16, P215; GUY PS, 1981, FEBS LETT, V132, P67, DOI 10.1016/0014-5793(81)80428-0; HA J, 1994, EUR J BIOCHEM, V219, P297, DOI 10.1111/j.1432-1033.1994.tb19941.x; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P19; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KONG IS, 1990, J BIOL CHEM, V265, P13695; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE KH, 1979, J BIOL CHEM, V254, P1450; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LOPEZCASILLAS F, 1989, GENE, V83, P311, DOI 10.1016/0378-1119(89)90117-0; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; Numa S, 1984, FATTY ACID METABOLIS, P1; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; SONG CS, 1981, J BIOL CHEM, V256, P7786; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWANSON RF, 1967, P NATL ACAD SCI USA, V58, P1243, DOI 10.1073/pnas.58.3.1243; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; THAMPY KG, 1986, ADV PROTEIN PHOSPHAT, V3, P257; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WITTERS LA, 1983, J BIOL CHEM, V258, P5463	38	264	276	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22162	22168						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915280				2022-12-27	WOS:A1994PE09800038
J	MIAO, SC; MCCARTER, JD; GRACE, ME; GRABOWSKI, GA; AEBERSOLD, R; WITHERS, SG				MIAO, SC; MCCARTER, JD; GRACE, ME; GRABOWSKI, GA; AEBERSOLD, R; WITHERS, SG			IDENTIFICATION OF GLU(340) AS THE ACTIVE-SITE NUCLEOPHILE IN HUMAN GLUCOCEREBROSIDASE BY USE OF ELECTROSPRAY TANDEM MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACID BETA-GLUCOSIDASE; GAUCHER DISEASE; ENZYME INTERMEDIATE; MOLECULAR-BIOLOGY; GLYCOSIDASE; MECHANISM; SEQUENCE; BINDING	disease is an inherited lysosomal storage disorder caused by a deficiency of human acid beta-glucosidase (glucocerebrosidase). This enzyme is inactivated by the specific, mechanism-based enzyme inactivator 2-deoxy-2-fluoro-beta-D-glucopyranosyl fluoride, which functions by forming a stable 2-deoxy-2-fluoro-alpha-D-glucopyranosyl-enzyme intermediate. The key nucleophilic amino acid residue involved in formation of this intermediate was conclusively identified by tandem mass spectrometry as Glu340, and not Asp443 as thought previously. This was confirmed by site-directed mutagenesis. Identification, and mass determination, of the labeled peptide in a proteolytic hydrolysate involved detection of a collision-induced fragmentation reaction specific to the sugar-peptide linkage. Confirmation of the identity of the labeled peptide was obtained both by tandem mass spectrometric sequencing and by chemical degradation of the purified peptide. This method allowed the rapid, sensitive, and non-isotopic determination of an essential amino acid residue in a clinically important enzyme.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER V6T 1Z1,BC,CANADA; CHILDRENS HOSP MED CTR,DEPT PEDIAT,DIV HUMAN GENET,CINCINNATI,OH 45229; MT SINAI MED CTR,DEPT HUMAN GENET,NEW YORK,NY 10029; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z1,BC,CANADA	University of British Columbia; Cincinnati Children's Hospital Medical Center; Icahn School of Medicine at Mount Sinai; University of British Columbia								BALLARDIE F, 1973, J CHEM SOC PERK T 1, P2418, DOI 10.1039/p19730002418; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; BRADY RO, 1966, J CLIN INVEST, V45, P1112, DOI 10.1172/JCI105417; BUSCH KL, 1983, TANDEM MASS SPECTROM, P31; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; FALLET S, 1992, PEDIATR RES, V31, P496, DOI 10.1203/00006450-199205000-00018; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRABOWSKI GA, 1988, LIPID STORAGE DISORD, P793; Grabowski Gregory A., 1993, V21, P377; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRACE ME, 1994, J BIOL CHEM, V269, P2283; HALL L, 1971, CAN J CHEM, V47, P118; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; ONEILL RR, 1989, P NATL ACAD SCI USA, V86, P5049, DOI 10.1073/pnas.86.13.5049; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; OSIECKINEWMAN KM, 1986, ENZYME, V35, P147, DOI 10.1159/000469336; PASTORES GM, 1993, BLOOD, V82, P408; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SORGE J, 1985, P NATL ACAD SCI USA, V82, P7289, DOI 10.1073/pnas.82.21.7289; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAKASAKI S, 1984, J BIOL CHEM, V259, P112; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; WANG QP, 1993, J BIOL CHEM, V268, P14096; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043	35	82	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10975	10978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7908905				2022-12-27	WOS:A1994NF96600003
J	MOYLE, M; FOSTER, DL; MCGRATH, DE; BROWN, SM; LAROCHE, Y; DEMEUTTER, J; STANSSENS, P; BOGOWITZ, CA; FRIED, VA; ELY, JA; SOULE, HR; VLASUK, GP				MOYLE, M; FOSTER, DL; MCGRATH, DE; BROWN, SM; LAROCHE, Y; DEMEUTTER, J; STANSSENS, P; BOGOWITZ, CA; FRIED, VA; ELY, JA; SOULE, HR; VLASUK, GP			A HOOKWORM GLYCOPROTEIN THAT INHIBITS NEUTROPHIL FUNCTION IS A LIGAND OF THE INTEGRIN CD11B CD18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODY; LEUKOCYTE DIFFERENTIATION; HEMORRHAGIC-SHOCK; ENDOTHELIAL-CELLS; MAC-1; ADHESION; RECEPTOR; LFA-1; ADHERENCE	The chronic survival of many endoparasites is dependent on the ability of these organisms to escape the host immune response. Identification of the molecular mechanisms by which these organisms evade this response may yield novel approaches in the development of anti-inflammatory agents. We describe here the discovery and characterization of a novel 41-kilodalton glycoprotein from the canine hookworm (Ancylostoma caninum) that potently inhibits CD11/CD18-dependent neutrophil function in vitro. Neutrophil inhibitory factor (NIF) blocks the adhesion of activated human neutrophils to vascular endothelial cells as well as the release of H2O2 from activated neutrophils, over a similar concentration range (IC50 10-20 nM). Studies aimed at determining the nature of the NIF binding site on neutrophils revealed selective, high affinity binding of this protein to the integrin CD11b/CD18. A cDNA encoding NIF was isolated from a canine hookworm cDNA library. NIF comprises a mature polypeptide of 257 amino acids, preceded by a 17-amino acid leader. The mature protein has 10 cysteines and has seven potential N-linked glycosylation sites. NIF has no significant sequence homologies to any previously reported protein. As such, NIF represents a prototype of a novel class of leukocyte function inhibitors.	CORVAS INT NV, GHENT, BELGIUM; NEW YORK MED COLL, DEPT CELL BIOL & ANAT, VALHALLA, NY 10595 USA	New York Medical College	MOYLE, M (corresponding author), CORVAS INT INC, 3030 SCI PK RD, SAN DIEGO, CA 92121 USA.							ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; BREARD J, 1980, J IMMUNOL, V124, P1943; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; CYBULSKY MI, 1988, LAB INVEST, V58, P365; DAVIES M, 1978, CLIN SCI MOL MED, V54, P233, DOI 10.1042/cs0540233; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; HARLAN JM, 1987, ACTA MED SCAND, P123; HARLAN JM, 1992, ADHESION ITS ROLE IN, P117; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HITZEMAN RA, 1990, METHOD ENZYMOL, V185, P421; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1985, EUR J IMMUNOL, V15, P713, DOI 10.1002/eji.1830150714; LO SK, 1989, J IMMUNOL, V143, P3325; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MIEDEMA F, 1984, EUR J IMMUNOL, V14, P518, DOI 10.1002/eji.1830140607; MILLER LJ, 1986, J IMMUNOL, V137, P2891; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; PRIETO J, 1988, IMMUNOLOGY, V63, P631; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH SM, 1987, GASTROENTEROLOGY, V93, P466, DOI 10.1016/0016-5085(87)90907-3; TONNESEN MG, 1989, J CLIN INVEST, V83, P637, DOI 10.1172/JCI113928; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLIS WJ, 1986, BLOOD, V67, P1007; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	40	208	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10008	10015						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7908286				2022-12-27	WOS:A1994NE05300092
J	SHAROM, FJ; YU, XH; DOIGE, CA				SHAROM, FJ; YU, XH; DOIGE, CA			FUNCTIONAL RECONSTITUTION OF DRUG TRANSPORT AND ATPASE ACTIVITY IN PROTEOLIPOSOMES CONTAINING PARTIALLY PURIFIED P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PERIPLASMIC PERMEASES; HAMSTER OVARY CELLS; MULTIDRUG-RESISTANCE; MEMBRANE-VESICLES; BINDING; PROTEIN; VINBLASTINE; HYDROLYSIS	P-glycoprotein, the multidrug transporter, is proposed to act as an ATP-driven drug efflux pump. We previously reported the partial purification of P-glycoprotein from multidrug-resistant cells (Doige, C. A., Yu, X., and Sharom, F. J. (1992) Biochim. Biophys. Acta 1109, 149-160). We now report the reconstitution of this preparation into phospholipid bilayers using rapid detergent removal by gel filtration chromatography. The resulting proteoliposomes displayed ATP-dependent [H-3]colchicine uptake over a time period of 0-4 min. No drug uptake was observed for liposomes of lipid alone, or liposomes reconstituted with a similar extract from drug-sensitive cells. Drug uptake was osmotically sensitive, and abolished by detergent permeabilization, indicating that it represented true transport into the vesicle lumen. Steady-state levels of drug uptake increased with drug concentration, approaching saturation at approximately 150 muM colchicine, with half-maximal accumulation at 50 muM. Drug was accumulated actively against a 5.6-fold concentration gradient. Multidrug resistance spectrum drugs and chemosensitizers inhibited colchicine uptake by P-glycoprotein proteoliposomes, whereas cytosine arabinoside and methotrexate had no effect. Reconstituted liposomes showed high levels of ATPase activity, which was stimulated over 2-fold by verapamil and trifluoperazine. These results suggest that P-glycoprotein functions as an active drug transporter with constitutive ATPase activity.			SHAROM, FJ (corresponding author), UNIV GUELPH,GUELPH WATERLOO CTR GRAD WORK CHEM,DEPT CHEM & BIOCHEM,GUELPH N1G 2W1,ONTARIO,CANADA.		Sharom, Frances/A-1613-2010	Sharom, Frances/0000-0002-9521-5367				AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CC, 1984, J BIOL CHEM, V259, P150; CHICKEN CA, 1983, BIOCHIM BIOPHYS ACTA, V729, P200, DOI 10.1016/0005-2736(83)90486-8; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Doige C A, 1991, Protein Expr Purif, V2, P256, DOI 10.1016/1046-5928(91)90081-S; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LOE DW, 1993, BRIT J CANCER, V68, P342, DOI 10.1038/bjc.1993.338; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; SAEKI T, 1992, BIOCHIM BIOPHYS ACTA, V1107, P105, DOI 10.1016/0005-2736(92)90334-I; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; VANZOELEN EJJ, 1978, EUR J BIOCHEM, V86, P539	23	253	258	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24197	24202						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7901214				2022-12-27	WOS:A1993MF29400072
J	CASELLI, A; CAMICI, G; MANAO, G; MONETI, G; PAZZAGLI, L; CAPPUGI, G; RAMPONI, G				CASELLI, A; CAMICI, G; MANAO, G; MONETI, G; PAZZAGLI, L; CAPPUGI, G; RAMPONI, G			NITRIC-OXIDE CAUSES INACTIVATION OF THE LOW-MOLECULAR-WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ACID-PHOSPHATASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TYROSINE PHOSPHATASES; S-NITROSYLATION; PURIFICATION; SEQUENCE; RECEPTOR; LIVER	The low M(r) phosphotyrosine protein phosphatase (PTPase) and Yersinia enterocolitica PTPase are inactivated by nitric oxide-generating compounds. Inorganic phosphate, a competitive inhibitor, protects the enzymes from inactivation, suggesting that the action of NO is directed to the active sites. Low M(r) PTPase from bovine liver lost two out of eight thiol groups present in the molecule during the inactivation with sodium nitro prusside and with other NO-producing compounds. The mass spectrometric analyses of tryptic fragments of the enzyme, performed after chemical modification of the NO-unreacted thiol groups, demonstrated that NO caused the oxidation of Cys-12 and Cys-17 to form an S-S bond. A similar reaction was described previously for the reaction of NO with N-methyl-D-aspartate receptor. The NO-inactivated low M(r) PTPase was reactivated by treating the inactive enzyme with thiol-containing reagents. Since all members of the PTPase family have the same reaction mechanism and possess a conserved active site motif that contains an essential cysteine residue, the findings on low M(r) and Yersinia PTPases are potentially interesting for all PTPases, an enzyme class that is involved in a number of important biological processes.	UNIV FLORENCE,DIPARTIMENTO SCI BIOCHIM,I-50134 FLORENCE,ITALY; UNIV FLORENCE,DIPARTIMENTO FARMACOL PRECLIN & CLIN,I-50134 FLORENCE,ITALY	University of Florence; University of Florence			Caselli, Anna/O-7512-2014; Camici, Giovanni/H-1631-2018	Caselli, Anna/0000-0001-8140-3415; Camici, Giovanni/0000-0002-0523-0695				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bates JN, 1990, BIOCHEM PHARMACOL, V42, P157, DOI DOI 10.1016/0006-2952(91)90406-U; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CASELLI A, 1994, J PROTEIN CHEM, V13, P107, DOI 10.1007/BF01891998; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; DISSING J, 1991, J BIOL CHEM, V266, P20619; FAULSTICH H, 1993, ANAL BIOCHEM, V208, P357, DOI 10.1006/abio.1993.1061; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; MANAO G, 1992, J PROTEIN CHEM, V11, P333, DOI 10.1007/BF01024871; MANAO G, 1991, 6TH P NAT M PROT 91, P96; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATAN C, 1992, FASEB J, V6, P3051; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; SHEKELS LL, 1992, PROTEIN SCI, V1, P710, DOI 10.1002/pro.5560010603; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; SU XD, 1994, FEBS LETT, V343, P107, DOI 10.1016/0014-5793(94)80299-8; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010	28	135	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24878	24882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929168				2022-12-27	WOS:A1994PQ49000055
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			FIS CANNOT SUPPORT ORIC DNA-REPLICATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; HISTONE-LIKE PROTEINS; PBR322 DNA; ENZYMATIC REPLICATION; ORIGIN; INITIATION; HU; BINDING; STRAND; IHF	The effects of the histone like proteins, HU, IHF, and Fis on DNA replication have been examined in vitro using the oriC and pBR322 DNA replication systems. In the oriC system, although low concentrations of HU and IHF stimulated DNA replication, no stimulation was observed upon the addition of Fis. On the contrary, high concentrations of Fis inhibited oriC DNA replication completely. The inhibitory effect of Fis could be overcome when HU, IHF, or RNA polymerase were also present in the reaction mixtures. Unwinding of duplex DNA at the origin correlated with the elevated level of DNA replication. In contrast, only inhibition, rather than stimulation, was observed when these proteins were added to the pBR322 DNA replication system. Thus, the observed dependence on Fis of oriC DNA replication in vivo cannot be attributed to a positive effect on localized DNA unwinding.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CROOKE E, 1991, RES MICROBIOL, V142, P127, DOI 10.1016/0923-2508(91)90019-7; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P2093; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23087; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KANO Y, 1992, GENE AMST, V126, P93; KORNBERG A, 1992, DNA REPLICATION, P523; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; POLACZEK P, 1990, New Biologist, V2, P265; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; ROTH A, 1994, IN PRESS BIOCHIMIE P; SKARSTAD K, 1993, J BIOL CHEM, V268, P5365; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SKARSTAD K, 1993, DNA REPLICATION CELL, V43, P15; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	40	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24999	25003						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929185				2022-12-27	WOS:A1994PQ49000072
J	NIIDOME, T; KITADA, S; SHIMOKATA, K; OGISHIMA, T; ITO, A				NIIDOME, T; KITADA, S; SHIMOKATA, K; OGISHIMA, T; ITO, A			ARGININE RESIDUES IN THE EXTENSION PEPTIDE ARE REQUIRED FOR CLEAVAGE OF A PRECURSOR BY MITOCHONDRIAL PROCESSING PEPTIDASE - DEMONSTRATION USING SYNTHETIC PEPTIDE AS A SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-ORNITHINE TRANSCARBAMYLASE; MALATE-DEHYDROGENASE; PROTEOLYTIC CLEAVAGE; PARTIAL-PURIFICATION; TRANSIT PEPTIDE; LEADER PEPTIDE; SIGNAL PEPTIDE; PROTEASE; PROTEINS; IMPORT	Mitochondrial processing peptidase (MPP) specifically recognizes a large variety of mitochondrial precursor proteins and correctly cleaves off the extension peptides. To determine the structure common to all the extension peptides that is required for specific recognition by MPP, we synthesized various oligopeptides of different chain lengths and amino acid sequences, based on the amino acid sequence of the extension peptide of pre-malate dehydrogenase, and determined kinetic parameters of the cleavage reactions. The minimal length of peptides for effective cleavage was 16 amino acid residues consisting of 11 and 5 residues from the cleavage site to the amino- and carboxyl-terminal sides, respectively. Two sets of basic amino acids in the peptide, the distal arginine residue at position -10 and the proximal ones at positions -3 and -2 relative to the cleavage site, were necessary for effective hydrolysis. Of these two, the residue at position -2 was more important for effective cleavage than the one at position -3 and could not be replaced by a lysine residue. The replacement of the distal arginine by lysine had no effect on the cleavage. Our study demonstrates that use of peptides with the proper length is essential for performing kinetic analyses on the cleavage reaction by MPP and that an arginine residue at position -2 to the cleavage site is necessary for the recognition and cleavage of the extension peptide.	KYUSHU UNIV, FAC SCI, DEPT CHEM, HIGASHI KU, FUKUOKA 812, JAPAN	Kyushu University			Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708				ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; CHU TW, 1987, J BIOL CHEM, V262, P12806; CHU TW, 1987, J BIOL CHEM, V262, P15759; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; FUJII N, 1987, CHEM PHARM BULL, V35, P3880; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; JOH T, 1987, BIOCHEMISTRY-US, V26, P2515, DOI 10.1021/bi00383a017; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KRAUS JP, 1988, P NATL ACAD SCI USA, V85, P8905, DOI 10.1073/pnas.85.23.8905; MCADA PC, 1982, J BIOL CHEM, V257, P3177; MIURA S, 1982, EUR J BIOCHEM, V122, P641; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSENBERG LE, 1986, ANN NY ACAD SCI, V488, P99; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; YANG M, 1991, J BIOL CHEM, V266, P6416; YEMM EW, 1955, ANALYST, V80, P209, DOI 10.1039/an9558000209; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	28	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24719	24722						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929146				2022-12-27	WOS:A1994PQ49000033
J	ZAIDI, SHE; DENMAN, R; MALTER, JS				ZAIDI, SHE; DENMAN, R; MALTER, JS			MULTIPLE PROTEINS INTERACT AT A UNIQUE CIS-ELEMENT IN THE 3'-UNTRANSLATED REGION OF AMYLOID PRECURSOR PROTEIN MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; MESSENGER-RNA DEGRADATION; ALZHEIMERS-DISEASE; 1ST STEP; EXPRESSION; CELLS; SEQUENCE; BRAIN; GENE	Growing evidence suggests that Alzheimer's disease results from dysregulated production and deposition of beta-amyloid in the central nervous system. beta-Amyloid is derived from proteolytic processing of one of multiple amyloid precursor protein (APP) isoforms. The production of APP in many somatic tissues and tumor cell lines provides a more accessible model to study the regulation of APP gene expression. Recent data suggest that APP mRNAs accumulate in activated lymphocytes and neuronal tumor lines. We are interested in defining the contribution of alterations in stability to changes in steady-state APP mRNA levels in these model systems. Herein we demonstrate by mobility shift assay that the 3'-untranslated region of APP RNAs which contain a contiguous 29-base region interacts in vitro with multiple mRNA-binding proteins found in cytosolic lysates prepared from normal and transformed human cells. UV cross-linking of radiolabeled APP RNAs to cytosolic protein extracts followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis identified six distinct RNA-protein complexes of 42, 47, 65, 73, 84, and 104 kDa Competition assays with APP, AU-rich, or irrelevant RNAs demonstrated that binding was specific and in some cases preferential for AU- or U-rich sequences by which we tentatively place the binding site of the proteins along the 29-base region. APP mRNA-binding proteins were constitutively active in all tumor lines examined as web as at diminished levels in whole human brain cytosolic lysates. The core element is AU-rich and highly conserved between human and some murine APP mRNAs. In the accompanying paper (Zaidi, S. H. E. and Malter, J. S. (1994) J. Biol. Chem. 269, 24007-24013) we show that this 29-base element in the 3'-untranslated region regulates the stability of APP mRNA. Cumulatively these data suggest that steady-state APP mRNA levels are modulated by cytosolic protein-RNA interactions.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, NEUROSCI PROGRAM, MADISON, WI 53792 USA; UNIV WISCONSIN, INST AGING, MADISON, WI 53792 USA; NEW YORK STATE INST BASIC RES DEV DISABIL, STATEN ISL, NY 10314 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Institute for Basic Research in Developmental Disabilities					NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER; NIA NIH HHS [AGO-4221, R01-AG 10675] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; ISHIURA S, 1991, J NEUROCHEM, V56, P363, DOI 10.1111/j.1471-4159.1991.tb08160.x; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MONNING U, 1992, J BIOL CHEM, V267, P23950; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PANTOPOULOS K, 1992, EUR J BIOCHEM, V207, P1045, DOI 10.1111/j.1432-1033.1992.tb17141.x; RAMAKRISHNA N, 1991, BIOCHEM BIOPH RES CO, V174, P983, DOI 10.1016/0006-291X(91)91515-E; SASSO MP, 1991, NUCLEIC ACIDS RES, V19, P6469, DOI 10.1093/nar/19.23.6469; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	26	54	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24000	24006						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929050				2022-12-27	WOS:A1994PQ34600026
J	HOOF, T; DEMMER, A; HADAM, MR; RIORDAN, JR; TUMMLER, B				HOOF, T; DEMMER, A; HADAM, MR; RIORDAN, JR; TUMMLER, B			CYSTIC FIBROSIS-TYPE MUTATIONAL ANALYSIS IN THE ATP-BINDING CASSETTE TRANSPORTER SIGNATURE OF HUMAN P-GLYCOPROTEIN MDR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HAMSTER OVARY CELLS; RESISTANT HUMAN-CELLS; MULTIDRUG-RESISTANCE; BACTERIAL TRANSPORT; ESCHERICHIA-COLI; CHLORIDE CHANNEL; CFTR GENE; DELTA-F508 MUTATION; EXPRESSION VECTOR	Members of the ATP-binding cassette transporter superfamily such as the P-glycoproteins (MDR) and the cystic fibrosis transmembrane conductance regulator (CFTR) share conserved sequence motifs in their nucleotide binding fold that are the major targets for CFTR mutations in patients with cystic fibrosis. Cystic fibrosis-type mutations were introduced at analogous positions into the human MDR1 gene. Heterologous expression of wild-type or mutated MDR1 revealed similar mRNA transcript levels in Chinese hamster ovary K1 recipients, but the subsequent processing was defective for all mutations that give rise to severe cystic fibrosis in the case of CFTR. Functional multidrug transporter MDR1, however, was obtained when amino acid substitutions were introduced into a less conserved position of the ATP-binding cassette transporter signature (codon 536 in MDR1). The profile of cross-resistance and chemosensitization was modulated in these codon 536 variants, which suggests that this region is involved in the drug transport function of P-glycoprotein.	HANNOVER MED SCH, PADIAT PNEUMOL ABT, D-30623 HANNOVER, GERMANY; HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO M5G 1X8, ON, CANADA	Hannover Medical School; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	HOOF, T (corresponding author), HANNOVER MED SCH, ZENTRUM BIOCHEM, BIOPHYS CHEM ABT, OE 4350, KONSTANTY GUTSCHOW STR 8, D-30623 HANNOVER, GERMANY.							AMES GF, 1986, CELL, V47, P323, DOI 10.1016/0092-8674(86)90585-4; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AMES GFL, 1992, ADV ENZYMOL RELAT AR, V6, P2660; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BUSCHE R, 1989, MOL PHARMACOL, V35, P414; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CABRAL F, 1980, CELL, V20, P29, DOI 10.1016/0092-8674(80)90231-7; CANOGAUCI DF, 1991, MOL CELLULAR BIOL MU, P337; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1991, MOL CELLULAR BIOL MU, P229; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DORK T, 1991, HUM GENET, V87, P441; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; Fonknechten N., 1992, Human Molecular Genetics, V1, P281, DOI 10.1093/hmg/1.4.281; GEIGER R, 1989, BIOCHEMISTRY-US, V28, P2667, DOI 10.1021/bi00432a046; GIBBS TW, 1992, MOL GEN GENET, V234, P121, DOI 10.1007/BF00272353; GILL DR, 1986, MOL GEN GENET, V205, P134, DOI 10.1007/BF02428043; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HAMADA H, 1991, MOL CELLULAR BIOL MU, P373; HAMOSH A, 1992, AM J HUM GENET, V51, P245; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOOF T, 1991, ANAL BIOCHEM, V196, P161, DOI 10.1016/0003-2697(91)90133-E; HOOF T, 1993, EUR J PHARM-MOLEC PH, V246, P53, DOI 10.1016/0922-4106(93)90009-X; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KOMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323; KRAMER W, 1981, NUCLEIC ACIDS RES, V8, P8441; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LING V, 1983, CANCER TREAT REP, V67, P869; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SANGIUOLO F, 1991, GENOMICS, V9, P788, DOI 10.1016/0888-7543(91)90380-W; SCHNEIDER E, 1991, MOL MICROBIOL, V5, P1375, DOI 10.1111/j.1365-2958.1991.tb00784.x; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SUGIMOTO Y, 1991, MOL CELLULAR BIOL MU, P57; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; TSURUO T, 1991, MOL CELLULAR BIOL MU, P349; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	80	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	1994	269	32					20575	20583						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PB317	7914197				2022-12-27	WOS:A1994PB31700058
J	ENGEL, AM; SCHOENFELD, JR; LOWE, DG				ENGEL, AM; SCHOENFELD, JR; LOWE, DG			A SINGLE RESIDUE DETERMINES THE DISTINCT PHARMACOLOGY OF RAT AND HUMAN NATRIURETIC PEPTIDE RECEPTOR-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CLEARANCE RECEPTOR; PROTEINS; SEQUENCE; FAILURE; ANALOGS; FAMILY	We report the cloning and expressing of rat natriuretic peptide receptor-C (NPR-C), which binds naturally occurring and synthetic ligands with higher affinity than human NPR-C. Using rat/human hybrids and site-directed mutagenesis, we identified residue 188, Ala for rat and Ile for human, which modulates hormone binding. Orthologous mutagenesis at position 188 for either rNPR-C or hNPR-C results in a complete reversal of the pharmacology. To our knowledge, this is the first example of a single transmembrane domain receptor for which a single residue dictates the ligand binding properties; previous examples are limited to seven transmembrane receptors.	GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOVY PR, 1990, MED RES REV, V10, P115, DOI 10.1002/med.2610100105; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; FULLER F, 1988, J BIOL CHEM, V263, P9395; KAMBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P599, DOI 10.1016/S0006-291X(05)80077-4; LEVIN ER, 1993, ENDOCRINOL METAB, V27, pE483; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1990, NUCLEIC ACIDS RES, V18, P3412, DOI 10.1093/nar/18.11.3412; MACCK T, 1992, ANN REV PHYSL, V54, P11; MIZUNO T, 1993, J BIOL CHEM, V268, P5162; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; NUTT RF, 1989, SYNTHETIC PEPTIDES A, P267; Sambrook J, 1989, MOL CLONING LABORATO; SHAW S, 1992, KIDNEY INT, V42, P1153, DOI 10.1038/ki.1992.399; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; THERIAULT Y, 1987, BIOPOLYMERS, V26, P1075, DOI 10.1002/bip.360260707; VONGELDERN TW, 1992, J MED CHEM, V35, P808, DOI 10.1021/jm00083a003; WEIS J, 1991, PHARMACOL TOXICOL, V68, P282, DOI 10.1111/j.1600-0773.1991.tb01239.x; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; YOSHIMURA M, 1991, CIRCULATION, V84, P1581, DOI 10.1161/01.CIR.84.4.1581; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	23	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 24	1994	269	25					17005	17008						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NT846	7911802				2022-12-27	WOS:A1994NT84600006
J	RANDI, AM; HOGG, N				RANDI, AM; HOGG, N			I-DOMAIN OF BETA(2) INTEGRIN LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 CONTAINS A BINDING-SITE FOR LIGAND INTERCELLULAR-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; LEUKOCYTE ADHESION; P150,95 MOLECULE; GLYCOPROTEIN; RECEPTOR; LFA-1; SUPERFAMILY; MECHANISMS; DISTINCT	Lymphocyte function-associated antigen-1 (LFA-1) is a beta(2) integrin that participates in a broad range of leukocyte functions through binding to its ligand intercellular adhesion molecule-1 (ICAM-1). The location of the ICAM-1 binding site on LFA-1 is not known. A similar to 200-amino acid ''inserted'' or ''I'' domain, which is part of the beta(2) integrin alpha subunit, is homologous to the ''A'' domains found in the adhesive protein von Willebrand factor and in a number of other proteins. In von Willebrand factor the A domains are involved in ligand binding, but their function in the other proteins is still unclear. In this report, we show that the LFA-1 I domain contains a binding site for ICAM-1, which can be expressed as an isolated functional unit. The I domain contains the epitopes for 18 out of 20 anti-LFA-1 monoclonal antibodies, many of which interfere with the interaction between LFA-1 and ICAM-1. The I domain binds directly to purified recombinant ICAM-1 and also inhibits LFA-1-dependent T cell adhesion to ICAM-1. This report establishes the I domain as an ICAM-1 binding region in LFA-1 and the first ligand binding site to be identified in a beta(2) integrin.	IMPERIAL CANC RES FUND,LEUKOCYTE ADHES LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; FLEMING JC, 1993, J IMMUNOL, V150, P480; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; HART MK, 1987, CELL IMMUNOL, V109, P306, DOI 10.1016/0008-8749(87)90314-5; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HOGG N, 1993, CURR OPIN IMMUNOL, V5, P383, DOI 10.1016/0952-7915(93)90057-Y; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KNOTT HM, 1992, BIOCHEMISTRY-US, V31, P11152, DOI 10.1021/bi00160a028; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; Luk John, 1993, Tissue Antigens, V42, P272; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHMIDT RE, 1989, LEUKOCYTE TYPING, V4, P517; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VONKOOYK Y, 1989, NATURE, V342, P811; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	37	143	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12395	12398						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909800				2022-12-27	WOS:A1994NH71600004
J	SEPULVEDA, AR; CARTER, BZ; HABIB, GM; LEBOVITZ, RM; LIEBERMAN, MW				SEPULVEDA, AR; CARTER, BZ; HABIB, GM; LEBOVITZ, RM; LIEBERMAN, MW			THE MOUSE GAMMA-GLUTAMYL-TRANSPEPTIDASE GENE IS TRANSCRIBED FROM AT LEAST 5 SEPARATE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; LIVER EPITHELIAL-CELLS; ALDOLASE-A GENE; RAT-LIVER; TRANSFERASE TRANSPEPTIDASE; RESPONSIVE ELEMENT; KIDNEY; SEQUENCE; ENHANCER; BINDING	The mouse gamma-glutamyl transpeptidase (gamma GT) gene encodes six distinct mRNAs that differ in their 5'-untranslated regions but appear to code for the same protein. To elucidate the mechanisms that generate these different mRNAs we determined the transcription start sites of gamma GT kidney mRNAs and investigated the ability of the 5'-flanking regions of mRNAs I, II, IV, V, and VI to direct transcription of chloramphenicol acetyltransferase (CAT) reporter gene constructs in a mouse kidney cell line. Types I, II, and VI mRNAs show heterogenous start sites, whereas types TV and V have more precise initiation sites. Only the type V 5'-flanking region contains a TATA-like element. The highest CAT activities were observed with 416 base pairs of type II and 240 base pairs of type IV flanking regions. We have also shown that types II and IV represent the predominant gamma GT mRNAs in kidney; therefore, these CAT activities correlate well with the relative amount of each gamma GT mRNA. This study shows that the mouse gamma GT gene is transcribed from at least five and possibly six different promoters. In addition, the gamma GT promoters show cell specificity because no significant CAT activity was detected when these constructs were introduced into NIH-3T3 fibroblasts.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NCI NIH HHS [CA-39392] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039392, R01CA039392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEER DG, 1987, ARCH TOXICOL, P68; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GARCIA M, 1986, EMBO J, V5, P127, DOI 10.1002/j.1460-2075.1986.tb04186.x; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GRIFFITHS SA, 1989, CANCER LETT, V46, P69, DOI 10.1016/0304-3835(89)90217-6; HABIB GM, 1992, MOL CARCINOGEN, V5, P75; HANIGAN MH, 1985, CARCINOGENESIS, V6, P165, DOI 10.1093/carcin/6.2.165; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P21; JACQUEMIN E, 1990, J PEDIATR GASTR NUTR, V11, P89, DOI 10.1097/00005176-199007000-00018; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KURAUCHI O, 1991, BIOCHEMISTRY-US, V30, P1618, DOI 10.1021/bi00220a025; LAHUNA O, 1992, BIOCHEMISTRY-US, V31, P9190, DOI 10.1021/bi00153a011; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI Y, 1989, ONCOGENE, V4, P795; LI YC, 1988, P NATL ACAD SCI USA, V85, P344, DOI 10.1073/pnas.85.2.344; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; RAJAGOPALAN S, 1990, J BIOL CHEM, V265, P11721; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SIEGRIST S, 1990, BIOCHEM J, V267, P621, DOI 10.1042/bj2670621; SINHA S, 1986, CANCER RES, V46, P1440; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TATE SS, 1985, METHOD ENZYMOL, V113, P400; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; VINA J, 1990, GLUTATHIONE METABOLI, P79; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WUTHRICH RP, 1990, KIDNEY INT, V37, P783, DOI 10.1038/ki.1990.46	47	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10699	10705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908294				2022-12-27	WOS:A1994NF01700076
J	JOSHI, AA; MCDONALD, MJ				JOSHI, AA; MCDONALD, MJ			ROLE OF ALPHA-CARBOXYL-TERMINAL AND BETA-CARBOXYL-TERMINAL RESIDUES IN THE KINETICS OF HUMAN OXYHEMOGLOBIN DIMER ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-HEMOGLOBIN; CHAIN; STATE	Human oxyhemoglobin assembly was evaluated in the Soret region by rapidly mixing normal and carboxypeptidase-digested chains (1-10 x 10(-6) M, heme basis) in 0.1 M Tris-HCl, 0.1 M NaCl, 1 mM EDTA, pH 7.4, at 21.5 degrees C. Rate constants of 1.14 (+/- 0.09) and 2.11 (+/- 0.06) x 10(5) M(-1) s(-1) were measured for the association of Des(Arg-141)alpha with beta(A) and alpha(A) with beta(A) chains, respectively. The slower combination rate of Des(Arg-141)alpha with beta(A) chains is in agreement with that predicted solely on the basis of electrostatic considerations, as are the measured rate constants of 0.75 (+/- 0.12) and 1.86 (+/- 0.08) x 10(5) M(-1) s(-1) obtained for the combination of Des(Arg-141)alpha with variant beta(S) (Glu-6 --> Val) and beta(N Baltimore) (Lys-95 --> Glu) chains, respectively. However, the combination rates of alpha(A) and Des(Arg-141)alpha with beta(A) chains measured in the pH range from 7.0 to 9.0 demonstrated that the altered overall surface charge was not the only determinant of the assembly rates observed for Des(Arg-141)alpha chains. Furthermore, a rate constant of 11.3 (+/- 0.05) x 10(5) M(-1) s(-1) (which is 5.4-fold faster than the rate of alpha(A) beta(A) dimer assembly) was observed for Des(His-146,Tyr-145)beta chains. These kinetic studies suggest a critical role for the carboxyl-terminal domain in the assembly of human hemoglobin in vitro and perhaps in vivo.	UNIV MASSACHUSETTS,COLL ARTS & SCI,DEPT CHEM,BIOCHEM PROGRAM,LOWELL,MA 01854	University of Massachusetts System; University of Massachusetts Lowell					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038456] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; ANTONINI E, 1966, J MOL BIOL, V17, P29, DOI 10.1016/S0022-2836(66)80092-X; ARNONE A, 1982, HEMOGLOBIN OXYGEN BI, P127; BAUDIN V, 1993, PROTEIN SCI, V2, P1320, DOI 10.1002/pro.5560020815; BONAVENT.J, 1972, P NATL ACAD SCI USA, V69, P2174, DOI 10.1073/pnas.69.8.2174; BUCCI E, 1965, J BIOL CHEM, V240, pPC551; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1987, BLOOD, V69, P1; CHIANCONE E, 1974, J BIOL CHEM, V249, P5689; Creighton T.E., 1992, PROTEIN FOLDING, P405; FRIEDMAN FK, 1979, ANNU REV BIOCHEM, V48, P217, DOI 10.1146/annurev.bi.48.070179.001245; HEWITT JA, 1973, J MOL BIOL, V74, P489, DOI 10.1016/0022-2836(73)90041-7; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAWAMURA Y, 1983, J BIOCHEM-TOKYO, V93, P1159, DOI 10.1093/oxfordjournals.jbchem.a134241; Kilmartin J V, 1981, Methods Enzymol, V76, P167; KILMARTIN JV, 1970, NATURE, V228, P766, DOI 10.1038/228766a0; KURTZ A, 1978, BIOCHEM BIOPH RES CO, V84, P852, DOI 10.1016/0006-291X(78)91662-5; KWIATKOWSKI LD, 1982, J BIOL CHEM, V257, P8891; MCDONALD MJ, 1981, J BIOL CHEM, V256, P6487; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; MCGOVERN P, 1976, J BIOL CHEM, V251, P7871; MRABET NT, 1986, J BIOL CHEM, V261, P5222; PERUTZ MF, 1971, COLD SPRING HARB SYM, V36, P295; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; POYART C, 1980, J BIOL CHEM, V255, P9465; ROLLEMA HS, 1980, J BIOL CHEM, V255, P2756; SUGITA Y, 1975, J BIOL CHEM, V250, P1251; TURCI SM, 1985, J CHROMATOGR, V343, P168, DOI 10.1016/S0378-4347(00)84581-8; VALDES R, 1977, J BIOL CHEM, V252, P74; WINSLOW RM, 1976, J CLIN INVEST, V57, P772, DOI 10.1172/JCI108336	30	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8549	8553						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7907594				2022-12-27	WOS:A1994NB40900108
J	CHEN, M; CHEN, LR; FROMM, HJ				CHEN, M; CHEN, LR; FROMM, HJ			REPLACEMENT OF GLUTAMIC-ACID-29 WITH GLUTAMINE LEADS TO A LOSS OF COOPERATIVITY FOR AMP WITH PORCINE FRUCTOSE-1,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; 2.8-A RESOLUTION; INHIBITION; PHOSPHOFRUCTOKINASE; BISPHOSPHATASE; STIMULATOR; MECHANISM; GLUCAGON; GLUCOSE	Mutations in the AMP binding site of porcine fructose-1,6-bisphosphatase were carried out by site-specific mutagenesis based on the crystal structure of the enzyme (Re, Ef., Zhang, Y., and Lipscomb, m. L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5243-5247). The mutant and wild-type enzymes were characterized by SDS-polyacrylamide gel electrophoresis, circular dichroism spectrometry, and initial rate kinetics. One of the mutant forms of fructose-1,6-bisphosphatase, Glu-29 --> Gln, is ligated to the phosphoryl moiety of AMP, a potent inhibitor of the reaction, whereas the other mutant, Thr-31 --> Val, is associated with the purine base of AMP. No discernible alteration in structure as measured by circular dichroism spectrometry was noted for the mutants relative to the wild-type enzyme. As expected, major changes in kinetic parameters between the mutants and the wild-type enzyme were associated with inhibition by AMP. AMP, a competitive inhibitor with respect to Mg2+ in the fructose-1,6-bisphosphatase reaction, exhibits cooperativity in the case of the wild-type and the mutant Thr-31 --> Val enzymes with a Hill coefficient of 2.0. On the other hand, cooperativity is completely lost in the case of Glu-29 --> Gln fructose-1,6-bisphosphatase.			CHEN, M (corresponding author), IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA.		Chen, Meng/C-7109-2014	Chen, Meng/0000-0003-0351-5897	NINDS NIH HHS [NS10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHEN LR, 1993, ARCH BIOCHEM BIOPHYS, V307, P350, DOI 10.1006/abbi.1993.1599; ELMAGHRABI MR, 1992, J BIOL CHEM, V267, P6526; Gomori G, 1943, J BIOL CHEM, V148, P139; HERS HG, 1982, BIOCHEM J, V206, P1; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1989, P NATL ACAD SCI USA, V86, P1475, DOI 10.1073/pnas.86.5.1475; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; OPIE LH, 1967, BIOCHEM J, V104, P353, DOI 10.1042/bj1040353; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1980, BIOCHEM BIOPH RES CO, V96, P1524; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897	28	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5554	5558						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7907084				2022-12-27	WOS:A1994MY84000016
J	TOYOFUKU, T; KURZYDLOWSKI, K; TADA, M; MACLENNAN, DH				TOYOFUKU, T; KURZYDLOWSKI, K; TADA, M; MACLENNAN, DH			AMINO-ACIDS GLU(2) TO ILE(18) IN THE CYTOPLASMIC DOMAIN OF PHOSPHOLAMBAN ARE ESSENTIAL FOR FUNCTIONAL ASSOCIATION WITH THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN KINASE; SITE-SPECIFIC MUTAGENESIS; CALCIUM-TRANSPORT; CA-2+ TRANSPORT; PUMP ATPASE; PHOSPHORYLATION; MECHANISM; SEQUENCE; RECONSTITUTION; CA-2+-ATPASE	Phospholamban inhibits the Ca2+-ATPase of cardiac sarcoplasmic reticulum by lowering its affinity for Ca2+. In earlier studies (Toyofuku, T., Kazimierz, K., Tada, M., and MacLennan, D. H. (1993) J. Biol. Chem. 268, 2809-2815), parts of the phosphorylation and nucleotide binding/hinge domains of the Ca2+-ATPase were shown to be essential for phospholamban interaction. In order to identify the sites in phospholamban which interact with the Ca2+-ATPase, a series of mutants containing amino acid replacements in the cytoplasmic and transmembrane regions of phospholamban were co-expressed with the cardiac/slow-twitch muscle Ca2+-ATPase isozyme, SERCA2a, in HEK-293 cells. Mutation of residues in the cytoplasmic 1A domain of phospholamban, including positively charged residues, Lys3, Arg9, Arg13, and Arg14, negatively charged residue, Glu2, hydrophobic residues, Val4, Leu7, Ala11, Ile12, Ala15, and Ile18, and phosphorylation site residues, Ser16 and Thr17, resulted in loss of the inhibitory effect of phospholamban on Ca2+ transport by the Ca2+-ATPase. By contrast, mutation of Met1, Gln5, Tyr6, Thr8, Ser10, Glu19, or Met20 or of residues in the cytoplasmic 1B domain (Pro21 to Asn30) and of Cys41 in the transmembrane domain (Leu31 to Leu52) did not diminish the inhibitory effects of phospholamban on Ca2+ transport. These results suggest that a region essential for functional association of phospholamban with the Ca2+-ATPase lies in the cytoplasmic 1A domain of phospholamban.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA; OSAKA UNIV,SCH MED,DEPT MED 1,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOPHYSIOL,OSAKA 565,JAPAN	University of Toronto; Osaka University; Osaka University								CHIESI M, 1989, FEBS LETT, V244, P241, DOI 10.1016/0014-5793(89)81201-3; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; COLYER J, 1991, J BIOL CHEM, V266, P17486; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INUI M, 1986, J BIOL CHEM, V261, P1794; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KIM HW, 1990, J BIOL CHEM, V265, P1702; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUZUKI T, 1986, J BIOL CHEM, V261, P7081; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1974, J BIOL CHEM, V249, P6174; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TERZI E, 1992, FEBS LETT, V309, P413, DOI 10.1016/0014-5793(92)80819-3; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; XU ZC, 1989, J BIOL CHEM, V264, P16644; YOUNG EF, 1989, MEMBRANE BIOCHEM, V8, P95, DOI 10.3109/09687688909082263	32	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3088	3094						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905483				2022-12-27	WOS:A1994MV43200104
J	ZIMNIAK, P; SINGHAL, SS; SRIVASTAVA, SK; AWASTHI, S; SHARMA, R; HAYDEN, JB; AWASTHI, YC				ZIMNIAK, P; SINGHAL, SS; SRIVASTAVA, SK; AWASTHI, S; SHARMA, R; HAYDEN, JB; AWASTHI, YC			ESTIMATION OF GENOMIC COMPLEXITY, HETEROLOGOUS EXPRESSION, AND ENZYMATIC CHARACTERIZATION OF MOUSE GLUTATHIONE-S-TRANSFERASE MGSTA4-4 (GST-5.7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CATALYTIC ACTIVITY; RAT-LIVER; HUMAN LUNG; PURIFICATION; PROTEINS; CLONING; ISOZYMES; ACID; STEP	We have previously isolated a cDNA clone for a unique mouse lung glutathione S-transferase, mGSTA4-4 (GST 5.7) (Zimniak, P., Eckles, M. A., Saxena, M., and Awasthi, Y. C. (1992) FEBS Lett. 313,173-176). By genomic Southern blotting and polymerase chain reaction single strand conformation polymorphism analysis we have now demonstrated the presence of at least two mGSTA4-related genes in the mouse. The heterogeneity of mGSTA4-4 was further examined by comparing the structural and kinetic properties of mGSTA4-4 isolated from mouse lung with those of recomhinant recmGSTA4-4 expressed in Escherichia coli. Except for the isoelectric point, the physical properties of the two proteins were indistinguishable. Western blots using antibodies against rec-mGSTA4-4 have shown selective expression of the enzyme in mouse tissues. Even though the substrate specificity profiles of the tissue-isolated and recombinant enzymes, which point to a role of mGSTA4-4 in the detoxification of lipid peroxidation products, were generally similar, significant differences were observed with selected substrates. The existence of functionally distinct forms of mGSTA4-4 and the presence of more than one gene strongly suggest that the previously observed differences in properties of mGSTA4-4 isolated from various mouse tissues (Awasthi, S., Singhal, S. S., Srivastava, S. K., and Awasthi, Y. C. (1993) Arch. Biochem. Biophys. 301, 143-150) may be due to tissue-specific expression of mGSTA4-related genes.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, 2138 MED RES BLDG, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, DEPT INTERNAL MED, GALVESTON, TX 77550 USA; UNIV ARKANSAS MED SCI HOSP, DEPT MED, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA; VET ADM JOHN MCCLELLAN MEM HOSP, LITTLE ROCK, AR USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences			Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NATIONAL CANCER INSTITUTE [R01CA027967] Funding Source: NIH RePORTER; NCI NIH HHS [CA-27967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD H, 1988, ARCH BIOCHEM BIOPHYS, V266, P416, DOI 10.1016/0003-9861(88)90273-1; AHMAD H, 1989, ENZYME, V42, P129, DOI 10.1159/000469022; ALIN P, 1989, BIOCHEM J, V261, P531, DOI 10.1042/bj2610531; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AWASTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1164, P173, DOI 10.1016/0167-4838(93)90245-M; AWASTHI S, 1993, ARCH BIOCHEM BIOPHYS, V301, P143, DOI 10.1006/abbi.1993.1126; AWASTHI YC, 1975, J BIOL CHEM, V250, P5144; AWASTHI YC, 1985, COMP BIOCHEM PHYS B, V82, P17, DOI 10.1016/0305-0491(85)90121-X; BALDINO F, 1989, METHOD ENZYMOL, V168, P761; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; CHANG LH, 1993, EUR J BIOCHEM, V211, P805, DOI 10.1111/j.1432-1033.1993.tb17612.x; CHANG LH, 1992, BIOCHEM J, V281, P545, DOI 10.1042/bj2810545; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUAN YJ, 1988, J BIOL CHEM, V263, P19003; GOON D, 1993, TOXICOL APPL PHARM, V119, P175, DOI 10.1006/taap.1993.1058; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HE M, 1990, NUCLEIC ACIDS RES, V18, P1660, DOI 10.1093/nar/18.6.1660; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JENSSON H, 1986, FEBS LETT, V203, P207, DOI 10.1016/0014-5793(86)80743-8; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON JA, 1992, BIOCHEM J, V282, P279, DOI 10.1042/bj2820279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEDH RD, 1991, BIOCHEM J, V278, P793, DOI 10.1042/bj2780793; MEDH RD, 1990, CLIN CHEM ENZYM COMM, V3, P267; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SHARMA R, 1991, J BIOCHEM TOXICOL, V6, P147, DOI 10.1002/jbt.2570060209; SHARMA R, 1993, COMP BIOCHEM PHYS C, V105, P31, DOI 10.1016/0742-8413(93)90053-N; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SINGHAL SS, 1992, ARCH BIOCHEM BIOPHYS, V299, P232, DOI 10.1016/0003-9861(92)90269-3; SINGHAL SS, 1991, ARCH BIOCHEM BIOPHYS, V285, P64, DOI 10.1016/0003-9861(91)90329-H; SINGHAL SS, 1990, ARCH BIOCHEM BIOPHYS, V279, P45, DOI 10.1016/0003-9861(90)90461-7; SINGHAL SS, 1992, BIOCHIM BIOPHYS ACTA, V1116, P137, DOI 10.1016/0304-4165(92)90110-G; SINGHAL SS, 1991, BIOCHIM BIOPHYS ACTA, V1079, P285, DOI 10.1016/0167-4838(91)90071-7; SRIVASTAVA SK, 1993, BIOCHEM ARCH, V9, P73; STENBERG G, 1992, BIOCHEM J, V284, P313, DOI 10.1042/bj2840313; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TELAKOWSKIHOPKINS CA, 1986, P NATL ACAD SCI USA, V83, P9393, DOI 10.1073/pnas.83.24.9393; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; ZIMNIAK P, 1992, FEBS LETT, V313, P173, DOI 10.1016/0014-5793(92)81438-R; ZIMNIAK P, 1993, HDB EXPT PHARM, V105, P123	56	113	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					992	1000						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904605				2022-12-27	WOS:A1994MR22000036
J	SADDIK, M; GAMBLE, J; WITTERS, LA; LOPASCHUK, GD				SADDIK, M; GAMBLE, J; WITTERS, LA; LOPASCHUK, GD			ACETYL-COA CARBOXYLASE REGULATION OF FATTY-ACID OXIDATION IN THE HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; RAT-HEART; CARNITINE PALMITOYLTRANSFERASE; MALONYL-COA; PHOSPHORYLATION STATE; LIVER-MITOCHONDRIA; PROTEIN-KINASE; MESSENGER-RNA; KI VALUES; INHIBITION	The role of acetyl-coenzyme A carboxylase (ACC) in regulating fatty acid oxidation was investigated in isolated fatty acid perfused working rat hearts. Overall fatty acid oxidation rates were determined by addition of 1.2 mM [H-3]palmitate to the perfusate of hearts in which the endogenous triglyceride pool was prelabeled with [C-14]palmitate. Rates of both exogenous and endogenous fatty acid oxidation were measured by simultaneous measurement of (H2O)-H-3 and (CO2)-C-14 production, respectively. A second series of hearts were perfused under similar conditions except that [U-C-14]glucose was present in the perfusate for measurement of glucose oxidation rates. Addition of dichloroacetate (DCA, 1 mM) to the perfusate resulted in a dramatic stimulation of glucose oxidation (a 411% increase), with a parallel decrease in fatty acid oxidation (from 305 +/- 51 to 206 +/- 40 nmol/g dry weight.min.unit work). DCA treatment increased the contribution of glucose oxidation to ATP production from 7.1 to 30.6%, while decreasing the contribution of overall fatty acid oxidation from 92.9 to 69.4%. Tissue levels of malonyl-CoA in hearts treated with DCA were higher compared to controls (14.0 +/- 0.6 and 10.0 +/- 0.7 nmol/g dry weight, respectively) and were negatively correlated (r = -0.85) with overall fatty acid oxidation rates. Acetyl-CoA levels were also significantly higher in DCA-treated hearts, and a positive correlation (r = 0.88) was seen between myocardial acetyl-CoA and malonyl-CoA levels. This suggests that DCA treatment increased the supply of acetyl-CoA for ACC. Western blots revealed the presence of both the 280-kDa (ACC-280) and the 265-kDa (ACC-265) isoforms of ACC in cardiac tissue, with a predominance of ACC-280. The activity of ACC extracted from hearts was similar in both groups when assayed under optimal conditions of acetyl-CoA and citrate. However, using affinity purified ACC, it was demonstrated that heart ACC (predominantly ACC-280) had a higher K(m) for acetyl-CoA than ACC isolated from white adipose tissue (predominantly ACC-265). We conclude that ACC is an important regulator of fatty acid oxidation in the heart and that acetyl-CoA supply is a key determinant of heart ACC-280 activity. As acetyl-CoA levels increase, ACC-280 is activated resulting in an increase in malonyl-CoA inhibition of fatty acid oxidation.	UNIV ALBERTA, DEPT PEDIAT, CARDIOVASC DIS RES GRP, 423 HERITAGE MED RES BLDG, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT PHARMACOL, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2S2, AB, CANADA; DARTMOUTH COLL, HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED, DIV ENDOCRINE METAB, HANOVER, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT BIOCHEM, HANOVER, NH 03756 USA	University of Alberta; University of Alberta; Dartmouth College; Dartmouth College					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BOWYER DE, 1977, J CHROMATOGR, V143, P473, DOI 10.1016/S0378-4347(00)81794-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; BRODERICK TL, 1992, J BIOL CHEM, V267, P3758; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1987, J BIOL CHEM, V262, P2050; COOK GA, 1992, MOL CELL BIOCHEM, V116, P39, DOI 10.1007/BF01270567; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; HOLLAND R, 1984, EUR J BIOCHEM, V140, P325, DOI 10.1111/j.1432-1033.1984.tb08105.x; HULSMANN WC, 1966, BIOCHIM BIOPHYS ACTA, V178, P137; IDELLWENGER JA, 1982, ANAL BIOCHEM, V125, P269, DOI 10.1016/0003-2697(82)90006-9; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; JAMIL H, 1987, J BIOL CHEM, V262, P638; JAMIL H, 1987, J BIOL CHEM, V262, P630; KING MT, 1988, METHOD ENZYMOL, V166, P70; KONG IS, 1990, J BIOL CHEM, V265, P13695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE MD, 1979, CRC CR REV BIOCH MOL, V7, P121, DOI 10.3109/10409237909105429; LOPASCHUK GD, 1992, MOL CELL BIOCHEM, V116, P111, DOI 10.1007/BF01270577; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LYSIAK W, 1986, J BIOL CHEM, V261, P3698; LYSIAK W, 1988, J BIOL CHEM, V263, P1151; MABROUK GM, 1990, J BIOL CHEM, V265, P6330; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PAULSON DJ, 1984, FEBS LETT, V176, P381, DOI 10.1016/0014-5793(84)81201-6; PEARSON DJ, 1967, BIOCHEM J, V105, P953, DOI 10.1042/bj1050953; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SCHOLTE HR, 1986, FEBS LETT, V198, P47, DOI 10.1016/0014-5793(86)81182-6; SINGH B, 1984, ANAL BIOCHEM, V138, P107, DOI 10.1016/0003-2697(84)90776-0; SWENSON TL, 1985, J BIOL CHEM, V260, P3791; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; TRUMBLE GE, 1991, LIFE SCI, V49, P39, DOI 10.1016/0024-3205(91)90577-X; WAKIL SJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P225, DOI 10.1016/0006-3002(58)90177-X; Williamson J R, 1979, Methods Enzymol, V55, P200; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1986, ADV PROTEIN PHOSPHAT, V3, P201	43	315	322	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25836	25845						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902355				2022-12-27	WOS:A1993MK10000081
J	BEAUMELLE, B; ALAMI, M; HOPKINS, CR				BEAUMELLE, B; ALAMI, M; HOPKINS, CR			ATP-DEPENDENT TRANSLOCATION OF RICIN ACROSS THE MEMBRANE OF PURIFIED ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; A-CHAIN IMMUNOTOXINS; CYTO-TOXIC ACTIVITY; DIPHTHERIA-TOXIN; BREFELDIN-A; PROTEIN TRANSLOCATION; INTERNALIZED RICIN; B-CHAIN; CELLS; LYMPHOCYTES	Ricin translocation was demonstrated (using both fluorescence- and radiolabel-based assays) across the membrane of endosomes purified from mouse lymphocytes. Selectivity of the process was shown by the absence of translocation 'activity of transferrin and horseradish peroxidase used as membrane-bound and fluid-phase endosome labels, respectively. Endocytosed I-125-ricin translocation was found to be strictly ATP- (K(m) almost-equal-to 4 mM) and temperature-dependent, with up to 30% endosomal I-125-ricin appearing in the external medium after 2 h at 37-degrees-C. No treatments neutralizing the acidic endosome pH (ammonium chloride, nigericin, chloroquine) significantly impaired ricin translocation, and the pH gradient across the endosome membrane is not required for this process. Chase experiments showed that the ability of I-125-ricin to translocate increases with its depth in the endocytic system (i.e. plasma membrane << early endosomes < late endosomes). Both A and B ricin chains displayed translocation ability as demonstrated by the results of our assay on ricin, ricin B, transferrin-ricin A, and transferrin-ricin B conjugates. Biological activity of both ricin chains is preserved after translocation as shown by the inhibitory effect of the A chain on cell-free protein synthesis and the binding of the B chain to lactose-agarose.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND; UNIV LONDON UNIV COLL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND	Imperial College London; University of London; University College London	BEAUMELLE, B (corresponding author), UNIV MONTPELLIER 2, DEPT BIOL SANTE, CNRS, URA 530, CASE 107, F-34095 MONTPELLIER 5, FRANCE.			Beaumelle, Bruno/0000-0002-4912-9134				BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; CALAFAT J, 1988, CANCER RES, V48, P3822; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CARRIERE D, 1989, EXP CELL RES, V182, P114, DOI 10.1016/0014-4827(89)90284-X; CREWS JR, 1992, INT J CANCER, V51, P772, DOI 10.1002/ijc.2910510518; DIAZ R, 1988, J BIOL CHEM, V263, P6093; EMMANUEL F, 1988, ANAL BIOCHEM, V173, P134, DOI 10.1016/0003-2697(88)90170-4; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRENOY JP, 1992, BIOCHEM J, V284, P249, DOI 10.1042/bj2840249; HOWELL KE, 1989, TRENDS BIOCHEM SCI, V14, P44, DOI 10.1016/0968-0004(89)90040-6; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; HUNZIKER W, 1992, FEBS LETT, V307, P93, DOI 10.1016/0014-5793(92)80908-Y; HURTLEY SM, 1990, TRENDS BIOCHEM SCI, V15, P211, DOI 10.1016/0968-0004(90)90026-8; ISHIDA B, 1983, J BIOL CHEM, V258, P5933; KNOWLES PP, 1987, ANAL BIOCHEM, V160, P440, DOI 10.1016/0003-2697(87)90073-X; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Meyer D I, 1991, Trends Cell Biol, V1, P154, DOI 10.1016/0962-8924(91)90016-3; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S, 1988, Cancer Treat Res, V37, P39; OLSNES S, 1989, IMMUNOL TODAY, V10, P291; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PREIJERS FWMB, 1988, BRIT J HAEMATOL, V70, P289, DOI 10.1111/j.1365-2141.1988.tb02484.x; PRESS OW, 1988, J IMMUNOL, V141, P4410; RASO V, 1984, J BIOL CHEM, V259, P1143; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; TIMAR J, 1991, BRIT J CANCER, V64, P655, DOI 10.1038/bjc.1991.377; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VANDEURS B, 1985, EXP CELL RES, V159, P287, DOI 10.1016/S0014-4827(85)80003-3; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; Vitetta E S, 1991, Semin Cell Biol, V2, P47; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WARGALLA UC, 1989, P NATL ACAD SCI USA, V86, P5146, DOI 10.1073/pnas.86.13.5146; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; YOULE RJ, 1987, J BIOL CHEM, V262, P4676	48	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23661	23669						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7901210				2022-12-27	WOS:A1993MF51500106
J	ORMO, M; REGNSTROM, K; WANG, ZG; QUE, L; SAHLIN, M; SJOBERG, BM				ORMO, M; REGNSTROM, K; WANG, ZG; QUE, L; SAHLIN, M; SJOBERG, BM			RESIDUES IMPORTANT FOR RADICAL STABILITY IN RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHENOTYPIC SELECTION; SUBUNIT INTERACTION; PHOTOSYSTEM-II; IRON CENTER; PROTEIN R2; ACTIVATION; MECHANISM; SYSTEM; DNA	The R2 protein of ribonucleotide reductase contains at the side chain of tyrosine 122 a stable free radical, which is essential for enzyme catalysis. The tyrosyl radical is buried in the protein matrix close to a dinuclear iron center and a cluster of three hydrophobic residues (Phe 208, Phe-212, and Ile-234) conserved throughout the R2 family. A key step in the generation of the tyrosyl radical is the activation of molecular oxygen at the iron center. It has been suggested that the hydrophobic cluster provides an inert binding pocket for molecular oxygen bound to the iron center and that it may play a role in directing the oxidative power of a highly reactive intermediate toward tyrosine 122. We have tested these hypotheses by constructing the following mutant R2 proteins: F208Y, F212Y, F212W, and I234N. The resulting mutant proteins all have the ability to form a tyrosine radical, which indicates that binding of molecular oxygen can occur. In the case of F208Y, the yield of tyrosyl radical is substantially lower than in the wild-type case. A competing reaction resulting in hydroxylation of Tyr-208 implies that the phenylalanine at position 208 may influence the choice of target for electron abstraction. The most prominent result is that all mutant proteins show impaired radical half-life; in three of the four mutants, the half-lives are several orders of magnitude shorter than that of the wild type radical. This suggests that the major role of the hydrophobic pocket is to stabilize the tyrosyl radical. This hypothesis is corroborated by comparative studies of the environment of other naturally occurring tyrosyl radicals.	UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA	Stockholm University; University of Minnesota System; University of Minnesota Twin Cities				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, NATURE, V361, P276, DOI 10.1038/361276a0; ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1992, J BIOL CHEM, V267, P20682; Bernitz U, 1993, NYA KONKURRENSLAGEN; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; GREENE PJ, 1974, METHODS MOLECULAR BI, V7, P87; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LARSSON A, 1988, J BIOL CHEM, V263, P17780; LING JS, 1994, J BIOL CHEM, V269, P5595; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1992, J BIOL CHEM, V267, P8711; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REGNSTROM K, 1994, J BIOL CHEM, V269, P6355; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SAHLIN M, 1982, J BIOL CHEM, V257, P366; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1980, J BIOL CHEM, V255, P8027; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; TWEEDY NB, 1990, BIOCHEMISTRY-US, V29, P1539, DOI 10.1021/bi00458a027; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; ZHANG JH, 1992, P NATL ACAD SCI USA, V89, P7065, DOI 10.1073/pnas.89.15.7065	43	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6570	6576		10.1074/jbc.270.12.6570	http://dx.doi.org/10.1074/jbc.270.12.6570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896794	hybrid			2022-12-27	WOS:A1995QQ85500024
J	CAZAUBON, SM; RAMOSMORALES, F; FISCHER, S; SCHWEIGHOFFER, F; STROSBERG, AD; COURAUD, PO				CAZAUBON, SM; RAMOSMORALES, F; FISCHER, S; SCHWEIGHOFFER, F; STROSBERG, AD; COURAUD, PO			ENDOTHELIN INDUCES TYROSINE PHOSPHORYLATION AND GRB2 ASSOCIATION OF SHC IN ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P42/MITOGEN-ACTIVATED PROTEIN-KINASE; SIGNAL TRANSDUCTION; MAP KINASE; RAS; ACTIVATION; RAF-1; RECEPTORS; INTERACTS; PATHWAY; FAMILY	While the mitogen-activated protein kinase (MAPK) pathway coupled to receptor tyrosine kinases has been largely clarified, little is known about MAPK activation mediated by heterotrimeric G protein coupled receptors. In a previous study, it has been shown that endothelin-1 (ET-1) signaling through heterotrimeric G protein-coupled receptors stimulates MAPK activity in primary cultures of astrocytes (Cazaubon, S., Parker, P. J., Strosberg, A. D., and Couraud, P. O. (1993) Biochem. J. 293, 381-386). To clarify the molecular mechanism responsible for this response, involvement of the adapter proteins, Shc and Grb2, has now keen investigated. It is shown here that in these cells, ET-1 stimulates tyrosine phosphorylation of Shc, resulting in its stable association with Grb2 but not with Grb3-3, a Grb2 isoform with partially deleted SH2 domain. These results demonstrate that tyrosine-phosphorylated She specifically interacts with the SH2 domain of Grb2. This response was rapid and transient, showing a maximum at 10 min and declining at 60 min. Interestingly, direct activation of G proteins by fluoroaluminate mimics the ET-1 effect. In addition, a shift to a higher apparent molecular mass of Raf-1 kinase, likely reflecting its hyperphosphorylation, was also detected in ET-1-treated cells. These data strongly suggest that ET-1-induced MAPK activation is a G protein-coupled pathway that involves Shc, Grb2, and probably Raf-1. In conclusion, the Shc-Grb2 complex may be involved in the activation of the MAPK pathway, not only by several receptor tyrosine kinases but also by heterotrimeric G protein-coupled receptors, such as ET-1 receptors.	HOP COCHIN,ONCOL CELLULAIRE & MOLEC LAB,INSERM,U363,F-75014 PARIS,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,VITRY ALFORVILLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	CAZAUBON, SM (corresponding author), UNIV PARIS 07,INST COCHIN GENET MOLEC,IMMUNOPHARMACOL MOLEC LAB,CNRS,UPR 0415,22 RUE MECHAIN,F-75014 PARIS,FRANCE.		Ramos-Morales, Francisco/C-5734-2008	Ramos-Morales, Francisco/0000-0002-1151-4547				AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; COURAUD PO, 1991, EUR J PHARM-MOLEC PH, V206, P191, DOI 10.1016/S0922-4106(05)80018-5; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DURIEUTRAUTMANN O, 1993, J CELL PHYSIOL, V155, P104, DOI 10.1002/jcp.1041550114; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LADENHEIM RG, 1993, J NEUROCHEM, V60, P260, DOI 10.1111/j.1471-4159.1993.tb05846.x; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WINITZ S, 1993, J BIOL CHEM, V268, P19196	34	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24805	24809						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929159				2022-12-27	WOS:A1994PQ49000046
J	FISCHER, I; SAPIRSTEIN, VS				FISCHER, I; SAPIRSTEIN, VS			MOLECULAR-CLONING OF PLASMOLIPIN - CHARACTERIZATION OF A NOVEL PROTEOLIPID RESTRICTED TO BRAIN AND KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; MESSENGER-RNA; RAT-BRAIN; NUCLEOTIDE-SEQUENCES; COATED VESICLES; LIPID BILAYERS; NERVOUS-SYSTEM; BASIC-PROTEIN; GENE FAMILY; EXPRESSION	Plasmolipin is an 18-kDa proteolipid protein found in kidney and brain, where it is restricted to the apical surface of tubular epithelial cells and to mammalian myelinated tracts, respectively (Sapirstein, V. S., Nolan, C. E., Stadler, I. I., and Fischer, I, (1992) J. Neurosci. Res. 31, 96-102; Cochary, E. F., Bizzozero, O. A., Sapirstein, V. S., Nolan, C. E., and Fischer, I. (1990) J. Neurochem. 55, 602-610). Addition of plasmolipin to lipid bilayers induces the formation of ion channels, which are voltage-dependent and K+-selective (Tosteson, M. T., and Sapirstein, V. S. (1981) J. Membr. Biol 63, 77-84). The present study describes the isolation and cloning of plasmolipin cDNA that includes the sequence of the complete coding region of the protein, the analysis of plasmolipin mRNA expression and a proposed model for its membrane structure. Northern blot analysis 1) shows that plasmolipin is encoded by a 1.7-kilobase mRNA, 2) confirms that the distribution of plasmolipin is restricted to kidney and brain, and 3) indicates that the expression of plasmolipin mRNA in cultured oligodendrocytes increases with cell maturation consistent with changes in the level of the protein. Restriction enzyme digestion of DNA followed by Southern blot analysis indicates that plasmolipin is encoded by a single gene. Sequence analysis of plasmolipin cDNA shows an open reading frame encoding a 157-amino acid protein of 17.4 kDa. The deduced amino acid sequence confirms the hydrophobic nature and high helical content of the protein and predicts a structure with four transmembrane domains similar to several other small hydrophobic proteins implicated in ion movement. The proposed model for membrane topology shows an enrichment of hydroxyl groups within two of the transmembrane domains and places cysteine residues near the extracellular membrane surface. Examination of protein sequence data bases reveals little overall homology with other proteins including proteolipids; however, three of the four transmembrane segments of plasmolipin show strong similarity with known membrane transport proteins. These results indicate that plasmolipin is an unique proteolipid protein that may participate in ion transport events specific to select membrane domains.	NATHAN S KLINE INST PSYCHIAT RES,DIV NEUROBIOL,ORANGEBURG,NY 10962; MED COLL PENN,DEPT ANAT & NEUROBIOL,PHILADELPHIA,PA 19129; NYU,DEPT PSYCHIAT,NEW YORK,NY 10016	Nathan Kline Institute for Psychiatric Research; Drexel University; New York University			Fischer, Itzhak/D-1080-2012	Fischer, Itzhak/0000-0003-3187-8740; Fischer, Ilene/0000-0003-1517-7143	NINDS NIH HHS [NS 24894] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024894] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; ANDERSEN OS, 1992, PHYSIOL REV, V72, pS89, DOI 10.1152/physrev.1992.72.suppl_4.S89; ARAI H, 1987, J BIOL CHEM, V262, P11006; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COCHARY EF, 1990, J NEUROCHEM, V55, P602, DOI 10.1111/j.1471-4159.1990.tb04176.x; COCKLE SA, 1978, BIOCHEMISTRY-US, V17, P630, DOI 10.1021/bi00597a011; CRANDALL JE, 1989, J NEUROCHEM, V53, P1910, DOI 10.1111/j.1471-4159.1989.tb09261.x; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; EYTAN GD, 1977, J BIOL CHEM, V252, P3208; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FISCHER I, 1990, J NEUROSCI RES, V27, P112, DOI 10.1002/jnr.490270117; FISCHER I, 1991, J NEUROSCI RES, V28, P81, DOI 10.1002/jnr.490280108; FISCHER I, 1986, J NEUROCHEM, V47, P2132; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; FUJITA Y, 1986, J BIOL CHEM, V261, P3744; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHINO T, 1990, J BACTERIOL, V172, P5531, DOI 10.1128/jb.172.10.5531-5539.1990; HUDSON LD, 1990, ANN NY ACAD SCI, V605, P155, DOI 10.1111/j.1749-6632.1990.tb42390.x; Innis M S, 1992, Biotechnology, V24, P6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI S, 1991, J BIOL CHEM, V266, P16078; LEES MB, 1979, BIOCHIM BIOPHYS ACTA, V559, P209, DOI 10.1016/0304-4157(79)90002-9; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MAZET JL, 1984, BIOPHYS J, V45, P263, DOI 10.1016/S0006-3495(84)84153-3; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RUSSELL L, 1991, DNA CELL BIOL, V10, P581, DOI 10.1089/dna.1991.10.581; SAFAEI R, 1989, J NEUROCHEM, V52, P1871, DOI 10.1111/j.1471-4159.1989.tb07270.x; SAFAEI R, 1989, J MOL NEUROSCI, V1, P189, DOI 10.1007/BF02918906; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SAPIRSTEIN VS, 1992, J NEUROSCI RES, V32, P593, DOI 10.1002/jnr.490320415; SAPIRSTEIN VS, 1983, BIOCHEMISTRY-US, V22, P3330, DOI 10.1021/bi00283a005; SAPIRSTEIN VS, 1993, J NEUROSCI RES, V35, P83, DOI 10.1002/jnr.490350110; SAPIRSTEIN VS, 1992, J NEUROSCI RES, V31, P96, DOI 10.1002/jnr.490310114; SAPIRSTEIN VS, 1994, J NEUROSCI RES, V37, P348, DOI 10.1002/jnr.490370307; SAPIRSTEIN VS, 1991, NEUROCHEM RES, V16, P123, DOI 10.1007/BF00965699; SAPIRSTEIN VS, 1992, J NEUROCHEM, V58, P1372, DOI 10.1111/j.1471-4159.1992.tb11352.x; SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TINGBEALL HP, 1979, J MEMBRANE BIOL, V51, P33, DOI 10.1007/BF01869342; TOSTESON MT, 1981, J MEMBRANE BIOL, V63, P77, DOI 10.1007/BF01969448; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; YAN YM, 1993, NEURON, V11, P423, DOI 10.1016/0896-6273(93)90147-J	55	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24912	24919						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929173				2022-12-27	WOS:A1994PQ49000060
J	KIM, HH; SIERKE, SL; KOLAND, JG				KIM, HH; SIERKE, SL; KOLAND, JG			EPIDERMAL GROWTH FACTOR-DEPENDENT ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH THE ERBB3 GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; SH2 DOMAIN PROTEINS; EGF RECEPTOR; CATALYTIC SUBUNIT; HUMAN-BREAST; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; CARCINOMA-CELLS	The ErbB3 protein is a member of the ErbB subfamily of receptor protein tyrosine kinases. In the present study, the mechanism by which the ErbB3 protein is phosphorylated and the signal-transducing functions of this phosphorylated protein were investigated. When phosphorylated by the epidermal growth factor receptor in vitro, the ErbB3 protein strongly associated with the regulatory p85 subunit and the catalytic activity of phosphatidylinositol (PI) 3-kinase. The association of PI 3-kinase with ErbB3 in human breast cancer cells was found to be correlated with the constitutive phosphorylation of ErbB3 on tyrosine residues. In MDA-MB-468 breast cancer cells in which the ErbB3 protein is not constitutively phosphorylated, stimulation with epidermal growth factor led to the phosphorylation of ErbB3 on tyrosine residues and the formation of a functional signal transduction complex involving the ErbB3 protein and PI 3-kinase. These results suggest that the ErbB3 protein can be phosphorylated on tyrosine residues by a cross-phosphorylation mechanism and that the phosphorylated ErbB3 protein can couple other growth factor receptor protein tyrosine kinases to the PI 3-kinase pathway in a manner similar to the insulin receptor substrate 1 protein.	UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa				Koland, John/0000-0002-5028-4297	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044684, P30DK025295, R29DK044684] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25295, DK-44684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; COCHET C, 1991, J BIOL CHEM, V266, P637; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GULLICK WJ, 1990, INT J CANCER, P55; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1988, ONCOGENE, V3, P665; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAINSBURY JRC, 1987, LANCET, V1, P1398; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SIERKE SL, 1993, BIOCHEMISTRY-US, V32, P10102, DOI 10.1021/bi00089a028; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	65	181	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24747	24755						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929151				2022-12-27	WOS:A1994PQ49000038
J	WU, RY; GILL, GN				WU, RY; GILL, GN			LIM DOMAIN RECOGNITION OF A TYROSINE-CONTAINING TIGHT TURN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-INDUCED INTERNALIZATION; INSULIN-RECEPTOR; JUXTAMEMBRANE REGION; PROTEIN; GENE; MOTIF; ENDOCYTOSIS; SEQUENCE; BINDING	Endocytosis of cell surface receptors requires sequence ''codes'' consisting of tight turn structures with an essential Tyr or Phe residue. To determine mechanisms through which cells recognize this information, we utilized exon 16 of the human insulin receptor in the two-hybrid system to isolate a novel 455-amino acid cytoplasmic protein that contains two LIM domains within its carboxyl terminus. Mutational analyses indicate that one of the Cys-rich Zn2+ binding LIM domains specifically recognizes active but not inactive endocytic codes contained in exon 16. These findings suggest that LIM domain structures in proteins provide molecular recognition of Tyr-containing tight turn structures.	UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, DIV ENDOCRINOL METAB 0650, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [P01 CA58689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; CADENA DL, 1994, J BIOL CHEM, V269, P260; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHIEST RH, 1986, CURR GENET, V16, P339; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; THIES RS, 1990, J BIOL CHEM, V265, P10132; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Welchman Gordon, 1982, HUT 6 STORY BREAKING; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	112	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25085	25090						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929196				2022-12-27	WOS:A1994PQ49000085
J	HAYASHI, Y; DEPAOLI, AM; BURANT, CF; REFETOFF, S				HAYASHI, Y; DEPAOLI, AM; BURANT, CF; REFETOFF, S			EXPRESSION OF A THYROID HORMONE-RESPONSIVE RECOMBINANT GENE INTRODUCED INTO ADULT MICE LIVERS BY REPLICATION-DEFECTIVE ADENOVIRUS CAN BE REGULATED BY ENDOGENOUS THYROID-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEDIATED TRANSFER; TRANSCRIPTIONAL REGULATION; CYSTIC-FIBROSIS; MUSCLE; DELIVERY; TYPE-5; DNA	We constructed a recombinant adenovirus carrying the firefly luciferase gene driven by the thymidine kinase promoter and controlled by the palindromic thyroid hormone/retinoic acid-responsive element. The same adenovirus vector without the hormone-responsive element was used as control. Regulation of the luciferase gene expression was tested in pituitary-derived GH cells and hepatoma-derived HepG2 cells infected with the recombinant adenoviruses. Administration of triiodothyronine to GH cells and all-trans-retinoic acid to HepG2 cells resulted in 8.0 +/- 0.3-fold and 4.6 +/- 0.5-fold induction of luciferase activity, respectively. No significant increase was observed with the control adenovirus. Hormonal regulation was also examined in adult mice. Mice depleted of thyroid hormone were injected intravenously with the recombinant adenoviruses and given 4 times the replacement dose of triiodothyronine or vehicle only for 4 days. Hormone administration resulted in 4.2-fold increase of luciferase activity in liver homogenates, No significant effect was observed in animals injected with the control adenovirus. This recombinant adenovirus provides a new experimental system in the study of thyroid hormone and retinoic acid action and offers the potential to regulate by physiological means the expression of genes transferred for the purpose of therapy.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago			Refetoff, Samuel/ABB-1263-2021; Burant, Charles/GPC-5690-2022; Hayashi, Yoshitaka/I-6168-2014	Refetoff, Samuel/0000-0003-0164-8231; Burant, Charles/0000-0001-9189-5003; Hayashi, Yoshitaka/0000-0002-7557-4303	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015070, R01DK015070] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15070] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DELUZE A, 1993, P NATL ACAD SCI USA, V90, P7322, DOI 10.1073/pnas.90.15.7322; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAUPNER G, 1989, NATURE, V340, P635; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCPHAUL MJ, 1993, J BIOL CHEM, V268, P26063; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SHIH W, 1991, MOL ENDOCRINOL, V5, P300; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	24	34	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23872	23875						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929032				2022-12-27	WOS:A1994PQ34600006
J	PIMENTELMUINOS, FX; MAZANA, J; FRESNO, M				PIMENTELMUINOS, FX; MAZANA, J; FRESNO, M			REGULATION OF INTERLEUKIN-2 RECEPTOR-ALPHA CHAIN EXPRESSION AND NUCLEAR FACTOR-CENTER-DOT-KAPPA-B ACTIVATION BY PROTEIN-KINASE-C IN T-LYMPHOCYTES - AUTOCRINE ROLE OF TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-2 RECEPTOR; GENE-EXPRESSION; CYCLOSPORINE-A; TRANSCRIPTION FACTORS; BINDING-PROTEINS; SIGNAL TRANSDUCTION; CELL ACTIVATION; ENHANCER; INDUCTION; REL	The regulation of interleukin-2 receptor alpha chain (IL-2R alpha) expression and nuclear factor (NF) activation by protein kinase C (PKC) in resting T cells, has been studied. Treatment of human resting T cells with phorbol esters strongly induced the expression of IL-2R alpha and the activation of NF.kappa B. This activation was due to the translocation of p65 and c-Rel NF.kappa B proteins from cytoplasmic stores to the nucleus, where they bound the kappa B sequence of the IL-2R alpha promoter either as p50.p65 or as p50.c-Rel heterodimers. Interestingly, all of those events were largely indirect and mediated by endogenously secreted tumor necrosis factor alpha (TNF alpha), as they were strongly inhibited by a neutralizing anti-TNF alpha monoclonal antibody. Furthermore, cyclosporin A, which blocked TNF alpha production induced by PKC, strongly inhibited IL-2R alpha and NF.kappa B activation. The addition of either TNF alpha or IL-2 partially recovered cyclosporin A-induced IL-2R alpha inhibition, but only TNF alpha completely recovered NF.kappa B activation. Those results indicate that, in resting T cells, PKC activation has only a triggering role, whereas the endogenously secreted TNF alpha plays an essential role in the quantitative control of the expression of IL-2R alpha chain or NF.kappa B activation.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			; Pimentel-Muinos, Felipe/K-4557-2014	Fresno Escudero, Manuel/0000-0002-9223-5477; Pimentel-Muinos, Felipe/0000-0002-0258-2855				Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ARIMA N, 1992, J IMMUNOL, V149, P83; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; DEPPER JM, 1984, J IMMUNOL, V133, P3054; ENGLISH BK, 1991, J BIOL CHEM, V266, P7108; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FREIMUTH WW, 1989, J IMMUNOL, V143, P3064; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GOSH S, 1990, CELL, V62, P1019; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HEMAR A, 1990, EUR J IMMUNOL, V20, P2629, DOI 10.1002/eji.1830201216; HEMAR A, 1991, NEW BIOL, V3, P1097; HSIOUCHI L, 1993, CURR OPIN CELL BIOL, V5, P477; JAMIESON C, 1991, J IMMUNOL, V147, P416; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEE JC, 1987, J IMMUNOL, V139, P1935; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; Lorre K, 1992, Eur Cytokine Netw, V3, P321; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUNOZFERNANDEZ MA, 1990, EUR J IMMUNOL, V20, P605; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; REED JC, 1986, J IMMUNOL, V137, P150; ROMAN D, 1990, New Biologist, V2, P642; Sambrook J, 1989, MOL CLONING LABORATO; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STEFFEN M, 1988, J IMMUNOL, V140, P2621; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; SZAMEL M, 1993, EUR J IMMUNOL, V23, P3072, DOI 10.1002/eji.1830231205; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELTE K, 1984, J EXP MED, V160, P1690; WERNER C, 1977, TISSUE ANTIGENS, V9, P227; YOKOTA S, 1988, J IMMUNOL, V140, P531	59	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24424	24429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929104				2022-12-27	WOS:A1994PQ34600089
J	THEVENOD, F; ANDERIE, I; SCHULZ, I				THEVENOD, F; ANDERIE, I; SCHULZ, I			MONOCLONAL-ANTIBODIES AGAINST MDR1 P-GLYCOPROTEIN INHIBIT CHLORIDE CONDUCTANCE AND LABEL A 65KDA PROTEIN IN PANCREATIC ZYMOGEN GRANULE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNELS; CYSTIC-FIBROSIS GENE; RAT EXOCRINE PANCREAS; RESISTANT HUMAN-CELLS; PLASMA-MEMBRANE; ACINAR-CELLS; CHO-CELLS; TRANSPORT; LOCALIZATION; SECRETION	The regulation of Cl- and cation conductances by the nonhydrolyzabIe ATP analog adenosine 5'-(beta,gamma-methylene)triphosphate (AMP-PCP) was characterized in isolated zymogen granules (ZG) from pancreatic acinar cells. ZG were purified from rat pancreas homogenate by Percoll gradient centrifugation. Cl- conductance was assayed by suspending ZG in isotonic KCl buffer and measuring osmotic lysis induced by maximal permeabilization of ZG membranes (ZGM) for K+ with the K+ ionophore valinomycin (Val). This resulted in influx of K+ through the artificial pathway and of Cl- through endogenous channels. To measure cation conductances ZG (pH(i) approximate to 6) were suspended in pH 7 buffered isotonic monovalent cation acetate salts. The pH gradient was converted into an outside-directed H+ diffusion potential by maximally increasing H+ conductance of ZGM with the protonophore carbonyl cyanide p-chlorophenylhydrazone. Osmotic lysis of ZG was induced by H+ diffusion potential driven influx of monovalent cations through endogenous channels and non-ionic diffusion of the counterion acetate. In the absence of Val, ZG were stable in KCl buffer up to 2 h. AMP-PCP enhanced osmotic lysis approximate to 4-fold compared to control, due to activation of Cl- conductance by AMP-PCP and K+ influx through an AMP-PCP-insensitive nonselective cation pathway, which could be blocked by 0.1 mM Ba2+, 0.5 mM quinine, or 0.2 mM flufenamate. In addition, a K+ and Rb+ selective cation conductance was found which was completely blocked by 0.5 mM AMP-PCP or 0.5 mM quinine. AMP-PCP induced C1(-) conductance was strongly inhibited by two monoclonal antibodies against MDR1 P-glycoprotein (JSB-1 and 0219; 5-10 mu g/ml), but not by a monoclonal antibody against the cystic fibrosis transmembrane conductance regulator (M3A7; 5 mu g/ml) or by mouse IgG. The AMP-PCP insensitive nonselective cation conductance was not blocked by monoclonal antibodies against MDR1 P-glycoprotein (MDR1). Immunoblot studies of ZG membranes revealed the presence of a major immunoreactive protein band of approximate to 65 kDa with both monoclonal antibodies against MDR1, but no protein of the approximate size of MDR1 (approximate to 170 kDa) was detected. We propose that the C1(-) channel or a regulator of the channel, that is activated by the non-hydrolyzable ATP analog AMP-PCP in ZG membranes, is a member of the ATP binding cassette superfamily of transporters and may have homology to MDR1 P-glycoprotein.			THEVENOD, F (corresponding author), UNIV SAARLAND,FAC MED,DEPT PHYSIOL 2,D-66421 HOMBURG,GERMANY.							ALTENBERG GA, 1994, J BIOL CHEM, V269, P7145; ALTENBERG GA, 1994, CANCER RES, V54, P618; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEGAULT B, 1993, BIOCHIM BIOPHYS ACTA, V1152, P319, DOI 10.1016/0005-2736(93)90264-Z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; DELISLE RC, 1986, AM J PHYSIOL, V250, pG489, DOI 10.1152/ajpgi.1986.250.4.G489; FINN AL, 1989, P NATL ACAD SCI USA, V86, P7649, DOI 10.1073/pnas.86.19.7649; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V413, P385, DOI 10.1007/BF00584488; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V415, P29, DOI 10.1007/BF00373138; GASSER KW, 1988, AM J PHYSIOL, V254, pG93, DOI 10.1152/ajpgi.1988.254.1.G93; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOGELEIN H, 1990, BIOCHIM BIOPHYS ACTA, V1027, P191, DOI 10.1016/0005-2736(90)90084-2; GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1029, P33, DOI 10.1016/0005-2736(90)90433-O; Hille B., 1992, IONIC CHANNELS EXCIT, P130; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KAWAI K, 1994, BIOCHEM BIOPH RES CO, V198, P804, DOI 10.1006/bbrc.1994.1115; KIMURA T, 1985, AM J PHYSIOL, V250, pG698; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; MARTY A, 1984, J PHYSIOL-LONDON, V357, P293, DOI 10.1113/jphysiol.1984.sp015501; MARUYAMA Y, 1983, NATURE, V302, P827, DOI 10.1038/302827a0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RANDRIAMAMPITA C, 1988, PFLUG ARCH EUR J PHY, V411, P53, DOI 10.1007/BF00581646; RASOLA A, 1994, J BIOL CHEM, V269, P1432; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHEPER RJ, 1988, INT J CANCER, V42, P389, DOI 10.1002/ijc.2910420314; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THEVENOD F, 1992, ANAL BIOCHEM, V202, P54, DOI 10.1016/0003-2697(92)90205-L; THEVENOD F, 1990, BIOCHEM J, V272, P119, DOI 10.1042/bj2720119; THEVENOD F, 1992, J MEMBRANE BIOL, V129, P253; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LM, 1991, J GEN PHYSIOL, V98, P723, DOI 10.1085/jgp.98.4.723; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WILLINGHAM MC, 1987, J HISTOCHEM CYTOCHEM, V35, P1451, DOI 10.1177/35.12.2890686	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24410	24417						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929102				2022-12-27	WOS:A1994PQ34600087
J	ZWEIER, JL; BRODERICK, R; KUPPUSAMY, P; THOMPSONGORMAN, S; LUTTY, GA				ZWEIER, JL; BRODERICK, R; KUPPUSAMY, P; THOMPSONGORMAN, S; LUTTY, GA			DETERMINATION OF THE MECHANISM OF FREE-RADICAL GENERATION IN HUMAN AORTIC ENDOTHELIAL-CELLS EXPOSED TO ANOXIA AND REOXYGENATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT SUPEROXIDE-DISMUTASE; MYOCARDIAL ISCHEMIA-REPERFUSION; XANTHINE-OXIDASE; NITRIC-OXIDE; HYDROGEN-PEROXIDE; RELAXING FACTOR; INJURY; IRON; IDENTIFICATION; INVITRO	Endothelial cell-derived oxygen free radicals are important mediators of postischemic injury; however, the mechanisms that trigger this radical generation are not known, and it is not known if this process can occur in human cells and tissues. The enzyme xanthine oxidase can be an important source of radical generation; however, it has been reported that this enzyme may not be present in human endothelium. To determine the presence and mechanisms of radical generation in human vascular endothelial cells subjected to anoxia and reoxygenation, electron paramagnetic resonance measurements were performed on cultured human aortic endothelial cells using the spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO). These measurements were correlated with cellular injury, xanthine oxidase activity, and alterations in cellular nucleotides. Upon reoxygenation after 60 min of anoxia, large DMPO-OH (a(N) = a(H) = 14.9 G) and smaller DMPO-R (a(N) = 15.8 G, a(H) = 22.8 G) signals were seen. Superoxide dismutase totally quenched this radical generation. The ferric iron chelator deferoxamine prevented cell death and totally quenched the DMPO-R signal with a 40% decrease in the DMPO-OH signal. Xanthine oxidase was shown to be present in these cells and to be the primary source of free radicals. While the concentration of this enzyme did not change after anoxia, the concentration of its substrate, hypoxanthine, markedly increased, resulting in increased free radical generation upon reoxygenation. Thus, reoxygenated human vascular endothelial cells generate superoxide free radicals, which further react with iron to form the reactive hydroxyl radical, which in turn causes cell death. Xanthine oxidase was the primary source of radical generation with this process triggered by the breakdown of ATP to the substrate hypoxanthine during anoxia.	JOHNS HOPKINS UNIV, SCH MED, WILMER OPHTHALMOL INST, BALTIMORE, MD 21224 USA; UNIV MARYLAND, SCH MED, DEPT PHARMACOL, BALTIMORE, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore	ZWEIER, JL (corresponding author), JOHNS HOPKINS UNIV, SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR, DEPT MED,EPR LABS, RM LA-14, BALTIMORE, MD 21224 USA.				NHLBI NIH HHS [HL-17655, HL-38324, HL-07227] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, P50HL017655, R01HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1987, CIRCULATION, V76, P906, DOI 10.1161/01.CIR.76.4.906; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; BALLA G, 1990, J LAB CLIN MED, V116, P546; BALLA G, 1991, LAB INVEST, V64, P648; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLASIG IE, 1986, STUD BIOPHYS, V116, P35; CERUTTI PA, 1988, OXYRADICALS MOL BIOL, P1; EDDY LJ, 1987, AM J PHYSIOL, V253, pH709, DOI 10.1152/ajpheart.1987.253.3.H709; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FREDERIKS WM, 1993, INT J EXP PATHOL, V74, P21; GRILL HP, 1992, J AM COLL CARDIOL, V20, P1604, DOI 10.1016/0735-1097(92)90457-X; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HOSHI H, 1986, IN VITRO CELL DEV B, V22, P51; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; JARASCH ED, 1986, ACTA PHYSIOL SCAND, V126, P39; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; KUPPUSAMY P, 1993, APPL RADIAT ISOTOPES, V44, P367, DOI 10.1016/0969-8043(93)90249-A; LEFER DJ, 1993, CIRCULATION, V88, P1779, DOI 10.1161/01.CIR.88.4.1779; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MORIWAKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1164, P327, DOI 10.1016/0167-4838(93)90266-T; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHANDELYA SML, 1993, CIRCULATION, V87, P536, DOI 10.1161/01.CIR.87.2.536; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL, P1; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VARANI J, 1992, LAB INVEST, V66, P708; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1987, J CLIN INVEST, V80, P1728, DOI 10.1172/JCI113264; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	34	194	199	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24156	24162						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929072				2022-12-27	WOS:A1994PQ34600050
J	RODRIGUEZ, JC; GILGOMEZ, G; HEGARDT, FG; HARON, D				RODRIGUEZ, JC; GILGOMEZ, G; HEGARDT, FG; HARON, D			PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR MEDIATES INDUCTION OF THE MITOCHONDRIAL 3-HYDROXY-3 METHYLGLUTARYL-COA SYNTHASE GENE BY FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; CARNITINE PALMITOYLTRANSFERASE-I; RAT HYDRATASE-DEHYDROGENASE; 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE; RESPONSIVE ELEMENT; CLOFIBRIC ACID; OXIDASE GENE; KETOGENESIS; PROTEIN; EXPRESSION	Fatty acids induce an increase in the transcription of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase gene, which encodes an enzyme that has been proposed as a control site of ketogenesis. We studied whether the peroxisome proliferator-activated receptor (PPAR) is involved in the mechanism of this transcriptional induction. We found that cotransfection of a rat mitochondrial HMG-CoA synthase promoter-chloramphenicol acetyltransferase reporter plasmid and a PPAR expression plasmid in the presence of the peroxisome proliferator clofibrate led to a more than 30-fold increase in chloramphenicol acetyltransferase activity, relative to the activity in the absence of both PPAR and inducer. Linoleic acid, a polyunsaturated fatty acid, increased this activity as potently as does clofibrate and more effectively than does monounsaturated oleic acid. We have identified, by deletional analysis, an element located 104 base pairs upstream of the mitochondrial HMG-CoA synthase gene, which confers PPAR responsiveness to homologous and heterologous promoters. This is the first example of a peroxisome proliferator-responsive element (PPRE) in a gene encoding a mitochondrial protein. This element contains an imperfect direct repeat that is similar to those described in the PPREs of other genes. Furthermore, gel retardation and cotransfection assays revealed that, as for other genes, PPAR heterodimerizes with retinoid X receptor and that both receptors cooperate for binding to the mitochondrial HMG-CoA synthase PPRE and subsequent activation of the gene. In conclusion, our data demonstrate that regulation of mitochondrial HMG-CoA synthase gene expression by fatty acids is mediated by PPAR, supporting the hypothesis that PPAR has an important role at the transcriptional level in the regulation of lipid metabolism.	UNIV BARCELONA,SCH PHARM,FAC FARM,BIOCHEM UNIT,E-08028 BARCELONA,SPAIN	University of Barcelona			Haro, Diego/I-4623-2015; Gil-Gomez, G/H-6307-2014	Haro, Diego/0000-0001-9147-0486; Gil-Gomez, G/0000-0002-9790-7308				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; DASHTI N, 1979, BIOCHEM MED METAB B, V22, P365, DOI 10.1016/0006-2944(79)90024-3; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GILGOMEZ G, 1993, EUR J BIOCHEM, V213, P773, DOI 10.1111/j.1432-1033.1993.tb17819.x; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRANTHAM BD, 1988, BIOCHEM J, V249, P409, DOI 10.1042/bj2490409; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUZMAN M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P227, DOI 10.1016/0005-2760(93)90224-W; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; QUANT PA, 1990, EUR J BIOCHEM, V187, P169, DOI 10.1111/j.1432-1033.1990.tb15291.x; QUANT PA, 1991, EUR J BIOCHEM, V195, P449, DOI 10.1111/j.1432-1033.1991.tb15724.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOFIELD PS, 1987, BIOCHEM J, V241, P475, DOI 10.1042/bj2410475; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V307, P40, DOI 10.1006/abbi.1993.1557; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS.DH, 1968, BIOCHEM J, V108, P353, DOI 10.1042/bj1080353; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	37	342	345	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18767	18772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913466				2022-12-27	WOS:A1994NX32700015
J	BOEHLEIN, SK; RICHARDS, NGJ; SCHUSTER, SM				BOEHLEIN, SK; RICHARDS, NGJ; SCHUSTER, SM			GLUTAMINE-DEPENDENT NITROGEN TRANSFER IN ESCHERICHIA-COLI ASPARAGINE SYNTHETASE-B - SEARCHING FOR THE CATALYTIC TRIAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; AMIDE TRANSFER-FUNCTION; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; NUCLEOTIDE-SEQUENCE; CARBAMYL-PHOSPHATE; MECHANISM; CYSTEINE; GENES; PURF	The mechanism of nitrogen transfer in glutamine dependent amidotransferases remains to be unambiguously established. We now report the overexpression, purification, and kinetic characterization of both the glutamine- and ammonia-dependent activities of Escherichia coli asparagine synthetase B (AS-B) and a series of mutants. In common with other members of the purF family of amidotransferases, the recombinant enzyme possesses an NH, terminal cysteine residue. Replacement of Cys-1 by either alanine or serine results in a loss of glutaminase and glutamine dependent activity, without any significant effect upon ammonia-dependent asparagine synthesis. As previously observed for human AS (Sheng, S., Moraga-Amador, D., Van Heeke, G., Allison, R. D., Richards, N. G. J., and Schuster, S. M. (1993) J. Biol. Chem. 268, 16771-16780), glutamine is an inhibitor of the ammonia-dependent reaction catalyzed by both the Cys-1 --> Ala (C1A) and Cys-1 --> Ser (C1S) mutants of AS-B. In the case of C1A, the inhibition pattern suggests that an abortive complex is formed. This is consistent with a recent proposal implicating the formation of an imide intermediate in the nitrogen transfer reaction (Richards, N. G. J., and Schuster, S. M. (1992) FEBS Lett. 313, 98-102). In contrast, glutamine appears to be only a competitive inhibitor of the ammonia-dependent activity of C1S. Cys-1 does not appear to be required for glutamine binding. Replacement of Asp-33 by either asparagine or glutamic acid has little effect on the kinetic properties of the mutant enzymes when compared to wild-type AS-B. Cys-1 and Asp-33 are cognate to residues Cys-1 and Asp-29 in glutamine phosphoribosylpyrophosphate amidotransferase which have been proposed to be members of a catalytic triad responsible for mediating nitrogen transfer in this enzyme (Mei, B., and Zalkin, H. (1989) J. Biol. Chem. 264, 16613-16619). In the case of AS-B, although Cys-1 is essential for glutamine-dependent activity, Asp-33 does not appear to participate in mediating nitrogen transfer. In an effort to locate other residues which might form part of a ''catalytic triad'' in the glutamine amidotransferase domain of AS-B, we have expressed and characterized mutant proteins in which His-29 and His-80, which are conserved within the glutamine amidotransferase domain of purF amidotransferases, are replaced by alanine (H29A and H80A). For both mutant enzymes, although the kinetic parameters for the ammonia-dependent activity of H29A and H80A are unchanged with respect to wild type AS-B, the apparent glutamine K-m is increased by a factor of 4.5 in glutamine-dependent asparagine synthesis.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, INTERDISCIPLINARY CTR BIOTECHNOL RES, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, DEPT CHEM, GAINESVILLE, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida					NCI NIH HHS [CA-28725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMURO N, 1985, J BIOL CHEM, V260, P4844; ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BAKER EN, 1976, J MOL BIOL, V101, P185, DOI 10.1016/0022-2836(76)90371-5; BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; BERAN RK, 1981, INT J BIOCHEM, V13, P165, DOI 10.1016/0020-711X(81)90152-X; BROOME JD, 1968, J EXP MED, V127, P1055, DOI 10.1084/jem.127.6.1055; BURCHALL JJ, 1964, J BIOL CHEM, V239, P1794; CEDAR H, 1969, J BIOL CHEM, V244, P4112; CEDAR H, 1969, J BIOL CHEM, V244, P4122; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRENTH J, 1971, ENZYMES, V3, P609; FELTON J, 1980, J BACTERIOL, V142, P221, DOI 10.1128/JB.142.1.221-228.1980; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOROWITZ B, 1972, J BIOL CHEM, V247, P6708; HUANG YZ, 1975, ENZYME, V19, P314, DOI 10.1159/000459006; HUMBERT R, 1980, J BACTERIOL, V142, P212, DOI 10.1128/JB.142.1.212-220.1980; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LUEHR CA, 1985, ARCH BIOCHEM BIOPHYS, V237, P335, DOI 10.1016/0003-9861(85)90285-1; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MACPHEE KG, 1983, J BACTERIOL, V156, P475, DOI 10.1128/JB.156.1.475-478.1983; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MARKIN RS, 1981, BIOCHEMISTRY-US, V20, P7226, DOI 10.1021/bi00528a027; MEHLHAFF PM, 1985, BIOCHEMISTRY-US, V24, P1104, DOI 10.1021/bi00326a006; MEI B, 1989, J BIOL CHEM, V264, P16613; MILMAN HA, 1979, BIOCHEM J, V181, P51, DOI 10.1042/bj1810051; MILMAN HA, 1980, J BIOL CHEM, V255, P1862; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; PFEIFFER NE, 1987, J BIOL CHEM, V262, P11565; RAMOS F, 1980, EUR J BIOCHEM, V108, P373, DOI 10.1111/j.1432-1033.1980.tb04732.x; RAVEL JM, 1962, J BIOL CHEM, V237, P2845; REITZER LJ, 1982, J BACTERIOL, V151, P1299, DOI 10.1128/JB.151.3.1299-1313.1982; RICHARDS NGJ, 1992, FEBS LETT, V313, P98, DOI 10.1016/0014-5793(92)81421-H; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SATAR G, 1990, BIOTECHNIQUES, V8, P404; SCOFIELD MA, 1990, J BIOL CHEM, V265, P12895; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHENG S, 1993, J BIOL CHEM, V268, P16771; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; TEMPEST DW, 1970, BIOCHEM J, V117, P405, DOI 10.1042/bj1170405; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1982, J BIOL CHEM, V257, P3532; VANHEEKE G, 1989, J BIOL CHEM, V264, P19475; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZALKIN H, 1977, J BIOL CHEM, V252, P5431	49	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7450	7457						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907328				2022-12-27	WOS:A1994NA03200067
J	RICHARME, G; KOHIYAMA, M				RICHARME, G; KOHIYAMA, M			AMINO-ACID SPECIFICITY OF THE ESCHERICHIA-COLI CHAPERONE GROEL (HEAT-SHOCK PROTEIN-60)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING; SURFACE; DNAK; CATALYSTS	The chaperones GroEL/hsp60 are present in all prokaryotes and in mitochondria and chloroplasts of eukaryotic cells. They are involved in protein folding, protein targeting to membranes, protein renaturation, and control of protein-protein interactions. They interact with many polypeptides in an ATP-dependent manner and possess a peptide-dependent ATPase activity. The nature of the structural elements of substrate proteins recognized by GroEL/hsp60 is still unknown. In this study, we show that the GroEL chaperone of Escherichia coli interacts with single amino acids. The hydrophobic amino acids Ile, Phe, Val, Leu, and Trp present the strongest interaction with GroEL. While most of these hydrophobic amino acids are beta-sheet formers, GroEL interacts also with the alpha-helix formers Glu, Ale, Gln, and His. The multiple interactions of GroEL with the side chains of hydrophobic and polar amino acids, including the strongest alpha-helix and beta-sheet formers would allow this chaperone to act as an amphiphilic organizer of protein folding.			RICHARME, G (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,2 PL JUSSIEU,F-75005 PARIS,FRANCE.							CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HERINGA J, 1991, J MOL BIOL, V220, P151, DOI 10.1016/0022-2836(91)90388-M; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MORIMOTO R I, 1990, P1; PTITSYN OB, 1992, CONFORMATIONS FORCES, P155; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHULZ GE, 1988, ANNU REV BIOPHYS BIO, V17, P1; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WILLIAMS RW, 1987, BIOCHIM BIOPHYS ACTA, V916, P200, DOI 10.1016/0167-4838(87)90109-9	25	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7095	7098						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907325				2022-12-27	WOS:A1994NA03200011
J	LEHNER, R; KUKSIS, A				LEHNER, R; KUKSIS, A			PURIFICATION OF AN ACYL-COA HYDROLASE FROM RAT INTESTINAL MICROSOMES - A CANDIDATE ACYL-ENZYME INTERMEDIATE IN GLYCEROLIPID ACYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOACYLGLYCEROL LIPASE; MEMBRANE-PROTEINS; LIVER MICROSOMES; LIPID PROFILES; COENZYME; ACID; SIMPLIFICATION; CHROMATOGRAPHY; BRAIN	We have purified to apparent homogeneity an acyl-CoA hydrolase activity from rat intestinal villus cell microsomes by heparin and anion exchange and affinity chromatography. The purified 54-kDa acyl-CoA hydrolase along with several microsomal proteins form a covalent acyl-protein bond upon incubation with an activated fatty acid (acyl-CoA). The acyl moiety of the acylated acyl-CoA hydrolase is stable to denaturation and extraction with organic solvents, but is displaced by neutral hydroxylamine or mercaptoethanol, indicating a labile high energy (thio)ester linkage. The enzyme activity is inhibited by thiol-directed reagents and activated by the presence of dithiothreitol suggesting the presence of a cysteine residue(s) at or near the active site. Common serine-esterase inhibitors (NaF, phenylmethylsulfonyl fluoride) and activators (Mg2+, Ca2+) had no effect on the hydrolase activity. The enzyme hydrolyzed (transferred to water) 14-20 carbon acyl-CoA with similar efficiencies and did not utilize glycerophospholipids or mono- and diacylglycerols as potential acyl donors/acceptors. Phospholipids and mono- and diradylglycerols at concentrations below 100 muM or polyclonal antibodies raised against the purified hydrolase did not inhibit the enzyme activity. However, the acyl-CoA hydrolase activity could be immunoprecipitated from solubilized microsomes or purified enzyme preparations with corresponding decrease of the hydrolase activity in the supernatant of the immunoprecipitate. Immunoblotting studies show cross-reactivity with a protein of an identical molecular mass in other rat or human tissues. It is concluded that the microsomal acyl-CoA hydrolase deserves consideration as a candidate acyl-enzyme intermediate in glycerolipid synthesis when associated with appropriate acyltransferases.	UNIV TORONTO,CH BEST INST,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto				Lehner, Richard/0000-0002-6008-1805				ANDERSON AD, 1971, J NEUROCHEM, V18, P1179, DOI 10.1111/j.1471-4159.1971.tb00216.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; DEJONG BJP, 1978, BIOCHIM BIOPHYS ACTA, V530, P56, DOI 10.1016/0005-2760(78)90126-1; FOLCH J, 1957, J BIOL CHEM, V226, P449; GREENSPAN MD, 1969, J BIOL CHEM, V244, P6477; GROSS RW, 1984, BIOCHIM BIOPHYS ACTA, V802, P197, DOI 10.1016/0304-4165(84)90161-2; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; HOFFMAN AGD, 1979, CAN J PHYSIOL PHARM, V57, P832, DOI 10.1139/y79-127; KNAUER TE, 1979, BIOCHEM J, V179, P515, DOI 10.1042/bj1790515; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER R, 1993, LIPIDS, V28, P29, DOI 10.1007/BF02536356; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; LIN AY, 1985, NEUROCHEM RES, V9, P1571; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P107, DOI 10.1139/o85-016; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; MYHER JJ, 1984, J BIOCHEM BIOPH METH, V10, P13, DOI 10.1016/0165-022X(84)90046-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIENDEAU D, 1986, J BIOL CHEM, V261, P976; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; SANJANWALA M, 1987, ARCH BIOCHEM BIOPHYS, V258, P299, DOI 10.1016/0003-9861(87)90348-1; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; WALL L, 1986, J BIOL CHEM, V261, P5981	30	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24726	24733						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901219				2022-12-27	WOS:A1993MG67300034
J	CAMP, LA; HOFMANN, SL				CAMP, LA; HOFMANN, SL			PURIFICATION AND PROPERTIES OF A PALMITOYL-PROTEIN THIOESTERASE THAT CLEAVES PALMITATE FROM H-RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; GTP-BINDING PROTEINS; GUANINE-NUCLEOTIDE; COA HYDROLASE; BETA-GAMMA; MONOACYLGLYCEROL LIPASE; PLASMA-MEMBRANE; HUMAN-PLATELETS; MAMMARY-GLAND; SUBUNITS	H-Ras, the protein product of the cellular homologue of the Harvey ras oncogene, undergoes a complex series of post-translational modifications that include C-terminal isoprenylation, proteolysis, methylation, and palmitoylation. Palmitoylation has been shown to enhance the transformation efficiency of H-Pas about 10-fold in vivo. A recent study (Magee, A. I., Gutierrez, L., McKay, I. A., Marshall, C. J., and Hall, A. (1987) EMBO J. 6, 3353-3357) has provided strong evidence that the palmitate undergoes a dynamic acylation-deacylation cycle, but details concerning the enzymology of this process and its regulation are lacking. To begin to dissect this event, we have developed an assay for the enzymatic removal of palmitate from [H-3]palmitate-labeled H-Ras. This substrate was produced in a baculovirus expression system and was used to purify to homogeneity a novel 37-kDa enzyme from bovine brain cytosol that removes the radiolabeled palmitate. The purified enzyme is sensitive to diethyl pyrocarbonate and insensitive to phenylmethyl-sulfonyl fluoride and N-ethylmaleimide. Interestingly, the thioesterase recognizes H-Ras as a substrate only when H-Ras is in its native conformation (bound to Mg2+ and guanine nucleotide). The palmitoylated alpha subunits of the heterotrimeric G proteins are also substrates for the enzyme.	UNIV TEXAS, SW MED CTR, SIMMONS CANC CTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas					NIGMS NIH HHS [GM08014] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL JC, 1981, BIOCHEMISTRY-US, V20, P899, DOI 10.1021/bi00507a038; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGER M, 1986, J BIOL CHEM, V261, P4912; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BIZZOZERO OA, 1992, J BIOL CHEM, V267, P7886; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDON RH, 1986, TECHNIQUES LIPIDOL 2, V3, P107; BURDON RH, 1986, TECHNIQUES LIPIDOL 2, V3, P290; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DERENOBALES M, 1980, ARCH BIOCHEM BIOPHYS, V205, P464, DOI 10.1016/0003-9861(80)90129-0; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; ERLANSON CH, 1970, SCAND J GASTROENTERO, V5, P333; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; GORBUNOFF MJ, 1990, METHOD ENZYMOL, V182, P329; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRAND RJA, 1989, FEBS LETT, V253, P281, DOI 10.1016/0014-5793(89)80976-7; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P403; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOFMANN SL, 1982, ARCH BIOCHEM BIOPHYS, V215, P237, DOI 10.1016/0003-9861(82)90300-9; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; Kato K, 1992, Semin Cancer Biol, V3, P179; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAZIRANDEH M, 1989, J BIOL CHEM, V264, P18195; Penefsky H S, 1979, Methods Enzymol, V56, P527; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Shaltiel S, 1974, Methods Enzymol, V34, P126; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	59	294	295	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22566	22574						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7901201				2022-12-27	WOS:A1993MD34800059
J	WILCKE, M; HULTENBY, K; ALEXSON, SEH				WILCKE, M; HULTENBY, K; ALEXSON, SEH			NOVEL PEROXISOMAL POPULATIONS IN SUBCELLULAR-FRACTIONS FROM RAT-LIVER - IMPLICATIONS FOR PEROXISOME STRUCTURE AND BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBODY TARGETING SIGNAL; ACYL-COA OXIDASE; ZELLWEGER SYNDROME; 3-DIMENSIONAL RECONSTRUCTION; ENDOPLASMIC-RETICULUM; HEPATIC PEROXISOMES; MEMBRANE-PROTEINS; MAMMALIAN-CELLS; CYTO-CHEMISTRY; FREE POLYSOMES	According to current concepts, new peroxisomes are formed by division of pre-existing peroxisomes or by budding from a peroxisomal reticulum. Recent cytochemical and biochemical data indicate that protein content in peroxisomes are heterogenous and that import of newly synthesized proteins may be restricted to certain protein import-competent peroxisomal subcompartments (Yamamoto, K., and Fahimi, H. D. (1987) J. Cell Biol. 105, 713-722; Heinemann, P., and Just, W. W. (1992) FEBS Lett. 300, 179-182; Luers, G., Hashimoto, T., Fahimi, H. D., and Volkl, A. (1993) J. Cell Biol. 121, 1271-1280). We have observed that substantial amounts of peroxisomal proteins are found together with ''microsomes'' (100,000 x g pellet) after subcellular fractionation of rat liver homogenates. In this study we have investigated the origin of these peroxisomal proteins by modified gradient centrifugation procedures in Nycodenz and by analysis of enzyme activity distributions, Western blotting, and immunoelectron microscopy. It is concluded that much of this material is confined to novel populations of ''peroxisomes.'' Immunocytochemistry on gradient fractions showed that some vesicles were enriched in acyl-CoA oxidase and peroxisomal multifunctional enzyme (''catalase-negative'') whereas others were enriched in catalase and thiolase (''acyl-CoA oxidase-negative''). Double immunolabeling experiments verified the strong heterogeneity in the protein contents of these vesicles and also identified peroxisomes varying in size from about 0.5 mu m (''normal peroxisomes'') to extremely small vesicles of less than 100 nm in diameter. The possibility that these vesicles may be related to different subcompartments of a larger peroxisomal structure involved in protein import and biogenesis will be discussed.	HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN; UNIV STOCKHOLM,ARRHENIUS LAB F3,WENNER GREN INST,DEPT METAB RES,STOCKHOLM,SWEDEN; HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Stockholm University								AIKAWA J, 1991, P NATL ACAD SCI USA, V88, P10084, DOI 10.1073/pnas.88.22.10084; AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; BALFE A, 1990, PEDIATR RES, V27, P304, DOI 10.1203/00006450-199003000-00023; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BAUMGART E, 1989, J CELL BIOL, V108, P2221, DOI 10.1083/jcb.108.6.2221; BAUMGART E, 1987, LAB INVEST, V56, P554; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DONALDSO.RP, 1972, ARCH BIOCHEM BIOPHYS, V152, P199, DOI 10.1016/0003-9861(72)90208-1; ESSNER E, 1967, LAB INVEST, V17, P71; FAHIMI HD, 1993, BIOCHIMIE, V75, P201, DOI 10.1016/0300-9084(93)90078-7; FLATMARK T, 1981, EUR J CELL BIOL, V24, P62; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; GOGLIA F, 1989, EXP BIOL, V48, P127; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOLDMAN BM, 1978, P NATL ACAD SCI USA, V75, P5066, DOI 10.1073/pnas.75.10.5066; GORGAS K, 1984, ANAT EMBRYOL, V169, P261, DOI 10.1007/BF00315631; GORGAS K, 1985, ANAT EMBRYOL, V172, P21, DOI 10.1007/BF00318940; GORGAS K, 1982, ANN NY ACAD SCI, V386, P519, DOI 10.1111/j.1749-6632.1982.tb21468.x; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; GULATI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P90, DOI 10.1016/0003-9861(92)90492-F; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HEINEMANN P, 1992, FEBS LETT, V300, P179, DOI 10.1016/0014-5793(92)80191-I; JUST WW, 1982, EUR J CELL BIOL, V26, P249; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KLUCIS E, 1991, BIOCHIM BIOPHYS ACTA, V1074, P294, DOI 10.1016/0304-4165(91)90167-F; Lazarow P. B., 1980, 31ST MOSB C BIOL CHE, P187, DOI [DOI 10.1007/978-3-642-81557-7_14, 10.1007/978-3-642-81557-7_14]; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1973, J CELL BIOL, V59, P507, DOI 10.1083/jcb.59.2.507; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LUERS G, 1990, EUR J CELL BIOL, V52, P175; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; MEIJER J, 1993, EUR J CELL BIOL, V60, P291; MIURA S, 1994, J BIOCHEM-TOKYO, V115, P1064, DOI 10.1093/oxfordjournals.jbchem.a124458; MIURA S, 1994, EUR J BIOCHEM, V223, P141, DOI 10.1111/j.1432-1033.1994.tb18975.x; MIURA S, 1992, J BIOL CHEM, V267, P14405; Novikoff A.B., 1964, J MICROSC-PARIS, V3, P187; NOVIKOFF PM, 1973, J HISTOCHEM CYTOCHEM, V21, P540, DOI 10.1177/21.6.540; OHNO S, 1990, HISTOCHEM J, V22, P143, DOI 10.1007/BF01003534; OSUMI T, 1978, BIOCHEM BIOPH RES CO, V83, P479, DOI 10.1016/0006-291X(78)91015-X; PALOSAARI PM, 1990, J BIOL CHEM, V265, P10750; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POOLE B, 1969, J CELL BIOL, V41, P536, DOI 10.1083/jcb.41.2.536; RACHUBINSKI RA, 1984, J CELL BIOL, V99, P2241, DOI 10.1083/jcb.99.6.2241; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SHIO H, 1981, J HISTOCHEM CYTOCHEM, V29, P1263, DOI 10.1177/29.11.6274950; STAUBLI W, 1977, J CELL BIOL, V74, P665, DOI 10.1083/jcb.74.3.665; SUZUKI Y, 1992, CELL STRUCT FUNCT, V17, P1, DOI 10.1247/csf.17.1; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; VEENHUIS M, 1989, ARCH MICROBIOL, V151, P105, DOI 10.1007/BF00414422; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WATERHAM HR, 1992, J BACTERIOL, V174, P4057, DOI 10.1128/jb.174.12.4057-4063.1992; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; YAMAMOTO K, 1987, J CELL BIOL, V105, P713, DOI 10.1083/jcb.105.2.713; YAMAMOTO K, 1987, EUR J CELL BIOL, V43, P293; ZHANG JW, 1993, MOL BIOL CELL, V4, P1351, DOI 10.1091/mbc.4.12.1351	68	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6949	6958		10.1074/jbc.270.12.6949	http://dx.doi.org/10.1074/jbc.270.12.6949			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896845	hybrid			2022-12-27	WOS:A1995QQ85500076
J	CALAKOS, N; SCHELLER, RH				CALAKOS, N; SCHELLER, RH			VESICLE-ASSOCIATED MEMBRANE-PROTEIN AND SYNAPTOPHYSIN ARE ASSOCIATED ON THE SYNAPTIC VESICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEUROTRANSMITTER RELEASE; TRANSMITTER SECRETION; VAMP FAMILY; RAT-BRAIN; SYNAPTOBREVIN; GENES; TETANUS; FUSION; CDNA; LOCALIZATIONS	The synaptic vesicle membrane protein VAMP ((v) under bar esicle-(a) under bar ssociated (m) under bar embrane (p) under bar rotein or synaptobrevin) has been implicated in synaptic vesicle docking and fusion. Synaptophysin (p38), also a synaptic vesicle membrane protein, has four transmembrane domains and may function as a gap junction-like pore or channel. Here we report evidence for a direct interaction between VAMP and synaptophysin using chemical cross-linking followed by the identification of immunoreactive protein complexes. A prominent complex of 56 kDa was found to consist of VAMP and synaptophysin. Furthermore, we demonstrate that this VAMP-synaptophysin complex is enriched in the synaptic vesicle fraction of rat brain, is independent of detergent solubilization, and is present in PC12 cells subjected to in vivo cross-linking.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University								ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HUTTNER WB, 1983, J CELL BIOL, V96, P1373; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; ZHONG CZ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P235, DOI 10.1016/0167-4781(92)90495-L	33	194	198	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24534	24537						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929121				2022-12-27	WOS:A1994PQ49000005
J	JOHNSON, JL; TOFT, DO				JOHNSON, JL; TOFT, DO			A NOVEL CHAPERONE COMPLEX FOR STEROID-RECEPTORS INVOLVING HEAT-SHOCK PROTEINS, IMMUNOPHILINS, AND P23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN PROGESTERONE-RECEPTOR; ROUS-SARCOMA VIRUS; GLUCOCORTICOID RECEPTOR; FK506-BINDING PROTEIN; 59-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; POLYCLONAL ANTIBODY; FK506 BINDING; HSP90; COMPONENT	In the absence of hormone, the avian progesterone receptor exists in a large multiprotein complex that is inactive but able to bind and respond to progestins. This inactive complex can be reconstituted in vitro by incubation of receptor monomer in rabbit reticulocyte lysate in the presence of ATP and magnesium. This results in receptor binding to the two heat shock proteins, hsp90 and hsp70, the FK506 binding-proteins, FKBP54 and FKBP52, the cyclosporin A-binding protein, cyclophilin-40, and the recently characterized protein p23. Immune isolation of p23 from rabbit reticulocyte lysate in the absence of receptor reveals an ATP-dependent complex containing the major proteins associated with steroid receptors. Depletion of p23 from lysate prevents the assembly of progesterone receptor complexes, and the addition of purified p23 restores this activity, indicating that the p23 protein complex is an essential precursor to the formation of progesterone receptor complexes.	MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic					NICHD NIH HHS [HD09140] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALNEMRI ES, 1993, P NATL ACAD SCI USA, V90, P6839, DOI 10.1073/pnas.90.14.6839; BIHAN SL, 1993, BIOCHEM BIOPH RES CO, V195, P600; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NING YM, 1993, J BIOL CHEM, V268, P6073; NYGARD O, 1991, J BIOL CHEM, V266, P16425; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1989, J BIOL CHEM, V264, P6239; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULLIVAN WP, 1985, BIOCHEMISTRY-US, V24, P4214, DOI 10.1021/bi00336a060; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0	50	209	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24989	24993						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929183				2022-12-27	WOS:A1994PQ49000070
J	BEERLI, RR; WELS, W; HYNES, NE				BEERLI, RR; WELS, W; HYNES, NE			INTRACELLULAR EXPRESSION OF SINGLE-CHAIN ANTIBODIES REVERTS ERBB-2 TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; HER-2 NEU ONCOGENE; TUMOR-CELL GROWTH; HUMAN-BREAST; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; PROTEIN EXPRESSION; GENE; CANCER	We report a novel approach for specific in vivo inactivation of the ErbB-2 receptor tyrosine kinase and suppression of ErbB-2-induced transformation. Genes encoding single chain antibodies that specifically bind to the extracellular domain of human ErbB-2 were constructed and expressed intracellularly in NIH/3T3 fibroblasts transformed by activated ErbB-2. The single chain antibodies are derived from monoclonal antibodies FRP5 and FWP51 (Harwerth, I. M., Wels, W., Marte, B. M., and Hynes, N. E. (1992) J. Biol. Chem. 267, 15160-15167) and are composed of heavy and light chain variable domains connected by a flexible peptide linker. The antibodies were provided with: 1) an N-terminal hydrophobic leader sequence to target their synthesis to the lumen of the endoplasmic reticulum, and 2) a C-terminal retention signal to prevent secretion. When expressed in ErbB-2-transformed cells, the single chain antibodies bound to the receptor and prevented its transit through the endoplasmic reticulum. This resulted in the functional inactivation of the receptor and reversion of the transformed phenotype. This is the first demonstration of a targeted and stable inactivation of a cellular onco-protein via intracellular antibody expression. The use of such a strategy represents a simple and powerful approach to study the in vivo function of receptors and other cellular proteins.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Wels, Winfried/0000-0001-9858-3643				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CARLSON JR, 1988, MOL CELL BIOL, V8, P2638, DOI 10.1128/MCB.8.6.2638; CEPKO C, 1992, CURR PROTOCOLS MOL B, V1; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HUANG SS, 1990, J BIOL CHEM, V265, P3340; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KABAT EA, 1991, US DHHS NIH913242 PU, P23; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHAWVER LK, 1994, CANCER RES, V54, P1367; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WELS W, 1992, CANCER RES, V52, P6310; WELS W, 1992, J STEROID BIOCHEM, V43, P1, DOI 10.1016/0960-0760(92)90180-Q; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	43	144	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23931	23936						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929040				2022-12-27	WOS:A1994PQ34600015
J	HENRICKSEN, LA; WOLD, MS				HENRICKSEN, LA; WOLD, MS			REPLICATION PROTEIN-A MUTANTS LACKING PHOSPHORYLATION SITES FOR P34(CDC2) KINASE SUPPORT DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL-CYCLE; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; A PHOSPHORYLATION; POLYMERASE-ALPHA; MULTIPLE STAGES; RP-A; INVITRO; CDC2	Replication Protein A (RPA) is a multisubunit, single-stranded DNA-binding protein essential for DNA metabolism in eukaryotic cells. The 32-kDa subunit of RPA is phosphorylated in a cell cycle-dependent manner becoming phosphorylated during S phase. It has been postulated that this phosphorylation may regulate the activities of RPA and that the family of p34(cdc2) kinases directly catalyzes the phosphorylation of RPA in the cell, We have mutated the two consensus p34(cdc2) sites in the 32-kDa subunit of RPA individually and in combination and purified the mutant protein complexes. Mutant RPA with both consensus p34(cdc2) sites converted to alanine was not phosphorylated by purified p34(cdc2) kinase. Nevertheless, we found that the properties of these RPA mutants were identical to those of the wild-type protein. The mutated RPA proteins had normal single-stranded DNA binding activity and were completely functional for DNA replication. In addition, the mutants became hyperphosphorylated when incubated under DNA replication conditions. These results demonstrate that phosphorylation by p34(cdc2) kinase is not essential for RPA function in DNA replication in vitro. Possible roles of RPA phosphorylation on DNA metabolism are discussed.	UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NIGMS NIH HHS [GM44721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MELENDY T, 1993, J BIOL CHEM, V268, P3389; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEO YS, 1991, J BIOL CHEM, V266, P13161; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	33	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24203	24208						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929076				2022-12-27	WOS:A1994PQ34600057
J	MACLACHLAN, I; NIMPF, J; SCHNEIDER, WJ				MACLACHLAN, I; NIMPF, J; SCHNEIDER, WJ			AVIAN RIBOFLAVIN BINDING-PROTEIN BINDS TO LIPOPROTEIN RECEPTORS IN ASSOCIATION WITH VITELLOGENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; EGG-WHITE RIBOFLAVIN; CHICKEN OOCYTE RECEPTOR; YOLK-RIBOFLAVIN; CALCIUM-PHOSPHATE; SEQUENCE; CHAINS; SITE	Riboflavin binding protein (ribBP) is an essential component of chicken eggs; it supplies the oocyte (i.e. yolk) and egg white with sufficient amounts of the vitamin riboflavin to sustain embryonic development until hatching. There are three forms of ribBP in the laying hen; synthesized by the liver under the control of estrogen, it enters the serum (sribBP) and is delivered to yolk where it becomes carboxyl-terminally truncated (yribBP). The egg white form (wribBP), synthesized by the oviduct, is a product of the same gene as sribBP but has a different glycosylation pattern. Our efforts to delineate the mechanism for uptake of yolk precursors into rapidly growing chicken oocytes have previously identified a multifunctional oocyte-specific 95-kDa lipoprotein receptor that belongs to the low density lipoprotein receptor gem family (Barber, D. L., Sanders, E. J., Aebersold, R., and Schneider, W. J. (1991) J. Biol. Chem. 266, 18761-18770). We now report that in serum, ribBP associates with another yolk precursor, the lipid-, phosphate, and ion-carrier vitellogenin (VTG), a known ligand of the 95-kDa receptor. In the presence of VTG, I-125-labeled sribBP binds to the 95-kDa receptor and, under certain conditions, also to the avian oocyte low density lipoprotein receptor-related protein (Stifani, S., Barber, D. L., Aebersold, R., Steyrer, E., Shen, X., Nimpf, J., and Schneider, W. J. (1991) J. Biol. Chem. 266, 19079-19087). The interaction between ribBP and the 95-kDa receptor and/or VTG requires Ca2+ and PO43-. Interestingly, sribBP, yribBP, and wribBP are all capable of VTG-associated receptor binding. This demonstrates that (i) the carboxyl-terminal 11 or 13 amino acids, which are removed from sribBP upon oocytic uptake, are not involved in receptor binding and (ii) receptor binding and/or association of ribBP with VTG is not dependent on the carbohydrate structure present on sribBP. The results indicate that the oocytic uptake of sribBP is mediated, through association with VTG, by the 95-kDa receptor and possibly other oocytic members of the low density lipoprotein receptor gene family, adding an interesting and novel variation to ligand recognition by these receptors.	UNIV & BIOCTR VIENNA,DEPT MOLEC GENET,A-1030 VIENNA,AUSTRIA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA	University of Vienna; University of Alberta				Nimpf, Johannes/0000-0002-9273-3492				ABRAMS VAM, 1988, COMP BIOCHEM PHYS B, V90, P243, DOI 10.1016/0305-0491(88)90068-5; ABRAMS VAM, 1989, COMP BIOCHEM PHYS B, V93, P291, DOI 10.1016/0305-0491(89)90084-9; AOKI T, 1993, ARCH BIOCHEM BIOPHYS, V305, P242, DOI 10.1006/abbi.1993.1417; AOKI T, 1987, BIOCHIM BIOPHYS ACTA, V911, P238, DOI 10.1016/0167-4838(87)90013-6; BAILEY GS, 1990, RADIOISOTOPES BIOL P, P191; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BEISIEGEL U, 1981, J BIOL CHEM, V256, P4071; BENOREPARSONS M, 1988, NUTR RES, V8, P789, DOI 10.1016/S0271-5317(88)80159-3; BENOREPARSONS M, 1986, TRANSPORT RIBOFLAVIN; FREUND J, 1956, Bibl Tuberc, P130; GEORGE R, 1987, J BIOL CHEM, V262, P16838; HAMAZUME Y, 1984, J BIOCHEM-TOKYO, V95, P1633, DOI 10.1093/oxfordjournals.jbchem.a134776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIKHOSHERSTOV LM, 1991, BIOORG KHIM+, V17, P246; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLACHLAN I, 1993, J BIOL CHEM, V268, P23222; MALHOTRA P, 1991, BIOCHEM INT, V23, P127; MILLER MS, 1982, J BIOL CHEM, V257, P6818; MILLER MS, 1986, METHOD ENZYMOL, V122, P227; MILLER MS, 1982, BIOCHIM BIOPHYS ACTA, V715, P126, DOI 10.1016/0304-4165(82)90058-7; MURTHY US, 1976, BIOCHIM BIOPHYS ACTA, V434, P69, DOI 10.1016/0005-2795(76)90036-2; NIMPF J, 1994, J BIOL CHEM, V269, P212; NORIOKA N, 1985, J BIOCHEM-TOKYO, V97, P19, DOI 10.1093/oxfordjournals.jbchem.a135044; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1990, J BIOL CHEM, V265, P882; STIFANI S, 1990, BIOCHIM BIOPHYS ACTA, V1045, P271, DOI 10.1016/0005-2760(90)90130-P; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; TARUTANI M, 1993, J BIOCHEM-TOKYO, V113, P677, DOI 10.1093/oxfordjournals.jbchem.a124102; WALKER M, 1991, COMP BIOCHEM PHYS B, V100, P77, DOI 10.1016/0305-0491(91)90088-U; WHITE HB, 1986, BIOCHEM J, V238, P671, DOI 10.1042/bj2380671; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P897, DOI 10.1016/0010-406X(67)90780-3; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P889, DOI 10.1016/0010-406X(67)90779-7; ZHENG DB, 1988, J BIOL CHEM, V263, P11126	39	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24127	24132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929067				2022-12-27	WOS:A1994PQ34600045
J	NELSON, H; MANDIYAN, S; NELSON, N				NELSON, H; MANDIYAN, S; NELSON, N			THE SACCHAROMYCES-CEREVISIAE VMA7 GENE ENCODES A 14-KDA SUBUNIT OF THE VACUOLAR H+-ATPASE CATALYTIC SECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; NEUROSPORA-CRASSA; BOVINE KIDNEY; V-ATPASES; MEMBRANE; EVOLUTION; PURIFICATION; TRIPHOSPHATASE	Yeast vacuoles contain an H+-ATPase that acidifies the vacuolar lumen and generates an electrochemical gradient of protons across their membranes. Five polypeptides, denoted as subunits A to E in the order of decreasing molecular masses from 69 to 27 kDa, were identified in the catalytic sector of the enzyme. However, other polypeptides may be necessary for the activity of the enzyme. When a 14-kDa polypeptide was suggested to be a subunit of a specialized V-ATPase in Manduca sexta, and a homologous short sequence was detected downstream of the UGA1 gene in yeast, we cloned this counterpart gene from yeast. The gene VMA7 encodes a protein Vma7p of about 14 kDa. The predicted protein is highly homologous to the above mentioned M. sexta protein. The Delta vma7::URA3 null mutant exhibits growth characteristics typical of other VMA disruptant mutants in genes encoding subunits of the catalytic sector. The Delta vma7::URA3 null mutants are not able to grow on a medium buffered at pH 7.5, they fail to accumulate quinacrine into their vacuoles and the other subunits of the catalytic sector are not assembled onto the vacuolar membrane in its absence. Epitope-tagged Vma7p was constructed and the proton uptake activity of isolated vacuoles from this yeast strain was markedly inhibited by a monoclonal antibody against the epitope-tag. A cold inactivation experiment demonstrated that Vma7p is a genuine subunit of the catalytic sector of V-ATPase and it is denoted as subunit F.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ADACHI I, 1990, J BIOL CHEM, V265, P967; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GLUCK S, 1992, J EXP BIOL, V172, P29; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRAF R, 1994, J BIOL CHEM, V269, P3767; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P221; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NELSON N, 1988, METHOD ENZYMOL, V157, P619; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1983, METHODS YEAST GENETI; SHIN CK, 1988, MOL CELL BIOL, V8, P3094; STEVENS TH, 1992, J EXP BIOL, V172, P47; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WARD JM, 1992, PLANT PHYSIOL, V99, P925, DOI 10.1104/pp.99.3.925	48	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24150	24155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929071				2022-12-27	WOS:A1994PQ34600049
J	SPARKS, AB; QUILLIAM, LA; THORN, JM; DER, CJ; KAY, BK				SPARKS, AB; QUILLIAM, LA; THORN, JM; DER, CJ; KAY, BK			IDENTIFICATION AND CHARACTERIZATION OF SRC SH3 LIGANDS FROM PHAGE-DISPLAYED RANDOM PEPTIDE LIBRARIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-SRC; SIGNALING PROTEINS; DOMAINS; BINDING; SH3-DOMAIN; ACTIVATOR; TYROSINE; AFFINITY; OOCYTES; KINASE	We have used the Src homology 3 (SH3) domain to screen two phage displayed random peptide libraries, each containing 2 x 10(8) unique members, and have identified a series of high affinity peptide ligands. The peptides possess similar proline-rich regions, which yield a consensus Src SH3-binding motif of RPLPPLP. We have confirmed this motif by screening a phage-displayed peptide library biased for SH3 ligands and identifying the same consensus sequence. Binding studies using synthetic peptides suggest that the RPLPPLP motif is important for SH3 binding and confers specificity for the Src SH3 domain, and that residues which flank the motif may also contribute to binding. Peptides that contain the RPLPPLP motif compete Src, but not Abl or phospholipase C gamma, SH3 interactions with SH3-binding proteins from cell lysates (IC50 = 1-5 mu M). Furthermore, RPLPPLP-related peptides are able to accelerate progesterone-induced maturation of Xenopus laevis oocytes. A similar acceleration has been observed in oocytes treated with activated, but not normal, Xenopus Src, suggesting the possibility that the peptides are able to antagonize the negative regulation of Src activity by Src SH3 in vivo.	UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R01CA042978, R01CA055008] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAY BK, 1991, METHOD CELL BIOL, V36, P663; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OKADA M, 1993, J BIOL CHEM, V268, P18070; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	149	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23853	23856						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929027				2022-12-27	WOS:A1994PQ34600001
J	TANAKA, T; NISHIDA, J; MITANI, K; OGAWA, S; YAZAKI, Y; HIRAI, H				TANAKA, T; NISHIDA, J; MITANI, K; OGAWA, S; YAZAKI, Y; HIRAI, H			EVI-1 RAISES AP-1 ACTIVITY AND STIMULATES C-FOS PROMOTER TRANSACTIVATION WITH DEPENDENCE ON THE 2ND ZINC-FINGER DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MYELOID-TRANSFORMING GENE; PROTO-ONCOGENE FOS; DNA-BINDING ACTIVITY; RETROVIRAL INSERTIONS; AUTO-REGULATION; GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; JUN	Evi-1 is a gene, encoding a zinc finger protein, associated with a common viral integration site in murine leukemias. It is suggested that Evi-1 plays important roles in embryogenesis and transformation of myeloid cells. To elucidate mechanisms by which Evi-1 induces such biological effects, we analyzed the relationship between Evi-1 and AP-1 which could regulate cellular proliferation and differentiation. When Evi-1 was expressed, transactivation through a 12-O-tetradecanoylphorbol 13-acetate-responsive element was observed in NIH3T3 and P19 cells. Evi-1-transfected P19 cells showed some differentiated phenotypes and increased expression of endogenous c-Jun and c-Fos. These results indicate that Evi-1 raises AP-1 activity. Evi-1 caused stimulation of the c-fos promoter transactivation, which seems to be a main mechanism of AP-1 activation, through at least two portions of the promoter. Evi-1 has the first zinc finger domain at the N terminus and the second zinc finger domain near the C-terminus. We constructed deletion mutants of Evi-1 and investigated the functions of these domains. It was shown that the second zinc finger domain is essential for the activation of AP-1 and transactivation of the c-fos promoter,	JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Jichi Medical University; University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008					ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CACERES J, 1990, ONCOGENE, V5, P59; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FICHELSON S, 1992, LEUKEMIA, V6, P93; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; OVAL J, 1992, LEUKEMIA, V6, P446; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SATAKE M, 1988, ONCOGENE, V3, P69; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	59	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24020	24026						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929053				2022-12-27	WOS:A1994PQ34600029
J	HARRISON, KA; DRUEY, KM; DEGUCHI, Y; TUSCANO, JM; KEHRL, JH				HARRISON, KA; DRUEY, KM; DEGUCHI, Y; TUSCANO, JM; KEHRL, JH			A NOVEL HUMAN HOMEOBOX GENE DISTANTLY RELATED TO PROBOSCIPEDIA IS EXPRESSED IN LYMPHOID AND PANCREATIC TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DROSOPHILA HOMEOTIC GENES; CELL-SURFACE-ANTIGEN; HUMAN-BONE-MARROW; ANTENNAPEDIA HOMEODOMAIN; TRANSCRIPTION FACTOR; DNA-SEQUENCES; HUMAN PROTEIN; BINDING; DOMAIN	A novel human homeobox gene, HB9, was isolated from a cDNA library prepared from in vitro stimulated human tonsil B lymphocytes and from a human genomic library. The HB9 gene is composed of 3 exons spread over 6 kilobases of DNA. An open reading frame of 1206 nucleotides is in frame with a diverged homeodomain. The predicted HB9 protein has a molecular mass of 41 kilodaltons and is enriched for alanine, glycine, and leucine. The HB9 homeodomain is most similar to that of the Drosophila melanogaster homeobox gene proboscipedia. Northern blot analysis of poly(A) RNA purified from the human B cell line RPMI 8226 and from activated T cells revealed a major mRNA transcript of 2.2 kilobases. Similar analysis of poly(A) RNA from a variety of adult tissues demonstrated HB9 transcripts in pancreas, small intestine, and colon. Reverse transcriptase-polymerase chain reaction was used to examine HB9 RNA transcripts in hematopoietic cell lines. HB9 RNA transcripts were most prevalent in several human B cell lines and K562 cells. In addition, transcripts were detected in RNA prepared from tonsil B cells and in situ hybridization studies localized them in the germinal center region of adult tonsil. These findings suggest the involvement of HB9 in regulating gene transcription in lymphoid and pancreatic tissues.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; BAIER LJ, 1991, BLOOD, V78, P1047; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BONCINELLI E, 1989, GENOME, V31, P745, DOI 10.1139/g89-133; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; CRIBBS DL, 1992, EMBO J, V11, P1437, DOI 10.1002/j.1460-2075.1992.tb05188.x; DEGUCHI Y, 1991, NUCLEIC ACIDS RES, V19, P3742, DOI 10.1093/nar/19.13.3742; DEGUCHI Y, 1991, NEW BIOL, V3, P353; DEGUCHI Y, 1993, LEUKEMIA, V7, P446; DEGUCHI Y, 1991, BLOOD, V78, P323; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAZIOSI C, 1993, CURR PROTOCOLS IMMUN, V5; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HOEY T, 1988, MOL CELL BIOL, V8, P4598, DOI 10.1128/MCB.8.11.4598; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KEHRL JH, 1994, CRIT REV ONCOL HEMAT, V16, P145, DOI 10.1016/1040-8428(94)90046-9; KIN Y, 1989, P NATL ACAD SCI USA, V86, P7716; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEVINE M, 1984, CELL, V38, P667, DOI 10.1016/0092-8674(84)90261-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MOORE KL, 1988, DEV HUMAN, P89; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURAGUCHI A, 1983, J EXP MED, V157, P530, DOI 10.1084/jem.157.2.530; NAJFELD V, 1992, GENE CHROMOSOME CANC, V5, P343, DOI 10.1002/gcc.2870050410; NASMYTH KA, 1980, COLD SPRING HARB SYM, V45, P961; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUGHART K, 1989, P NATL ACAD SCI USA, V86, P7067, DOI 10.1073/pnas.86.18.7067; SCOTT MP, 1993, NUCLEIC ACIDS RES, V21, P1687, DOI 10.1093/nar/21.8.1687; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; WEDEEN CJ, 1990, NUCLEIC ACIDS RES, V18, P1908, DOI 10.1093/nar/18.7.1908; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787	66	76	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19968	19975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914194				2022-12-27	WOS:A1994PA12600049
J	HAGIWARA, H; SAKAGUCHI, H; ITAKURA, M; YOSHIMOTO, T; FURUYA, M; TANAKA, S; HIROSE, S				HAGIWARA, H; SAKAGUCHI, H; ITAKURA, M; YOSHIMOTO, T; FURUYA, M; TANAKA, S; HIROSE, S			AUTOCRINE REGULATION OF RAT CHONDROCYTE PROLIFERATION BY NATRIURETIC PEPTIDE-C AND ITS RECEPTOR, NATRIURETIC PEPTIDE RECEPTOR-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; GUANYLATE-CYCLASE; PORCINE BRAIN; ENDOTHELIAL-CELLS; ATRIAL; HORMONE; CNP; FAMILY; VASODILATORS	Natriuretic peptide receptor-B (NPR-B) was identified in rat chondrocytes, and its physiological functions were investigated. Rat tissues, including the xiphoid cartilage, brain, lung, liver, adrenal gland, and kidney, were screened for NPR-B activity, which we assayed by receptor guanylate cyclase activity specifically stimulated by C-type natriuretic peptide (CNP), a known selective activator of NPR-B. Cartilage showed distinctly higher NPR-B activity. Furthermore, exposure of cultured rat chondrocytes to CNP (10(-6) M) resulted in a large increase in intracellular cGMP production (376 +/- 38 pmol/well), with threshold responses occurring between 10(-10) and 10(-9) M CNP. Atrial natriuretic peptide and brain natriuretic peptide also stimulated cGMP production in rat chondrocytes but with a potency that was at least 10 times less than that of CNP. Polymerase chain reaction analysis also demonstrated NPR-B gene expression in adult rat xiphisternum and cultured chondrocytes. These findings indicate that NPR-B is present in rat chondrocytes. In rat chondrocytes exposed to CNP, [H-3]thymidine incorporation was inhibited in a dose-dependent manner (half-maximal response, 10(-11) M). However, much higher concentrations of atrial natriuretic peptide were required to induce the inhibition of thymidine incorporation. Interestingly, CNP-like immunoreactivity was detected in the conditioned medium from chondrocyte cultures. In addition, TGF-beta 1, a multifunctional cytokine, induced a marked increase in CNP se cretion and CNP mRNA levels in chondrocytes. These results indicate that autocrine CNP inhibits mitogenesis in chondrocytes via NPR-B under the control of TGF-beta 1.	SUNTORY INST BIOMED RES,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd	HAGIWARA, H (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,4259 NAGATSUTA CHO,YOKOHAMA 227,JAPAN.							APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; APPEL RG, 1990, AM J PHYSIOL, V259, pE312, DOI 10.1152/ajpendo.1990.259.3.E312; CAHILL PA, 1993, J CELL PHYSIOL, V154, P28, DOI 10.1002/jcp.1041540105; CANAANKUHL S, 1992, ENDOCRINOLOGY, V130, P550, DOI 10.1210/en.130.1.550; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DUDA T, 1993, BIOCHEMISTRY-US, V32, P1391, DOI 10.1021/bi00057a001; EGUCHI S, 1992, EUR J PHARM-MOLEC PH, V225, P79, DOI 10.1016/0922-4106(92)90043-U; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; FURUYA M, 1990, BIOCHEM BIOPH RES CO, V170, P201, DOI 10.1016/0006-291X(90)91260-Y; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARG UC, 1989, AM J PHYSIOL, V257, pF60, DOI 10.1152/ajprenal.1989.257.1.F60; HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167-4889(88)90092-4; HOLDER AT, 1980, J ENDOCRINOL, V85, P35, DOI 10.1677/joe.0.0850035; HOSKINS WE, 1977, J DENT RES, V56, P509, DOI 10.1177/00220345770560051101; ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756; ISHIZAKA Y, 1992, BIOCHEM BIOPH RES CO, V189, P697, DOI 10.1016/0006-291X(92)92257-X; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; KARIYA K, 1989, ATHEROSCLEROSIS, V80, P143, DOI 10.1016/0021-9150(89)90022-1; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KONRAD EM, 1992, REGUL PEPTIDES, V39, P177, DOI 10.1016/0167-0115(92)90539-7; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; MIZUNO T, 1990, BIOCHEM BIOPH RES CO, V173, P886, DOI 10.1016/S0006-291X(05)80869-1; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; PINES M, 1988, ENDOCRINOLOGY, V123, P360, DOI 10.1210/endo-123-1-360; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLECHTER NL, 1986, AM J PHYSIOL, V250, pE231, DOI 10.1152/ajpendo.1986.250.3.E231; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TSCHAN T, 1993, J BIOL CHEM, V268, P5156; VIGNE P, 1992, BIOCHEM BIOPH RES CO, V183, P640, DOI 10.1016/0006-291X(92)90530-X; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454	47	105	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10729	10733						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7908295				2022-12-27	WOS:A1994NF01700080
J	LINKENS, HJ; BARTHOLMES, P; KAUFMANN, M				LINKENS, HJ; BARTHOLMES, P; KAUFMANN, M			THE ROLE OF THE HINGE REGION OF THE BETA-2-SUBUNIT IN BETA-REPLACEMENT SPECIFICITY OF TRYPTOPHAN SYNTHASE FROM ESCHERICHIA-COLI - ANALYSIS OF PROTEOLYTICALLY MODIFIED BETA-SPECIES CLEAVED BY ENDOPROTEINASE GLU-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; SALMONELLA-TYPHIMURIUM; ALPHA-SUBUNIT; BIENZYME COMPLEX; ACTIVE-SITE; SYNTHETASE; MECHANISM; BINDING; SUBSTRATE; PROTEIN	The beta2-subunit of tryptophan synthase from Escherichia coli was proteolyzed between Glu-296 and Ser-297 (Glu-nicked beta2), using staphylococcal protease V-8. Recombining Glu-nicked beta1 with native alpha-subunits yields an enzymatically active and stable complex (alpha2.Glu-nicked beta2) with K(d) = 3 muM. Comparing the properties of alpha2.Glu-nicked beta2 with those of isolated native beta2-subunits revealed that the corresponding beta-chains are almost identical with respect to enzymatic specificities as well as to some spectral characteristics. The ratio of beta-replacement to beta-elimination activity is approximately 0.6 for both species. In the presence Of L-serine, alpha2.Glu-nicked beta2 as well as native beta2 exhibits ''aqua'' fluorescence emission at 500 nm, and no ''amber'' absorption at 468 nm can be detected with both species. However, when ammonium ions are added, the alpha2.Glu-nicked beta2 complex dramatically alters its properties. Similar to the native alpha2beta2 enzyme, the ratio of beta-replacement/beta-elimination activity increases by a factor of about 10, the aqua fluorescence disappears, and the amber complex becomes detectable. We conclude that the continuity of the hinge region in the tryptophan synthase beta2-subunit plays a crucial role in the alpha-mediated structural alteration creating beta-replacement specificity. The addition of NH4+ ions to the alpha2.Glu-nicked beta2 complex partially restores the structure-function relationships as described for native alpha2beta2 tryptophan synthase.	UNIV WITTEN HERDECKE, INST BIOCHEM, STOCKUMER STR 10, D-58448 WITTEN, GERMANY	Witten Herdecke University								ADACHI O, 1974, J BIOL CHEM, V249, P5430; AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; AHMED SA, 1991, J BIOL CHEM, V266, P21548; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNSTEIN AE, 1984, ADV ENZYMOL RAMB, V56, P1; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; CRAWFORD IP, 1980, J MOL BIOL, V142, P489, DOI 10.1016/0022-2836(80)90259-4; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; FRIGUET B, 1989, RES IMMUNOL, V140, P355, DOI 10.1016/0923-2494(89)90142-9; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; HATHAWAY GM, 1972, J BIOL CHEM, V247, P1440; HOGBERGRAIBAUD A, 1977, P NATL ACAD SCI USA, V74, P442, DOI 10.1073/pnas.74.2.442; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAUFMANN M, 1991, BIOCHEMISTRY-US, V30, P4173, DOI 10.1021/bi00231a010; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KUMAGAI H, 1971, BIOCHEM BIOPH RES CO, V44, P1271, DOI 10.1016/S0006-291X(71)80223-1; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V133, P531, DOI 10.1111/j.1432-1033.1983.tb07496.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LINKENS HJ, 1993, FEBS LETT, V320, P224, DOI 10.1016/0014-5793(93)80591-H; LU ZC, 1993, J BIOL CHEM, V268, P8727; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MURRYBRELIER A, 1990, J BIOL CHEM, V265, P7987; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; WIESINGER H, 1979, BIOCHEMISTRY-US, V18, P1979, DOI 10.1021/bi00577a020; WILHELM P, 1982, EUR J BIOCHEM, V129, P51, DOI 10.1111/j.1432-1033.1982.tb07019.x; WILHELM P, 1987, EUR J BIOCHEM, V164, P103, DOI 10.1111/j.1432-1033.1987.tb10999.x; WILSON DA, 1965, J BIOL CHEM, V240, P4801; YANOFSKY C, 1972, ENZYMES, V7, P1; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029; ZHAO GP, 1993, J BIOL CHEM, V268, P14912; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; ZHAO GP, 1992, J BIOL CHEM, V267, P526	41	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9783	9789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7908288				2022-12-27	WOS:A1994NE05300061
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			RECONSTITUTION OF DRUG-STIMULATED ATPASE ACTIVITY FOLLOWING COEXPRESSION OF EACH HALF OF HUMAN P-GLYCOPROTEIN AS SEPARATE POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGING HOMOLOGOUS DOMAINS; RESISTANT HUMAN-CELLS; MULTIDRUG-RESISTANCE; SARCOPLASMIC-RETICULUM; INSECT CELLS; MOUSE MDR1; FUNCTIONAL-ANALYSIS; BINDING SITES; KB CELLS; PROTEINS	P-glycoprotein consists of two homologous halves, each composed of six potential transmembrane sequences and an ATP-binding domain. The cDNA coding for human P-glycoprotein was divided in half and subcloned into separate plasmids in order to express each half as a separate polypeptide and to characterize its contribution to function. Expression of cDNAs coding for either the NH2- or COOH-terminal half-molecules in HEK 293 cells yielded products of 88 and 64 kDa, respectively. The NH2-terminal half-molecule was glycosylated, since its size decreased from 88 to 79 kDa when expressed in the presence of tunicamycin. No change was observed in the size of the COOH-terminal half-molecule when it was expressed in the presence of tunicamycin, indicating that it was not glycosylated. The cDNAs coding for each half of P-glycoprotein were transfected into NIH-3T3 cells to test for biological activity. No drug-resistant colonies were obtained when cells were transfected with cDNA coding for each half-molecule or when cells were co-transfected with both cDNAs, although stable expression of each half-molecule was detected. The inability to confer drug resistance was likely due to a defect in targeting of the half-molecules to the cell surface. Each half-molecule was then expressed in Sf9 insect cells using a baculovirus vector to allow measurement of partial function. The half-molecules exhibited ATPase activity, but their activities were not stimulated by drug substrates. Drug-stimulatable ATPase activity was present, however, when the half-molecules were expressed together. These results suggest that coupling of ATPase activity to drug binding requires interaction between both halves of P-glycoprotein.	UNIV TORONTO,DEPT MED,MED RES COUNCIL,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BETZ R, 1987, J BIOL CHEM, V262, P546; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Gartner J, 1993, Semin Cell Biol, V4, P45, DOI 10.1006/scel.1993.1006; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1993, SEMIN CELL BIOL, V4, P1; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHURR E, 1989, CANCER RES, V49, P2729; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; Summers MD, 1987, TEXAS AGR EXPT STATI; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	47	176	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7750	7755						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907331				2022-12-27	WOS:A1994NA03200110
J	SAMUEL, JE; GORDON, VM				SAMUEL, JE; GORDON, VM			EVIDENCE THAT PROTEOLYTIC SEPARATION OF SHIGA-LIKE TOXIN TYPE-IIV A SUBUNIT INTO A(1) AND A(2), SUBUNITS IS NOT REQUIRED FOR TOXIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIGELLA-DYSENTERIAE TYPE-1; ESCHERICHIA-COLI O157-H7; PSEUDOMONAS EXOTOXIN; CHOLERA-TOXIN; EDEMA DISEASE; ENTERO-TOXIN; PROTEASE; CLEAVAGE; FRAGMENT; CYTOSOL	The role for proteolytic activation of Shiga-like toxin type II variant (SLT-IIv) A subunit was examined using site-directed mutagenesis. Processing of the enzymatically active A subunit by trypsin results in cleavage at an arginine residue(s) (Arg(247) and/or Arg(25O)) located between two cysteines. After reduction of the disulfide bond, the processed A subunit separates into an enzymatically active A(1) and an A(2) peptide. Substitution mutations were created in SLT-IIv that replaced each or both of the two arginines with either glutamic acid (R247E, R250E, or R247E/R250E) or histidine (R247H, R250H, or R247H/R250H). The products of all glutamic acid substitution mutations were immunoreactive but were not cytotoxic due to an inability to assemble into holotoxin. The products of all histidine substitution mutations had cytotoxic activities, enzymatic activities, and a lethal dose for mice similar to that of native toxin. R247H and R250H were susceptible to proteolytic cleavage while R247H/R250H was resistant to processing by exogenously added trypsin. Native toxin incubated with Vero cells was completely cleaved while only a fraction of R247H/R250H was cleaved. These results demonstrate that cleavage of SLT-IIv can be mediated by proteases with different specificities and suggest efficient cleavage is not required for toxicity.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	SAMUEL, JE (corresponding author), MICROCARB INC,GAITHERSBURG,MD 20879, USA.				NIAID NIH HHS [5T32-AI07308-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007308] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOOTH BA, 1984, INFECT IMMUN, V45, P558, DOI 10.1128/IAI.45.3.558-560.1984; BROWN JE, 1980, FEBS LETT, V117, P84, DOI 10.1016/0014-5793(80)80918-5; CLEMENTS JD, 1979, INFECT IMMUN, V24, P760, DOI 10.1128/IAI.24.3.760-769.1979; CRITCHLEY DR, 1981, J BIOL CHEM, V256, P8724; DOWNES FP, 1988, INFECT IMMUN, V56, P1926, DOI 10.1128/IAI.56.8.1926-1933.1988; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; ENDO Y, 1987, J BIOL CHEM, V262, P5908; GENTRY MK, 1980, J CLIN MICROBIOL, V12, P361, DOI 10.1128/JCM.12.3.361-366.1980; GILL DM, 1979, J INFECT DIS, V139, P674, DOI 10.1093/infdis/139.6.674; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; JOBLING MG, 1991, 27TH JOINT C CHOL RE, P217; KITTELL FB, 1991, J AGR FOOD CHEM, V39, P141, DOI 10.1021/jf00001a027; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KONGMUANG U, 1988, FEMS MICROBIOL LETT, V56, P105, DOI 10.1016/0378-1097(88)90135-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; MACLEOD DL, 1990, INFECT IMMUN, V58, P1232, DOI 10.1128/IAI.58.5.1232-1239.1990; Maniatis T., 1982, MOL CLONING; MARQUES LRM, 1987, FEMS MICROBIOL LETT, V44, P33, DOI 10.1016/0378-1097(87)90195-9; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; OBRIEN AD, 1983, INFECT IMMUN, V40, P675, DOI 10.1128/IAI.40.2.675-683.1983; OGATA M, 1990, J BIOL CHEM, V265, P20678; OGATA M, 1992, J BIOL CHEM, V267, P25396; OLSNES S, 1981, J BIOL CHEM, V256, P8732; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; OLSNES S, 1985, ENDOCYTOSIS, V1, P195; ORLANDI PA, 1993, J BIOL CHEM, V268; PERERA LP, 1988, J CLIN MICROBIOL, V26, P2127, DOI 10.1128/JCM.26.10.2127-2131.1988; RAPPAPORT RS, 1976, J INFECT DIS, V133, pS41, DOI 10.1093/infdis/133.Supplement_1.S41; REED L. J., 1938, AMER JOUR HYG, V27, P493; REISBIG R, 1981, J BIOL CHEM, V256, P8739; SAMUEL JE, 1990, INFECT IMMUN, V58, P611, DOI 10.1128/IAI.58.3.611-618.1990; SANDVIG K, 1993, ZBL BAKT-INT J MED M, V278, P296, DOI 10.1016/S0934-8840(11)80846-7; SANDVIG K, 1992, NATURE, V358, P296; STROCKBINE NA, 1988, J BACTERIOL, V170, P1116, DOI 10.1128/jb.170.3.1116-1122.1988; STROCKBINE NA, 1986, INFECT IMMUN, V53, P135, DOI 10.1128/IAI.53.1.135-140.1986; TESH VL, 1993, INFECT IMMUN, V61, P3392, DOI 10.1128/IAI.61.8.3392-3402.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI T, 1984, INFECT IMMUN, V46, P94, DOI 10.1128/IAI.46.1.94-97.1984; VASIL ML, 1977, INFECT IMMUN, V16, P353, DOI 10.1128/IAI.16.1.353-361.1977; WEINSTEIN DL, 1988, J BACTERIOL, V170, P4223, DOI 10.1128/jb.170.9.4223-4230.1988; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673	45	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4853	4859						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7906271				2022-12-27	WOS:A1994MX57100026
J	BECKER, S; PALM, D; SCHINZEL, R				BECKER, S; PALM, D; SCHINZEL, R			DISSECTING DIFFERENTIAL BINDING IN THE FORWARD AND REVERSE REACTION OF ESCHERICHIA-COLI MALTODEXTRIN PHOSPHORYLASE USING 2-DEOXYGLUCOSYL SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-PHOSPHORYLASE; PYRIDOXAL 5'-PHOSPHATE; ALPHA; PHOSPHATE; COMPLEX; SITE; SPECIFICITY; DERIVATIVES; ACTIVATION; CATALYSIS	Substrate analogs are used in combination with site-directed mutagenesis to probe specific interactions between substrate and enzyme in the forward and reverse direction of the Escherichia coli maltodextrin phosphorylase reaction. In the phosphorolysis (degradation) mode, removal of the 2-OH group of the terminal glucose of the polysaccharide results in a 30-fold reduction of K(m) awhile similar changes were of no influence when the same polysaccharide was used for priming the synthesis. Mutation of active site residues Glu637 or Tyr538 does not change apparent affinity of substrates during degradation. In the synthesis mode, 2-deoxyglucose-1-P as substrate causes a 2-fold reduction of the wild-type k(cat)/K(m) while for the Y538F mutant a approximately 7-fold reduction is observed. In contrast, the mutation of Glu637 to Asp causes a 10-fold increase in k(cat)/K(m). Therefore, different binding sites for the terminal glucose residue of the oligosaccharide and glucose-1-P exist. Glu637 and Tyr-538 are part of the glucose-1-P binding site and do not interact with the terminal glucose residue. A 2-fold increase in rate was observed in both directions using the 2-deoxy derivatives. This confirms the role of intrinsic electronic effects in stabilizing the transition state. Uncompetitive substrate inhibition at high concentrations of maltoheptaose in the phosphorolysis direction is explained by inhibitory binding of the sugar in the synthesis mode.	THEODOR BOVERI INST BIOWISSENSCH, BIOZENTRUM PHYSIOL CHEM I, HUBLAND, D-97074 WURZBURG, GERMANY									BARFORD D, 1989, NATURE, V218, P233; Bergmeyer H.U., 1983, METHOD ENZYMAT AN, V2, P204; BISSWANGER H, 1979, THEORIE ENZYMKINETIK, P101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO J, 1969, BIOCHEMISTRY-US, V8, P1459, DOI 10.1021/bi00832a022; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRENCH D, 1953, J AM CHEM SOC, V75, P4490, DOI 10.1021/ja01114a028; GOLD MH, 1974, ARCH BIOCHEM BIOPHYS, V161, P515, DOI 10.1016/0003-9861(74)90334-8; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; KLEIN HW, 1982, BIOCHEMISTRY-US, V21, P6675, DOI 10.1021/bi00269a010; LEATHERBARROW RJ, 1992, GRAFIT VERSION 30; LEONIDAS DD, 1992, PROTEIN SCI, V1, P1112, DOI 10.1002/pro.5560010905; MADSEN NB, 1986, COENZYMES COFACTORS, V1, P355; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PALM D, 1990, BIOCHEMISTRY-US, V29, P1099, DOI 10.1021/bi00457a001; PALM D, 1991, INT UNION B, V199, P377; PHILIP G, 1982, BIOCHEMISTRY-US, V21, P3043, DOI 10.1021/bi00256a002; SAHEKI S, 1985, ANAL BIOCHEM, V148, P277, DOI 10.1016/0003-2697(85)90229-5; SCHINZEL R, 1990, BIOCHEMISTRY-US, V29, P9956, DOI 10.1021/bi00494a028; SEGEL I, 1975, ENZYME KINETICS, P316; SIERKS MR, 1992, PROTEIN ENG, V5, P185, DOI 10.1093/protein/5.2.185; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; SPRANG SR, 1992, PROTEIN SCI, V1, P1100, DOI 10.1002/pro.5560010904; STREET IP, 1989, BIOCHEMISTRY-US, V28, P1581, DOI 10.1021/bi00430a024; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; SUGANUMA T, 1991, CARBOHYD RES, V217, P213, DOI 10.1016/0008-6215(91)84131-W; WITHERS SG, 1986, CARBOHYD RES, V154, P127, DOI 10.1016/S0008-6215(00)90028-4	31	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2485	2490						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905479				2022-12-27	WOS:A1994MV43200024
J	BAKER, DP; STEBBINS, JW; DESENA, E; KANTROWITZ, ER				BAKER, DP; STEBBINS, JW; DESENA, E; KANTROWITZ, ER			GLUTAMIC-ACID-86 IS IMPORTANT FOR POSITIONING THE 80S LOOP AND ARGININE-54 AT THE ACTIVE-SITE OF ESCHERICHIA-COLI ASPARTATE TRANSCARBAMOYLASE AND FOR THE STRUCTURAL STABILIZATION OF THE C1-C2 INTERFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURES; CATALYTIC CHAIN; LIGATED-T; CARBAMOYLTRANSFERASE; BINDING; RESOLUTION; MUTANTS; ANALOG; STATE	Glu-86, which interacts with the side chain of Arg-54 across the C1-C2 interface of Escherichia coli aspartate transcarbamoylase, tethers the end of the flexible 80's loop, which moves into the active site during the T to R transition. In order to determine whether this interaction is important for the correct positioning of the 80's loop and Arg-54 at the active site and also for the structural stabilization of the enzyme, a mutant version was created in which Glu-86 was replaced by Gln (Glu-86 --> Gln). Although the mutant holoenzyme exhibits almost normal homotropic cooperativity, both the holoenzyme and catalytic subunit exhibit substantial reductions in activity and affinity for aspartate and carbamyl phosphate. Furthermore, the mutant holoenzyme shows a marked decrease in the activation by ATP and by the bisubstrate analog N-(phosphonoacetyl)-L-aspartate, reduced inhibition by CTP, as well as reduced affinities for these ligands. Results from molecular dynamics simulations of the Glu-86 --> Gln and Glu-86 --> Ala enzymes suggest that the positions of the 80's loop and Arg-54 are significantly perturbed by the introduction of these mutations. Taken together, these results indicate that the interaction between Glu-86 and Arg-54 is important for the formation of the high affinity, high activity form of the enzyme by stabilizing the correct position of the 80's loop and Arg-54 at the active site. Heat inactivation experiments also demonstrated that Glu-86 plays a significant role in the structural stabilization of the C1-C2 interface, since the temperature required for loss of half of the activity of the Glu-86 --> Gln catalytic subunit is reduced by 5 degrees C relative to the wild-type catalytic subunit.	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College					NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline; NIGMS NIH HHS [NIGMS GM26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURZ DS, 1990, BIOPHYS CHEM, V37, P31, DOI 10.1016/0301-4622(90)88005-D; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P389, DOI 10.1021/bi00454a013; GOUAUX JE, 1988, P NATL ACAD SCI USA, V85, P4205, DOI 10.1073/pnas.85.12.4205; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KE HM, 1984, P NATL ACAD SCI USA, V81, P4027; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KOSMAN RP, 1993, PROTEINS, V15, P147, DOI 10.1002/prot.340150206; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; MIDDLETON SA, 1989, BIOCHEMISTRY-US, V28, P1617, DOI 10.1021/bi00430a029; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; REICHARD P, 1956, ACTA CHEM SCAND, V10, P548, DOI 10.3891/acta.chem.scand.10-0548; ROBEY EA, 1986, P NATL ACAD SCI USA, V83, P5935; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STEBBINS JW, 1992, PROTEIN SCI, V1, P1435, DOI 10.1002/pro.5560011105; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; WEST TP, 1985, BIOCHIM BIOPHYS ACTA, V839, P32, DOI 10.1016/0304-4165(85)90178-3; WU CW, 1973, BIOCHEMISTRY-US, V12, P1400, DOI 10.1021/bi00731a021; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018; XU W, 1991, BIOCHEMISTRY-US, V30, P2535, DOI 10.1021/bi00223a034; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	40	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24608	24614						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929132				2022-12-27	WOS:A1994PQ49000018
J	CHANOCK, SJ; ELBENNA, J; SMITH, RM; BABIOR, BM				CHANOCK, SJ; ELBENNA, J; SMITH, RM; BABIOR, BM			THE RESPIRATORY BURST OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; NEUTROPHIL NADPH OXIDASE; CYTOCHROME-B; BINDING SITE; CYTOSOLIC COMPONENTS; GUANINE-NUCLEOTIDES; PHAGOCYTE OXIDASE; HYDROGEN-PEROXIDE; INTERFERON-GAMMA		SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	CHANOCK, SJ (corresponding author), NCI, PEDIAT BRANCH, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028479, R01AI024838, R37AI024227, R01AI024227] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24227, AI-24838, AI-28479] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABRAMSON SL, 1990, CLIN RES, V38, pA236; AKARD LP, 1988, BLOOD, V72, P322; ANDERSON DP, 1992, VET IMMUNOL IMMUNOP, V30, P419, DOI 10.1016/0165-2427(92)90110-C; ARIGA T, 1993, EUR J PEDIATR, V152, P469, DOI 10.1007/BF01955051; BABIOR BM, 1976, J CLIN INVEST, V58, P989, DOI 10.1172/JCI108553; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BISHOP A, 1994, IN PRESS FREE RADIC; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; CHANOCK SJ, 1992, P NATL ACAD SCI USA, V89, P10174, DOI 10.1073/pnas.89.21.10174; CHIBA T, 1990, BIOCHEM BIOPH RES CO, V173, P376, DOI 10.1016/S0006-291X(05)81068-X; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COMBADIERE C, 1993, BLOOD, V82, P2890; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; DAPINO P, 1993, CLIN EXP IMMUNOL, V94, P533; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DING JB, 1993, J BIOL CHEM, V268, P17326; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FINAN P, 1994, J BIOL CHEM, V269, P13752; FOROOZAN R, 1992, J BIOL CHEM, V267, P24400; GREEN TR, 1988, J BIOL CHEM, V263, P5617; HANCOCK JT, 1989, BIOCHEM J, V262, P373, DOI 10.1042/bj2620373; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HIE RD, 1994, AM REV RESPIR DIS, V149, pA549; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KRECK ML, 1994, J BIOL CHEM, V269, P4161; LAURINDO FRM, 1994, CIRC RES, V74, P700, DOI 10.1161/01.RES.74.4.700; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MALY FE, 1994, J BIOL CHEM, V269, P18743; MALY FE, 1993, J EXP MED, V178, P2047, DOI 10.1084/jem.178.6.2047; MAY JM, 1979, J BIOL CHEM, V254, P9017; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MIKI T, 1992, J BIOL CHEM, V267, P18695; NACCACHE PH, 1990, BLOOD, V76, P2098; NAKAMURA M, 1988, BLOOD, V72, P1550; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1989, BLOOD, V73, P1416; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEGAL AW, 1978, LANCET, V2, P446; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEKHSARIA S, 1993, P NATL ACAD SCI USA, V90, P7446, DOI 10.1073/pnas.90.16.7446; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; SMITH RM, 1991, BLOOD, V77, P673; SMITH RM, 1989, J BIOL CHEM, V264, P1958; SMITH RM, 1991, BLOOD CELL BIOCH LYM, V3, P215; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAKASUGI S, 1989, J BIOCHEM-TOKYO, V105, P155, DOI 10.1093/oxfordjournals.jbchem.a122630; TAMURA M, 1992, J BIOL CHEM, V267, P7529; TORU A, 1994, J INSECT PHYSIOL, V40, P165, DOI 10.1016/0022-1910(94)90088-4; TSUNAWAKI S, 1994, J EXP MED, V179, P291, DOI 10.1084/jem.179.1.291; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	75	473	485	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24519	24522						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929117				2022-12-27	WOS:A1994PQ49000001
J	CHEN, XH; HARDEN, TK; NICHOLAS, RA				CHEN, XH; HARDEN, TK; NICHOLAS, RA			MOLECULAR-CLONING AND CHARACTERIZATION OF A NOVEL BETA-ADRENERGIC-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-3-ADRENERGIC RECEPTOR; HAMSTER OVARY CELLS; TURKEY ERYTHROCYTE; G-PROTEIN; BETA-1-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; AGONIST ACTIVATION; GENE; RAT; ADRENOCEPTOR	In an attempt to isolate new G protein-coupled receptors from turkey erythrocytes, reverse transcribed polymerase chain reaction was performed on fetal turkey blood RNA using degenerate primers based on conserved sequences present in seven transmembrane receptors. An open reading frame in one of the clones, designated 4C (497 base pairs), displayed approximately 50-60% identity to all of the previously cloned beta-adrenergic receptors (beta-ARs). A lambda-DASH turkey genomic library was screened with a probe generated from the partial 4C cDNA, and the gene encoding this receptor was localized to a 3.5-kilobase pair HindIII fragment. Ribonuclease protection analysis of turkey lung mRNA indicated that the 3' end of the coding sequence of the 4C gene, like beta(3)-AR, was interrupted by an intron. To obtain the cDNA sequence of 4C, RNA-polymerase chain reaction was performed using primers complementary to regions identified by ribonuclease protection analysis to be present in 4C mRNA. Comparison of the genomic and cDNA sequences of 4C indicated that the first exon encodes 414 amino acids of the protein, the second exon (68 base pairs) encodes an additional 12 residues followed by a stop codon, and the third exon is composed of 3'-untranslated sequence. The 4C receptor was transiently expressed in COS-1 cells, and the apparent affinities of a series of beta-AR agonists and antagonists were determined using [I-125]iodocyanopindolol. As implicated by its amino acid sequence, 4C displayed a pharmacological selectivity that was consistent with that of a beta-AR but distinct from other cloned beta-ARs. Isoproterenol, epinephrine, and norepinephrine stimulated cyclic AMP accumulation in a concentration dependent manner in mouse L cells stably expressing the 4C receptor. No effect on phospholipase C activity was observed. Ribonuclease protection assays indicated that 4C mRNA exhibits a broad tissue distribution, which suggests that it may play an important role in avian physiology.	UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BENSAID M, 1993, FEBS LETT, V318, P223, DOI 10.1016/0014-5793(93)80516-W; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLIN N, 1993, MOL PHARMACOL, V44, P1094; BOND RA, 1987, BRIT J PHARMACOL, V91, P683, DOI 10.1111/j.1476-5381.1987.tb11262.x; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CHALLISS RAJ, 1988, BIOCHEM PHARMACOL, V37, P947, DOI 10.1016/0006-2952(88)90186-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Fourney R.M., 1988, FOCUS, V10, P5; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GRANNEMAN JG, 1992, MOL PHARMACOL, V42, P964; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264; HARDEN TK, 1982, MOL PHARMACOL, V21, P570; HERTEL C, 1990, J BIOL CHEM, V265, P17988; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIGGETT SB, 1992, MOL PHARMACOL, V42, P634; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MAURICE DH, 1993, BIOCHEM J, V290, P765, DOI 10.1042/bj2900765; MAURIEGE P, 1988, J LIPID RES, V29, P587; MINNEMAN KP, 1980, MOL PHARMACOL, V17, P1; MONOPOLI A, 1989, J CARDIOVASC PHARM, V14, P114, DOI 10.1097/00005344-198907000-00020; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; NANTEL F, 1993, MOL PHARMACOL, V43, P548; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SELDEN RF, 1993, CURRENT PROTOCOLS MO; SHORR RGL, 1982, J BIOL CHEM, V257, P2341; SIMPSON IA, 1980, FEBS LETT, V115, P113, DOI 10.1016/0014-5793(80)80738-1; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, J BIOL CHEM, V264, P16470; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; TSUKAHARA T, 1986, STROKE, V17, P202, DOI 10.1161/01.STR.17.2.202; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; WILSON C, 1984, EUR J PHARMACOL, V100, P309, DOI 10.1016/0014-2999(84)90007-4; WITKIN KM, 1981, J CYCLIC NUCL PROT, V7, P235; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; ZAAGSMA J, 1990, TRENDS PHARMACOL SCI, V11, P3, DOI 10.1016/0165-6147(90)90032-4	58	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24810	24819						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929160				2022-12-27	WOS:A1994PQ49000047
J	ZANI, ML; POURCHER, T; LEBLANC, G				ZANI, ML; POURCHER, T; LEBLANC, G			MUTATION OF POLAR AND CHARGED RESIDUES IN THE HYDROPHOBIC NH2-TERMINAL DOMAINS OF THE MELIBIOSE PERMEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENTS; CATION SPECIFICITY; TRANSPORT-SYSTEM; KLEBSIELLA-PNEUMONIAE; POTASSIUM CHANNELS; BINDING-PROPERTIES; ACIDIC RESIDUES; SUGAR BINDING; CARRIER; NA+	The suggestion that acidic residues in the hydrophobic NH2-terminal domains of Mel permease (Asp-31 in helix I, Asp-51 and Asp-55 in helix II, Asp-120 in helix IV) may be essential components of a coordination network involved in cation recognition (Pourcher, T., Zani, M. L., and Leblanc, G. (1993) J. Biol. Chem. 268, 3209-3215) is further analyzed using site-directed mutagenesis. To study whether nearby polar residues also contribute to the cation recognition process, Tyr-24, Tyr-27 and Tyr-28 (aligned with Asp-31) and Tyr-109 and Tyr-116 (aligned with Asp-120) were individually converted into a phenylalanine. The effect of replacing Arg-48 (aligned with Asp-51 and Asp-55) or Asn-83 (in the middle of helix III) by an alanine was also studied. The importance of the position of the carboxylate of the residue at position 31, 51, 55, or 120 was next examined by replacing each Asp by a Glu residue. Sugar binding and/or transport activity measurements indicate that all polar --> apolar or Asp --> Glu mutants use Na+ or Li+ for active sugar transport. Moreover, two groups of mutants could be distinguished. One group, composed of Y27F, Y28F, D31E, and Y109F mutants, retains wild type permease properties. A second group (Y24F, N83A, and Y116F and also D51E, D55E, and D120E) exhibits concomitant reduction of affinity for sodium and sugars and altered sugar specificity but conserves wild type cation selectivity profile. The data reinforce the notion that Asp-51, Asp-55, and Asp-120 residues and the position of their carboxyl side chains are of primary importance for cation recognition. Finally, since Mel permease properties are predominantly modified by mutagenizing residues located in the cytoplasmic half of the permease, we propose that Mel permease has a well-like shape opened toward the periplasmic space and is closed at its cytoplasmic extremity by a gate.	CEA, DEPT BIOL CELLULAIRE & MOLEC, LAB J MAETZ, F-06230 VILLEFRANCHE MER, FRANCE	CEA				Pourcher, Thierry/0000-0003-2839-4622				BASSILANA M, 1985, BIOCHEM BIOPH RES CO, V129, P626, DOI 10.1016/0006-291X(85)91937-0; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1990, RES MICROBIOL, V141, P328, DOI 10.1016/0923-2508(90)90006-C; BOYER PD, 1988, TRENDS BIOCHEM SCI, V13, P5, DOI 10.1016/0968-0004(88)90005-9; COHN DE, 1980, BIOCHEMISTRY-US, V19, P4237, DOI 10.1021/bi00559a015; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; HAMA H, 1994, J BIOL CHEM, V269, P1063; HAMA H, 1993, J BIOL CHEM, V268, P10060; HAMA H, 1992, J BIOL CHEM, V267, P18371; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Kaback H R, 1974, Methods Enzymol, V31, P698; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LEBLANC G, 1993, SOC GEN PHY, V48, P213; LEBLANC G, 1992, 7TH EUR BIOEN C; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1990, BIOCHEMISTRY-US, V29, P690, DOI 10.1021/bi00455a014; POURCHER T, 1990, P NATL ACAD SCI USA, V87, P468, DOI 10.1073/pnas.87.1.468; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOTA S, 1985, J BACTERIOL, V162, P106, DOI 10.1128/JB.162.1.106-109.1985; TSUCHIYA T, 1983, J BIOL CHEM, V258, P2765; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WILSON DM, 1994, BBA-BIOMEMBRANES, V1190, P225, DOI 10.1016/0005-2736(94)90078-7; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YAZYU H, 1984, J BIOL CHEM, V259, P4320; ZANI ML, 1993, J BIOL CHEM, V268, P3216	37	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24883	24889						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929169				2022-12-27	WOS:A1994PQ49000056
J	ASKEW, GR; LINGREL, JB				ASKEW, GR; LINGREL, JB			IDENTIFICATION OF ALL AMINO-ACID SUBSTITUTION IN HUMAN ALPHA-1 NA,K-ATPASE WHICH CONFERS DIFFERENTIALLY REDUCED AFFINITY FOR 2 RELATED CARDIAC-GLYCOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; OUABAIN-RESISTANT ENZYME; SUBUNIT; SENSITIVITY; MUTATION; SEQUENCE; RESIDUES; BINDING; CELLS	The ouabain-resistant cell line H1C1 displays a 30-fold differential of reduced sensitivity to the structurally related cardiac glycosides digoxin and digitoxin (Baker, R. M. (1976) in Biogenesis and Turnover of Membrane Macromolecules (Cook, J. S., ed) pp. 93-103, Raven Press, New York). Since these ligand congeners differ only by the presence of a hydroxyl group at C-12 of digoxin we predicted that the H1C1 phenotype must reflect a mutation which alters the binding site of the cardiac glycoside receptor (Na,K-ATPase). Complementary DNA encoding the al Na,g-ATPase was prepared from H1C1 cell total RNA by reverse transcription-coupled polymerase chain reaction and these cDNAs were cloned. Sequence analysis of the reverse transcriptase-polymerase chain reaction clones revealed several independent isolates containing a G>A transition at nucleotide 332 of the propeptide coding sequence, generating the amino acid substitution C108Y. The ability of this substitution to confer differential sensitivity for digoxin and digitoxin was tested and confirmed by expressing a human al C108Y-Na,K-ATPase in wild type HeLa cells and assaying for inhibition of cell growth and inhibition of Na,K-ATPase activity. Phenylalanine or alanine substitutions of this cysteine also confer this pattern of ligand discrimination. Ouabain-resistant Na,K-ATPase substitutions, at positions other than Cys-108 failed to exhibit differential sensitivity indicating that this ligand discrimination is unique to Cys-108 substitutions rather than a general property of cardiac glycoside resistant mutants. It is proposed that differential resistance of the C108Y receptor for these ligands is a consequence of altering two features of the ligand-receptor interaction; one, a disruption of a common hydrogen bond resulting in general loss of affinity for cardiac glycosides and the other, formation of a new H-bond between the C-12 hydroxyl of digoxin and the receptor, specifically augmenting the stability of this ligand-receptor complex.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NHLBI NIH HHS [HL 41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akera T., 1978, PHARMACOL REV, V29, P187; BAKER RM, 1976, BIOGENESIS TURNOVER, P93; BURNS EL, 1993, J BIOL CHEM, V268, P25632; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; GRUPP G, 1987, MOL CELL BIOCHEM, V76, P97; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; MCPARLAND RA, 1991, SODIUM PUMP RECENT D, P297; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; NAIDOO BK, 1974, J PHARM SCI, V63, P1391, DOI 10.1002/jps.2600630912; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCHWARTZ A, 1969, J PHARMACOL EXP THER, V168, P31; Thomas R., 1990, ADV DRUG RES, P311; ZHOU C, 1990, BIOTECHNIQUES, V8, P172	27	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24120	24126						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929066				2022-12-27	WOS:A1994PQ34600044
J	CASSARDDOULCIER, AM; LAROSE, M; MATAMALA, JC; CHAMPIGNY, O; BOUILLAUD, F; RICQUIER, D				CASSARDDOULCIER, AM; LAROSE, M; MATAMALA, JC; CHAMPIGNY, O; BOUILLAUD, F; RICQUIER, D			IN-VITRO INTERACTIONS BETWEEN NUCLEAR PROTEINS AND UNCOUPLING PROTEIN GENE PROMOTER REVEAL SEVERAL PUTATIVE TRANSACTIVATING FACTORS INCLUDING ETS1, RETINOID-X RECEPTOR, THYROID-HORMONE RECEPTOR, AND A CACCC BOX-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TRANSCRIPTION FACTORS; RESPONSE ELEMENTS; TRANSGENIC MICE; EXPRESSION; TISSUE; ACID; REGION; UCP	Previous studies of rat ucp (uncoupling protein) gene organization carried out in this laboratory identified regulatory sequences located in the 5'-flanking region. In this work, DNase I footprint analysis of the enhancer revealed two domains at base pairs (bp) -2444 to -2423 and bp -2352 to -2319. The former domain can bind in vitro, in a cooperative manner, factors related to nuclear factor 1 and Ets1; the latter domain contains a type 3 directly repeated sequence that was shown to be able to bind the retinoid X and triiodothyronine receptors. Moreover, a positive effect of retinoic acid on ucp mRNA levels in immortalized brown adipocytes was observed. DNase I footprint analysis identified two hypersensitive regions, A and B, at bp -509 to -472 and bp -403 to -350, respectively; region A contains a repeated CACCC box, and region B can bind protein related to Ets1. The A box differentially binds liver and brown adipose tissue nuclear proteins and could be involved in uncoupling protein induction. Further analysis showed three footprinted boxes, C-E, at bp -182 to -159, -147 to -120, and -111 to -85, able to bind in vitro proteins related to nuclear factor 1, cAMP response element-binding protein, and Sp1, respectively.	CNRS,CEREMOD,F-92190 MEUDON,FRANCE; UNIV ILLES BALEARS,DEPT BIOL FONAMENTAL & CIENCES SALUT,E-07071 PALMA DE MALLORCA,SPAIN	Centre National de la Recherche Scientifique (CNRS); Universitat de les Illes Balears			Bouillaud, Frédéric R/L-3238-2017; CASSARD, Anne-Marie/B-6095-2019	Bouillaud, Frédéric R/0000-0002-7518-9237; CASSARD, Anne-Marie/0000-0002-1813-5128				BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; BOUILLAUD F, 1988, BIOCHEM BIOPH RES CO, V157, P783, DOI 10.1016/S0006-291X(88)80318-8; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; CANNON B, 1985, ESSAYS BIOCHEM, V20, P111; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; IRELAND RC, 1986, J BIOL CHEM, V261, P1779; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLAUS S, 1991, J CELL BIOL, V115, P1783, DOI 10.1083/jcb.115.6.1783; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOZAK LP, 1988, J BIOL CHEM, V263, P12274; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, J BIOL CHEM, V268, P591; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	31	86	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24335	24342						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929091				2022-12-27	WOS:A1994PQ34600075
J	REYNAUD, D; DEMIN, P; PACEASCIAK, CR				REYNAUD, D; DEMIN, P; PACEASCIAK, CR			HEPOXILIN A(3) FORMATION IN THE RAT PINEAL-GLAND SELECTIVELY UTILIZES (12S)-HYDROPEROXYEICOSATETRAENOIC ACID (HPETE), BUT NOT (12R)-HPETE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ARACHIDONIC-ACID; HUMAN-PLATELETS; 8,11,12-TRIHYDROXYEICOSATRIENOIC ACID; CATALYZED TRANSFORMATION; PANCREATIC-ISLETS; HUMAN NEUTROPHILS; NERVOUS-SYSTEM; PRODUCTS; APLYSIA	Hepoxilins A(3) and B-3 have previously been shown to be formed from 12-hydroperoxyeicosatetraenoic acid (12-HPETE) through a heat-insensitive ferriheme catalysis as indicated by experiments with hemin or hemoglobin, typical of nonenzymatic rearrangement (Pace-Asciak, C. B (1984) Biochim. Biophys. Acta 793, 485-488; Pace-Asciak, C. R. (1984) J. Biol. Chem. 259, 8332-8337). In this paper, we demonstrate through use of a mixture of (12S)- and (12R)-HPETE that an enzyme system exists in the rat pineal gland that selectively utilizes (12S)-HPETE for the transformation into hepoxilin A(3), while the hemin catalyzed transformation is not selective, with both (12S)- and (12R)-HPETE being utilized. A new procedure was established to rapidly extract (in the absence of acid) and directly derivatize from the incubation mixture the products of incubation using 9-anthryldiazomethane reagent to form the 9-anthryldiazomethane derivatives of the hydroxyeicosatetraenoic acids (HETEs), hepoxilins and trioxilins, which could be detected by high performance liquid chromatography using a flow-through fluorescence detector. The following observations were made: 1) the pineal experiments showed a high preference for the formation of hepoxilin A(3) with minor amounts of hepoxilin B-3, while experiments with heme catalysis showed formation of both hepoxilins B-3 and A(3); 2) chiral phase analysis of the HETEs recovered from the incubation mixture showed the predominance of (12R)-HETE from the pineal experiments, indicating that (12S)-HPETE was selectively used up, whereas both (12S)- and (12R)-HPETE were utilized in the hemin experiments; 3) chiral phase analysis of hepoxilin A(3) indicated the presence in the pineal experiments of only hepoxilin with the 11S,12S-configuration formed from (12S)-HPETE, while the hemin experiments contained both the native 11S,12S-configuration as well as the unnative or ''bis-epi''-11R,12R-configuration in the epoxide group of hepoxilin A(3); 4) reverse phase analysis of the epoxide hydrolase product of hepoxilin A(3), i.e. trioxilin A(3), showed that the pineal experiments contained only the products of enzymatic hydrolysis derived from the native hepoxilin A(3), whose formation was inhibited by the epoxide hydrolase inhibitor, trichloropropene oxide. The pineal system is heat-sensitive, with formation of hepoxilins being abolished by tissue boiling, while the hemin system is insensitive to boiling. These experiments demonstrate that hepoxilin A(3) formation in the pineal gland utilizes (12S)-HPETE exclusively, being transformed by a ''hepoxilin synthase'' primarily into hepoxilin A(3).	HOSP SICK CHILDREN, RES INST, DIV NEUROSCI, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, FAC MED, DEPT PHARMACOL, TORONTO M5S 1A8, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; BRYANT RW, 1979, PROSTAGLANDINS, V17, P9, DOI 10.1016/0090-6980(79)90071-6; BRYANT RW, 1980, BIOCHEM BIOPH RES CO, V92, P268, DOI 10.1016/0006-291X(80)91548-X; CARLEN PL, 1994, NEUROSCIENCE, V58, P493, DOI 10.1016/0306-4522(94)90075-2; CARLEN PL, 1989, BRAIN RES, V497, P171, DOI 10.1016/0006-8993(89)90984-0; DEMIN PM, 1991, BIOORG KHIM+, V17, P1133; DEMIN PM, 1994, 207TH AM CHEM SOC M; DHO S, 1990, BIOCHEM J, V266, P63, DOI 10.1042/bj2660063; HADA T, 1994, BBA-LIPID LIPID MET, V1211, P221, DOI 10.1016/0005-2760(94)90272-0; JONES RL, 1978, PROSTAGLANDINS, V16, P583, DOI 10.1016/0090-6980(78)90188-0; LANEUVILLE O, 1991, EICOSANOIDS, V4, P95; LANEUVILLE O, 1990, J BIOL CHEM, V265, P21415; LANEUVILLE O, 1993, BIOCHEM J, V295, P393, DOI 10.1042/bj2950393; LANEUVILLE O, 1992, BRIT J PHARMACOL, V107, P808, DOI 10.1111/j.1476-5381.1992.tb14528.x; LANEUVILLE O, 1992, BRIT J PHARMACOL, V105, P297, DOI 10.1111/j.1476-5381.1992.tb14249.x; LANEUVILLE O, 1991, PROSTAGLANDINS LEUKO; MARGALIT A, 1993, P NATL ACAD SCI USA, V90, P2589, DOI 10.1073/pnas.90.7.2589; MARGALIT A, 1993, J MEMBRANE BIOL, V136, P1; NIGAM S, 1993, DEV ONCOL, V71, P249; NIGAM S, 1990, BIOCHEM BIOPH RES CO, V171, P944, DOI 10.1016/0006-291X(90)90775-I; PACEASCIAK CR, 1989, J BIOL CHEM, V264, P9310; PACEASCIAK CR, 1982, BIOCHIM BIOPHYS ACTA, V712, P142, DOI 10.1016/0005-2760(82)90095-9; PACEASCIAK CR, 1983, PROSTAGLANDINS, V25, P79, DOI 10.1016/0090-6980(83)90137-5; PACEASCIAK CR, 1986, BIOCHIM BIOPHYS ACTA, V875, P406, DOI 10.1016/0005-2760(86)90193-1; PACEASCIAK CR, 1990, BIOCHEM BIOPH RES CO, V173, P949, DOI 10.1016/S0006-291X(05)80877-0; PACEASCIAK CR, 1984, J BIOL CHEM, V259, P8332; PACEASCIAK CR, 1989, BIOCHEM BIOPH RES CO, V163, P1230, DOI 10.1016/0006-291X(89)91109-1; PACEASCIAK CR, 1990, P NATL ACAD SCI USA, V87, P3037, DOI 10.1073/pnas.87.8.3037; PACEASCIAK CR, 1993, GEN PHARMACOL-VASC S, V24, P805, DOI 10.1016/0306-3623(93)90153-O; PACEASCIAK CR, 1984, BIOCHIM BIOPHYS ACTA, V793, P485, DOI 10.1016/0005-2760(84)90267-4; PACEASCIAK CR, 1983, J BIOL CHEM, V258, P6835; PACEASCIAK CR, 1984, PROSTA LEUKOTR MED, V16, P173, DOI 10.1016/0262-1746(84)90069-6; PACEASCIAK CR, 1985, BIOCHEM BIOPH RES CO, V128, P942, DOI 10.1016/0006-291X(85)90137-8; PACEASCIAK CR, 1990, ADV PROSTAGLANDIN TH, V21, P731; PACEASCIAK CR, 1990, BIOL OXIDATION SYSTE, V2, P725; PIOMELLI D, 1987, J NEUROSCI, V7, P3675; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P1721, DOI 10.1073/pnas.86.5.1721; REYNAUD D, 1994, J NEUROCHEM, V62, P126; VASILJEVA LL, 1993, TETRAHEDRON, V49, P4099, DOI 10.1016/S0040-4020(01)89921-X; YAMAKI K, 1986, CHEM PHARM BULL, V34, P3526	40	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23976	23980						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929046				2022-12-27	WOS:A1994PQ34600022
J	HANSON, RL; WASYLYK, JM; NANDURI, VB; CAZZULINO, DL; PATEL, RN; SZARKA, LJ				HANSON, RL; WASYLYK, JM; NANDURI, VB; CAZZULINO, DL; PATEL, RN; SZARKA, LJ			SITE-SPECIFIC ENZYMATIC-HYDROLYSIS OF TAXANES AT C-10 AND C-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE TAXOL ANALOGS; TAXUS-BREVIFOLIA; BACCATIN-III; SIDE-CHAINS; EFFICIENT; AGENT	The production of large amounts of paclitaxel for use as an anticancer treatment has been a challenging problem because of the low concentration of the compound in yew trees and its occurrence as part of a mixture of other taxanes. Two novel enzymes were isolated to facilitate the production of 10-deacetylbaccatin III, a precursor used for semisynthesis of paclitaxel and analogs. A strain of Nocardioides albus (SC13911) was isolated from soil and found to produce an extracellular enzyme that specifically removed the C-13 side chain from paclitaxel, cephalomannine, 7-beta-xylosyltaxol, 7-beta-xylosyl-10-deacetyltaxol, and 10-deacetyltaxol, The enzyme was purified to near homogeneity to give a polypeptide with 47,000 M(r) on a sodium dodecyl sulfate gel. A strain of Nocardioides luteus (SC13912) isolated from soil was found to produce an intracellular 10-deacetylase that removed the 10 acetate from baccatin III and paclitaxel. The 10-deacetylase was purified to give a polypeptide with 40,000 M(r) on a sodium dodecyl sulfate gel. Treatment of extracts prepared from a variety of yew cultivars with the C-13-deacylase and C-10-deacetylase converted a complex mixture of taxanes primarily to 10-deacetylbaccatin III and increased the amount of this key precursor by 4-24 times.			HANSON, RL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MICROBIAL TECHNOL,1 SQUIBB DR,NEW BRUNSWICK,NJ 08903, USA.							CHEN SH, 1993, TETRAHEDRON, V49, P2805, DOI 10.1016/S0040-4020(01)80381-1; COMMERCON A, 1992, TETRAHEDRON LETT, V33, P5185, DOI 10.1016/S0040-4039(00)79128-3; DENIS JN, 1988, J AM CHEM SOC, V110, P5917, DOI 10.1021/ja00225a063; GEORG GI, 1992, J MED CHEM, V35, P4230, DOI 10.1021/jm00100a031; GEORG GI, 1992, BIOORG MED CHEM LETT, V2, P295, DOI 10.1016/S0960-894X(01)80203-1; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HOLTON RA, 1990, CHEM ABST 16458Q, V114; HOLTON RA, 1991, CHEM ABST 159485B, V115; KINGSTONDGI, 1991, PHARMACOL THERAPEUT, V52, P1; MAGRI NF, 1986, J ORG CHEM, V51, P3239, DOI 10.1021/jo00366a043; OJIMA I, 1992, TETRAHEDRON, V48, P6985, DOI 10.1016/S0040-4020(01)91210-4; RAO KV, 1993, PHARMACEUT RES, V10, P521, DOI 10.1023/A:1018937700459; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SENILH V, 1984, CR ACAD SCI II, V299, P1039; SWINDELL CS, 1991, J MED CHEM, V34, P1176, DOI 10.1021/jm00107a042; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045	17	38	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22145	22149						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915279				2022-12-27	WOS:A1994PE09800035
J	ZHU, Y; TASSI, L; LANE, W; MENDELSOHN, ME				ZHU, Y; TASSI, L; LANE, W; MENDELSOHN, ME			SPECIFIC BINDING OF THE TRANSGLUTAMINASE, PLATELET FACTOR-XIII, TO HSP27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; CATALYZED CROSS-LINKING; TUMOR-NECROSIS-FACTOR; ALPHA-B-CRYSTALLIN; TRANSAMIDATING ENZYMES; STRUCTURAL PROTEINS; ESTROGEN-RECEPTOR; SEQUENCE-ANALYSIS; ACTIN-FILAMENTS	HSP27, the unique mammalian low molecular weight heat shock protein, is prominently phosphorylated upon activation of a wide variety of cells and has a role in thermotolerance, growth events, and regulation of actin cytoskeletal dynamics. In thrombin-stimulated platelets, HSP27 is rapidly and prominently phosphorylated in a manner highly correlated with platelet secretion. However, the function of HSP27 and the identity of proteins that interact with HSP27 remain unknown. To identify specific HSP27-protein interactions, a recombinant fusion protein affinity reagent was constructed and used to identify proteins associating with HSP27 from human platelet lysates and erythroleukemia cells. An 84-kDa protein was found to associate specifically with HSP27 and was isolated from platelet lysates, resolved on preparative gels, transferred to nitrocellulose, subjected to enzymatic digestion, and microsequenced. A 20-amino acid sequence derived from p84 proved identical to amino acids 484-503 of the transglutaminase, platelet Factor XIII. Immunoblotting studies were used to confirm the binding of FXIII from fresh platelet lysates to the HSP27 fusion protein. FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass-activated platelets. The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and/or enzymatic regulation of platelet FXIII.	TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, MOLEC CARDIOL RES CTR, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, HARVARD MICROCHEM FACIL, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL02154] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002154] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ASIJEE GM, 1988, BIOCHIM BIOPHYS ACTA, V954, P303, DOI 10.1016/0167-4838(88)90085-4; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CAIRNS J, 1994, J BIOL CHEM, V269, P9176; CHAMBARD JC, 1983, BIOCHEM BIOPH RES CO, V111, P1034, DOI 10.1016/0006-291X(83)91404-3; COFFER AI, 1985, CANCER RES, V45, P3694; COHEN I, 1981, BIOCHIM BIOPHYS ACTA, V676, P137, DOI 10.1016/0304-4165(81)90181-1; COHEN I, 1980, BIOCHIM BIOPHYS ACTA, V628, P365, DOI 10.1016/0304-4165(80)90386-4; COHEN I, 1979, ARCH BIOCHEM BIOPHYS, V192, P100, DOI 10.1016/0003-9861(79)90075-4; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; Goldschmidt-Clermont P. J., 1992, Current Biology, V2, P669, DOI 10.1016/0960-9822(92)90135-W; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HASLAM RJ, 1980, PLATELETS CELLULAR R, P213; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAHN DR, 1981, BIOCHIM BIOPHYS ACTA, V668, P490, DOI 10.1016/0005-2795(81)90184-7; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KROLL MH, 1989, BLOOD, V74, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LEICHT BG, 1986, P NATL ACAD SCI USA, V83, P90, DOI 10.1073/pnas.83.1.90; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVITZKI A, 1980, P NATL ACAD SCI-BIOL, V77, P2706, DOI 10.1073/pnas.77.5.2706; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOPACIUK S, 1976, THROMB RES, V8, P453, DOI 10.1016/0049-3848(76)90223-1; LORAND L, 1979, ANAL BIOCHEM, V93, P453, DOI 10.1016/S0003-2697(79)80178-5; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUSZBEK L, 1993, THROMB HAEMOSTASIS, V69, P282; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PONCZ M, 1987, BLOOD, V69, P219; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REED GL, 1992, THROMB HAEMOSTASIS, V68, P315; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; WALLACE WC, 1980, J BIOL CHEM, V255, P1932; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WHITE JG, 1987, ANN NY ACAD SCI, V509, P156, DOI 10.1111/j.1749-6632.1987.tb30993.x; ZHU Y, 1992, CIRCULATION, V86, P2941	63	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	1994	269	35					22379	22384						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PE098	7915282				2022-12-27	WOS:A1994PE09800068
J	POTTER, LR; GARBERS, DL				POTTER, LR; GARBERS, DL			PROTEIN-KINASE C-DEPENDENT DESENSITIZATION OF THE ATRIAL-NATRIURETIC-PEPTIDE RECEPTOR IS MEDIATED BY DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP ACCUMULATION; SMOOTH-MUSCLE CELLS; GUANYLATE-CYCLASE; PHORBOL ESTER; CGMP ACCUMULATION; RAT; INHIBITION; ACTIVATION; CHIMAERIN; BINDING	Stimulation of guanylyl cyclase A (GC-A) by atrial natriuretic peptide (ANP) is antagonized by activators of protein kinase C (PKC). Thus, it has been suggested that PHC phosphorylates and desensitizes GC-A. Here, we have developed stable GC-A transfectants of NIH3T3 cells, which display marked reductions in hormone-dependent cGMP elevations and guanylyl cyclase activity after incubation with ANP or phorbol 12-myristate 13-acetate (PMA). ANP binding and immunoblot analysis indicated that the decreases were not due to receptor internalization or degradation. GC-A isolated from (PO4)-P-32-labeled cells contained phosphoserine and phosphothreonine. ANP and/or PMA addition caused substantial decreases in the P-32 content of the receptor that coincided with reductions in hormone-dependent guanylyl cyclase activity. The specific PKC inhibitor, GF-109203X, completely blocked the PMA-dependent dephosphorylation and desensitization of GC-A but failed to inhibit either ANP-dependent process. Tryptic phosphopeptide maps of GC-A isolated from ANP- or PMA-treated cells were unique, suggesting that the sites that dephosphorylated in response to each agent were different. In contrast to previous reports, we conclude that PMA and ANP desensitization of GC-A are distinct events mediated by dephosphorylation of specific residues through PHC-dependent and -independent pathways, respectively.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	POTTER, LR (corresponding author), VANDERBILT UNIV, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010254] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10254] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CAMPO MS, 1985, DNA CLONING, V2, P213; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; GARBERS DL, 1992, CELL, V71, P1; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; POTTER LR, 1992, J BIOL CHEM, V267, P14531; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SMITH JB, 1987, AM J PHYSIOL, V253, pC147, DOI 10.1152/ajpcell.1987.253.1.C147; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314	31	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14636	14642						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7910166				2022-12-27	WOS:A1994NM06500053
J	WINZ, R; HESS, D; AEBERSOLD, R; BROWNSEY, RW				WINZ, R; HESS, D; AEBERSOLD, R; BROWNSEY, RW			UNIQUE STRUCTURAL FEATURES AND DIFFERENTIAL PHOSPHORYLATION OF THE 280-KDA COMPONENT (ISOZYME) OF RAT-LIVER ACETYL-COA CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; FATTY-ACID SYNTHESIS; GEL-ELECTROPHORESIS; MOBILIZATION ACTIVATION; SEQUENCE-ANALYSIS; PROTEIN-KINASE; ADIPOSE-TISSUE; INSULIN; NITROCELLULOSE; IDENTIFICATION	Rat liver acetyl-CoA carboxylase (ACC, EC 6.4.1.2) exhibits major and minor subunits (M(r) of 265,000 and 280,000 respectively), the structure and function of which are compared in this study. The two subunits copurified and each contained biotin as demonstrated by avidin reactivity and direct determination of biocytin. In agreement with previous studies, the ACC subunits could be distinguished with specific monoclonal antibodies and differential tissue expression. We now report extensive differences in primary structure revealed by peptide mapping, mass spectrometric analysis of peptides following reverse phase high performance liquid chromatography, and microsequencing of selected peptides. Four peptides derived from the 265-kDa subunit were sequenced and matched sequences within the predicted structure of rat 265-kDa ACC. Although one identical peptide sequence was detected within both subunits (residues 2009-2024 of the 265-kDa subunit), 12 peptides derived from the 280-kDa subunit exhibited entirely novel sequences or matched partially (average 70% identity) with sequences within the 265-kDa subunit. The 280-kDa subunit may also exhibit distinct functional properties, since the initial rate of phosphorylation was at least 10-fold greater than that of the 265-kDa subunit in the presence of cAMP-dependent protein kinase. Two-dimensional mapping demonstrated that the tryptic phosphopeptides released from the two ACC subunits are distinct. These structural studies suggest that the 265- and 280-kDa components (isozymes) of ACC are so distinct they may be encoded by separate genes, while the differential phosphorylation observed in vitro suggests a key role for the 280-kDa subunit in regulating enzyme activity within intact cells.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia								AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P517, DOI 10.1002/elps.1150110702; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; ALLRED JB, 1989, J NUTR, V119, P478, DOI 10.1093/jn/119.3.478; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BAI DH, 1986, J BIOL CHEM, V261, P2395; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BORTHWICK AC, 1987, BIOCHEM J, V241, P773, DOI 10.1042/bj2410773; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSEY RW, 1982, BIOCHEM J, V202, P77, DOI 10.1042/bj2020077; BROWNSEY RW, 1979, BIOCHEM J, V184, P23, DOI 10.1042/bj1840023; BROWNSEY RW, 1987, ENZYMES B, V18, P123, DOI DOI 10.1016/S1874-6047(08)60256-5; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CLARKE SD, 1979, J LIPID RES, V20, P974; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EBRAHIM H, 1987, ANAL BIOCHEM, V162, P319, DOI 10.1016/0003-2697(87)90398-8; EVANS JL, 1990, BIOCHEM J, V270, P665, DOI 10.1042/bj2700665; GREGOLIN C, 1966, P NATL ACAD SCI USA, V56, P1751, DOI 10.1073/pnas.56.6.1751; HALESTRA.AP, 1973, BIOCHEM J, V132, P509, DOI 10.1042/bj1320509; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; Harlow E., 1988, ANTIBODIES LABORATOR, P63; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; HOFFMAN WL, 1989, ANAL BIOCHEM, V181, P318, DOI 10.1016/0003-2697(89)90250-9; Hood R L, 1979, Methods Enzymol, V62, P279, DOI 10.1016/0076-6879(79)62229-2; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KOHANSKI RA, 1990, METHOD ENZYMOL, V184, P194; KONG IS, 1990, J BIOL CHEM, V265, P13695; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LOPEZCASILLAS F, 1991, EUR J BIOCHEM, V201, P119, DOI 10.1111/j.1432-1033.1991.tb16264.x; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MCGARRY JD, 1978, J BIOL CHEM, V253, P8294; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; Numa S, 1974, Curr Top Cell Regul, V8, P197; Numa S, 1984, FATTY ACID METABOLIS, P1; OCONNOR CG, 1982, J IMMUNOL METHODS, V54, P267, DOI 10.1016/0022-1759(82)90068-0; PATTERSON SD, 1992, ANAL BIOCHEM, V202, P193, DOI 10.1016/0003-2697(92)90227-X; QUAYLE KA, 1993, BIOCHEM J, V292, P75, DOI 10.1042/bj2920075; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P286; ROMANLOPEZ CR, 1989, BIOCHEM J, V260, P927, DOI 10.1042/bj2600927; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Shi Q., 1990, GEL ELECTROPHORESIS; SONG CS, 1981, J BIOL CHEM, V256, P7786; TAKAI T, 1988, J BIOL CHEM, V263, P2651; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WINZ R, 1989, 32ND P ANN M CAN FED	48	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14438	14445						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7910165				2022-12-27	WOS:A1994NM06500023
J	DURIEUTRAUTMANN, O; CHAVEROT, N; CAZAUBON, S; STROSBERG, AD; COURAUD, PO				DURIEUTRAUTMANN, O; CHAVEROT, N; CAZAUBON, S; STROSBERG, AD; COURAUD, PO			INTERCELLULAR-ADHESION MOLECULE-1 ACTIVATION INDUCES TYROSINE PHOSPHORYLATION OF THE CYTOSKELETON-ASSOCIATED PROTEIN CORTACTIN IN BRAIN MICROVESSEL ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; SIGNAL TRANSDUCTION; ICAM-1; GROWTH; IDENTIFICATION; MODULATION; PP60C-SRC; SUBSTRATE; RECEPTORS; SYSTEM	Inflammatory diseases of the central nervous system, such as multiple sclerosis or experimental autoimmune encephalomyelitis, are characterized by adhesion of lymphocytes on cerebral microvascular endothelium, followed by transendothelial migration into the brain parenchyma. T lymphocyte adhesion to vascular endothelial cells is mediated by several types of adhesion molecules, including the integrin leukocyte function associated molecule 1 and its endothelial counter receptor intercellular adhesion molecule 1 (ICAM-1), of the immunoglobulin superfamily. In order to understand the molecular mechanisms that support lymphocyte extravasation, we intended to investigate a putative role of ICAM-1 in signal transduction in brain microvessel endothelial cells. Here we describe, using a well differentiated rat brain endothelial cell line (RBE4 cells), that ICAM-1 activation by a specific monoclonal antibody, or by syngeneic encephalitogenic T cells, induces tyrosine phosphorylation of several proteins together with stimulation of the tyrosine kinase p60(src) activity. One of the major tyrosine-phosphorylated proteins, of 85 kDa, has been identified by immunoprecipitation and immunoblotting, as the recently described actin-binding protein, p60(src) substrate, cortactin. These findings demonstrate that ICAM-1 activation transduces signals in brain endothelial cells, which may lead to cytoskeleton changes and transendothelial migration of lymphocytes into the brain.	UNIV PARIS 07,INST COCHIN GENET MOLEC,CNRS,UPR 0415,IMMUNOPHARMACOL MOLEC LAB,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BERAUD E, 1993, J NEUROIMMUNOL, V47, P41, DOI 10.1016/0165-5728(93)90283-5; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CUSHLEY W, 1993, BIOCHEM J, V292, P313, DOI 10.1042/bj2920313; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; DURIEUTRAUTMANN O, 1993, J CELL PHYSIOL, V155, P104, DOI 10.1002/jcp.1041550114; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KELLIE S, 1991, J CELL SCI, V99, P207; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MAA MC, 1992, ONCOGENE, V7, P2429; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; RANKIN BM, 1993, J IMMUNOL, V150, P605; ROUX F, 1994, IN PRESS J CELL PHYS; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOGETSEDER W, 1991, IMMUNOBIOLOGY, V182, P143, DOI 10.1016/S0171-2985(11)80198-1; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	37	212	213	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12536	12540						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909803				2022-12-27	WOS:A1994NH71600028
J	LOW, SH; TANG, BL; WONG, SH; HONG, WJ				LOW, SH; TANG, BL; WONG, SH; HONG, WJ			GOLGI RETARDATION IN MADIN-DARBY CANINE KIDNEY AND CHINESE-HAMSTER OVARY CELLS OF A TRANSMEMBRANE CHIMERA OF 2 SURFACE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ROUGH ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; AMINOPEPTIDASE-N; RETENTION; TRANSPORT; APPARATUS; DOMAIN	Dipeptidyl peptidase IV (DDD) is a type II plasma membrane protein. Replacement of its transmembrane domain with that of another surface protein, aminopeptidase N, resulted in accumulation in the Golgi apparatus of Madin-Darby canine kidney cells and a delayed Golgi to surface transport in Chinese hamster ovary (CHO) cells. The compartment of retardation was identified as post medial-Golgi, most likely to be the trans-Golgi/trans Golgi network (TGN). Compared to native DDD, the rate of endoplasmic reticulum to Golgi transport for the chimera was largely unchanged in both cell types. On the other hand, Golgi to surface transport was delayed by more than 2 h in CHO cells and essentially undetectable up to 22 h of chase in Madin-Darby canine kidney cells. The decrease in the rate of Golgi to surface transport in CHO cells resulted in a significant accumulation of the fusion protein in the trans-Golgi/TGN. This phenomena is very unlikely to be due to any drastic conformational changes, as neither the enzyme activity nor the dimerization of the constructed molecule was affected. The findings of this study indicate that the transmembrane domain, in the context of its flanking sequences, is important for efficient Golgi to cell surface transport.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010; Tang, Bor Luen/E-4548-2012	Tang, Bor Luen/0000-0002-1925-636X				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; GABEL CA, 1985, J CELL BIOL, V101, P460, DOI 10.1083/jcb.101.2.460; GARTEN W, 1992, J VIROL, V66, P1495, DOI 10.1128/JVI.66.3.1495-1505.1992; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HONG WJ, 1989, EXP CELL RES, V182, P256, DOI 10.1016/0014-4827(89)90296-6; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1989, BIOCHEMISTRY-US, V28, P8474, DOI 10.1021/bi00447a030; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LOW SH, 1991, J BIOL CHEM, V266, P19710; LOW SH, 1991, J BIOL CHEM, V266, P13391; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1982, J CELL BIOL, V92, P223; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SIVASUBRAMANIAN N, 1987, P NATL ACAD SCI USA, V84, P1, DOI 10.1073/pnas.84.1.1; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; TANG BL, 1992, J BIOL CHEM, V267, P7072; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	52	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1985	1994						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7904997				2022-12-27	WOS:A1994MR98800068
J	HANDFORD, P; DOWNING, AK; RAO, ZH; HEWETT, DR; SYKES, BC; KIELTY, CM				HANDFORD, P; DOWNING, AK; RAO, ZH; HEWETT, DR; SYKES, BC; KIELTY, CM			THE CALCIUM-BINDING PROPERTIES AND MOLECULAR-ORGANIZATION OF EPIDERMAL GROWTH FACTOR-LIKE DOMAINS IN HUMAN FIBRILLIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MODULE; HUMAN FACTOR-IX; MARFAN-SYNDROME; FACTOR-X; EGF; GENE; MICROFIBRILS; COMPONENT; MUTATION; RESIDUES	Human fibrillin-1 is a 350-kDa glycoprotein found in 10-nm connective tissue microfibrils. Mutations in the gene encoding this protein cause the Marfan syndrome, a disease characterized by cardiovascular, ocular, and skeletal abnormalities. Fibrillin-1 has a modular structure that includes 47 epidermal growth factor-like (EGF-like) domains, 43 of which contain a consensus sequence associated with calcium binding. A mutation causing an Asn-2144 --> Ser amino acid change in one of the potential calcium binding residues has been described in a patient with the Marfan syndrome. We have chemically synthesized a wild-type EGF-like domain (residues 2126-2165 of human fibrillin-1) and a mutant EGF-like domain containing the Asn-2144 --> Ser amino acid change and measured calcium binding to each using H-1-NMR spectroscopy. The wild-type domain binds calcium with a similar affinity to isolated EGF-like domains from coagulation factors IX and X; however, the mutant domain exhibits >5-fold reduction in affinity. Rotary shadowing of fibrillin-containing microfibrils, isolated from dermal fibroblast cultures obtained from the Marfan patient, shows that the mutation does not prevent assembly of fibrillin into microfibrils but does alter the appearance of the interbead region. We have modeled a region of fibrillin-1 (residues 2126-2331) encompassing five calcium binding FGF-like domains, using data derived from the recently determined crystal structure of a calcium binding EGF-like domain from human factor IX. Our model suggests that these fibrillin-1 EGF-like domains adopt a helical arrangement stabilized by calcium and that defective calcium binding to a single EGF-like domain results in distortion of the helix. We propose a mechanism for the interaction of contiguous arrays of calcium binding EGF-like domains within the microfibril.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; LAB MOLEC BIOPHYS,OXFORD OX1 3QU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER,LANCS,ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of Manchester	HANDFORD, P (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Rao, Zihe/HCH-6944-2022					BARON M, 1992, PROTEIN SCI, V1, P81; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GLANVILLE RW, 1994, 3RD INT S MARF S BER; HANDFORD PA, 1991, NATURE, V353, P395, DOI 10.1038/353395a0; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; JAENICKE R, 1989, PROTEIN STRUCTURE PR, P208; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KIELTY CM, 1993, MATRIX, V13, P103, DOI 10.1016/S0934-8832(11)80069-7; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASLEN CL, 1993, 9TH ANN C NAT MARF F; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; RING CS, 1993, FASEB J, V7, P783, DOI 10.1096/fasebj.7.9.8330685; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; VALCARCE C, 1993, J BIOL CHEM, V268, P26673	24	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6751	6756		10.1074/jbc.270.12.6751	http://dx.doi.org/10.1074/jbc.270.12.6751			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896820	hybrid			2022-12-27	WOS:A1995QQ85500051
J	JENSEN, DE; RICH, CB; TERPSTRA, AJ; FARMER, SR; FOSTER, JA				JENSEN, DE; RICH, CB; TERPSTRA, AJ; FARMER, SR; FOSTER, JA			TRANSCRIPTIONAL REGULATION OF THE ELASTIN GENE BY INSULIN-LIKE GROWTH-FACTOR-I INVOLVES DISRUPTION OF SP1 BINDING - EVIDENCE FOR THE ROLE OF RB IN MEDIATING SP1 BINDING IN AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-FLANKING REGION; MESSENGER-RNA; PROMOTER; TROPOELASTIN; EXPRESSION; PROTEINS; ELEMENT; ELASTOGENESIS; ACTIVATION; SEQUENCE	We have recently identified a novel element (EFE 5/6) in the human elastin gene promoter that modulates the ability of insulin-like growth factor I (IGF-I) to up-regulate elastin gene transcription in aortic smooth muscle cells. In the present study, we have pursued the identification of those nuclear proteins binding to the EFE 5/6 element and affected by IGF-I treatment. Chelation inactivation and metal reactivation experiments together with supershift gel analyses demonstrated that Spl was one of the proteins affected by IGF-I. Southwestern and Western analyses showed that Sp1 was present in IGF-I nuclear extracts and capable of binding DNA after fractionation. Addition of retinoblastoma gene product (Rb) antibody mimicked the effect of IGF-I in gel shift analysis, suggesting that Sp1 binding may be regulated by an inhibitor normally associated with Rb. The fact that the phosphorylation state of Rb was affected by IGF-I was shown by Western blot analysis. The control smooth muscle. cells transcribed the elastin gene at a high level without addition of IGF-I, so it is likely that disruption of Sp1 binding is the first step in allowing the binding of a more potent activating factor.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University				Farmer, Stephen/0000-0003-2483-2795	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, T32HL007429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13262, HL07429] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DAVIDSON JM, 1986, BIOL EXTRACELLULAR M, V1, P177; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FOSTER J, 1987, COLLAGEN REL RES, V7, P161; FOSTER JA, 1989, MATRIX, V9, P328, DOI 10.1016/S0934-8832(89)80009-5; FOSTER JA, 1990, J GERONTOL, V45, pB113, DOI 10.1093/geronj/45.4.B113; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUTOH E, 1993, BIOCHEM BIOPH RES CO, V194, P1475, DOI 10.1006/bbrc.1993.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEVRE M, 1983, BIOCHIM BIOPHYS ACTA, V743, P338, DOI 10.1016/0167-4838(83)90391-6; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; RICH CB, 1993, BIOCHEM BIOPH RES CO, V196, P1316, DOI 10.1006/bbrc.1993.2396; RICH CB, 1992, AM J PHYSIOL, V263, pL276, DOI 10.1152/ajplung.1992.263.2.L276; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; SAMBROOK J, 1989, MOL CLONING LABORATO, pL42; SHIBAHARA S, 1981, BIOCHEMISTRY-US, V20, P6577, DOI 10.1021/bi00526a009; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TERPSTRA AJ, 1994, THESIS BOSTON U, P55; TOSELLI P, 1992, MATRIX, V12, P321, DOI 10.1016/S0934-8832(11)80084-3; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003; YU CY, 1991, J BIOL CHEM, V266, P8907	35	78	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6555	6563		10.1074/jbc.270.12.6555	http://dx.doi.org/10.1074/jbc.270.12.6555			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896792	hybrid			2022-12-27	WOS:A1995QQ85500022
J	LESAUTEUR, L; WEI, L; GIBBS, BF; SARAGOVI, HU				LESAUTEUR, L; WEI, L; GIBBS, BF; SARAGOVI, HU			SMALL PEPTIDE MIMICS OF NERVE GROWTH-FACTOR BIND TRKA RECEPTORS AND AFFECT BIOLOGICAL RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY NGF RECEPTOR; PHEOCHROMOCYTOMA CELLS; NEUROTROPHIN RECEPTORS; MOLECULAR-CLONING; GENE-TRANSFER; PROTOONCOGENE; ANTIBODIES; BDNF; DIFFERENTIATION; ASSOCIATION	Small monomeric cyclic analogs that mimic the beta-turn regions of nerve growth factor (NGF) were designed and synthesized. Potent competitive antagonists were de rived from the NGF beta-turn C-D, which inhibited [I-125] NGF binding to TrkA receptors and specifically inhibited optimal NGF-mediated neurite outgrowth in PC12 cells. The cyclic beta-turn A'-A'' analog also inhibited NGF binding to TrkA receptors but with lower potency. These data indicate that beta-turns C-D and A'-A'' are critical for TrkA binding and may confer neurotrophin receptor specificity. Furthermore, structural requirements for binding are absolute, because unconstrained analogs derived from the same regions had no effect. Compounds that mimic NGF will be useful in deciphering the interactions of NGF and its receptors and in rational drug design.	MCGILL UNIV,DEPT THERAPEUT & PHARMACOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA; BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA	McGill University; McGill University; National Research Council Canada								BERG MM, 1992, J BIOL CHEM, V267, P13; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHEN SX, 1992, P NATL ACAD SCI USA, V89, P5872, DOI 10.1073/pnas.89.13.5872; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; EBENDAL T, 1989, J NEUROSCI RES, V22, P223, DOI 10.1002/jnr.490220302; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LOEB DM, 1993, J NEUROSCI, V13, P2919; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MCDONALD NQ, 1991, NATURE, V345, P411; MEIER R, 1986, EMBO J, V5, P1489, DOI 10.1002/j.1460-2075.1986.tb04387.x; MURPHY RA, 1993, J NEUROSCI, V13, P2853; NANDURI J, 1994, J NEUROSCI RES, V37, P433, DOI 10.1002/jnr.490370402; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; SARAGOVI HU, 1992, IMMUNOMETHODS, V1, P3; Server A C, 1977, Adv Protein Chem, V31, P339, DOI 10.1016/S0065-3233(08)60221-1; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VOLONTE C, 1993, J BIOL CHEM, V268, P21410	43	106	128	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6564	6569		10.1074/jbc.270.12.6564	http://dx.doi.org/10.1074/jbc.270.12.6564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896793	hybrid			2022-12-27	WOS:A1995QQ85500023
J	NAGAI, K; TAKATA, M; YAMAMURA, H; KUROSAKISO, T				NAGAI, K; TAKATA, M; YAMAMURA, H; KUROSAKISO, T			TYROSINE PHOSPHORYLATION OF SHC IS MEDIATED THROUGH LYN AND SYK IN B-CELL RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EPIDERMAL GROWTH-FACTOR; ANTIGEN RECEPTOR; LYMPHOCYTES-B; IG-ALPHA; ZETA-CHAIN; PROTEIN; RAS; ACTIVATION; KINASES	She protein is tyrosine phosphorylated upon B cell receptor (BCR) activation and after its phosphorylation interacts with the adaptor protein Grb2. In turn, Grb2 interacts with the guanine nucleotide exchange factor for Ras, mSOS. Several protein-tyrosine kinases (PTKs) participate in BCR signaling. However, it is not clear which PTK is involved in the phosphorylation of Shc, resulting in coupling to the Ras pathway. Tyrosine phosphorylation of Shc and its association with Grb2 were profoundly reduced in both Lyn- and Syk-deficient B cells upon BCR stimulation. Furthermore, kinase activity of these PTKs was required for phosphorylation of Shc. Shc interacted with Syk in B cells. This interaction and the requirement of Syk kinase activity for phosphorylation of Shc were also demonstrated by cotransfection in COS cells. Because Lyn is required for activation of Syk upon receptor stimulation, our results suggest that the Lyn-activated Syk phosphorylates Shc during BCR signaling.	AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965; FUKUI MED SCH,DEPT BIOCHEM,MATUOKA,FUKUI 91011,JAPAN; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	University of Fukui; Yale University				Takata, Minoru/0000-0002-4926-3675				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; EAGAN SE, 1993, NATURE, V363, P45; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GULBINS E, 1994, J IMMUNOL, V152, P2123; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUROYA K, 1992, ONCOGENE, V7, P277; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMIT L, 1994, J BIOL CHEM, V269, P20209; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKEUCHI F, 1993, BIOCHEM BIOPH RES CO, V194, P91, DOI 10.1006/bbrc.1993.1789; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TORDAI A, 1994, J BIOL CHEM, V269, P7538; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	58	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6824	6829		10.1074/jbc.270.12.6824	http://dx.doi.org/10.1074/jbc.270.12.6824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896829	hybrid			2022-12-27	WOS:A1995QQ85500060
J	CAI, H; WANG, CC; TSOU, CL				CAI, H; WANG, CC; TSOU, CL			CHAPERONE-LIKE ACTIVITY OF PROTEIN DISULFIDE-ISOMERASE IN THE REFOLDING OF A PROTEIN WITH NO DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CATALYSIS; ENZYME; AGGREGATION	D-Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a protein containing no disulfide bonds; the guanidine HCl-denatured enzyme shows only a limited extent of refolding and reactivation upon dilution, and the enzyme is particularly prone to aggregation during the dilution process. With increasing GAPDH concentration, reactivation decreases and aggregation increases, The presence of protein disulfide isomerase in the dilution mixture markedly increases reactivation of GAPDH and at the same time prevents the aggregation of GAPDH as shown by light-scattering measurements. It is suggested that upon dilution, denatured GAPDH is faced with two competing processes of correct folding and assembly to yield the native enzyme and non-productive association of the partially refolded species to form aggregates. Independent of the isomerase activity as no disulfide bond is present in GAPDH, protein disulfide isomerase assists the refolding of GAPDH to its active state by suppressing aggregation in a way closely similar to the action of chaperones.	ACAD SINICA,INST BIOPHYS,NATL LAB BIOMACROMOLECULES,BEIJING 100101,PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Biophysics, CAS								BUCHNER J, 1992, BIO-TECHNOL, V10, P682, DOI 10.1038/nbt0692-682; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; HU CH, 1991, FEBS LETT, V290, P87, DOI 10.1016/0014-5793(91)81232-W; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; MARANGOS PJ, 1974, BIOCHEMISTRY-US, V13, P904, DOI 10.1021/bi00702a012; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OTSU M, 1994, J BIOL CHEM, V269, P6874; PUIG A, 1994, J BIOL CHEM, V269, P7764; TAGUCHI H, 1994, J BIOL CHEM, V269, P15325; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YU XC, 1994, BBA-PROTEIN STRUCT M, V1207, P109, DOI 10.1016/0167-4838(94)90058-2	23	235	250	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24550	24552						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929125				2022-12-27	WOS:A1994PQ49000009
J	SHWORAK, NW; SHIRAKAWA, M; COLLIECJOUAULT, S; LIU, J; MULLIGAN, RC; BIRINYI, LK; ROSENBERG, RD				SHWORAK, NW; SHIRAKAWA, M; COLLIECJOUAULT, S; LIU, J; MULLIGAN, RC; BIRINYI, LK; ROSENBERG, RD			PATHWAY-SPECIFIC REGULATION OF THE SYNTHESIS OF ANTICOAGULANTLY ACTIVE HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ANTITHROMBIN-BINDING SEQUENCE; HIGH-AFFINITY; N-SULFOTRANSFERASE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; CORE PROTEIN; PROTEOGLYCANS; BIOSYNTHESIS; IDENTIFICATION	L cells and endothelial cells synthesize a heparan sulfate (HS) subpopulation, HSact, that exhibits anticoagulant activity due to a specific monosaccharide sequence; the remaining heparan sulfate, HSinact, lacks this region of defined structure and is anticoagulantly inactive. HSact biosynthesis was examined in these two cell types by stably expressing epitope-tagged rat ryudocan (ryudocan(12CA5)), which possesses three glycosaminoglycan (GAG) acceptor sites. Both HSact and HSinact were present on ryudocan(12CA5) isolated from L cells and endothelial cells; thus, a core protein with a unique primary sequence initiates the synthesis of both GAGs. The expression in L cells of ryudocan(12CA5) variants containing a single functional GAG acceptor site demonstrated that each of the three acceptor regions initiates the synthesis of both types of GAGs to a similar extent. Most importantly, in both cell types total HSact generation declined as a function of ryudocan(12CA5) overexpression even though HSinact production increased linearly as a function of this variable. This discordant relationship is a general property of the biosynthetic machinery since in both cell types HSact production was reduced to an equal extent on protein cores of either exogenous or endogenous origins. The suppression of HSact generation was also observed with a secreted form of core protein lacking transmembrane and cytoplasmic domains or by a GAG acceptor site mutated form of core protein incapable of augmenting GAG synthesis. These results suggest that elevated intracellular levels of core protein saturate the capacity of a critical component of the HSact biosynthetic machinery. This critical component is not a member of the common set of biosynthetic enzymes involved in the production of HSact and HSinact since no structural changes were observed in either GAG during overexpression of core protein. Based upon the above data, we conclude that increased intracellular levels of ryudocan probably act by saturating the capacity of components which regulate HSact production by coordinating the function of biosynthetic enzymes.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043771, P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43771, HL-33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HORNER AA, 1982, J BIOL CHEM, V257, P8749; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; KATO M, 1991, J CELL BIOL, V115, P729; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Lindahl U., 1989, HEPARIN, P159; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1989, BIOCHEMISTRY-US, V28, P2888, DOI 10.1021/bi00433a021; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; MERTENS G, 1992, J BIOL CHEM, V267, P20435; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	61	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24941	24952						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929177				2022-12-27	WOS:A1994PQ49000064
J	TONG, JJ; FEINBERG, BA				TONG, JJ; FEINBERG, BA			DIRECT SQUARE-WAVE VOLTAMMETRY OF SUPEROXIDIZED [4FE-4S](3+) ACONITASE AND ASSOCIATED 3FE/4FE CLUSTER INTERCONVERSIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; VINELANDII FERREDOXIN-I; IRON-SULFUR CLUSTERS; 4FE-4S CLUSTER; ACTIVATED ACONITASE; 3FE-4S CLUSTERS; REDUCTION; PROTEINS; BINDING; CRYSTAL	We report a direct square-wave voltammetric study of the iron-surfur enzyme, aconitase, at the pyrolytic graphite edge electrode. New and established redox driven reactions were observed and the equilibrium reduction potential for each couple was determined: E([3Fe-4S]1+/0)(0') = -268 mV, E([4Fe-4S]2+/1+) = -450 mV, E([4Fe-4S]3+/2+) = +100 mV, E(Linear Form) (0') = -281 mV, and putatively, E([3Fe-4S]0/2-)(0') similar or equal to -1000 mV, all versus normal hydrogen electrode. Most importantly we have directly observed the superoxidized [4Fe-4S](3+) form of aconitase (originally proposed by Emptage, M. H., Dreyer, J. L., Kennedy, M. C., and Beinert, H. (1983) J. Biol. Chem. 258, 11106-11111) and directly followed its conversion to the [3Fe-4S](1+) form; this intermediate is required for the deactivation of aconitase, Without exogenous ferrous iron, [3Fe-4S](0) aconitase is apparently super-reduced at very negative potentials to the [3Fe-4S](2-) form and the concomitant formation of [4Fe-4S](2+) aconitase was followed over time. It is the apparent decomposition of super-reduced [3Fe-4S](2-) aconitase that provides the source of ferrous iron for the interconversion of [3Fe-4S](0) aconitase to the [4Fe-4S](2+) form. Voltammetry of free and substrate bound [4Fe-4S]2+ aconitase showed that the latter is less susceptible to oxidation but, surprisingly, has the same E([4Fe-4S]3+/2+)(0').	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201	University of Wisconsin System; University of Wisconsin Milwaukee			Feinberg, Bruce/AAX-9378-2021	Feinberg, Bruce/0000-0001-9267-9994	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG FA, 1989, FEBS LETT, V259, P15, DOI 10.1016/0014-5793(89)81483-8; ARMSTRONG FA, 1989, J AM CHEM SOC, V111, P9185, DOI 10.1021/ja00208a008; ARMSTRONG FA, 1990, STRUCT BOND, V72, P137; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; CAMMACK R, 1992, NATURE, V356, P288, DOI 10.1038/356288b0; CAMMACK R, 1973, BIOCHEM BIOPH RES CO, V54, P548, DOI 10.1016/0006-291X(73)91457-5; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; GEORGE SJ, 1989, BIOCHEM J, V264, P265; HENSON CP, 1967, J BIOL CHEM, V242, P3833; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; KENNEDY C, 1972, BIOCHEM BIOPH RES CO, V47, P740; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; MORENO C, 1994, J INORG BIOCHEM, V53, P219, DOI 10.1016/0162-0134(94)80006-5; OSTERYOUNG J, 1986, ELECTROANAL CHEM, V14, P209; Osteryoung JG, 1885, ANAL CHEM, V57, P101, DOI DOI 10.1021/AC00279A004; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; SMITH ET, 1991, ANAL CHIM ACTA, V251, P27, DOI 10.1016/0003-2670(91)87111-J; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; YOCH DC, 1978, J BACTERIOL, V136, P822, DOI 10.1128/JB.136.2.822-824.1978; ZHUANG HY, 1992, INORG CHIM ACTA, V201, P239	29	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24920	24927						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929174				2022-12-27	WOS:A1994PQ49000061
J	DELOSMONTEROS, AE; SAWAYA, BE; GUILLOU, F; ZAKIN, MM; DEVELLIS, J; SCHAEFFER, E				DELOSMONTEROS, AE; SAWAYA, BE; GUILLOU, F; ZAKIN, MM; DEVELLIS, J; SCHAEFFER, E			BRAIN-SPECIFIC EXPRESSION OF THE HUMAN TRANSFERRIN GENE - SIMILAR ELEMENTS GOVERN TRANSCRIPTION IN OLIGODENDROCYTES AND IN A NEURONAL CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; CAMP RESPONSE ELEMENT; DNA-BINDING DOMAINS; CHOROID-PLEXUS; RAT-BRAIN; CYCLIC-AMP; PROTEIN CRE-BP1; MESSENGER-RNA; SERTOLI CELLS; ENHANCER	We have identified the regulatory sequences that govern the expression of the human transferrin gene in cultured brain cells and compared them with the data obtained with the neuronal cell line B103. Oligodendrocytes and epithelial choroid plexus cells from rat brain were cultured and used for transient expression experiments. Deletion analysis of 1.8 kilobase pairs of the 5' regulatory sequences revealed a -1530/-1140 positive-acting region in oligodendrocytes. The -164/+1 promoter region was sufficient to confer cell type-specific transcription in oligodendrocytes, epithelial choroid plexus cells, and B103 cells. DNase I footprinting experiments revealed three protected sequences, the proximal regions I and II, and the central region I. Gel retardation and antibody reactivity data allowed us to identify most of the nuclear factors present in oligodendrocytes interacting with the promoter sequences. Chicken ovalbumin upstream promoter transcription factor, a CAAT/enhancer-binding protein, and a cAMP response element-binding protein called CRI-BP interact with the proximal regions I and II and central region I sites, respectively. These data confirm the results obtained with the neuronal cell line and emphasize the importance of the three promoter elements for the transferrin gene-specific expression in the central nervous system compared with only two elements required for liver- and testis-specific expression.	UNIV CALIF LOS ANGELES,MENTAL RETARDAT RES CTR,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MENTAL RETARDAT RES CTR,DEPT PSYCHIAT,LOS ANGELES,CA 90024; INST PASTEUR,UNITE EXPRESS GENES EUCARYOTES,F-75724 PARIS 15,FRANCE; INRA,PHYSIOL REPROD STN,F-37380 NOUZILLY,FRANCE	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006576] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-06576] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRED AR, 1987, J BIOL CHEM, V262, P5293; BARTLETT WP, 1991, J NEUROCHEM, V57, P318, DOI 10.1111/j.1471-4159.1991.tb02130.x; BERNDT JA, 1992, J BIOL CHEM, V267, P14730; BLOCH B, 1987, BRAIN RES BULL, V18, P573, DOI 10.1016/0361-9230(87)90122-5; BLOCH B, 1985, P NATL ACAD SCI USA, V82, P6706, DOI 10.1073/pnas.82.19.6706; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; Cole R., 1989, DISSECTION TISSUE CU, P121; CONNOR JR, 1987, J NEUROSCI RES, V17, P51, DOI 10.1002/jnr.490170108; DELOSMONTEROS AE, 1990, J NEUROSCI RES, V25, P576, DOI 10.1002/jnr.490250416; DELOSMONTEROS AE, 1988, INT J DEV NEUROSCI, V6, P167, DOI 10.1016/0736-5748(88)90042-1; DELOSMONTEROS AE, 1989, J NEUROSCI RES, V24, P125, DOI 10.1002/jnr.490240202; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DICKSON PW, 1985, BIOCHEM BIOPH RES CO, V127, P890, DOI 10.1016/S0006-291X(85)80027-9; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARABEDIAN MJ, 1986, CELL, V45, P859, DOI 10.1016/0092-8674(86)90560-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAHN A, 1987, ONCOGENES GENES GROW, P277; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEMAGUERESSE B, 1988, J ENDOCRINOL, V118, pR13, DOI 10.1677/joe.0.118R013; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OH TH, 1986, DEV BRAIN RES, V30, P207, DOI 10.1016/0165-3806(86)90111-2; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; SCHAEFFER E, 1987, GENE, V56, P109, DOI 10.1016/0378-1119(87)90163-6; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SKINNER MK, 1980, J BIOL CHEM, V255, P9523; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TSUTSUMI M, 1989, J BIOL CHEM, V264, P9626; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, MOLCELL BIOL, V12, P1708; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YUAN J, 1992, J NEUROSCI RES, V31, P68, DOI 10.1002/jnr.490310110	46	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24504	24510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929115				2022-12-27	WOS:A1994PQ34600100
J	URBANCIKOVA, M; HITCHCOCKDEGREGORI, SE				URBANCIKOVA, M; HITCHCOCKDEGREGORI, SE			REQUIREMENT OF AMINO-TERMINAL MODIFICATION FOR STRIATED-MUSCLE ALPHA-TROPOMYOSIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; POLYMERIZABLE TROPOMYOSIN; LYSINE REACTIVITIES; ESCHERICHIA-COLI; SMOOTH-MUSCLE; TROPONIN; ACTIN; BINDING; RESOLUTION; FILAMENT	Striated muscle cy-tropomyosin expressed in Escherichia coli is unacetylated, polymerizes poorly, and binds weakly to F-actin (Hitchcock-DeGregori, S. E., and Heald, R. W. (1987) J. Biol. Chem. 262, 9730-9735). To define the structural requirements of NH2-terminal modification for striated tropomyosin function, an acetylated recombinant tropomyosin and an unacetylated short fusion recombinant tropomyosin were compared. An acetylated recombinant chicken striated muscle alpha-tropomyosin was expressed in insect Sf9 cells using the baculovirus expression vector system. The purified tropomyosin (similar to 15 mg/liter of insect cell suspension) polymerized, comigrated with chicken striated alpha-tropomyosin purified from muscle on two-dimensional polyacrylamide gels, was blocked at the NH2 terminus, and had the same actin affinity as muscle tropomyosin. These results conclusively show the importance of NH2-terminal acetylation for striated tropomyosin function. To learn if a short fusion peptide would substitute for amino-terminal acetylation, tropomyosin with AlaSer-Arg on the NH2 terminus was constructed and expressed in E. coli as an unacetylated protein. This f3-tropomyosin bound to actin with a 10-fold higher affinity than striated muscle alpha-TM and, unlike muscle tropomyosin, exhibited a shear dependent viscosity. The altered function of f3-tropomyosin shows that the naturally occurring acetylated NH2 terminus is required for full, normal function. It is proposed that a major requirement for cooperative binding of striated muscle tropomyosin to actin is modification of the alpha-amino group of methionine to be an amide, as when acetylated or in a peptide bond in a fusion protein, to make the extreme NH2 terminus more hydrophobic. The results are discussed in terms of known coiled coil structure.	RUTGERS STATE UNIV, ROBERT WOOD JOHNSON MED SCH, DEPT NEUROSCI & CELL BIOL, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [HL 35726] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHO YJ, 1990, J BIOL CHEM, V265, P538; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; DABROWSKA R, 1983, J MUSCLE RES CELL M, V4, P143, DOI 10.1007/BF00712027; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; GRACEFFA P, 1992, BIOCHIM BIOPHYS ACTA, V1120, P205, DOI 10.1016/0167-4838(92)90271-E; GREENFIELD NJ, 1994, PROTEIN SCI, V3, P402; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; HEELEY DH, 1994, EUR J BIOCHEM, V221, P129, DOI 10.1111/j.1432-1033.1994.tb18721.x; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HITCHCOCKDEGREGORI SE, 1985, BIOCHEMISTRY-US, V24, P3305, DOI 10.1021/bi00334a035; ISHII Y, 1992, PROTEIN SCI, V1, P1319, DOI 10.1002/pro.5560011011; JOHNSON P, 1977, BIOCHEMISTRY-US, V16, P2264, DOI 10.1021/bi00629a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; MAK AS, 1981, BIOCHEM BIOPH RES CO, V101, P208, DOI 10.1016/S0006-291X(81)80032-0; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; NOVY RE, 1993, BIOCHIM BIOPHYS ACTA, V1162, P255, DOI 10.1016/0167-4838(93)90289-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Sambrook J, 1989, MOL CLONING LABORATO; STONE D B, 1989, Biophysical Journal, V55, p277A; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUMMERS MD, 1987, MANUAL METHODS BACUL, V1555; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO H, 1976, J BIOCHEM, V80, P283, DOI 10.1093/oxfordjournals.jbchem.a131275; Urbancikova M., 1993, Molecular Biology of the Cell, V4, p259A; URBANCIKOVA M, 1993, BIOPHYS J, V64, pA137; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WHITBY FG, 1992, J MOL BIOL, V227, P441, DOI 10.1016/0022-2836(92)90899-U; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	42	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24310	24315						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929088				2022-12-27	WOS:A1994PQ34600071
J	ZHANG, YM; PINES, G; KANNER, BI				ZHANG, YM; PINES, G; KANNER, BI			HISTIDINE 326 IS CRITICAL FOR THE FUNCTION OF GLT-1, A (NA++K+) COUPLED GLUTAMATE TRANSPORTER FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; LACTOSE PERMEASE; NEUROTRANSMITTER TRANSPORTERS; RECONSTITUTED PREPARATIONS; MEMBRANE-VESICLES; GABA TRANSPORTER; ACTIVE-TRANSPORT; HIGH-AFFINITY	Removal of glutamate from the synaptic cleft is carried out by transporter molecules located in presynaptic nerve terminals and fine glial processes surrounding the cleft. Three such transporters, which are similar to 55% identical to each other, have recently been cloned. They catalyze electrogenic transport of this neurotransmitter, which is coupled to the fluxes of three ions: sodium, potassium, and protons (or hydroxyl). One of these transporters, GLT-1, contains 573 amino acids and 6-10 putative membrane spanning alpha-helices. These helices contain only two positively charged amino acid residues (lysine 298 and histidine 326) that are fully conserved in the glutamate transporters and two related neutral amino acid transporters. Using site-directed mutagenesis we have investigated the role of these residues, each of which was replaced by small hydrophilic as well as by positively charged amino acids. Expression of all replacement mutants at the histidine 326 position reveals that they are severely impaired in sodium-dependent glutamate transport. On the other hand, mutations at lysine 298 retain significant activity, especially if a positively charged amino acid replaces the lysine. After prelabeling of the proteins with [S-35]methionine, immunoprecipitation of all mutant transporters indicates that their expression levels are similar to those of wild type. Reconstitution experiments, aimed to reveal the activity of transporter molecules not located in the plasma membrane, indicate that the lowered activity of the K298T and K298N transporters in intact cells is partly due to a targeting defect. Histidine residue 326 appears to be required for the intrinsic activity of the transporter. As histidine residues have been implicated in the mechanism of H+ transport in several systems, we propose that histidine 326 may be involved in the proton translocation accompanying sodium- and potassium coupled glutamate transport.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ARRIZA JL, 1993, J BIOL CHEM, V268, P1529; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Iversen L. L., 1975, HDB PSYCHOPHARMACOLO, V2, P381; KABACK HR, 1988, ANNU REV PHYSIOL, V50, P243; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUHAR MJ, 1973, LIFE SCI, V13, P1623, DOI 10.1016/0024-3205(73)90110-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PADAN E, 1985, P NATL ACAD SCI USA, V82, P6765, DOI 10.1073/pnas.82.20.6765; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1990, J NEUROSCI, V10, P1319; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J	39	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 29	1994	269	30					19573	19577						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY332	7913472				2022-12-27	WOS:A1994NY33200058
J	BUESA, C; MARTINEZGONZALEZ, J; CASALS, N; HARO, D; PIULACHS, MD; BELLES, X; HEGARDT, FG				BUESA, C; MARTINEZGONZALEZ, J; CASALS, N; HARO, D; PIULACHS, MD; BELLES, X; HEGARDT, FG			BLATTELLA-GERMANICA HAS 2 HMG-COA SYNTHASE GENES - BOTH ARE REGULATED IN THE OVARY DURING THE GONADOTROPIC CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHASE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; CORPORA ALLATA; JUVENILE-HORMONE; ISOPRENOID SYNTHESIS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; CDNA; REDUCTASE; CELLS	The isoprenoid pathway leads to various essential non-sterol products in insects. These end products have a crucial role in growth, differentiation, sexual maturation, and reproduction. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase (EC 4.1.3.5.) has generally been considered one of the committed steps of the pathway. We had previously reported the cloning of a cytosolic HMG-CoA synthase cDNA in Blattella germanica; we have now isolated and characterized a new cDNA clone for HMG-CoA synthase in this insect. Analysis of this 1716 base pair cDNA reveals a deduced protein of 455 residues with a molecular mass of 51,424 Da. The two HMG-CoA synthases have 69% identical amino acid residues, and both lack an N-terminal leader peptide to target the protein into mitochondria. This HMG-CoA synthase cDNA can revert the Chinese hamster ovary-K1-derived cell line, Mev-1, which is a defective mutant for HMG-CoA synthase. Both HMG-CoA synthase genes are expressed differently throughout development. Analysis of adult tissues shows higher expression in ovary and fat body. The expression of HMG-CoA synthase (EC 4.1.3.5.) and reductase (EC 1.1.1.34) genes during the gonadotrophic cycle in B. germanica shows that the three genes of the isoprenoid pathway are developmentally regulated in the ovary.	UNIV BARCELONA,SCH PHARM,BIOCHEM UNIT,E-08028 BARCELONA,SPAIN; CSIC,CID,DEPT AGROBIOL,E-08034 BARCELONA,SPAIN	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC)			Casals, Nuria/L-3378-2014; Piulachs, Maria-Dolors/C-3992-2011; Belles, Xavier/G-2354-2015; Haro, Diego/I-4623-2015	Casals, Nuria/0000-0002-6719-4300; Piulachs, Maria-Dolors/0000-0002-4500-2718; Belles, Xavier/0000-0002-1566-303X; Haro, Diego/0000-0001-9147-0486; Martinez-Gonzalez, Jose/0000-0002-3894-7166				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; AYTE J, 1990, NUCLEIC ACIDS RES, V18, P3642, DOI 10.1093/nar/18.12.3642; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BEENAKKERS AMT, 1985, PROG LIPID RES, V24, P19; BELLES X, 1987, INSECT BIOCHEM, V17, P1007, DOI 10.1016/0020-1790(87)90111-9; BELLES X, 1993, TISSUE CELL, V25, P195, DOI 10.1016/0040-8166(93)90019-H; CHAUBET N, 1991, PLANT MOL BIOL, V17, P935, DOI 10.1007/BF00037077; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clinkenbeard K D, 1975, Methods Enzymol, V35, P160, DOI 10.1016/0076-6879(75)35151-3; COUILLAUD F, 1991, MOL CELL ENDOCRINOL, V77, P159, DOI 10.1016/0303-7207(91)90070-9; COUILLAUD F, 1991, ARCH INSECT BIOCHEM, V18, P273, DOI 10.1002/arch.940180409; COUILLAUD F, 1991, INSECT BIOCHEM, V21, P131, DOI 10.1016/0020-1790(91)90042-D; DELPINO JC, 1989, INSECT BIOCHEM, V19, P657, DOI 10.1016/0020-1790(89)90101-7; Feyereisen R., 1985, P391; GAUGER A, 1987, DEVELOPMENT, V100, P237; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GIBBONS GF, 1984, J BIOL CHEM, V259, P4399; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KATTARCOOLEY PA, 1990, ARCH BIOCHEM BIOPHYS, V283, P523, DOI 10.1016/0003-9861(90)90677-Q; Kaulenas M, 1992, INSECT ACCESSORY REP, P33; Koeppe J.K., 1985, P165; KOEPPE JK, 1984, JUVENILE HORMONE BIO, P215; LAPOINTE MC, 1985, J INSECT PHYSIOL, V31, P187, DOI 10.1016/0022-1910(85)90119-2; LUSTIGMAN S, 1985, EXP PARASITOL, V59, P59, DOI 10.1016/0014-4894(85)90057-8; MALTESE WA, 1988, J BIOL CHEM, V263, P10104; MARTINEZGONZALEZ J, 1993, EUR J BIOCHEM, V213, P233, DOI 10.1111/j.1432-1033.1993.tb17753.x; MARTINEZGONZALEZ J, 1993, EUR J BIOCHEM, V217, P691, DOI 10.1111/j.1432-1033.1993.tb18295.x; MISRA I, 1993, J BIOL CHEM, V268, P12129; MONGER DJ, 1985, METHOD ENZYMOL, V110, P51; PASCUAL N, 1992, J INSECT PHYSIOL, V38, P339, DOI 10.1016/0022-1910(92)90058-L; PIULACHS MD, 1992, COMP BIOCHEM PHYS A, V102, P477, DOI 10.1016/0300-9629(92)90197-X; Regier J.C., 1985, P113; ROYO T, 1991, BIOCHEM J, V280, P61, DOI 10.1042/bj2800061; RUSS AP, 1992, BIOCHIM BIOPHYS ACTA, V1132, P329, DOI 10.1016/0167-4781(92)90172-V; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; TANAKA A, 1976, Kontyu, V44, P512; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOODWARD HD, 1988, J BIOL CHEM, V263, P2513	48	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11707	11713						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	7909314				2022-12-27	WOS:A1994NG37700009
J	VALERA, A; PELEGRIN, M; ASINS, G; FILLAT, C; SABATER, J; PUJOL, A; HEGARDT, FG; BOSCH, F				VALERA, A; PELEGRIN, M; ASINS, G; FILLAT, C; SABATER, J; PUJOL, A; HEGARDT, FG; BOSCH, F			OVEREXPRESSION OF MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE IN TRANSGENIC MICE CAUSES HEPATIC HYPERKETOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; GROWTH-HORMONE GENE; DIETARY-REGULATION; MESSENGER-RNA; RAT; LIVER; TRANSCRIPTION; EXPRESSION; KETOGENESIS; METABOLISM	Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase) is a key enzyme in the ketone body pathway. To determine its role in the regulation of liver ketogenesis, transgenic mice expressing a P-enol-pyruvate carboxykinase/HMG-CoA synthase chimeric gene have been obtained. An increase in the concentration of mitochondrial HMG-CoA synthase mRNA was detected in these mice, which was associated with a 3-fold increase in HMG-CoA synthase activity in liver mitochondrial extracts. Transgenic mice were normoglycemic and had normal levels of plasma triglycerides and lower free fatty acids. However, the plasma concentration of ketone bodies was about three times higher in transgenic mice than in control animals. Hepatocytes in primary culture from transgenic mice expressed the chimeric gene in a regulated manner and showed a 3-fold increase in beta-hydroxybutyrate and acetoacetate concentrations in the medium. This animal model thus shows that the overexpression of mitochondrial HMG-CoA synthase causes ketone body overproduction, suggesting that this enzyme may be a regulatory step in liver ketogenesis.	AUTONOMOUS UNIV BARCELONA,SCH VET MED,DEPT BIOCHEM & MOLEC BIOL,E-08193 BARCELONA,SPAIN; UNIV BARCELONA,SCH PHARM,BIOCHEM UNIT,E-08028 BARCELONA,SPAIN	Autonomous University of Barcelona; University of Barcelona			Fillat, Cristina/ABH-1674-2020	Fillat, Cristina/0000-0002-0801-3338; BOSCH, FATIMA/0000-0002-7705-5515; Pelegrin, Mireia/0000-0002-0117-2010; Pujol, Anna/0000-0002-3484-598X				AVOGARO A, 1992, DIABETES, V41, P968, DOI 10.2337/diabetes.41.8.968; AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BERGMEYER HU, 1974, METHODS ENZYMATIC AN, V4; BERGMEYER HU, 1974, METHODS ENZYMATIC AN, V3; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; CASALS N, 1992, BIOCHEM J, V283, P261, DOI 10.1042/bj2830261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; DECAUX JF, 1988, FEBS LETT, V232, P156, DOI 10.1016/0014-5793(88)80407-1; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HOGAN B, 1986, MANIPULATING MOUSE E, P81; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KIOUSSIS D, 1978, J BIOL CHEM, V253, P4327; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LECAM A, 1976, EXP CELL RES, V98, P382, DOI 10.1016/0014-4827(76)90448-1; LIU JS, 1991, J BIOL CHEM, V266, P19095; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; QUANT PA, 1990, EUR J BIOCHEM, V187, P169, DOI 10.1111/j.1432-1033.1990.tb15291.x; QUANT PA, 1991, EUR J BIOCHEM, V195, P449, DOI 10.1111/j.1432-1033.1991.tb15724.x; QUANT PA, 1989, BIOCHEM J, V262, P159, DOI 10.1042/bj2620159; REED WD, 1975, J BIOL CHEM, V250, P3117; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V301, P445, DOI 10.1006/abbi.1993.1169; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; THUMELIN S, 1993, BIOCHEM J, V292, P493, DOI 10.1042/bj2920493; TILGHMAN S M, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1304, DOI 10.1073/pnas.71.4.1304; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; ZAMMIT VA, 1984, PROG LIPID RES, V23, P39, DOI 10.1016/0163-7827(84)90005-5	32	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6267	6270						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7907092				2022-12-27	WOS:A1994MZ50300003
J	MITCHELHILL, KI; STAPLETON, D; GAO, G; HOUSE, C; MICHELL, B; KATSIS, F; WITTERS, LA; KEMP, BE				MITCHELHILL, KI; STAPLETON, D; GAO, G; HOUSE, C; MICHELL, B; KATSIS, F; WITTERS, LA; KEMP, BE			MAMMALIAN AMP-ACTIVATED PROTEIN-KINASE SHARES STRUCTURAL AND FUNCTIONAL HOMOLOGY WITH THE CATALYTIC DOMAIN OF YEAST SNF1 PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETYL-COA CARBOXYLASE; REDUCTASE KINASE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; FATTY-ACID; PHOSPHORYLATION; GENE; PURIFICATION; METABOLISM; SUBUNIT; SITES	The AMP-activated protein kinase is responsible for the regulation of fatty acid synthesis by phosphorylation of acetyl-CoA carboxylase. It may also regulate cholesterol synthesis via phosphorylation and inactivation of hormone-sensitive lipase and hydroxymethylglutaryl-CoA reductase. We have purified the AMP-activated protein kinase 14,000-fold from porcine liver. The 63-kDa catalytic subunit co-purifies with two proteins of 40 and 38 kDa that may function as subunits. Partial amino acid sequence of the 63-kDa subunit revealed a striking homology with the catalytic domain of the yeast protein kinase transcriptional regulator Snf1 and its plant homologs. The Snf1 (72 kDa) and Snf4 (36 kDa) complex was also purified and found to phosphorylate the AMP-activated protein kinase peptide substrate, HMRSAMSGLHLVKRR-amide, but was not activated by AMP. Both Snf1/4 and the AMP-activated protein kinase phosphorylate and inactivate yeast acetyl-CoA carboxylase in vitro. These results indicate that during evolution the catalytic domain sequences of the Snf1 protein kinase subfamily have been exploited in the control of mammalian lipid metabolism and raise the possibilities that the AMP-activated protein kinase may have other substrates involved in regulating gene expression pathways, as well as Snf1 homologs participating in the control of lipid metabolism in many eukaryotic organisms.	ST VINCENTS INST MED RES, 41 VICTORIA PARADE, FITZROY, VIC 3065, AUSTRALIA; DARTMOUTH COLL, SCH MED, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA	St. Vincent's Institute of Medical Research; Dartmouth College			Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CELENZA JL, 1991, METHOD ENZYMOL, V200, P423; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; FERRER A, 1984, ARCH BIOCHEM BIOPHYS, V230, P227, DOI 10.1016/0003-9861(84)90104-8; FERRER A, 1985, BIOCHEM BIOPH RES CO, V132, P497, DOI 10.1016/0006-291X(85)91161-1; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; HALFORD NG, 1992, PLANT J, V2, P791, DOI 10.1046/j.1365-313X.1992.t01-16-00999.x; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEGUEN L, 1992, GENE, V120, P249, DOI 10.1016/0378-1119(92)90100-4; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; ROSEN EM, 1990, BIOCHEM BIOPH RES CO, V168, P1082, DOI 10.1016/0006-291X(90)91140-N; TETAZ T, 1993, TECHNIQUES PROTEIN C, V4, P389; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1990, BIOCHEM BIOPH RES CO, V169, P369, DOI 10.1016/0006-291X(90)90341-J; WOODGETT JR, 1991, METHOD ENZYMOL, V200, P169; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; YEH LA, 1980, J BIOL CHEM, V255, P2308	27	280	292	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2361	2364						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905477				2022-12-27	WOS:A1994MV43200004
J	BALZARINI, J; KARLSSON, A; WANG, LY; BOHMAN, C; HORSKA, K; VOTRUBA, I; FRIDLAND, A; VANAERSCHOT, A; HERDEWIJN, P; DECLERCQ, E				BALZARINI, J; KARLSSON, A; WANG, LY; BOHMAN, C; HORSKA, K; VOTRUBA, I; FRIDLAND, A; VANAERSCHOT, A; HERDEWIJN, P; DECLERCQ, E			EICAR (5-ETHYNYL-1-BETA-D-RIBOFURANOSYLIMIDAZOLE-4-CARBOXAMIDE) - A NOVEL POTENT INHIBITOR OF INOSINATE DEHYDROGENASE-ACTIVITY AND GUANYLATE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE NSC 286193; IMP DEHYDROGENASE; MECHANISM; TIAZOFURIN; RIBAVIRIN; CHEMOTHERAPY; METABOLITES; NUCLEOSIDE; EXPRESSION; VIRAZOLE	EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide) is a cytostatic agent that inhibits murine leukemia L1210 and human lymphocyte CEM cells at a 50% inhibitory concentration of 0.80-1.4 muM, respectively. EICAR causes a rapid and marked inhibition of inosinate (IMP) dehydrogenase (EC 1.1.1.205) activity in intact L1210 and CEM cells reflected by a concentration-dependent accumulation of IMP and depletion of GTP and dGTP levels. EICAR 5'-monophosphate is a potent inhibitor of purified L1210 cell IMP dehydrogenase (K(i)/K(m) 0.06). Inhibition of IMP dehydrogenase by EICAR 5'-monophosphate is competitive with respect to IMP. L1210 cells that were selected for resistance to the cytostatic action of EICAR proved to be adenosine kinase-deficient. Also, studies with other mutant L1210 and CEM cell lines revealed that adenosine kinase, as well as an alternative pathway, may be responsible for the conversion of EICAR to its 5'-monophosphate. Purified 2'-deoxycytidine kinase, 2'-deoxyguanosine kinase, cytosolic 5'-nucleotidase, and nicotinamide dinucleotide (NAD) pyrophosphorylase do not seem to be markedly involved in the metabolism of EICAR.	KAROLINSKA INST, S-10401 STOCKHOLM 60, SWEDEN; ACAD SCI CZECH REPUBL, INST ORGAN CHEM & BIOCHEM, CS-16610 PRAGUE 6, CZECHOSLOVAKIA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA	Karolinska Institutet; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; St Jude Children's Research Hospital	BALZARINI, J (corresponding author), CATHOLIC UNIV LEUVEN, REGA INST MED RES, B-3000 LOUVAIN, BELGIUM.		Karlsson, Anna/E-7945-2018	Herdewijn, Piet/0000-0003-3589-8503; Van Aerschot, Arthur/0000-0003-3528-8588; De Clercq, Erik/0000-0002-2985-8890; Karlsson, Anna/0000-0001-6843-6685				BALZARINI J, 1991, J BIOL CHEM, V266, P21509; BALZARINI J, 1992, BIOCHEM J, V287, P785, DOI 10.1042/bj2870785; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BROWNE MJ, 1979, ANTIMICROB AGENTS CH, V15, P747, DOI 10.1128/AAC.15.6.747; COONEY DA, 1982, BIOCHEM PHARMACOL, V31, P2133, DOI 10.1016/0006-2952(82)90436-1; DECLERCQ E, 1991, ANTIMICROB AGENTS CH, V35, P679, DOI 10.1128/AAC.35.4.679; EARLE MF, 1983, CANCER RES, V43, P133; GARRETT C, 1979, ANAL BIOCHEM, V99, P268, DOI 10.1016/S0003-2697(79)80005-6; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P3839, DOI 10.1016/0006-2952(82)90300-8; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P2557, DOI 10.1016/0006-2952(82)90071-5; JAYARAM HN, 1982, BIOCHEM PHARMACOL, V31, P2371, DOI 10.1016/0006-2952(82)90532-9; KHYM JX, 1975, CLIN CHEM, V21, P1245; KUTTAN R, 1982, BIOCHEM BIOPH RES CO, V107, P862, DOI 10.1016/0006-291X(82)90602-7; LUI MS, 1984, J BIOL CHEM, V259, P5078; MATSUDA A, 1988, CHEM PHARM BULL, V36, P2730; NAGAI M, 1991, CANCER RES, V51, P3886; SCHOLTISSEK C, 1976, ARCH VIROL, V50, P349, DOI 10.1007/BF01317961; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; VERHOEF V, 1981, CANCER RES, V41, P4478; WEBER G, 1991, CANCER COMMUN-US, V3, P61, DOI 10.3727/095535491820873579; WEBER G, 1990, BIOCHEM SOC T, V18, P74, DOI 10.1042/bst0180074; WEBER G, 1983, CANCER RES, V43, P3466; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057; YOSHIKAWA M, 1969, B CHEM SOC JPN, V42, P3505, DOI 10.1246/bcsj.42.3505; YVES DH, 1978, METHOD ENZYMOL, V51, P337	26	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24591	24598						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7901217				2022-12-27	WOS:A1993MG67300016
J	BUERMEYER, AB; STRASHEIM, LA; MCMAHON, SL; FARNHAM, PJ				BUERMEYER, AB; STRASHEIM, LA; MCMAHON, SL; FARNHAM, PJ			IDENTIFICATION OF CIS-ACTING ELEMENTS THAT CAN OBVIATE A REQUIREMENT FOR THE C-TERMINAL DOMAIN OF RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; ACCURATE TRANSCRIPTION INITIATION; TATA-BINDING PROTEIN; MAJOR LATE PROMOTER; LARGEST SUBUNIT; CELL-CYCLE; NONPHOSPHORYLATED FORM; FUNCTIONAL INTERACTION; PREINITIATION COMPLEX; SEQUENCES DOWNSTREAM	We have used an in vitro RNA polymerase II (RNAP II) inhibition-restimulation assay to investigate the inability of a form of RNAP II (RNAP IIB) that lacks the conserved, C-terminal heptapeptide repeat domain (CTD) to transcribe the dihydrofolate reductase (dhfr) promoter. Our previous studies demonstrated promoter-specific responses to RNAP IIB in the inhibition-restimulation assay and suggested the existence of cis-acting elements that alleviate the requirement for the CTD. We have now identified elements from two different classes of promoters that can convert dhfr to a CTD-independent promoter. First, addition of a consensus TATA box to the dhfr promoter resulted in a promoter capable of CTD-independent transcription and increased the promoter's affinity for the general transcription factor TFIID. These results suggest that high affinity for TFIID correlates with an ability to be transcribed by RNAP IIB, supporting a proposed interaction between the CTD and TFIID. Second, transfer of a combination of two elements (located at -25 and +1) from the rep-3b promoter, which does not contain a consensus TATA box but can nonetheless be transcribed by RNAP IIB, into the dhfr promoter also allowed CTD-independent transcription. These elements do not constitute a high affinity binding site for TFIID, indicating that an additional mechanism exists to allow CTD-independent transcription. Thus, elements from two classes of CTD-independent promoters that can obviate a requirement for the CTD appear to function via distinct mechanisms. Our finding that a change in a basal element can affect a requirement for the CTD is consistent with a role for the CTD during the formation of the transcriptional preinitiation complex.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Buermeyer, Andrew/AAW-4099-2020	Buermeyer, Andrew/0000-0003-4502-4666; Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA59524, CA45240] Funding Source: Medline; NIGMS NIH HHS [GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045240, R01CA059524, R29CA045240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUANG XF, 1994, BIOCHEM BIOPH RES CO, V198, P712, DOI 10.1006/bbrc.1994.1103; KANG ME, 1993, J BIOL CHEM, V268, P25033; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEANS AL, 1991, THESIS U WISCONSIN M; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Sambrook J, 1989, MOL CLONING LABORATO; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHILLING LJ, 1989, MOL CELL BIOL, V9, P4568, DOI 10.1128/MCB.9.10.4568; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SOPTA M, 1985, J BIOL CHEM, V260, P353; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	51	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6798	6807		10.1074/jbc.270.12.6798	http://dx.doi.org/10.1074/jbc.270.12.6798			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896826	hybrid			2022-12-27	WOS:A1995QQ85500057
J	SECKL, MJ; MORII, N; NARUMIYA, S; ROZENGURT, E				SECKL, MJ; MORII, N; NARUMIYA, S; ROZENGURT, E			GUANOSINE 5'-3-O-(THIO)TRIPHOSPHATE STIMULATES TYROSINE PHOSPHORYLATION OF P125(FAK) AND PAXILLIN IN PERMEABILIZED SWISS 3T3 CELLS - ROLE OF P21(RHO)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOCAL ADHESION KINASE; GTP-BINDING PROTEIN; RAPIDLY STIMULATE; ADP-RIBOSYLTRANSFERASE; BOMBESIN STIMULATION; ANGIOTENSIN-II; PHORBOL ESTERS; RNA-POLYMERASE; GENE-PRODUCT	Addition of guanosine 5'-3-O-(thio) triphosphate (GTP gamma S) to streptolysin O-permeabilized Swiss 3T3 cells induced tyrosine phosphorylation of M(r) 110,000-130,000 and 70,000-80,000 bands. Specifically, GTP gamma S stimulated tyrosine phosphorylation of both focal adhesion kinase (p125(FAK)) and paxillin. GTP gamma S induced tyrosine phosphorylation was dose-dependent (EC(50) of 2.5 mu M) and reached maximum levels after 1.5 min for the M(r) 110,000-130,000 band and 2 min for the M(r) 70,000-80,000 paxillin band. Guanosine 5'-O-(2-thiodiphosphate) inhibited GTP gamma S-induced tyrosine phosphorylation with an IC50 of 100 mu M. Protein kinase C did not mediate GTP gamma S-induced tyrosine phosphorylation. Varying the Ca2+ concentration from 0 to 6 mu M did not increase tyrosine phosphorylation above basal levels and did not affect the ability of GTP gamma S to induce tyrosine phosphorylation. GTP gamma S was able to stimulate tyrosine phosphorylation in the presence of nanomolar concentrations of Mg2+. Furthermore, 30 mu M AlF4- only weakly induced tyrosine phosphorylation in permeabilized cells. Pretreatment with the Clostridium botulinum C3 exoenzyme which inactivates p21(rho), markedly reduced the ability of GTP gamma S to stimulate tyrosine phosphorylation of M(r) 110,000-130,000 and 70,000-80,000 bands including p125(FAK) and paxillin in permeabilized Swiss 3T3 cells. Furthermore, a peptide of p21(rho) (p21(rho17-44)) inhibited GTP gamma S-induced tyrosine phosphorylation in a dose-dependent manner (IC50 1 mu M). This peptide also inhibited tyrosine phosphorylation of p125(FAK) and paxillin. In contrast, 20 mu M p21(ras17-44) peptide failed to inhibit GTP gamma S-induced tyrosine phosphorylation. Using permeabilized cells, our findings demonstrate that GTP gamma S stimulates tyrosine phosphorylation of p125(FAK) and paxillin and that a functional p21(rho) is implicated in this process.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; KYOTO UNIV,FAC MED,DEPT PHARMACOL 2,SAKYO KU,KYOTO 606,JAPAN	Cancer Research UK; Kyoto University								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FORCE T, 1991, J BIOL CHEM, V266, P6650; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V238, P24535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; MIURA Y, 1993, J BIOL CHEM, V268, P510; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SECKL MJ, 1995, IN PRESS J CELL PHYS; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VUORI K, 1993, J BIOL CHEM, V268, P21459; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XUEMIN X, 1994, J BIOL CHEM, V269, P23569; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	57	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6984	6990		10.1074/jbc.270.12.6984	http://dx.doi.org/10.1074/jbc.270.12.6984			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896849	hybrid			2022-12-27	WOS:A1995QQ85500080
J	SHEN, JR; VERMAAS, W; INOUE, Y				SHEN, JR; VERMAAS, W; INOUE, Y			THE ROLE OF CYTOCHROME C-550 AS STUDIED THROUGH REVERSE GENETICS AND MUTANT CHARACTERIZATION IN SYNECHOCYSTIS SP PCC-6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIAL PHOTOSYSTEM-II; MANGANESE-STABILIZING POLYPEPTIDE; PHOTOSYNTHETIC REACTION CENTER; SP PCC-6803; CHLAMYDOMONAS-REINHARDTII; PEROXIDASE-ACTIVITY; OXYGEN EVOLUTION; 12-KDA PROTEIN; DELETION; COMPLEX	The gene coding for cytochrome c-550 in Synechocystis sp. PCC 6803 was cloned based on the N-terminal sequence of the mature polypeptide. Using the most probable translation start codon, the gene is expected to code for 160 amino acid residues. This includes a cleavable N-terminal leader sequence of 25 residues. This leader sequence has an Arg-Asn-Arg sequence immediately before the cleavage site; this is characteristic for transit peptides in prokaryotes. Comparison of this sequence with the leader sequence of the photosystem II-associated extrinsic 33-kDa protein from the same cyanobacterium showed an identity of 13 out of 25 residues. These results suggest that after synthesis of the apoprotein, cytochrome c-550 is transported into the thylakoid lumen. Using the cloned gene, insertion and deletion mutants of Synechocystis sp. PCC 6803 were constructed. In the absence of cytochrome c-550, both mutants were capable of photoautotrophic growth but at a significantly reduced rate. Atrazine binding and Western blot analysis showed that these mutants on a per-chlorophyll basis contained 53-67% of the amount of photosystem II as compared with wild type. The photosystem II- specific oxygen-evolving activity at saturating light intensity was reduced to about 40% of that in the wild type strain. Taken together, these results indicate that the cytochrome c-550 is transported into the thylakoid lumen and contributes to optimal functional stability of photosystem II in cyanobacteria. This supports our biochemical evidence that cytochrome c-550 is associated with the lumenal side of photosystem II as one of the extrinsic proteins enhancing oxygen evolution (Shen, J.-R., Ikeuchi, M., and Inoue, Y. (1992) FEBS Lett. 301, 145-149; Shen, J.-R., and Inoue, Y. (1993) Biochemistry 32, 1825-1832). Based on these results, the gene for cytochrome c-550 was named psbV. The possible evolutionary relationship among extrinsic proteins of the photosystem II donor side is discussed.	ARIZONA STATE UNIV, DEPT BOT, TEMPE, AZ 85287 USA; ARIZONA STATE UNIV, CTR STUDY EARLY EVENTS PHOTOSYNTH, TEMPE, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	SHEN, JR (corresponding author), INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, WAKO, SAITAMA 35101, JAPAN.		Shen, Jian-Ren/B-2558-2011					BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; COHN CL, 1989, ARCH BIOCHEM BIOPHYS, V270, P227, DOI 10.1016/0003-9861(89)90024-6; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; GIERASCH LM, 1994, NATO ASI SERIES H, V82, P191; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; GUIKEMA JA, 1981, BIOCHIM BIOPHYS ACTA, V637, P189, DOI 10.1016/0005-2728(81)90157-2; HAN KC, 1994, FEBS LETT, V355, P121, DOI 10.1016/0014-5793(94)01182-6; HURT EC, 1984, FEBS LETT, V168, P149, DOI 10.1016/0014-5793(84)80225-2; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1989, FEBS LETT, V251, P155, DOI 10.1016/0014-5793(89)81446-2; KANG C, 1994, FEBS LETT, V344, P5, DOI 10.1016/0014-5793(94)00341-6; Krogmann D.W., 1990, CURRENT RES PHOTOSYN, VII, P687; KROGMANN DW, 1991, BIOCHIM BIOPHYS ACTA, V1058, P35, DOI 10.1016/S0005-2728(05)80264-6; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MAYFIELD SP, 1987, P NATL ACAD SCI USA, V84, P749, DOI 10.1073/pnas.84.3.749; MIYAO M, 1987, TOPICS PHOTOSYNTHESI, V9, P289; NISHIYAMA Y, 1994, PLANT PHYSIOL, V105, P1313, DOI 10.1104/pp.105.4.1313; NITSCHKE W, 1991, TRENDS BIOCHEM SCI, V16, P241, DOI 10.1016/0968-0004(91)90095-D; OKKELS JS, 1992, J BIOL CHEM, V267, P21139; OMATA T, 1984, BIOCHIM BIOPHYS ACTA, V766, P395, DOI 10.1016/0005-2728(84)90255-X; PHILBRICK JB, 1988, MOL GEN GENET, V212, P418, DOI 10.1007/BF00330845; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; SHEN JR, 1993, J BIOL CHEM, V268, P20408; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TOMMOS C, 1993, BIOCHEMISTRY-US, V32, P5436, DOI 10.1021/bi00071a020; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V1102, P195, DOI 10.1016/0005-2728(92)90100-G; VERMAAS W, 1990, Z NATURFORSCH C, V45, P359; Whitmarsh J., 1986, ENCY PLANT PHYSL, V19, P508; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YU JJ, 1990, PLANT CELL, V2, P315	37	78	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6901	6907		10.1074/jbc.270.12.6901	http://dx.doi.org/10.1074/jbc.270.12.6901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896839	hybrid			2022-12-27	WOS:A1995QQ85500070
J	CAPRANICO, G; PALUMBO, M; TINELLI, S; ZUNINO, F				CAPRANICO, G; PALUMBO, M; TINELLI, S; ZUNINO, F			UNIQUE SEQUENCE SPECIFICITY OF TOPOISOMERASE-II DNA CLEAVAGE STIMULATION AND DNA-BINDING MODE OF STREPTONIGRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIREMENTS; MITOXANTRONE; CYTOTOXICITY; DERIVATIVES; RESISTANCE; AMSACRINE	Streptonigrin stimulated unique intensity patterns of topoisomerase II-mediated DNA cleavage in agarose and sequencing gels with no similarity to those of doxorubicin, VM-26, 4'(9-acridinylamino)-methanesulfon-m anisidide, genistein, and mitoxantrone. Surprisingly, a statistical analysis of 60 sites stimulated by streptonigrin in SV40 and pBR322 DNAs showed that the drug required the dinucleotide 5'-TA-3' from 2- to 3-positions at the DNA cleavage site. Streptonigrin did not intercalate into the double helix; however, a positive value of the reduced linear dichroism indicated that indeed the drug interacted with the DNA. An angle of 45 degrees was found between the major drug and local DNA axes, suggesting a minor groove binding mode. Moreover, a DNA winding assay showed that streptonigrin may tighten the helical twist of DNA, similar to the known minor groove binder distamycin. Drug competition for receptor site binding was then evaluated by drug combination in the cleavage reaction. DNA cleavage intensity patterns were altered only with the streptonigrin/mitoxantrone combination, suggesting that the two compounds may compete for ternary complex formation. The results indicate that streptonigrin may bind to the DNA in a manner similar to that of minor groove binders and that its pharmacophore, possibly different from other topoisomerase II inhibitors, may be an important determinant of its unique sequence position specificity.	UNIV PADUA, DEPT PHARMACEUT SCI, I-35100 PADUA, ITALY	University of Padua	CAPRANICO, G (corresponding author), IST NAZL STUDIO & CURA TUMORI, DIV EXPTL ONCOL B, VIA VENEZIAN 1, I-20133 MILAN, ITALY.		Capranico, Giovanni/K-1678-2014	Capranico, Giovanni/0000-0002-8708-6454; Palumbo, Manlio/0000-0002-3163-1564				[Anonymous], DEV CANC CHEMOTHERAP; BIGIONI M, 1994, NUCLEIC ACIDS RES, V22, P2274, DOI 10.1093/nar/22.12.2274; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; CAPRANICO G, 1993, BIOCHEMISTRY-US, V32, P3038, DOI 10.1021/bi00063a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; CHEN AY, 1993, CANCER RES, V53, P1332; CHEN AY, 1993, P NATL ACAD SCI USA, V90, P8131, DOI 10.1073/pnas.90.17.8131; COHEN MM, 1963, P NATL ACAD SCI USA, V50, P16, DOI 10.1073/pnas.50.1.16; DEISABELLA P, 1993, MOL PHARMACOL, V43, P715; DEISABELLA P, 1990, MOL PHARMACOL, V37, P11; FOSSE P, 1991, NUCLEIC ACIDS RES, V19, P2861, DOI 10.1093/nar/19.11.2861; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; LEE CH, 1981, P NATL ACAD SCI-BIOL, V78, P2838, DOI 10.1073/pnas.78.5.2838; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Macdonald T. L., 1991, DNA TOPOISOMERASES C, P199; MINFORD J, 1986, BIOCHEMISTRY-US, V25, P9, DOI 10.1021/bi00349a002; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; NORDEN B, 1990, JERUS SYM Q, V23, P23; NORDEN B, 1978, APPL SPECTROSC REV, V14, P157, DOI 10.1080/05704927808060393; OLESON JJ, 1961, ANTIBIOT CHEMOTHER, V11, P158; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; ROWE TC, 1986, CANCER RES, V46, P2021; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YAMASHITA Y, 1990, CANCER RES, V50, P5841; ZWELLING LA, 1992, CANCER RES, V52, P209	30	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25004	25009						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929186				2022-12-27	WOS:A1994PQ49000073
J	VANDERSTAAY, GWM; STAEHELIN, LA				VANDERSTAAY, GWM; STAEHELIN, LA			BIOCHEMICAL-CHARACTERIZATION OF PROTEIN-COMPOSITION AND PROTEIN-PHOSPHORYLATION PATTERNS IN STACKED AND UNSTACKED THYLAKOID MEMBRANES OF THE PROCHLOROPHYTE PROCHLOROTHRIX-HOLLANDICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B ANTENNA; MULTIPLE EVOLUTIONARY ORIGINS; PHOTOSYSTEM-II; PHOTOSYNTHETIC PROKARYOTE; POLYACRYLAMIDE GELS; CHLAMYDOMONAS-REINHARDTII; SUPRAMOLECULAR STRUCTURE; IONIC-STRENGTH; CYANOBACTERIA; ORGANIZATION	We describe a procedure to separate stacked and unstacked membranes from the prochlorophyte Prochlorothrix hollandica that is based on methods used for the separation of grana and stroma thylakoids from chloroplasts. Stacked membranes were isolated from Triton X-100-treated whole thylakoid preparations, unstacked membranes from French press disrupted cells. Membrane fractions were isolated by differential centrifugation. The stacked membranes were enriched in photosystem (PS) II and a chlorophyll a/b-binding antenna complex, whereas the unstacked membranes contained PS I and the ATP synthase. No evidence for a PS I-associated chlorophyll a/b antenna system was obtained. The PS II-associated chlorophyll a/b antenna complex is composed of several apoproteins in the molecular mass range from 32 to 38 kDa. The 38-kDa protein of this complex becomes phosphorylated on its stromal surface by a light-activated kinase, but, unlike the light-harvesting II complex of chloroplasts, it does not migrate from grana to stroma membrane regions. Overall, the thylakoid membranes of Prochlorothrix exhibit a remarkably similar organization to those of chloroplasts, especially in terms of the non-random distribution of protein complexes between grana and stroma thylakoid membranes. However, in contrast to the rapidly reversible phosphorylation-dependent state 1-state 2 response of light-harvesting complex associated with PS II in chloroplasts, the slowly reversible phosphorylation in Prochlorothrix leads only to a functional uncoupling from PS II but not to its redistribution between stacked and unstacked membrane regions.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder				Staehelin, Andrew/0000-0002-0611-4346	NIGMS NIH HHS [GM 22912] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022912] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ALLEN KD, 1991, ANAL BIOCHEM, V194, P214, DOI 10.1016/0003-2697(91)90170-X; BASSI R, 1991, PLANTA, V183, P423, DOI 10.1007/BF00197742; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BULLERJAHN GS, 1990, FEMS MICROBIOL LETT, V67, P99, DOI 10.1111/j.1574-6968.1990.tb13844.x; BULLERJAHN GS, 1987, EUR J BIOCHEM, V168, P295, DOI 10.1111/j.1432-1033.1987.tb13420.x; BULLERJAHN GS, 1993, CRIT REV MICROBIOL, V19, P43, DOI 10.3109/10408419309113522; BULLERJAHN GS, 1992, PLANT PHYSL S, V99, P589; BURGERWIERSMA T, 1986, NATURE, V320, P262, DOI 10.1038/320262a0; BURGERWIERSMA T, 1989, INT J SYST BACTERIOL, V39, P250, DOI 10.1099/00207713-39-3-250; BURGERWIERSMA T, 1989, PLANT PHYSIOL, V91, P770, DOI 10.1104/pp.91.2.770; BURGESS SC, 1990, MEAS SCI TECHNOL, V1, P1, DOI 10.1088/0957-0233/1/1/001; CARTER DP, 1980, ARCH BIOCHEM BIOPHYS, V200, P364, DOI 10.1016/0003-9861(80)90366-5; CHAPMAN RL, 1986, FREEZE FRACTURE ETCH, P213; CHEETHAM PSJ, 1979, ANAL BIOCHEM, V92, P447, DOI 10.1016/0003-2697(79)90683-3; DUNAHAY TG, 1984, BIOCHIM BIOPHYS ACTA, V764, P179, DOI 10.1016/0005-2728(84)90027-6; ENGLE JM, 1991, ARCH MICROBIOL, V155, P453, DOI 10.1007/BF00244961; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GHANOTAKIS DF, 1986, FEBS LETT, V197, P244, DOI 10.1016/0014-5793(86)80335-0; GIDDINGS TH, 1980, P NATL ACAD SCI-BIOL, V77, P352, DOI 10.1073/pnas.77.1.352; GOLECKI JR, 1989, ARCH MICROBIOL, V152, P77, DOI 10.1007/BF00447015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER KR, 1988, J CELL SCI, V91, P577; MOR TS, 1993, BIOCHIM BIOPHYS ACTA, V1141, P206, DOI 10.1016/0005-2728(93)90044-G; NEALE PJ, 1991, BIOCHIM BIOPHYS ACTA, V1056, P195, DOI 10.1016/S0005-2728(05)80287-7; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OLIVE J, 1991, J ELECTRON MICR TECH, V18, P360, DOI 10.1002/jemt.1060180405; PALENIK B, 1992, NATURE, V355, P265, DOI 10.1038/355265a0; POST AF, 1993, BIOCHIM BIOPHYS ACTA, V1144, P374, DOI 10.1016/0005-2728(93)90123-W; POST AF, 1992, BIOCHIM BIOPHYS ACTA, V1100, P75, DOI 10.1016/0005-2728(92)90128-O; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SANE PV, 1970, BIOCHIM BIOPHYS ACTA, V216, P162, DOI 10.1016/0005-2728(70)90168-4; SILVERSTEIN T, 1993, FEBS LETT, V334, P101, DOI 10.1016/0014-5793(93)81690-2; SIMPSON DJ, 1986, ENCY PLANT PHYSL, V19, P665; STAEHELIN LA, 1983, J CELL BIOL, V97, P1327, DOI 10.1083/jcb.97.5.1327; STAEHELIN LA, 1986, ENCY PLANT PHYSL, V19, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRISSL HW, 1993, TRENDS BIOCHEM SCI, V18, P411; TURNER S, 1989, NATURE, V337, P380, DOI 10.1038/337380a0; URBACH E, 1992, NATURE, V355, P267, DOI 10.1038/355267a0; VANDERSTAAY GWM, 1989, BIOCHIM BIOPHYS ACTA, V975, P317, DOI 10.1016/S0005-2728(89)80338-X; VANDERSTAAY GWM, 1993, BIOCHIM BIOPHYS ACTA, V1142, P189, DOI 10.1016/0005-2728(93)90101-K; VANDERSTAAY GWM, 1992, BIOCHIM BIOPHYS ACTA, V1102, P220, DOI 10.1016/0167-4838(92)90513-D; VANDERSTAAY GWM, 1992, RES PHOTOSYNTHESIS, V1, P207; VANDERSTAAY GWM, 1992, THESIS U AMSTERDAM	46	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24834	24844						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929163				2022-12-27	WOS:A1994PQ49000050
J	CHAZOT, PL; COLEMAN, SK; CIK, M; STEPHENSON, FA				CHAZOT, PL; COLEMAN, SK; CIK, M; STEPHENSON, FA			MOLECULAR CHARACTERIZATION OF N-METHYL-D-ASPARTATE RECEPTORS EXPRESSED IN MAMMALIAN-CELLS YIELDS EVIDENCE FOR THE COEXISTENCE OF 3 SUBUNIT TYPES WITHIN A DISCRETE RECEPTOR MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; ISO-OLIGOMERS; CLONED CDNAS; CHANNEL; SUBTYPES; PURIFICATION; PROTEINS	The N-methyl-D-aspartate R1 (NMDA R1), NMDA R2A, and NMDA R2C subunits were expressed transiently in double or triple combinations in human embryonic kidney (HEK) 293 cells. The biochemical and pharmacological properties of the cloned receptors were compared with those of adult mouse forebrain and cerebellum. Under conditions established for maximal expression, cotransfection of the NMDA R1 and R2C subunits yielded a protein detected immunologically with a molecular size of 780,000-850,000 daltons. No cell death was observed in the transfected cells, and the K-D for [H-3]MK801 binding to the NMDA R1/R2C receptor was 346 +/- 158 nM. This was in contrast to a value of K-D = 22 +/- 9 nM found for native cerebellar receptors. Co-transfection with NMDA R1/R2A/R2C subunits with a DNA ratio, 1:3:3, resulted in the expression of a protein with a size similar to the NMDA R1/R2C combination, but the affinity of [H-3]MK801 was now 22 +/- 5 nM, and the percentage cell death post-transfection was 89 +/- 17%. Immunoprecipitation assays of detergent-solubilized transfected cells with NMDA R1 subunit-specific antibodies co-precipitated the NMDA R2A and NMDA R2C subunits in 1/2A and 1/2C transfections, respectively. Similarly, immunoprecipitations with either NMDA R1 or NMDA R2C subunit-specific antibodies co-precipitated the NMDA R2A subunit in the R1/2A/2C triple transfections. These results show that the three NMDA receptor subunit types can co-assemble following their co-expression in mammalian cells with a pharmacological profile that is similar to that found for adult cerebellar NMDA receptors.	UNIV LONDON,SCH PHARM,DEPT PHARMACEUT CHEM,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London School of Pharmacy				Coleman, Sarah/0000-0002-1066-8296				BROSE N, 1993, J BIOL CHEM, V268, P22663; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CHAZOT PL, 1993, BIOCHEM PHARMACOL, V45, P605, DOI 10.1016/0006-2952(93)90133-H; CIK M, 1994, EUR J PHARM-MOLEC PH, V266, pR1; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; EBERT B, 1991, EUR J PHARM-MOLEC PH, V208, P49, DOI 10.1016/0922-4106(91)90050-R; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISHII T, 1993, J BIOL CHEM, V268, P2836; KOPKE AKE, 1993, PROTEIN SCI, V2, P2066; KUONEN DR, 1986, ANAL BIOCHEM, V153, P221, DOI 10.1016/0003-2697(86)90084-9; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STEPHENSON FA, 1991, MOL NEUROBIOL, P183; STERN P, 1994, J PHYSIOL-LONDON, V476, P391, DOI 10.1113/jphysiol.1994.sp020140; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WILLIAMS K, 1991, MOL PHARMACOL, V40, P774; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; YAMAKURA T, 1993, NEUROREPORT, V4, P687, DOI 10.1097/00001756-199306000-00021	30	175	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24403	24409						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929101				2022-12-27	WOS:A1994PQ34600086
J	DONG, AC; HUANG, P; ZHAO, XJ; SAMPATH, V; CAUGHEY, WS				DONG, AC; HUANG, P; ZHAO, XJ; SAMPATH, V; CAUGHEY, WS			CHARACTERIZATION OF SITES OCCUPIED BY THE ANESTHETIC NITROUS-OXIDE WITHIN PROTEINS BY INFRARED-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CARBON-MONOXIDE BINDING; BOVINE HEART MYOGLOBIN; MOLECULAR MECHANISMS; GENERAL-ANESTHETICS; SERUM-ALBUMIN; SECONDARY STRUCTURE; SULFHYDRYL GROUPS; LIGAND-BINDING; HEMOGLOBIN	We report here a comprehensive infrared spectroscopic study of the interactions between the anesthetic nitrous oxide (N2O) and six proteins: lysozyme, cytochrome c, myoglobin, hemoglobin, serum albumin, and cytochrome c oxidase. Sites occupied by N2O molecules within these proteins were characterized. Three types of hydrophobic sites were found within the proteins. One with nu(3) near 2225 cm(-1) is likely to be near peptide bond carbonyls; one with nu(3) near 2219 cm(-1) may be near a benzene-like structure such as the side chains of phenylalanine and tyrosine; and the other with nu(3) near 2215 cm(-1) is likely to be in a nonpolar alkane-like environment provided by the side chains of Leu, Ile, and Val residues. The amount of N2O molecules bound to myoglobin increases as the pH decreases from 9.2 to 5.2. N2O-protein interactions produced no detectable changes in the ligand-binding pockets of myoglobin, hemoglobin, and cytochrome c oxidase. N2O-induced secondary structure changes were detected only in the fully reduced cytochrome c oxidase, not in the fully oxidized oxidase and the other five proteins. N2O-indueed conformational changes in the alpha beta-interface of hemoglobin and the h2 and h3 alpha-helices of human serum albumin were detected by monitoring the S-H stretch vibrations of cysteine residues. These findings provide direct evidence that anesthetic N2O interacts with proteins and occupies sites in the interior of the proteins.	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523	Colorado State University								ALBEN JO, 1974, NATURE, V252, P736, DOI 10.1038/252736a0; BALASUBR.D, 1966, P NATL ACAD SCI USA, V55, P762, DOI 10.1073/pnas.55.4.762; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARE GH, 1975, BIOCHEMISTRY-US, V14, P1578, DOI 10.1021/bi00679a005; BOWLER BE, 1993, BIOCHEMISTRY-US, V32, P183, DOI 10.1021/bi00052a024; BROWN FF, 1976, PROC R SOC SER B-BIO, V193, P387, DOI 10.1098/rspb.1976.0053; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAUGHEY JM, 1977, BIOCHEM BIOPH RES CO, V78, P897, DOI 10.1016/0006-291X(77)90507-1; Caughey W. S., 1980, METHODS DETERMINING, P95; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1981, P NATL ACAD SCI-BIOL, V78, P2903, DOI 10.1073/pnas.78.5.2903; CAUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CURRY S, 1990, BIOCHEMISTRY-US, V29, P4641, DOI 10.1021/bi00471a020; DODSON BA, 1984, MOL CELL BIOCHEM, V64, P97; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DONG A, 1992, BIOCHEMISTRY-US, V31, P9364, DOI 10.1021/bi00154a006; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG A, 1989, J CELL BIOL, V107, pA641; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P9199; FIRESTONE LL, 1986, SEMIN ANESTH PERIO M, V5, P286; FRANKS NP, 1981, NATURE, V292, P248, DOI 10.1038/292248a0; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GORGA JC, 1985, ARCH BIOCHEM BIOPHYS, V240, P734, DOI 10.1016/0003-9861(85)90082-7; HALSEY MJ, 1984, BRIT J ANAESTH, V56, pS9; HAZZARD JH, 1985, ARCH BIOCHEM BIOPHYS, V240, P747, DOI 10.1016/0003-9861(85)90083-9; HAZZARD JH, 1982, BIOPHYS J, V37, pA154; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HEIDNER EJ, 1976, J MOL BIOL, V104, P707, DOI 10.1016/0022-2836(76)90130-3; KAGANN RH, 1982, J MOL SPECTROSC, V95, P297, DOI 10.1016/0022-2852(82)90130-8; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAASBERG LH, 1971, J BIOL CHEM, V246, P4886; MASHIMO T, 1986, MOL PHARMACOL, V29, P149; Meyer HZur, 1899, ARCH EXP PATHOL PHAR, V42, P109, DOI [10.1007/BF01834479, DOI 10.1007/BF01834479]; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; MOH PP, 1987, BIOCHEMISTRY-US, V26, P6243, DOI 10.1021/bi00393a044; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; Overton E., 1901, STUDIEN NARKOSE; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PLYLER EK, 1964, J RES NBS A PHYS CH, VA 68, P79, DOI 10.6028/jres.068A.006; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RICHARDS CD, 1978, NATURE, V276, P775, DOI 10.1038/276775a0; RICHARDS CD, 1980, TOPICAL REV ANAESTHE, V1, P1; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SCHOENBO.BP, 1967, NATURE, V214, P1120, DOI 10.1038/2141120a0; SCHOENBORN BP, 1969, J MOL BIOL, V45, P297, DOI 10.1016/0022-2836(69)90106-5; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1976, P NATL ACAD SCI USA, V73, P4195, DOI 10.1073/pnas.73.11.4195; SEEMAN P, 1972, PHARMACOL REV, V24, P583; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHIMADA H, 1982, J BIOL CHEM, V257, P1893; SHULMAN RG, 1970, J MOL BIOL, V48, P517, DOI 10.1016/0022-2836(70)90063-X; SOWA S, 1987, BIOCHEM BIOPH RES CO, V144, P643, DOI 10.1016/S0006-291X(87)80014-1; SUSI H, 1986, METHOD ENZYMOL, V130, P290; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TORII H, 1992, J CHEM PHYS, V96, P3379, DOI 10.1063/1.461939; UEDA I, 1984, ANESTH ANALG, V63, P929; Vincent-Geisse J., 1970, Canadian Journal of Chemistry, V48, P3918, DOI 10.1139/v70-657; VINCENTGEISSE J, 1971, BERICH BUNSEN GESELL, V75, P348; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; ZHU L, 1992, J MOL BIOL, V224, P207, DOI 10.1016/0022-2836(92)90584-7	66	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					23911	23917						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929038				2022-12-27	WOS:A1994PQ34600013
J	STARBORG, M; BRUNDELL, E; GELL, K; HOOG, C				STARBORG, M; BRUNDELL, E; GELL, K; HOOG, C			A NOVEL MURINE GENE ENCODING A 216-KDA PROTEIN IS RELATED TO A MITOTIC CHECKPOINT REGULATOR PREVIOUSLY IDENTIFIED IN ASPERGILLUS-NIDULANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; DNA-REPLICATION SITES; CHROMOSOME CONDENSATION; BINDING PROTEIN; RCC1 PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMATIN-CONDENSATION; CONFOCAL MICROSCOPY; LARGE NUMBER; S-PHASE	We describe the isolation and characterization of a novel mouse gene, tsg24, which displays striking sequence similarities to the Aspergillus nidulans bimE gene. The bimE gene has been shown to be a mitotic checkpoint regulator, negatively regulating entry into mitosis in A. nidulans. The tsg24 gene was found to contain a long open reading frame of 1944 amino acids, encoding a polypeptide with a calculated molecular mass of 216,087 Da. We have developed an antibody directed against the product of the tsg24 gene and identified a protein with a molecular mass of approximately 200 kDa. This protein was found to be uniformly expressed throughout interphase of the cell cycle, whereas the level of this protein was lower in protein extracts prepared from mitotic cells.	KAROLINSKA INST,MED NOBEL INST,DEPT MOLEC & CELL BIOL,GENET MOLEC LAB,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet								BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CLARK KL, 1991, CELL REGUL, V2, P781, DOI 10.1091/mbc.2.10.781; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FOX MH, 1991, J CELL SCI, V99, P247; FRASCH M, 1991, EMBO J, V10, P1225, DOI 10.1002/j.1460-2075.1991.tb08064.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; HUMBERT C, 1992, J CELL SCI, V103, P97; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MATSUMOTO T, 1993, MOL BIOL CELL, V4, P337, DOI 10.1091/mbc.4.3.337; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MORRIS NR, 1976, EXP CELL RES, V98, P204, DOI 10.1016/0014-4827(76)90480-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1993, CURR BIOL, V3, P291, DOI 10.1016/0960-9822(93)90182-N; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHIMOTO T, 1992, Current Opinion in Cell Biology, V4, P174, DOI 10.1016/0955-0674(92)90029-C; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P1667; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SEINO H, 1992, J CELL SCI, V102, P393; STARBORG M, 1992, MOL REPROD DEV, V33, P243, DOI 10.1002/mrd.1080330303; TOBEY RA, 1967, J CELL PHYSIOL, V70, P63, DOI 10.1002/jcp.1040700109; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	47	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24133	24137						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929068				2022-12-27	WOS:A1994PQ34600046
J	SCOTT, GK; DANIEL, JC; XIONG, XH; MAKI, RA; KABAT, D; BENZ, CC				SCOTT, GK; DANIEL, JC; XIONG, XH; MAKI, RA; KABAT, D; BENZ, CC			BINDING OF AN ETS-RELATED PROTEIN WITHIN THE DNASE-I HYPERSENSITIVE SITE OF THE HER2/NEU PROMOTER IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NEU PROTOONCOGENE; NUCLEAR FACTOR; MESSENGER-RNA; GENE; EXPRESSION; ONCOGENE; C-ERBB-2; OVEREXPRESSION; REPRESSION	Promoter elements accounting for HER2 (c-erbB-2/ neu) overexpression were searched for in several human breast cancer cell lines (MDA-453, BT-474, ZR-75-1, MCF-7) known to express constitutively a 30-fold range in HER2 transcripts per gene copy. HER2 overexpress ing cells showed a single prominent DNase I hypersensitive site near a conserved and hitherto unrecognized ets response element (GAGGAA), located 38 bases down-stream from the CAAT box and directly 5' of the TATA box in the human HERB promoter. Transient transfection of HER2 promoter constructs (0.125, 0.5, and 2.0 kilobase pairs (kb)) demonstrated that the most proximal promoter region (0.125 kb) was capable of conferring up to 30-fold enhanced activity in HER2-overexpressing cell lines relative to low HER2-expressing control lines. Site directed mutagenesis of the ets response element (GAGGAA --> GAGAGA) caused a greater than or equal to 60% reduction in promoter activity affecting at least 0.5 kb of upstream HERB regulatory sequence. Gel-shift assays with nuclear extracts and oligonucleotide sequences spanning the 0.125-kb promoter region detected an ETS-immunoreactive complex, present most abundantly in cells overexpressing HERB, whose high-affinity binding depended on the GAGGAA response element. Methylation interference confirmed the ETS-specific pattern of protein binding by this complex to guanine bases in the ets response element. UV cross-linking and immunoprecipitation implicate a similar to 60-kDa ETS protein, and candidate ETS genes expressed in these breast cancer cells include GABP alpha, elk-1, elf-1, and PEA3.	UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; OREGON HLTH SCI UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	University of California System; University of California San Francisco; Sanford Burnham Prebys Medical Discovery Institute; Oregon Health & Science University					NCI NIH HHS [CA-58207, CA-44768, CA-36773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, R01CA036773, P01CA044768] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENZ CC, 1989, JNCI-J NATL CANCER I, V81, P1704, DOI 10.1093/jnci/81.22.1704; BERGER MS, 1988, CANCER RES, V48, P1238; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1989, MOL CELL BIOL, V9, P5143, DOI 10.1128/MCB.9.11.5143; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FERNANDEZPOL JA, 1989, J BIOL CHEM, V264, P4151; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KAMEDA T, 1990, CANCER RES, V50, P8002; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KEMPER B, 1987, MOL CELL BIOL, V7, P2059, DOI 10.1128/MCB.7.6.2059; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1989, CANCER RES, V49, P4185; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN CS, 1993, J BIOL CHEM, V268, P2793; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MANIATIS T, 1989, MOL CLONING LABORATO, P16; Maxam A M, 1980, Methods Enzymol, V65, P499; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PASLEAU F, 1993, ONCOGENE, V8, P849; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1990, ONCOGENE, V5, P663; RUSSELL KS, 1992, CANCER RES, V52, P6624; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Tripathy D., 1993, ONCOGENES TUMOR SUPP, P15; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WHITE MRA, 1992, ONCOGENE, V7, P677; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	51	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1994	269	31					19848	19858						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PA126	7914192				2022-12-27	WOS:A1994PA12600032
J	KAGAWA, N; OGO, A; TAKAHASHI, Y; IWAMATSU, A; WATERMAN, MR				KAGAWA, N; OGO, A; TAKAHASHI, Y; IWAMATSU, A; WATERMAN, MR			A CAMP-REGULATORY SEQUENCE (CRS1) OF CYP17 IS A CELLULAR TARGET FOR THE HOMEODOMAIN PROTEIN PBX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN PROTOONCOGENE PBX1; PRE-B; TRANSCRIPTION FACTOR; DEVELOPMENTAL EXPRESSION; TRANSLOCATION PROTEIN; FREE-EXTRACTS; GENE; P-45017-ALPHA; DROSOPHILA; RESPONSIVENESS	Cytochrome P450c17 encoded by CYP17, whose expression is regulated by peptide hormones via cAMP, is required for cortisol and sex hormone biosynthesis thereby playing a key role in biological processes including sexual differentiation. Utilizing the cAMP-regulatory sequence CRS1 of the bovine CYP17 gene as an affinity ligand, four CRS1-binding proteins have been purified from nuclear extracts of mouse adrenocortical Y1 cells and shown to enhance the in vitro transcription of a reporter gene promoted by CRS1. Microsequencing of these four proteins established two of them to be the homeodomain proteins Pbx1a and Pbx1b, originally discovered by their involvement in the t(1;19) chromosomal translocation in pre-B-cell acute lymphoblastic leukemias. Overexpression of Pbx1 in Y1 cells enhances cAMP-dependent transcription of the CRS1-dependent reporter gene. These results identify the CRS1 of bovine CYP17 as a cellular target for Pbx1 and suggest that one role of this homeodomain protein is in the regulation of steroidogenesis and subsequently sexual development.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 221,JAPAN	Vanderbilt University; Kirin Brewery Company Limited					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28350] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLU H, 1987, ELECTROPHORESIS, V8, P93; BURGLIN TR, 1992, NAT GENET, V1, P319, DOI 10.1038/ng0892-319; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LUND J, 1990, J BIOL CHEM, V265, P3304; LUND J, 1988, J BIOL CHEM, V263, P16195; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; ZANGER UM, 1991, J BIOL CHEM, V266, P11417; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	27	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 22	1994	269	29					18716	18719						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NX327	7913464				2022-12-27	WOS:A1994NX32700004
J	GUDAS, LJ				GUDAS, LJ			RETINOIDS AND VERTEBRATE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TERATOCARCINOMA STEM-CELLS; ACID RESPONSE ELEMENT; HOMEOBOX GENE HOX-16; RECEPTOR-GAMMA; HENSEN NODE; LIMB BUD; EXPRESSION; PROTEIN; DIFFERENTIATION; IDENTIFICATION				GUDAS, LJ (corresponding author), CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021, USA.							ALLES AJ, 1990, DEVELOPMENT, V108, P73; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; CHEN YP, 1994, DEV BIOL, V161, P70, DOI 10.1006/dbio.1994.1008; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; CHUONG CM, 1993, BIOESSAYS, V15, P513, DOI 10.1002/bies.950150804; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; CONLON RA, 1992, DEVELOPMENT, V116, P357; COREY DP, 1994, P NATL ACAD SCI USA, V91, P433, DOI 10.1073/pnas.91.2.433; DE LUCA LM, 1991, FASEB J, V5, P2924; DERGUINI F, 1994, BIOCHEMISTRY-US, V33, P623, DOI 10.1021/bi00169a001; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETMER K, 1993, J INVEST DERMATOL, V101, P517, DOI 10.1111/1523-1747.ep12365890; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; Goliger Jeffrey A., 1992, Gene Expression, V2, P147; Gudas Lorraine J., 1994, P443; HOFMANN C, 1994, RETINOIDS BIOL CHEM, P441; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; Hong Waun Ki, 1994, P597; HOSLER BA, 1993, MOL CELL BIOL, V13, P2919, DOI 10.1128/MCB.13.5.2919; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; KRUYT FAE, 1993, MOL ENDOCRINOL, V7, P604, DOI 10.1210/me.7.4.604; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEFEBVRE PP, 1993, SCIENCE, V260, P692, DOI 10.1126/science.8480180; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mangelsdorf David J., 1994, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MORRISH AH, 1991, STRUCT CHEM, V2, P211, DOI 10.1007/BF00672217; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; Ong David E., 1994, P283; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; REICHEL RR, 1993, FASEB J, V7, P427, DOI 10.1096/fasebj.7.5.8385039; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1992, DEVELOPMENT, V116, P289; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEBSTER WS, 1986, J CRAN GENET DEV BIO, V6, P211	61	296	299	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15399	15402						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	7910825				2022-12-27	WOS:A1994NP51300001
J	KATZ, J; WALS, P; LEE, WNP				KATZ, J; WALS, P; LEE, WNP			ISOTOPOMER STUDIES OF GLUCONEOGENESIS AND THE KREBS CYCLE WITH C-13-LABELED LACTATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; C-14-LABELED LACTATE; GLYCOGEN-SYNTHESIS; PYRUVATE-KINASE; STARVED RATS; METABOLISM; <U-C-13>GLUCOSE; PATHWAYS; INSULIN; INVIVO	Fasted rats were intragastrically infused with either [2,3-C-13]lactate or [1,2,3-C-13]lactate. The infusate also contained C-14-labeled lactate and [3-H-3]glucose. Glucose, alanine, glutamate, and glutamine were isolated from liver and blood. There was near complete equilibration of lactate and alanine, and the relative specific activities and relative enrichments were the same in blood and liver. Glucose was cleaved enzymatically to lactate. The compounds were examined by gas chromatography-mass spectroscopy. From the mass isotopomer spectra of the lactate, glutamate, and glutamine and their cleavage fragments the positional isotopomer composition of these compounds was obtained. The enrichment and isotopomer pattern in the lactate from cleaved glucose represents that in phosphoenolpyruvate (PEP). When [1,2,3-C-13]lactate was infused the mass isotopomer spectrum of glutamates consisted only of compounds containing either one, two, or three C-13 carbons per molecule (m1, m2, and m3). There was little C-13 in C-4 and C-5 of glutamate. The rate of pyruvate decarboxylation is low, and 3-4% of the acetyl-CoA flux in the Krebs cycle is contributed by lactate carbon. The major isotopomers in lactate, alanine, and PEP were m3 and m2 with C-13 in C-2 and C-3. The predominant isotopomer in PEP from [2,3-C-13]lactate was m2 with C-13 in C-2 and C-3. There was much more of m1 isotopomer with C-13 in C-3 and C-2 than the m1 isotopomer with C-13 in C-1. There was very little m3, the isotopomer with C-13 in all three carbons. Most of the C-13 in C-3 and C-4 of glucose and C-1 of glutamate was introduced via (CO2)-C-13 fixation. From the isotopomer distribution and the rate of glucose turnover we deduced, applying the analysis described in the ''Appendix,'' the absolute rates of gluconeogenic pathways, recycling of PEP and the Cori cycle, and flux in the Krebs cycle. The flux from oxaloacetate (OAA) --> PEP was seven times that of OAA --> citrate, and about half of PEP was recycled to pyruvate via pyruvate kinase. The mass isotopomer patterns in glutamate and glutamine were similar but differed from those of lactate and glucose. It appears that the glutamates are derived from alpha-ketoglutarate from a different Krebs cycle pool than PEP. The flux from OAA to PEP in this pool was two to three times that of OAA to citrate. Our results indicate that the oxidation via the Krebs cycle is not sufficient for the energy needs of the cell and that fatty acids rather than the Krebs cycle provide most of the energy needs of gluconeogenic cells. A major regulatory role of pyruvate kinase is suggested.	UNIV CALIF LOS ANGELES, HARBOR MED CTR, TORRANCE, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	KATZ, J (corresponding author), CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036449] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 4271] Funding Source: Medline; NIDDK NIH HHS [R01 DK36449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAIR JB, 1976, J BIOL CHEM, V251, P3756; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P573, DOI 10.1021/bi00376a032; CONSOLI A, 1993, DIABETES, V42, P732, DOI 10.2337/diabetes.42.5.732; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; DIDONATO L, 1992, FASEB J*, V1520, P3381; DRAKE RL, 1983, J BIOL CHEM, V258, P6008; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; FREEDMAN AD, 1958, J BIOL CHEM, V233, P292; FRIEDMANN B, 1971, ARCH BIOCHEM BIOPHYS, V143, P566; GAWEHN K, 1984, METHOD ENZYMAT AN, V6, P588; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; GROEN AK, 1983, J BIOL CHEM, V258, P4346; GRUNNET N, 1978, BIOCHEM J, V172, P595, DOI 10.1042/bj1720595; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1976, H-S Z PHYSIOL CHEM, V357, P1387, DOI 10.1515/bchm2.1976.357.2.1387; KATZ J, 1991, P NATL ACAD SCI USA, V88, P2103, DOI 10.1073/pnas.88.6.2103; KATZ J, 1979, TECHNIQUES METABOLIC, P1; KOEPPE RE, 1955, J BIOL CHEM, V216, P813; KRAUSFRIEDMAN N, 1981, PHYSIOL REV, V64, P170; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; NIEWOEHNER CB, 1988, DIABETES, V37, P1559, DOI 10.2337/diabetes.37.11.1559; OKAJIMA F, 1981, BIOCHEM J, V194, P525, DOI 10.1042/bj1940525; ROGNSTAD R, 1968, ANAL BIOCHEM, V25, P448, DOI 10.1016/0003-2697(68)90121-8; ROGNSTAD R, 1988, Medical Science Research, V16, P293; RONGSTAD R, 1977, J BIOL CHEM, V252, P1831; RONGSTAD R, 1976, INT J BIOCHEM, V7, P403; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; TOMERA JF, 1982, BIOCHEM J, V208, P231, DOI 10.1042/bj2080231; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; WALS PA, 1993, IN PRESS METABOLISM	37	113	114	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25509	25521						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902352				2022-12-27	WOS:A1993MK10000037
J	ANDRESSON, T; SPARKOWSKI, J; GOLDSTEIN, DJ; SCHLEGEL, R				ANDRESSON, T; SPARKOWSKI, J; GOLDSTEIN, DJ; SCHLEGEL, R			VACUOLAR H+-ATPASE MUTANTS TRANSFORM CELLS AND DEFINE A BINDING-SITE FOR THE PAPILLOMAVIRUS E5 ONCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PORE-FORMING PROTEIN; PROTON PUMP; RECONSTITUTION; KERATINOCYTES; ACTIVATION; COMPONENT; COMPLEX; YEAST; GENE	The 16K subunit of the vacuolar H+-ATPase binds specifically to the bovine (BPV) and human (HPV) papillomavirus E5 oncoproteins, and it has been suggested that this interaction may contribute to cell transformation (Goldstein, D. J., and Schlegel, R. (1990) EMBO J. 9, 137-146; Goldstein, D. J., Finbow, M. E., Andresson, T., McLean, P., Smith, K., Bubb, V. J., and Schlegel, R. (1991) Nature 352, 347-349; Conrad, M., Bubb, V. J., and Schlegel, R. (1993) J. Virol. 67, 6170-6178; Goldstein, D. J., Toyama, R., Schlegel, R., and Dhar, R. (1992) Virology 190, 889-893). We generated mutations within the 16K protein to define binding domains for BPV-1 E5 as well as to characterize the role of 16K in cell transformation. 16K consists predominantly of 4 transmembrane (TM) domains. We showed that mutations within the TM4 domain severely inhibited E5 binding. More specifically, conversion of glutamic acid 143 to arginine within TM4 severely reduced 16K/E5 binding, suggesting that charged interactions facilitated efficient binding. This hypothesis was confirmed by demonstrating that binding to the defective 16K arginine mutant could be restored by complementary charge mutations in E5; conversion of E5 glutamine 17 to glutamic acid or aspartic acid enhanced interactions with the 16K arginine mutant. Surprisingly, mutants in TM4 not only bound poorly to wild-type E5 but were converted into an oncoprotein and induced anchorage-independent growth of NIH 3T3 cells. These data define glutamic acid 143 in the 16K TM4 domain and glutamine 17 within E5 as important contributors to E5/16K binding and suggest a role for the 16K protein in the regulation of cell proliferation.	GEORGETOWN UNIV,SCH MED,DEPT PATHOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University								ARAI H, 1988, J BIOL CHEM, V258, P8796; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; COHEN BD, 1993, J VIROL, V6, P5303; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, VIROLOGY, V190, P889, DOI 10.1016/0042-6822(92)90932-F; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1992, J VIROL, V66, P404; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; KLINNSKY DJ, 1992, J EXP BIOL, V172, P83; LIM PS, 1990, J INFECT DIS, V162, P1623; MANDEL M, 1988, P NATL ACAD SCI USA, V88, P5521; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MELLMAN I, 1992, J EXP BIOL, V172, P39; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1992, J EXP BIOL, V172, P19; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P8736; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SCHLEGEL R, 1987, CANCER CELL, V5, P87; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; SUN SZ, 1987, J BIOL CHEM, V262, P14790; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; ZHANG F, 1983, BIOCHEM BIOPH RES CO, V114, P620, DOI 10.1016/0006-291X(83)90825-2; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	40	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6830	6837		10.1074/jbc.270.12.6830	http://dx.doi.org/10.1074/jbc.270.12.6830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896830	hybrid			2022-12-27	WOS:A1995QQ85500061
J	KRAMER, B; WIEGMANN, K; KRONKE, M				KRAMER, B; WIEGMANN, K; KRONKE, M			REGULATION OF THE HUMAN TNF PROMOTER BY THE TRANSCRIPTION FACTOR ETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA GENE; DNA-BINDING; FACTOR CACHECTIN; CELL-LINES; T-CELL; EXPRESSION; ELEMENT; SEQUENCES; FAMILY	Tumor necrosis factor (TNF) affects the growth, differentiation, and function of a multitude of cell types and is viewed as a potent mediator of inflammation and cellular immune responses. In order to delineate functional domains that control TNF gene transcription, we have analyzed a 5' flanking region of the human TNF promoter spanning base pairs -115 to -98. This region contains a PEA3/Ets-1 binding motif 5' GAGGA 3' in direct juxtaposition to an AP-1/ATF-like palindromic sequence motif 5' TGAGCTCA 3'. Specific binding of Ets and Jun to their respective elements is demonstrated by competition analysis as well as by supershift assays. As shown by promoter deletion analysis, these two binding sites were essential for both basal promoter activity and responsiveness to the phorbol ester phorbol 12-myristate 13-acetate. Cotransfection of c-ets or c-jun expression plasmids along with TNF promoter-CAT reporter constructs revealed the participation of both transcription factors in the regulation of TNF gene transcription. Correspondingly, site specific mutation of either Ets or Jun sites led to a complete loss of responsiveness to the respective transcription factor. These data suggest an essential role of Ets for the activation of TNF gene transcription.	TECH UNIV MUNICH,INST MED MIKROBIOL & HYG,D-81675 MUNICH,GERMANY	Technical University of Munich								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHANTRY D, 1989, J IMMUNOL, V142, P4295; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CUTURI MC, 1987, J EXP MED, V165, P1581, DOI 10.1084/jem.165.6.1581; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; ESSNER R, 1989, J IMMUNOL, V142, P3857; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HELD W, 1990, P NATL ACAD SCI USA, V87, P2239, DOI 10.1073/pnas.87.6.2239; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1989, TRENDS GENET, V5, P65, DOI 10.1016/0168-9525(89)90027-9; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KRONKE M, 1988, CANCER RES, V48, P5417; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIMB GA, 1989, IMMUNOLOGY, V68, P514; Maxam A M, 1980, Methods Enzymol, V65, P499; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHNO I, 1990, IMMUNOLOGY, V70, P88; OLD LJ, 1985, SCIENCE, V230, P680; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; RAO VN, 1992, ONCOGENE, V7, P65; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; ROESLER WJ, 1988, TRENDS GENET, V5, P65; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; SMITH DB, 1988, GENE AMST, P29541; SMITH DB, 1988, GENE AMST, P25708; Spriggs D R, 1992, Immunol Ser, V56, P3; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TRACEY KJ, 1989, CURR OPIN IMMUNOL, V1, P454, DOI 10.1016/0952-7915(88)90026-X; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	51	119	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	1995	270	12					6577	6583						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ855	7896795				2022-12-27	WOS:A1995QQ85500025
J	BARON, AJ; STEVENS, C; WILMOT, C; SENEVIRATNE, KD; BLAKELEY, V; DOOLEY, DM; PHILLIPS, SEV; KNOWLES, PF; MCPHERSON, MJ				BARON, AJ; STEVENS, C; WILMOT, C; SENEVIRATNE, KD; BLAKELEY, V; DOOLEY, DM; PHILLIPS, SEV; KNOWLES, PF; MCPHERSON, MJ			STRUCTURE AND MECHANISM OF GALACTOSE-OXIDASE - THE FREE-RADICAL SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OROTIDINE-5'-PHOSPHATE DECARBOXYLASE GENE; ASPERGILLUS-NIDULANS; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; TRANSFORMATION; RESONANCE; PROTEINS; NUCLEAR; CLONING	Crystallographic and spectroscopic studies on galactose oxidase have shown that the active site involves a free radical on tyrosine 272, one of the ligands coordinated to the Cu2+ cofactor. A novel thioether bond between tyrosine 272 and cysteine 228, and a stacking tryptophan 290, over this bond, are features of the crystal structure. The present study describes the development of a high level heterologous expression system for galactose oxidase and the construction of mutational variants at these key active site residues. The expressed wildtype enzyme and mutational variants (W290H and C228G) have been characterized by x-ray crystallography, visible spectroscopy, and catalytic activity measurements. A further variant protein, Y272F, could not be purified. The data establish that the thioether bond and stacking tryptophan are essential for activity and further support a role for tryptophan 290 as a component of the free radical site.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA	University of Leeds; Montana State University System; Montana State University Bozeman				McPherson, Michael/0000-0002-0719-6427; Phillips, Simon/0000-0001-8922-0250				AMARAL D, 1963, J BIOL CHEM, V238, P2281; BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BALLANCE DJ, 1985, GENE, V36, P321, DOI 10.1016/0378-1119(85)90187-8; BALLANCE DJ, 1983, BIOCHEM BIOPH RES CO, V112, P284, DOI 10.1016/0006-291X(83)91828-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ETTINGER MJ, 1974, BIOCHEMISTRY-US, V13, P1242, DOI 10.1021/bi00703a029; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRIES DG, 1984, BIOCHEM J, V223, P551, DOI 10.1042/bj2230551; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1992, FARADAY DISCUSS, V93, P75, DOI 10.1039/fd9929300075; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JUDICE JK, 1993, SCIENCE, V261, P1578, DOI 10.1126/science.8103944; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Knowles P. F., 1994, PERSPECTIVES BIO INO, V2, P207; KOSMAN DJ, 1974, ARCH BIOCHEM BIOPHYS, V165, P456, DOI 10.1016/0003-9861(74)90271-9; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KWIATKOWSKI LD, 1981, J INORG BIOCHEM, V14, P209, DOI 10.1016/S0162-0134(00)80001-X; MCPHERSON M.J., 1992, MOL PLANT PATHOL, VI, P123; MCPHERSON MJ, 1992, J BIOL CHEM, V267, P8146; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; OAKLEY BR, 1987, GENE, V61, P385, DOI 10.1016/0378-1119(87)90201-0; OGEL ZB, 1994, MYCOL RES, V98, P474, DOI 10.1016/S0953-7562(09)81207-0; OGEL ZB, 1993, THESIS U LEEDS UK, P81; ORMO M, 1992, J BIOL CHEM, V267, P8711; ROWLANDS RT, 1973, MOL GEN GENET, V126, P201, DOI 10.1007/BF00267531; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STURA EA, 1991, J CRYST GROWTH, V110, P270, DOI 10.1016/0022-0248(91)90896-D; WARD M, 1990, BIO-TECHNOL, V8, P435, DOI 10.1038/nbt0590-435; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1993, BIOPHYS J, V64, P762, DOI 10.1016/S0006-3495(93)81437-1; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610	39	128	131	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25095	25105						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929198				2022-12-27	WOS:A1994PQ49000087
J	NISHIMURA, K; HIGAKI, T; OKAMURA, H; TANASE, S				NISHIMURA, K; HIGAKI, T; OKAMURA, H; TANASE, S			FUNCTIONAL-ROLE OF THE AMINO-TERMINAL MOBILE SEGMENT IN CATALYSIS BY PORCINE CYTOSOLIC ASPARTATE-AMINOTRANSFERASE - CRITICAL IMPORTANCE OF VAL(17) AND PHE(18) FOR PRODUCTIVE BINDING OF SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DOMAIN CLOSURE; ENZYME; DEHYDROGENASE; RESOLUTION; YEAST; LOOP	A notable feature of porcine cytosolic aspartate aminotransferase is the closure of the active site cleft by a mobile amino-terminal segment (residues 15-40) upon binding substrate. The functional roles of Va1(17) and Phe(18), residues that are part of the mobile loop, have been studied in the site-directed mutants in which the size and hydrophobic nature of these residues have been changed. Absorption, circular dichroism spectra, susceptibility to protease 401, and thermal stability did not differ appreciably between wild type and mutant enzymes. In the overall transamination between aspartate and 2-oxoglutarate, V17A represented a typical K-m mutant while V17I retained the substrate binding affinity fairly well. In contrast, replacement of Phe(18) by Ala resulted in a large decrease in both catalytic rate and binding affinity for substrates. F18W, F18Y, and F18H showed a moderate decrease in k(cat) and a considerable increase in K-m values. Single-turnover reactions with four individual substrates yielded analogous results to those obtained for the overall reaction and, in addition, revealed that k/K-d values of mutants F18A and F18H were over 10 times lower for C-5 substrates (glutamate and 2-oxoglutarate) than those for C-4 substrates (aspartate and oxalacetate). All mutant enzymes showed variously increased K-d values for substrate analogs such as 2-methylaspartate, succinate, and glutarate. H-1 MMR observations of F18H, in which His(18) served as a built-in probe, were in accord with the behavior that would be expected from the conformational transition. We conclude that, although Val(17) and Phe(18) may not be essential for catalysis, the presence of a bulky residue of appropriate size at each position is critical for productive binding of substrate.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT OBSTET & GYNECOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,COLL MED SCI,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University; Kumamoto University								Arnone A, 1985, TRANSAMINASES, P138; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; Cleland W W, 1979, Methods Enzymol, V63, P103; DREUSICKE D, 1988, J MOL BIOL, V203, P1021, DOI 10.1016/0022-2836(88)90126-X; FASELLA P, 1966, BIOCHEMISTRY-US, V5, P197, DOI 10.1021/bi00865a026; FUKUMOTO Y, 1991, J BIOL CHEM, V266, P4187; GERSTEIN M, 1991, J MOL BIOL, V220, P133, DOI 10.1016/0022-2836(91)90387-L; INOUE K, 1991, BIOCHEMISTRY-US, V30, P7796, DOI 10.1021/bi00245a019; JANSONIUS JN, 1985, TRANSAMINASES, P110; JENKINS WT, 1959, J BIOL CHEM, V234, P51; JENKINS WT, 1966, J BIOL CHEM, V241, P5667; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MORINO Y, 1984, J BIOL CHEM, V259, P3877; NAGASHIMA F, 1989, BIOCHEMISTRY-US, V28, P1153, DOI 10.1021/bi00429a033; NAGASHIMA F, 1986, J BIOCHEM, V99, P1017, DOI 10.1093/oxfordjournals.jbchem.a135565; PAN QW, 1993, J BIOL CHEM, V268, P24758; Sambrook J, 1989, MOL CLONING LABORATO; SKARZYNSKI T, 1988, J MOL BIOL, V203, P1097, DOI 10.1016/0022-2836(88)90130-1; WIERENGA RK, 1992, J MOL BIOL, V224, P1115, DOI 10.1016/0022-2836(92)90473-W	23	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24712	24718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929145				2022-12-27	WOS:A1994PQ49000032
J	SUPEK, F; SUPEKOVA, L; MANDIYAN, S; PAN, YCE; NELSON, H; NELSON, N				SUPEK, F; SUPEKOVA, L; MANDIYAN, S; PAN, YCE; NELSON, H; NELSON, N			A NOVEL ACCESSORY SUBUNIT FOR VACUOLAR H+-ATPASE FROM CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; GENE ENCODES; YEAST; SEQUENCE; POLYPEPTIDE; MEMBRANES; EVOLUTION	Three subunits, Ac115, Ac39, and the proteolipid, were positively identified in the membrane sectors of V-ATPases from different sources. We searched for organelle-specific protein in purified preparations of V-ATPase from bovine chromaffin granules. A diffused protein band at a position of about 45 kDa was identified in SDS-polyacrylamide gels of the above preparation. Following digestion with endopeptidase Glu-C (V-8), a polypeptide of about 10 kDa was isolated and subjected to amino acid sequencing. Hence, the cDNA encoding the protein Ac45 was cloned from a bovine adrenal me dulla library. The cDNA sequence contains an open read ing frame encoding a protein of 468 amino acids with a calculated molecular mass of 51,786 daltons. A potential signal sequence comprised of the first 35 amino acids and a potential transmembrane domain at the C terminus of the protein were identified. There exist seven potential glycosylation sites between the aforementioned protein motifs. Experiments with a specific antibody against Ac45 demonstrated that it is copurifying with the V-ATPase from chromaffin granules. Immuno logical cross-reactivity was observed with purified V-ATPase from bovine kidney microsomes but not from plasma membranes of epithelial cells. Cell-free expression of the protein from synthetic mRNA produced a single protein band at about 50 kDa on SDS gels. Upon inclusion of dog pancreas microsomes in the reaction mixture, a slow migrating band sensitive to peptide:N-glycosidase F was observed.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								ARAI H, 1988, J BIOL CHEM, V263, P8796; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; FOURY F, 1990, J BIOL CHEM, V265, P18554; FREEZE HH, 1993, CURR PROT MOL BIOL, V2, P1; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; KANE PM, 1992, J BIOL CHEM, V267, P447; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P1064; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1983, METHOD ENZYMOL, V97, P510; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; Sambrook J, 1989, MOL CLONING LABORATO; STEVENS TH, 1992, J EXP BIOL, V172, P47; SZE H, 1992, J EXP BIOL, V172, P123; WANG SY, 1988, J BIOL CHEM, V263, P17638	38	104	108	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24102	24106						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929063				2022-12-27	WOS:A1994PQ34600041
J	PETIT, MA; BEDALE, W; OSIPIUK, J; LU, C; RAJAGOPALAN, M; MCINERNEY, P; GOODMAN, MF; ECHOLS, H				PETIT, MA; BEDALE, W; OSIPIUK, J; LU, C; RAJAGOPALAN, M; MCINERNEY, P; GOODMAN, MF; ECHOLS, H			SEQUENTIAL FOLDING OF UMUC BY THE HSP70 AND HSP60 CHAPERONE COMPLEXES OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA-REPLICATION; HEAT-SHOCK PROTEINS; UV MUTAGENESIS; RECA PROTEIN; REPRESSOR CLEAVAGE; RNA-POLYMERASE; GROE MUTANTS; PURIFICATION; MUTATIONS; GRPE	Replication-blocking lesions generate a signal in Escherichia coli that leads to the induction of the multigene SOS response. Among the SOS-induced genes are umuD and umuC, whose products are necessary for the increased mutation rate in induced bacteria. The mutations are likely to result from replication across the DNA lesion, and such a bypass event has been reconstituted in vitro (Rajagopalan, M., Lu, C., Woodgate, R., O'Donnel, M., Goodman, M. F., Echols, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10777-10781). In this work, we show that the chaperone proteins promote the proper folding of UmuC protein in vitro. We treated purified and inactive UmuC with Hsp70 and Hsp60. After Hsp70 treatment, the DNA binding activity of UmuC was recovered, but the ability to promote replication across DNA lesions was not. However, lesion bypass activity was recovered upon further treatment with Hsp60. The biological significance of such a folding pathway for UmuC protein is strengthened by in vivo evidence for a role of DnaK in UV-induced mutagenesis.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA	University of California System; University of California Berkeley; University of Southern California				Petit, Marie-Agnes/0000-0003-2242-2768; Bedale, Wendy/0000-0002-0122-4255	NCI NIH HHS [CA 41655] Funding Source: Medline; NIGMS NIH HHS [GM-42554, GM-21422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554, R37GM021422, R01GM021422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DONNELLY CE, 1989, J BACTERIOL, V171, P6117, DOI 10.1128/jb.171.11.6117-6125.1989; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; ECHOLS H, 1982, BIOCHIMIE, V64, P571, DOI 10.1016/S0300-9084(82)80089-8; ENNIS DG, 1989, J BACTERIOL, V171, P2533, DOI 10.1128/jb.171.5.2533-2541.1989; FRANCKE B, 1971, VIROLOGY, V44, P168, DOI 10.1016/0042-6822(71)90163-2; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; KUBO T, 1993, J BIOL CHEM, V268, P19346; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MAKI H, 1988, J BIOL CHEM, V263, P6570; MILLER JH, 1992, SHORT COURSE BACTERI, P293; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Radman M., 1975, MOL MECHANISMS REPAI, P355; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SCHENDEL PF, 1978, J BACTERIOL, V135, P466, DOI 10.1128/JB.135.2.466-475.1978; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1816; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WILD J, 1992, P NATL ACAD SCI USA, V89, P7139, DOI 10.1073/pnas.89.15.7139; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	1994	269	38					23824	23829						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ345	7916347				2022-12-27	WOS:A1994PQ34500066
J	JACOBDUBUISSON, F; STRIKER, R; HULTGREN, SJ				JACOBDUBUISSON, F; STRIKER, R; HULTGREN, SJ			CHAPERONE-ASSISTED SELF-ASSEMBLY OF PILI INDEPENDENT OF CELLULAR-ENERGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; BACTERIAL OUTER MEMBRANES; SALMONELLA-TYPHIMURIUM; PROTEIN TRANSLOCATION; PROTONMOTIVE FORCE; RECEPTOR-BINDING; VIBRIO-CHOLERAE; SECRETION; TRANSPORT; SUBUNITS	Assembly of P pili on the surface of pyelonephritic Escherichia coli proceeds from periplasmic chaperone-subunit complexes. The outer membrane protein PapC, which has been termed a molecular usher, is thought to be the site of assembly, where the chaperone dissociates from the subunits as they are incorporated into the pilus across the outer membrane. The kinetics of assembly and the energy requirements of the ''secretion'' events at the outer membrane were investigated using a pulse-chase analysis in which preformed labeled periplasmic chaperone-subunit complexes were assembled into pili in synchrony by the induction of PapC. Provided that a sufficient amount of PapC was present and functional in the outer membrane, the incorporation of the major PapA subunit into pili was shown to be completed in less than 5 min. Our results also indicated that the targeting of PapC to the outer membrane may be a rate-limiting factor for pilus assembly. Following the arrival of PapC, the formation of pili seemed to proceed spontaneously and was not sensitive to a pH shift or an inhibitor of the electrochemical gradient across the cytoplasmic membrane. We suggest that the secretion of pili across the outer membrane may be independent of cellular energy and thermodynamically driven.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Jacob-Dubuisson, Françoise/F-1610-2018	Jacob-Dubuisson, Françoise/0000-0002-5102-1704; Striker, Rob/0000-0002-0454-895X	NIAID NIH HHS [R01AI29549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; COVACCI A, 1993, MOL MICROBIOL, V8, P429, DOI 10.1111/j.1365-2958.1993.tb01587.x; DODD DC, 1984, J BACTERIOL, V160, P227, DOI 10.1128/JB.160.1.227-232.1984; DODD DC, 1984, J BACTERIOL, V159, P1077, DOI 10.1128/JB.159.3.1077-1079.1984; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUPERSZTOCH YM, 1990, J BACTERIOL, V172, P2427, DOI 10.1128/jb.172.5.2427-2432.1990; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LORY S, 1992, J BACTERIOL, V174, P3423; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; PAGES JM, 1988, EUR J BIOCHEM, V176, P655, DOI 10.1111/j.1432-1033.1988.tb14327.x; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEN K, 1988, J BIOL CHEM, V263, P1182; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; STRIKER R, 1994, J BIOL CHEM, V269, P12233; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; WANDERSMAN C, 1993, MOL MICROBIOL, V7, P141, DOI 10.1111/j.1365-2958.1993.tb01105.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WONG KR, 1989, SCIENCE, V246, P654, DOI 10.1126/science.2814486	45	102	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12447	12455						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	7909802				2022-12-27	WOS:A1994NH71600015
J	KUROSE, H; LEFKOWITZ, RJ				KUROSE, H; LEFKOWITZ, RJ			DIFFERENTIAL DESENSITIZATION AND PHOSPHORYLATION OF 3 CLONED AND TRANSFECTED ALPHA-2-ADRENERGIC RECEPTOR SUBTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; AGONIST-PROMOTED DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; G-PROTEINS; KINASE; EXPRESSION; CLONING; FAMILY; MECHANISMS	Genes encoding 3 distinct subtypes of human alpha2-adrenergic receptor are known and are found, respectively, on chromosome 10, 4, and 2 (alpha2-C10 alpha2-C4, and alpha2-C2 adrenergic receptors). All 3 receptors inhibit adenylyl cyclase via G(i) proteins. To study and compare their regulatory properties we assessed the ability of each to undergo agonist-promoted desensitization and phosphorylation. When Chinese hamster ovary cells stably expressing each of the three receptor genes were incubated with epinephrine for 20 min, a marked decrease in sensitivity to subsequent agonist-mediated inhibition of adenylyl cyclase was observed for the alpha2-C10 and alpha2-C2 receptors but not for the alpha2-C4 receptors. When similar incubations were performed with P-32i-labeled cells and the receptors were immunoprecipitated with specific antibodies, alpha2-C10 and alpha2-C2 receptors were found to undergo an approximately 3-fold increase in receptor phosphorylation after epinephrine exposure. When transfected into COS cells epinephrine also stimulated phosphorylation of alpha2-C10 and alpha2-C2 receptors while having only a slight effect on alpha2-C4 receptors. Cotransfection of the cells with the cDNA encoding the beta-adrenergic receptor kinase further increased receptor phosphorylation for alpha2-C10 and alpha2-C2 receptors while having little or no effect on alpha2-C4 receptors. Moreover purified and reconstituted recombinant alpha2-C10 receptors could be phosphorylated in an agonist-dependent fashion whereas alpha2-C4 receptors could not. These observations suggest receptor subtype-specific differences in susceptibility to regulatory phosphorylation and desensitization.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, BOX 3821, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1992, J BIOL CHEM, V267, P25473; EASON MG, 1993, BIOCHEM BIOPH RES CO, V193, P318, DOI 10.1006/bbrc.1993.1626; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; KUROSE H, 1993, MOL PHARMACOL, V43, P444; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PLASSAT JL, 1993, MOL PHARMACOL, V44, P229; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2	33	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10093	10099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7908287				2022-12-27	WOS:A1994NE05300104
J	FRANCO, PJ; BROOKER, RJ				FRANCO, PJ; BROOKER, RJ			FUNCTIONAL ROLES OF GLU-269 AND GLU-325 WITHIN THE LACTOSE PERMEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; MEMBRANE-VESICLES; CARRIER PROTEIN; DIRECTED MUTAGENESIS; ENHANCED RECOGNITION; PLASMID DNA; TRANSPORT; MUTANTS; MECHANISM; MALTOSE	Acidic residues which are found on transmembrane segments within the lactose permease may play an important role in H+ and/or sugar recognition. To examine the functional roles of Glu-269 and Glu-325, we have constructed a variety of amino acid substitutions (e.g. aspartate, glycine, alanine, serine, or glutamine) via site-directed mutagenesis. At position 269, all mutations appear to have a detrimental effect on sugar affinity, downhill transport, and counterflow. The Asp-269 mutant was able to accumulate lactose against a concentration gradient, whereas all of the nonionizable substitutions at position 269 were completely defective. Nevertheless, in spite of their inability to actively accumulate sugars, Gly-269, Ala-269, and Gln-269 mutants were observed to transport H+ upon the addition of galactosides. Mutations at position 325 had a markedly different phenotype. For example, the Asp-325, Gly-325, and Gln-325 mutants exhibited an apparent K-m for lactose transport (e.g. 0.21, 0.47, and 0.50 mM, respectively), which was actually lower than that of the wild-type strain (1.44 mM). In counterflow assays, all position 325 mutants also appear to catalyze lactose exchange. Similar to the results obtained at position 269, the Asp-325 mutant exhibited moderate levels of accumulation, whereas none of the nonionizable mutations at position 325 were able to accumulate galactosides against a concentration gradient. However, unlike the position 269 mutants, no H+ transport was observed in the Gly-325, Ala-325, Ser-325, or Gln-325 strains upon the addition of lactose, S-beta-D-galactopyranosyl-(1,1)-beta-thiogalactopy- ranoside, 1-O-methyl-beta-D-galactopyranoside, or melibiose. Furthermore, in these mutants, the efflux of lactose during counterflow assays became insensitive to Delta pH. Overall, these results are consistent with the notion that an acidic residue at position 325 is required for H+ transport via the lactose permease. Alternative hypotheses are also discussed.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIAID NIH HHS [AI24204] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024204] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYER PD, 1988, TRENDS BIOCHEM SCI, V13, P5, DOI 10.1016/0968-0004(88)90005-9; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; FLAGG JL, 1977, J MEMBRANE BIOL, V31, P223; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HOPPE J, 1980, FEBS LETT, V109, P107, DOI 10.1016/0014-5793(80)81321-4; KABACK HR, 1974, SCIENCE, V186, P882, DOI 10.1126/science.186.4167.882; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3691, DOI 10.1021/bi00584a009; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1989, BIOCHIM BIOPHYS ACTA, V982, P253, DOI 10.1016/0005-2736(89)90062-X; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JI, 1993, J BIOL CHEM, V268, P20007; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; Mandel M, 1970, J MOL BIOL, V53, P154; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBALD W, 1978, ENERGY CONSERVATION, P228; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	45	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7379	7386						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7907327				2022-12-27	WOS:A1994NA03200055
J	ARIGA, T; TAO, RV; LEE, BC; YAMAWAKI, M; YOSHINO, H; SCARSDALE, NJ; KASAMA, T; KUSHI, Y; YU, RK				ARIGA, T; TAO, RV; LEE, BC; YAMAWAKI, M; YOSHINO, H; SCARSDALE, NJ; KASAMA, T; KUSHI, Y; YU, RK			GLYCOLIPID COMPOSITION OF HUMAN CATARACTOUS LENSES - CHARACTERIZATION OF LEWIS(X) GLYCOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITOMETRIC DETERMINATION; PHEOCHROMOCYTOMA CELLS; NEUTRAL GLYCOLIPIDS; MASS-SPECTROMETRY; EMBRYONIC ANTIGEN; SENILE CATARACT; TYPE-2 CHAIN; LUNG-CANCER; GANGLIOSIDES; BRAIN	We have studied the glycolipid composition of human cataractous lenses. Neutral and acidic lipid fractions were isolated by column chromatographies on DEAE-Sephadex and Iatrobeads. The neutral glycolipid fraction and acidic glycolipid fraction contained 0.6-0.9 mug of lipid-bound glucose (Glc) per mg of protein and 0.8-1.3 mug of lipid-bound sialic acid (NeuAc) per mg of protein, respectively. The neutral glycolipid fraction was found to contain LacCer (39.0% of total neutral glycolipids), Gb3 (16.2%), Gb4 (1.1%), nLc4 (5.0%), X (29.0%), and Y (9.2%). The acidic lipid fraction was found to contain mainly GM3 (33.1% of the total ganglioside fraction), GM1 (8.3%), LM1 (7.3%), GD1a (16.0%), and G (30.1%). The structures of neutral glycolipids X and Y and ganglioside G were elucidated by high performance thin-layer chromatography overlay method of glycolipids, gas-liquid chromatography, proton NMR spectrometry, and liquid secondary ion mass spectrometry as follows: 1) X, Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta1-1'Cer, III3FucnLc4 (Le(x)); 2) Y, Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta1-'Cer, V3FucIII3FucnLc6; and 3) G, NeuAcalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Gal-beta1-4Glcbeta1-1'Cer, IV3NeuAcIII3FucnLc4 (sialosyl-Le(x)). A minor neutral glycolipid Z was isolated and tentatively characterized as GlcNAcbeta1-3?Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta1-1'Cer (GlcNAc-Le(x)), suggesting that may be the precursor of glycolipid Y. The major long-chain base of these human cataract glycolipids was C18:0 sphingosine (sphinganine). The major fatty acids were C16:0, C24:1 and C24:0, and monounsaturated fatty acids accounted for 40-55% of the total fatty acids.	UNIV ILLINOIS, MED CTR, DEPT OPHTHALMOL, CHICAGO, IL 60612 USA; TOKYO MED & DENT UNIV, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Tokyo Medical & Dental University (TMDU)	ARIGA, T (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT BIOCHEM & MOLEC BIOPHYS, 1101 E MARSHALL ST, RICHMOND, VA 23298 USA.				NEI NIH HHS [EY-01821] Funding Source: Medline; NINDS NIH HHS [NS-11853] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1978, ANAL BIOCHEM, V89, P437, DOI 10.1016/0003-2697(78)90373-1; ANDO S, 1979, J BIOL CHEM, V254, P2224; [Anonymous], 1976, LIPIDS, V12, P455; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; ARIGA T, 1991, BIOCHEMISTRY-US, V30, P7953, DOI 10.1021/bi00246a012; ARIGA T, 1982, J BIOL CHEM, V257, P2230; ARIGA T, 1980, J LIPID RES, V21, P879; ARIGA T, 1987, J BIOL CHEM, V262, P14146; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; CARTER HE, 1967, J LIPID RES, V8, P391; FELDMAN GERALD L., 1965, INVEST OPHTHAL MOL, V4, P162; FELDMAN GL, 1965, J AM OIL CHEM SOC, V42, P742, DOI 10.1007/BF02540054; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FUKSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1983, J NATL CANCER I, V63, P843; HAKOMORI SI, 1981, BIOCHEM BIOPH RES CO, V10, P1578; HIRABAYASHI Y, 1986, BIOCHIM BIOPHYS ACTA, V876, P178; KASAI N, 1982, LIPIDS, V17, P107, DOI 10.1007/BF02535184; KASAMA T, 1991, BIOCHEMISTRY-US, V30, P5621, DOI 10.1021/bi00236a041; KYOGASHIMA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P309, DOI 10.1016/0003-9861(89)90378-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; OGISO M, 1990, EXP EYE RES, V50, P51, DOI 10.1016/0014-4835(90)90010-R; OGISO M, 1990, INVEST OPHTH VIS SCI, V31, P2171; OGISO M, 1992, J BIOL CHEM, V267, P6467; RAUVALA H, 1976, J BIOL CHEM, V251, P7517; REN SL, 1992, J BIOL CHEM, V267, P12632; ROSENFELD L, 1981, EXP EYE RES, V33, P641, DOI 10.1016/S0014-4835(81)80104-2; SAITO M, 1985, ANAL BIOCHEM, V148, P54, DOI 10.1016/0003-2697(85)90627-X; SARKAR CP, 1982, BIOCHIM BIOPHYS ACTA, V711, P503, DOI 10.1016/0005-2760(82)90065-0; SEKINE M, 1984, J BIOCHEM-TOKYO, V96, P237, DOI 10.1093/oxfordjournals.jbchem.a134818; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SWINDELL RT, 1988, OPHTHALMIC RES, V20, P232, DOI 10.1159/000266650; TAO R V P, 1983, Current Eye Research, V2, P427; TAO RVP, 1975, BIOCHIM BIOPHYS ACTA, V409, P329, DOI 10.1016/0005-2760(75)90029-6; TAO RVP, 1983, BIOCHIM BIOPHYS ACTA, V753, P89, DOI 10.1016/0005-2760(83)90102-9; VANCE DE, 1967, J LIPID RES, V8, P391; VAUGHN D, 1989, GENERAL OPHTHALMOLOG, P144; WINDELER AS, 1970, BIOCHIM BIOPHYS ACTA, V202, P361, DOI 10.1016/0005-2760(70)90199-2; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YU RK, 1970, J LIPID RES, V11, P506; YU RK, 1986, CHEM PHYS LIPIDS, V42, P42; ZELENKA PS, 1984, CURR EYE RES, V3, P1337, DOI 10.3109/02713688409007421; ZENITA K, 1988, INT J CANCER, V41, P344, DOI 10.1002/ijc.2910410304	48	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2667	2675						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7905480				2022-12-27	WOS:A1994MV43200049
J	BIARDI, L; SREEDHAR, A; ZOKAEI, A; VARTAK, NB; BOZEAT, RL; SHACKELFORD, JE; KELLER, GA; KRISANS, SK				BIARDI, L; SREEDHAR, A; ZOKAEI, A; VARTAK, NB; BOZEAT, RL; SHACKELFORD, JE; KELLER, GA; KRISANS, SK			MEVALONATE KINASE IS PREDOMINANTLY LOCALIZED IN PEROXISOMES AND IS DEFECTIVE IN PATIENTS WITH PEROXISOME DEFICIENCY DISORDERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; IMMUNOELECTRON MICROSCOPY; CHOLESTEROL-SYNTHESIS; ZELLWEGER SYNDROME; MOLECULAR-CLONING; ACETOACETYL-COA; REFSUMS DISEASE; ACETYL-COA; METABOLISM	We reported recently that mevalonate kinase (EC 2.7.1.36; ATP:mevalonate 5-phosphotransferase) that was isolated from rat liver and believed to be a cytosolic protein was localized in rat liver peroxisomes. In addition, we found that the mevalonate kinase monoclonal antibody used in the study also reacted with several other proteins present in the mitochondrial and cytosolic fractions. These findings raised the prospect of the presence of several isoenzymes of mevalonate kinase localized in different compartments of the cell. In the current study we produced four new polyclonal antibodies against different epitopes of mevalonate kinase to investigate the subcellular localization of the protein by several different approaches: (i) by analytical subcellular fractionation and immunoblotting of mevalonate kinase in the isolated subcellular fractions with the monospecific antibodies; (ii) by immunocryoelectron microscopy techniques; and (iii) by expressing the CDNA encoding mevalonate kinase in maMmalian cells. The data obtained demonstrate that there is only one mevalonate kinase protein that is predominately localized in peroxisomes. We also illustrate that the protein is targeted to and imported into peroxisomes. In addition, we show that in cells and tissues obtained from patients with peroxisomal deficiency diseases mevalonate kinase protein and its activity are severely reduced.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; GENENTECH INC,DEPT PRECLIN PHARMACOL,S SAN FRANCISCO,CA 94080	California State University System; San Diego State University; Roche Holding; Genentech					NIDDK NIH HHS [DK 32852, DK 44350] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032852, R01DK044350] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTH PG, 1987, J INHERIT METAB DIS, V10, P253, DOI 10.1007/BF01800071; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; ERIKSSON AM, 1992, FEBS LETT, V308, P211, DOI 10.1016/0014-5793(92)81276-R; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; HOVIK R, 1991, J LIPID RES, V32, P993; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; PARKER RA, 1989, J BIOL CHEM, V264, P4877; POLLTHE BT, 1987, EUR J PEDIATR, V146, P477, DOI 10.1007/BF00441598; POULOS A, 1984, NEUROLOGY, V34, P1606, DOI 10.1212/WNL.34.12.1606; Sambrook J, 1989, MOL CLONING LABORATO; SAWAMURA M, 1992, J BIOL CHEM, V267, P6051; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SCOTTO JM, 1982, J INHERIT METAB DIS, V5, P83, DOI 10.1007/BF01799998; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; STAMELLO SKD, 1992, J BIOL CHEM, V267, P5560; STAMELLOS KD, 1993, J BIOL CHEM, V268, P12825; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TANAKA RD, 1990, J BIOL CHEM, V265, P9123; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551	36	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1197	1205						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904598				2022-12-27	WOS:A1994MR22000068
J	GROENEN, PJTA; GROOTJANS, JJ; LUBSEN, NH; BLOEMENDAL, H; DEJONG, WW				GROENEN, PJTA; GROOTJANS, JJ; LUBSEN, NH; BLOEMENDAL, H; DEJONG, WW			LYS-17 IS THE AMINE-DONOR SUBSTRATE SITE FOR TRANSGLUTAMINASE IN BETA-A3-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOMERIC GAMMA-CRYSTALLIN; PROGRAMMED CELL-DEATH; BETA-CRYSTALLIN; TISSUE TRANSGLUTAMINASE; LENS TRANSGLUTAMINASE; ACCEPTOR SITES; PROTEINS; LYSINE; IDENTIFICATION; APOPTOSIS	The bovine lens protein betaA3-crystallin has recently been shown to be an amine-donor (Lys) substrate for tissue-type transglutaminase, using a newly developed amine-acceptor hexapeptide as a probe (Groenen, P. J. T. A., Seccia, M., Smulders, R. H. P. H., Gravela, E., Cheeseman, K. H., Bloemendal, H., and de Jong, W. W. (1993) Biochem. J. 295, 399-404). In the present study, the reactive amine-donor site has been identified by site-directed mutagenesis of the putative substrate lysine. The mutation Lys-17 --> Arg abolishes the substrate capacity. This residue, located in the N-terminal extension of the polypeptide, thus acts as the sole amine-donor substrate in betaA3-crystallin. Our finding reinforces the notion that, in the crystallins, all amine-donor as well as amine-acceptor substrate sites reside in the N- or C-terminal arms. Transglutaminase-mediated cross-linking of betaA3-crystallin also gives rise to a betaA3 dimer, presumably due to the fact that Lys-17 can be cross-linked to the previously established Gln-7 or Gln-8 amine-acceptor site.	CATHOLIC UNIV NIJMEGEN,DEPT BIOCHEM,POB 9101,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT MOLEC BIOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Lubsen, Nicolette H./B-8426-2011; Groenen, Patricia/L-4336-2015	Groenen, Patricia/0000-0003-4314-228X				AARTS HJM, 1989, J MOL EVOL, V28, P313, DOI 10.1007/BF02103427; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BERBERS GAM, 1984, EUR J BIOCHEM, V139, P467, DOI 10.1111/j.1432-1033.1984.tb08029.x; BIRCKBICHLER PJ, 1977, CANCER RES, V37, P1340; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1993, EUR J BIOCHEM, V213, P313, DOI 10.1111/j.1432-1033.1993.tb17764.x; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GORIN MB, 1984, CURR EYE RES, V3, P939, DOI 10.3109/02713688409167211; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROENEN PJTA, 1993, BIOCHEM J, V295, P399, DOI 10.1042/bj2950399; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; MCFALNGAI M, 1986, CURR EYE RES, V5, P387, DOI 10.3109/02713688609025178; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MULDERS JWM, 1987, EXP CELL RES, V171, P296, DOI 10.1016/0014-4827(87)90163-7; PORTA R, 1991, BIOCHEMISTRY-US, V30, P3114, DOI 10.1021/bi00226a019; PUCCI P, 1988, BIOCHEM BIOPH RES CO, V154, P735, DOI 10.1016/0006-291X(88)90201-X; QUAXJEUKEN Y, 1984, J MOL BIOL, V180, P457, DOI 10.1016/0022-2836(84)90022-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WISTOW G, 1981, FEBS LETT, V133, P9, DOI 10.1016/0014-5793(81)80460-7	32	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					831	833						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7904603				2022-12-27	WOS:A1994MR22000013
J	DANIELLO, A; DONOFRIO, G; PISCHETOLA, M; DANIELLO, G; VETERE, A; PETRUCELLI, L; FISHER, GH				DANIELLO, A; DONOFRIO, G; PISCHETOLA, M; DANIELLO, G; VETERE, A; PETRUCELLI, L; FISHER, GH			BIOLOGICAL ROLE OF D-AMINO-ACID OXIDASE AND D-ASPARTATE OXIDASE - EFFECTS OF D-AMINO ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; D-ALANINE; HUMAN-BRAIN; VULGARIS LAM; PIG-KIDNEY; D-SERINE; RACEMIZATION; PURIFICATION; RAT	D-Amino acids administered to animals are absorbed by the intestine and transported through the blood-stream to solid tissues where they are oxidized in vivo by D-amino acid oxidase and D-aspartate oxidase to produce the same compounds they do in vitro; i.e. NH3, H2O2, and the keto acid corresponding to the amino acid ingested. In the liver and kidneys of the animals, an inverse relationship exists between the occurrence of D-amino acids and these oxidative enzymes. For example, younger animals have lower amounts of these oxidases and consequently higher concentrations of free D-amino acids compared to adult animals. If the ingested D-amino acids are not metabolized by these enzymes, they will accumulate in the tissues and may provoke serious damage, e.g. suppression of the synthesis of other essential enzymes and inhibition of the growth rate of the animals. A specific enzyme induction for these D-amino acid oxidases exists in young rats following ingestion of free D-amino acids by the mother. Specifically, when a mother rat ingests D-Ala or D-Asp during pregnancy and suckling, an increase in D-amino acid oxidase or D-aspartate oxidase is observed in the liver and kidneys of the baby rats. These results suggest that the in vivo biological role of these oxidases in animals is to act as detoxifying agents to metabolize D-amino acids which may have accumulated during aging.	BARRY UNIV, DEPT CHEM, MIAMI, FL 33161 USA		DANIELLO, A (corresponding author), STAZ ZOOL ANTON DOHRN, DEPT BIOCHEM & MOLEC BIOL, VILLA COMUNALE, I-80121 NAPLES, ITALY.			Vetere, Amedeo/0000-0001-5608-0773				ARMANI E, 1988, J CHROMATOGR, V441, P287, DOI 10.1016/S0021-9673(01)83872-3; BLASCHKO H, 1952, BIOCHEM J, V52, P306, DOI 10.1042/bj0520306; BURNS CL, 1984, BIOCHEM BIOPH RES CO, V125, P1039, DOI 10.1016/0006-291X(84)91388-3; CONNO R, 1988, BIOCHIM BIOPHYS ACTA, V297, P382; CONNO R, 1988, BIOCHEM J, V261, P285; CORRIGAN JJ, 1969, SCIENCE, V164, P142, DOI 10.1126/science.164.3876.142; CURTI B, 1973, BIOCHIM BIOPHYS ACTA, V327, P266, DOI 10.1016/0005-2744(73)90409-9; DANIELLO A, 1993, LIFE SCI, V52, P733, DOI 10.1016/0024-3205(93)90235-U; DANIELLO A, 1975, COMP BIOCHEM PHYSIOL, V50, P209, DOI 10.1016/0305-0491(75)90324-7; DANIELLO A, 1984, J BIOL CHEM, V259, P4237; DANIELLO A, 1978, J NEUROCHEM, V31, P1107, DOI 10.1111/j.1471-4159.1978.tb00155.x; DANIELLO A, 1980, COMP BIOCHEM PHYS B, V66, P319, DOI 10.1016/0305-0491(80)90071-1; DANIELLO A, 1977, J NEUROCHEM, V29, P1053, DOI 10.1111/j.1471-4159.1977.tb06508.x; DANIELLO A, 1990, COMP BIOCHEM PHYS B, V97, P291, DOI 10.1016/0305-0491(90)90283-Y; DANIELLO A, 1990, BIOCHIM BIOPHYS ACTA, V1037, P200, DOI 10.1016/0167-4838(90)90168-F; DANIELLO A, 1992, COMP BIOCHEM PHYS B, V102, P795, DOI 10.1016/0305-0491(92)90082-3; DANIELLO A, 1992, BRAIN RES, V592, P44, DOI 10.1016/0006-8993(92)91656-Y; DANIELLO A, 1987, ITAL J BIOCHEM, V36, pA322; DANIELLO A, 1972, COMP BIOCHEM PHYSIOL, V41, P625, DOI 10.1016/0305-0491(72)90124-1; DAVIES LP, 1975, J NEUROCHEM, V25, P299; DEMARCHI WJ, 1969, J NEUROCHEM, V16, P355; DEMARCO C, 1967, ENZYMOLOGIA, V33, P325; DEMARCO C, 1969, ENZYMOLOGIA, V36, P111; DEMORAES GHK, 1987, POULTRY SCI, V66, P98, DOI 10.3382/ps.0660098; DIXON M, 1967, BIOCHIM BIOPHYS ACTA, V146, P54, DOI 10.1016/0005-2744(67)90073-3; DIXON M, 1965, BIOCHIM BIOPHYS ACTA, V96, P357, DOI 10.1016/0005-2787(65)90556-3; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; FELBECK H, 1985, J EXP ZOOL, V234, P145, DOI 10.1002/jez.1402340116; FELBECK H, 1987, BIOL BULL, V173, P252, DOI 10.2307/1541877; FICKEISEN DH, 1977, J FISH BIOL, V10, P457, DOI 10.1111/j.1095-8649.1977.tb04078.x; FISHER GH, 1992, BRAIN RES BULL, V28, P127, DOI 10.1016/0361-9230(92)90239-T; FISHER GH, 1992, NEUROSCI LETT, V143, P215, DOI 10.1016/0304-3940(92)90268-C; FISHER GH, 1986, BIOCHEM BIOPH RES CO, V135, P683, DOI 10.1016/0006-291X(86)90047-1; FISHER GH, 1991, BRAIN RES BULL, V26, P983, DOI 10.1016/0361-9230(91)90266-M; Fishman WH, 1942, J BIOL CHEM, V145, P345; FRANK H, 1978, J CHROMATOGR, V167, P187, DOI 10.1016/S0021-9673(00)91157-9; FRIEDMAN M, 1981, J FOOD SCI, V46, P127, DOI 10.1111/j.1365-2621.1981.tb14545.x; FUKUI K, 1987, BIOCHEMISTRY-US, V26, P3612, DOI 10.1021/bi00386a054; GOLDSTEIN DB, 1966, J NEUROCHEM, V13, P1011, DOI 10.1111/j.1471-4159.1966.tb10299.x; GROENEN PJTA, 1990, FEBS LETT, V269, P109, DOI 10.1016/0014-5793(90)81131-7; HAMILTON GA, 1979, P NATL ACAD SCI USA, V76, P2625, DOI 10.1073/pnas.76.6.2625; HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELLERMA.L, 1965, J BIOL CHEM, V240, P290; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; KONNO R, 1982, COMP BIOCHEM PHYS B, V71, P735, DOI 10.1016/0305-0491(82)90490-4; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1620; LIARDON R, 1981, J CHROMATOGR, V203, P385, DOI 10.1016/S0021-9673(00)80309-X; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; MAN EH, 1987, ANNU REV NUTR, V7, P209, DOI 10.1146/annurev.nu.07.070187.001233; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; MASSEY V, 1966, J BIOL CHEM, V241, P2347; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; NAGATA Y, 1989, EXPERIENTIA, V45, P330, DOI 10.1007/BF01957466; NAGATA Y, 1987, CLIN SCI, V73, P105, DOI 10.1042/cs0730105; NAGATA Y, 1985, ANAL BIOCHEM, V150, P238, DOI 10.1016/0003-2697(85)90465-8; NAGATA Y, 1992, BIOCHIM BIOPHYS ACTA, V1115, P208, DOI 10.1016/0304-4165(92)90055-Y; NAGATA Y, 1988, COMP BIOCHEM PHYS B, V91, P503, DOI 10.1016/0305-0491(88)90012-0; NEGRI A, 1987, J BIOL CHEM, V262, P10026; NEIDLE A, 1990, LIFE SCI, V46, P1517, DOI 10.1016/0024-3205(90)90424-P; NEIMS AH, 1970, ANNU REV BIOCHEM, V39, P867, DOI 10.1146/annurev.bi.39.070170.004251; NEIMS AH, 1966, J NEUROCHEM, V13, P163, DOI 10.1111/j.1471-4159.1966.tb07508.x; NEIMS AH, 1962, J BIOL CHEM, V237, pP976; PALLA G, 1989, J CHROMATOGR, V475, P45, DOI 10.1016/S0021-9673(00)91414-6; PAYAN IL, 1992, NEUROCHEM RES, V17, P187, DOI 10.1007/BF00966798; PISTORIUS EK, 1977, BIOCHIM BIOPHYS ACTA, V481, P395, DOI 10.1016/0005-2744(77)90273-X; PRESTON RL, 1987, COMP BIOCHEM PHYS B, V87, P55, DOI 10.1016/0305-0491(87)90470-6; PRESTON RL, 1987, COMP BIOCHEM PHYS B, V87, P63, DOI 10.1016/0305-0491(87)90471-8; RONCHI S, 1982, J BIOL CHEM, V257, P8824; SHAPIRA R, 1988, J NEUROCHEM, V50, P649, DOI 10.1111/j.1471-4159.1988.tb02960.x; SHAPIRA R, 1987, BIOCHEM BIOPH RES CO, V146, P1342, DOI 10.1016/0006-291X(87)90797-2; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; SIMONETTA MP, 1982, FEMS MICROBIOL LETT, V15, P27, DOI 10.1016/0378-1097(82)90006-4; STILL JL, 1950, J BIOL CHEM, V182, P585; TADA M, 1990, GENE, V90, P293, DOI 10.1016/0378-1119(90)90193-U; WEIMAR WR, 1977, J NEUROCHEM, V29, P649, DOI 10.1111/j.1471-4159.1977.tb07782.x; YAGI K, 1962, BIOCHIM BIOPHYS ACTA, V56, P413, DOI 10.1016/0006-3002(62)90592-9; YAGI K, 1967, J BIOCHEM-TOKYO, V61, P580, DOI 10.1093/oxfordjournals.jbchem.a128588; 1974, J CLIN LAB INV, V33, P287	79	232	243	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26941	26949						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903300				2022-12-27	WOS:A1993MM26200019
J	HU, YL; KAZENWADEL, J; JAMES, R				HU, YL; KAZENWADEL, J; JAMES, R			ISOLATION AND CHARACTERIZATION OF THE MURINE HOMEOBOX GENE CDX-1 REGULATION OF EXPRESSION IN INTESTINAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; TRANSGENIC MICE; BINDING-PROTEIN; CPG ISLANDS; TRANSCRIPTION INVITRO; DENOVO METHYLATION; CORE PROMOTER; TATA BOX; DIFFERENTIATION; DNA	The murine homeobox gene Cdx-1 is postulated to play an important role in the process of cellular commitment in the intestinal epithelium based upon its graded, tissue-specific expression pattern in the adult animal. We have isolated and sequenced both cDNA and genomic clones in order to understand how this expression pattern is regulated and to determine the amino acid sequence of the encoded protein. Our studies show that the Cdx-1 gene contains 3 exons and 2 introns and encodes a 268-amino acid protein which is translated from a 1.7-1.8-kilobase mRNA. Transcription of the Cdx-1 gene initiates some 30 base pairs downstream from a typical TATA box which, together with the 5' end of the gene, is located within a CpG island. Transient transfection experiments have shown three regions which regulate Cdx-1 gene expression. These include a typical silencer element at -589 to -380, an element at -887 to -1040 which blocks the effect of the silencer and a positive element at -47 to +66; the only one which shows epithelial cell specificity. Using gel shift and footprinting assays we have detected proteins in nuclear extracts prepared from colonic epithelial cells which bind to the silencer element. These initial results suggest that Cdx-1 gene expression is regulated by multiple positive and negative transcription factors.	UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; University of Melbourne; Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Kazenwadel, Jan/E-6620-2012; Hu, Yinling/G-5682-2015	Kazenwadel, Jan/0000-0001-6216-3444; Hu, Yinling/0000-0002-4795-8537				ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BIRD AP, 1989, NUCLEIC ACIDS RES, V17, P9485, DOI 10.1093/nar/17.22.9485; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1982, ANAT REC, V203, P251, DOI 10.1002/ar.1092030207; COLONY PC, 1989, CELLULAR MOL BIOL CO, P2; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; FALB D, 1992, MOL CELL BIOL, V12, P4093, DOI 10.1128/MCB.12.9.4093; FINELY D, 1989, NATURE, V338, P394; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAFFEN K, 1989, HUMAN GASTROINTESTIN, P19; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V14, P3555; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAMES R, 1991, J BIOL CHEM, V266, P3246; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KEDINGER M, 1987, CELL DIFFER DEV, V20, P171, DOI 10.1016/0045-6039(87)90431-3; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRESS C, 1990, DEVELOPMENT, V109, P775; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASKENS AP, 1981, CELL TISSUE KINET, V14, P467, DOI 10.1111/j.1365-2184.1981.tb00553.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONTGOMERY RK, 1981, DEV BIOL, V87, P76, DOI 10.1016/0012-1606(81)90062-2; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; STALLMACH A, 1989, GUT, V30, P959, DOI 10.1136/gut.30.7.959; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; THOMPSON EM, 1990, DEVELOPMENT, V110, P477; THOMPSON J, 1987, ANAL BIOCHEM, V163, P281, DOI 10.1016/0003-2697(87)90225-9; TUGGLE CK, 1990, GENE DEV, V4, P180, DOI 10.1101/gad.4.2.180; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059	64	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27214	27225						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7903305				2022-12-27	WOS:A1993MM26200058
J	SEN, I; KASTURI, S; JABBAR, MA; SEN, GC				SEN, I; KASTURI, S; JABBAR, MA; SEN, GC			MUTATIONS IN 2 SPECIFIC RESIDUES OF TESTICULAR ANGIOTENSIN-CONVERTING ENZYME CHANGE ITS CATALYTIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL CARBOXYPEPTIDASE; HOMOLOGOUS DOMAINS; MESSENGER-RNAS; EXPRESSION; ISOENZYMES; ACTIVATION; SUBSTRATE; RABBIT; GENE	Chemical modifications of 2 specific residues present in angiotensin-converting enzyme (ACE) result in its inactivation, thereby suggesting that these 2 residues may be important for its enzyme activity. We directly tested this hypothesis by substituting Tyr-236 with Phe and Lys-154 with Glu in rabbit testicular ACE (ACE(T)) using site-directed mutagenesis of the corresponding cDNA. Wild type ACE(T), the two single mutants, and the double mutant were expressed in HeLa cells using the vaccinia virus-T7 polymerase expression system. The rate of synthesis, post-translational modifications, and cleavage secretion pattern of all four proteins were indistinguishable. The enzymatic properties of the two single mutants and the wild type enzyme were also very similar. In contrast, the double mutant had about a 20-fold lower specific activity although its K(m) was only 6-fold higher than that of the wild type protein. The double mutant also had a 100-fold higher K(i) for lisinopril, a competitive inhibitor of ACE(T), and was 17-fold less sensitive to stimulation by NaCl, an activator of ACE(T). These results directly demonstrate that Tyr-236 and Lys-154 are indeed critical for the catalytic activity, lisinopril inhibition, and NaCl activation of ACE(T).	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	SEN, I (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOVASC BIOL,FFB,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALHENCGELAS F, 1983, J LAB CLIN MED, V101, P83; BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BUNNING P, 1990, BIOCHEMISTRY-US, V29, P10488; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; CHEN YNP, 1990, BIOCHEMISTRY-US, V29, P10493, DOI 10.1021/bi00498a011; CHEN YNP, 1992, BIOCHEM BIOPH RES CO, V184, P306, DOI 10.1016/0006-291X(92)91193-T; DAS M, 1975, J BIOL CHEM, V250, P6762; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; EHLERS MRW, 1988, BIOCHEMISTRY-US, V27, P5538, DOI 10.1021/bi00415a023; ELDORRY HA, 1982, P NATL ACAD SCI-BIOL, V79, P4295, DOI 10.1073/pnas.79.14.4295; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUBERT C, 1991, J BIOL CHEM, V266, P15377; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LANZILLO JJ, 1976, BIOCHIM BIOPHYS ACTA, V439, P125, DOI 10.1016/0005-2795(76)90168-9; NG KKF, 1967, NATURE, V216, P762, DOI 10.1038/216762a0; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SEN I, 1991, J BIOL CHEM, V266, P21985; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SKEGGS LT, 1954, J EXP MED, V99, P275, DOI 10.1084/jem.99.3.275; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	30	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25748	25754						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7902354				2022-12-27	WOS:A1993MK10000069
